Generated by All in One SEO v4.8.9, this is an llms.txt file, used by LLMs to index the site.

# DNDi

Best science for the most neglected

## Sitemaps

- [XML Sitemap](https://dndi.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Home](https://dndi.org/) - DNDi has created medical history for neglected patients, globally. Since 2003, we have developed 14 affordable treatments for 6 deadly diseases, saving millions of lives.
- [Neglected Tropical Diseases (NTDs)](https://dndi.org/diseases/neglected-tropical-diseases/) - Over 1 billion people around the world are affected by neglected tropical diseases but they have largely been ignored by the traditional pharmaceutical industry.
- [Symptoms, transmission, and current treatments for dengue](https://dndi.org/diseases/dengue/facts/) - Dengue is the most widely distributed mosquito-borne viral disease in the world. It spreads rapidly because of climate change, rapid urbanization, and population growth.
- [Privacy Policy](https://dndi.org/privacy/) - Privacy Policy Privacy Policy Version 15 June 2020 What's in these terms? We are committed to protecting and respecting your privacy. This policy sets out the basis on which any personal data we collect from you, or that you provide to us, will be processed by us. This Privacy Policy doesn’t cover clinical data collected
- [Our story: 20 years of DNDi](https://dndi.org/about/our-story-20-years-dndi/) - Our story is about turning frustration into action to ensure all people can benefit from the fruits of scientific progress. Browse through the timeline of DNDi's first 20 years.
- [Evidence for impact](https://dndi.org/research-development/evidence-for-impact/) - The translational research stage of R&D takes promising drug candidates from drug discovery to early clinical development.
- [Research and development](https://dndi.org/research-development/) - Since 2003 DNDi has addressed gaps in the traditional biomedical R&D system that lead to serious unmet medical needs for neglected patients.
- [Our R&D portfolio for dengue](https://dndi.org/diseases/dengue/projects-achievements/) - We are bringing together partners in dengue-endemic countries to find urgently needed treatments for dengue.
- [Symptoms, transmission, and current treatments for lymphatic filariasis](https://dndi.org/diseases/parasitic-worms/lymphatic-filariasis/symptoms-transmission-treatments/) - Also known as elephantiasis due to the extreme swelling that can result from the disease, lymphatic filariasis is caused by parasitic worms spread by the bites of infected mosquitoes.
- [Symptoms, transmission, and current treatments for schistosomiasis](https://dndi.org/diseases/parasitic-worms/schistosomiasis/symptoms-transmission-treatments/) - Also known as bilharzia or snail fever, schistosomiasis is a water-borne, parasitic disease caused by tiny blood-dwelling worms. People can become infected with schistosomiasis when they come into contact with contaminated water.
- [eNews Newsletter](https://dndi.org/news-and-stories/newsletters/) - Our eNews shares updates on our work developing better treatments for neglected diseases.
- [Gender equity in drug development](https://dndi.org/advocacy/gender-equity-in-drug-development/) - Women’s specific medical needs are widely overlooked in traditional biomedical R&D. In addition, women are often under-represented among those leading research in this field. We are working to upend this persistent and harmful status quo.
- [Get involved](https://dndi.org/about/donors/get-involved/) - Support DNDi through philanthropy
- [Our donors](https://dndi.org/about/donors/) - On behalf of our patients, medical staff, and research teams, DNDi would like to thank all our donors, who have been making medical history with us since 2003.
- [Strategy](https://dndi.org/about/strategy/) - DNDi's Strategic Plan 2021-2028 charts a journey to deliver 25 treatments in our first 25 years and contribute to a more equitable system of innovation & access.
- [Registration & access](https://dndi.org/research-development/registration-and-access/) - DNDi’s commitment to ensure equitable and affordable access to the treatments we develop is one of the most challenging aspects of our mission.
- [Treatments delivered](https://dndi.org/research-development/treatments-delivered/) - We have developed 14 treatments for 6 deadly diseases by working with our worldwide network of partners.
- [Regional Boards](https://dndi.org/our-people/regional-boards/) - Boards of Directors of our regional offices Boards of Directors of our regional offices DNDi India Foundation Board of Directors Farhat Mantoo, Director-General of Médecins Sans Frontières IndiaDr Lalit Kant, formerly Deputy Director General of the Indian Council of Medical Research, India DNDi Japan Board of Directors Prof. Tomoyoshi Nozaki, Chair; Professor at the Graduate
- [Diversity, equity & inclusion](https://dndi.org/work-with-us/diversity-equity-inclusion/) - We are committed to creating a work environment that values human dignity and equality.
- [Donate](https://dndi.org/donate/) - Help us make medical history!
- [Portfolio](https://dndi.org/research-development/portfolio/) - With our partners, we are working on over 40 projects. We are committed to developing safe, effective, and affordable treatments for neglected patients.
- [Who we are](https://dndi.org/about/who-we-are/) - Founded in 2003 by MSF, WHO and 5 health research institutions, DNDi is a nonprofit research organization that develops new treatments for neglected patients.
- [Innovating for children’s health](https://dndi.org/advocacy/innovating-for-childrens-health/) - When it comes to treatment, children face even greater neglect than adults affected by the same diseases.
- [Our R&D portfolio for lymphatic filariasis](https://dndi.org/diseases/parasitic-worms/lymphatic-filariasis/projects-achievements/) - We aim to test and develop a new treatment that can prevent disability and help eliminate lymphatic filariasis as a public health problem.
- [Our R&D portfolio for schistosomiasis](https://dndi.org/diseases/parasitic-worms/schistosomiasis/projects-achievements/) - We aim to identify a combination treatment of existing drugs to better treat the painful symptoms of female genital schistosomiasis. We are also working to develop and register at least one new safe, affordable, and field-adapted drug that can kill both adult and juvenile worms.
- [Symptoms, transmission, and current treatments for lymphatic filariasis](https://dndi.org/diseases/parasitic-worms/lymphatic-filariasis/facts/) - Also known as elephantiasis due to the extreme swelling that can result from the disease, lymphatic filariasis is caused by parasitic worms spread by the bites of infected mosquitoes.
- [Symptoms, transmission, and current treatments for schistosomiasis](https://dndi.org/diseases/parasitic-worms/schistosomiasis/facts/) - Also known as bilharzia or snail fever, schistosomiasis is a water-borne, parasitic disease caused by tiny blood-dwelling worms. People can become infected with schistosomiasis when they come into contact with contaminated water.
- [Target product profile for schistosomiasis](https://dndi.org/diseases/parasitic-worms/schistosomiasis/target-product-profile/) - DNDi aims to develop a single-dose oral treatment for schistosomiasis that is active against both adult and juvenile worms across all Schistosoma species and that is suitable for all ages and for women who are or may become pregnant.
- [Target product profile for filarial diseases](https://dndi.org/diseases/parasitic-worms/river-blindness/target-product-profile/) - DNDi aims to develop a three-day oral treatment for river blindness, suitable for all ages and superior to current options, active against adult and immature worms, and safe for use in patients co-infected with Loa Loa.
- [Our R&D portfolio for filarial diseases](https://dndi.org/diseases/parasitic-worms/river-blindness/projects-achievements/) - We aim to complete development and register at least one new drug for river blindness. We are also seeking to identify potential new drug candidates by evaluating registered drugs, as well as pre-clinical and clinical drug candidates to populate the empty drug pipeline.
- [Symptoms, transmission, and current treatments for filarial diseases](https://dndi.org/diseases/parasitic-worms/river-blindness/facts/) - We aim to deliver a safe, effective, affordable, and field-adapted drug that can kill adult filarial worms (a ‘macrofilaricide’) and be used for prevention or individual treatment.
- [Contact us](https://dndi.org/our-people/contact-us/) - If you are interested in collaborating with DNDi, have comments or questions about our work, or feedback about our website, please contact us via your nearest office.
- [Target product profile for sleeping sickness](https://dndi.org/diseases/sleeping-sickness/target-product-profile/) - DNDi aims to develop an oral or intramuscular treatment for sleeping sickness (human African trypanosomiasis), maximum one week in duration, that is effective against T.b. gambiense and rhodesiense parasites in all patients in both stages of the disease.
- [Our R&D portfolio for sleeping sickness](https://dndi.org/diseases/sleeping-sickness/projects-achievements/) - Through our HAT Platform, a multi-country clinical research network, we continue to train local researchers and conduct clinical trials in remote and conflict-affected areas to develop even better tools to prevent resurgence.
- [Symptoms, transmission, and current treatments for sleeping sickness](https://dndi.org/diseases/sleeping-sickness/facts/) - We aim to deliver new oral treatments to cure sleeping sickness to support the sustainable elimination of the disease.
- [Advocacy Toolkit](https://dndi.org/diseases/paediatric-hiv/advocacy-toolkit/) - The Paediatric HIV Advocacy Toolkit has been developed for caregivers and healthworkers looking after children with HIV.
- [Target product profile for paediatric HIV](https://dndi.org/diseases/paediatric-hiv/target-product-profile/) - DNDi aims to develop a once-daily, pleasant-tasting 4-in-1 fixed-dose antiretroviral treatment for HIV in all children under three years, including neonates, that is easily swallowed and does not require a cold-chain.
- [Our R&D portfolio for paediatric HIV](https://dndi.org/diseases/paediatric-hiv/projects-achievements/) - While R&D efforts have succeeded in developing life-saving diagnosis and treatment innovations for adults, innovation for children lags far behind. Thankfully, new paediatric formulations are finally becoming available after decades of poor options. Our work is a key part of this revolution in paediatric HIV diagnosis and treatment.
- [Symptoms, transmission, and current treatments for paediatric HIV](https://dndi.org/diseases/paediatric-hiv/facts/) - We aim to help end the neglect of paediatric HIV by developing optimal child-friendly antiretroviral formulations for children living with HIV, with a special focus on babies and young children who are at the highest risk of dying without treatment.
- [Target product profile for mycetoma](https://dndi.org/diseases/mycetoma/target-product-profile/) - DNDi aims to develop a less than six-month oral, daily treatment for eumycetoma for all patients in all regions, with high efficacy and no need to monitor for safety.
- [Our R&D portfolio for mycetoma](https://dndi.org/diseases/mycetoma/projects-achievements/) - We are bringing much needed attention to mycetoma to help end the neglect of people with the disease.
- [Symptoms, transmission, and current treatments for mycetoma](https://dndi.org/diseases/mycetoma/facts/) - There is a desperate need for an effective, safe, affordable, and shorter-term treatment for fungal mycetoma that can be used in rural areas. We aim to develop an effective, safe, affordable, and simpler treatment.
- [Target product profile for Chagas disease](https://dndi.org/diseases/chagas/target-product-profile/) - DNDi aims to develop an oral, age-adapted shorter-course treatment for Chagas disease that is safer and more effective than current options, for use in all regions and in both chronic and acute patients, including during pregnancy.
- [Our R&D portfolio for Chagas disease](https://dndi.org/diseases/chagas/projects-achievements/) - Our goal is to make treatment safer and more effective. We are also working to improve access to testing and treatment.
- [Symptoms, transmission, and current treatments for Chagas disease](https://dndi.org/diseases/chagas/facts/) - We aim to deliver new, safer, more affordable and effective treatments for people affected by Chagas disease.
- [Target product profile for visceral leishmaniasis](https://dndi.org/diseases/visceral-leishmaniasis/target-product-profile/) - DNDi aims to develop a treatment for primary visceral leishmaniasis, visceral leishmaniasis combination therapies, and post-kala-azar dermal leishmaniasis.
- [Our R&D portfolio for visceral leishmaniasis](https://dndi.org/diseases/visceral-leishmaniasis/projects-achievements/) - We are working to deliver better combination treatments and new drugs. Together with our partners, we have built an unprecedented portfolio of six new chemical classes, with different mechanisms of action against Leishmania parasites.
- [Symptoms, transmission, and current treatments for visceral leishmaniasis](https://dndi.org/diseases/visceral-leishmaniasis/facts/) - Existing drugs have serious drawbacks in terms of safety, resistance, stability, and cost. We aim to make treatments safer, shorter and more affordable and effective.
- [Symptoms, transmission, and current treatments for cutaneous leishmaniasis](https://dndi.org/diseases/cutaneous-leishmaniasis/facts/) - We aim to make treatments safer, shorter and more affordable and effective. In the long term, the goal is to develop an entirely new generation of all-oral drugs.
- [Symptoms, transmission, and current treatments for hepatitis C](https://dndi.org/diseases/hepatitis-c/facts/) - Hepatitis C is a liver disease caused by the hepatitis C virus. Hepatitis C can cause a mild illness of a few weeks or develop into a serious, lifelong, chronic illness.
- [Our R&D portfolio for hepatitis C](https://dndi.org/diseases/hepatitis-c/projects-achievements/) - We delivered a new treatment that is equal to the best hepatitis C drugs, at a fraction of the cost.
- [Our R&D portfolio for cutaneous leishmaniasis](https://dndi.org/diseases/cutaneous-leishmaniasis/projects-achievements/) - Our goal is to deliver short, safe, non-invasive, efficacious, affordable, and field-friendly treatments for all forms of cutaneous leishmaniasis, including topical, oral, and immunomodulator therapies.
- [Target product profile for cutaneous leishmaniasis](https://dndi.org/diseases/cutaneous-leishmaniasis/target-product-profile/) - DNDi aims to develop a topical or oral treatment for all species of leishmania causing cutaneous or mucocutaneous leishmaniasis that is safe and effective for all patients and does not require a cold chain.
- [How we work](https://dndi.org/about/how-we-work/) - Collaborating with public, private, academic, non-profit, and philanthropic sectors, we leverage unique solutions for neglected populations.
- [Our prizes and awards](https://dndi.org/about/prizes-and-awards/) - DNDi is very honoured to have been awarded several prizes and awards through the years, giving much-needed visibility to our mission of bringing the best science to the most neglected.
- [Our policies](https://dndi.org/about/dndi-policies/) - At DNDi we strive to hold ourselves to the highest standards of accountability, transparency, ethics, and best practice in all we do, internally and programmatically.
- [Cookie Policy](https://dndi.org/cookie-policy/) - Cookie Policy Cookie Policy Version 6 July 2018 Who we are and how to contact us www.dndi.org, www.africoleish.org, www.afrikadia.org, anticov.org, www.dndial.org, www.dndijapan.org, www.dndina.org, eliminateworms.org, www.treatchagas.org and our other websites are sites operated by the Drugs for Neglected Diseases initiative (”We”). We are a Swiss charitable foundation and have our principal office at Chemin Camille-Vidart 15,
- [Acceptable Use Policy](https://dndi.org/acceptable-use-policy/) - Acceptable Use Policy Acceptable Use Policy Version 6 July 2018 PLEASE READ THE TERMS OF THIS POLICY CAREFULLY BEFORE USING THE SITE What's in these terms? This Acceptable Use Policy sets out the Content Standards that apply when you upload content to our sites, make contact with other users on our sites, link to
- [Terms of Use](https://dndi.org/terms-of-use/) - Terms of Use Terms of Use Version 6 July 2018 PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE USING OUR WEBSITES What's in these terms? These terms tell you the rules for using our websites. Who we are and how to contact us www.dndi.org, www.africoleish.org, www.afrikadia.org, anticov.org, www.dndial.org, www.dndijapan.org, www.dndina.org, eliminateworms.org, www.treatchagas.org and
- [About](https://dndi.org/about/) - DNDi is an international, non-profit R&D organization. We discover, develop, and deliver affordable treatments for neglected patients – saving millions of lives, globally.
- [Open and collaborative R&D](https://dndi.org/advocacy/open-and-collaborative-rd/) - DNDi’s open and collaborative approach to R&D is driven by patient needs, not profits - a practical illustration of an alternative to the prevailing system.
- [Our leadership](https://dndi.org/our-people/our-leadership/) - Our diverse leadership collaborates across programmes, departments, and regional offices to deliver treatments for neglected patients.
- [Requests for proposal](https://dndi.org/work-with-us/requests-for-proposals/) - DNDi is inviting offers for Requests for Proposal (RFPs) as currently listed here. Please do not hesitate to download and review DNDi’s Procurement Policy.
- [Our people](https://dndi.org/our-people/) - Representing more than 30 nationalities, DNDi’s diverse global team includes around 250 staff who bring essential skills and experience from the academic, non-profit, private, and public sectors.
- [Global networks](https://dndi.org/global-networks/) - Our global network includes in-country clinicians, scientists, and experts. Initiatives to utilize and strengthen research capacities in low- and middle-income countries are central to the DNDi model.
- [Clinical trials](https://dndi.org/research-development/clinical-trials/) - DNDi works with global research partners to evaluate new and improved medicines and treatment regimens. This enables us to deliver safe, affordable treatments.
- [Annual Report 2024](https://dndi.org/about/annual-reports/annual-report-2024/) - Browse our interactive Annual Report to learn how solidarity in science is benefiting the most neglected.
- [Annual Report 2023](https://dndi.org/about/annual-reports/annual-report-2023/) - Browse our interactive Annual Report to learn how we’re putting equity at the heart of medical innovation.
- [Putting patients at the centre – start to finish](https://dndi.org/about/annual-reports/annual-report-2024/putting-patients-at-the-centre-start-to-finish/) - Our commitment to innovation and equitable access for neglected populations
- [Shaping a fairer response to future pandemics](https://dndi.org/about/annual-reports/annual-report-2024/shaping-a-fairer-response-to-future-pandemics/) - Ensuring the fruits of scientific progress reach the most neglected
- [Confronting the climate crisis](https://dndi.org/about/annual-reports/annual-report-2024/confronting-the-climate-crisis/) - Advancing science and equity to face surging threats
- [Pushing to end the double neglect](https://dndi.org/about/annual-reports/annual-report-2024/pushing-to-end-the-double-neglect/) - Innovation to address the unmet needs of women and children
- [Bringing elimination within reach](https://dndi.org/about/annual-reports/annual-report-2024/bringing-elimination-within-reach/) - How science and solidarity are ending neglected diseases
- [Foreword](https://dndi.org/about/annual-reports/annual-report-2024/foreword/) - Message from Dr Marie-Paule Kieny, Chair of the Board of Directors, and Dr Luis Pizarro, Executive Director
- [Theory of Change Detailed](https://dndi.org/theoryofchange-detailed/)
- [Our governance](https://dndi.org/our-people/our-governance/) - DNDi is governed by a Board of Directors that approves project selection and sets policies on IP, finance, and ethics.
- [Media workshops](https://dndi.org/press/media-workshops-fellowships/) - Our media workshops and fellowships bring together science and health reporters with top researchers working on neglected diseases in an interactive and educational environment.
- [Partnerships](https://dndi.org/partnerships/) - Collaboration is an essential part of DNDi’s model: we cannot carry out our work without the engagement of public and private partners.
- [Integrity Line](https://dndi.org/work-with-us/integrity-line/) - DNDi’s Integrity Line is an online third-party platform that can be used for the anonymous reporting of misconduct by DNDi staff or anyone outside the organization in connection with DNDi activities.
- [Work with us](https://dndi.org/work-with-us/) - We are looking for committed and talented individuals to join us in our efforts to develop safe, effective, and affordable treatments for diseases affecting some of the world’s poorest and most neglected communities.
- [Code of Conduct](https://dndi.org/work-with-us/code-of-conduct/) - Our Code of Conduct aims to strengthen the ethical culture at DNDi to support decision-making based on our values, and to maintain the respect and confidence of our colleagues, partners, and the donors who support us.
- [Working at DNDi](https://dndi.org/work-with-us/working-at-dndi/) - At DNDi, our work begins with our people: we aim to recruit people who both reflect and understand the diversity of needs and experiences of those we serve.
- [Transparency](https://dndi.org/about/donors/transparency/) - DNDi is committed to publishing timely and transparent information on our funding and projects. In 2019, we signed up to the International Aid Transparency Initiative.
- [Partners: Ministries of health and governments](https://dndi.org/partnerships/ministries-health-and-governments/) - Find out about the ministries of health and governments that partner with us.
- [Partners: Healthcare providers](https://dndi.org/partnerships/healthcare-providers/) - Find out about the healthcare providers that partner with us.
- [Partners: Non-profit organizations, NGOs, and networks](https://dndi.org/partnerships/non-profit-organizations-and-networks/) - Find out about the non-profit organizations, NGOs, and networks that partner with us.
- [Partners: Universities and research centres](https://dndi.org/partnerships/universities-and-research-centres/) - Find out about the universities and research centres that partner with us.
- [Confronting the effects of climate change on human health](https://dndi.org/advocacy/confronting-climate-change/) - Developing innovative treatments for climate-sensitive diseases while reducing our carbon footprint
- [Partnering with us](https://dndi.org/partnerships/partnering-with-us/) - We work with with public and private partners around the world to accelerate the R&D process, prioritizing the urgent treatment needs of neglected patients.
- [Our partners](https://dndi.org/partnerships/industry-partners/) - Find out about the industry partners and service providers that partner with us.
- [Thank you for your donation!](https://dndi.org/thank-you/) - Thank you for your generosity. Your gift supports our efforts to develop urgently needed treatments for neglected patients. If you wish to know more about DNDi’s activities and projects please subscribe to our eNews or follow us on social media!
- [Friends of DNDi](https://dndi.org/our-people/friends-of-dndi/) - Friends of DNDi recognizes select individuals who support DNDi’s mission and vision by engaging global influencers, policymakers and supporters to help DNDi succeed in reaching its objectives.
- [DNDi worldwide](https://dndi.org/dndi-worldwide/) - DNDi has eight offices around the world: in Geneva, Kinshasa, Kuala Lumpur, Nairobi, New Delhi, New York, Rio de Janeiro, and Tokyo.
- [Recruitment process](https://dndi.org/work-with-us/recruitment-process/) - We ensure equal opportunities for all candidates during the recruitment process.
- [Job opportunities](https://dndi.org/work-with-us/job-opportunities/) - Join us in our efforts to develop safe, effective affordable treatments for diseases affecting some of the world’s poorest and most neglected communities.
- [The quest to eliminate neglected diseases](https://dndi.org/about/annual-reports/annual-report-2023/the-quest-to-eliminate-neglected-diseases/) - Read highlights of DNDi’s progress and work with partners in our 2023 Annual Report.
- [Confronting the neglect of women and children in R&D​](https://dndi.org/about/annual-reports/annual-report-2023/confronting-the-double-neglect-of-women-and-children/) - Read highlights of DNDi’s progress and work with partners in our 2023 Annual Report.
- [Responding to the climate crisis](https://dndi.org/about/annual-reports/annual-report-2023/responding-to-the-climate-crisis/) - Read highlights of DNDi’s progress and work with partners in our 2023 Annual Report.
- [Preparing for future pandemics](https://dndi.org/about/annual-reports/annual-report-2023/preparing-for-future-pandemics/) - Read highlights of DNDi’s progress and work with partners in our 2023 Annual Report.
- [Foreword](https://dndi.org/about/annual-reports/annual-report-2023/foreword/) - Message from Dr Marie-Paule Kieny, Chair of the Board of Directors and Dr Luis Pizarro, Executive Director.
- [Annual Report 2022](https://dndi.org/about/annual-reports/annual-report-2022/) - Browse our interactive Annual Report to learn more about how we're innovating together for the most neglected.
- [Annual reports](https://dndi.org/about/annual-reports/) - We have 20 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review.
- [Our grants](https://dndi.org/about/donors/our-grants/) - Our grants Our grants Thank you to our donors!
- [Pro-access policies for intellectual property and licensing](https://dndi.org/advocacy/pro-access-policies-intellectual-property-licensing/) - DNDi’s IP Policy addresses the barriers to innovation and equitable access by basing itself on two guiding principles that inform all contract negotiations.
- [Clinical trial protocol synopses](https://dndi.org/research-and-development/clinical-trials/clinical-trial-protocol-synopses/) - DNDi works with global research partners to evaluate new and improved medicines and treatment regimens. This enables us to deliver safe, affordable treatments.
- [Test](https://dndi.org/test/)
- [Advocacy](https://dndi.org/advocacy/) - Since our inception in 2003, DNDi has advocated for public responsibility and public policies required to meet the medical needs of the most neglected patients.
- [Our R&D portfolio for pandemic preparedness](https://dndi.org/diseases/pandemic-preparedness/projects/) - Using our experience in non-profit drug development and our partnerships with medical research institutions worldwide to prepare for future viral pandemics.
- [Press](https://dndi.org/press/) - DNDi’s media team welcomes inquiries from journalists, academia, and the general public. You can contact us at media@dndi.org. Would you like to receive our news and press releases in your inbox as soon as they are published? Please send us an email and we will add you to our media directory.
- [Podcasts, radio & TV](https://dndi.org/press/podcasts-radio-tv/)
- [Diseases](https://dndi.org/diseases/) - We are working on over 48 research projects for Chagas, leishmaniasis, sleeping sickness, filaria, mycetoma, paediatric HIV, and hepatitis C.
- [Harnessing AI & new technologies for pharmaceutical R&D](https://dndi.org/advocacy/ai-and-new-technologies-for-pharmaceutical-rd/) - DNDi is committed to employing new technologies to improve the efficiency and accelerate the pace of the R&D process, including AI-driven drug discovery tools.
- [Annual Report 2021](https://dndi.org/about/annual-reports/annual-report-2021/) - Browse our interactive Annual Report to learn more about the strides our partnerships are making for neglected patients.
- [2022 Asia highlights](https://dndi.org/about/annual-reports/annual-report-2022/2022-asia-highlights/) - Take a tour of highlights of the year from our teams and partners in Asia.
- [2022 Latin America highlights](https://dndi.org/about/annual-reports/annual-report-2022/2022-latin-america-highlights/) - Take a tour of highlights of the year from our teams and partners in Latin America.
- [Foreword](https://dndi.org/about/annual-reports/annual-report-2022/foreword/) - Message from Dr Marie-Paule Kieny, Chair of the Board of Directors & Dr Luis Pizarro, Executive Director.
- [2022 Africa highlights](https://dndi.org/about/annual-reports/annual-report-2022/2022-africa-highlights/) - Take a tour of highlights of the year from our teams and partners in Africa.
- [Our leishmaniasis partners](https://dndi.org/partnerships/leishmaniasis-partners/) - Our leishmaniasis partners Our leishmaniasis partners We're deeply grateful to the more than 250 R&D partners that have propelled our leishmaniasis programme since 2003. AbbVie, USA Academic Medical Center in Amsterdam, The Netherlands Accelera, Italy Addis Ababa University, Ethiopia Advinus Therapeutics Ltd., India Amatsi Aquitaine (formerly Bertin Pharma), France Amudat Hospital, Uganda Aptuit, Italy Arba Minch Hospital, Ethiopia Armauer Hansen Research Institute (AHRI), EthiopiaAstellas
- [Completed projects](https://dndi.org/research-and-development/portfolio/completed-projects/) - Completed projects Loading… Project portfolio We are working on over 40 research projects, including more than 20 new chemical entities. SEE PORTFOLIO
- [Transparency of R&D costs](https://dndi.org/advocacy/transparency-rd-costs/) - DNDi views R&D cost transparency as important for any institution that benefits from public and philanthropic support for the development of health tools.
- [Drug discovery](https://dndi.org/research-development/drug-discovery/) - DNDi invests in bringing all-new treatments through the R&D pipeline, by repurposing or modifying drugs and by developing entirely new chemical entities.
- [Translational research](https://dndi.org/research-development/translational-research/) - The translational research stage of R&D takes promising drug candidates from drug discovery to early clinical development.
- [Events](https://dndi.org/events/) - Events Events Loading… 1 2 … 34 ›
- [Our R&D portfolio for cryptococcal meningitis](https://dndi.org/diseases/cryptococcal-meningitis/projects-achievements/) - Our aim is to facilitate the scale-up of key medicines in selected, trailblazer African low- and middle-income countries through a comprehensive action plan.
- [Innovating for children's health](https://dndi.org/about/annual-reports/annual-report-2021/innovating-for-childrens-health/) - At DNDi, we believe that decisive action and broad-based collaboration on access and availability of paediatric medicines are central to achieving the 2030 health targets of the UN Sustainable Development Goals.
- [Foreword](https://dndi.org/about/annual-reports/annual-report-2021/foreword/) - Message from Dr Marie-Paule Kieny, Chair of the Board of Directors & Dr Bernard Pécoul, Executive Director.
- [2021 Latin America highlights](https://dndi.org/about/annual-reports/annual-report-2021/2021-latin-america-highlights/) - Take a tour of highlights of the year from our teams and partners in Latin America.
- [2021 Asia highlights](https://dndi.org/about/annual-reports/annual-report-2021/2021-asia-highlights/) - Take a tour of highlights of the year from our teams and partners in Asia.
- [2021 Africa highlights](https://dndi.org/about/annual-reports/annual-report-2021/2021-africa-highlights/) - Take a tour of highlights of the year from our teams and partners in Africa.
- [Harnessing AI and new technologies to meet neglected patients' needs](https://dndi.org/about/annual-reports/annual-report-2021/harnessing-ai-and-new-technologies-to-meet-neglected-patients-needs/) - Digitalization, machine learning, artificial intelligence, and new technologies and platforms are bringing transformational benefits to the field of medicine. We are working to ensure these extend to the most neglected.
- [Confronting climate-sensitive diseases and reducing our carbon footprint](https://dndi.org/about/annual-reports/annual-report-2021/confronting-climate-sensitive-diseases-and-reducing-our-carbon-footprint/) - In 2021, DNDi developed a four-pronged roadmap on health, climate, and the environment in response to four cross-cutting priorities, which we commit to address in our 2021-2028 Strategic Plan.
- [Advancing gender equity and gender-responsive R&D](https://dndi.org/about/annual-reports/annual-report-2021/advancing-gender-equity-and-gender-responsive-rd/) - Despite representing half of the world’s population, women are a neglected population when it comes to drug development. Women are often excluded from clinical trials, resulting in a lack of data, especially data concerning pregnant or breastfeeding women.
- [Annual Report 2020](https://dndi.org/about/annual-reports/annual-report-2020/) - Browse our interactive Annual Report to learn more about the strides our partnerships are making for neglected patients.
- [Symptoms, transmission, and current treatments for cryptococcal meningitis](https://dndi.org/diseases/cryptococcal-meningitis/facts/) - Cryptococcal meningitis is a fungal infection. It is a major cause of illness and death in people with advanced HIV disease, whose impaired immune system makes them more likely to get this infection.
- [## CTAs ##](https://dndi.org/blocks/)
- [Informe anual del 2020](https://dndi.org/about/annual-reports/informe-anual-del-2020/) - Explora nuestro Informe Anual interactivo para obtener más informaciones sobre los avances que nuestras asociaciones están logrando para los pacientes desatendidos.
- [Relatório Anual 2020](https://dndi.org/about/annual-reports/relatorio-anual-2020/) - Nossas equipes e parceiros avançaram em mais de 40 projetos de P&D em 2020, incluindo 22 ensaios clínicos conduzidos em 83 centros localizados em 28 países. Confira nosso Relatório Anual para saber mais sobre os avanços que nossas parcerias estão trazendo para pacientes negligenciados.
- [TEST Regional page](https://dndi.org/test-regional-page/)
- [Social media](https://dndi.org/news-and-stories/social-media/) - Social media Social media Latest activity
- [News & resources](https://dndi.org/news-and-resources/) - News & resources Loading… All News Press releases Publications Scientific articles Statements Stories Videos Viewpoints 16 Apr 2021 15 Apr 2021 15 Apr 2021 The Lancet Gastroenterology and Hepatology 14 Apr 2021 14 Apr 2021 Memorias do Instituto Oswaldo Cruz 14 Apr 2021 Memorias do Instituto Oswaldo Cruz 14 Apr 2021 Memorias do Instituto Oswaldo
- [Test filters](https://dndi.org/test-filters/) - News In the media Press releases Publications Scientific articles Statements Stories Videos Viewpoints Apply filters Remove filters
- [* Demo map](https://dndi.org/demo-map/)
- [test search field](https://dndi.org/test-search-field/)
- [Target product profiles](https://dndi.org/research-and-development/target-product-profiles/) - As a prerequisite to building a portfolio strategy, the desired R&D outcome for each disease is defined as the target product profile (TPP). Each R&D project in the portfolio is selected, progressed, and managed according to well-defined decision matrices based on these TPPs.
- [News & stories](https://dndi.org/news-and-stories/) - News & stories News & stories News 30 Jul 2020 27 Jul 2020 23 Jul 2020 23 Jul 2020 see ALL Stories 1 Dec 2019 22 Jul 2019 2 May 2019 18 Jan 2019 see ALL Viewpoints 3 Apr 2020 26 Jan 2018 24 May 2017 15 Feb 2017 see ALL Statements 29 May 2020
- [Resources](https://dndi.org/resources/) - Resources Resources​ Scientific Articles 25 Aug 2020 RSC Medicinal Chemistry 19 Aug 2020 Expert Opinion on Drug Discovery 17 Aug 2020 PLOS Neglected Tropical Diseases 11 Aug 2020 Journal of Antimicrobial Chemotherapy see ALL Publications 26 Aug 2020 22 Jul 2020 29 Jun 2020 12 May 2020 see ALL Videos 28 Jul 2020 30 Oct
- [Test Inline Newsletter](https://dndi.org/test-inline-newsletter/) - Insert heading Insert paragraph text
- [Not Available](https://dndi.org/not-available/) - Whoops! We couldn’t find the page you were looking for.

## AE Global Templates

- [AE- related content project wide format with Project Phase label with featured](https://dndi.org/ae-related-content-projects-treatment-delivered-small-size/)
- [AE- People profile](https://dndi.org/ae-people-profile/)
- [AE- donor list](https://dndi.org/ae-donor-list-sr/)
- [AE-Clinical Trials](https://dndi.org/ae-clinical-trials/) - New benznidazole regimens
- [AE-testimonials](https://dndi.org/ae-testimonials/) - Fexinidazole is a true game-changer for sleeping sickness. If acoziborole, a single-dose treatment, is shown to be safe and effective, we’re hopeful it would provide national programmes an even better tool to help achieve global elimination goals.
- [AE- related content project wide format with Disease label with featured](https://dndi.org/?ae_global_templates=ae-related-content-projects-one-diseases-small-size)
- [AE Prizes Slider](https://dndi.org/?ae_global_templates=ae-prizes-slider) - Our prizes and awards Princess of Asturias Award for International Cooperation Prix Galien Africa Prince Mahidol Award Golan Christie Taglia Patient Impact Philanthropy Award Learn more
- [AE-related content modules(default)](https://dndi.org/?ae_global_templates=ae-related-content-modulesdefault)
- [AE- related content projects with project phase, featured and description (treatment delivered)](https://dndi.org/ae-related-content-projects-treatment-delivered/) - icon-treatments Treatment Delivered Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. icon-treatments Treatment Delivered Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [AE-People profile no photo](https://dndi.org/elementor-103978/)
- [AE-people profile event list](https://dndi.org/ae-people-profile-event-list/)
- [AE-funding list](https://dndi.org/funding-list/)
- [AE-partner list](https://dndi.org/ae-partner-list/)
- [AE- related content modules (scientific article)](https://dndi.org/?ae_global_templates=ae-related-content-modules-scientific-article)
- [AE-people profile news list](https://dndi.org/ae-people-profile-news-list/)
- [AE-Job Opportunity wide card](https://dndi.org/ae-job-opportunity-wide-card/)
- [AE- related content project wide format with Disease label](https://dndi.org/ae-template-project-wide-format-with-disease-label/)
- [AE- related content projects with diseases type, featured and description](https://dndi.org/?ae_global_templates=ae-related-content-modules-projects-module) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [AE- related content projects with featured and description(projects we're working on)](https://dndi.org/?ae_global_templates=related-content-projects-one-diseases) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [AE-related content modules(default)  original](https://dndi.org/?ae_global_templates=ae-related-content-modulesdefault-original) - Pods Embed Error: Pod not found.Pods Embed Error: Pod not found.
- [AE - Event cards](https://dndi.org/ae-event-cards/)
- [AE-related content modules(general news)](https://dndi.org/ae-related-content-modulesrelated-stories/)
- [AE-related content modules (publications)](https://dndi.org/ae-related-content-modules-publications/)
- [AE-More dndi Offices](https://dndi.org/ae-more-dndi-offices/)
- [AE- Project and Disease list](https://dndi.org/test-project/)
- [AE-partner list with project](https://dndi.org/ae-partner-list-with-project/)
- [AE-Requests for proposals](https://dndi.org/ae-requests-for-proposals/)
- [AE- hero-image project landing page](https://dndi.org/?ae_global_templates=ae-hero-image-project-landing-page)

## My Templates

- [Dengue Disease tab: Facts](https://dndi.org/?elementor_library=dengue-disease-tab-facts) - What is dengue? Dengue is caused by a virus that is mostly transmitted by the bite of female mosquitoes of the species Aedes aegypti. Dengue symptoms range from none to serious flu-like symptoms. A small proportion of people develop severe dengue, which can be fatal. There are four closely related dengue viruses, which are called
- [Dengue Disease Detail tab: Overview](https://dndi.org/?elementor_library=dengue-disease-detail-tab-overview) - We are partnering with dengue-endemic countries to find a safe, affordable, and effective treatment for dengue. Through this global collaboration we are working on joint projects to advance the pre-clinical development of new drug candidates and run clinical trials to test the most promising ones. Dengue is mostly spread by the bite of the Aeades aegypti mosquito. Some
- [RFP listing](https://dndi.org/?elementor_library=rfp-listing) - Current requests for proposals There are no requests for proposals at the moment. Request for proposals (RFP) from interior architecture and design firms to develop and implement the workplace layout for DNDi’s new office space in Geneva. Loading…
- [Annual and financial reports](https://dndi.org/?elementor_library=annual-and-financial-reports) - 2024 Annual Report DOWNLOAD PDF Browse online 2025 Financial Report DOWNLOAD PDF Previous Annual Reports Loading… 15 Jul 2025 11 Jul 2024 14 Jul 2023 15 Jul 2022 1 2 … 5 › DNDi Financial Reports Loading… 30 Jun 2026 27 Jun 2025 1 Jul 2024 27 Jun 2023 1 2 … 6 ›
- [Mycetoma Disease Detail tab: Overview](https://dndi.org/?elementor_library=mycetoma-disease-detail-tab-overview) - Global burden is unknown of mycetoma cases worldwide are fungal 0 % DOWNLOAD FACTSHEET SEE DISEASE FACTS ‘I got mycetoma 19 years ago after I was pricked by a thorn. Even after numerous treatments, eight surgeries, and finally an amputation of my leg, I don’t think I am healed.’ Alsadik Mohammed Musa Omer, Khartoum, Sudan
- [CL Disease Detail tab: Overview](https://dndi.org/?elementor_library=disease-detail-about-tab-cl) - We are advancing R&D for promising new patient-friendly treatments that are affordable, safe, and effective for both children and adults and helping to build and consolidate research capacity in the most affected countries. Cutaneous leishmaniasis is transmitted through the bite of sandflies that carry the Leishmania parasite. People affected by poverty, malnutrition, displacement, and poor housing conditions are
- [Pandemic Prep Disease tab: Overview](https://dndi.org/?elementor_library=pandemic-prep-disease-tab-overview) - We are combining our not-for-profit drug discovery and development experience and our collaborative, open-science model to help prepare for future pandemics. COVID-19 threw longstanding global health injustices into stark relief. Wealthy countries had access to advanced vaccines and treatments as soon as they were approved. In lower-income countries, hospitals and communities were left grasping for the most basic supplies. Today, the
- [_core global-style-dndi](https://dndi.org/?elementor_library=_core-global-style-dndi)
- [CL Disease tab: Facts](https://dndi.org/?elementor_library=cl-disease-tab-facts) - What is cutaneous leishmaniasis? Cutaneous leishmaniasis is the most common form of leishmaniasis. It is caused by over 15 different species of the protozoan parasite Leishmania, transmitted by the bites of infected female sandflies. Although cutaneous leishmaniasis is not life-threatening, it can have devastating effects – leaving lifelong scars, including on the face, that can cause acute social stigma, particularly
- [_core Events single page template](https://dndi.org/?elementor_library=_core-events-single-page-template) - Pods Embed Error: Pod not found. Other events Loading… See all Stay connected Get our latest news, personal stories, research articles, and job opportunities.
- [_core In the Media single template {old version}](https://dndi.org/?elementor_library=_core-in-the-media-single-template) - Pods Embed Error: Pod not found. read the article Pods Embed Error: Pod not found. Read, watch, share Loading… 31 Mar 2026 26 Mar 2026 4 Mar 2026 VIEW ALL Speak out Please help us raise awareness by sharing this story.
- [_core News single page template](https://dndi.org/?elementor_library=_core-news-single-page-template) - Pods Embed Error: Pod not found. Home Pods Embed Error: Pod not found. by Kratz JM, Gonçalves KR, Romera LMD, Moraes CB, Bittencourt-Cunha P, Schenkman S, Chatelain E, Sosa-Estani S. Memorias do Instituto Oswaldo Cruz 2021; 116: e200501. doi: 10.1590/0074-02760200501 Summary: There is an urgent need for safe, effective, and accessible new treatments for Chagas
- [_core Social Sharing Buttons](https://dndi.org/?elementor_library=_core-social-sharing-buttons)
- [_core Default Footer](https://dndi.org/?elementor_library=default-footer) - Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f International non-profit developing safe, effective, and affordable treatments for the most neglected patients. Learn more Diseases Neglected tropical diseases R&D portfolio Policy advocacy Get in touch Our offices Contact us Integrity Line Support us Donate Subscribe to eNews Work with us Join research networks Jobs RFPs Terms of Use
- [Chagas Disease tab: Facts](https://dndi.org/?elementor_library=chagas-disease-tab-facts) - What is Chagas disease? Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening disease caused by the parasite Trypanosoma cruzi. It is most commonly transmitted by biting insects known as ‘kissing bugs’ that are infected with the parasite. It can also be passed from mother to child during pregnancy and childbirth. As people typically show
- [Chagas Disease Detail tab: Overview](https://dndi.org/?elementor_library=chagas-disease-detail-tab-overview) - We developed the first-ever treatment for children and established a research network of over 400 people representing 150 organizations on three continents to advance new treatments and improve patients’ lives. Our teams are now working to develop safer, more effective medicines and to break down barriers to testing and treatment. There are only two drugs
- [_core Default Header](https://dndi.org/?elementor_library=default-header)
- [River Blindness Disease tab: Facts](https://dndi.org/?elementor_library=filaria-disease-tab-facts) - What are filarial diseases? Filarial diseases are caused by parasitic worms that are transmitted by the bite of blood-feeding insects. This debilitating group of diseases includes river blindness and lymphatic filariasis (commonly known as elephantiasis). What is river blindness? Onchocerciasis, commonly known as river blindness, is a filarial disease caused by the parasitic nematode worm
- [River Blindness Detail tab: Overview](https://dndi.org/?elementor_library=filaria-disease-detail-tab-overview) - With a portfolio of four R&D projects, we are advancing the development of new drug candidates to develop a safe, effective, field-adapted treatment for river blindness. Filarial diseases, including river blindness and lymphatic filariasis, are a debilitating group of diseases caused by parasitic worms transmitted by the bite of blood-feeding insects. People are infected with river blindness
- [Crypto Disease Detail tab: Overview](https://dndi.org/?elementor_library=crypto-disease-detail-tab-overview) - We are building partnerships to make treatment more widely available and developing an easier to use treatment. Together with partners, we are mobilising support for life-saving treatments to reach more patients in African countries. Cryptococcal meningitis is a devastating fungal infection. It is caused by the fungus cryptococcus neoformans that is often found in soil and bird droppings.
- [_page donors public](https://dndi.org/?elementor_library=_page-donors-public) - Loading…
- [Dengue: Project & Achievements](https://dndi.org/?elementor_library=dengue-project-achievements) - What we have achieved We are bringing together partners in dengue-endemic countries to find urgently needed treatments for dengue. Loading… What we’re doing for people with dengue Together with our partners, we have started preclinical studies and will be starting clinical trials aiming to deliver an affordable and accessible treatment within five years. We are
- [_global Featured Diseases Grid](https://dndi.org/?elementor_library=other-modules-disease-grid) - Making medical history for neglected patients We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them VIEW ALL DISEASES
- [Lymphatic filariasis Disease tab: Facts](https://dndi.org/?elementor_library=lymphatic-filariasis-disease-tab-facts) - What is lymphatic filariasis? Lymphatic filariasis – also called elephantiasis – is caused by parasitic worms spread by the bites of infected mosquitoes. The larvae migrate to the lymphatic vessels, where they mature and reproduce. Over time, adult filarial worms trigger inflammation in the lymphatic system, causing damage to lymphatic vessels, even in individuals who
- [Lymphatic Filariasis: Google Ads Landing Page](https://dndi.org/?elementor_library=lymphatic-filariasis-google-ads-landing-page) - What is lymphatic filariasis? Lymphatic filariasis – also called elephantiasis – is caused by parasitic worms spread by the bites of infected mosquitoes. The larvae migrate to the lymphatic vessels, where they mature and reproduce. Over time, adult filarial worms trigger inflammation in the lymphatic system, causing damage to lymphatic vessels, even in individuals who
- [Schisto Disease tab: Facts](https://dndi.org/?elementor_library=schisto-disease-tab-facts) - What is schistosomiasis? Also known as bilharzia or snail fever, schistosomiasis is a disease caused by Schistosoma parasitic worms that spread via contaminated freshwater sources, such as rivers, ponds, lakes, and streams. There are different forms of schistosomiasis, depending on which body system is most affected. The symptoms of schistosomiasis vary depending on the species
- [Schisto: Google Ads landing page](https://dndi.org/?elementor_library=schisto-google-ads-landing-page) - What is schistosomiasis? Also known as bilharzia or snail fever, schistosomiasis is a disease caused by Schistosoma parasitic worms that spread via contaminated freshwater sources, such as rivers, ponds, lakes, and streams. There are different forms of schistosomiasis, depending on which body system is most affected. The symptoms of schistosomiasis vary depending on the species
- [Evidence for impact - list of projects](https://dndi.org/?elementor_library=evidence-for-impact-list-of-projects) - Projects Loading… see all projects Read, watch, share Loading… filter by ALL In the media Scientific articles 17 Jul 2025 MIT Technology Review 7 May 2024 eBioMedicine 27 Nov 2023 PLOS Computational Biology see ALL
- [Mycetoma Disease tab: Projects & Achievements](https://dndi.org/?elementor_library=mycetoma-disease-tab-projects-achievements) - What we have achieved We are bringing much needed attention to mycetoma to help end the neglect of people with the disease. Advocating for one of the world’s most neglected diseases Mycetoma was added to WHO’s official list of neglected tropical diseases in 2016. We also endorsed a ‘Call for Action’ to accelerate global efforts to address
- [Schisto Detail tab: Overview](https://dndi.org/?elementor_library=schisto-detail-tab-overview-2) - We are leveraging our partnerships and experience in drug discovery and development to identify and deliver safe, effective, field-adapted treatments to end suffering from schistosomiasis and help eliminate the disease as a public health problem. Also known as bilharzia or snail fever, schistosomiasis is a water-borne, parasitic disease caused by tiny blood-dwelling worms. People can become infected with schistosomiasis when they come into contact with contaminated water. For children, chronic
- [_core Non R&D Project objective](https://dndi.org/?elementor_library=_core-non-rd-project-objective) - objective project status project start
- [_global Donation patient photo](https://dndi.org/?elementor_library=_global-donate-now-tout) - Help neglected patients To date, we have delivered fourteen new treatments, saving millions of lives. Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. GIVE NOW
- [HAT Disease tab: Projects & Achievements](https://dndi.org/?elementor_library=hat-disease-tab-projects-achievements) - What we have achieved We have revolutionized the treatment of sleeping sickness, replacing toxic, cumbersome medicines with two simple all-oral cures. Loading… What we are doing for people living with sleeping sickness We are working to transform treatment for sleeping sickness by testing simplified test-and-treat strategies to bring treatment closer to communities. Through the DNDi-supported
- [HAT Disease tab: Facts](https://dndi.org/?elementor_library=hat-disease-tab-facts) - What is sleeping sickness? Sleeping sickness, or human African trypanosomiasis, is a life-threatening disease caused by related parasite strains, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, transmitted by the tsetse fly. People with early-stage sleeping sickness often are not diagnosed. If not treated, the parasite crosses the blood-brain barrier and invades the central nervous system causing advanced
- [_page section reg and access](https://dndi.org/?elementor_library=_page-section-reg-and-access) - Our registration & access projects Loading… SEE ALL PROJECTS Read, watch, share Loading… filter by All News Press releases Publications Scientific articles Stories Videos 27 Feb 2026 30 Jan 2026 28 Jan 2026 22 Jan 2026 PLOS Neglected Tropical Diseases see ALL
- [_core Featured Content: 3 touts](https://dndi.org/?elementor_library=highlight-keythemes) - Since 2003, the Drugs for Neglected Diseases initiative has developed 14 treatments for 6 deadly diseases, saving millions of lives. We innovate to save lives We develop urgently needed treatments for neglected patients and work to ensure they’re affordable, available, and adapted to the communities who need them our research We foster sustainable solutions We
- [_global Donation orange banner](https://dndi.org/?elementor_library=_global-donation-orange-banner) - Help neglected patients To date, we have delivered fourteen new treatments, saving millions of lives. Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. GIVE NOW
- [_homepage featured: Acoziborole EMA](https://dndi.org/?elementor_library=_homepage-featured-acoziborole-ema)
- [Treatments delivered timeline](https://dndi.org/?elementor_library=treatments-achieved-timeline) - Treatments delivered 2026 Acoziborole A paradigm-shifting, single-dose cure for T.b. gambiense Partnership with Sanofi, the HAT Platform, and national control programmes. Learn more 2023 Fexinidazole for T.b. rhodesiense sleeping sickness Safe and effective oral cure for acute form of sleeping sickness Partnership with Sanofi and the HAT-r-ACC consortium Learn more 2022 New recommendations for treating
- [HAT Disease Detail tab: Overview](https://dndi.org/?elementor_library=hat-disease-detail-tab-overview) - We revolutionized the treatment of sleeping sickness with two simple, all-oral cures to replace toxic, cumbersome medicines. We are now advancing studies that could enable simplified test-and-treat strategies to bring treatment closer to affected communities and boost efforts to achieve sustainable elimination. Caused by parasites transmitted by the tsetse fly, people develop sleeping sickness (human African
- [Clinical trials: Projects block and below](https://dndi.org/?elementor_library=clinical-trials-projects-block-and-below) - Clinical trial data transparency DNDi recognizes the value to researchers in public health, and other actors, of sharing and disseminating our clinical data. Sharing responsibly can contribute to knowledge for the improvement of the lives of neglected patients whose needs are often overlooked as research priorities. We are committed to sharing our clinical trial data
- [_Home image tout featured: WorldNTDDay 2026](https://dndi.org/?elementor_library=_home-worldntdday-2026)
- [_page NTDs only NTDs Diseases Grid](https://dndi.org/?elementor_library=_page-ntds-only-ntds-diseases-grid) - Neglected tropical diseases researched by DNDi DNDi is working to develop new treatments for 8 neglected tropical diseases: Chagas disease, dengue, cutaneous and visceral leishmaniasis, mycetoma, sleeping sickness, and parasitic worms which include lymphatic filariasis, onchocerciasis (river blindness), and schistosomiasis. Our portfolio also includes other neglected diseases and diseases where medical innovation for specific populations
- [Parasitic worms: Overview](https://dndi.org/?elementor_library=parasitic-worms-overview) - Caused by parasitic worms and most common in tropical and subtropical regions, river blindness, lymphatic filariasis, and schistosomiasis affect millions of people worldwide. They take their greatest toll on people affected by poverty, malnutrition, and poor sanitation and housing – and can cause debilitating illness, social exclusion, long-term disability and, in severe cases, death. There are no cures for neglected parasitic worm diseases. Current strategies to control
- [global Portfolio tout](https://dndi.org/?elementor_library=global-portfolio-tout) - We are committed to developing safe, effective, and affordable treatments for people with neglected diseases and neglected patients. Together with our partners, we are working on over 40 projects, including 21 focused on identifying or developing new chemical entities. We are also running 16 clinical trials. Download R&D Portfolio December 2025
- [Drug Discovery: stats block & below](https://dndi.org/?elementor_library=drug-discovery-stat-block) - compounds screened to date > 0 of compounds screened were accessed free-of-charge through partnerships 0 % projects focused on identifying or developing new chemical entities 0 Screening DNDi accesses compounds either free of charge, through collaborations with pharmaceutical companies, private and public research institutions, and product development partnerships, or by purchasing them from chemical vendors.
- [Pandemic Prep Disease tab: Projects](https://dndi.org/?elementor_library=covid-disease-tab-projects) - What we are doing for pandemic preparedness In the complex field of drug discovery for diseases of pandemic potential, our teams and partners are united by a common goal: placing on humanity’s shelf a collection of potential broad-spectrum antiviral drugs that will be ready for clinical evaluation and scale-up manufacturing to confront new pandemics, and which
- [CL: Google Ads Landing page](https://dndi.org/?elementor_library=cl-google-ads-landing-page) - What is cutaneous leishmaniasis? Cutaneous leishmaniasis is the most common form of leishmaniasis. It is caused by over 15 different species of the protozoan parasite Leishmania, transmitted by the bites of infected female sandflies. Although cutaneous leishmaniasis is not life-threatening, it can have devastating effects – leaving lifelong scars, including on the face, that can cause acute social stigma, particularly
- [VL: Google Ads Landing page](https://dndi.org/?elementor_library=vl-google-ads-landing-page) - What is visceral leishmaniasis? Also known as kala-azar, visceral leishmaniasis is a life-threatening disease caused by Leishmania parasites which are transmitted by female sandflies. Visceral leishmaniasis causes fever, weight loss, spleen and liver enlargement, and, if not treated, death. Visceral leishmaniasis has strong links to poverty, taking its heaviest toll on people affected by malnutrition, poor housing,
- [VL Disease tab: Facts](https://dndi.org/?elementor_library=vl-disease-tab-facts) - What is visceral leishmaniasis? Also known as kala-azar, visceral leishmaniasis is a life-threatening disease caused by Leishmania parasites which are transmitted by female sandflies. Visceral leishmaniasis causes fever, weight loss, spleen and liver enlargement, and, if not treated, death. Visceral leishmaniasis has strong links to poverty, taking its heaviest toll on people affected by malnutrition, poor housing,
- [Research Consortiums](https://dndi.org/?elementor_library=research-consortiums) - 5FC HIV-Crypto Cryptococcal meningitis learn more ACOZI-KIDS Children with T.b. gambiense sleeping sickness learn more AfriKADIA Visceral leishmaniasis learn more eWHORM Worm infections (helminthiases) learn more FAME River blindness learn more FEX-g-HAT Access for T.b. gambiense sleeping sickness learn more HAT-r-ACC T.b. rhodesiense sleeping sickness learn more HELP Platform Filarial diseases learn more IVM-KIDS Paediatric
- [Lymphatic filariasis Detail tab: Overview](https://dndi.org/?elementor_library=lymphatic-filariasis-detail-tab-overview) - We are working to develop a safe, effective, affordable treatment to help eliminate lymphatic filariasis. Also known as elephantiasis due to the extreme swelling (lymphedema) that can result from the disease, lymphatic filariasis is caused by parasitic worms spread by the bites of infected mosquitoes. While people of all ages can get the disease, it’s most painful and disfiguring effects are only seen years
- [Schisto tab: Projects & Achievements](https://dndi.org/?elementor_library=schisto-tab-projects-achievements) - What we are doing for people with schistosomiasis We are working to identify a combination treatment using existing drugs to better treat female genital schistosomiasis. We also aim to develop at least one all-new treatment that is safe, affordable, field-adapted, and effective against both adult and juvenile worms. Loading… our r&d portfolio
- [Lymphatic filariasis tab: Projects & Achievements](https://dndi.org/?elementor_library=lymphatic-filariasis-tab-projects-achievements) - What we have achieved R&D progress in the development of a macrofilaricide (a treatment able to kill adult worms) could benefit all filarial diseases. After testing oxfendazole for river blindness and other filarial diseases as part of the eWHORM consortium, DNDi is supporting partners now working to test the drug against lymphatic filariasis. What we
- [_core Hero Image: Filarial Diseases tab(static)](https://dndi.org/?elementor_library=_core-hero-image-filarial-diseases-tabstatic) - River blindness River blindness
- [_core Hero Image: Disease detail](https://dndi.org/?elementor_library=hero-images-disease-detail-landing-page)
- [River Blindness tab: Projects & Achievements](https://dndi.org/?elementor_library=filaria-disease-tab-projects-achievements) - What we have achieved We have built a portfolio of four R&D projects for river blindness and are pursuing the pre-clinical development of drug candidates. What we are doing for people with river blindness We aim to complete development and register at least one new drug for river blindness. We are also seeking to identify
- [HCV Disease tab: Facts](https://dndi.org/?elementor_library=hcv-disease-tab-facts) - What is hepatitis C? Hepatitis C is a liver disease caused by the hepatitis C virus. Hepatitis C can cause a mild illness of a few weeks or develop into a serious, lifelong, chronic illness. It is a major cause of cancer and cirrhosis of the liver, and if not treated, it can be fatal.
- [HCV: Google Ads Landing page](https://dndi.org/?elementor_library=hcv-google-ads-landing-page) - What is hepatitis C? Hepatitis C is a liver disease caused by the hepatitis C virus. Hepatitis C can cause a mild illness of a few weeks or develop into a serious, lifelong, chronic illness. It is a major cause of cancer and cirrhosis of the liver, and if not treated, it can be fatal.
- [_global Connect and share orange banner](https://dndi.org/?elementor_library=_global-connect-and-share-orange-banner) - Connect and share Follow us on social media to stay updated and help us share the stories of neglected patients. Linkedin Instagram X-twitter Facebook Youtube EM PORTUGUÊS EN ESPAÑOL
- [_home Video Beni: Surviving Sleeping Sickness](https://dndi.org/?elementor_library=_home-video-beni-surviving-sleeping-sickness)
- [HCV Disease Detail tab: Overview](https://dndi.org/?elementor_library=hcv-disease-detail-tab-overview) - We have developed a simple-to-use, affordable cure and tested new strategies to link patients to lifesaving treatment and care. We are also working to foster the political will needed for wide-scale roll-out of test-and-treat strategies. Hepatitis C is caused by the blood-borne hepatitis C virus and can lead to chronic liver disease, cirrhosis, cancer, and, if
- [VL Disease Detail tab: Overview](https://dndi.org/?elementor_library=vl-disease-detail-tab-overview) - We delivered four new treatments using existing drugs to make treatment shorter, safer, and more effective. We are now working to revolutionize the standard of care, advancing an unprecedented portfolio of all-new potential drugs to treat people suffering from all forms of the disease. Visceral leishmaniasis – also known as kala-azar – causes fever, weight
- [_global Inline Newsletter Sign-up](https://dndi.org/?elementor_library=_global-inline-newsletter-sign-up) - Stay updated Get the latest news, science, and stories from our teams putting equity at the heart of medical innovation. SIGN UP ON LINKEDIN
- [Open Synthesis Network](https://dndi.org/?elementor_library=open-synthesis-network) - Project information More on the OSN current and historical projects. Project updates Project snapshots Assay Glossary Free, open source software for reading SDF files: Datawarrior Current projects LEISHMANIASIS OSN P7 Status: Hit series identified Goal: Identify lead compound(s) for in vivo proof of concept studies P7 project background P7 master target list: sdf / xls P7
- [Crypto: Google Ads Landing page](https://dndi.org/?elementor_library=crypto-google-ads-landing-page) - What is cryptococcal meningitis? Cryptococcal meningitis is a fungal infection caused by Cryptococcus neoformans, which is often found in bird droppings. If breathed in, the spores can multiply and spread from the lungs to the membranes that cover the brain or spinal cord, causing meningitis. Cryptococcal meningitis is rare in healthy people, but it is
- [Crypto Disease tab: Projects & Achievements](https://dndi.org/?elementor_library=crypto-disease-tab-projects-achievements) - What we have achieved We have joined a broad network of partner organizations in the End AIDS Action Group, AHD Alliance, and Improved Access to AHD Care and Treatment for HIV (IMPAACT4HIV) project consortium, advocating for better access to life-saving treatment combinations for people with cryptococcal meningitis and advanced HIV disease. Loading… What we are
- [Crypto Disease tab: Facts](https://dndi.org/?elementor_library=crypto-disease-tab-facts) - What is cryptococcal meningitis? Cryptococcal meningitis is a fungal infection caused by Cryptococcus neoformans, which is often found in bird droppings. If breathed in, the spores can multiply and spread from the lungs to the membranes that cover the brain or spinal cord, causing meningitis. Cryptococcal meningitis is rare in healthy people, but it is
- [Paed HIV Disease Detail tab: Overview](https://dndi.org/?elementor_library=disease-detail-tab-paed-hiv-overview) - We developed an easy-to-administer, strawberry-flavoured combination of four antiretroviral medicines to meet the needs of young children, who are at the highest risk of dying without treatment. This new treatment was approved in South Africa in 2022 – the first country globally to grant regulatory approval for the 4-in-1 – followed by approvals in Mali, Uganda,
- [Paed HIV Disease tab: Facts](https://dndi.org/?elementor_library=paed-hiv-disease-tab-facts) - What is HIV? The human immunodeficiency virus (HIV) is a virus that weakens the immune system, making the body less able to fight infections and cancers. Without treatment, HIV continues replicating within the body leading to an advanced stage of HIV infection called Acquired Immunodeficiency Syndrome (AIDS). At this stage, the body is very vulnerable
- [Paed HIV Disease tab: Projects & Achievements](https://dndi.org/?elementor_library=paed-hiv-disease-tab-projects-achievements) - What we have achieved Our research has helped countries replace older, difficult-to-use, and sometimes ineffective formulations and scale up new, optimum treatments for young children. Loading…
- [_home Video The Boy Who Beat the Sandfly](https://dndi.org/?elementor_library=_home-video-the-boy-who-beat-the-sandfly)
- [_core homepage: Hero header no gradient](https://dndi.org/?elementor_library=homepage-hero-header) - BEST SCIENCE FOR THE MOST NEGLECTED We develop life-saving medicines for people with neglected diseases around the world BEST SCIENCE FOR THE MOST NEGLECTED We develop lifesaving medicines for people with neglected diseases around the world
- [Mycetoma Disease tab: Facts](https://dndi.org/?elementor_library=mycetoma-disease-tab-facts) - What is mycetoma? Mycetoma is a chronic slow-growing infection that is either bacterial (actinomycetoma) or fungal (eumycetoma) The fungal form of mycetoma is a highly neglected disease that is not well understood or widely studied. Infection begins most often in the foot, probably after a cut or thorn prick allows bacteria or fungi to enter
- [Chagas Disease tab: Projects & Achievements](https://dndi.org/?elementor_library=chagas-disease-tab-projects-achievements) - What we have achieved We have been active in Chagas research and development, treatment access, and advocacy for more than two decades. Together with our research partners, we helped create the Chagas Clinical Research Platform, a network of over 400 members representing 150 organizations across three continents, to utilize and strengthen R&D capacity in endemic countries.
- [CL Disease tab: Projects & Achievements](https://dndi.org/?elementor_library=cl-disease-tab-projects-achievements) - What we have achieved Through collaborations with the pharmaceutical industry, biotechnology companies, academia, and other product development partnerships, we have identified several promising compounds that are now in different stages of development. We have also worked with our partners to improve on treatments using existing drugs and therapies. Our support for regional disease research platforms
- [_global What they say about us](https://dndi.org/?elementor_library=_global-what-they-say-about-us) - What they say about us See what our partners, donors, and friends say about how we’re delivering innovation for the most neglected. find out more
- [_core Full-width tout: DNDi Brochure](https://dndi.org/?elementor_library=_core-full-width-tout-dndi-brochure) - Our brochure Find out more about our mission to discover, develop, and deliver safe, effective, and affordable treatments for the most neglected patients. Download
- [Clinical Trials Listing](https://dndi.org/?elementor_library=clinical-trials-listing-2) - Browse our clinical trial protocol synopses Loading… All Chagas disease Cryptococcal meningitis Cutaneous leishmaniasis Filaria: river blindness Hepatitis C Mycetoma Paediatric HIV Pandemic Preparedness Sleeping sickness Visceral leishmaniasis Emodepside CpG-D35 (DNDI-2319) DNDI-6148 DNDI-0690 DNDI-0690 Emodepside DNDI-6899 (GSK899/DDD853651) 4-in-1 (ABC/3TC/LPV/r) Acoziborole Emodepside Fosravuconazole ANTICOV Acoziborole Acoziborole Ravidasvir + sofosbuvir LXE408 Novartis for CL LXE408 Novartis for
- [_home Image tout Featured – Hideyo Noguchi Africa Prize](https://dndi.org/?elementor_library=_home-image-tout-featured-hideyo-noguchi-africa-prize) - Hideyo Noguchi Africa Prize 2025 DNDi has been awarded the fifth Hideyo Noguchi Africa Prize in recognition of our work developing and delivering new treatments for neglected diseases in Africa. READ MORE SHARE THE NEWS DR LUIS PIZARRO’S ACCEPTANCE ADDRESS
- [event-filter](https://dndi.org/?elementor_library=event-filter-2) - filters Type & Disease Topic Location Date Range Type & Disease By Type news type News In the media Press releases Publications Scientific articles Statements Stories Videos Viewpoints By Disease diseases Antimicrobial resistance Chagas disease Pandemic Preparedness Cryptococcal meningitis Cutaneous leishmaniasis Dengue Filaria: river blindness Hepatitis C Malaria Mycetoma Paediatric HIV Sleeping sickness Visceral leishmaniasis
- [_core Hero Image: Lymphatic Filariasis tab(static)](https://dndi.org/?elementor_library=_core-hero-image-lymphatic-filariasis-tabstatic) - Lymphatic filariasis Lymphatic filariasis
- [_page donors charts](https://dndi.org/?elementor_library=_page-donors-charts) - Social mission ratio 2024 expenses Public and private funding 2004-2024 on total funding of EUR 881.8 million Donor funding 2004-2024 on total funding of EUR 881.8 million
- [Working at DNDi: stats and below](https://dndi.org/?elementor_library=working-at-dndi-stats-and-below) - employees > 0 nationalities 0 offices worldwide 0 As of January 2025
- [Partnerships: Stats](https://dndi.org/?elementor_library=partnerships-stats) - partners in nearly 50 countries > 0 of partner institutions are based in low- and middle-income countries 0 % full-time-equivalent positions outside DNDi supporting our research for neglected patients for every-full-time DNDi position 0 A worldwide footprint anchored in endemic countries Key statistics on our partnerships Partner institutions by country income group Partner institutions by
- [Clinical trials: stats block](https://dndi.org/?elementor_library=clinical-trials-stats-block) - in 7 diseases areas at 60 sites in 23 countries last year 0 clinical trials research networks to strengthen research capacity in Africa, Asia, and Latin America 0 patients enrolled in clinical trials at any given time > 0
- [_core Full-width Tout: illustration background Portfolio](https://dndi.org/?elementor_library=touts-example1-touts) - Project portfolio We are working on more than 40 research and treatment access projects, including 21 focused on identifying or developing new chemical entities. see portfolio
- [_core homepage: Hero Header Annual Report 2024](https://dndi.org/?elementor_library=_core-homepage-hero-header-annual-report-2024) - SOLIDARITY IN SCIENCE 2024 Annual Report BROWSE ONLINE DOWNLOAD REPORT SOLIDARITY IN SCIENCE 2024 Annual Report BROWSE ONLINE DOWNLOAD REPORT
- [AR24 - Highlight 5](https://dndi.org/?elementor_library=ar24-highlight-5) - Highlights Our commitment to innovation and equitable access for neglected populations Throughout 2024 – the mid-point of DNDi’s 2021-2028 Strategic Plan – our teams conducted a comprehensive mid-term review to take stock of our progress in the context of a rapidly evolving external environment and to evaluate the strategic and organizational changes necessary to ensure
- [AR24 - Highlight 4](https://dndi.org/?elementor_library=ar24-highlight-4) - Highlights Ensuring the fruits of scientific progress reach the most neglected Scientific progress during the COVID-19 pandemic delivered vaccines, diagnostics, and treatments at record speed, but solidarity faltered when it came to sharing those breakthroughs. The consequences for countries and communities shut out from timely access to new health tools was devastating. From our start, DNDi
- [AR24 - Highlight 3](https://dndi.org/?elementor_library=ar24-highlight-3) - Highlights Advancing science and equity to face surging threats Dengue infections have doubled year on year since 2021, and half of the world’s population is now at risk of the mosquito-borne climate-sensitive disease. Outbreaks in Latin America, South-East Asia, and Africa made 2024 dengue’s deadliest year on record – overwhelming health systems and causing widespread
- [AR24 - Highlight 2](https://dndi.org/?elementor_library=ar24-highlight-2) - Highlights Innovation to address the unmet needs of women and children Neglected tropical diseases (NTDs) affect over a billion people worldwide – cutting lives short, trapping families in poverty, and causing immeasurable anguish, disability, and stigma. Their impact is even more devastating for pregnant women and children, for whom treatments are frequently unavailable, unsuitable, or
- [AR24 - Highlight 1](https://dndi.org/?elementor_library=ar24-highlight-1) - Highlights How science and solidarity are ending neglected diseases The mangrove forests of Guinea provide a livelihood for hundreds of thousands of people along the coast of this small country, but they are also fertile breeding grounds for the tsetse fly, which can transmit sleeping sickness. Historically, Guinea was the country in West Africa most
- [AR24 - Foreword](https://dndi.org/?elementor_library=ar24-foreword) - FOREWORD Our founding partners established DNDi more than two decades ago with a bold but simple shared conviction: medical innovation should serve everyone, everywhere. Our founding motto, ‘Best Science for the Most Neglected’, remains our calling. Dr Marie-Paule Kieny Chair of the Board of Directors Dr Luis Pizarro Executive Director Dr Marie-Paule Kieny Chair of
- [AR24 - Home](https://dndi.org/?elementor_library=ar24-home) - 2024 ANNUAL REPORT SOLIDARITY IN SCIENCE 2024 ANNUAL REPORT 2024 FINANCIAL REPORT Medical innovation should serve everyone, everywhere. Our founding motto, ‘Best Science for the Most Neglected’, remains our calling. Foreword 2024 will be remembered as a year of geopolitical turbulence that also saw the beginnings of drastic cuts to global health programmes and assaults
- [_home Image tout Featured – 2024 Annual Report](https://dndi.org/?elementor_library=_home-image-tout-featured-2024-annual-report) - 2024 Annual Report Solidarity in science unites our teams and partners and propels our progress. 2024 will be remembered as a year of geopolitical turbulence that also saw the beginnings of drastic cuts to global health programmes and assaults on international health cooperation. Amidst great worry and uncertainty, we are proud to share highlights of
- [press releases overview](https://dndi.org/?elementor_library=press-releases-overview) - Loading… Press releases Press Releases Translations 1 Jul 2025 13 Jun 2025 13 Jun 2025 5 Jun 2025 22 May 2025 13 May 2025 24 Apr 2025 23 Apr 2025 15 Apr 2025 18 Mar 2025 13 Feb 2025 10 Feb 2025 4 Feb 2025 30 Jan 2025 30 Jan 2025 31 Oct 2024 1
- [_core News Videos single template](https://dndi.org/?elementor_library=_core-news-with-newstype-no-featured-image-single-page-template) - Pods Embed Error: Pod not found. DNDi interventions at the 146th session of the WHO Executive Board: Agenda Item 13: Neglected tropical diseases DNDi welcomes the development of the NTD Roadmap, key to guide progress towards the SDG target of eliminating NTDs as a public health threat by 2030. We particularly welcome the inclusion of
- [_core News Scientific Article plain header template](https://dndi.org/?elementor_library=_core-news-scientific-article-plain-header-template) - Pods Embed Error: Pod not found. by Zijlstra E, Liberton N, Musa AM, te Slaa S, Wolff J. The American Journal of Tropical Medicine and Hygiene 2019, 0(0): 1-3. doi: 10.4269/ajtmh.19-0370 Summary: Post-kala-azar dermal leishmaniasis is a skin condition that may occur after successful treatment of visceral leishmaniasis. There are no reliable biomarkers, so response
- [_core Publications single page template, no Featured Image  Date](https://dndi.org/?elementor_library=_core-publications-single-page-template-no-featured-image-date) - DNDi interventions at the 146th session of the WHO Executive Board: Agenda Item 13: Neglected tropical diseases DNDi welcomes the development of the NTD Roadmap, key to guide progress towards the SDG target of eliminating NTDs as a public health threat by 2030. We particularly welcome the inclusion of all 20 diseases on the WHO
- [VL Disease tab: Projects & Achievements](https://dndi.org/?elementor_library=vl-disease-tab-projects-achievements) - What we have achieved We have delivered new treatments using existing drugs to make treatments shorter, safer and more effective. Loading… What we are doing for people with visceral leishmaniasis We are working to deliver better combination treatments and new drugs. Together with our partners, we have built an unprecedented portfolio of six new chemical
- [Project Related Clinical Trials](https://dndi.org/?elementor_library=project-related-clinical-trials) - Clinical trials documents
- [_home Video The Children of the Sierra](https://dndi.org/?elementor_library=_home-video-the-children-of-the-sierra)
- [_core Partners: listing](https://dndi.org/?elementor_library=other-modules-partners-list) - Partners & service providers Fungal Infections Study Forum (FISF), India Gaston Berger University, Senegal ​
- [News-filter](https://dndi.org/?elementor_library=news-filter) - filters Type & Disease Topic Location Date Range Type & Disease By Type news type Viewpoints Translations News In the media Press releases Publications Scientific articles Statements Stories Videos Viewpoints By Disease diseases Antimicrobial resistance Chagas disease Pandemic Preparedness Cryptococcal meningitis Cutaneous leishmaniasis Dengue Filaria: river blindness Hepatitis C Malaria Mycetoma Paediatric HIV Sleeping sickness
- [Scientific Articles archive template](https://dndi.org/?elementor_library=scientific-articles-archive-template) - Loading… 29 Apr 2025 The Lancet Global Health 29 Apr 2025 The Lancet Global Health 21 Apr 2025 PLOS Neglected Tropical Diseases 17 Apr 2025 The Lancet Child & Adolescent Health 31 Mar 2025 Journal of Medicinal Chemistry 11 Mar 2025 PLOS Neglected Tropical Diseases 25 Feb 2025 PLOS Neglected Tropical Diseases 10 Jan 2025
- [_core Funding:list](https://dndi.org/?elementor_library=_core-fundinglist) - Funding ​ ​
- [_core Project Related News](https://dndi.org/?elementor_library=_core-project-related-news)
- [_core Partners: listing without suppliers](https://dndi.org/?elementor_library=_core-partners-listing-for-platforms) - Partners Fungal Infections Study Forum (FISF), India Gaston Berger University, Senegal Loading…
- [Single Base Template](https://dndi.org/?elementor_library=elementor-single-page-121675)
- [Search_r](https://dndi.org/?elementor_library=search_r) - Search Results Search filter by Disease diseases Antimicrobial resistance Chagas disease Pandemic Preparedness Cryptococcal meningitis Cutaneous leishmaniasis Dengue Filaria: river blindness Hepatitis C Malaria Mycetoma Paediatric HIV Sleeping sickness Visceral leishmaniasis article type news type Viewpoints Translations News In the media Press releases Publications Scientific articles Statements Stories Videos Viewpoints event event type Event topic
- [_core News In the Media template with plain header](https://dndi.org/?elementor_library=_core-news-in-the-media-template-with-plain-header) - Pods Embed Error: Pod not found. Share on twitter Share on facebook Share on linkedin Share on email Share on print Click here to read the article Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Pods Embed Error: Pod not found. Read, watch, share Loading…
- [Prize slider](https://dndi.org/?elementor_library=prize-slider) - Our prizes and awards Hideyo Noguchi Africa Prize Princess of Asturias Award for International Cooperation Prince Mahidol Award Research!America Advocacy Award Learn more
- [Translational research: projects block & below](https://dndi.org/?elementor_library=translational-research-projects-block-below) - Our translational research projects Loading… see all projects Read, watch, share Loading… filter by ALL News Press releases Publications Scientific articles 4 Mar 2025 4 Mar 2025 4 Mar 2025 4 Mar 2025 see ALL
- [HCV Disease tab: Projects & Achievements](https://dndi.org/?elementor_library=hcv-disease-tab-projects-achievements) - What we have achieved We delivered a new treatment that is equal to the best hepatitis C drugs, at a fraction of the cost. Loading… What we are doing for people living with hepatitis C We are working to help foster an enabling environment for improved availability of hepatitis C diagnostics and treatments in low- and middle-income countries and supporting innovative ‘test-and-treat’ programmes in several
- [_core Project: What we are doing for.. (manual selection)](https://dndi.org/?elementor_library=related-content-modules-projects-module) - What we are doing We are committed to developing safe, effective, and affordable treatments for people with neglected tropical diseases and neglected patients. Here are some projects we are working on. Loading… Loading… see all projects
- [_core Hero Image: Schisto tab(static)](https://dndi.org/?elementor_library=_core-hero-image-schisto-tabstatic) - Schistosomiasis Schistosomiasis
- [_core Hero Image: Parasitic worms tab(static)](https://dndi.org/?elementor_library=_core-hero-image-parasitic-worms-tabstatic) - Parasitic worms Parasitic worms
- [Schisto tab: Facts](https://dndi.org/?elementor_library=schisto-tab-facts) - What is schistosomiasis? Text What is the impact of schistosomiasis? STATS What are current treatments for schistosomiasis? Text What new treatments for schistosomiasis are needed? Text What schistosomiasis treatments are we working on? Text Find out about our work developing treatments for schistosomiasis [ADD LINK]. How do you get schistosomiasis? Text What are the symptoms of
- [_home Video Guinea Film](https://dndi.org/?elementor_library=_home-video-guinea-film)
- [_home Image tout Featured – World NTD Day 2025](https://dndi.org/?elementor_library=_home-image-tout-featured-world-ntd-day-2025)
- [_core Hero R&D Portfolio header](https://dndi.org/?elementor_library=_core-hero-rd-portfolio-header) - Research & development portfolio Share on linkedin Share on twitter Share on facebook Share on email Share on print Research & development portfolio Share on linkedin Share on twitter Share on facebook Share on email Share on print
- [_core Project date and social share section](https://dndi.org/?elementor_library=_core-project-date-and-social-share-section) - Share on linkedin Share on twitter Share on facebook Share on email Share on print Share on linkedin Share on twitter Share on facebook Share on email Share on print
- [_core People Profile single template](https://dndi.org/?elementor_library=_core-single-people-profile) - Share on linkedin Share on twitter Share on facebook Share on email Share on print Pods Embed Error: Pod not found. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a
- [_core News, no Featured Image single page template {Used for statements}](https://dndi.org/?elementor_library=news-without-featured-image-single-template) - Pods Embed Error: Pod not found. Share on linkedin Share on twitter Share on facebook Share on email Share on print DNDi interventions at the 146th session of the WHO Executive Board: Agenda Item 13: Neglected tropical diseases DNDi welcomes the development of the NTD Roadmap, key to guide progress towards the SDG target of
- [Giving Tuesday campaign](https://dndi.org/?elementor_library=giving-tuesday-campaign-2) - Giving Tuesday 3X Match Extended Triple your impact to help DNDi advance and deliver more treatments for children and adults with neglected diseases before midnight tonight EST! Triple my gift
- [_home Video tout Treating a feverish planet](https://dndi.org/?elementor_library=_home-video-tout-treating-a-feverish-planet)
- [_core Link to current jobs](https://dndi.org/?elementor_library=_core-current-jobs) - Job opportunities There are no job opportunities available at this time. Please check back soon. Loading… ALL JOBS & RECRUITMENT PROCESS
- [Job vacancies listing](https://dndi.org/?elementor_library=job-vacancies-listing) - Current job opportunities There are no job opportunities available at this time. Please check back soon. Loading…
- [_disease_stats_chagas](https://dndi.org/?elementor_library=_disease_stats_chagas) - > 0 million people living with Chagas < 0 % people diagnosed 0 % people experience cardiac or other organ damage 0 million people are at risk DOWNLOAD FACTSHEET SEE DISEASE FACTS
- [_disease_stats_vl](https://dndi.org/?elementor_library=_disease_stats_vl) - 0 million people and more are at risk of visceral leishmaniasis across the globe 0 deaths in 2019 0 – 90,000 new cases each year more than 0 x The risk of developing active visceral leishmaniasis is more than 100 times greater in people living with HIV Download factsheet see disease facts
- [_disease_stats_paedhiv](https://dndi.org/?elementor_library=_disease_stats_paedhiv) - 0 % of children with HIV will die before their second birthday without treatment 0 million children are living with HIV 0 % children receive lifesaving treatment DOWNLOAD FACTSHEET SEE DISEASE FACTS
- [_disease_stats_mycetoma](https://dndi.org/?elementor_library=_disease_stats_mycetoma) - Global burden is unknown 0 % of mycetoma cases worldwide are fungal DOWNLOAD FACTSHEET SEE DISEASE FACTS
- [_disease_stats_hcv](https://dndi.org/?elementor_library=_disease_stats_hcv) - 0 million people have hepatitis C 0 % are unaware they are infected 0 % have had access to treatment > 0 people die every day DOWNLOAD FACTSHEET SEE DISEASE FACTS
- [_disease_stats_filaria](https://dndi.org/?elementor_library=_disease_stats_filaria) - million people are infected with river blindness 0 million people with vision loss 0 % infected people live in 31 African countries DOWNLOAD FACTSHEET SEE DISEASE FACTS
- [_disease_stats_dengue](https://dndi.org/?elementor_library=_disease_stats_dengue) - 0 billion people at risk 0 million infections per year 0 % increase in number of cases from 1990 to 2019 DOWNLOAD FACT SHEET SEE DISEASE FACTS
- [_disease_stats_cutaneous](https://dndi.org/?elementor_library=_disease_stats_cutaneous) - 0 people infected every year 0 countries are endemic 0 % effectiveness of current treatments can be as low as DOWNLOAD FACTSHEET SEE DISEASE FACTS
- [_disease_stats_cryptococal](https://dndi.org/?elementor_library=_disease_stats_cryptococal) - 0 people die from cryptococcal meningitis every year 0 deaths are in sub-Saharan Africa 0 % of affected people could survive if they receive the right treatment combinations DOWNLOAD FACTSHEET SEE DISEASE FACTS
- [_home Video tout Featured – Kissing Bug Doctors](https://dndi.org/?elementor_library=_home-video-tout-featured-kissing-bug-doctors)
- [20 years of DNDi](https://dndi.org/?elementor_library=20-years-of-dndi-2) - Our story: 20 years of DNDi Share on twitter Share on facebook Share on linkedin Share on email Share on print Our story: 20 years of DNDi Share on twitter Share on facebook Share on linkedin Share on email Share on print 20 years of making medicines for people, not profits Our founding partners established
- [_core homepage: Hero header Annual Report 2023](https://dndi.org/?elementor_library=_core-homepage-hero-header-annual-report-2023) - EQUITY AT THE HEART OF MEDICAL INNOVATION 2023 Annual Report BROWSE ONLINE DOWNLOAD REPORT EQUITY AT THE HEART OF MEDICAL INNOVATION 2023 Annual Report BROWSE ONLINE DOWNLOAD REPORT
- [AR 2023 - Pandemics](https://dndi.org/?elementor_library=ar-2023-pandemics) - Share on facebook Share on twitter Share on linkedin Share on email Share on print 2023 Highlights Preparing for future pandemics Driving research and advocacy for the benefit of all Share on facebook Share on twitter Share on linkedin Share on email Share on print The World Health Organization (WHO) declared an end to the
- [AR 2023 - Neglect](https://dndi.org/?elementor_library=ar-2023-neglect) - Share on facebook Share on twitter Share on linkedin Share on email Share on print 2023 Highlights Confronting the double neglect of women and children An R&D agenda to upend a harmful status quo Share on facebook Share on twitter Share on linkedin Share on email Share on print Chagas disease in Colombia. Dengue fever
- [AR 2023 - innovating](https://dndi.org/?elementor_library=ar-2023-innovating) - Share on facebook Share on twitter Share on linkedin Share on email Share on print 2023 Highlights The quest to eliminate neglected diseases From the first reported case to the very last Share on facebook Share on twitter Share on linkedin Share on email Share on print In 1827, a surgeon in what is today
- [AR 2023 - Foreword](https://dndi.org/?elementor_library=ar-2023-foreword) - Share on facebook Share on twitter Share on linkedin Share on email Share on print FOREWORD 2023 marked 20 years since our founding partners established DNDi, initiating an experiment in innovation and collaborative, not-for-profit pharmaceutical R&D centred on the needs of neglected patients. Dr Marie-Paule Kieny Chair of the Board of Directors Dr Luis Pizarro
- [AR 2023 - Climate](https://dndi.org/?elementor_library=ar-2023-climate) - Share on facebook Share on twitter Share on linkedin Share on email Share on print 2023 Highlights Responding to the climate crisis Innovation and advocacy for the most neglected Share on facebook Share on twitter Share on linkedin Share on email Share on print For the second time in just a few years, Brazil’s army
- [AR 2023 Voices Mobile](https://dndi.org/?elementor_library=ar-2023-voices-mobile) - Sleeping sickness Dr Westain Nyirenda Northern Malawi “T.b. rhodesiense sleeping sickness is a terrifying disease, killing quickly if untreated. A simpler, safer oral treatment will help us save many lives.” Learn about our progress Leishmaniasis Jorge Santa Fe de Antioquia, Colombia “There was one time they applied the injection right in the wound. And it
- [AR 2023](https://dndi.org/?elementor_library=ar-2023) - 2023 ANNUAL REPORT Equity at the heart of medical innovation 2023 ANNUAL REPORT 2023 FINANCIAL REPORT If there is a single highlight to look back on from 2023, it is the phenomenal power of partnership – the highlight of every one of our 20 years. Foreword 2023 marked 20 years since our founding partners established
- [_global How Donations Help stats](https://dndi.org/?elementor_library=_global-how-donations-help-stats) - How we use our funding We use the funds we receive to conduct life-saving research, build research networks, develop medicines, and advocate for neglected patients. 0 % general management 0 % social mission 0 % fundraising GIVE NOW OUR DONORS * 2023 financial year
- [search result](https://dndi.org/?elementor_library=search-result)
- [_home Image tout Featured – World NTD Day 2024](https://dndi.org/?elementor_library=_home-image-tout-featured-world-ntd-day-2023)
- [_core homepage: Hero header rHAT Fexi 2023](https://dndi.org/?elementor_library=_core-homepage-hero-header-rhat-fexi-2023) - NEW TREATMENT FOR ACUTE FORM OF SLEEPING SICKNESS The European Medicines Agency has adopted a positive scientific opinion of fexinidazole for treating T.b. rhodesiense sleeping sickness READ PRESS RELEASE DISCOVER THE PROJECT NEW TREATMENT FOR ACUTE FORM OF SLEEPING SICKNESS The European Medicines Agency has adopted a positive scientific opinion of fexinidazole for treating T.b.
- [Testimonials Archive Template](https://dndi.org/?elementor_library=testimonials-archive-template) - What they say about us What they say about us Loading… In the DRC, the treatment of NTDs over the past 17 years has been supported by DNDi in a broad partnership with the government and other donors. We urge governments, public and private funders around the world to continue to support research and development
- [_home Video tout Featured – Out of the Shadows](https://dndi.org/?elementor_library=_home-video-tout-featured-out-of-the-shadows)
- [_core Scientific Articles: all diseases](https://dndi.org/?elementor_library=related-content-modules-scientific-article) - Scientific articles Loading… 24 Oct 2023 BMJ Open 24 Oct 2023 Pan American Journal of Public Health 23 Oct 2023 Mycoses 27 Sep 2023 Frontiers in Tropical Diseases see all
- [Clinical-Trials-Listing](https://dndi.org/?elementor_library=clinical-trials-listing) - Loading… All Chagas disease Cryptococcal meningitis Cutaneous leishmaniasis Filaria: river blindness Hepatitis C Mycetoma Pandemic Preparedness Sleeping sickness Visceral leishmaniasis Miltefosine + thermotherapy for cutaneous leishmaniasis Ravidasvir + sofosbuvir Acoziborole Acoziborole Acoziborole Miltefosine + Paromomycin combination (Africa) LXE408 Novartis LXE408 Novartis Ravidasvir + sofosbuvir Fexinidazole for Chagas Emodepside Emodepside CpG-D35 (DNDI-2319) 5FC HIV-Crypto 5FC HIV-Crypto
- [loop for news filter](https://dndi.org/?elementor_library=loop-for-news-filter) - 5 Dec 2019 5 Dec 2019
- [20 years of DNDi](https://dndi.org/?elementor_library=20-years-of-dndi) - Our story Share on twitter Share on facebook Share on linkedin Share on email Share on print Our story Share on twitter Share on facebook Share on linkedin Share on email Share on print 20 years of making medicines for people, not profits Our founding partners established DNDi in 2003 in response to shocking neglect:
- [_home Image tout Featured – Princess Asturias](https://dndi.org/?elementor_library=_home-image-tout-featured-princess-asturias)
- [_homepage Princess of Asturias Award banner](https://dndi.org/?elementor_library=_homepage-princess-of-asturias-award-banner) - DNDI RECEIVES 2023 PRINCESS OF ASTURIAS AWARD The Princess of Asturias Award for International Cooperation gives much-needed visibility to millions of people neglected by policymakers and commercially driven pharmaceutical research DNDI RECEIVES 2023 PRINCESS OF ASTURIAS AWARD The Princess of Asturias Award for International Cooperation gives much-needed visibility to millions of people neglected by policymakers and
- [_home Image tout Featured – 20 Years](https://dndi.org/?elementor_library=_home-image-tout-featured-20-years)
- [_core Hero Image: COVID-19 tab(static)](https://dndi.org/?elementor_library=_core-hero-image-covid-19-tabstatic) - Pandemic preparedness Pandemic preparedness
- [Press Releases archive template](https://dndi.org/?elementor_library=press-releases-archive-template) - Loading… Press releases Press Releases Translations 31 Jul 2023 20 Jul 2023 5 Jul 2023 12 Apr 2023 7 Apr 2023 4 Apr 2023 30 Mar 2023 1 Mar 2023 2 Feb 2023 14 Dec 2022 1 Dec 2022 30 Nov 2022 15 Nov 2022 6 Oct 2022 29 Sep 2022 5 Sep 2022 1
- [In the Media archive template](https://dndi.org/?elementor_library=in-the-media-archive-template) - Loading… 29 Aug 2023 Nation Africa 29 Aug 2023 Cadena SER 24 Aug 2023 African Arguments 21 Aug 2023 Rukhmabai Initiatives 16 Aug 2023 Le Monde 5 Aug 2023 Free Malaysia Today 3 Aug 2023 British Medical Journal (BMJ) 1 Aug 2023 The Telegraph 1 Aug 2023 FDI Intelligence 28 Jul 2023 Fundación io 26
- [Podcasts, radio & TV](https://dndi.org/?elementor_library=podcasts-tv-and-radio) - Podcasts, radio & TV Podcasts, radio & TV Loading… ALL TV Radio Podcasts 29 Aug 2023 Cadena SER 21 Jul 2023 BFM 29 Jun 2023 Astro AWANI 28 Jun 2023 The World 24 Jun 2023 Telemadrid 15 Jun 2023 BFM 13 Jun 2023 La zone d’écoute 12 Jun 2023 University of Oxford Podcasts 7 Jun
- [CERCLE Founding members](https://dndi.org/?elementor_library=cercle-founding-members) - Founding members Drugs for Neglected Diseases initiative (DNDi), Switzerland Infectious Diseases Data Observatory (IDDO), UK Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand
- [related content modules( related stories, Filter bar #01)](https://dndi.org/?elementor_library=test-2) - Read, Watch, Share Loading… FILTER BY All News In the media Press releases Scientific articles Videos 31 Jul 2023 20 Jul 2023 11 Jul 2023 7 Jul 2023 VIEW ALL
- [_core Full-width Tout: orange background patients](https://dndi.org/?elementor_library=_core-full-width-tout-orange-background-patients) - Partnering for patients Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in nearly 50 countries. find out more
- [_core homepage: 2022 Annual Report](https://dndi.org/?elementor_library=_core-homepage-2022-annual-report)
- [AI & New Tech Related news](https://dndi.org/?elementor_library=ai-new-tech-related-news) - News & resources on AI & new technologies Loading… filter by ALL News In the media Press releases Publications 1 Jun 2023 Nature Medicine 10 Feb 2023 GlobalData 30 Jan 2023 ABC 2 Aug 2022 The Economist See all news
- [AR 2022 Voices Mobile](https://dndi.org/?elementor_library=ar-2022-voices-mobile) - Sleeping sickness François Masi Manimba, Democratic Republic of the Congo (DRC) ‘I was always agitated. I always wanted to fight with other children and ended up getting into fights at school. I no longer pick fights. I no longer feel like I used to when I had sleeping sickness.’ Learn about our progress Leishmaniasis Tekla
- [AR 2022 In numbers mobile - Finances](https://dndi.org/?elementor_library=ar-2022-in-numbers-mobile-finances) - Finances € 75.9 million in annual expenditure € 10.3 million in in-kind contributions and collaborative funding from partners 91% of expenditure on social mission to maximize impact for neglected patients
- [AR 2022 In numbers mobile - R&D Portfolio](https://dndi.org/?elementor_library=ar-2022-in-numbers-mobile-rd-portfolio) - R&D Portfolio 34 projects in our R&D portfolio, and an additional 12 projects in the treatment access phase 19 projects focused on identifying or developing new chemical entities
- [AR 2022 In numbers mobile - Sharing knowledge](https://dndi.org/?elementor_library=ar-2022-in-numbers-mobile-sharing-knowledge) - Sharing knowledge 50 peer-reviewed scientific articles on DNDi research 96% of peer-reviewed scientific articles published in open-access journals
- [AR 2022 In numbers mobile - Genderand diversity](https://dndi.org/?elementor_library=ar-2022-in-numbers-mobile-genderand-diversity) - Gender and diversity 52% of DNDi leadership positions held by women 70% of peer-reviewed scientific articles on DNDi research had at least one author from a partner institution in an endemic country 60% of peer-reviewed scientific articles had a female first or last author
- [AR 2022 In numbers mobile - Clinical trials](https://dndi.org/?elementor_library=ar-2022-in-numbers-mobile-clinical-trials) - Clinical trials 27 clinical trials in 8 disease areas, including 18 trials testing new chemical entities 86 clinical trial sites in 28 countries 3,242 patients enrolled in active DNDi clinical studies
- [AR 2022 In numbers mobile - Maximizing the partnership model](https://dndi.org/?elementor_library=ar-2022-in-numbers-mobile-maximizing-the-partnership-model) - Maximizing the partnership model 228 R&D partner institutions in nearly 50 countries 6:1 ratio of partner staff vs DNDi staff worldwide
- [AR 2022 In numbers mobile - Fostering sustainable solutions](https://dndi.org/?elementor_library=ar-2022-in-numbers-mobile-fostering-sustainable-solutions) - Fostering sustainable solutions 668 people trained to support clinical research in Africa, Asia, and Latin America 82% of all R&D partner staff are based in low and middle-income countries (LMICs) 5 research networks to strengthen research capacity in Africa, Asia, and Latin America
- [Platforms and Networks](https://dndi.org/?elementor_library=platforms-and-networks) - Chagas Platform Chagas disease learn more Dengue Alliance Dengue learn more HAT Platform Sleeping sickness learn more LEAP Platform Leishmaniasis learn more redeLEISH Network Leishmaniasis learn more
- [_core featured content: 3 touts 2 line](https://dndi.org/?elementor_library=_core-featured-content-3-touts-2-line) - Our not-for-profit R&D model follows six main principles Needs-driven We ensure all of our work is rooted in the medical needs of the people we serve – from defining the characteristics needed for new treatments to discovering and developing new drugs and ensuring they are accessible and affordable. our target product profiles Independent We maintain
- [_core Hero Image: Dengue tab(static) 2](https://dndi.org/?elementor_library=_core-hero-image-dengue-tabstatic-2) - Dengue Dengue
- [_core homepage: Princess of Asturias Award](https://dndi.org/?elementor_library=_core-homepage-princess-of-asturias-award)
- [_global Diseases Grid Virals](https://dndi.org/?elementor_library=_global-diseases-grid-virals) - Our research for neglected populations living with viral diseases We develop urgently needed treatments for neglected populations affected by viral diseases and ensure they’re affordable, available, and adapted to the communities who need them. Our portfolio also includes neglected tropical diseases that mostly occur in tropical climates and are caused by bacteria, viruses, fungi, parasites,
- [_global Diseases Grid NTDs](https://dndi.org/?elementor_library=_global-diseases-grid-ntds) - Our research for people living with neglected tropical diseases We develop urgently needed treatments for 6 neglected tropical diseases and ensure they’re affordable, available, and adapted to the communities who need them. Our portfolio also includes other neglected diseases and diseases where medical innovation for specific populations – such as children or people in low-
- [_home Video tout Homepage Featured – Hope for Leish 2022](https://dndi.org/?elementor_library=_home-video-tout-homepage-featured-hope-for-leish-2022)
- [Acozi-Kids Partners_1](https://dndi.org/?elementor_library=test-block) - Partners Drugs for Neglected Diseases initiative (DNDi), DRC and Switzerland Epicentre, France Institut de Recherche pour le Développement (IRD), France Institut National de Recherche Biomédicale (INRB), Democratic Republic of Congo Institute of Hygiene and Tropical Medicine (IHMT/NOVA), Nova University Lisbon, Portugal National HAT Control Programme of the Democratic Republic of Congo National HAT Control Programme
- [_global Inline Donate](https://dndi.org/?elementor_library=_global-inline-donate) - Donate now Your gift will help us develop life-saving treatments for people with neglected and other infectious diseases. Donate
- [Publications archive template](https://dndi.org/?elementor_library=publications-archive-template) - Our publications Our publications Loading… ALL Annual reports Financial reports Factsheets Disease briefs Newsletters Policy documents Regional brochures Strategic plans Other publications 22 Feb 2023 30 Sep 2022 29 Sep 2022 1 Aug 2022 31 Jul 2022 16 Jul 2022 16 Jul 2022 16 Jul 2022 16 Jul 2022 16 Jul 2022 16 Jul 2022
- [Gender News & Resources](https://dndi.org/?elementor_library=gender-news-resources) - News & resources on gender equity Loading… filter by ALL In the media Press releases Publications Scientific articles Statements Stories Viewpoints 8 Mar 2023 2 Feb 2023 3 Jan 2023 Missing Perspectives 1 Aug 2022 See all news
- [Climate News & Resources](https://dndi.org/?elementor_library=climate-news-resources) - News & resources on climate change Loading… filter by ALL News In the media Publications Scientific articles Statements Viewpoints 28 Feb 2023 20 Feb 2023 6 Jan 2023 The Telegraph 3 Jan 2023 Missing Perspectives See all news
- [Child Health News & Resources](https://dndi.org/?elementor_library=child-health-related-news-resources) - News & resources on children’s health Loading… filter by ALL News In the media Press releases Publications Scientific articles Statements Stories Videos 3 Mar 2023 22 Feb 2023 Nation Africa 23 Jan 2023 PLOS Neglected Tropical Diseases 19 Dec 2022 PLOS Neglected Tropical Diseases See all news
- [Dengue Alliance Partners](https://dndi.org/?elementor_library=dengue-alliance-partners) - Partners Drugs for Neglected Diseases initiative (DNDi), Switzerland Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand Ministry of Health, Malaysia Oswaldo Cruz Foundation (Fiocruz), Brazil Translational Health Science and Technology Institute (THSTI), India Universidade Federal de Minas Gerais (UFMG), Brazil
- [HEP C PACT Partners](https://dndi.org/?elementor_library=hep-c-pact-partners) - Partners Drugs for Neglected Diseases initiative (DNDi), Switzerland FIND, the global alliance for diagnostics, Switzerland Médecins Sans Frontières (MSF) Treatment Action Group (TAG), USA
- [LeishAccess Partners](https://dndi.org/?elementor_library=leishaccess-partners) - Partners Armauer Hansen Research Institute (AHRI), Ethiopia Drugs for Neglected Diseases initiative (DNDi), Kenya and Switzerland Epicentre, France FIND, the global alliance for diagnostics, Kenya and Switzerland Instituto de Salud Carlos III (ISCIII), Spain Institute of Endemic Diseases (IEND), Sudan Makerere University, Uganda Medecins Sans Frontières (MSF) Amsterdam, The Netherlands University of Gondar, Ethiopia
- [Fex-G-HAT Partners](https://dndi.org/?elementor_library=fex-g-hat-partners) - Partners Drugs for Neglected Diseases initiative (DNDi), DRC and Switzerland Institut de Recherche pour le Développement (IRD), France Institute of Tropical Medicine Antwerp, Belgium National HAT Control Programme of the Democratic Republic of Congo National HAT Control Programme of the Republic of Guinea
- [VL-INNO Partners](https://dndi.org/?elementor_library=vl-inno-partners) - Partners Drugs for Neglected Diseases initiative (DNDi), Switzerland FIND, the global alliance for diagnostics, Switzerland Institute of Tropical Medicine (ITM), Belgium Instituto de Salud Carlos III (ISCIII), Spain Kenya Medical Research Institute (KEMRI), Kenya Pharmetheus AB, Sweden Spotlab, Spain University of Gondar, Ethiopia University of York, United Kingdom
- [AfriKADIA partners_1](https://dndi.org/?elementor_library=afrikadia-partners_1) - Partners Academisch Medisch Centrum bij de Universiteit van Amsterdam, The Netherlands Drugs for Neglected Diseases initiative (DNDi), Kenya and Switzerland FIND, the global alliance for diagnostics, Switzerland Instituto de Salud Carlos III (ISCIII), Spain Kenya Medical Research Institute (KEMRI), Kenya London School of Hygiene and Tropical Medicine (LSHTM), UK Makerere University, Uganda Stichting Het Nederlands
- [Advocacy landing page](https://dndi.org/?elementor_library=advocacy-landing-page) - DNDi advocates for a sustainable global framework for R&D, including: A global body to identify R&D needs Globally agreed, public health-driven R&D priority-setting Coordination of R&D efforts to reduce duplication Sustainable financing for public health-driven R&D Globally agreed norms that guide R&D initiatives in a way that encourages collaboration over competition and ensures affordability of
- [_global Contact us](https://dndi.org/?elementor_library=_global-contact-us) - Contact us Do you have questions about collaborating with DNDi, comments about our work, or questions for our team? GET IN TOUCH
- [AI News & Resources](https://dndi.org/?elementor_library=ai-news-resources) - Related news & resources Loading… filter by ALL News In the media Press releases Publications Scientific articles Statements Stories Videos Viewpoints 16 Dec 2022 16 Dec 2022 Pharmaceutical Technology 13 Dec 2022 Telesud 6 Dec 2022 Nikkeii Business See all news
- [_core Stories](https://dndi.org/?elementor_library=_core-stories) - Read the stories of neglected patients Loading… 16 Dec 2022 21 Oct 2022 13 Oct 2022 13 Apr 2022 View all stories
- [VL/CL_FeaturedQuote_Voices of leishmaniasis](https://dndi.org/?elementor_library=vl-cl_featuredquote_voices-of-leishmaniasis) - ‘The fever is too much. The headache is too much. There’s pain all over. I was started on treatment and it was another hell.’ Luke Kanyang’areng’ was diagnosed with leishmaniasis 30 years ago. Today, he’s the nursing officer in charge of the same facility where his life was saved. His hope for leishmaniasis is to
- [searchfilterwidget](https://dndi.org/?elementor_library=search-widget-for-search-page)
- [_core Full-width tout: Black Global Networks](https://dndi.org/?elementor_library=_core-full-width-tout-black-global-networks) - Building capacity, uniting expertise Research platforms and consortiums that bring together researchers and strengthen research capacities in low- and middle-income countries are central to our virtual R&D model. find out more
- [COVID-19 News & resources](https://dndi.org/?elementor_library=covid-19-news-resources) - COVID-19 news & resources Loading… filter by ALL News Press releases Publications Scientific articles Statements Stories Videos Viewpoints 5 Oct 2022 Journal of Clinical Medicine 26 Sep 2022 Frontiers in Microbiology 4 Sep 2022 Expert Review of Clinical Pharmacology 19 Jul 2022 PLOS Global Public Health See all news
- [_core Diseases News & resources](https://dndi.org/?elementor_library=_core-diseases-news-resources) - Dengue news & resources Loading… filter by ALL News Press releases Publications Scientific articles Statements Stories Videos Viewpoints 15 Jul 2022 29 Apr 2022 20 Apr 2022 4 Apr 2022 See all news
- [Project Related News with title](https://dndi.org/?elementor_library=project-related-news-2) - Pods Embed Error: Pod not found.​
- [_page Diseases ALL Diseases Grid](https://dndi.org/?elementor_library=_page-diseases-all-diseases-grid) - Making medical history for neglected patients We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them. The disease areas we research include some of the least researched diseases, including neglected tropical diseases.
- [WorldLeish7 publications](https://dndi.org/?elementor_library=worldleish7-publications) - Publications Loading… 30 Mar 2021 Scientific articles Loading… 4 Jul 2022 Journal of Chromatography B 1 Jul 2022 Yakugaku Zasshi 7 Mar 2022 PLOS Neglected Tropical Diseases 3 Mar 2022 Journal of Chemical Education 11 Feb 2022 Clinical Infectious Diseases 17 Nov 2021 The Lancet Global Health 28 Oct 2021 Journal of Medicinal Chemistry 20
- [_core homepage: Hero header Annual Report 2021](https://dndi.org/?elementor_library=_core-homepage-hero-header-annual-report-2021) - UNLOCKING THE PROMISE OF MEDICAL INNOVATION FOR ALL 2021 Annual Report BROWSE ONLINE DOWNLOAD REPORT UNLOCKING THE PROMISE OF MEDICAL INNOVATION FOR ALL 2021 Annual Report BROWSE ONLINE DOWNLOAD REPORT
- [_global Newsletter Sign-up](https://dndi.org/?elementor_library=stay-updated-newsletter-signup) - Stay connected Get our latest news, personal stories, research articles, and job opportunities.
- [_core Hero Image: Dengue tab(static)](https://dndi.org/?elementor_library=_core-hero-image-dengue-tabstatic) - Dengue Dengue
- [ae tesitmonial template](https://dndi.org/?elementor_library=ae-tesitmonial-template)
- [_page Home Diseases Grid](https://dndi.org/?elementor_library=_page-home-diseases-grid) - Making medical history for neglected patients We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
- [news module: Tag AMR Press releases News Sci articles](https://dndi.org/?elementor_library=news-module-disease-amr-press-releases-news-sci-articles) - News & press releases Loading… 2 Apr 2019 10 Nov 2017 8 Nov 2017 4 Sep 2017 8 Aug 2017 7 Jul 2017 6 Jul 2017 1 Jun 2017 22 Dec 2016 22 Sep 2016 24 May 2016
- [_home Image tout Featured – Dengue](https://dndi.org/?elementor_library=_home-image-tout-featured-dengue)
- [_core Hero Image: Crypto tab(static)](https://dndi.org/?elementor_library=_core-hero-image-crypto-tabstatic) - Cryptococcal meningitis Cryptococcal meningitis
- [_core homepage: Hero header WorldNTDDay 2022](https://dndi.org/?elementor_library=_core-homepage-hero-header-worldntdday-2022) - INNOVATING FOR THE MOST NEGLECTED 30 January is World Neglected Tropical Diseases Day. Join us in calling for innovation to bring the #BestScienceforAll. SEE OUR CAMPAIGN DISCOVER STORIES OF INNOVATION INNOVATING FOR THE MOST NEGLECTED 30 January is World Neglected Tropical Diseases Day. Join us in calling for innovation to bring the #BestScienceforAll. SEE OUR
- [_core Job Opportunity single page template](https://dndi.org/?elementor_library=_core-job-opportunity-single-page-template) - Pods Embed Error: Pod not found. Share on twitter Share on facebook Share on linkedin Share on email Share on print Geneva, Switzerland [Closing date: 13 August 2016] Summary of Role The Clinical Program Assistant will play a key role in the Clinical Team. S/he will act as a central point of communication for
- [_core Latest News: featured only](https://dndi.org/?elementor_library=related-content-modules-related-stories-8-featured-only) - Read, watch, share Loading… 10 Nov 2021 4 Nov 2021 31 Oct 2021 29 Oct 2021 21 Oct 2021 21 Oct 2021 20 Oct 2021 6 Oct 2021 VIEW ALL NEWS
- [Portfolio section link to Completed Projects](https://dndi.org/?elementor_library=portfolio-section-link-to-completed-projects) - Completed projects
- [_core Related News: no filters](https://dndi.org/?elementor_library=related-content-modules-related-stroriesno-filters) - Read, watch, share Loading… 10 Nov 2021 4 Nov 2021 31 Oct 2021 29 Oct 2021 VIEW ALL
- [_page donors private](https://dndi.org/?elementor_library=_page-donors) - Private donors Loading…
- [_home Image tout Featured – COVID-19 Policy Report](https://dndi.org/?elementor_library=_home-image-tout-featured-covid-19-policy-report)
- [_core RFP single page template](https://dndi.org/?elementor_library=_core-rfp-single-page-template) - Pods Embed Error: Pod not found. [Published: 10 July 2020] In the context of Phase I clinical trials developing oxantel pamoate as an alternative treatment for Trichuriasis, DNDi is sourcing a Contract Development and Manufacturing Organisation (CDMO) for formulation development and GMP manufacturing of clinical product and placebo. Request for Proposal Annex 1: Intent to
- [_global Follow us on LinkedIn](https://dndi.org/?elementor_library=_global-follow-us-on-linkedin) - Follow us on LinkedIn Don’t miss our latest job opportunities. Stay in touch with news from our team. Linkedin
- [_core people profile news: listing](https://dndi.org/?elementor_library=_core-people-profile-news-listing) - Featured news & publications Loading… Featured events Loading…
- [_home Image tout Featured – 2020 Annual Report](https://dndi.org/?elementor_library=_home-image-tout-featured-2020-annual-report)
- [AR 2020 Foreword](https://dndi.org/?elementor_library=ar-2020-foreword) - FOREWORD From the Chair of the Board and the Executive Director 2020 will be forever remembered for the tragic loss and devastating disruption the COVID-19 pandemic brought to bear on families and communities around the world. While the scientific response to COVID-19 is enabling major advances and the development of new health technologies at unprecedented
- [_home Image tout Featured – Strategic Plan](https://dndi.org/?elementor_library=image-tout-homepage-featured-world-ntd-day)
- [partner list with project-Non-profit organizations and networks](https://dndi.org/?elementor_library=partner-list-with-project-non-profit-organizations-and-networks) - Non-profit organizations, NGOs, and networks Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading…
- [partner list with project-Pharmaceutical and biotech industry](https://dndi.org/?elementor_library=partner-list-with-project-pharmaceutical-and-biotech-industry) - Industry partners and service providers Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading…
- [partner list with project-hospitals](https://dndi.org/?elementor_library=partner-list-with-project) - Healthcare providers Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading… Loading…
- [Africa regional page](https://dndi.org/?elementor_library=africa-regional-page) - Regional related news & stories Loading… filter by ALL News Press releases Publications Scientific articles Statements Stories Viewpoints 18 Jun 2021 14 Jun 2021 14 Jun 2021 The Lancet Global Health 7 May 2021 1 2 … 6 Next » see ALL Regional events Loading… See all Regional projects Nullam id dolor id nibh ultricies
- [_home Video tout Homepage Featured – HepC Malaysia](https://dndi.org/?elementor_library=_home-video-tout-homepage-featured-hepc-malaysia)
- [_home Video tout Homepage Featured - Borna](https://dndi.org/?elementor_library=video-tout-homepage-featured-borna)
- [_home Video tout Homepage Featured - Doctors Dream](https://dndi.org/?elementor_library=video-tout-homepage-featured-doctors)
- [_core Regional offices](https://dndi.org/?elementor_library=_core-regional-offices) - Projects Loading… filter by All PROJECTS Drug discovery Translational research Clinical trials Registration & access our r&d portfolio Related news & stories Loading… filter by ALL News Press releases Publications Scientific articles Statements Stories Viewpoints 18 May 2021 14 May 2021 International Journal of the Commons 13 May 2021 7 May 2021 1 2 …
- [_projects Related news](https://dndi.org/?elementor_library=_projects-related-news) - Related news & resources Loading…
- [Viewpoints archive template](https://dndi.org/?elementor_library=viewpoints-archive-template) - Loading… 16 Apr 2021 8 Mar 2021 28 Jan 2021 18 Dec 2020 12 Oct 2020 3 Apr 2020 26 Jan 2018 24 May 2017 15 Feb 2017 30 Jun 2016 28 Apr 2016 23 Feb 2016 28 Nov 2015 26 Jun 2015 30 Apr 2015 26 Feb 2015 1 2 ›
- [Statements archive template](https://dndi.org/?elementor_library=statements-archive-template) - Loading… 25 Jan 2021 12 Nov 2020 12 Oct 2020 29 Sep 2020 29 May 2020 18 May 2020 4 Feb 2020 30 Jan 2020 22 May 2019 29 Jan 2019 23 Jan 2019 15 Oct 2018 10 Sep 2018 24 May 2018 27 Jan 2018 21 Sep 2016 1 2 ›
- [Stories archive template](https://dndi.org/?elementor_library=stories-archive-template) - Loading… 28 Jan 2021 1 Dec 2019 22 Jul 2019 2 May 2019 18 Jan 2019 17 Dec 2018 16 Dec 2018 1 Nov 2018 14 Apr 2018 13 Apr 2018 30 Mar 2018 29 Jan 2018 19 Dec 2017 22 Nov 2017 24 May 2017 15 Feb 2017 1 2 ›
- [404](https://dndi.org/?elementor_library=404) - Whoops! We couldn’t find the page you were looking for. Read, watch, share Loading… 27 Apr 2021 16 Apr 2021 15 Apr 2021 14 Apr 2021 VIEW ALL
- [type disease (news filter)](https://dndi.org/?elementor_library=type-diseases-filter) - By Type News In the media Press releases Publications Scientific articles Statements Stories Videos Viewpoints By Disease Antimicrobial resistance Chagas disease COVID-19 Cutaneous leishmaniasis Hepatitis C Filaria: river blindness Mycetoma Malaria Paediatric HIV Sleeping sickness Visceral leishmaniasis filter now
- [search- (search-filter)](https://dndi.org/?elementor_library=search-filter)
- [News archive template](https://dndi.org/?elementor_library=news-archive-template) - Loading… News News Translations 15 Apr 2021 14 Apr 2021 1 Feb 2021 10 Nov 2020 4 Sep 2020 30 Jul 2020 27 Jul 2020 23 Jul 2020 23 Jul 2020 23 Jul 2020 16 Jun 2020 22 Apr 2020 1 Apr 2020 20 Mar 2020 26 Feb 2020 26 Feb 2020 1 2 …
- [_core Upcoming events](https://dndi.org/?elementor_library=_core-upcoming-events) - Events See all
- [_core values block: 4 touts 1 line](https://dndi.org/?elementor_library=_core-values-block-4-touts-1-line) - Our values People-centred We value our colleagues and recognize their contributions We care about the well-being of neglected patients and the communities we work with We nurture a respectful, diverse and inclusive working environment Integrity We are trustworthy and ethical We are fair, transparent, and honest We work to the highest quality to deliver the
- [news module: Press Releases](https://dndi.org/?elementor_library=news-module-press-releases) - Press Releases filter by Press releases Press Releases Translations 4 Sep 2020 13 May 2020 14 Apr 2020 13 Apr 2020 see ALL
- [Videos archive template](https://dndi.org/?elementor_library=videos-archive-template) - 28 Jul 2020 30 Oct 2019 30 Oct 2019 23 Jul 2019 23 Jul 2019 17 Jun 2019 14 Mar 2019 5 Feb 2019 16 Nov 2018 30 Mar 2018 1 Mar 2018 23 May 2016 7 Sep 2015 28 May 2015 Connect and share Follow us on social media to stay updated and help
- [disease (news filter)](https://dndi.org/?elementor_library=disease-news-filter) - By Disease Antimicrobial resistance Chagas disease COVID-19 Cutaneous leishmaniasis Hepatitis C Filaria: river blindness Mycetoma Malaria Paediatric HIV Sleeping sickness Visceral leishmaniasis filter now
- [location (news filter)](https://dndi.org/?elementor_library=location-news-filter) - By Location Africa Asia Europe Latin America North America Oceania filter now
- [topic (news filter)](https://dndi.org/?elementor_library=newstopic-filter) - By Topic Drug discovery Translational research Clinical trials Registration & access Children Funding Partnership Policy advocacy Strengthening Capacities Sustainable Development Universal Health Coverage filter now
- [Social media feed](https://dndi.org/?elementor_library=social-media-feed) - Social Media Feed
- [Events card](https://dndi.org/?elementor_library=events-card) - Upcoming Events
- [AE Events Card v1](https://dndi.org/?elementor_library=ae-events-card-v1)
- [Events archive template](https://dndi.org/?elementor_library=events-archive-template) - Events 1 2 … 23 ›
- [News-filter-content](https://dndi.org/?elementor_library=news-filter-content) - Type & Disease Topic Location Date Range Type & Disease By Type News In the Media Press Releases Publications Scientific Articles Statements Stories Videos Viewpoints By Disease Antimicrobial resistance COVID-19 Malaria Sleeping sickness Visceral leishmaniasis Cutaneous leishmaniasis Chagas disease Filaria: river blindness Mycetoma Paediatric HIV Hepatitis C filter now Topic By Topic Drug discovery Translational
- [location (search filter)](https://dndi.org/?elementor_library=location-filter) - Africa Asia Europe Latin America North America Oceania
- [date (news filter)](https://dndi.org/?elementor_library=date-news-filter) - By Year 1999 — 2020 filter now
- [date (search filter)](https://dndi.org/?elementor_library=date-filter) - 1999 — 2020 filter now
- [loop for event](https://dndi.org/?elementor_library=loop-for-event)
- [_core Hero Image: HCV tab(static)](https://dndi.org/?elementor_library=test-hero) - Hepatitis C Hepatitis C
- [_core Hero Image: Mycetoma tab(static)](https://dndi.org/?elementor_library=_core-hero-image-mycetoma-tabstatic) - Mycetoma Mycetoma
- [_core Hero Image: Sleepingsickness tab(static)](https://dndi.org/?elementor_library=_core-hero-image-sleepingsickness-tabstatic) - Sleeping sickness Sleeping sickness
- [_core Hero Image: Visceral Leishmaniasis tab(static)](https://dndi.org/?elementor_library=_core-hero-image-visceral-leishmaniasis-tabstatic) - Visceral leishmaniasis Visceral leishmaniasis
- [_core Hero Image: Chagas disease tab(static)](https://dndi.org/?elementor_library=_core-hero-image-chagas-disease-tabstatic) - Chagas disease Chagas disease
- [_core Hero Image: Cutaneous Leishmaniasis tab(static)](https://dndi.org/?elementor_library=_core-hero-image-cutaneous-leishmaniasis-tabstatic) - Cutaneous leishmaniasis Cutaneous leishmaniasis
- [_core Hero Image: Paediatric HIV tab(static)](https://dndi.org/?elementor_library=_core-hero-image-paediatric-hiv-tabstatic) - Paediatric HIV Paediatric HIV
- [_core Project: Objective](https://dndi.org/?elementor_library=_core-project-objectiveafter-heroimage) - objective project cost project start project status current phase of drug development last phase of drug development Drug Discovery Drug Discovery Translational research Translational research Clinical trials Clinical trials Registration & access Registration & access
- [_core Full-width Tout: black overlay background Donors](https://dndi.org/?elementor_library=touts-example-2-touts) - Our donors We are grateful for the support received from all our donors, who enable us to discover, develop, and deliver patient-friendly treatments for neglected communities. find out more
- [_core Hero banner narrow](https://dndi.org/?elementor_library=_core-hero-banner-narrow)
- [_core hero banner:breadcrumb](https://dndi.org/?elementor_library=_core-hero-bannerbreadcrumb)
- [_core Hero Short Format with Image](https://dndi.org/?elementor_library=_core-hero-short-format-with-image-v-2) - Our governance Share on twitter Share on facebook Share on linkedin Share on email Share on print
- [location (news filter)-backup](https://dndi.org/?elementor_library=location-news-filter-backup) - Africa Africa Asia Asia Europe Africa Australia United States Bangladesh Argentina Asia India Bolivia Europe Japan Brazil Latin America Malaysia Colombia North America Democratic Republic of Congo Mexico Nepal Oceania Peru Switzerland Thailand Ethiopia United Kingdom Guinea Kenya Malawi Republic of Congo South Africa South Sudan Sudan Uganda Latin America Latin America North America Africa
- [_core Full-width Tout: photo background](https://dndi.org/?elementor_library=touts-example-touts) - Help All Patients Our research has delivered the first all-oral treatment for sleeping sickness. Help us develop the next generation of medicines to neglected patients. donate now
- [_core Full-width Tout: orange overlay background](https://dndi.org/?elementor_library=touts-example-3-touts) - Become a partner Help us bring the best science to the most neglected. contact us
- [_global Our Policies](https://dndi.org/?elementor_library=_global-our-policies) - Our policies We strive to hold ourselves to the highest standards of accountability, transparency, ethics, and best practice in all we do. read more
- [_core Hero Image: Project detail](https://dndi.org/?elementor_library=_core-hero-images-project-landing-page)
- [news module: In the Media x4](https://dndi.org/?elementor_library=news-module-in-the-media) - In the Media 4 Jun 2020 Fanaposten 20 May 2020 The East African 20 May 2020 O Globo 19 May 2020 CodeBlue, Galen Centre see ALL
- [diseases (search filter)](https://dndi.org/?elementor_library=test-select) - Antimicrobial resistance COVID-19 Malaria Sleeping sickness Visceral leishmaniasis Cutaneous leishmaniasis Chagas disease Filaria: river blindness Mycetoma Paediatric HIV Hepatitis C
- [topic (search filter)](https://dndi.org/?elementor_library=topic-search-filter) - Policy advocacy Funding Partnership Regulatory Strengthening Capacities Climate change Gender Children Stigma Drug discovery Clinical trials Registration & access Sleeping sickness (HAT) Treatment Access Mycetoma
- [event (search filter)](https://dndi.org/?elementor_library=event-filter) - Event
- [newstype (search filter)](https://dndi.org/?elementor_library=projectphase-filter) - News Press Releases In the Media Scientific Articles Videos Viewpoints Stories Press Releases Translations Statements News Translations Publications
- [Temporary Maintenance](https://dndi.org/?elementor_library=temporary-maintenance) - ‘Caught us doing more good… We’re making some enhancements to the website.It’ll take a few more minutes. Please come back soon.
- [_core Corporate publications](https://dndi.org/?elementor_library=_core-corporate-publications) - Latest publications 12 May 2020 4 Nov 2019 1 Nov 2019 31 Oct 2019 See all
- [Our offices: cards](https://dndi.org/?elementor_library=our-offices-cards) - Our global footprint
- [Project and Disease list](https://dndi.org/?elementor_library=test-project)
- [_core Project: What we’ve achieved (manual selection)](https://dndi.org/?elementor_library=_core-projects-what-weve-achieved-manual-selection) - What we have achieved Our research is helping… nullam id dolor id nibh ultricies vehicula ut id elit. Cras mattis consectetur purus sit amet fermentum. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus.
- [news module: Publications](https://dndi.org/?elementor_library=news-module-publications) - Publications Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod
- [partner list with project-Ministries of health and governments](https://dndi.org/?elementor_library=partner-list-with-project-ministries-of-health-and-governments) - Ministries of health and governments
- [partner list with project-Universities and research centres](https://dndi.org/?elementor_library=partner-list-with-project-universities-and-research-centres) - Universities and research centres
- [Transparency of R&D costs: Posts](https://dndi.org/?elementor_library=transparency-of-rd-costs-posts) - Read additional documents on transparency of R&D costs 31 Oct 2019 24 Aug 2016 Nature 31 Jan 2014
- [_core people profile by lastname](https://dndi.org/?elementor_library=_core-people-profile-by-lastname)
- [Job Opportunity listing wide card format](https://dndi.org/?elementor_library=job-opportunity-listing-wide-card-format) - Current Job Opportunities Founded in 2003 to address the needs of patients with the most neglected diseases, DNDi is a collaborative, patients’ needs-driven, not-for-profit drug R&D organization. Our work begins with our people: we aim to recruit people who both reflect and understand the diversity of needs and experiences of those we serve. Our staff of
- [donor list with details](https://dndi.org/?elementor_library=donor-list-with-details) - Public Institutional donors
- [top navigation ( popup )](https://dndi.org/?elementor_library=popup-header) - Add Your Heading Text Here
- [other modules ( interactive map)](https://dndi.org/?elementor_library=other-modules-interactive-map) - [PLACEHOLDER FOR A MAP]
- [related content modules( related stories, Filter bar #02)](https://dndi.org/?elementor_library=related-content-modules-related-stories-filter-bar-02) - Read, Watch, Share FILTER BY All News Press Releases Scientific Articles 5 Feb 2020 30 Jan 2020 27 Jan 2020 PLOS NTDs 30 Dec 2019 The American Journal of Tropical Medicine and Hygiene 11 Dec 2019 ACS Infectious Diseases 11 Dec 2019 Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease 4 Dec 2019
- [_core Projects listing section module with Disease labels](https://dndi.org/?elementor_library=_core-projects-listing-module-with-disease-labels) - Completed Projects Placeholder copy for completed projects. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. OPTIONAL CTA BUTTON
- [_core Projects listing wide format](https://dndi.org/?elementor_library=_core-project-listing-wide-format) - Projects Nullam id dolor id nibh ultricies vehicula ut id elit. Cras mattis consectetur purus sit amet fermentum. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. OPTIONAL CTA BUTTON filter by All PROJECTS Drug discovery Translational research Clinical trials Registration & access see all projects
- [news module: Scientific Articles](https://dndi.org/?elementor_library=news-module-scientific-articles) - Scientific Articles Please provide a Pod name Please provide a Pod name Please provide a Pod name Please provide a Pod name see ALL
- [_core Latest News Types module](https://dndi.org/?elementor_library=_core-latest-news-types-module) - Latest news & stories filter by News Press Releases Scientific Articles Viewpoints Stories Statements Publications 5 Feb 2020 30 Jan 2020 30 Jan 2020 27 Nov 2019 1 2 … 27 Next » see ALL
- [_global Speak out orange banner](https://dndi.org/?elementor_library=_global-speak-out-orange-block) - Speak out Please help us raise awareness by sharing this story. Share on twitter Share on facebook Share on linkedin Share on email Share on whatsapp
- [news module: Latest News & Stories](https://dndi.org/?elementor_library=news-module-latest-news-stories) - Latest News & Stories 5 Feb 2020 4 Feb 2020 30 Jan 2020 30 Jan 2020 1 Dec 2019 27 Nov 2019 1 Nov 2019 31 Oct 2019 1 2 … 28 Next » see ALL
- [_core Statistics module: single CTA](https://dndi.org/?elementor_library=highlights-statistics-one-cta) - 1.7M children living with HIV 160K newly infected in 2018 50% will die before their second birthday without treatment 300 children die every day from paediatric HIV VIEW FACT SHEET
- [Home Page section](https://dndi.org/?elementor_library=home-page-section) - BEST SCIENCE FOR THE MOST NEGLECTED We are a not-for-profit research and development organization that develops medicines for millions of people affected by neglected diseases We innovate to save lives Developing urgently needed treatments for neglected patients and ensuring they’re affordable, available, and adapted to the communities who need them learn more We partner for
- [stats tout: How we use our funding](https://dndi.org/?elementor_library=stats-tout-how-we-use-our-funding) - How We Use Our Funding We use the funds we receive to conduct life-saving research, build research networks, and advocate for neglected patients. 0 % social mission 0 % general management 0 % fundraising OUR DONORS
- [_core Statistics module: wide format](https://dndi.org/?elementor_library=_core-statistics-block-new-version) - 0 million people and more are at risk of visceral leishmaniasis across the globe 0 million deaths annually 0 – 900 new cases each year 0 x The risk of developing active visceral leishmaniasis is up to 2,000 times greater in people living with HIV see disease facts download fact sheet
- [_core Statistics module: with subtitle and description (4 cols)](https://dndi.org/?elementor_library=_core-statistics-module-with-subtitle-and-description-4-cols) - How does… ? Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Sed posuere consectetur est at lobortis. Fusce dapibus. 0 % social mission 0 % fundraising 0 % general administration 0 % general administraion DONATE NOW
- [_core Statistics module: two CTAs](https://dndi.org/?elementor_library=highlights-statistics-two-ctas) - 0 M children living with HIV​ 0 K newly infected in 2018​ 0 % will die before their second birthday without treatment​ 0 children die every day from paediatric HIV SEE DISEASE FACTS DOWNLOAD FACT SHEET
- [_core Story Quote tout: image left, single CTA](https://dndi.org/?elementor_library=touts-story-tout) - Subtitle or “Some quote…. Lorem ipsum dolor sit amet, consectetur adipiscing elit sed.” Short description about person making quote and/or photo. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed. READ MORE
- [_core Related Projects for a disease: all project phases](https://dndi.org/?elementor_library=related-content-projects-display-all-project-phase) - What We Are Doing for Children with HIV In order to help end the neglect of babies and young children with HIV, we are working with the Indian generic company Cipla Ltd. to develop a sweet-tasting and easy-to-administer ‘4-in-1’ pill that contains four drugs recommended by the World Health Organization (WHO). Our engagement goes well
- [_core Project: What we are doing for..  (auto related to disease)](https://dndi.org/?elementor_library=related-content-projects-one-diseases) - What we’re doing for… Our goal is to deliver lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,ac facilisis in, egestas eget quam. SEE TARGET PRODUCT PROFILE Super-booster therapy Drugs used to treat tuberculosis can interfere with HIV treatment, reducing
- [_core Story Quote tout: image right, single CTA](https://dndi.org/?elementor_library=touts-story-tout-2) - Subtitle or “Some quote…. Lorem ipsum dolor sit amet, consectetur adipiscing elit sed.” Short description about person making quote and/or photo. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. READ MORE
- [_core Videos: all diseases](https://dndi.org/?elementor_library=related-content-modules-videos) - Videos 23 Jul 2019 30 Oct 2019 30 Oct 2019 23 Jul 2019 VIEW ALL
- [related content modules( generic list of links, filter bar )](https://dndi.org/?elementor_library=related-content-modules-generic-list-of-links-filter-bar) - Generic Text-Based Module with Filter Bar FILTER BY All Scientific Articles 27 Jan 2020 30 Dec 2019 11 Dec 2019 11 Dec 2019 4 Dec 2019 31 Oct 2019 27 Sep 2019 26 Sep 2019 see ALL
- [related content Manual Selection](https://dndi.org/?elementor_library=related-content-manual-selection) - Other related content 12 Jan 2016 VIEW ALL
- [_core Related Projects for a disease: with phases filter](https://dndi.org/?elementor_library=related-content-projects-filter-bar) - Projects Nullam id dolor id nibh ultricies vehicula ut id elit. Cras mattis consectetur purus sit amet fermentum. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. OPTIONAL CTA BUTTON filter by All PROJECTS Clinical development Drug discovery Translational research Treatment access see all projects
- [Project loop for portfolio](https://dndi.org/?elementor_library=project-loop-for-portfolio)
- [loop for video](https://dndi.org/?elementor_library=loop-for-video) - 1 Nov 2019
- [project-archive](https://dndi.org/?elementor_library=__trashed-5) - filter by All PROJECTS Clinical development Drug discovery Translational research Treatment access 1 2 … 7 Next »
- [_core Hero: Article Detail](https://dndi.org/?elementor_library=_core-hero-article-detail)
- [xx_sub Hero Image: Landing Page, text on left](https://dndi.org/?elementor_library=hero-landing-page-text-on-left) - Advance drug development using AI READ MORE
- [_core people profile by manually](https://dndi.org/?elementor_library=_core-people-profile-by-manually)
- [_core hero-images ( article detail page-without image )](https://dndi.org/?elementor_library=_core-hero-images-article-detail-page-without-image)
- [_core homepage: Hero header with dark gradient](https://dndi.org/?elementor_library=hompage-hero-header-with-gradient) - BEST SCIENCE FOR THE MOST NEGLECTED We develop medicines to save lives and stop disabilities of people with neglected diseases BEST SCIENCE FOR THE MOST NEGLECTED We develop medicines to save lives and stop disabilities of people with neglected diseases
- [_core Completed Project: Objective](https://dndi.org/?elementor_library=_core-completed-project-objective) - objective project cost project start project status current phase of drug development
- [_core Hero header plain text](https://dndi.org/?elementor_library=_core-hero-header-plain-text)
- [_core Hero Image: landing page only](https://dndi.org/?elementor_library=hero-images-landing-page-only) - BEST SCIENCE FOR THE MOST NEGLECTED We develop medicines to save lives and stop disabilities of people with neglected diseases BEST SCIENCE FOR THE MOST NEGLECTED
- [_sub Hero Image: Article detail, text on left](https://dndi.org/?elementor_library=hero-images-artical-detail-page-2) - DNDi congratulates the TB Alliance for the FDA approval of a new treatment desperately-needed for drug-resistant forms of tuberculosis Additional proof that not-for-profit drug development offers a way forward for neglected patients.
- [_core Statistics module: with subtitle and description (3 cols)](https://dndi.org/?elementor_library=highlights-statistics-home-page) - How does… ? Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Sed posuere consectetur est at lobortis. Fusce dapibus. 0 % social mission 0 % general management 0 % fundraising DONATE NOW
- [default disease loop](https://dndi.org/?elementor_library=default-disease-loop) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [_core Partners: logos grid](https://dndi.org/?elementor_library=other-modules-partners-greyscale) - Partners
- [VL Disease Tabs set](https://dndi.org/?elementor_library=vl-disease-tabs-set) - Overview Facts Projects & Achievements Overview 0 % of children with HIV will die before their second birthday without treatment 0 M children are living with HIV 0 % children receive lifesaving treatment 0 infants infected every day in 2018 SEE DISEASE FACTS DOWNLOAD FACT SHEET “Some quote…. Lorem ipsum dolor sit amet, consectetur adipiscing
- [Paed HIV Disease Tabs](https://dndi.org/?elementor_library=disease-tabs-paed-hiv) - Overview Facts Projects & Achievements Overview 0 % of children with HIV will die before their second birthday without treatment 0 M children are living with HIV 0 % children receive lifesaving treatment SEE DISEASE FACTS DOWNLOAD FACT SHEET “The initial treatment was difficult to administer because of their bitter taste. Many times, Emmanuel would
- [CL Disease Tabs set](https://dndi.org/?elementor_library=cl-disease-tabs) - Overview Facts Projects & Achievements Overview > 0 M more new cases a year 0 endemic countries 0 % effectiveness of current treatments can be as low as SEE DISEASE FACTS DOWNLOAD FACT SHEET ‘There is a huge lack of information on the disease that leads to the use of several things to get cured,
- [_core Disease Detail ( tab )](https://dndi.org/?elementor_library=disease-detail-tab) - Overview Facts Projects & Achievements Overview 0 M children living with HIV​ 0 K newly infected in 2018​ 0 % will die before their second birthday without treatment​ 0 children die every day from paediatric HIV SEE DISEASE FACTS DOWNLOAD FACT SHEET Subtitle or “Some quote…. Lorem ipsum dolor sit amet, consectetur adipiscing elit sed.”
- [Mycetoma Disease Tabs set](https://dndi.org/?elementor_library=mycetoma-disease-tabs-set) - Overview Facts Projects & Achievements Overview 0 % of children with HIV will die before their second birthday without treatment 0 M children are living with HIV 0 % children receive lifesaving treatment 0 infants infected every day in 2018 SEE DISEASE FACTS DOWNLOAD FACT SHEET “Some quote…. Lorem ipsum dolor sit amet, consectetur adipiscing
- [HAT Disease Tabs set](https://dndi.org/?elementor_library=hat-disease-tabs) - Overview Facts Projects & Achievements Overview 0 M people live in areas at moderate to very high risk 0 % of sleeping sickness cases in 2018 were reported in DRC 0 cases of the T.b. gambiense strain diagnosed in 2018 SEE DISEASE FACTS DOWNLOAD FACT SHEET “I lost weight, I had fever, I started talking to
- [HCV Disease Tabs set](https://dndi.org/?elementor_library=hcv-disease-tabs) - Overview Facts Projects & Achievements Overview 0 % of children with HIV will die before their second birthday without treatment 0 M children are living with HIV 0 % children receive lifesaving treatment 0 infants infected every day in 2018 SEE DISEASE FACTS DOWNLOAD FACT SHEET “Some quote…. Lorem ipsum dolor sit amet, consectetur adipiscing
- [Filaria Disease Tabs set](https://dndi.org/?elementor_library=filaria-disease-tabs) - Overview Facts Projects & Achievements Overview 0 M people are infected with river blindness 0 nd River blindness is the world’s second-leading infectious cause of blindness 0 % of infected people live in 31 African countries SEE DISEASE FACTS DOWNLOAD FACT SHEET ‘Sometimes I cry all night, sometimes from suffering, sometimes from misery, and sometimes
- [Chagas Disease Tabs set](https://dndi.org/?elementor_library=chagas-disease-tabs) - Overview Facts Projects & Achievements Overview 0 % of children with HIV will die before their second birthday without treatment 0 M children are living with HIV 0 % children receive lifesaving treatment 0 infants infected every day in 2018 SEE DISEASE FACTS DOWNLOAD FACT SHEET “Some quote…. Lorem ipsum dolor sit amet, consectetur adipiscing
- [Chagas_Detail](https://dndi.org/?elementor_library=chagas_detail) - Overview Facts Projects & Achievements Overview 0 % of children with HIV will die before their second birthday without treatment 0 M children are living with HIV 0 % children receive lifesaving treatment 0 infants infected every day in 2018 SEE DISEASE FACTS DOWNLOAD FACT SHEET “Some quote…. Lorem ipsum dolor sit amet, consectetur adipiscing
- [_core Project: Description](https://dndi.org/?elementor_library=_core-project-description) - Share on twitter Share on facebook Share on linkedin Share on email Share on print Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [list(Filterable list, R&D Portfolio)](https://dndi.org/?elementor_library=listfilterable-list-rd-portfolio-2) - Browse Portfolio filter by diseases Visceral leishmaniasis Hepatitis C Mycetoma Filarial diseases Chagas disease Paediatric HIV Cutaneous leishmaniasis Sleeping sickness (HAT) phases Clinical development Drug discovery Translational research Treatment access discovery translation clinical trials implementation
- [Default Kit](https://dndi.org/?elementor_library=default-kit)
- [_core hero-images ( project landing page-without image )](https://dndi.org/?elementor_library=_core-hero-images-project-landing-page-without-image)
- [_core General Post main content](https://dndi.org/?elementor_library=_core-general-post-main-content) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [_core Project: What we’ve achieved (auto to disease)](https://dndi.org/?elementor_library=related-content-projects-treatment-delivered) - What we’ve achieved Our research is helping… nullam id dolor id nibh ultricies vehicula ut id elit. Cras mattis consectetur purus sit amet fermentum. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. 4-IN-1 (ABC/3TC/LPV/R) 2-IN-1 LPV/R PELLETS AND ABC/3TC OR AZT/3TC
- [_core Press Releases: all diseases](https://dndi.org/?elementor_library=related-content-modules-press-release) - 11/29/2019 12/05/2019
- [Browse Portfolio Groupby Columns](https://dndi.org/?elementor_library=browse-portfolio-groupby-columns) - Browse Portfolio diseases Visceral Leishmaniasis Hepatitis C Mycetoma Filarial Chagas disease Paediatric HIV Cutaneous Leishmaniasis Sleeping Sickness phases Clinical Development Drug Discovery Implementation Translational research Treatment access
- [list(Filterable list, R&D Portfolio)](https://dndi.org/?elementor_library=listfilterable-list-rd-portfolio) - Browse Portfolio filter by diseases Visceral Leishmaniasis Hepatitis C Mycetoma Filarial Chagas disease Paediatric HIV Cutaneous Leishmaniasis Sleeping Sickness phases Clinical Development Drug Discovery Implementation Translational research Treatment access discovery translation clinical trials implementation
- [_core Disease About (dynamic)](https://dndi.org/?elementor_library=disease-aboutdynamic) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [_core General News Archive: no filters](https://dndi.org/?elementor_library=test) - 01/21/2019 08/15/2019 10/04/2019 11/07/2019 11/04/2019
- [loop for general](https://dndi.org/?elementor_library=loop-for-general)
- [list(Filterable list, R&D Portfolio)](https://dndi.org/?elementor_library=demo-test) - Browse Portfolio diseases Visceral leishmaniasis Hepatitis C Mycetoma Filarial Chagas Paediatric HIV Cutaneous Leishmaniasis Sleeping Sickness phases Clinical Development Implementation Translational research Treatment access

## Timeline Stories

- [Fexinidazole for T.b. rhodesiense sleeping sickness](https://dndi.org/timeline/fexinidazole-for-t-b-rhodesiense-sleeping-sickness/) - Safe and effective oral cure for acute form of sleeping sickness Partnership with Sanofi and the HAT-r-ACC consortium
- [New treatments for HIV/VL](https://dndi.org/timeline/new-treatments-for-hiv-vl/) - Better treatments for people living with both HIV and visceral leishmaniasis Partnership with Médecins Sans Frontières and other partners.
- [GARDP](https://dndi.org/timeline/gardp/) - Incubation of the Global Antibiotic Research & Development Partnership (GARDP) to address antimicrobial resistance Partnership with WHO
- [Fexinidazole](https://dndi.org/timeline/fexinidazole/) - First all-oral cure for all stages of sleeping sickness Partnership with Sanofi, the Human African Trypanosomiasis Platform, Médecins Sans Frontières, national control programmes, and WHO.
- [New visceral leishmaniasis treatments in Asia](https://dndi.org/timeline/new-visceral-leishmaniasis-treatments-in-asia/) - Better treatments in South Asia Partnerships with kala-azar actors in South Asia including ministries of health, research institutes, NGOs, and WHO-TDR.
- [Paediatric Benznidazole](https://dndi.org/timeline/paediatric-benznidazole/) - First paediatric drug for Chagas disease Partnership with LAFEPE (Brazil) to develop the first paediatric treatment for Chagas (2011); subsequent partnerships with Chemo Research, Exeltis USA, Mundo Sano Foundation, and Laboratorio ELEA PHOENIX.
- [SSG&PM](https://dndi.org/timeline/ssgpm/) - Cheaper, more effective visceral leishmaniasis treatment in Africa Partnership with the Leishmaniasis East Africa Platform (LEAP), national control programmes, Médecins Sans Frontières, and WHO.
- [Nifurtimox-eflornithine combination therapy (NECT)](https://dndi.org/timeline/nifurtimox-eflornithine-combination-therapy-nect/) - Better, safer treatment for sleeping sickness Partnership with Médecins Sans Frontières, Epicentre, national control programmes, and WHO.
- [New recommendations for treating visceral leishmaniasis in Latin America](https://dndi.org/timeline/new-visceral-leishmaniasis-treatment-in-latin-america/) - Liposomal amphotericin B recommended instead of pentavalent antimonials Partnership with the University of Brasilia and the Oswaldo Cruz Foundation of Brazil.
- ['4-in-1' antiretroviral treatment](https://dndi.org/timeline/4-in-1-antiretroviral-treatment/) - Child-friendly treatment specifically designed for infants and young children with HIV Partnership with Cipla Limited
- [Ravidasvir](https://dndi.org/timeline/ravidasvir/) - An affordable hepatitis C cure to leave no one behind Partnership with Ministries of Health of Malaysia and Thailand, Pharmaniaga, Pharco Pharmaceuticals, and Médecins Sans Frontières France.
- [ASAQ*](https://dndi.org/timeline/asaq/) - Fixed-dose combination of artesunate and amodiaquine to treat malaria Partnership with Sanofi *Project handed over to Medicines for Malaria Venture in 2015
- [Super-booster therapy](https://dndi.org/timeline/super-booster-therapy/) - More effective treatment for children with HIV and TB Partnership with the Department of Health, South Africa
- [ASMQ*](https://dndi.org/timeline/asmq/) - Fixed-dose combination of artesunate and mefloquine for malaria Partnership with Farmanguinhos/Fiocruz (Brazil) and Cipla (India) *Project handed over to Medicines for Malaria Venture in 2015

## Clinical Trials

- [Safety and tolerability  of acoziborole for seropositive non-parisitologically confirmed <i>T. b. gambiense</i> sleeping sickness](https://dndi.org/clinical-trial/safety-and-tolerability-of-acoziborole-for-seropositive-non-parisitologically-confirmed-t-b-gambiense-sleeping-sickness/)
- [Efficacy and safety of shorter benznidazole regimens for chronic Chagas disease](https://dndi.org/clinical-trial/efficacy-and-safety-of-shorter-benznidazole-regimens-for-chronic-chagas-disease/)
- [Safety, tolerability, and pharmacokinetics of single dose DNDI-6148 for visceral leishmaniasis (in healthy participants)](https://dndi.org/clinical-trial/safety-tolerability-and-pharmacokinetics-of-single-dose-dndi-6148-for-visceral-leishmaniasis-in-healthy-participants/)
- [Safety, tolerability, and pharmacokinetics of DNDI-6899 (in healthy volunteers)](https://dndi.org/clinical-trial/safety-tolerability-and-pharmacokinetics-of-dndi-6899-in-healthy-volunteers/)
- [Retrospective descriptive study to detect recurrence of eumycetoma during long-term follow-up](https://dndi.org/clinical-trial/retrospective-descriptive-study-to-detect-recurrence-of-eumycetoma-during-long-term-follow-up/)
- [Epidemiology study and safety of acoziborole for sleeping sickness (in seropositive participants)](https://dndi.org/clinical-trial/epidemiology-study-and-safety-of-acoziborole-for-sleeping-sickness-in-seropositive-participants/)
- [Bioavailability, efficacy, and safety of sustained release flucytosine for cryptococcal meningitis](https://dndi.org/clinical-trial/bioavailability-efficacy-and-safety-of-sustained-release-flucytosine-for-cryptococcal-meningitis/)
- [Safety and efficacy of emodepside for river blindness](https://dndi.org/clinical-trial/safety-and-efficacy-of-emodepside-for-river-blindness/)
- [Efficacy, safety, and pharmacokinetics of two LXE408 regimens for localized cutaneous leishmaniasis in the region of the Americas](https://dndi.org/clinical-trial/efficacy-safety-and-pharmacokinetics-of-two-lxe408-regimens-for-localized-cutaneous-leishmaniasis-in-the-region-of-the-americas/)
- [Efficacy, safety, and pharmacokinetics of LXE408 for primary visceral leishmaniasis in Ethiopia](https://dndi.org/clinical-trial/efficacy-safety-and-pharmacokinetics-of-lxe408-for-primary-visceral-leishmaniasis-in-ethiopia/)
- [Pharmacokinetics, efficacy, safety, and tolerability of acoziborole in children with <i>T. b. gambiense</i> sleeping sickness](https://dndi.org/clinical-trial/pharmacokinetics-efficacy-safety-and-tolerability-of-acoziborole-in-children-with-t-b-gambiense-sleeping-sickness/)
- [A drug-drug interaction study of acoziborole  for <i>T. b. gambiense</i> sleeping sickness (in healthy male participants)](https://dndi.org/clinical-trial/a-drug-drug-interaction-study-of-acoziborole-for-t-b-gambiense-sleeping-sickness-in-healthy-male-participants/)
- [Bioequivalence study of test and reference ravidasvir tablets for chronic HCV (in healthy fed participants)](https://dndi.org/clinical-trial/bioequivalence-study-of-test-and-reference-ravidasvir-tablets-for-chronic-hcv-in-healthy-fed-participants/)
- [Bioequivalence study of test and reference ravidasvir for chronic HCV (in healthy fed participants)](https://dndi.org/clinical-trial/bioequivalence-study-of-test-and-reference-ravidasvir-for-chronic-hcv-in-healthy-fed-participants/)
- [Efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir for chronic HCV](https://dndi.org/clinical-trial/efficacy-safety-tolerance-and-pharmacokinetics-of-sofosbuvir-plus-ravidasvir-for-chronic-hcv/)
- [Tylamac phase-II trial for treatment of onchocerciasis](https://dndi.org/clinical-trial/tylamac-phase-ii-trial-for-treatment-of-onchocerciasis/)
- [Safety, tolerability, and pharmacokinetics of multiple dose DNDI-0690 for visceral leishmaniasis (in healthy participants)](https://dndi.org/clinical-trial/safety-tolerability-and-pharmacokinetics-of-multiple-dose-dndi-0690-for-visceral-leishmaniasis-in-healthy-participants/)
- [Absorption, metabolism, and excretion of acoziborole for sleeping sickness (in healthy participants)](https://dndi.org/clinical-trial/absorption-metabolism-and-excretion-of-acoziborole-for-sleeping-sickness-in-healthy-participants/)
- [Efficacy and safety of acoziborole for <i>T.b. gambiense</i> sleeping sickness](https://dndi.org/clinical-trial/efficacy-and-safety-of-acoziborole-for-t-b-gambiense-sleeping-sickness/)
- [Efficacy and safety of paromomycin plus miltefosine or sodium stibogluconate for visceral leishmaniasis in Africa](https://dndi.org/clinical-trial/efficacy-and-safety-of-paromomycin-plus-miltefosine-or-sodium-stibogluconate-for-visceral-leishmaniasis-in-africa/)
- [Efficacy and safety of thermotherapy plus miltefosine for cutaneous leishmaniasis in South America](https://dndi.org/clinical-trial/efficacy-and-safety-of-thermotherapy-plus-miltefosine-for-cutaneous-leishmaniasis-in-south-america/)
- [Efficacy and safety of miltefosine plus either liposomal amphotericin B or paromomycin for PKDL in Sudan](https://dndi.org/clinical-trial/efficacy-and-safety-of-miltefosine-plus-either-liposomal-amphotericin-b-or-paromomycin-for-pkdl-in-sudan/)
- [Efficacy and safety of liposomal amphotericin B alone and in combination with miltefosine for PKDL in Asia](https://dndi.org/clinical-trial/efficacy-and-safety-of-liposomal-amphotericin-b-alone-and-in-combination-with-miltefosine-for-pkdl-in-asia/)
- [Efficacy and safety of two LXE408 regimens for primary visceral leishmaniasis in India](https://dndi.org/clinical-trial/efficacy-and-safety-of-two-lxe408-regimens-for-primary-visceral-leishmaniasis-in-india/)
- [Efficacy and safety of fexinidazole for <i>T. b. gambiense</i> sleeping sickness in children](https://dndi.org/clinical-trial/efficacy-and-safety-of-fexinidazole-for-t-b-gambiense-sleeping-sickness-in-children/)
- [Efficacy and safety of fexinidazole for stage 1 & early stage 2 <i>T. b. gambiense</i> sleeping sickness](https://dndi.org/clinical-trial/efficacy-and-safety-of-fexinidazole-for-stage-1-early-stage-2-t-b-gambiense-sleeping-sickness/)
- [Comparative efficacy of two fosravuconazole doses with itraconazole for eumycetoma, in combination with surgery](https://dndi.org/clinical-trial/comparative-efficacy-of-two-fosravuconazole-doses-with-itraconazole-for-eumycetoma-in-combination-with-surgery/)
- [Efficacy and safety of fexinidazole for undetermined chronic Chagas disease](https://dndi.org/clinical-trial/efficacy-and-safety-of-fexinidazole-for-undetermined-chronic-chagas-disease/)
- [Safety, tolerability, pharmacokinetics, and pharmacodynamics of CpG ODN D35 for cutaneous leishmaniasis (in healthy participants)](https://dndi.org/clinical-trial/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-cpg-odn-d35-for-cutaneous-leishmaniasis-in-healthy-participants/)
- [Safety, tolerability, and pharmacokinetics of emodepside for river blindness (in healthy participants)](https://dndi.org/clinical-trial/safety-tolerability-and-pharmacokinetics-of-emodepside-for-river-blindness-in-healthy-participants/)
- [Tolerability, safety, and bioavailability study of  immediate release emodepside for river blindness (in healthy participants)](https://dndi.org/clinical-trial/tolerability-safety-and-bioavailability-study-of-immediate-release-emodepside-for-river-blindness-in-healthy-participants/)
- [Efficacy and safety of fexinidazole for late-stage <i>T.b. gambiense</i> sleeping sickness](https://dndi.org/clinical-trial/dndi-fex-004/)
- [Efficacy and safety of fexinidazole for  <i>T.b. rhodesiense</i> sleeping sickness](https://dndi.org/clinical-trial/dndi-fex-07-hat/)
- [Efficacy, safety and adherence with fexinidazole for any stage of <i>T.b. gambiense</i> sleeping sickness](https://dndi.org/clinical-trial/dndi-fex-09-hat/)
- [Efficacy and safety of shorter benznidazole regimens and E1224 for chronic Chagas disease](https://dndi.org/clinical-trial/efficacy-and-safety-of-shorter-benznidazole-regimens-and-e1224-for-chronic-chagas-disease/)
- [Bioavailability study of immediate release flucytosine for cryptococcal meningitis (in healthy fed participants)](https://dndi.org/clinical-trial/bioavailability-study-of-immediate-release-flucytosine-for-cryptococcal-meningitis-in-healthy-fed-participants/)
- [Bioavailability study of immediate release flucytosine for cryptococcal meningitis (in healthy fasting participants)](https://dndi.org/clinical-trial/bioavailability-study-of-immediate-release-flucytosine-for-cryptococcal-meningitis-in-healthy-fasting-participants/)
- [Safety, tolerability, and pharmacokinetics of single dose DNDI-0690 for visceral and cutaneous leishmaniasis (in healthy participants)](https://dndi.org/clinical-trial/safety-tolerability-and-pharmacokinetics-of-single-dose-dndi-0690-for-visceral-and-cutaneous-leishmaniasis-in-healthy-participants/)
- [Platform trial of efficacy and safety of several therapies for mild / moderate COVID-19](https://dndi.org/clinical-trial/platform-trial-of-efficacy-and-safety-of-several-therapies-for-mild-moderate-covid-19/)

## Diseases

- [Dengue](https://dndi.org/diseases/dengue/) - Dengue is a rapidly spreading climate-sensitive disease with no specific treatment. We’re building a global partnership with dengue-endemic countries to develop a first treatment.
- [Cryptococcal meningitis](https://dndi.org/diseases/cryptococcal-meningitis/) - Without treatment, it's deadly for thousands of people with advanced HIV. We’re working to improve access to life-saving treatments and developing an easier-to-use formulation.
- [Pandemic Preparedness](https://dndi.org/diseases/pandemic-preparedness/) - We are combining our not-for-profit drug discovery and development experience and our collaborative, open-science model to help prepare for future pandemics.
- [Schistosomiasis](https://dndi.org/diseases/parasitic-worms/schistosomiasis/) - Schistosomiasis is a water-borne infection causing chronic ill-health and prolonged suffering, especially for women and children. We’re working to develop new anthelminthic treatments to stop the cycle of infection and prevent lifelong harm.
- [Visceral leishmaniasis](https://dndi.org/diseases/visceral-leishmaniasis/) - Visceral leishmaniasis is one of the world’s leading parasitic killers. We're working on a new generation of treatments to replace painful, ineffective drugs.
- [Sleeping sickness](https://dndi.org/diseases/sleeping-sickness/) - We revolutionized the treatment of fatal sleeping sickness with an oral cure to replace toxic, cumbersome medicines. We are now advancing to a single-dose pill.
- [River blindness](https://dndi.org/diseases/parasitic-worms/river-blindness/) - River blindness is caused by parasitic worms transmitted by blood-feeding insects. We aim to develop an effective, field-adapted treatment.
- [Parasitic worms](https://dndi.org/diseases/parasitic-worms/) - We are joining forces with partners to develop new treatments that can cure parasitic worms before they cause lasting harm – and working to make sure they are suitable for all people who need them, including young children and pregnant women.
- [Lymphatic filariasis](https://dndi.org/diseases/parasitic-worms/lymphatic-filariasis/) - Transmitted by mosquitoes, lymphatic filariasis causes painful swelling of the limbs and lifelong disability. We’re working to develop a safe, effective, affordable treatment to help eliminate this stigmatizing disease.
- [Hepatitis C](https://dndi.org/diseases/hepatitis-c/) - Hepatitis C is caused by a blood-borne, silent virus, leading to cirrhosis, cancer, and death. We have developed a simple-to-use, affordable cure.
- [Mycetoma](https://dndi.org/diseases/mycetoma/) - Fungal mycetoma is a slow-growing infection that causes severe disabilities. There is no effective cure. We ran the world’s first mycetoma clinical trial.
- [Paediatric HIV](https://dndi.org/diseases/paediatric-hiv/) - The needs of children with HIV have long been neglected. We have developed child-friendly formulations to replace bitter-tasting, refrigerated treatments.
- [Chagas disease](https://dndi.org/diseases/chagas/) - Potentially fatal Chagas disease is transmitted by kissing bugs. We're searching for new drug candidates and working to boost access to care.
- [Cutaneous leishmaniasis](https://dndi.org/diseases/cutaneous-leishmaniasis/) - Cutaneous leishmaniasis is transmitted through sandfly parasites, causing disfiguring skin lesions. We are developing safer, shorter, affordable treatments.
- [Antimicrobial resistance](https://dndi.org/diseases/amr/) - In 2016 we launched the Global Antibiotic Research and Development Partnership (GARDP) together with the WHO. We continue to share R&D expertise and capacity.
- [Malaria](https://dndi.org/disease/malaria/) - Access to effective treatment is central in the fight against malaria. The recently published PREGACT study has shown that artemisinin-based combination therapies are effective in pregnant women with malaria in Africa, without the safety concerns of other treatment types. Another success for malaria treatment comes with the World Health Organization’s announcement that the fixed-dose combination of artesunate+mefloquine (ASMQ) shelf-life has been extended from two to three years, which will greatly help with storage and distribution.

## Donors

- [Brazilian Innovation Agency (Financiadora de Estudos e Projetos - FINEP)/ Through the Regional and National Finep Awards for Innovation in Social Technology](https://dndi.org/about/public-donors/cnpq-finep/)
- [Brazilian Innovation Agency (Financiadora de Estudos e Projetos - FINEP)](https://dndi.org/about/public-donors/science-and-technology-innovation-agency-finep/)
- [UBS Optimus Foundation](https://dndi.org/about/private-donors/ubs-optimus-foundation/)
- [The Rockefeller Foundation (through the “Next Century Innovators Award”)](https://dndi.org/about/private-donors/rockefeller-foundation/)
- [The ELMA Foundation](https://dndi.org/about/private-donors/the-elma-foundation/)
- [Takeda Pharmaceutical Company Limited](https://dndi.org/about/private-donors/takeda-pharmaceutical-company-limited/)
- [Stavros Niarchos Foundation (SNF)](https://dndi.org/about/private-donors/stavros-niarchos-foundation/)
- [Starr International Foundation](https://dndi.org/about/starr-international-foundation/)
- [Pharmaniaga](https://dndi.org/about/private-donors/pharmaniaga/)
- [Other private foundations and individuals](https://dndi.org/about/private-donors/other-private-foundations-and-individuals/)
- [Novo Nordisk Foundation and the Pandemic Antiviral Discovery (PAD) Initiative](https://dndi.org/about/private-donors/novo-nordisk/)
- [Nationale Postcode Loterij & Dutch Postcode Lottery](https://dndi.org/about/private-donors/nationale-postcode-loterij-dutch-postcode-lottery/)
- [Medicor Foundation](https://dndi.org/about/private-donors/medicor-foundation-liechtenstein/)
- [Leo Model Foundation, Inc.](https://dndi.org/about/private-donors/leo-model-foundation-inc/)
- [Fundación Mundo Sano](https://dndi.org/about/fundacion-mundo-sano/)
- [J.A. Delmas](https://dndi.org/about/private-donors/j-a-delmas/)
- [Fundación La Caixa](https://dndi.org/about/fundacion-la-caixa/)
- [Fondation ARPE](https://dndi.org/about/fondation-arpe/)
- [Fondation Anne Maurer-Cecchini](https://dndi.org/about/private-foundations-and-private-individual-donors/fondation-anne-maurer-cecchini/)
- [Fondation André & Cyprien](https://dndi.org/about/fondation-andre-cyprien/)
- [Else Kröner Fresenius Award for Development Cooperation in Medicine 2020](https://dndi.org/about/private-donors/else-kroner-fresenius-award-for-development-cooperation-in-medicine-2020/)
- [Dioraphte Foundation](https://dndi.org/about/private-donors/dioraphte-foundation/)
- [Deerfield Foundation](https://dndi.org/about/private-donors/deerfield-foundation/)
- [Carlos Slim Foundation through the Carlos Slim Health Award](https://dndi.org/about/private-donors/carlos-slim-foundation-through-the-carlos-slim-health-award/)
- [Bem-Te-Vi Diversidade](https://dndi.org/about/private-donors/associacao-bem-te-vi-diversidade/)
- [BBVA Foundation (through the “Frontiers of Knowledge Award in Development Cooperation”)](https://dndi.org/about/private-donors/bbva-foundation/)
- [Brian Mercer Trust](https://dndi.org/about/brian-mercer-charitable-trust/)
- [Federal Ministry of Education and Research (BMBF)](https://dndi.org/about/public-donors/federal-ministry-of-education-and-research-bmbf/)
- [European and Developing Countries Clinical Trials Partnership (Global Health EDCTP3 Joint Undertaking)](https://dndi.org/about/public-donors/global-health-edctp3/)
- [European and Developing Countries Clinical Trials Partnership (EDCTP2)](https://dndi.org/about/public-donors/european-and-developing-countries-clinical-trials-partnership-edctp2/)
- [Global Health Innovative Technology Fund (GHIT Fund)](https://dndi.org/about/public-donors/global-health-innovative-technology-ghit-fund/)
- [PANAFTOSA – Organização Pan-Americana da Saúde/Organização Mundial da Saúde (OPAS/OMS)](https://dndi.org/about/public-donors/panaftosa-opas-oms/)
- [Gates Foundation](https://dndi.org/about/private-donors/gates-foundation/)
- [UK International Development](https://dndi.org/about/public-donors/uk-aid/)
- [Federal Ministry of Research, Technology and Space (BMFTR) through KfW](https://dndi.org/about/public-donors/federal-ministry-of-education-and-research-bmbf-through-kfw/)
- [Swiss Agency for Development and Cooperation (SDC)](https://dndi.org/about/public-donors/swiss-agency-for-development-and-cooperation-sdc/)
- [Swiss State Secretariat for Education, Research and Innovation (SERI)](https://dndi.org/about/public-donors/swiss-state-secretariat-for-education-research-and-innovation-seri/)
- [Research Investment for Global Health Technology Foundation (RIGHT Foundation)](https://dndi.org/about/public-donors/the-right-fund/)
- [Municipality of Corsier (Commune de Corsier)](https://dndi.org/about/public-donors/municipality-of-corsier-commune-de-corsier/)
- [Spanish Agency for International Development Cooperation (AECID)](https://dndi.org/about/public-donors/spanish-agency-for-international-development-cooperation-aecid/)
- [Wellcome](https://dndi.org/about/private-donors/wellcome-trust/)
- [International Development Research Centre (IDRC)](https://dndi.org/about/public-donors/international-development-research-centre-idrc/)
- [Federal Ministry for Economic Cooperation and Development (BMZ) through KfW](https://dndi.org/about/public-donors/federal-ministry-for-economic-cooperation-and-development-bmz-through-kfw/)
- [Médecins Sans Frontières Switzerland](https://dndi.org/about/private-donors/medecins-sans-frontieres-switzerland/)
- [Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)](https://dndi.org/about/public-donors/fundacao-de-amparo-a-pesquisa-do-estado-de-sao-paulo-fapesp/)
- [Médecins Sans Frontières International](https://dndi.org/about/private-donors/medecins-sans-frontieres-doctors-without-borders/)
- [Unitaid](https://dndi.org/about/public-donors/unitaid/)
- [Ministry of Health Brazil](https://dndi.org/about/public-donors/ministry-of-health/)
- [Prix Galien AFRICA](https://dndi.org/about/prizes/prix-galien-africa/)
- [National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)](https://dndi.org/about/public-donors/national-institutes-of-health-nih/)
- [Médecins sans Frontières – Transformational Investment Capacity (MSF-TIC)](https://dndi.org/about/private-donors/msf-transformational-investment-capacity-msf-tic/)
- [Médecins Sans Frontières Norway](https://dndi.org/about/private-donors/medecins-sans-frontieres/)
- [Médecins Sans Frontières Italy](https://dndi.org/about/private-donors/medecins-sans-frontieres-italy/)
- [Médecins Sans Frontières Brazil](https://dndi.org/about/private-donors/medecins-sans-frontieres-brazil/)
- [Médecins Sans Frontières (Doctors without Borders) USA](https://dndi.org/about/private-donors/medecins-sans-frontieres-doctors-without-borders-usa/)
- [Wellcome through the COVID-19 Therapeutics Accelerator](https://dndi.org/about/covid-19-therapeutics-accelerator/)
- [Department of Health and Social Care (DHSC)](https://dndi.org/about/public-donors/department-of-health-and-social-care-dhsc/)
- [Dutch Ministry of Health, Welfare and Sport (VWS)](https://dndi.org/about/public-donors/dutch-ministry-of-health-welfare-and-sport-vws/)
- [Federal Office of Public Health (FOPH)](https://dndi.org/about/public-donors/federal-office-of-public-health-foph/)
- [South African Medical Research Council (SAMRC)](https://dndi.org/about/public-donors/south-african-medical-research-council-samrc/)
- [Horizon Europe](https://dndi.org/about/public-donors/horizon-europe/)
- [United States Agency for International Development (USAID)](https://dndi.org/about/public-donors/united-states-agency-for-international-development-usaid/)
- [Norwegian Agency for Development Cooperation (Norad), Norwegian Ministry of Foreign Affairs, as part of Norway’s in-kind contribution to EDCTP2](https://dndi.org/about/public-donors/norwegian-agency-for-development-cooperation-norad-norwegian-ministry-of-foreign-affairs-as-part-of-norways-in-kind-contribution-to-edctp2/)
- [Ministry of Health Malaysia](https://dndi.org/about/public-donors/ministry-of-health-malaysia/)
- [USAID via the 4th Sector Health Project implemented by Abt Associates, Inc.](https://dndi.org/about/public-donors/united-states-agency-for-international-development-usaid-via-the-4th-sector-health-project-implemented-by-abt-associates-inc/)
- [Dutch Ministry of Foreign Affairs (DGIS)](https://dndi.org/about/public-donors/dutch-ministry-of-foreign-affairs-dgis/)
- [National Science and Technology Development Agency (NSTDA), Ministry of Science and Technology](https://dndi.org/about/public-donors/national-science-and-technology-development-agency-nstda-ministry-of-science-and-technology/)
- [Innosuisse, Swiss Innovation Agency](https://dndi.org/about/public-donors/innosuisse-swiss-innovation-agency/)
- [FIND, the global alliance for diagnostics, HEAD-START project (funded by Unitaid)](https://dndi.org/about/public-donors/find/)
- [The Global Fund to fight AIDS, Tuberculosis and Malaria](https://dndi.org/about/public-donors/the-global-fund-to-fight-aids-tuberculosis-and-malaria/)
- [Republic and Canton of Geneva, International Solidarity Service](https://dndi.org/about/public-donors/republic-and-canton-of-geneva-international-solidarity-service/)
- [National Research Foundation](https://dndi.org/about/public-donors/national-research-foundation/)
- [Fundação para a Ciência e a Tecnologia (FCT)](https://dndi.org/about/public-donors/fundacao-para-a-ciencia-e-a-tecnologia-fct/)
- [Norwegian Government](https://dndi.org/about/public-donors/norwegian-government/)
- [Monegasque Cooperation for development](https://dndi.org/about/public-donors/monegasque-cooperation-for-development/)
- [Grand Duchy of Luxembourg](https://dndi.org/about/public-donors/grand-duchy-of-luxembourg/)
- [Federal Ministry of Health (BMG)](https://dndi.org/about/public-donors/federal-ministry-of-health/)
- [European and Developing Countries Clinical Trials Partnership (EDCTP1)](https://dndi.org/about/public-donors/european-and-developing-countries-clinical-trials-partnership-edctp/)
- [European Union – Framework Programme 6](https://dndi.org/about/public-donors/european-union-framework-programme-6/)
- [European Union – Framework Programme 5](https://dndi.org/about/public-donors/european-union-specific-international-scientific-cooperation-activities-fp5/)
- [European Union – Framework Programme 7](https://dndi.org/about/public-donors/european-union-specific-international-scientific-cooperation-activities-fp7/)
- [Region of Tuscany](https://dndi.org/about/public-donors/region-of-tuscany/)
- [World Health Organization – Special Programme for Research and Training in Tropical Diseases (WHO-TDR)](https://dndi.org/about/public-donors/special-programme-for-research-and-training-in-tropical-diseases-who-tdr/)
- [German Corporation for International Cooperation (GIZ) on behalf of the Government of the Federal Republic of Germany](https://dndi.org/about/public-donors/german-corporation-for-international-cooperation-giz-on-behalf-of-the-government-of-the-federal-republic-of-germany/)
- [Deutsches Zentrum für Infektionsforschung - German Center for Infection Research (DZIF)](https://dndi.org/about/public-donors/deutsches-zentrum-fur-infektionsforschung-german-center-for-infection-research-dzif/)
- [Ministry For Europe and Foreign Affairs](https://dndi.org/about/public-donors/french-ministry-for-europe-and-foreign-affairs-meae/)
- [French Development Agency (AFD)](https://dndi.org/about/public-donors/french-development-agency-afd/)
- [Horizon 2020](https://dndi.org/about/public-donors/horizon-2020/)
- [Ministère de la Santé de la République Démocratique du Congo (Projet de Développement du Système de Santé financé par la Banque Mondiale)](https://dndi.org/about/public-donors/ministere-de-la-sante-de-la-republique-democratique-du-congo-projet-de-developpement-du-systeme-de-sante-finance-par-la-banque-mondiale/)
- [Ruta-N / City of Medellin](https://dndi.org/about/public-donors/buck-foundation-ruta-n-medellin/)
- [Fundação Oswaldo Cruz (Fiocruz)](https://dndi.org/about/public-donors/fundacao-oswaldo-cruz-fiocruz/)
- [Banco Nacional de Desenvolvimento Econômico e Social (BNDES)](https://dndi.org/about/public-donors/brazilian-development-bank-bndes/)
- [Australian Trade and Investment Commission (Austrade)](https://dndi.org/about/public-donors/australian-trade-and-investment-commission-austrade/)
- [Mundo Sano (PRV)](https://dndi.org/about/mundo-sano-prv/)

## Events

- [26th International AIDS Conference](https://dndi.org/events/2026/26th-international-aids-conference/) - The world’s largest conference on HIV and AIDS will unite people living with HIV, researchers, policy makers, healthcare professionals, funders, media and communities. DNDi participation - Satellite Session Adapting AHD for routine care and outbreak response: Country implementation experiences Date: 28 July 2026Time: 18:00-19:30Moderators: Soo Fern Lee, DNDi, Switzerland; Remilekun Roland Peregrino, Aurum Institute, Ghana
- [61st Congress of the Brazilian Society of Tropical Medicine (Medtrop)](https://dndi.org/events/2026/61st-congress-of-the-brazilian-society-of-tropical-medicine-medtrop/) - The 61st Congress of the Brazilian Society of Tropical Medicine (Medtrop 2026) will convene under the theme Health in the tropics: an integrative vision from the perspective of the Global South, framing discussions around health challenges specific to tropical regions with an emphasis on South-South collaboration and equitable partnerships with the Global North. The event
- [EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026](https://dndi.org/events/2026/efmc-acsmedi-medicinal-chemistry-frontiers-2026/) - The EFMC-ACSMEDI Medicinal Chemistry Frontiers is co-organised by EFMC (European Federation for Medicinal chemistry and Chemical biology) and ACS MEDI (Division of Medicinal Chemistry of the American Chemical Society). ACSMEDI-EFMC Medicinal Chemistry Frontiers Meeting attracts a highly targeted audience composed of experts, researchers and early career trainees in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields
- [Patient Engagement Open Forum 2026](https://dndi.org/events/2026/patient-engagement-open-forum-2026/) - Once a year, PEOF brings together a unique global gathering, uniting a network of multicultural and multidisciplinary visionaries to shape the future of Patient Engagement (PE). This dynamic patient-led community collaborates, fosters innovation, and co-creates solutions that challenge the status quo and pave the way for systematic PE. Co-organized by PFMD, EPF, and EUPATI, PEOF
- [ICOPA 202616th International Congress of Parasitology](https://dndi.org/events/2026/icopa-202616th-international-congress-of-parasitology/) - The sixteenth edition of the International Congress of Parasitology – ICOPA XVI organised by the World Federation of Parasitologists (WFP) will take place in Montréal, Canada, on August 16-21, 2026. This event will see the global parasitology community gathering together and advance science. Under the theme “Parasites in a Changing World” ICOPA XVI will showcase
- [MSF Scientific Days](https://dndi.org/events/2026/msf-scientific-days-2026/) - The MSF Scientific Days bring together researchers, innovators, and advocates in humanitarian global health to discuss and challenge research from within the sector. DNDi participation Poster Contraception requirements for women’s access to leishmaniasis and Chagasdisease treatment and research: findings from a community-informed multi-country study. Authors: G. Cota, L. Persoz , A. Marchiol, D. Galvão, M.-J.
- [Strengthening global health financing through digital infrastructure: Introducing HealthFund Hub](https://dndi.org/events/2026/strengthening-global-health-financing-through-digital-infrastructure-introducing-healthfund-hub/) - This high-level side event at the World Health Assembly, hosted by the Global Health Finance Coalition (GHFC), will introduce HealthFund Hub, a digital infrastructure initiative aimed at improving coordination, transparency, and efficiency in global health financing. Date: 19 May 2026Time: 7:30-9:30Location: SDG Solutions Space, GenevaDNDi participation : Thi Hanh Cao, External Relations Director, DNDi More
- [9th Asia Dengue summit 2026](https://dndi.org/events/2026/9th-asia-dengue-summit-2026/) - The annual ADS serves as a platform for the community of clinicians, public health officials and scientists to meet, exchange the latest knowledge and establish new collaborative networks. Thought leaders in the dengue field will gather to synthesize the evidence and distil it into actionable insights. The latest findings from those at the forefront of
- [79th World Health Assembly: ISNTD Side Events](https://dndi.org/events/2026/79th-world-health-assembly-isntd-side-events/) - On the occasion of the 79th World Health Assembly, the International Society for Neglected Tropical Diseases is organizing a side event. Arboviruses: Shaking or shaping the future of global health Date: 19 May 2026Time: 8:30-10:00Location: Hotel President Wilson, GenevaDNDi participation : Isabela Ribeiro, Viral Diseases Cluster Director, DNDi More information and register
- [CRM Trial Connect 2026](https://dndi.org/events/2026/crm-trial-connect-2026/) - CRM Trial Connect 2026 is Asia's premier clinical research conference, uniting over 1,000 delegates from leading research centres, hospitals, regulators, CROs, and sponsors across 17 countries. The event focuses on oncology research excellence, trial site operations and advancing cross-border collaboration in clinical trials. It serves as a one-stop platform for accelerating clinical research readiness and
- [World Hepatitis Summit 2026](https://dndi.org/events/2026/world-hepatitis-summit-2026/) - The Ministry of Public Health of Thailand is hosting the 2026 edition of the World Hepatitis Summit under the theme 'Elimination for everyone, everywhere, right now!' Posters Date: Thursday, 30 April 2026Time: 10:30 - 11:00 More information Event website
- [Sustaining the momentum: cross-border collaboration to achieve malaria and neglected tropical diseases (NTD) elimination](https://dndi.org/events/2026/sustaining-the-momentum-cross-border-collaboration-to-achieve-malaria-and-neglected-tropical-diseases-ntd-elimination/) - Join global health leader for a high-level dialogue on accelerating disease elimination, highlighting practical solutions through strong leadership, resilient health systems, and cross-border collaboration. Agenda and speakers Time: 7:30 - 9:30 Venue: Restaurant Vieux Bois, Avenue de la Paix 12, Geneva Panel chair: Dr Michael Adekunle Charles, CEO RBM Partnership to End Malaria In this
- [World Health Summit Regional Meeting 2026](https://dndi.org/events/2026/world-health-summit-regional-meeting-2026/) - The World Health Summit (WHS) Regional Meeting 2026 will be held at the United Nations Office at Nairobi (UNON). Leaders, innovators, and changemakers will gather to explore solutions that strengthen Africa’s health systems and advance global health progress. DNDi participation Driving Health Innovation and Economic Resilience: Strengthening Africa-­Europe Cooperation on Digital Health, Local Manufacturing, and
- [Open forum: Rebuilding global health on solidarity principles](https://dndi.org/events/2026/open-forum-rebuilding-global-health-on-solidarity-principles/) - Since 2023, the Global Health Solidarity Project has worked to clarify what solidarity means in practice and how it might be operationalised within global health. Through regional workshops, stakeholders interviews, and cross-regional dialogue, the project has developed a set of principles intended to provide a normative framework for reflection and action. This open forum will
- [6th Dengue Alliance Meeting](https://dndi.org/events/2026/dengue-alliance-meeting/) - The 6th Dengue Alliance & Joint Steering Committee (JSC) Meeting will convene Dengue Alliance partners including Translational Health Science and Technology Institute (THSTI), Drugs for Neglected Diseases initiative (DNDi), the Ministry of Health Malaysia, Oswaldo Cruz Foundation (Fiocruz), Universidade Federal de Minas Gerais (UFMG), and the Faculty of Medicine Siriraj Hospital, Mahidol University. Discussions will
- [One Health Summit 2026](https://dndi.org/events/2026/one-health-summit-2026/) - The One Health Summit brings together, for the first time, Heads of State and Government from around the world, Heads of International and Regional Organizations, parliamentarians, representatives of the scientific and academic community, the private sector, civil society, local authorities, and youth to accelerate the implementation of the "One Health" approach. The theme of the
- [2026 The World NTD Day Webinar](https://dndi.org/events/2026/2026-the-world-ntd-day-webinar/) - This webinar, hosted by the Japan Organizing Committee, aims to deepen understanding of NTDs and promote action toward their control and elimination. Watch the recording
- [ACS Spring 2026](https://dndi.org/events/2026/acs-spring-2026/) - ACS Spring 2026 will take place in Atlanta, GA, and is one of the largest annual gatherings in the chemistry field. The event features thousands of oral presentations spanning a wide range of chemistry specialties, as well as poster sessions showcasing current research. The program also includes the Open Board Session, the Priestley Medalist Address,
- [ICAR 2026](https://dndi.org/events/2026/icar-2026/) - The International Society for Antiviral Research (ISAR) is hosting the 39th International Conference on Antiviral Research (ICAR), bringing together leading scientists, researchers, and industry professionals to discuss the latest advancements and breakthroughs in antiviral research. Poster More information Event website
- [MycoCon 2026](https://dndi.org/events/2026/mycocon-2026/) - Organized by the Fungal Infections Study Forum (FISF) and the International Society for Human and Animal Mycology, the 6th International Conference on Fungal Infections & Mycology Masterclass (MycoCon 2026) brings together national and international experts to exchange knowledge, present cutting-edge research, and share collaborative discussions on the management of complex fungal infections. Symposium Superficial and
- [From discovery to delivery: Advancing care for neglected tropical diseases](https://dndi.org/events/2026/from-discovery-to-delivery-advancing-care-for-neglected-tropical-diseases/) - Charité – Universitätsmedizin Berlin and the Drugs for Neglected Diseases initiative (DNDi) are organizing a scientific exchange, bringing together clinicians and researchers, to highlight practical advances in NTD care, explore collaboration between academia and product development partnerships, and offer space for discussion and networking. The event is open to clinicians, researchers, students, and everyone interested
- [16th KASH conference](https://dndi.org/events/2026/16th-kash-conference/) - KASH is the KEMRI Annual Scientific and Health Conference launched in 2011 with the mission to mainstream the scientific and health agenda of KEMRI by dissemination, sharing and digesting various scientific outputs and other allied products including networking and strengthening partnerships and collaborations with a view to improving on health and quality of life of
- [Eastern Africa Regional Global Health Security Summit 2026](https://dndi.org/events/2026/eastern-africa-regional-global-health-security-summit-2026/) - The 2nd Eastern Africa Regional Global Health Security Summit brings together global and regional leaders, health experts, policymakers, and innovators to advance Africa’s journey toward sovereign health security. The theme of this year's summit is 'Catalyzing collaboration & local manufacturing of health commodities for Africa's sovereign health security'. Panel discussion How do neglected diseases compound
- [36th Annual Scientific Meeting of the Japan Epidemiological Association & 3rd Joint Scientific Meeting with the IEA Western Pacific Region](https://dndi.org/events/2026/36th-annual-scientific-meeting-of-the-japan-epidemiological-association-3rd-joint-scientific-meeting-with-the-iea-western-pacific-region/) - The 36th Annual Scientific Meeting of the Japan Epidemiological Association, held jointly with the IEA Western Pacific Region, aims to advance epidemiological science in the face of increasingly complex global health challenges by fostering international collaboration, embracing diversity and inclusion, and strengthening methodological innovation. Grounded in the theme 'Epidemiology and global issues: Addressing diversity, complexity,
- [DZIF/PEG Joint Meeting 2026](https://dndi.org/events/2026/dzif-peg-joint-meeting-2026/) - The 2026 joint meeting of the German Center for Infection Research (DZIF) and Paul-Ehrlich Society for Infection Therapy (PEG) aims to address the complexity of infectious disease research and the necessity of interdisciplinary collaboration to combat the growing threats of drug resistance, and epidemic and pandemic events. Key topics include innovations in drug research, development,
- [Bridging gaps in neglected tropical diseases data](https://dndi.org/events/2026/bridging-gaps-in-neglected-tropical-diseases-data/) - As part of the World NTD Day 2026 celebrations, this webinar aims to explore the experience of different strategies for collecting, managing, and disseminating data on Neglected Tropical Diseases (NTDs) with the collaboration of health systems, civil society organizations and researchers that can help address critical data gaps and support more informed public health responses.
- [ASTMH 2024](https://dndi.org/events/2024/astmh-2024/) - The ASTMH Annual Meeting draws tropical medicine and global health professionals representing academia, foundations, government, not for profit organizations, non-governmental organizations, the private sector, military and private practice. download dndi @ astmh 2024 Keynote Address Decolonizing science to benefit all: Reflections of an African researcher on the frontlines Date: Wednesday, 13 November 2024Time: 17:30 -
- [MSF Scientific Days](https://dndi.org/events/2019/msf-scientific-days/) - The aim of MSF Scientific Days is to help improve the quality of care provided to the patients and populations, by sharing and discussing the research conducted in MSF field programmes. Presentation Date: Thursday, 9 May 2019 More information: Event website
- [16th International Conference on Vector Borne Diseases](https://dndi.org/events/2025/16th-international-conference-on-vector-borne-diseases/) - The International Conference on Vector Borne Diseases is organized by the Centre of Excellence for Environment & Public Health Department of Zoology, Ravenshaw University, Cuttack and the National Academy of Vector Borne Diseases (NAVBD). The theme of the 16th edition is 'Innovations to Impact'. Session Understanding severe dengue and advancing therapeutics: An alliance approach Date:
- [Bridging the gap between research and policy for NTDs amid a changing funding landscape](https://dndi.org/events/2025/bridging-gap-between-research-and-policy-for-ntds-amid-changing-funding-landscape/) - With less than five years remaining to achieve the 2030 NTDs elimination targets—and in the context of a rapidly changing global funding landscape - it is more critical than ever to ensure that research evidence translates into actionable policy and real-world impact. The African Population and Health Research Center (APHRC) and the Drugs for Neglected
- [DND<em>i</em> Making Medical History Gala](https://dndi.org/events/2018/making-medical-history-gala/) - DNDi celebrates 15 years of bringing the best science to the world's most neglected patients. Join us for the Making Medical History Gala at the Bowery Hotel, New York. Presented by Sanofi Agenda Honorees Award design by Congolese sculptor Alfred Liyolo Featuring Emcee: Dr Javid Abdelmonein, BBC TV Presenter and President, Médecins Sans Frontières UK Special guests:
- [ASTMH 2025](https://dndi.org/events/2025/astmh-2025/) - The ASTMH Annual Meeting draws tropical medicine and global health professionals representing academia, foundations, government, not for profit organizations, non-governmental organizations, the private sector, military and private practice. Find us at BOOTH #215 where we are sharing a space with Médecins Sans Frontières/Doctors without Borders. We are honoured to host Mulikat Okanlawon, noma survivor and
- [COP30](https://dndi.org/events/2025/cop30/) - The Conference of the Parties (COP) is the largest global United Nations event for discussions and negotiations on climate change. Brasil is hosting the 30th Conference of the Parties (COP30). With a focus on scientific innovation and equity, DNDi aims to bring to COP30 the perspective of the most vulnerable communities and share our commitment
- [One Sustainable Health for All Forum](https://dndi.org/events/2025/one-sustainable-health-for-all-forum/) - On the occasion of World One Health Day on November 3, Lyon is hosting the One Sustainable Health for All Forum bringing together international experts in human, animal, and environmental health. OSH for All Lyon 2025 is organized by the One Sustainable Health for All Foundation, under the aegis of the Institut Pasteur, in synergy
- [Nigeria-EU Health Investment Forum](https://dndi.org/events/2025/nigeria-eu-health-investment-forum/) - The Nigeria-EU Health Investment Forum is hosted by the EU Delegation to Nigeria and ECOWAS, PVAC, and the National Institute for Pharmaceutical Research and Development (NIPRD) and aims to bring together leaders from government, industry, research, and finance. Panel discussion Enabling health sector growth Time: 11:00 – 12:10 Speakers include: Borna Nyaoke-Anoke, Head of Mycetoma
- [66th Annual Meeting for the Japanese Society of Tropical Medicine](https://dndi.org/events/2025/66th-annual-meeting-for-the-japanese-society-of-tropical-medicine/) - The 66th Annual Meeting of the Japanese Society of Tropical Medicine focuses on the theme 'toward equity in healthcare'. It aims to promote fair and inclusive healthcare in tropical and resource-limited settings by sharing research, fostering collaboration, and addressing global health challenges such as vaccine access and neglected tropical diseases. Symposium Challenges of providing care
- [ISNTD Climate & Health 2025](https://dndi.org/events/2025/isntd-climate-health-2025/) - From climate signals to health systems: A new era for infectious and tropical diseases The ISNTD Climate & Health 2025 conference aims to explore how climate change influences infectious diseases, particularly neglected tropical diseases (NTDs), and to strengthen climate resilience in health systems. It brings together experts across disciplines to integrate climate intelligence into disease
- [MedTrop 2025](https://dndi.org/events/2025/medtrop-2025/) - MedTrop 2025, the 60th Congress of the Brazilian Society of Tropical Medicine, brings together a diverse community of researchers, healthcare professionals, and students to address critical issues in tropical medicine and public health. The congress aims to foster scientific exchange and innovation in Latin America. The 2025 edition focuses on communicable diseases, including arboviruses and
- [65th ITM Colloquium](https://dndi.org/events/2025/65th-itm-colloquium/) - The Institute of Tropical Medicine (ITM) Antwerp is organizing a colloquium on Innovations in Infectious Disease Research, uniting leading scientists, policymakers, healthcare practitioners and innovators to reflect on current challenges, explore transformative ideas, and stimulate open debate on the future of infectious disease research, prevention and control. Roundtable Moderator: Gorik Ooms, Health Policy, Institute of Tropical Medicine
- [Sustaining Gains, Expanding Horizons – Side event marking the 20th anniversary of South Asia's Kala-azar Elimination Initiative](https://dndi.org/events/2025/sustaining-gains-expanding-horizons-side-event-20th-anniversary-south-asias-kala-azar-elimination-initiative/) - From A 20-Year Journey of Regional Kala-azar Elimination Commitment and Innovation Toward a Healthier South-East Asia through Multi-Disease Elimination Building on the legacy of kala-azar elimination for integrated public health delivery Kala-azar, or visceral leishmaniasis, has long been one of the most devastating neglected tropical diseases in South Asia, with Bangladesh, India, and Nepal carrying
- [DND<em>i</em> Making Medical History Gala - After Party](https://dndi.org/events/2018/makingmedicalhistory-gala-afterparty/) - DNDi celebrates 15 years of bringing the best science to the world's most neglected patients. Join us for the Making Medical History Gala After Party at the Bowery Hotel, New York. Featuring DJ Logic As one of the world's most accomplished turntablists, DJ Logic is widely credited for introducing jazz into the hip-hop realms and is
- [CPHIA 2025](https://dndi.org/events/2025/cphia-2025/) - The International Conference on Public Health in Africa (CPHIA) is organized by the Africa Centres for Disease Control and Prevention (Africa CDC) and provides an African-led platform for leaders across the continent to reflect on lessons learned in health and science, and align on a way forward for creating more resilient health systems. The theme
- [8th COLDA 2025](https://dndi.org/events/2025/8th-colda-2025/) - The 8th Edition of the Conference on Liver Disease in Africa (COLDA) will take place as a hybrid meeting from 18 - 20 September 2025 in Accra, Ghana, at the Fiesta Royale Hotel. Co-organized by SOLDA and Academic Medical Education in close collaboration with regional societies, COLDA 2025 aims at empowering healthcare professionals to diagnose, prevent, treat, and achieve a cure for liver diseases
- [World Health Summit 2025](https://dndi.org/events/2025/world-health-summit-2025/) - The World Health Summit is one of the world’s leading strategic forums for global health bringing together stakeholders from politics, science, the private sector, and civil society from around the world. Held under the theme 'Taking responsibility for health in a fragmenting world', WHS 2025 aims to set the agenda for a healthier future by
- [European Health Forum Gastein 2025](https://dndi.org/events/2025/european-health-forum-gastein-2025/) - Co-organized and co-funded by the Federal Ministry Labour, Social Affairs, Health care and Consumer Protection of the Republic of Austria and the European Union, the theme of the 2025 edition of the European Health Forum Gastein (EHFG) is 'Rethinking solidarity in health: Healing Europe's fractured social contract'. Session Transparency of public contributions to drug development:
- [NNN Conference 2025](https://dndi.org/events/2025/nnn-conference-2025/) - The 16th Annual NNN Conference gathers NTD practitioners, government leaders, researchers, policymakers, and other stakeholders from over 50 countries to discuss challenges and solutions for NTD elimination. Workshop Bridging the gap: Overcoming barriers to VL elimination in Eastern Africa Organized by DNDi and The End Fund Dates: Monday, 29 September - Wednesday, 1 October 2025
- [ECTMIH 2025](https://dndi.org/events/2025/ectmih-2025/) - The 14th European Congress on Tropical Medicine and International Health (ECTMIH 2025) is hosted by the Federation of European Societies for Tropical Medicine and International Health (FESTMIH), in collaboration with the Bernhard Nocht Institute for Tropical Medicine (BNITM), which also celebrates its anniversary during the congress. Under the banner ‘Better health for all in a
- [BrazMedChem 2025](https://dndi.org/events/2025/brazmedchem-2025/) - The Brazilian Symposium on Medicinal Chemistry (BrazMedChem) is an international scientific event with the main objective of bringing together Brazilian Medicinal Chemists and students to discuss state-of-the-art drug discovery and development tools and strategies. Posters More information Event website
- [Science Summit 2025 UNGA80](https://dndi.org/events/2025/science-summit-2025-unga80/) - The Science Summit 2025 focuses on the pivotal role of science in addressing global challenges while respecting planetary boundaries. Session Transforming women’s health through science and sustainable partnerships Organized by The Society for Women’s Health Research (SWHR) and ECHAlliance – The Global Health Connector Date: Monday, 22 September 2025Time: 9:00-13:00Venue: CURE - 2nd Floor Speakers include:
- [RSTMH Annual Meeting 2025](https://dndi.org/events/2025/rstmh-annual-meeting-2025/) - The Royal Society of Tropical Medicine & Hygiene (RSTMH) 2025 Annual Meeting brings together a wide range of professionals, academics, and students working in the field of tropical medicine and global health, particularly those exploring the intersection of AI, ethics, and equity in healthcare. The RSTMH 2025 annual meeting is organised around the theme 'AI in global
- [EFMC-ASMC 2025](https://dndi.org/events/2025/efmc-asmc-2025/) - The 10th edition of the International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC 2025) will be held in Porto, Portugal, from 31 August - 4 September 2025, and will bring together leading scientists from around the world to explore the latest developments in synthetic chemistry, medicinal chemistry, chemical biology, and drug discovery. The
- [The 5th Hideyo Noguchi Africa Prize Special Lectures at Nagasaki University](https://dndi.org/events/2025/5th-hideyo-noguchi-africa-prize-special-lectures-nagasaki-university/) - The Nagasaki University is hosting a special commemorative lecture with the recipients of theHideyo Noguchi Africa Prize. Time: 11:00-12:30Venue: Nagasaki University TMGH Building Lecture Room 1FL Speakers: Dr Abdoulaye Djimdé, Director, Parasites & Microbes Research & Training Center (PMRTC), University of Science, Techniques and Technologies of Bamako Dr Luis Pizarro, Executive Director, DNDi Dr Wilfried
- [TICAD 9](https://dndi.org/events/2025/ticad-9/) - TICAD stands for Tokyo International Conference on African Development. The Government of Japan has been leading this conference since 1993. Side event Co-Creating with Africa to end NTDs: Industry, academia, government collaboration and the power of youth Organized by Nagasaki University Date: Wednesday, 20 August 2025Time: 12:40-14:10Venue: PACIFICO YOKOHAMA Hall D REgister for the side
- [Mycetoma: a neglected disease affecting thousands of people](https://dndi.org/events/2025/mycetoma-a-neglected-disease-affecting-thousands-of-people/) - The Mycetoma Research Centre (MRC) in Khartoum has spent decades advancing knowledge of mycetoma, pioneering diagnostics to enable early detection in remote settings, and providing comprehensive care through its clinics and telehealth network. A leading partner in regional and global collaborations driving progress in the fight against mycetoma, MRC provided training for health professionals and
- [Accelerating innovation and access to #bettermeds4kids](https://dndi.org/events/2023/accelerating-innovation-access-to-bettermeds4kids/) - A spotlight on medicines for children Date: Wednesday, 24 May 2023Time: 18:30-20:00Venue: Hotel Warwick, rue de Lausanne 14, 1201 Geneva Convened by the Drugs for Neglected Diseases initiative (DNDi), the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), and the Medicines Patent Pool (MPP) on behalf of the Global Accelerator for Paediatric Formulations (GAP-f), this World Health
- [Twelfth EDCTP Forum](https://dndi.org/events/2025/twelfth-edctp-forum/) - The twelfth edition of the EDCTP Forum aims to showcase the impact of the EDCTP programmes in the last two decades under the theme ‘Better health through global research partnerships’. The event brings together policymakers, researchers, and stakeholders to discuss how we can advance global health through equitable partnerships, collaborative research, innovation, and capacity-building in sub-Saharan
- [Antiviral Drug Discovery (AViDD) Open Science Forum](https://dndi.org/events/2025/antiviral-drug-discovery-avidd-open-science-forum-4/) - The Open Science Forum features monthly talks from scientists from NIH-funded Antiviral Drug Discovery (AViDD) Centers who elect to provide updates on target priorities, advertise available resources and reagents, disclose chemical matter (such as hits, leads, and chemical tool compounds) and associated antiviral data, share findings regarding in vivo efficacy models, discuss downstream development and translation models,
- [EASL Congress 2025](https://dndi.org/events/2025/easl-congress-2025/) - The EASL Congress 2025 brings together over 8,000 delegates working in the field of hepatology to share the latest advancements in the field. Poster presentation Date: Wednesday, 7 May 2025Time: 8:30 More information Event website
- [SciBiz Conference 2025](https://dndi.org/events/2025/scibiz-conference-2025/) - SciBiz Conference aims to bring together researchers, entrepreneurs, and investors to accelerate and scale up the process of turning invention into innovation. Session Criando interfaces e oportunidades entre setores público e privado para P&D Date: Tuesday, 17 June 2025Time: 10:40-10:55 Speakers: Luiza Cruz, Drug Discovery Coordinator, DNDi Carolina Borsoi Moraes, FCF-USP More information Event website
- [XIX Jornadas sobre la enfermedad de Chagas](https://dndi.org/events/2025/xix-jornadas-sobre-la-enfermedad-de-chagas/) - Organized by IS Global, the theme of the 19th Conference on Chagas disease is 'Access to comprehensive management of Chagas disease and cardiovascular disease care.' Presentation Date: Thursday, 29 May 2025Time: 12:10-12:30 More information Event website
- [13th edition of the Carlos Chagas Lecture Cycle](https://dndi.org/events/2025/13th-carlos-chagas-lecture-cycle/) - Organized by the Oswaldo Cruz Institute (IOC/Fiocruz), the event brings together researchers, health professionals and associations of people with the disease to reflect on the main findings and contemporary challenges of Chagas disease. Poster More information Event website
- [NTDs around the world - Colombia](https://dndi.org/events/2025/ntds-around-the-world-colombia/) - Organized by the German Society for Tropical Medicine (DTG) and the Federation of European Societies for Tropical Medicine and International Health (FESTMIH), the next session of the “NTDs Around the World” series highlights neglected tropical diseases in Colombia and will discuss dermatological conditions in the Pacific region, remote surveillance of leishmaniasis, and new therapeutic approaches for Chagas disease. Agenda Moderators: Barbora Jara-Režnáková,
- [PAGE 2025](https://dndi.org/events/2025/page-2025/) - PAGE represents a community with a shared interest in data analysis using the population approach. Posters More information Event website
- [2ème Conférence Mondiale des Journalistes Scientifiques Francophones](https://dndi.org/events/2025/2eme-conference-mondiale-des-journalistes-scientifiques-francophones/) - The 2025 World Conference of Francophone Journalists highlights the challenges of reporting on health and environmental crises. It brings together science journalists and researchers for debates, workshops, roundtables, meetings, collaborations, and knowledge sharing. Panel discussion Lutte contre la maladie du sommeil, cas d’école d’une seule santé (en partenariat avec l’ONG de recherche médicale contre les
- [8th Asia Dengue Summit](https://dndi.org/events/2025/8th-asia-dengue-summit/) - Under the theme 'Towards zero dengue deaths: Science, strategy, and solidarity,' the 8th edition of the Asia Dengue Summit aims to foster collaborative efforts and innovative approaches to combat the growing threat of dengue. Key discussions centers around pivotal topics, including policy and burden of disease, advancements in vector control, vaccine development, clinical management, outbreak control through surveillance
- [AIDS 2016](https://dndi.org/events/2016/aids2016peds/) - The International AIDS Conference brings together science, leadership, and community to advance treatment and prevention of HIV. DNDi co-hosted a satellite session on paediatric HIV. Satellite Session Scale up HIV treatment for children:The right tools, right now! Date: 21 July 2016 The Drugs for Neglected Diseases initiative (DNDi), the Clinton Health Access Initiative (CHAI), UNITAID,
- [ICASA 2017](https://dndi.org/events/2017/icasa-2017/) - The ICASA 2017 theme was 'Africa: Ending AIDS-delivering differently' and aimed to engage the whole continent and all stakeholders in the post sustainable development goal (SDG) framework, especially in relation to reaching the UNAIDS target of 90-90-90. DNDi participated at the event. Satellite Session The role of point-of-care testing for early infant diagnosis and improved treatment
- [Strengthening the global ecosystem for paediatric medicines: leadership, collaboration, and impact](https://dndi.org/events/2025/strengthening-global-ecosystem-for-paediatric-medicines/) - Co-organized by Temasek Foundation, Medicines for Malaria Venture, Medicines Patent Pool, Drugs for Neglected Diseases initiative, Global Antibiotic Research and Development Partnership, and the International AIDS Society, this strategy launch and panel discussion will bring together country leaders and global health partners. Together, we will explore how to strengthen the ecosystem that supports the development, approval,
- [Innovation meets unity: Advancing global health solutions for Africa](https://dndi.org/events/2025/innovation-meets-unity-advancing-global-health-solutions-for-africa/) - On the margins of the 78th World Health Assembly, Merck is organizing a high-level ministerial dialogue bringing together African Ministers of Health, global partners, and industry leaders to explore strategic innovation, public-private partnerships, and resilient health financing. Date: Thursday, 22 May 2025Time: 12:00Venue: Intercontinental Hotel, Geneva Speakers: Minister of Health, Egypt Minister of Health, Nigeria
- [MSF Scientific Days 2024 – A Conference Without Borders](https://dndi.org/events/2024/msf-scientific-days-2024-a-conference-without-borders/) - The MSF Scientific Days International conference is a platform for researchers, innovators, and advocates in humanitarian global health to come together to discuss and challenge research from within the sector. Session From trials to tools: solutions for humanitarian health Presentation More information Event website
- [MSF Scientific Days](https://dndi.org/events/2025/msf-scientific-days-2025/) - The MSF Scientific Days bring together researchers, innovators, and advocates in humanitarian global health to discuss and challenge research from within the sector. Session Melioidosis, microbes, and mosquitoes: pushing boundaries for the most neglected and most vulnerable Time: 22 May 2025 Chairs: Laurent Fraisse, R&D Director, DNDi and Daniela Garone, MSF More information Event website
- [DNDi Short Film Premiere 'The Children of the Sierra'](https://dndi.org/events/2025/film-premiere-the-children-of-the-sierra/) - On the occasion of Colombia's Chagas Day on 20 May, DNDi is organizing an event to premiere our short film 'The Children of the Sierra'. Date: Tuesday, 20 May 2025Time: 8:30 AMVenue: Ministry of Health and Social Protection - Carrera 13 No. 32-76, Bogota, Colombia Watch the film
- [HERA Industry days 2025](https://dndi.org/events/2025/hera-industry-days-2025/) - This flagship event will bring together key industry stakeholders, innovators, and policymakers to advance medical countermeasure innovation and enhance strategic collaboration in health preparedness. Session Medical countermeasures for vector-borne diseases: industry challenges and funding opportunities Date: Tuesday, 3 June 2025Time: 11:30-13:00 Speakers include: Isabela Ribeiro, Viral Diseases Cluster Director, DNDi More information Event website
- [Scaling impact: Climate & health solutions that drive change](https://dndi.org/events/2025/scaling-impact-climate-health-solutions-that-drive-change/) - Climate change is already reshaping the world’s health landscape. On the sidelines of the 78th World Health Assembly, Geneva Health Forum is organizing an event bringing together leading actors to move beyond discussion and into action, showcasing concrete solutions from the field and highlighting urgent challenges that demand collective response. Date: Wednesday, 21 May 2025Time: 9:00
- [Accelerating neglected tropical disease elimination through country-driven efforts and cross-border collaboration](https://dndi.org/events/2025/accelerating-ntd-elimination-country-driver-cross-border-collaboration/) - African countries will convene in the spirit of cross-border collaboration to celebrate the signing of a historic memorandum of understanding to eliminate visceral leishmaniasis. Countries will champion the endorsement of a powerful call to action on cross-border collaboration in combating neglected tropical diseases (NTDs) - Uniting for Impact - fast-tracking progress towards ending NTDs. Now
- [78th World Health Assembly: ISNTD Side Events](https://dndi.org/events/2025/78th-world-health-assembly-isntd-side-events/) - On the occasion of the 78th World Health Assembly, the International Society for Neglected Tropical Diseases is organizing two side events. Health Financing: What now? What next? Insights from malaria, dengue & neglected tropical diseases Date: Tuesday, 20 May 2025Time: 8:00-10:00Venue: Hotel Royal Speakers include: Thi Hanh Cao, External Relations Director, DNDi More information and to
- [World Health Summit Regional Meeting 2025](https://dndi.org/events/2025/world-health-summit-regional-meeting-2025/) - The World Health Summit is an international platform for global health bringing together stakeholders from politics, science, the private sector, and civil society from around the world to set the agenda for a healthier future and well-being for all. The theme for the 2025 WHS Regional Meeting is 'Scaling access to ensure health equity'. Panel discussion Leveraging
- [EASL Congress](https://dndi.org/events/2024/easl-congress/) - The EASL Congress 2024 brings together over 7,000 professionals, including clinicians, researchers, allied health professionals, patient representatives, and industry professionals. This event includes four interactive days with hands-on learning sessions led by world-class faculty, presenting a fantastic opportunity for the liver community to share research, network, and engage with leading hepatology experts. Poster More information
- [InSciLead: Gender-Inclusive Science, Access & Leadership Dialogue](https://dndi.org/events/2024/inscilead-gender-inclusive-science-access-leadership-dialogue/) - This dialogue will address gender disparities in neglected tropical disease research and treatment. Emphasizing the importance of including women in clinical trials, especially women of childbearing potential, the dialogue will promote gender-responsive strategies and equitable access to treatment. It will also focus on empowering women in scientific leadership by identifying barriers they face and advocating
- [Forecasting Healthy Futures Global Summit](https://dndi.org/events/2025/forecasting-healthy-futures-global-summit/) - The FHF Summit 2025 aims to advocate for urgent action in climate change and health financing, explore coordinated adaptation strategies, and build health systems fit for the future. Session Dengue: Cost effective scale for multiple preventative interventions Date: Tuesday, 8 April 2025Time: 10:30 Chair: Martin Edlund, Executive Director, Health Finance Coalition Speakers: Natalia Ferreira, Brazil Country
- [Pre-TICAD Summit on Infectious Diseases and UHC in Africa](https://dndi.org/events/2025/pre-ticad-summit-on-infectious-diseases-and-uhc-in-africa/) - Organized by Malaria No More Japan and Malaria No More US, the Pre-TICAD Summit on Infectious Diseases and UHC in Africa aims to discuss Japan-led multilateral support and new support approaches through multi-sector collaboration involving private companies and research institutions on issues affecting the realization of Universal Health Coverage (UHC) in Africa, such as the
- [Mycetoma Research Club](https://dndi.org/events/2025/mycetoma-research-club/) - Organized by the Mycetoma Research Center, the Mycetoma Research Club hosts online meetings featuring experts working in the field of mycetoma. In this session of the 19th Mycetoma Research Club, Borna Nyaoke-Anoke, Head of the Global Mycetoma Disease at DNDi, will discuss neglected tropical diseases (NTDs), mycetoma, and DNDi's work in these areas, sharing valuable
- [Drug Discovery Africa 2025](https://dndi.org/events/2025/drug-discovery-africa-2025/) - Drug Discovery Africa aims to showcase African led drug discovery research against endemic infectious diseases. The conference will bring together leading drug discovery researchers from across Africa and those from Industry and Product Partner Development organizations working alongside them. Presentation Date: Wednesday, 12 March 2025Time: 16:00 More information Event website
- [AHAIC 2025](https://dndi.org/events/2025/ahaic-2025/) - The Africa Health Agenda International Conference (AHAIC) is a biennial conference that brings together stakeholders from across the globe to discuss and address pressing health challenges in Africa. Session From ethics to equity: Ethical storytelling as a catalyst for improving health outcomes Co-organized by The End Fund, NNN, Amref, Unlimit Health, and DNDi Date: Wednesday,
- [6th Joint Scientific Meeting HAT Platform - EANETT](https://dndi.org/events/2024/6th-joint-scientific-meeting-hat-platform-eanett/) - This innovation-focused scientific meeting is being organized to contribute to the World Health Organization's roadmap for interrupting HAT transmission by 2030.
- [3<sup>rd</sup> World Local Production Forum](https://dndi.org/events/2025/3rd-world-local-production-forum/) - The World Local Production Forum (WLPF), led by the WHO, aims to enhance global access to medicines through local production. It brings together stakeholders to address production challenges and promote collaboration, emphasizing local production as key to equitable access. Plenary session Fostering innovation, technology transfer, and production along the value chain Date: Tuesday, 8 April
- [22<sup>nd</sup> ISHAM Congress](https://dndi.org/events/2025/22nd-isham-congress/) - The International Society for Human and Animal Mycology (ISHAM) organizes its general congress every three years and provides clinicians, scientists and students an opportunity to meet key leaders in the field of medical mycology from all continents. The 22nd ISHAM Congress 2025 is organized together with the 23rd INFOCUS annual meeting and the International Meeting on Endemic Mycoses of the Americas
- [ESCMID Global](https://dndi.org/events/2025/escmid-global/) - ESCMID is the Congress of the European Society of Clinical Microbiology and Infectious Diseases. The event brings together experts in infectious diseases and clinical microbiology to exchange ideas and explore the latest innovations in the field of infection. Session Date: Tuesday, 15 April 2025Time: 8:30Room: Hall 15 Chairs: Ana Alastruey-Izquierdo, Spain and Rita Oladele, Nigeria
- [Fostering Ibero-American scientific collaboration for a sustainable future: Health and climate change](https://dndi.org/events/2025/fostering-ibero-american-scientific-collaboration-for-a-sustainable-future-health-and-climate-change/) - The Instituto de Salud Carlos III is organizing this event to strengthen ties between Europe and Latin America bringing together researchers, institutional representatives, and experts from both regions. Roundtable Climate change and health – Institutional and organizational perspectives Date: Tuesday, 25 February 2025Time: 9:30-10:30 Chairs: Marina López and Ana Pérez, Instituto de Salud Carlos III
- [ISNTD Connect: Paving the way for sleeping sickness elimination](https://dndi.org/events/2025/isntd-connect-paving-the-way-for-sleeping-sickness-elimination/) - ISNTD Connect is a forum and series of short meetings online, where researchers and professionals in the fields of tropical diseases and public health are able to present and discuss ongoing research and topics. This online meeting focuses on sleeping sickness elimination. Speakers: José-Antonio Ruiz-Postigo, Global Neglected Tropical Diseases (NTD) Programme, World Health OrganizationPhilippe Neau,
- [Scientific writing skills for young researchers](https://dndi.org/events/2025/scientific-writing-skills-for-young-researchers/) - DNDi is organizing a workshop on scientific writing addressed to early career scientists, and anyone interested in mastering the process of drafting, submitting, and finalizing scientific manuscripts. The aim of the workshop is to help attendees communicate their research more effectively, learn how to approach writing manuscripts, choose a target journal, and approach ethical issues
- [Seminar on Evidence in Action](https://dndi.org/events/2018/seminar-on-evidence-in-action/) - Subang Jaya, Malaysia Organized at the Monash University, the Seminar on Evidence in Action aims to provide an understanding of Health Technology Assessment (HTA) and how it can be utilized in various areas, including hepatitis C. Presentation Time: 15:00 More information: Event websiteProgramme
- [DND<em>i</em> 15th Anniversary and Open House in South-East Asia](https://dndi.org/events/2019/dndi-15th-anniversary-south-east-asia/) - DNDi South-East Asia is organizing a 15-year anniversary celebration event in Kuala Lumpur, Malaysia on , in collaboration with the Foundation for Innovative New Diagnostics (FIND). Since 2004, the DNDi office in Malaysia has supported a variety of R&D activities across the Asian region, including key preclinical and early clinical studies for the FACT Project, as
- [Conference on Liver Disease in Africa 2019](https://dndi.org/events/2019/colda-2019/) - Organized by Virology Education in close collaboration with local societies, Conference on Liver Disease in Africa (COLDA) 2019 aims at empowering African healthcare professionals to diagnose, prevent, treat, and achieve a cure for liver diseases to improve the lives of patients in Africa. Industry supported symposium Pharco: Innovation of access to treatment: Real life scenarios
- [Hepatitis C: A silent killer](https://dndi.org/events/2021/hepatitis-c-a-silent-killer/) - Doctors Without Borders / Médecins Sans Frontières (MSF) organizes a webinar series, “Overshadowed by COVID-19: Neglected diseases in the spotlight.” The first in the series is “Hepatitis C: A silent killer.” Date: Thursday, 29 July 2021Time: 3:00 – 4:00 PM (Hong Kong) / 2:00 – 3:00 PM (Jakarta) Moderator: Leena Menghaney, Regional Head for South
- [Hepatitis C can't wait, Malaysia isn't waiting](https://dndi.org/events/2021/hepatitis-c-cant-wait-malaysia-isnt-waiting/) - FIND and DNDi are organizing a webinar that will be webcast via FIND's YouTube Live Stream on Tuesday 27 July 2021 at 15:00 MYT / 09:00 CEST to observe World Hepatitis Day (WHD) with the support from the World Health Organization (WHO), the Ministry of Health Malaysia (MOH) and the Malaysian AIDS Council (MAC) under the theme ─ "Hepatitis C can't wait, Malaysia isn't waiting". Speakers
- [Webinar: World Hepatitis Day 2020](https://dndi.org/events/2020/webinar-world-hepatitis-day-2020/) - For World Hepatitis Day 2020, FIND is organizing a webinar in partnership with the World Hepatitis Alliance (WHA) and DNDi to showcase the preliminary outcomes of the Unitaid-supported Hepatitis C Elimination through Access to Diagnostics (HEAD-Start) project. Discussion Date: Thursday, 30 July 2020Time: 10:30–12:30 (CEST) Speakers include: Sonjelle Shilton, Deputy Head HCV Access, FINDPhilippa Easterbrook, Senior
- [South-South Leadership: Working together on medical R&D to meet the needs of all patients, the example of dengue](https://dndi.org/events/2022/south-south-leadership-working-together-medical-rd-meet-needs-all-patients-example-dengue/) - The Drugs for Neglected Diseases initiative (DNDi), Siriraj Institute for Clinical Research (SICRES), and Siriraj Hospital, Mahidol University hosted the DNDi South-East Asia Strategic Plan Launch webinar “South-South Leadership: Working together on medical R&D to meet the needs of all patients, the example of dengue”. Last year, DNDi launched a new Strategic Plan 2021-2028, charting a
- [CRM Trial Connect 2022](https://dndi.org/events/2022/crm-trial-connect-2022/) - CRM Trial Connect 2022 is the first international conference organised by Clinical Research Malaysia, aimed to showcase Malaysia’s capabilities, experience and achievements in multinational clinical research, including sponsored clinical trials. Sessions Forum with Honourable Minister of Health, Mr. Khairy Jamaluddin: Investing in today’s research for tomorrow’s health Date: Friday, 14 October 2022Time: 10:00-12:00 Panellists include:
- [Dengue-free South Asia: An evening of collaboration](https://dndi.org/events/2023/dengue-free-south-asia-an-evening-of-collaboration/) - Organized by DNDi in partnership with the British Council, this event aims to provide a platform to foster awareness and collaboration on combating dengue. Activities include a film screening of DNDi's 20-year film 'Out of the Shadows', expert talks, and networking opportunities. Speakers: Neelika Malavige, Head of Dengue Global Programme and Scientific Affairs, DNDiJean-Michel Piedagnel,
- [Clinical Data Disclosure, Transparency & Plain Language Summaries 2025 conference](https://dndi.org/events/2025/clinical-data-disclosure-transparency-plain-language-summaries-2025-conference/) - This conference brings together experts, thought leaders, and professionals from the pharmaceutical, biotech, and clinical research industries to discuss and share best practices on clinical data disclosure and transparency. Presentation Case study: Balancing data sharing and privacy in neglected tropical disease research Date: Tuesday, 25 February 2025Time: 13:30-14:15 Speakers: Obaraboye Olude, Senior Clinical Trial Transparency Advisor
- [15th KASH conference](https://dndi.org/events/2025/15th-kash-conference/) - KASH is the KEMRI Annual Scientific and Health Conference launched in 2011 with the mission to mainstream the scientific and health agenda of KEMRI by dissemination, sharing and digesting various scientific outputs and other allied products including networking and strengthening partnerships and collaborations with a view to improving on health and quality of life of
- [GHIT R&D Forum 2024](https://dndi.org/events/2024/ghit-rd-forum-2024/) - GHIT Fund facilitates partnerships for global health R&D product development between Japanese and non-Japanese entities. The 2024 GHIT R&D Forum aims to strengthen existing and catalyze new partnerships while fostering in-depth discussions among a diverse group of key stakeholders. Session Linking NTD innovations with health systems for pandemic preparedness Time: 11:20 -12:20 Speakers: Masahiro Kajihara,
- [Symposium on drug discovery - Success stories](https://dndi.org/events/2025/symposium-drug-discovery-success-stories/) - The Translational Health Science and Technology Institue (THSTI), BRIC, and DNDi are organizing a session on drug discovery with insights from industry experts. The event can be joined both in-person or virtually. Registration is mandatory. Register
- [LCI Symposium 2025](https://dndi.org/events/2025/lci-symposium-2025/) - The Leibniz Center Infection (LCI) organizes a symposium on the theme 'One health - infections without boundaries'. Session Response Date: Wednesday, 29 January 2025Time: 13:00-16:30 Chair: Margo Diricks, RCB, Germany More information Event website
- [Prince Mahidol Award Conference 2025](https://dndi.org/events/2025/prince-mahidol-award-conference-2025/) - The theme of the 2025 edition of the Prince Mahidol Award Conference is 'Harnessing technologies in an age of AI to build a healthier world'. Side meeting South-South collaborations against neglected tropical diseases for health security and equity in an era of polycrises Co-organized by Faculty of Medicine Siriraj Hospital, DNDi, and the Dengue Alliance
- [ECTMIH 2019](https://dndi.org/events/2019/ectmih-2019/) - 11th European Congress on Tropical Medicine and International HealthOrganized by the Royal Society of Tropical Medicine & Hygiene (RSTMH), the 11th European Congress on Tropical Medicine and International Health (ECTMIH) aims to bring together scientists and experts to share research and innovation in the field of tropical medicine and global health. Free public side event
- [MSF Scientific Days International 2020](https://dndi.org/events/2020/msf-scientific-days-international-2020/) - MSF Scientific Days bring together researchers, practitioners, academics and patient representatives to catalyse improvements in the quality of care provided to patients and populations at risk. Presentation Session 4 – Evolving Thinking: Adapting Programming Date: Wednesday, 13 May 2020 Safety and efficacy data from a phase 2 randomized trial of a miltefosine/thermotherapycombination in uncomplicated New
- [ISNTD d3 2021](https://dndi.org/events/2021/isntd-d3-2021/) - ISNTD d³ 2021 addresses the current gaps and collaboration opportunities across tropical diseases and diseases of poverty to accelerate drug discovery & development, vaccine R&D and uptake, and diagnostics and surveillance opportunities. This year, against the backdrop of the recently launched WHO NTD Roadmap and the shock of the COVID-19 pandemic, ISNTD d³ focuses on
- [5<sup>ta</sup> Reunión Colombiana de Leishmaniasis y enfermedad de Chagas y XVII Simposio Pecet](https://dndi.org/events/2020/5ta-reunion-colombiana-de-leishmaniasis-y-enfermedad-de-chagas-y-xvii-simposio-pecet/) - PECET (Programa de Estudio y Control de Enfermedades Tropicales) from the University of Antioquia and the CIMPAT (Centro de Investigaciones en Microbiología y Parasitología Tropical) from the University of Los Andes invite researchers, students, professionals, pharmaceutical companies, and Colombian health authorities to participate in the 5th version of the Colombian Meeting on research in leishmaniasis
- [Webinar: Knowledge gaps and challenges in managing patients suffering from cutaneous leishmaniasis](https://dndi.org/events/2021/webinar-knowledge-gaps-challenges-managing-patients-cutaneous-leishmaniasis/) - Cutaneous leishmaniasis is a painful disease that exerts a serious toll on societies around the world that are afflicted by it. Although not life-threatening, the skin ulcers and scars it causes can lead to isolation and psychosocial pathologies due to social stigma, and its occurrence is often associated with regional conflicts. On 7 December 2020,
- [Leishmaniasis disease, explained](https://dndi.org/events/2021/leishmaniasis-disease-explained/) - Médecins Sans Frontières (MSF) is organizing a presentation and explainer session with Byron Arana, Suzette Karmin, and Mohammad Amin about cutaneous leishmaniasis, associated epidemiology in the Middle East, current treatment approaches, and potential innovation opportunities for diagnostics and care. Date: Monday, 26 July 2021Time: 1:30 pm Dubai time Moderator: Sakib Burza, MSF Medical Advisor Speakers: Byron
- [Innovative partnerships for the most neglected](https://dndi.org/events/2021/innovative-partnerships-for-the-most-neglected/) - The GHIT Fund organizes a series of webinar on product development partnerships (PDPs) and the R&D community’s role, challenges, and opportunities in the fight against neglected diseases during/post COVID-19 pandemic era. Webinars feature leaders from PDPs and their Japanese partners and address the critical role of PDPs today and tomorrow, innovative R&D partnerships for neglected
- [2nd LEAP Scientific Conference](https://dndi.org/events/2021/2nd-leap-scientific-conference/) - Overview Overview Programme and abstracts Event recordings Committee members Scientific innovation and access for leishmaniasis management The LEAP Conference brings together scientists, researchers, policy makers, public health practitioners and civil society to discuss the diagnosis, treatment, prevention, control, and elimination of leishmaniasis. The conference is organized by DNDi and LEAP (a clinical research network that brings
- [WorldLeish 7](https://dndi.org/events/2022/worldleish7/) - The 7th version of WorldLeish is taking place on 1-6 August 2022 in Cartagena, Colombia. Find out about the sessions with DNDi leishmaniasis & other NTDs experts.
- [MSF Scientific Days – Asia 2023](https://dndi.org/events/2023/msf-scientific-days-asia-2023/) - MSF Scientific Days – Asia 2023 is a conference to showcase research, innovation, and experiences from treatment and humanitarian programmes across the region. MSF Scientific Days bring together researchers, practitioners, academics, and patient representatives to catalyse improvements in the quality of care provided to patients and populations at risk. The experts in the humanitarian global
- [Festival de la Santé mondiale](https://dndi.org/events/2024/festival-de-la-sante-mondiale/) - The Festival de la Santé mondiale (Global Health Festival) brings together global health actors to discuss key global health themes, including strengthening health systems, training health professionals, lifelong learning in the health sector, the One Health approach, antimicrobial resistance, and health innovation. Panel discussion Climate and health in focus: Innovating climate-smart products and advancing solutions
- [Building Bridges Action Days 2024](https://dndi.org/events/2024/building-bridges-action-days-2024/) - Building Bridges is a joint initiative, launched in 2019 by Swiss public authorities, the finance community, the United Nations and other international partners to accelerate the transition to a global economic model aligned with the SDGs. The Action Days comprise a crowd-sourced programme of events planned by the Building Bridges Community to stimulate deeper levels
- [ICID 2024](https://dndi.org/events/2024/icid-2024/) - The 20th ICID 2024 in Cape Town brings together over 2,500 infectious disease experts from more than 100 countries. The conference focuses on clinical knowledge and practice, novel translational science, infection prevention protocols and the epidemic intelligence of infectious disease. One Health is an overarching theme. Oral session One Health Date: Thursday, 5 December 2024Time: 10:30
- [Quelle santé mondiale pour demain?](https://dndi.org/events/2024/quelle-sante-mondiale-pour-demain/) - The Paris School of International Affairs, the School of Public Affairs, Sciences Po Health Chair and the think tank Santé mondiale 2030, are organizing a public conference on the future of global health. Programme More information Event website
- [AHF Webinar Panel Discussion](https://dndi.org/events/2024/ahf-webinar-panel-discussion/) - AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab and the Mexican National Institute of Public Health, is cohosting a webinar on 'The Importance of the WHO Pandemic Agreement for Latin America.' Time: 13:00-14:00 GMT-5 / 19:00-20:00 CET Moderator: Jorge Saavedra, Executive Director, AHF Global Public Health Institute Speakers:
- [The 11th NIKKEI FT Communicable Diseases Conference](https://dndi.org/events/2024/the-11th-nikkei-ft-communicable-diseases-conference/) - Nikkei Inc. has been organizing the annual Nikkei FT Communicable Diseases Conference since 2014, gathering internationally renowned experts in the field, representatives of the private sector, and government officials responsible for health from both Japan and abroad. Special session A decade of progress: Eradicating jigger infestation in Kenya Organized by Saraya Co., Ltd Date: Tuesday,
- [7th ABCF Congress](https://dndi.org/events/2024/7th-abcf-congress/) - The Brazilian Association of Pharmaceutical Sciences (ABCF) is hosting its 7th Congress under the theme 'Pharmaceutical sciences in promoting technological innovation to guarantee healthcare access'. Session Developing and making available new treatments for neglected diseases and populations Date: Wednesday, 13 November 2024Time: 10:05-12:00 Chair: Camila Alves Areda, Professor, UnB Speakers: Sergio Sosa-Estani, Latin America Director,
- [Parlamentarischer Abend: Vom Labor zur Patient*in: Wie können vernachlässigte Bevölkerungsgruppen besser an innovative Medikamente kommen?](https://dndi.org/events/2024/parlamentarischer-abend-vom-labor-zur-patient/) - Auf dem Parlamentarische Abend erörtern wir die verschiedenen Hürden, die den Zugang zu neuen Innovationen für vernachlässigte Bevölkerungsgruppen behindern. Wir werden auch praktische Beispiele zeigen, wie „Access“ schon im Labor und während der Entwicklung eines Produkts mitgedacht werden können, um den Zugang zu neuen Produkten wie Medikamenten für Betroffene zu verbessern. Schirmerrschaft Tina Rudolph (SPD),
- [World Health Summit 2024](https://dndi.org/events/2024/world-health-summit-2024/) - The World Health Summit is one of the world’s leading strategic forums for global health bringing together stakeholders from politics, science, the private sector, and civil society from around the world. Held under the theme 'Building trust for a healthier world', WHS 2024 aims to set the agenda for a healthier future by inspiring innovative solutions
- [World Health Summit](https://dndi.org/events/2015/world-health-summit/) - The World Health Summit is the annual conference of the M8 Alliance of Academic Health Centers, Universities and National Academies. Through the Inter Academy Medical Panel (IAMP), it is organized in collaboration with national academies of science in more than 67 countries. DNDi participated in a workshop on global health research and development. Workshop Global
- [Enfermedades Tropicales Desatendidas: Compromisos nacionales y globales para frenar las enfermedades más olvidadas del planeta](https://dndi.org/events/2024/enfermedades-tropicales-desatendidas-compromisos-nacionales-y-globales-para-frenar-las-enfermedades-mas-olvidadas-del-planeta/) - Salud por Derecho, the Anesvad Foundation, Médecins Sans Frontières, and DNDi are organizing a roundtable on neglected tropical diseases (NTDs). The event brings together voices from different stakeholders to broaden the understanding, awareness, and actions needed to tackle NTDs and the challenges of access to medicines. Programme Welcome address Vanessa López, Director, Salud por Derecho
- [XIII CONGRESO SEMTSI](https://dndi.org/events/2024/xiii-congreso-semtsi/) - The theme of this year's congress of the Spanish Society of Tropical Medicine and International Health (SEMTSI) is 'Global health in children'. Roundtable Evidencia científica y consenso en Medicina Tropical: resultados de los Grupos de Trabajo de la SEMTSI Date: Thursday, 3 October 2024Time: 12:30 – 14:00Room: Sala Obradoiro II Moderator: Fernando Salvador More information
- [NNN Conference 2024](https://dndi.org/events/2024/nnn-conference-2024/) - The 15th Annual NNN Conference gathers NTD practitioners, government leaders, researchers, policymakers, and other stakeholders from over 50 countries to discuss challenges and solutions for NTD elimination. Workshops Civil society leadership in NTD advocacy and elimination a fourth pillar of the roadmap? Organized by Cristian Blind Mission (CBM) Date: Wednesday, 2 October 2024Time: 11:15 –
- [Mycetoma: Understanding the disease, seeking solutions](https://dndi.org/events/2024/mycetoma-understanding-the-disease-seeking-solutions/) - DNDi and the US CDC have organized a webinar focused on mycetoma, a neglected tropical disease that causes devastating disabilities and death. The webinar will take place during the Fungal Disease Awareness Week (FDAW 2024), and will be held on 18 September 2024, from 17:00-18:15 EAT. By bringing together leading experts, a patient advocate, and
- [ICTMM 2024](https://dndi.org/events/2024/ictmm-2024/) - The theme of the 21st International Congress for Tropical Medicine and Malaria (ICTMM 2024) is 'Global responses and interdisciplinary research towards eliminating tropical diseases'. Session Innovative R&D approaches for neglected tropical diseases: Bridging gaps and driving progress Date: Saturday 21 SeptemberTime: 14:30-16:00 MYT Moderator: Craig Tipple, Medical Director, DNDi Speakers: Dr. Yolanda Augustin, Clinical Oncologist,
- [Science Summit 2024](https://dndi.org/events/2024/science-summit-2024/) - The Science Summit unites thought leaders, scientists, policymakers, and innovators to address the pressing scientific and technological challenges of our time. Side event Investing in clinical research in Africa to develop local solutions against the global challenge of Antimicrobial Resistance (AMR) Organized by EDCTP Date: Thursday, 26 September 2024Time: 11:00-13:00Virtual session Moderator: Lara Pandya, Communications & Strategic
- [MedTrop 2024](https://dndi.org/events/2024/medtrop-2024/) - MedTrop 2024 is the 59th Congress of the Brazilian Society of Tropical Medicine. With the theme 'One Health', the event will explore the interconnection and interdependence between human, animal, plant, and environmental health. Pre-Congress Workshop Dates: 18-20 September 2024 Ahead of MedTrop, DNDi, in partnership with Netherlands Hanseniasis Relief (NHR), will offer an Empowerment Workshop
- [ASTMH 2023](https://dndi.org/events/2023/astmh-2023/) - The ASTMH Annual Meeting draws tropical medicine and global health professionals representing academia, foundations, government, not for profit organizations, non-governmental organizations, the private sector, military and private practice. Symposia From a single dataset to a million patients: Solutions to pool and harmonize IPD for effective and equitable reuse of data to generate new evidence in
- [Roundtable discussion: Why eliminate and control neglected tropical diseases?](https://dndi.org/events/2024/roundtable-discussion-why-eliminate-and-control-ntd/) - Strenghtening NTD advocacy and partnership in Japan NTDs Youth Organization is organizing a roundtable discussion to hear voices from the field on the fight against neglected tropical diseases (NTDs), unite stakeholders, share insights, and forge stronger partnerships in Japan to support NTD elimination and control. Discussion Why supporting elimination and control of NTDS? Motivation and
- [EFMC-ISMC 2024](https://dndi.org/events/2024/efmc-ismc-2024/) - The XXVIII EFMC International Symposium on Medicinal Chemistry is organised by the Medicinal Chemistry Division of the Società Chimica Italiana (Italian Chemical Society), on behalf of the European Federation for Medicinal Chemistry and Chemical Biology (EFMC). Posters More information Event website
- [5th Iberoamerican Symposium on Organic Chemistry (SIBEAQO-V)](https://dndi.org/events/2024/5th-iberoamerican-symposium-on-organic-chemistry-sibeaqo-v/) - The main objective of the Symposium is to promote a forum of scientific discussions among Organic Chemistry researchers of Iberoamerica, Spain, and Portugal to promote the exchange of ideas, expertise, and capabilities to build fruitful future collaborations across these countries. Poster More information Event website
- [26th North American ISSX and 39th JSSX Meeting](https://dndi.org/events/2024/26th-north-american-issx-and-39th-jssx-meeting/) - The International Society for the Study of Xenobiotics organizes its annual meeting bringing together researchers, from academia and industry alike, to learn, network, and exchange ideas. This year's meeting's theme is 'The Future of Translational Xenobiotic Research'. Posters More information Event website
- [DNDi 20th anniversary in SEA - Forum on gender, health, and science R&D](https://dndi.org/events/2023/dndi-20th-anniversary-in-sea-forum-on-gender-health-and-science-rd/) - As part of the Drugs for Neglected Diseases initiative’s (DNDi) 20th Anniversary celebration, marking two decades of the not-for-profit organization advocating for neglected populations and developing lifesaving, affordable treatments, we hosted a series of ‘Women in Science Networking’ events held in Malaysia (April 2023) and Thailand (August 2023). These events united women leaders and experts,
- [RSTMH In Conversation with Dr Luis Pizarro](https://dndi.org/events/2024/rstmh-in-conversation-with-dr-luis-pizarro/) - This webinar hosted by RSTMH will give attendees the opportunity to hear from Dr Luis Pizarro who has led the DNDi since September 2022. He also serves as founder and member of the Global Health 2030 think tank, as scientific advisor for Global Health at Sciences Po Paris, and as board member of Sidaction. The conversation will
- [Dengue: Addressing the global health challenge](https://dndi.org/events/2024/dengue-addressing-the-global-health-challenge/) - This webinar is hosted by RSTMH. It will delve into some of the challenges faced in dealing with the global burden of dengue and tackle areas of prevention, treatment, and research. Webinar Time: 12:00-13:30 BST Chairperson: Neelika Malavige, Head of Dengue Global Programme, DNDi Speakers: Professor Eng Eong Ooi, Professor, Programme in Emerging Infectious Diseases, Duke-NUS Medical
- [Webinar: Building on Experience](https://dndi.org/events/2024/building-on-experience-establishing-a-sustainable-value-chain-for-fit-for-purpose-health-product-innovation-and-regional-production-through-partnerships-and-enabling-ecosystems/) - This event is organized by Unitaid, DNDi, FIND, and the Pan-American Health Organization (PAHO/WHO). Panel Time: 8:00-9:30 Speakers include: Michelle Childs, Policy Advocacy Director, DNDi More information Event registration
- [International Pandemic Sciences Conference 2024](https://dndi.org/events/2024/international-pandemic-sciences-conference-2024/) - The International Pandemic Sciences Conference 2024 is hosted by the Pandemic Sciences Institute at the University of Oxford. The conference’s 2024 theme, Collaboration Beyond Boundaries, will explore how researchers can work together – beyond the boundaries of geography, discipline and sector – to accelerate practical solutions to global pandemic threats. Poster Oral presentation More information Event website
- [PAGE 2024](https://dndi.org/events/2024/page-2024/) - PAGE represents a community with a shared interest in data analysis using the population approach. Their 2024 meeting will be held at the Ergife Hotel in Rome, Italy. Poster More information Event website
- [10th NovAliX Conference: Reinventing drug discovery from retrospective to perspectives](https://dndi.org/events/2024/reinventing-drug-discovery-from-retrospective-to-perspectives/) - The10th anniversary edition of the NovAliX Conference aims to address the major developments of the last thirty years that affected the discovery sector, not only at the scientific level, but also in terms of industrial organisation of the drug discovery part and its financing, of the academia-industry relationships, and more. Session Unmet Therapeutic Needs: Current Challenges
- [DRUID 2024](https://dndi.org/events/2024/druid-2024/) - DRUID (Novel Drug Targets against Poverty-related and Neglected Tropical Infectious Diseases) addresses urgent problems regarding the identification and characterization of potential targets for the development of drugs and diagnostics against tropical infectious diseases. The International Conference of the LOEWE Centre DRUID will bring together scientists of multiple disciplines to report on their latest findings in
- [7th Asia Dengue Summit 2024](https://dndi.org/events/2024/7th-asia-dengue-summit-2024/) - Dengue is no more a Southeast Asian or Asian issue. It has become a global issue such that the World Health Organization (WHO) sees it fit to name it as one of the ten threats to global health in 2019. WHO has also set targets for member states to try and achieve by 2030. This
- [Impact Investing for Global Health: Cross Sectoral Learnings](https://dndi.org/events/2024/impact-investing-for-global-health-cross-sectoral-learnings/) - Triple I will be hosting a hybrid event "Impact Investing for Global Health: Cross Sectoral Learnings; What does it take to be an 'impact investor'/ 'impact investee' for global health?" on May 28, 2024. It will be held alongside the 77th World Health Assembly in Geneva, Switzerland. The event aims to bring together stakeholders from across health and
- [BIO International Convention](https://dndi.org/events/2024/bio-international-convention/) - The BIO International Convention is a comprehensive event for biotechnology attended by industry leaders from across the globe. Side event IX Summit Brasil - One Health: Climate, socially determined diseases, and governmental and institutional strategies to address emerging health challenges Date: Monday, 3 June 2024Time: 11:20 - 12:10Venue: University of California San Diego Moderator: Marina
- [Diagnostics Day 2024](https://dndi.org/events/2024/diagnostics-day-2024/) - FIND is hosting an event on the sidelines of the World Health Assembly in 2024, at the International Museum of the Red Cross and Red Crescent in Geneva. With a full day of conversations around key topics in diagnostic testing, the event also marks the first anniversary of the adoption of the landmark WHA Resolution on diagnostics. Session
- [Devex CheckUp @ WHA77](https://dndi.org/events/2024/devex-checkup-wha77/) - Millions suffer, yet NTDs remain largely unseen. This Devex panel tackles these overlooked health threats, exploring success stories, closing the knowledge gap, breaking the cycle, and the funding gap. Panel discussion From the Margins to Mainstream: Ending the Neglect of NTDs Date: 28 May 2024Time: 12:00-13:35 CEST Speakers: Monique Wasunna, DNDi Africa Ambassador, DNDiThoko Elphick-Pooley,
- [What is the health and economic impact of investing in global health R&D?](https://dndi.org/events/2024/policy-cures-research-health-economic-impact-rd/) - Policy Cures Research is launching a breakthrough report on the return on investment of R&D in global health. Online event Time: 17:30-19:00 CEST The event will explore remarkable outcomes achieved through two decades of investment in R&D for neglected diseases and share: Data on the breakthrough products of the last 20 years that have emerged to
- [Geneva Health Forum](https://dndi.org/events/2024/geneva-health-forum/) - The Geneva Health Forum Conference will take place alongside the World Health Assembly (WHA). As the WHA convenes a political audience, the GHF Conference provides a unique platform conveying the perspectives of scientists, medical practitioners and field actors on the main challenges and opportunities for global health. Sessions Reaching elimination of neglected tropical diseases: Challenges, lessons, and
- [Mycetoma situation in Africa, what is the current situation and what is the outlook?](https://dndi.org/events/2024/mycetoma-situation-in-africa-what-is-the-current-situation-and-what-is-the-outlook/) - The overall aim of this webinar is to help raise the profile of this disease, which is one of the most neglected of the neglected tropical diseases, so that appropriate attention can be paid to it. Specific objectives are to review the clinical and epidemiological situation of mycetoma in Africa, discuss the strategy for implementing
- [RSTMH Webinar: The uses and challenges of AI in Global Health](https://dndi.org/events/2024/the-uses-and-challenges-of-ai-in-global-health/) - Following discussions at the RSTMH 2023 Annual Meeting around the ethics, challenges and opportunities of utilising AI in Global Health, this webinar will be delivered in partnership between RSTMH and DNDi. During this 90 minute event we will delve a little deeper into some of the applications, challenges and considerations of the use of AI
- [TEDxGVAGrad 2024](https://dndi.org/events/2024/tedxgvagrad-2024/) - This conference aspires to present a unique opportunity to bring together Geneva’s academic and non-academic realities while stimulating the spread of varied viewpoints on contemporary issues affecting our society. This years theme, Seeds of Change, focuses the actions one takes in the present to create lasting change in the future. It focuses on targeted innovation
- [Achieving better health for children – leadership and accountability for access to #BetterMeds4Kids](https://dndi.org/events/2024/achieving-better-health-for-children-leadership-and-accountability-for-access-to-bettermeds4kids/) - At the 77th WHA, member states are deliberating over a resolution to ‘Accelerate progress towards reducing maternal, newborn, and child mortality in order to achieve SDG targets 3.1 and 3.2.’ This resolution states that ’63 countries will miss the neonatal mortality target, and 54 countries will miss the under-five mortality target by 2030′. One of
- [XI Chagas Platform Plenary Meeting](https://dndi.org/events/2024/xi-chagas-platform-plenary-meeting/) - The XI Plenary Meeting of the Chagas Platform will be held in Buenos Aires, Argentina, between May 8 and 9, 2024. Satellite meetings will also be held between May 6-7, such as the Annual Meeting of the Chagas Coalition. The Chagas Platform meeting will be an opportunity to review the current situation of Chagas disease
- [ISNTD Festival 2024](https://dndi.org/events/2024/isntd-festival-2024/) - The ISNTD Festival brings together communication, arts, entertainment and science to help complex public health messages reach patients, the public and global health professionals worldwide. The aim of our ISNTD Festival has always been to explore the black box between the end of operational research and actual change, whether that change is at policy level
- [Multilateral Initiative on Malaria (MIM Society) 8th Pan-African Malaria Conference](https://dndi.org/events/2024/multilateral-initiative-on-malaria-mim-society-8th-pan-african-malaria-conference/) - The Multilateral Initiative on Malaria (MIM) Society, in collaboration with the Ministry of Health (MoH)- Rwanda and the Rwanda Biomedical Center (RBC), is hosting the 8th Pan-African Malaria Conference. The conference aims to bring together leading researchers, policy makers, and innovators to deliberate on the status of malaria in Africa, share research findings, and discuss the
- [AFRAVIH 2024](https://dndi.org/events/2024/afravih-2024/) - The 12th edition of the AFRAVIH Conference will be an opportunity for researchers and decision-makers from the French-speaking world to gather around scientific news, but also for the associative and community world to discuss the best ways to continue the fight against discrimination, and for equal access to care for all. This event will be
- [ASCTP 2024 Annual Meeting](https://dndi.org/events/2024/asctp-2024-annual-meeting/) - The ASCPT 2024 Annual Meeting will be held as an in-person event March 27-29, at the Broadmoor in Colorado Springs, CO. Registrants for the meeting will enjoy three days filled with professional development, networking, and the latest research in clinical pharmacology and translational science. State of the art lecture Date: Friday, 29 March 2024Time: 9:30-10:30
- [Striking fair deals for equitable access to medicines](https://dndi.org/events/2024/striking-fair-deals-for-equitable-access-to-medicines/) - The case of pro-access IP policies of DNDi This online talk is organized by the TechEx.in team at Venture Center under the theme 'IP and the SDGs: Building our common future with innovation and creativity'. This session will address how drug development works with a look into DNDi's organizational mission and strategy, IP policy and
- [The Voices of Chagas Disease](https://dndi.org/events/2024/the-voices-of-chagas-disease/) - 'Listen and learn from those living with Chagas and impacted by the kissing bug. A celebration for making a difference for this neglected tropical disease affecting millions around the world'. Janeice Smith, President and founder of The National Kissing Bug Alliance hosts this event with DNDi just a few days before the World Chagas Disease
- [4th SCI / RSC Symposium on Anti-Infectives Drug Discovery](https://dndi.org/events/2024/4th-sci-rsc-symposium-on-anti-infectives-drug-discovery/) - With the ever-growing prevalence of drug-resistant pathogens, it has never been more important that we refresh the drug pipeline with new antimicrobials that act on new targets or exhibit novel modes of action. The recent COVID pandemic has served to highlight the importance of developing effective treatments for infection, driving the recent resurgence in anti-infectives
- [AI in Drug Discovery: A Snapshot of Current Use and Prospects for the Indian Drug Discovery Space](https://dndi.org/events/2024/ai-in-drug-discovery-a-snapshot-of-current-use-and-prospects-for-the-indian-drug-discovery-space/) - Explore the incredible role of AI in Drug Discovery in our upcoming webinar organized by Central Drug Research Laboratory and Drugs for Neglected Diseases initiative India Foundation. Join experts as they uncover how AI is reshaping medicine. Learn about its history, current applications, and potential in combating neglected tropical diseases (NTDs). Webinar Time: 15:30-17:00 IST
- [World Chagas Day: Necessity for early diagnosis and lifelong follow-up](https://dndi.org/events/2024/world-chagas-day-necessity-for-early-diagnosis-and-lifelong-follow-up/) - On Thursday 11 April 2024, 1-2:30pm BST, RSTMH will be hosting a webinar in honour of World Chagas Day. The focus would be around the theme: necessity for early diagnosis and lifelong follow-up of people affected by the disease. Webinar Chair: María Jesús Pinazo, Head of Chagas, DNDi Speakers: Pedro Albajar Viñas, Head, World Health
- [International Congress on Infectious Diseases 2022](https://dndi.org/events/2022/international-congress-on-infectious-diseases-2022/) - Organized by the International Society for Infectious Diseases, the International Congress on Infectious Diseases convenes clinicians, allied health professionals, and scientists to share world-class expertise to address global challenges. Parallel symposia Dengue updates Date: Friday, 18 November 2022Time: 14:00-15:30Venue: Conference Room 1 KLCC Chairs: Panisadee Avirutnam, Mahidol University, Thailand, and Sophie Yacoub, Dengue Research Group
- [Benefits and risks of using AI for pharmaceutical development and delivery](https://dndi.org/events/2024/benefits-and-risks-of-using-ai-for-pharmaceutical-development-and-delivery/) - WHO recognizes that artificial intelligence (AI) holds great promise for pharmaceutical development and delivery. However, AI also presents risks and ethical challenges that must be addressed if societies, health systems and individuals are to fully reap its benefits. A discussion paper has been developed to examine the expanding application of AI to each step of development and deployment
- [British Society for Parasitology Spring Meeting](https://dndi.org/events/2024/british-society-for-parasitology-spring-meeting/) - BSP 2024 will bring the parasitological community together to discuss the latest findings in parasite biology and progress in controlling disease. Their ambition is for the meeting to reach across divides, whether they be between parasites, all our scientific sessions that cut across taxonomy, or between countries, nearly half of our invited speakers come from
- [2024年「世界NTDの日」特設ページ](https://dndi.org/events/2023/2024年世界ntdの日特設ページ/) - January 30 is World NTD Day as defined by the World Health Organization (WHO). Since 2021, January 30 has been designated as World NTD Day, and campaigns to achieve the WHO NTD Roadmap have been carried out around the world. This year's theme is "Unite, Act, Eliminate." This webinar will be hosted by the The
- [Diagnosis and treatment: Challenges and the role of drugs for neglected diseases](https://dndi.org/events/2023/diagnosis-and-treatment-challenges-and-the-role-of-drugs-for-neglected-diseases/) - This webinar for neglected tropical diseases is hosted by the Kenya Medical Association and DNDi. Webinar Time: 17:00 CET Speakers: Borna Nyaoke-Anoke, Head of Mycetoma Disease, DNDiCherinet Bayuh Adera, Senior Market Access Manager, DNDi Eastern AfricaMartin Chege, Medical Superintendent, Kacheliba Sub-county HospitalLydia Omwansa, Medical Doctor Watch the recording
- [World Neglected Tropical Diseases Day: Overview, progress and highlights](https://dndi.org/events/2023/world-neglected-tropical-diseases-day-overview-progress-and-highlights/) - Many healthcare journalists come from communities where NTDs remain a challenge and interaction with global health experts can offer a deeper understanding of these diseases, their root causes, and what is being done to eliminate them. Important milestones have been achieved in making progress towards eliminating tropical diseases, but much more needs to be done
- [La enfermedad fúngica: una amenaza global oculta por olvidada](https://dndi.org/events/2023/enfermedad-fungica-amenaza-global-oculta-por-olvidada/) - This session commemorating World NTD Day will discuss priorities for reducing morbidity and mortality caused by neglected fungal diseases. The World Health Organization has developed the first list of priority fungal pathogens with the aim of boosting research and policies to combat fungal disease and antifungal resistance. To address this problem, it is essential to
- [Bridging gaps in neglected tropical disease treatment](https://dndi.org/events/2023/bridging-gaps-in-neglected-tropical-disease-treatment/) - A collaboration between DNDi and Médecins Sans Frontières (MSF) East Africa, this webinar focuses on bridging treatment gaps for NTDs with the goal of elimination. Webinar Moderator: Linet Otieno, Head of Communications, DNDi Speakers: Margriet den Boer, NTD Advisor, MSFSamuel Kariuki, Eastern Africa Director, DNDiSimon Bolo, Head of Leishmaniasis Access, DNDi Watch the recording
- [Enfermedades desatendidas: Perspectiva global y de salud pública<br>El ejemplo de la enfermedad del sueño](https://dndi.org/events/2023/enfermedades-desatendidasperspectiva-global-y-de-salud-publicael-ejemplo-de-la-enfermedad-del-sueno/) - Hosted by the Sociedad Murciana de Medicina Preventiva y Salud Pública (SMMPySP), this webinar examines the work of DNDi on the eve of World NTD Day. Webinar Time: 17:00 - 18:00 CET Speakers: Olaf Valverde, Clinical Project Leader (HAT), DNDiTerín Beca Martínez, Consultant, DNDi Watch the recording More information Event website
- [ISNTD D3 2024](https://dndi.org/events/2023/isntd-d3-2024/) - "50 down, 50 to go". 50 countries have eliminated at least one Neglected Tropical Disease, half way to the milestone of 100 countries achieving this goal by 2030. ISNTD d³ 2024 takes a closer look at how progress in drug discovery and diagnostics in the field of Neglected Tropical Diseases is critical is supporting this
- [Antiviral Drug Discovery (AViDD) Open Science Forum](https://dndi.org/events/2023/antiviral-drug-discovery-avidd-open-science-forum-3/) - The Open Science Forum features monthly talks from scientists from NIH-funded Antiviral Drug Discovery (AViDD) Centers who elect to provide updates on target priorities, advertise available resources and reagents, disclose chemical matter (such as hits, leads, and chemical tool compounds) and associated antiviral data, share findings regarding in vivo efficacy models, discuss downstream development and translation models,
- [Dengue Research Visibility Day 2024](https://dndi.org/events/2024/dengue-research-visibility-day-2024/) - Time: 14.30 – 17:30 MYTVenue: Auditorium Perdana, National Institutes of Health (NIH), Ministry of Health (MOH), Malaysia, Jalan Setia Murni U13/52, Seksyen U13 Setia Alam,40170, Shah Alam, Selangor, Malaysia. DNDi has co-organized this event in collaboration with the National Institutes of Health (NIH) and the international non-profit organisation, and Clinical Research Malaysia (CRM). It serves
- [Bridging boundaries: Innovating, connecting & reshaping drug repurposing](https://dndi.org/events/2024/bridging-boundaries-innovating-connecting-reshaping-drug-repurposing/) - In this global event, opinion leaders from both the research and patient communities, funders, regulators and representatives from the private sector will participate to collectively advance innovative drug repurposing in Europe and beyond. Session Turn of times: From opportunistic discovery to data-driven hypothesis generation in drug repurposing Date: Wednesday, 6 March 2024Time: 14:00-15:30 Speakers: Massimiliano
- [14th KASH conference](https://dndi.org/events/2023/14th-kash-conference/) - KASH is the KEMRI Annual Scientific and Health Conference launched in 2010 with the mission to mainstream the scientific and health agenda of KEMRI by Dissemination, sharing and digesting various scientific outputs and other allied products including networking and strengthening Partnerships and collaborations with a view to Improving on Health and Quality of life of
- [Eleventh EDCTP Forum](https://dndi.org/events/2023/eleventh-edctp-forum/) - The Forum programme will be crafted around the theme 'Partnering for global health research innovation and impact in Africa - Celebrating EDCTP: two decades and beyond.' At this Forum we will be reflecting on the achievements, impact, and challenges of the past 20 years of EDCTP, whilst looking forward to opportunities under the Global Health EDCTP3
- [AAPS 2023 PharmSci 360](https://dndi.org/events/2023/aaps-2023-pharmsci-360/) - The AAPS 2023 PharmSci 360 Meeting covers the pharmaceutical discovery and development process through the following themes: discovery and basic research, preclinical and translational sciences, bioanalytics, manufacturing and analytical characterization, formulation and delivery. Poster More information Event website
- [22nd ICASA Conference](https://dndi.org/events/2023/22nd-icasa-conference/) - The theme for the 22nd edition of the International Conference on AIDS and STIs in Africa Conference is 'AIDS is not over: Address inequalities, accelerate inclusion and innovation'. The objectives are to mainstream respect for equity, inclusion and diversity in the control and mitigation of the impact of diseases, sustain and increase domestic financing and
- [Accountability towards accelerated access to better medicines for children](https://dndi.org/events/2023/accountability-towards-accelerated-access-to-better-medicines-for-children/) - As part of a series of public briefings and policy debates hosted by the Geneva Global Health Hub (G2H2), 15-19 January 2024, ahead of WHO Executive Board 154, the Elizabeth Glaser Pediatric AIDS Foundation and GAP-f have organized a session on advocacy efforts to strengthen high-level political attention and accountability on innovation and access to
- [Maladies négligées : succès, défis, et modèles alternatifs d’innovation](https://dndi.org/events/2023/maladies-negligees-succes-defis-et-modeles-alternatifs-dinnovation/) - Réflexions sur 20 ans d’innovations et de partenariats, ainsi que sur les promesses d’un modèle de recherche pharmaceutique à but non-lucratif, face aux défis du réchauffement climatique et des menaces pandémiques, au lendemain de la journée mondiale des maladies tropicales négligées. Langue: français (certaines interventions peuvent se faire en anglais) Programme Date et heure :
- [Neglected Tropical Diseases Webinar](https://dndi.org/events/2023/neglected-tropical-diseases/) - SILF, the Swedish Society of Tropical Medicine, Doctors Without Borders, and Mediahuset hosts this free webinar with international speakers. Webinar Time: 16:00- 17:45 CET More information Watch the recordingEvent website
- [Improving access to healthcare in low- and middle-income countries (LMICs)](https://dndi.org/events/2023/improving-access-to-healthcare-in-low-and-middle-income-countries-lmics/) - Improving access to healthcare in low- and middle-income countries (LMICs) is a global issue. On 8 February 2024, Swiss TPH will bring together experts and key players from the pharmaceutical industry, academia and product development partnerships to assess current strategies and progress and to foster synergies between partners for more effective product development, licensing and
- [4th Alpine Winter Conference on Medicinal and Synthetic Chemistry](https://dndi.org/events/2023/4th-alpine-winter-conference-on-medicinal-and-synthetic-chemistry/) - The “Alpine Winter Conference on Medicinal and Synthetic Chemistry” exposes attending scientists to cutting edge synthetic and medicinal chemistry as well as developments in technologies that foster innovation in drug discovery. The main target audience will include medicinal and synthetic chemists, as well as related drug discovery disciplines from both industry and academia as well
- [World Skin Health Day](https://dndi.org/events/2023/world-skin-health-day/) - For its forth edition, the World Skin Health Day is celebrated in Guinea under the auspice of the International League of Dermatological Societies (ILDS) and the International Society of Dermatology (ISD), and introduced by the World Health Organisation (WHO). Expected more than 300+ scientific presentations of Thought-Leaders from 40+ countries covering 22 topics, CME accredited by UEMS-EACCME® for ECMEC®. Session Session 15: Skin NTDs Chairs: Rapelanoro Rabenja
- [Advancing neglected diseases drug discovery in endemic areas](https://dndi.org/events/2023/advancing-neglected-diseases-drug-discovery-in-endemic-areas/) - Our DNDi Latin America team and the Prof. Luiz Carlos Dias (UNICAMP) are organizing a two-day scientific event to celebrate the 10th anniversary of our Lead Optimization Latin American (LOLA) consortium. Entitled 'Advancing Neglected Diseases Drug Discovery in Endemic Areas', the symposium will be held in person in Campinas/Brazil combined with live streaming. The event will bring together
- [The DNDi Japan 20th anniversary seminar](https://dndi.org/events/2023/the-dndi-japan-20th-anniversary-seminar/) - DNDi is a non-profit organization dedicated mainly to the research and development of new treatments for patients suffering from neglected diseases including neglected tropical diseases. Since its founding in 2003 with a portion of 1999 Nobel Peace Prize awarded to Médecins Sans Frontières (MSF), the organization has delivered 12 new treatments in the past 20
- [20 years of DNDi: Sustainable solutions to develop the best science for still neglected populations](https://dndi.org/events/2023/20-years-of-dndi-sustainable-solutions-to-develop-the-best-science-for-still-neglected-populations/) - In celebration of its 20th anniversary, DNDi is organizing the DNDi 20 Years Symposium: Sustainable Solutions to Develop the Best Science for the Most Neglected on Tuesday 28 November 2023 at the Oswaldo Cruz Foundation (Fiocruz) campus in Rio de Janeiro. The event will address the advances made by DNDi and its partners since the
- [International symposium on pharmacology and medicinal chemistry](https://dndi.org/events/2023/international-symposium-on-pharmacology-and-medicinal-chemistry/) - This event was created as an internationalization activity of the Graduate Program in Pharmacology and Medicinal Chemistry (PPGFQM), aiming to facilitate experience exchange between invited international researchers and PPGFQM students and professors, with a focus on the area of drug discovery. Poster More information Event website
- [CPHIA 2023](https://dndi.org/events/2023/cphia-2023/) - The annual International Conference on Public Health in Africa (CPHIA) is organised by the Africa Centres for Disease Control and Prevention (Africa CDC) and provides an African-led platform for leaders across the continent to reflect on lessons learned in health and science, and align on a way forward for creating more resilient health systems. Plenary
- [Licensing and access to medicines and vaccines: Obstacles and proposals for improving access](https://dndi.org/events/2023/licensing-and-access-to-medicines-and-vaccines-obstacles-and-proposals-for-improving-access/) - SxD and HAI jointly convene a round-table titled “Licensing and access to medicines and vaccines: Obstacles and proposals for improving access” discussion to address ongoing discussions at EU (pharma strategy) and Global (INB) levels regarding access to results from publicly supported R&D, trends in dissemination of publicly generated knowledge: licensing strategies, access clauses and societal
- [ECTMIH 2023](https://dndi.org/events/2023/ectmih-2023/) - The European and Dutch Societies for Global Health and Tropical Medicine, Knowledge Centre Global Health, and University Medical Center Utrecht are hosting the 13th European Congress on Global Health. The aim at ECTMIH 2023 is to accelerate the understanding, appreciation, and connections between tropical medicine, global health, and the urgent field of planetary health. It will build
- [DNDi Charity Run: Run for Neglected Patients](https://dndi.org/events/2023/dndi-charity-run-for-neglected-patients/) - Join us on 18 November 2023, as the Drugs for Neglected Diseases initiative hosts a 10 km run themed ‘Run for Neglected Patients’ to commemorate its 20-year anniversary. The run aims to raise awareness about neglected diseases, spotlight the crucial need for research and development for innovative patient solutions, and address the treatment gaps faced by the
- [2nd World Local Production Forum](https://dndi.org/events/2023/2nd-world-local-production-forum/) - The World Local Production Forum: Enhancing access to medicines and other health technologies (WLPF) is a WHO initiative that provides Member States and the global community with a regular platform to shape strategies, galvanize collective action, and foster partnerships on sustainable local production to improve timely and equitable access to quality assured health products. Session Reaching the
- [iNTD second international colloquium](https://dndi.org/events/2023/intd-second-international-colloquium/) - The International Working Group on Neurotransmitter Related Disorders (iNTD) hosts their second international colloquium with the theme 'A pragmatic roadmap for elimination of NTDs with relevance to India'. Scientific Session Date: Wednesday 4 October 2023Time: 9:15 to 11:30 IST
- [Joint Conference on Global Health 2023](https://dndi.org/events/2023/joint-conference-on-global-health-2023/) - Coming together under the theme 'To the ocean of global health: Seeking richness that embraces diversity', this joint conference consists of the 64th Annual Meeting of the Japan Society of Tropical Medicine, the 38th Annual Meeting of the Japan Society for Global Health, the 27th Annual Meeting of the Japan Society of Travel Medicine, and
- [9th International Conference on Infectious Disease Dynamics](https://dndi.org/events/2023/9th-international-conference-on-infectious-disease-dynamics/) - The International Conference on Infectious Disease Dynamics is three days of dialogue on the latest ideas, data, insight, models and methods in infectious disease dynamics open to all infectious diseases of humans and animals. Poster More information Event website
- [BrazMedChem 2023](https://dndi.org/events/2023/brazmedchem-2023/) - The Brazilian Symposium on Medicinal Chemistry (BrazMedChem) is an international scientific event with the main objective of bringing together Brazilian Medicinal Chemists and students to discuss state-of-the-art discovery/development tools and strategies. Session Health innovation in neglected and infectious diseases Date: 26 October 2023 Time: 9:30 - 10:50 Chair: Jadel Kratz, Head of Discovery and R&D
- [2023 SAHCS Conference](https://dndi.org/events/2023/2023-sahcs-conference/) - The 2023 SAHCS Conference is organised by the Southern African HIV Clinicians Society (SAHCS). SAHCS’s mission is to promote evidence-based, quality HIV healthcare in Southern Africa. The SAHCS Conference focuses on HIV/AIDS clinical content. Session Skills building: Children and adolescents Date: Wednesday 8 November 2023Time: 11:00 to 12:30 Chairs: Moherndran Archary, Paediatric Infectious Disease Specialist,
- [The 65th annual meeting of the Korean Society for Parasitology and Tropical Medicine](https://dndi.org/events/2023/the-65th-annual-meeting-of-the-korean-society-for-parasitology-and-tropical-medicine/) - The Korean Society for Parasitology and Tropical Medicine was founded in 1959 with the goals of 1) researching and enhancing knowledge of parasites and parasitology, 2) facilitating academic exchanges with foreign societies, 3) educating the public on parasitology and 4) facilitating exchanges between the society members. Poster More information Event website
- [Innovations in paediatric drug development: focus on new delivery systems and priority antibiotics](https://dndi.org/events/2023/innovations-in-paediatric-drug-development-focus-on-new-delivery-systems-and-priority-antibiotics/) - The Global Accelerator for Paediatric formulations presents this webinar as part of their #BetterMeds4Kids Webinar Series Panel discussion Innovation in paediatric drug delivery Time: 14:15-15:00 CEST Moderator: Janice Lee, Access Leader, Viral Cluster, DNDi Speakers: Pavan Elisetty Kumar, General Manager Business Development, Laurus LabsCatherine Tuleu, Professor of Paediatric Pharmaceutics, University College LondonKhalid Farrag, Senior Director,
- [Parlamentarisches Frühstück der PDP Koalition](https://dndi.org/events/2023/parlamentarisches-fruhstuck/) - Event on innovative research for poverty-related neglected diseases through product development partnerships (PDPs) with new funding from the Ministry of Education and Research (BMBF). Ab Juli 2023 wird das Ministerium for Bildung und Forschung (BMBF) wieder ausgewählte fünf PDPs fördern, die Forschung und Entwicklung (F&E) für armutsassoziierte vernachlässigte Krankheiten in internationaler Kooperation und im Sinne
- [2023 COR-NTD Annual Meeting](https://dndi.org/events/2023/2023-cor-ntd-annual-meeting/) - The Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD) convenes coalition members annually to facilitate conversations between researchers, the World Health Organization, country program managers, implementers and donors. Working groups comprised of NTD experts from across the coalition lead conversations and identify key research priorities at COR-NTD meetings called Research Links throughout the year. These
- [Humanitarian Congress Berlin 2023](https://dndi.org/events/2023/humanitarian-congress-berlin-2023/) - In our interconnected and media-driven world, attention has emerged as a powerful force shaping humanitarian action. The allocation of attention and the control over narratives, whether driven by media, public, economic, or political influences, holds profound implications for crises response and humanitarian habits. Consequently, the in parts unjustifiably attention-based prioritization perpetuates systemic inequalities and often
- [ISCNP31 and ICOB11](https://dndi.org/events/2023/iscnp31-and-icob11/) - The 31st International symposium on the chemistry of natural products and 11th International congress on biodiversity aims to highlight advancements, innovations and future perspectives in these areas of research and to create an environment that promotes international collaborations and cross-fertilization of ideas. Poster More information Event website
- [RSTMH Annual Meeting 2023](https://dndi.org/events/2023/rstmh-annual-meeting-2023/) - The Royal Society of Tropical Medicine & Hygiene 2023 Annual Meeting will bring together members, Fellows and supporters from around the world to share knowledge, hear about the latest research and ideas, and encourage new collaborations. Attendees will learn about and discuss the priorities for the next 5 years for topics which include malaria, NTDs,
- [Youth voices for NTD-free world: Let's talk solutions](https://dndi.org/events/2023/youth-voices-for-ntd-free-world-lets-talk-solutions/) - Twitter Space Date: Wednesday, 4 October 2023Time: 19:00 - 20:30 EAT Host: Janet Machuka, Social Media & Content Marketing Expert Speakers: Sam Kariuki, Eastern Africa Director, DNDiElizabeth Juma, Team Lead, WHO African Region (ESPEN)Fatima Mohammed, Medical Student, YOUNGO HealthYonah Yangaza, NTDs Team Lead, One Health SocietyFaith Olanrewaju, Public Health Chairperson, Pharmaceutical Association of Nigerian StudentsMwanahawa
- [FPM Annual Symposium 2023](https://dndi.org/events/2023/fpm-annual-symposium-2023/) - The 2023 FPM Annual Symposium 'Navigating the future-scape of pharmaceutical medicine' will address some of the challenges and opportunities facing global healthcare. As countries and healthcare systems around the world do their best to recover from COVID-19, the lessons the pandemic taught are being infused into a new pioneering and collaborative spirit. Session Global health: An
- [Grand Challenges Annual Meeting 2023](https://dndi.org/events/2023/grand-challenges-annual-meeting-2023/) - The annual Grand Challenges meeting that brings together funding and research partners throughout the Grand Challenges network and beyond. Session The evolving role of pathogen genomics in public health surveillance The role of genomics in cholera control Date: Tuesday, 10 OctoberTime: 15:30 - 17:30 Session Chair: Natsuko Imai, Senior Research Manager, Disease Tracking, Wellcome Session
- [Cúpula Brasileira de Inovação em Saúde](https://dndi.org/events/2023/cupula-brasileira-de-inovacao-em-saude/) - Organized by the Sindicato da Indústria de Produtos Farmacêuticos (SINDUSFARMA), the Rede Brasileira de Inovação Farmacêutica (RBIF), and Biominas Brasil, the Brazilian Summit of Innovation in Health aims to explore collaboration and business opportunities in the field of innovation and health. Presentation Date: Friday, 6 October 2023Time: 9:00 - 9:45 More information Event website
- [36th General Conference of the International Scientific Council for Trypanosomiasis Research and Control](https://dndi.org/events/2023/36th-general-conference-of-the-international-scientific-council-for-trypanosomiasis-research-and-control/) - The 36th General Conference of the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) will be organised by the ISCTRC Council, comprising the Africa Union Member States, Africa Union Pan African Tsetse and Trypanosomiasis Eradication Campaign (AU-PATTEC), International organizations, including Food and Agricultural Organization (FAO), World Health Organization (WHO), and the International Atomic Energy Agency
- [Accelerating R&D for Snakebites: Building a Common Agenda for Progress](https://dndi.org/events/2023/accelerating-rd-for-snakebites-building-a-common-agenda-for-progress/) - The Geneva Health Forum, the University of Geneva, ​Médecins Sans Frontières and Policy Cures Research, with support from Wellcome, present an event on International Snakebite Awareness Day. This event will gather snakebite envenoming (SBE) actors, as well as traditional NTD stakeholders, to define the future direction of the SBE R&D ecosystem and apply learnings from
- [Shifting Paradigms: Can NTD innovations fit within existing pooled procurement mechanisms?](https://dndi.org/events/2023/shifting-paradigms-can-ntd-innovations-fit-within-existing-pooled-procurement-mechanisms/) - This discussion on the requirements for developing pooled procurement mechanisms for NTDs is co-hosted by the Global Institute for Disease Elimination (GLIDE) and Uniting Efforts for Innovation, Access and Delivery. Speakers: Mae Shieh, Head of Business Development, DNDiChristopher Lim, Chief, PAHO Strategic Fund Systems and Services, Pan American Health OrganizationSam Mayer, Vice President, Public Affairs
- [Ongoing pandemic (tuberculosis) response and future pandemic preparedness – How to make synergy](https://dndi.org/events/2023/ongoing-pandemic-tuberculosis-response-and-future-pandemic-preparedness-how-to-make-synergy/) - The 2023 UN High-Level Meeting will take place on September 20 agenda as they recommit to ending tuberculosis (TB), delivering universal health coverage (UHC) and strengthening pandemic prevention, preparedness, and response. The Global Health Innovative Technology Fund (GHIT Fund), in collaboration with Nikkei Inc., Government of Japan and Stop TB Partnership, will hold a side
- [Africa Climate Summit 2023](https://dndi.org/events/2023/africa-climate-summit-2023/) - The inaugural Africa Climate Summit aims to address the increasing exposure to climate change and its associated costs, both globally and particularly in Africa. With the expectation of escalating climate crises in terms of frequency and intensity, urgent action is required to mitigate these challenges. The Summit will serve as a platform to inform, frame,
- [NNN Conference 2023](https://dndi.org/events/2023/nnn-conference-2023/) - Hosted by the Neglected Tropical Disease NGO Network, the 14th Annual NNN Conference will take place 19-21 September 2023 in Dar Es Salaam, Tanzania, discussing the theme "Reaching new frontiers - powering a new generation of leadership and cross-sectoral collaborations to end NTDs". Rapid-fire session The power of storytelling in health advocacy: From neglect to hope for leishmaniasis
- [28th Leishmaniasis East Africa Platform (LEAP) Meeting](https://dndi.org/events/2023/28th-leishmaniasis-east-africa-platform-leap-meeting/) - The theme for this year's meeting is 'Innovation to foster elimination of visceral leishmaniasis in Africa'. More information Coming soon
- [Antiviral Drug Discovery (AViDD) Open Science Forum](https://dndi.org/events/2023/antiviral-drug-discovery-avidd-open-science-forum-2/) - The Open Science Forum features monthly talks from scientists from NIH-funded Antiviral Drug Discovery (AViDD) Centers who elect to provide updates on target priorities, advertise available resources and reagents, disclose chemical matter and associated antiviral data, share findings regarding in vivo efficacy models, discuss downstream development and translation models, and share ideas. Presentation Moderator: Peter Sjö, Head
- [16th National Conference on Clinical Research](https://dndi.org/events/2023/16th-national-conference-on-clinical-research/) - This year's conference's theme, 'Quantum leap in research leadership' represents Clinical Research Malaysia's aspiration to push the boundaries of knowledge and innovation in the realm of clinical research. Symposium Drug Development Date: Friday, 22 September 2023Time: 9:00 MYT Moderator: Chew Chun Keat, Technical Head, Centre for Clinical Trial, Institute for Clinical Research, National Institutes of Health
- [2nd Health & Climate Change Conference](https://dndi.org/events/2023/2nd-health-climate-change-conference/) - Kenya Medical Research Institute (KEMRI) is organizing a conference on health and climate change. The theme of this year's edition is 'Towards delivery of climate resilient universal health coverage leveraging on blue and green economy'. Speakers: James Mwitari, Senior Research Fellow, Principal Investigator and Co-Director, KEMRI- Clean Air (Africa) Global Health Research unitSamuel Kariuki, Eastern
- [ICASA 2019](https://dndi.org/events/2019/icasa-2019/) - ICASA 2019 is the 20th International Conference on AIDS and STIs in Africa. Satellite symposium From guidelines to reality: Accelerating access to optimal treatment for children with HIV Entre directives et réalité: Accélérer l'accès à un traitement adapté pour les enfants vivant avec le VIH Organized by DNDi, Sidaction, MSF Date: Monday, 2 December 2019Time:
- [13<sup>th</sup> EuPFI Conference](https://dndi.org/events/2021/13th-eupfi-conference/) - The European Paediatric Formulation Initiative (EuPFI) conference is an annual event that brings together pioneering scientists with young researchers and students to discuss the latest advancements and challenges facing the evolving field of paediatric medicines. Plenary session Double whammy: neglected formulation innovations for children with neglected diseases Date: Thursday, 23 September 2021 Speaker: Janice Lee,
- [Journée Scientifique de l'Initiative 2023](https://dndi.org/events/2023/journee-scientifique-de-linitiative-2023/) - L'initiative sida, tuberculose, paludisme is hosting an event on children living with HIV, TB, and malaria bringing together researchers, project leaders, and actors in the field working with the Initiative. Panel discussion Panel sur les particularités des produits de santé pour enfants : les enjeux technologiques et économiques sont-ils les seuls freins ? Time: 12:00-12:50
- [Chagas Platform Meeting 2020](https://dndi.org/events/2020/chagas-platform-meeting-2020/) - The Chagas Clinical Research Platform gathers different stakeholders from more than 20 countries, supporting the development of new drugs to treat the infection caused by the Trypanosoma cruzi parasite. The Chagas Platform's plenary meetings are held every two years and bring together prominent researchers and stakeholders involved with Chagas disease. During these meetings, participants discuss
- [ASTMH 2020](https://dndi.org/events/2020/astmh-2020/) - The American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting is designed for researchers, professors, government and public health officials, military personnel, travel clinic physicians, practicing physicians in tropical medicine, students and all health care providers working in the fields of tropical medicine, hygiene and global health. Posters More information Event websiteProgramme
- [Population Approach Group Europe Meeting 2021](https://dndi.org/events/2021/population-approach-group-europe-2021/) - The Population Approach Group in Europe (PAGE) represents a community with a shared interest in data analysis using the population approach. Posters More information Event website
- [3rd World Conference on Pharmacometrics (WCoP)](https://dndi.org/events/2022/3rd-world-conference-on-pharmacometrics-wcop/) - The World Conference on Pharmacometrics (WCoP) aims to showcase the latest in pharmacometrics updates and developments from around the world. Poster *Presenting author More information Event website
- [ASTMH 2022](https://dndi.org/events/2022/astmh-2022/) - The ASTMH Annual Meeting draws tropical medicine and global health professionals representing academia, foundations, government, not for profit organizations, non-governmental organizations, the private sector, military and private practice. Oral presentation Posters More information Event website
- [Life Science Career Day](https://dndi.org/events/2020/life-science-career-day/) - Organized by the University of Lausanne and BioScience Network Lausanne, the Life Science Career Day aims to help students and early career researchers to build their career map. Session How to find purpose and fulfillment in a career Time: 10:00-11:10 Speakers: Stéphanie Braillard, NonClinical Development Senior Manager, DNDiCarina Schey, Health Economist & international award-winning public speaker
- [Taking novel drugs from lab to clinic: Concepts and case studies](https://dndi.org/events/2022/taking-novel-drugs-from-lab-to-clinic/) - DNDi, the Indian Society for Clinical Research (ISCR), and BIRAC Regional Bio-Innovation Centre (a joint initiative of BIRAC and Venture Center) are hosting five days of virtual workshops titled 'Taking novel drugs from lab to clinic: Concepts and case studies'. This event is an exciting opportunity to hear from national and international experts as they
- [PAGE 2022 Meeting](https://dndi.org/events/2022/page-2022-meeting/) - The Population Approach Group Europe (PAGE) represents a community with a shared interest in data analysis using the population approach. The PAGE meeting is held in June each year at a different European location. Posters More information Event website
- [BSP Spring Meeting 2023](https://dndi.org/events/2023/bsp-spring-meeting-2023/) - The 2023 British Society for Parasitology Spring Meeting covers general parasitology themes across the discipline as well as dedicated stream focused on trypanosomiasis and leishmaniasis. Poster More information Event website
- [MedTrop 2023](https://dndi.org/events/2023/medtrop-2023/) - MedTrop 2023 is the 58th Congress of the Brazilian Society of Tropical Medicine. The congress hosts various side events including the ChagasLeish 2023. Pre-congress workshop Estratégias de integração entre os projetos de vigilância e cuidado para doença de Chagas: Em busca de harmonização de variáveis, indicadores e fontes de informações Date: Saturday, 9 September 2023Time:
- [Chagas e inmunosupresión: Pautas para el manejo de la reactivación de la infección por <i>T. cruzi</i>](https://dndi.org/events/2023/chagas-e-inmunosupresion-pautas-para-manejo-de-reactivacion-infeccion-tcruzi/) - Organized by DNDi, this seminar aims to develop a space for updating, analysis, and reflection on the clinical scenario of T. cruzi infection and the state of immunocompromised patients in different clinical situations. Chair: Andrea Marchiol, Senior Chagas Access Project Manager, DNDi Speakers: Israel Molina, Director, International Health Programme at the Catalan Institute of Health (PROSICS), and
- [Diálogo Nacional das Associações de Pessoas Afetadas pela Doença de Chagas com os diferentes atores envolvidos no estudo e controle da Doença de Chagas](https://dndi.org/events/2023/dialogo-nacional-associacoes-pessoas-afetadas-chagas/) - This event organized by Fiocruz, the Vice-Presidency for Research and Biological Collections – VPPCB, in partnership with FINDECHAGAS and DNDi, is the first National Dialogue of Associations of People Affected by Chagas Disease. The theme of the event is 'Interlocution with different actors involved in the study and control of Chagas disease.' The event is supported
- [Molecular helminthology meeting 2023](https://dndi.org/events/2023/molecular-helminthology-meeting-2023/) - This conference, organized by the Morgridge Institute for Research, discusses topics related to immunoparasitology and diagnostics, drugs and resistance, developmental biology, model organisms, new technologies and methods, and host-parasite interactions. Therapeutics and drug resistance Date: Wednesday, 28 June 2023Time: 17:50 - 19:30 More information Event website
- [Antimicrobial drug discovery: SAR optimization and QSAR](https://dndi.org/events/2023/antimicrobial-drug-discovery-sar-optimization-and-qsar/) - This webinar is organized by REVIVE, a project by GARDP to ensure knowledge is retained, and the antimicrobial R&D community is supported to connect, share, and acquire information. Chair: Charles Mowbray, Discovery Director, DNDi Speakers: Alastair Parkes, VP Medicinal Chemistry, Evotec - Structure activity relationship optimisation – case studiesJames Duffy, Senior Director, Drug Discovery, Medicines
- [The arboviral threat: a growing hazard in an uncertain world](https://dndi.org/events/2023/the-arboviral-threat-a-growing-hazard-in-an-uncertain-world/) - The All-Party Parliamentary Group on Malaria and Neglected Tropical Diseases and the International Society for Neglected Tropical Diseases are hosting a meeting and networking reception at the UK Parliament. Venue: Attlee Suite, Portcullis House, 1 Victoria Embankment, London SW1A 2JR Speakers: Ibrahima Socé Fall, Director of the Department of Control of Neglected Tropical Diseases, World
- [One Sustainable Health Forum](https://dndi.org/events/2023/one-sustainable-health-forum/) - Strategic round table and interactive discussion on Health innovation and the climate emergency: how to reduce the impact of global health?
- [Geneva Health Forum 2022](https://dndi.org/events/2022/geneva-health-forum-2022/) - The Global Health Forum (GHF) is the forum for innovative practices in global health. The theme of this year's edition is 'Covid-19 Pandemic and Environmental Emergency : Reinventing Global Health in times of Global Changes.' DNDi is a partner of the event. Plenary session Data sharing in the time of COVID-19: What works & what
- [Business Fights Poverty Global Summit](https://dndi.org/events/2023/business-fights-poverty-global-summit/) - The Business Fights Poverty organizes its global summit to explore the critical role of business in sustainable development. Twitter Space Amplifying social impact through business Date: Wednesday, 21 June 2023Time: 10:45 EST Moderator: Katie Hyson, COO, Business Fights Poverty Speakers: Cemre Ulker, UN Representative of JWF, UN DGC & Co-Founder, Set Them FreeJoelle Tanguy, Director of
- [Colloque de l’ISG: 20 ans de recherche médicale pour les populations négligées](https://dndi.org/events/2023/colloque-de-lisg-20-ans-de-recherche-medicale-pour-les-populations-negligees/) - The Institute of Global Health of the University of Geneva is hosting a conference on the occasion of DNDi’s 20th anniversary to discuss lessons learned over the past twenty years in not-for-profit drug development, and future challenges around innovation and access. Speakers: Luis Pizarro, Executive Director, DNDiFabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi More information
- [Treatment strategies for dengue infection](https://dndi.org/events/2023/treatment-strategies-for-dengue-infection/) - The International Society for Infectious Diseases is organizing a webinar to discuss treatment strategies for Dengue infection. Chair: Neelika Malavige, Head of Dengue Global Programme and Scientific Affairs, DNDi Co-Chair: Muhammed Niyas, Consultant in Infectious Diseases, KIMSHEALTH Speakers: Ashley St. John, Associate Professor, Duke-NUS Medical SchoolEng Eong Ooi, Professor, Saw Swee Hock School of Public
- [PAGE 2023 Meeting](https://dndi.org/events/2023/page-2023-meeting/) - The Population Approach Group Europe (PAGE) represents a community with a shared interest in data analysis using the population approach. The PAGE meeting is held in June each year at a different European location. Poster More information Event website
- [How can global action really meet local needs in emerging outbreaks?](https://dndi.org/events/2023/how-can-global-action-really-meet-local-needs-in-emerging-outbreaks/) - Date: Wednesday, 24 May 2023Time: 13:00-15:00Venue: Auditorium Ivan Pictet, Geneva Graduate Institute, Chem. Eugène-Rigot 2, 1202 Geneva The PANdemic preparedness plaTform for Health and Emerging infections Response (PANTHER) is hosting an event on the sidelines of the 76th World Health Assembly to discuss how to better prepare for and respond to outbreaks, before they hit
- [Commemorative Symposium for G7 Health Ministers Meeting in Nagasaki](https://dndi.org/events/2023/commemorative-symposium-g7-health-ministers-meeting-nagasaki/) - The Global Health Innovative Technology Fund (GHIT Fund), Nagasaki University, and Uniting to Combat NTDs are co-hosting a symposium on the theme 'Accelerating Research and Development, Access and Delivery for Neglected Tropical Diseases'. Agenda Session 1 Session 2 Closing Watch the recording More information Event websiteEvent summary
- [Tratamiento de la infección por <i>T. Cruzi</i>: superando frustraciones y abriendo caminos](https://dndi.org/events/2023/tratamiento-de-la-infeccion-por-t-cruzi-superando-frustraciones-y-abriendo-caminos/) - The Center for Research in Microbiology and Biotechnology of the Rosario University is hosting a webinar to discuss treatments for Chagas disease. Speakers: María Jesús Pinazo, Head of Chagas Disease, DNDiColin Forsyth, Senior Research and Project Manager, DNDiAlberto Paniz-Mondolfi, Associate Professor, Mount Sinai More information Event registration
- [Overcoming barriers of access to treatments for neglected patients](https://dndi.org/events/2023/overcoming-barriers-of-access-to-treatments-for-neglected-patients/) - The Rotary Club of Hurlingham Nairobi organizes an event on leishmaniasis with guest speaker Simon Bolo, Head of Leishmaniasis Access, DNDi. More information Event promotion
- [Accelerating universal health coverage with inclusive new tools](https://dndi.org/events/2023/accelerating-universal-health-coverage-with-inclusive-new-tools/) - On the occasion of DNDi’s 20th anniversary, this event will explore opportunities to strengthen universal health coverage through inclusive innovation, notably for the most vulnerable communities, against the background of a challenging and ever-changing world of infectious and noncommunicable diseases, pandemics, and climate change.
- [DNDi Mycetoma Strategic Plan (2023-2028) 1<sup>st</sup> Expert Meeting](https://dndi.org/events/2023/mycetoma-strategic-plan-2023-2028-1st-expert-meeting/) - DNDi is hosting an meeting with mycetoma experts to discuss DNDi's Mycetoma Strategic Plan (2023-2028). Agenda Thursday, 1 June 2023 Session 1: Global Overview of Mycetoma 9:00-10:30 Chair: Borna Nyaoke, Head of Mycetoma Disease, DNDi Session 2: Country Experiences 11:00-15:00 Chair: Augustin Ebeja, World Health Organization Technical discussions- Sessions 1 & 2 15:00-16:30 Friday, 2
- [1<sup>st</sup> PAMWG Conference](https://dndi.org/events/2023/1st-pamwg-conference/) - Hosted by the International Society for Human and Animal Mycology, the Pan-African Mycology Working Group (PAMWG) was set up to provide a better interaction and synergy among regional leaders in order to develop educational programs to aid in the diagnosis and care of patients with fungal infections in Africa. The theme of the 1st PAMWG
- [London NTDs Event - Uniting to Combat Neglected Tropical Diseases](https://dndi.org/events/2012/london-ntds-event/) - A group of international partners announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade. Uniting efforts with NTD-endemic countries, partners pledged to bring a unique focus to defeating these diseases and to work together to improve the lives of the 1.4
- [ISNTD Connect: Dengue: Sri Lanka in focus](https://dndi.org/events/2023/isntd-connect-dengue-sri-lanka-in-focus/) - ISNTD Connect is a forum and series of short meetings online, where researchers and professionals in the fields of tropical diseases and public health are able to present and discuss ongoing research and topics. This online meeting focuses on dengue in Sri Lanka. Speakers: Jagath Amarasekera, Consultant Community Physician, National Dengue Control Unit, Ministry of
- [Infectious Diseases Conference 2023](https://dndi.org/events/2023/infectious-diseases-conference-2023/) - The inaugural Infections Diseases Conference is organized by the Infectious Diseases Forum of the Ceylon College of Physicians in collaboration with DNDi, Sri Lanka College of Microbiologists, and Sri Lanka College of Internal Medicine. Symposium Control of vector borne diseases Date: Friday, 30 June 2023Time: 8:45 - 10:00 Plenary Date: Friday, 30 June 2023Time: 10:00-10:30
- [ASM Microbe 2023](https://dndi.org/events/2023/asm-microbe-2023/) - Organized by the American Society of Microbiology, ASM Microbe is a large microbial sciences gathering bringing together scientists, researchers, and healthcare professionals. Session Treating African sleeping sickness Date: Sunday, 18 June 2023Time: 8:00 - 9:00Venue: 330 AB-GRB Center Moderator: Boghuma Titanji, Assistant Professor, Department of Medicine, Emory University School of Medicine Speakers: Wilfried Mutombo Kalonji,
- [International Clinical Trials Day](https://dndi.org/events/2023/international-clinical-trials-day/) - On the occasion of International Clinical Trials Day, DNDi and CSIR-Central Drug Research Institute organize a symposium on 'Patient engagement-benchmark in clinical trials'. Agenda Time: 11:30-12:45Venue: Main Auditorium, CSIR-CDRI, Lucknow
- [MSF Scientific Days International 2023](https://dndi.org/events/2023/msf-scientific-days-international-2023/) - Organized by Médecins Sans Frontières, MSF Scientific Days bring together researchers, practitioners, academics, and patient representatives to discuss and critique medical humanitarian research and innovative practices from MSF projects worldwide. Session Evolutions in control and case management of outbreaks Time: 15:00 More information Event website
- [Together against dengue: Building a stronger and safer community](https://dndi.org/events/2023/together-against-dengue-building-a-stronger-and-safer-community/) - Dengue is the most rapidly increasing mosquito borne infection worldwide and dengue fever continues to be an important public health problem in India, as evidenced by the high proportion dengue positivity, severity, and case fatality. On the occasion of National Dengue Day observed in India on 16 May, the Indian Council of Medical Research (ICMR)
- [Devex CheckUp @ WHA 76](https://dndi.org/events/2023/devex-checkup-wha-76/) - Accelerating innovation in global health On the occasion of the 76th World Health Assembly, Devex is convening leaders in global health to discuss the lingering pandemic emergency and long-term effects of COVID-19, preparations for the next global health threat, and the innovation necessary to move the needle on access to medicines and quality health care
- [Successes in global health action and justice: Insights from tackling HIV/AIDS and neglected diseases](https://dndi.org/events/2023/successes-global-health-action-justice-insights-hiv-aids-neglected-diseases/) - On the occasion of DNDi’s 20th anniversary, this event will explore opportunities to strengthen universal health coverage through inclusive innovation, notably for the most vulnerable communities, against the background of a challenging and ever-changing world of infectious and noncommunicable diseases, pandemics, and climate change.
- [Global Hepatitis Summit 2023](https://dndi.org/events/2023/global-hepatitis-summit-2023/) - The 18th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD). Symposium NoHep Medical Visionaries Date: Thursday, 27 April 2023Time: 16:30-18:30 Moderators: Olufunmilayo Lesi, Nigeria and Su Wang, USA More information Event website
- [Second Plenary Meeting of the VolREthics Initiative](https://dndi.org/events/2023/second-plenary-meeting-of-the-volrethics-initiative/) - In 2022, Inserm set up an international initiative on ethical issues related to the participation of healthy volunteers in biomedical research. Called VolREthics (Volunteers in Research and Ethics), this initiative is supported by numerous international partners including DNDi. Its objective is to lead to the sharing and discussion of practices at international level, so that
- [SANTD Symposium 2023](https://dndi.org/events/2023/santd-symposium-2023/) - The Swiss Alliance against Neglected Tropical Diseases (SANTD) organizes a symposium for stakeholders in the Swiss global health sector to exchange on resource mobilization, integrated approaches, the importance of continued innovation and ensuring access to new tools and interventions, efficient and data driven use of existing resources, and the need for sustained financing. Panel discussion
- [How can non-profit drug developers counter AMR?](https://dndi.org/events/2023/how-can-non-profit-drug-developers-counter-amr/) - Who could viably fund development and secure global equitable access for new antibiotics? The Global Antibiotic Research & Development Partnership (GARDP) is hosting a webinar to discuss the role that nonprofit research and development organizations (like GARDP), with support from public funders, and unconstrained by commercial profitability requirements can play to provide new antibiotics to all
- [Humanitarian Congress Tokyo 2023](https://dndi.org/events/2023/humanitarian-congress-tokyo-2023/) - Médecins Sans Frontières (MSF) has established the "Humanitarian Congress Tokyo" since 2020 as a platform based in Japan to discuss various issues related to humanitarian aid, and has been organizing the event jointly with the International Committee of the Red Cross (ICRC) since 2021. The theme of the Humanitarian Congress Tokyo 2023 is ‘A spotlight
- [Global meeting on skin-related neglected tropical diseases](https://dndi.org/events/2023/global-meeting-skin-related-neglected-tropical-diseases/) - The World Health Organization is holding its first global meeting on skin-related neglected tropical diseases (skin NTDs) to discuss progress and challenges in implementing integrated skin NTDs activities at country level, as underscored in the WHO NTD road map 2021–2030. Session Operational research Date: Friday, 31 March 2023Time: 9:00-12:00 *Presenting author More information Event websiteEvent summary
- [World Chagas Disease Day Seminar 2023](https://dndi.org/events/2023/world-chagas-disease-day-seminar-2023/) - This event, co-organized by the Brazilian Embassy, San Diego State University, the University of California-San Diego, and DNDi, aims to highlight advances and remaining challenges for Chagas disease and the many people it impacts throughout the world. Presentation Time: 11:00 - 11:20 More information Event websiteRegister to attend onlineFull programme
- [Empowering endemic countries in delivering the best science for most neglected](https://dndi.org/events/2023/empowering-endemic-countries-in-delivering-the-best-science-for-most-neglected/) - The National Institutes of Health (NIH) of Malaysia is hosting a special talk on the occasion of DNDi's 20th anniversary. Welcome speech by Muhammad Radzi Bin Abu Hassan, Deputy Director-General of Health (Research & Technical Support), Ministry of Health Malaysia and Member of DNDi's Scientific Advisory Committee Speaker: Luis Pizarro, Executive Director, DNDi The event
- [PQMD 2023 Global Health Policy Forum](https://dndi.org/events/2023/pqmd-2023-global-health-policy-forum/) - The PQMD Global Health Policy Forum is a long-standing annual event featuring conversations with global health experts and leaders designed to inform public debate; address contemporary health policy approaches; and explore the most pressing challenges and innovative trends shaping development and the policies that impact them. Panel discussion Access, equity & economic development Date: Thursday,
- [World Conference of Science Journalists 2023](https://dndi.org/events/2023/world-conference-science-journalists-2023/) - The World Conference of Science Journalists is a large international event for science journalists to gather as peers, helping one another learn, grow, and thrive. Workshop Learning session: New tools for the global fight against dengue fever Organized by DNDi and World Mosquito Program Date: Monday, 27 March 2023Time: 13:00-16:30 Speakers: Patricia Arbeláez Montoya, Universidad
- [Palestra do Fio-Chagas](https://dndi.org/events/2023/palestra-do-fio-chagas/) - Fiocruz is organizing a webinar to discuss current challenges of clinical research networks to improve the control of Chagas disease. Time: 14:00-16:00 GMT-3 Moderator: Fred Luciano Neves Santos, Coordinator of Fio-Chagas, Instituto Gonçalo Moniz (Fiocruz-BA) Speakers: María Jesús Pinazo, Head of Chagas disease, DNDiIsrael Molina, Fiocruz-MG and Hospital Universitário vall d'HebronTania Araújo-Jorge, IOC-RJ More information
- [Ending the neglect of Chagas disease in the UK](https://dndi.org/events/2023/ending-the-neglect-of-chagas-disease-in-the-uk/) - The UK Chagas Hub and London School of Hygiene & Tropical Medicine are hosting an event for World Chagas Day to explore Chagas disease in the UK, bring into sharp focus the neglect of this condition and the need to work with communities to design and deliver innovative and impactful public health action. The symposium
- [Developer’s perspective: Fexinidazole for African trypanosomiasis](https://dndi.org/events/2021/developers-perspective-fexinidazole-for-african-trypanosomiasis/) - Organized by the Japan Alliance on Global NTDs, the theme of this webinar series is 'Challenges of expanding access to health products in the fight against neglected tropical diseases' and aims clarify some conceptual aspects about access, discuss key access challenges from different perspectives and how these can be overcome. The second session of the
- [LCNTDR & The HAT Platform Scientific Research Meeting](https://dndi.org/events/2022/lcntdr-hat-platform-scientific-research-meeting/) - The London Centre for Neglected Tropical Disease Research, the HAT Platform, and RSTMH are co-hosting a series of scientific research roundtable meetings to convene global researchers who are working to interrupt the transmission and elimination of HAT as a public health problem, or whose work in a related area who could contribute to the effort.
- [ISNTD d3 2022](https://dndi.org/events/2022/isntd-d3-2/) - ISNTD d³ 2022 addresses the current gaps and collaboration opportunities across tropical diseases and diseases of poverty to accelerate drug discovery & development, vaccine R&D and uptake, and diagnostics and surveillance opportunities. Session Disease focus: sleeping sickness, de-risking discovery through partnerships and driving sustainability through access Date: Wednesday, 29 June 2022Time: 14.00-16.00 UTC Speakers: Philippe
- [ISNTD Festival 2023](https://dndi.org/events/2023/isntd-festival-2023/) - The ISNTD Festival brings together communication, arts, entertainment and science to help complex public health messages reach patients, the public and global health professionals worldwide. Sessions From creative process to advocacy & workshop Date: Wednesday, 15 March 2023 Opportunities and innovation in apps for the control of neglected tropical diseases Date: Wednesday, 15 March 2023
- [Forecasting Healthy Futures Global Summit 2023](https://dndi.org/events/2023/forecasting-healthy-futures-global-summit-2023/) - The Forecasting Healthy Futures Global Summit 2023 is a global convening to explore solutions to the health challenges posed by climate change. Panel discussion Climate threats to neglected tropical disease control and elimination programmes: Progress at risk Date: Tuesday, 14 March 2023Time: 14:10 Chair: Priya Kanayson, Manager, Advocacy & Communications, Global Institute for Disease Elimination (GLIDE) Speakers:
- [Tropical Infectious Diseases Conference 2023](https://dndi.org/events/2023/tropical-infectious-diseases-conference-2023/) - The Tropical Infectious Diseases Conference is organized by the Ministry of Health of Malaysia and the Malaysian Society of Infection Control and Infectious Diseases and provides updates on management of important tropical infectious diseases. Session The dengue burden and climate change Date: Monday, 13 March 2023Time: 8:30-9:00 Chair: Giri Shan Rajahram, General Medicine & Infectious
- [La transmisión de la enfermedad de Chagas se puede prevenir. ¿A qué estamos esperando?](https://dndi.org/events/2023/transmision-enfermedad-chagas-se-puede-prevenir-a-que-estamos-esperando/) - Internews, IS Global, Global Chagas Coalition, and DNDi co-organized a webinar on the theme 'The transmission of Chagas disease can be prevented. What are we waiting for?' Moderator: Graziella Almendral, Journalist and Mentor, Internews Speakers: Javier Sancho, Coordinator, Global Chagas CoalitionMaría Jesús Pinazo, Head of Chagas Diseases, DNDiManuel Segovia Hernandez, Hospital Clinico Universitario Murcia, SpainElvira
- [16th Winter Conference on Medicinal & Bioorganic Chemistry](https://dndi.org/events/2023/16th-winter-conference-on-medicinal-bioorganic-chemistry/) - The 16th Winter Conference on Medicinal & Bioorganic Chemistry (WCMBC) is organized by the Medicinal & Bioorganic Chemistry Foundation (MBCF). Poster presentation More information Event website
- [ICAR 2023](https://dndi.org/events/2023/icar-2023/) - The International Conference on Antiviral Research (ICAR) is an annual event organized by the International Society for Antiviral Research (ISAR). Opening session and plenary session Date: Monday, 13 March 2023Time: 14:00-16:14 Chairs: Kathie Seley-Radtke, Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, and Luis Schang, Professor
- [XVIII Jornadas sobre la enfermedad de Chagas](https://dndi.org/events/2023/xviii-jornadas-sobre-la-enfermedad-de-chagas/) - Organized by IS Global, the theme of the 18th Conference on Chagas disease is 'Let's not let our guard down: epidemiological surveillance and cardiological management of Chagas disease'. Session More information Event website
- [ESPID 2023](https://dndi.org/events/2023/espid-2023/) - ESPID is the Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). Symposium Joint symposium MSF-ESPID Date: Friday, 12 May 2023Time: 11:40 - 13:10Venue: Auditorium II More information Event website
- [CROI 2023](https://dndi.org/events/2023/croi-2023/) - The Conference on Retroviruses and Opportunistic Infections (CROI) was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. Poster session Date: Monday, 20 February 2023Time: 14:30-16:00 More information Event website
- [3rd International Symposium on Clinical Research/Trials](https://dndi.org/events/2023/3rd-international-symposium-on-clinical-research-trials/) - Organized by the National Center for Global Health Medicine (Japan) and ARISE, the theme of the 3rd International Symposium on Clinical Research/Trials is 'Addressing the shortage of physician-scientists and clinical trial professionals'. Session Shortage of clinical research professionals Date: Tuesday, 7 February 2023Time: 15:00-18:00 Moderators: Muchanga Sifa, DIT, Center for Clinical Sciences, NCGM Japan, and
- [2030年SDGs達成およびNTD制圧に向けたロードマップ](https://dndi.org/events/2023/2030年sdgs達成およびntd制圧に向けたロードマップ/) - On the occasion of World NTD Day 2023, the Japan Alliance on Global NTDs is hosting an event on the roadmap to achieve the 2030 Sustainable Development Goals and elimination of neglected tropical diseases. Speakers: Dr Ibrahima Socé Fall, Director, the Department of Control of Neglected Tropical Diseases, WHOMs Ivete Kobashikawa, Chiarman, Japan Chagas Disease Patients and
- [CPHIA 2022](https://dndi.org/events/2022/cphia-2022/) - The 2nd International Conference on Public Health in Africa (CPHIA 2022) provides a platform for African researchers, policymakers, and stakeholders to come together and share perspectives and research findings in public health while ushering in a new era of strengthened scientific collaboration and innovation across the continent. Side events Harnessing the strength of collaboration: Lessons
- [Jornada enfermedades tropicales desatendidas, cooperación en salud y farmacia solidaria](https://dndi.org/events/2023/jornada-enfermedades-tropicales-desatendidas-cooperacion-en-salud-y-farmacia-solidaria/) - The Faculty of Pharmacy of the University of La Laguna, Santa Cruz de Tenerife, is hosting an event on the occasion of World Neglected Tropical Diseases Day. Oral presentation More information Registration
- [Honouring frontline heroes of NTDs](https://dndi.org/events/2023/honouring-frontline-heroes-of-ntds/) - On the occasion of World NTD Day 2023, DNDi is hosting an event to recognize the hard work done by frontline health staff to reach the last mile of neglected tropical diseases' elimination. Chief guest: Dr Binay Kumar Sharma, Additional Director cum SPO Bihar
- [World NTD Day 2023: Snack & Talk about NTDs](https://dndi.org/events/2023/snack-talk-about-ntds/) - On the occasion of World NTD Day 2023, the Bernhard Nocht Institute for Tropical Medicine (BNITM) is hosting an event in the Erika-Haus on the premises of the University Medical Center Hamburg-Eppendor (UKE) which includes a panel discussion with experts, a photo exhibition, and more. Speakers include: Sabine Specht, Head of Filarial Disease, DNDi More information Event website
- [How to build a health commons approach to pandemic preparedness and response](https://dndi.org/events/2023/how-to-build-a-health-commons-approach-to-pandemic-preparedness-and-response/) - Hybrid event, co-hosted by DNDi, UCL Institute for Innovation and Public Purpose, & Friends of the Independent Panel Participation in-person at DNDi office in Geneva or online In its May 2021 report, the Independent Panel for Pandemic Preparedness and Response (IPPPR) recommended a commons approach to research and development for pandemic tools, and several other
- [Día Mundial de las Enfermedades Tropicales Desatendidas](https://dndi.org/events/2023/dia-mundial-de-las-enfermedades-tropicales-desatendidas/) - The Association of Preventive Med and Public Health Resident Physicians (ARES) is hosting a webinar on World Neglected Tropical Diseases Day. Speaker: María Jesús Pinazo, Head of Chagas disease, DNDi More information Registration
- [La Salud Global y las Enfermedades Tropicales Desatendidas en su día mundial](https://dndi.org/events/2023/la-salud-global-y-las-enfermedades-tropicales-desatendidas-en-su-dia-mundial/) - The Royal Academy of Medicine of Spain and DNDi are hosting an extraordinary scientific session on global health and neglected tropical diseases on the occasion of World Neglected Tropical Diseases day. Chair: Eduardo Díaz-Rubio, Presidente de la Real Academia Nacional de Medicina de España Introduction and roundtable moderator: Jorge Alvar, Member of the Royal Academy
- [Regulatory Systems and regulations to support clinical trial conduct in Africa](https://dndi.org/events/2023/regulatory-systems-and-regulations-to-support-clinical-trial-conduct-in-africa/) - CIOMS and IFPMA are joining efforts to create a platform for dialog on clinical research in low- and middle-income countries. They are are convening a webinar on the importance of evolving regulatory systems and regulations to support clinical trial conduct as well as alignment to international regulatory standards. Moderators: Zainab Aziz, Associate Director for Regulatory
- [11<sup>th</sup> ICCC 2023](https://dndi.org/events/2023/11th-iccc-2023/) - The 11th International Conference on Cryptococcus & Cryptococcosis (ICCC) is hosted by Makerere University in partnership with the University of Minnesota. Oral presentation More information Event website
- [Antiviral Drug Discovery (AViDD) Open Science Forum](https://dndi.org/events/2022/antiviral-drug-discovery-avidd-open-science-forum/) - The Open Science Forum features monthly talks from scientists from NIH-funded Antiviral Drug Discovery (AViDD) Centers who elect to provide updates on target priorities, advertise available resources and reagents, disclose chemical matter and associated antiviral data, share findings regarding in vivo efficacy models, discuss downstream development and translation models, and share ideas. Presentation Moderator: Peter Sjö, Head
- [Changing global landscape of dengue disease and addressing the challenges](https://dndi.org/events/2022/changing-global-landscape-dengue-disease/) - Moderator: Neelika Malavige, Head of Dengue Global Programme and Scientific Affairs, DNDi Watch the recording
- [MSF Paediatric Days](https://dndi.org/events/2022/msf-paediatric-days/) - The Médecins Sans Frontières (MSF) Paediatric Days is an event for field staff, policy makers and academia to exchange ideas, align efforts, inspire and share frontline research to advance urgent paediatric issues of direct concern for the humanitarian field. Session Neglected tropical diseases Date: Thursday, 1 December 2022Time: 11:00-12:45 Speakers include: Fabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi
- [Roundtable: How can disclosing clinical trial costs increase access to medical products?](https://dndi.org/events/2022/roundtable-how-can-disclosing-clinical-trial-costs-increase-access-to-medical-products/) - Organized by the MSF Access Campaign, this roundtable - the second in this series - aims to explore practical implementation of disclosing clinical trial costs: why should this be done and how. Moderator: Rachel Cohen, North America Director, DNDi Speakers: Christopher Morten, Founding Director, Columbia Law School’s Science, Health, and Information ClinicBern-Thomas Nyang’wa, Medical Director,
- [World Extreme Medicine Conference](https://dndi.org/events/2022/world-extreme-medicine-conference/) - The World Extreme Medicine Conference brings together like-minded medical, humanitarian, space, and adventure professionals, who continually push the boundaries of their physical and mental limits to improve patient outcomes in the most extreme situations. Session Clinical trials on human African trypanosomiasis Date: Sunday, 20 November 2022Time: 9:45-10:30Room: Biosphere Speaker: Wilfried Mutombo, Clinical Project Leader and
- [Université des jeunes chercheurs 2022](https://dndi.org/events/2022/universite-des-jeunes-chercheurs-2022/) - L'Université des jeunes chercheurs (UJC) is a a one-week multidisciplinary HIV research training organized by Sidaction. It is aimed at doctoral students, post-docs, and associations involved in research who are working on HIV or topics of interest for the advancement of HIV research. Session Enjeux de la santé mondiale : quelle place pour le VIH?
- [Health of India Summit 2022](https://dndi.org/events/2022/health-of-india-summit-2022/) - The Health of India, 2022 summit is presented by YouTube Health and hosted by HealthLEADS. The summit is aimed at ‘building a robust Information Ecosystem for a Healthier India’. Plenary session Future of public health Moderator: Jisha Krishnan, Editor-HealthLEADS Speakers: K. Srinath Reddy, President, Public Health Foundation of IndiaNeeraj Jain, Country Director, PATH IndiaKavita Singh, South Asia/India Director, DNDiChandrakant
- [XVIII Congreso Colombiano de Parasitología e Medicina Tropical](https://dndi.org/events/2022/xviii-congreso-colombiano-de-parasitologia-e-medicina-tropical/) - The Colombian Congress of Parasitology and Tropical Medicine is organized biannually by the Colombian Association of Parasitology and Tropical Medicine (ACPMT). Opening session Desarrollo de nuevas herramientas para diagnosticar y tratar personas afectadas por enfermedades tropicales desatendidas Date: Wednesday, 30 November 2022Time: 14:30 - 15:30 Chair: Felipe Guhl, Director of the Tropical Parasitology Research Centre,
- [ISNTD Climate & Health](https://dndi.org/events/2022/isntd-climate-health/) - ISNTD Climate & Health covers research and discussions on the linkages between climate, infectious diseases (with a focus on neglected tropical diseases) and global health resilience. Session Partnerships between climate change & public health sector: Translating knowledge to action in climate-health nexus Date: Tuesday, 25 October 2022Time: 8:30-10:15 UTC More information Event website
- [MEDTROP 2022](https://dndi.org/events/2022/medtrop-2022/) - MEDTROP 2022 is the 57th Congress of the Brazilian Society of Tropical Medicine. The congress hosts various side events including the ChagasLeish 2022. Sessions Estratégias de acesso no primeiro nível de atenção para contribuir a eliminação de doenças silenciosas que acometem populações negligenciadas: Os casos da Hepatite C e doença de Chagas Date: Monday, 14
- [ChagasLeish 2022](https://dndi.org/events/2022/chagasleish-2022/) - As part of the 57th Congress of the Brazilian Society of Tropical Medicine (MEDTROP 2022), the ChagasLeish 2022 aims to promote exchanges between health professionals and researchers working on developing new strategies to control, prevent, and treat Chagas disease and leishmaniasis. Round table Melhora do acesso através da inovação para a atenção médica em leishmanioses
- [Sparks! Serendipity Forum at CERN: 2nd Edition](https://dndi.org/events/2022/sparks-serendipity-forum-at-cern-2nd-edition/) - Sparks! enables those serendipitous conversations for curious minds that lead to beautiful collaborations across disciplines. The theme for the second edition will be Future Technology for Health. Whether in the domains of prevention, diagnosis or treatment, the topics for this edition of Sparks! will seek to ask new questions linking medical technologies to fundamental science,
- [One Planet, One Health - New approaches to address climate change](https://dndi.org/events/2022/one-planet-one-health-new-approaches-to-address-climate-change/) - Sciences Po's Paris School of International Affairs (PSIA) organizes an event to discuss how global health is fundamental to addressing Climate Change. Chair: Luis Pizarro, Executive Director, DNDi and Lecturer at Sciences Po's Paris School of International Affairs (PSIA) Speakers: Serge Breysse Director General, Solthis, and Lecturer at Sciences Po's Paris School of International Affairs
- [World Health Summit 2022](https://dndi.org/events/2022/world-health-summit-2022/) - The World Health Summit is one of the world’s leading strategic forums for global health. The event brings together stakeholders and decision-makers from 100 countries and every field in healthcare to find solutions to global health challenges and set the agenda for a healthier future. Workshop Neglected tropical diseases in the context of the WHO-NTD-Roadmap
- [CROI 2022](https://dndi.org/events/2022/croi-2022/) - The Conference on Retroviruses and Opportunistic Infections (CROI) brings together basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. Posters * Presenting author More information Event website
- [TrypsSchool](https://dndi.org/events/2022/trypsschool/) - The São Paulo School of Advanced Science on pathogenic trypanosomatids is hosting this event to discuss two parasites causing two neglected diseases that are endemic in the Americas, leishmaniasis and Chagas disease. Presentations Date: Monday, 26 September 2022 More information Event website
- [BrazMedChem 2022](https://dndi.org/events/2022/brazmedchem-2022/) - The Brazilian Symposium on Medicinal Chemistry (BrazMedChem) is the largest scientific event exclusively dedicated to Medicinal Chemistry in Latin America. Posters *Presenting author More information Event website
- [Science Summit at UNGA77](https://dndi.org/events/2022/science-summit-at-unga77/) - ISC organises the 8th edition of the UNGA77 Science Summit around the 77th United Nations General Assembly. Session: Achieving health for all and meeting the Sustainable Development Goals through inclusive research and development and equitable access: Best practices and lessons learned Co-organized by DNDi, Medicines for Malaria Venture, and TB Alliance Nearly three years after
- [21st Congress of the International Society for Human and Animal Mycology](https://dndi.org/events/2022/21-congress-isham/) - The International Society for Human and Animal Mycology (ISHAM) is a world wide educational organization that represents all clinical scientists and fundamental researchers with interest in fungal diseases. Session Mycetoma clinical trial on fosravuconazole treatment in eumycetoma– Top line results Date: Thursday, 22 September 2022Time: 10:30-12:00 Chair: Ed Zijlstra, Consultant Expert PKDL/Mycetoma, DNDi Side event
- [10th Plenary Meeting of the Chagas Platform](https://dndi.org/events/2022/10th-plenary-meeting-chagas-platform/) - The Chagas Clinical Research Platform gathers different stakeholders from more than 20 countries, supporting the development of new drugs to treat the infection caused by the Trypanosoma cruzi parasite. The Chagas Platform's plenary meetings are held every two years and bring together prominent researchers and stakeholders involved with Chagas disease. During these meetings, participants discuss
- [Live talk: Infectious disease](https://dndi.org/events/2022/live-talk-infectious-disease/) - This live talk event is organized by Merck. More information Registration link
- [World Hepatitis Summit 2022](https://dndi.org/events/2022/world-hepatitis-summit-2022/) - The World Hepatitis Summit (WHS) is an innovative, large-scale, global meeting to advance the viral hepatitis agenda and provide a platform for a broad hepatitis community to take stock of progress to date, share ideas, experiences and best practice in addressing the many challenges of viral hepatitis. This year's theme is 'Achieving the elimination of
- [Extraordinary Scientific Session on dengue at the Royal Academy of Medicine of Spain](https://dndi.org/events/2022/extraordinary-scientific-session-ranm-dengue/) - DNDi and the Royal Academy of Medicine of Spain are hosting an extraordinary scientific session on dengue. III Conversatorio sobre Medicina Social: Avances en el control del dengue Co-chairs: Jorge Alvar, Member of the Royal Academy of Medicine of Spain and Senior Advisor at DNDi, and Ricardo Molina, Instituto de Salud Calos III More information
- [GUT 2022](https://dndi.org/events/2022/gut-2022/) - GUT is the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology (MSGH). The theme of this year's meeting is 'New beginning new science'. Poster presentation *Presenting author This poster won the first prize of the Best Poster Award. More information Event website
- [ICTMM 2020](https://dndi.org/events/2022/ictmm-2020/) - The 20th International Congress for Tropical Medicine and Malaria (ICTMM 2020) provides the opportunity for sharing research and experience in the field of tropical medicine and malaria. Symposium Exploiting Wolbachia as a public health tool for arbovirus and filariasis control Date: Tuesday, 25 October 2022Time: 10:30-12:00 Speakers: Joseph Turner, Centre for Drugs and Diagnostics, Department
- [3rd National Hepatitis Symposium 2018](https://dndi.org/events/2018/3rd-national-hepatitis-symposium-2018/) - Organized by the Ampang Hospital, DNDi, the Ministry of Health of Malaysia, and the Universiti Sains Islam Malaysia, the event aims to discuss access to hepatitis C treatments. The event's venue is the Connexion Conference & Event Centre in Bangsar. Panel Discussion Malaysia – A Unique Partnership for Access to Treatment Date: Thursday, 1 March
- [ICOPA 2022](https://dndi.org/events/2022/icopa-2022/) - Organized by the World Federation of Parasitologists (WFP), the 15th edition of ICOPA brings together delegates working within parasitology and related fields from all around the world. Presentation More information Event website
- [Venoms and Toxins 2022](https://dndi.org/events/2022/venoms-and-toxins-2022/) - The 9th International Toxinology Meeting 'Venoms & Toxins 2022' brings together the toxinology community from across the globe to discuss various aspects of toxinology research. Presentation Date: Tuesday, 23 August 2022Time: 14:40 More information Event website
- [International Workshop on HIV Pediatrics 2021](https://dndi.org/events/2021/international-workshop-on-hiv-pediatrics-2021/) - The HIV Pediatrics Workshop is entirely devoted to research in the prevention and treatment of HIV infections in infants, children, and adolescents, bringing together the world’s leading researchers. Poster presentation More information Event website
- [Interest Conference](https://dndi.org/events/2020/interest-conference/) - The annual INTEREST Conference is a scientific conference for HIV in Africa that brings together scientists involved in HIV treatment, pathogenesis, and prevention research from around the world. Posters * Presenting authors More information Event website
- [International Workshop on HIV Pediatrics 2020](https://dndi.org/events/2020/international-workshop-on-hiv-pediatrics-2020/) - The International Workshop on HIV Pediatrics provides a platform for presentations and discussions of the latest developments in Paediatric HIV, encourages young investigators to engage in the field of paediatric/perinatal HIV research, and stimulates new research activities and collaborations. Presentations Date: Monday, 16 November 2020Time: 11:30 *Presenting author More information Event websiteEvent flyerEvent endorsers
- [International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022](https://dndi.org/events/2022/international-workshop-on-clinical-pharmacology-of-hiv-hepatitis-and-other-antiviral-drugs-2022/) - The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs gathers leading experts to discuss all aspects of the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational and existing drugs, pharmacodynamics, drug dosing in underrepresented populations, post-marketing surveillance, and regulatory considerations. Poster More information Event website
- [SoHT-GTFI joint meeting](https://dndi.org/events/2022/soht-gtfi-joint-meeting/) - The 2022 edition of the Society of Hair Testing (SoHT)'s annual meeting is a joint meeting with the Italian Group of Forensic Toxicologists (GTFI) on the theme 'Hair analysis: the other side of the moon'. Presentation *Presenting author More information Event website
- [World Hepatitis Day 2022](https://dndi.org/events/2022/world-hepatitis-day-2022/) - On the occasion of World Hepatitis Day, the World Health Organization Regional Office for South-East Asia is hosting an event on the theme 'Bringing care closer to you'. Round table Community and civil society reflections on moving ahead on bringing care closer to people Time: 14:40-15:20 Moderator: Leena Menghaney, MSF Access Campaign, India Speakers: Caroline
- [5<sup>th</sup> Asia Dengue Summit](https://dndi.org/events/2022/5th-asia-dengue-summit/) - The Asia Dengue Summit provides an opportunity for everyone in the dengue community to come together to exchange ideas, updates, and achievements on dengue management strategies for the region. The theme of this year's summit is 'Roll Back Dengue'. Symposium Dengue antivirals Date: Tuesday, 14 June 2022Time: 13:30-15:00 Speakers: Tine De Marez, Senior Director, Compound Development
- [Kigali Summit on Malaria and NTDs](https://dndi.org/events/2022/kigali-summit-malaria-ntds/) - The Kigali Summit on Malaria and Neglected Tropical Diseases will take place alongside the 26th Commonwealth Heads of Government Meeting (CHOGM) and is hosted by the Government of Rwanda on 23 June 2022. The Summit brings together world leaders to reaffirm commitments to end malaria and neglected tropical diseases. Panel discussion The Innovation Agenda Date:
- [CogX Festival and Leadership Summit 2022](https://dndi.org/events/2022/cogx-festival-and-leadership-summit-2022/) - The CogX Festival and Leadership Summit brings together more than 200 speakers to discuss AI, blockchain, the metaverse, and all the latest transformational technologies. Session The protein folding revolution has arrived Date: Monday 13 June 2022Time: 16:30 - 17:15 Speakers: Pushmeet Kohli, Head of AI for Science, DeepMindBen Perry, Discovery Open Innovation Leader, DNDiMelissa Heikkilä,
- [22nd Drug Design & Development Seminar](https://dndi.org/events/2022/22nd-drug-design-development-seminar/) - The Drug Design & Development Seminar is organized by the German Society for Parasitology, in collaboration with Universität Bern, DNDi, and LMU Munich. Sessions Development of alternative treatments for filarial diseases Date: Tuesday, 12 July 2022Time: 9:20-11:00 Keynote: Sabine Specht, Head of Filarial Disease, DNDi Chair: Lucienne Tritten, University of Zurich, Switzerland Natural selection on
- [Conference on Tropical Medicine and Global Health (CTM 2022)](https://dndi.org/events/2022/conference-on-tropical-medicine-and-global-health-ctm-2022/) - The Conference on Tropical Medicine and Global Health is organized by the German Society for Tropical Medicine, Travel Medicine, and Global Health. Session Parasitologie Date: Thursday, 23 June 2022Time: 13:30-14:50Venue: Raum 3 Chairs: Egbert Tannich, Bernhard Nocht Institute for Tropical Medicine, and Achim Hörauf, Chair of Microbiology/Infection epidemiology, University Hospital Bonn Poster *Presenting author More
- [Global Health Security Conference 2022](https://dndi.org/events/2022/global-health-security-conference-2022/) - The Global Health Security Conference is organized by the Global Health Security Network. Panel discussion Climate-sensitive and pandemic-prone diseases: are we destined to fail in equitable access to innovation? Date: Wednesday, 29 June 2022 More information Event website
- [An SDG target we can reach: Financing viral hepatitis elimination](https://dndi.org/events/2022/an-sdg-target-we-can-reach-financing-viral-hepatitis-elimination/) - On the sidelines of the World Economic Forum, DNDi and the Hepatitis Fund (End Hep 2030) are hosting an event at the Davos SDG Tent on the elimination of viral hepatitis. The World Health Assembly calls for elimination of viral hepatitis as a public health threat by 2030 and yet most countries are not on
- [Gouverner en temps de pandémie: Faire des produits de santé un bien commun mondial](https://dndi.org/events/2022/gouverner-en-temps-de-pandemie-faire-des-produits-de-sante-un-bien-commun-mondial/) - Rapport Rapport final de recherche Gouverner en temps de pandémie: Faire des produits de santé un bien commun mondialRésultats principaux du travail de recherche Gouverner en temps de pandémie: Faire des produits de santé un bien commun mondialKey findings of the research project Governing pandemics: Turning health products into global common goods Conférence Quelles sont
- [WHA Special Briefing on Neglected Tropical Diseases (NTDs) and the Kigali Declaration on NTDs](https://dndi.org/events/2022/wha-special-briefing-on-neglected-tropical-diseases-ntds-and-the-kigali-declaration-on-ntds/) - This special briefing is co-sponsored by the Government of Rwanda, RBM Partnership to End Malaria, Women in Global Health, and DNDi. Time: 18:00-20:00Venue: InterContinental Hotel, Ballroom B Speakers: Teophile Dushime, Chief Technical Advisor to Minister of Health of RwandaGautam Biswas, Director a.i. UCN/NTD, WHO Departement of Control of NTDsMagda Robalo, Global Managing Director, Women in
- [MSF Access Campaign roundtable: How can disclosing clinical trial costs increase access to medical products?](https://dndi.org/events/2022/msf-access-campaign-roundtable-how-can-disclosing-clinical-trial-costs-increase-access-to-medical-products/) - The MSF Access Campaign is hosting a roundtable discussion to explore perspectives and opportunities for the upcoming resolution on clinical trials at the World Health Assembly. Moderator: Yannis Natsis, Director, European Social Insurance Platform (ESIP) Speakers: Benjamin J. Smith, Chief Health Counsel, U.S. House of Representatives, Committee on Oversight & ReformGlenda Gray, President & CEO,
- [FESTMIH webinar: Access to medicine for neglected tropical diseases](https://dndi.org/events/2022/festmih-webinar-access-to-medicine-for-neglected-tropical-diseases/) - The Federation of European Societies for Tropical Medicine and International Health (FESTMIH) is hosting a webinar to discuss the current state of access to medicine for neglected tropical diseases, from research and development, to innovation policy, and sustainable financing. Speakers: María Jesús Pinazo, Head of Chagas Programme, DNDiLaura Bohorquez, Trial Manager, FINDManuel Martin, Infectious Disease
- [Spanish Royal Society of Chemistry XXXVIII Biennial Meeting](https://dndi.org/events/2022/spanish-royal-society-of-chemistry-xxxviii-biennial-meeting/) - The Spanish Royal Society of Chemistry (RSEQ) biennial meeting is one of the most important event of Spanish chemistry. Presentation *Presenting author More information Event website
- [Pre-WorldLeish7 - Leishmaniasis in Africa: Challenges and the way forward](https://dndi.org/events/2022/pre-worldleish7-leishmaniasis-in-africa-challenges-and-the-way-forward/) - In preparation for WorldLeish7, PECET and the University of Antioquia are hosting pre-WorldLeish7 webinars to discuss important topics on leishmaniasis. DNDi is co-hosting a session on 'Leishmaniasis in Africa: Challenges and the way forward.' Moderator: Dr Monique Wasunna, Eastern Africa Regional Director, DNDi Speaker: Dr Asrat Hailu Mekuria, Immunoparasitology Professor, School of Medicine of Addis
- [Una mirada hacia enfermedades olvidadas: el Chagas y las migraciones internacionales](https://dndi.org/events/2022/a-look-at-neglected-diseases-chagas-and-international-migration/) - The Lancet migration Latin America Regional Hub is hosting a series of webinars to discuss emerging knowledge in Latin America on health and migration. Moderator: Carolina Batista, Advisory Board Member, Lancet Migration LAC Speakers: Karoline Belo, Regional Research Fellow, Lancet Migration LACAndrea Marchiol, Chagas Access Project Manager, DNDi More information Event website
- [Cenário das Doenças Negligenciadas: Saúde, diagnóstico e acesso](https://dndi.org/events/2022/cenario-das-doencas-negligenciadas-saude-diagnostico-et-acesso/) - ABIFINA is hosting a webinar to discuss the importance of public policies for neglected tropical diseases, the comprehensive approach to patient care, and strategies for increasing access to treatment. Moderator: Antonio Bezerra, Executive Director, ABIFINA Speakers and panelists: Sergio Sosa-Estani, Latin America Regional Director, DNDiFred Luciano Santos Neves, FiocruzMarcus Soalheiro, Nortec QuímicaAila Karla Mota Santana,
- [ISNTD Festival 2022](https://dndi.org/events/2022/isntd-festival-2022/) - The ISNTD Festival brings together communication, arts, entertainment and science to help complex public health messages reach patients, the public and global health professionals worldwide. Session Innovations in healthcare education Time: 14:15-15:45 More information Event website
- [Chagas Coalition Annual Meeting](https://dndi.org/events/2022/chagas-coalition-annual-meeting/) - The Chagas Coalition is hosting its annual meeting to share significant initiatives and updates of Coalition and Chagas disease. Presentations Time: 14:05 Time: 14:30 Time: 14:50 More information Event websiteProgramme
- [Extraordinary Scientific Session at the Royal Academy of Medicine of Spain](https://dndi.org/events/2022/extraordinary-scientific-session-royal-academy-medicine-spain/) - DNDi and the Royal Academy of Medicine of Spain are hosting an extraordinary scientific session on hepatitis C. Hepatitis C, an opportunity for innovation and international cooperation Moderators: Jorge Alvar, Member of the Royal Academy of Medicine of Spain and Senior Advisor at DNDi, and Alejandra Agudo, Journalist, El País – Planeta Futuro More information
- [XVII Workshop on Chagas Disease](https://dndi.org/events/2022/xvii-workshop-on-chagas-disease/) - The XVII Workshop on Chagas Disease is organized by IS Global. Round table Impact of COVID-19 on Chagas Date: Monday, 14 March 2022Time: 18:00 Oral presentation *Presenting author More information Event website
- [XII Congreso SEMTSI](https://dndi.org/events/2022/xii-congreso-semtsi/) - The XII Congress of the Spanish Society of Tropical Medicine and International Health (SEMTSI) is organized by the Institute of Tropical Health University of Navarra on the theme 'One Health: Improving the world'. Round tables Nuevas moléculas para el tratamiento/control de Enfermedades Tropicales Desatendidas (ETDs) Date: Wednesday, 9 March 2022Time: 10:30-12:00 Moderator: Basilio Valladares Hernández
- [Comment proposer une pige sur les maladies négligées ?](https://dndi.org/events/2022/comment-proposer-une-pige-sur-les-maladies-negligees/) - As part of the Pamela Howard Forum on Global Crisis Reporting, the International Center for Journalists is hosting a webinar on neglected tropical diseases. Speakers: Ilan Moss, Head of Media and Content, DNDiFrédéric Ojardias, Senior Press Officer, DNDi More information Register
- [Misdiagnosis, toxic treatments, and deadly insects: Meet the authors of “The Kissing Bug” and “Life Lessons from the Amazon.”](https://dndi.org/events/2022/meet-the-authors-of-the-kissing-bug-and-life-lessons-from-the-amazon/) - Former New York Times reporter Daisy Hernandez’s aunt died from Chagas disease after being repeatedly misdiagnosed – as happens to thousands of people in the Americas, the only region where the deadly insect, the "kissing bug", lives. UK-based explorer Pip Stewart contracted the flesh-eating disease leishmaniasis on an expedition to Guyana, which led to weeks
- [Can partnerships help bring and end to NTDs?](https://dndi.org/events/2022/can-partnerships-help-bring-and-end-to-ntds/) - On the occasion of World Neglected Tropical Diseases Day, AbbVie hosted an event for the world premiere of the documentary Journey of Sight, followed by a panel discussion. Panel discussion Moderator: Claudia Carravetta, VP, Corporate Responsibility & Global Philanthropy, AbbVie Speakers: Niki Alami, Group Medical Director, AbbVieSabine Specht, Head of Filarial Diseases, DNDi
- [Launch of the 2021 G-FINDER Neglected Disease Report](https://dndi.org/events/2022/launch-of-the-2021-g-finder-neglected-disease-report/) - Policy Cures Research is organizing an event to share the findings of the 2021 G-FINDER Neglected Disease Report. Panel discussion Moderator: Andrew Tuttle, Director of Research, Policy Cures Research Speakers: Dr Amadou Sall, CEO, Institut Pasteur de DakarJanet Ginnard, Director of Strategy, UnitaidKavita Singh, Director South Asia Regional Office, DNDiMelinda Moree, Senior Program Officer, Bill
- [COVID-19 therapeutics in resource-constrained settings: Where are we and what do we need?](https://dndi.org/events/2022/covid-19-therapeutics-in-resource-constrained-settings/) - To date, the few medications with proven effectiveness in COVID-19 are appropriate primarily for the treatment of severely ill, hospitalized patients in well-resourced healthcare settings. WHO recommends the use of monoclonal antibody treatment for people with early-stage COVID-19, but these treatments too are expensive and complex to use in resource-constrained settings. No proven medications for
- [Bridging diagnostic gaps to defeat NTDs](https://dndi.org/events/2022/bridging-diagnostic-gaps-to-defeat-ntds/) - FIND, the global alliance for diagnostics and the International Society for Neglected Tropical Diseases (ISNTD) invited a panel of experts to discuss and share insights on: The needs for innovative NTD diagnosticsThe NTD diagnostic landscape and the critical R&D and access gaps to addressHow innovation and collaboration can bring us closer to our common goal
- [Prince Mahidol Award Conference 2022](https://dndi.org/events/2022/prince-mahidol-award-conference-2022/) - Organized by the Prince Mahidol Award Foundation, the 2022 Prince Mahidol Award Conference, with the theme 'The world we want: Actions towards a sustainable, fairer and healthier society', aims to take a long view by focusing on the ‘mega trends’ that will shape the rest of this century and the complex interplay between them, including
- [From Medical Innovation to Access to Treatment for all: How endemic countries can lead efforts to ensure access for patients in the Global South](https://dndi.org/events/2022/from-medical-innovation-to-access-to-treatment-for-all-how-endemic-countries-can-lead-efforts-to-ensure-access/) - On the side lines of the Prince Mahidol Award Conference, DNDi, Siriraj Institute for Clinical Research (SICRES), and Siriraj Hospital, Mahidol University are organizing an academic session featuring Dr Bernard Pécoul, DNDi's Executive Director and Prince Mahidol Award Laureate 2020. Moderator: Prof. M.D. Kulkanya Chokephaibulkit, Director of the Siriraj Institute of Clinical Research Speakers: Dr
- [ISNTD Connect: Experience of a collaborative project to increase access to testing and treatment for Chagas disease in Colombia](https://dndi.org/events/2022/isntd-connect-experience-collaborative-project-access-chagas-disease-colombia/) - ISNTD Connect is a forum and series of short meetings online, where researchers and professionals in the fields of tropical diseases and public health are able to present and discuss ongoing research and topics. This online meeting focuses on the Chagas Access project, a collaborative programme to increase access to testing and treatment for Chagas
- [Rio Innovation Week](https://dndi.org/events/2022/rio-innovation-week/) - Rio Innovation Week brings together entrepreneurs, investors, executives, and government representatives to discuss the impact of technology on business and society. Session Hospital sem paredes Date: Sunday, 16 January 2022Time: 15:05 Speakers: Ricardo Rubio, Senior Strategy and Operations Manager, DNDiRenata Reis, Deputy General Manager, Médecins Sans Frontières Brazil More information Event website
- [A PR3 Challenge: Preparedness and response in the era of systemic environment and health crises](https://dndi.org/events/2022/pr3-challenge-preparedness-and-response-in-the-era-of-systemic-environment-and-health-crises/) - ISGlobal is hosting this workshop to draw lessons related to PR3 (the different phases of preparing for and responding to crises: preparedness, response, recovery, and resilience) from different complementary environmental and public health crises and discuss how best to incorporate them into future all-hazards preparedness plans at the global, regional, country and local levels. Roundtable
- [Anti-Helmintics: Drugs, Resistance & Vaccines V](https://dndi.org/events/2022/anti-helmintics-drugs-resistance-vaccines/) - Anti-Helmintics V aims to review recent process in anthelmintic drug development, medicinal chemistry, modes of action of anthelmintic drugs, and how resistance to anthelmintic drugs emerges. Sabine Specht, Head of Filarial Diseases, DNDi is part of the Scientific Advisory Committee More information Event website
- [Pharma Partnering Summit 2022](https://dndi.org/events/2022/pharma-partnering-summit-2022/) - The Pharma Partnering Summit brings together professionals in the field of life science and aims to help them expand their network, put together deals, and develop their business. Panel discussion Best practice in structuring deals, preparing for when things go well but also when things go wrong Date: Friday, 13 May 2022Time: 11:05-11:35 Speakers: Ariel
- [Hepatitis C PACT Webinar Series: HCV models of care – Moving towards elimination with sharing from Cambodia, Vietnam & Thailand](https://dndi.org/events/2021/hepatitis-c-pact-webinar-series-moving-towards-elimination-cambodia-vietnam-thailand/) - As the world continues to battle the COVID-19 pandemic in 2020-2021, countries with high HCV disease burden are working hard to ensure that HCV care disruption is minimised and those most in need have access to care and services. There are government and community actors responding to the needs of people living with HCV, and
- [International Conference on Public Health in Africa 2021](https://dndi.org/events/2021/international-conference-on-public-health-in-africa-2021/) - The inaugural Conference on Public Health in Africa (CPHIA 2021) will put a spotlight on emergency health response in Africa and allow participants from around the world to share and learn about progress made, best practices in public health interventions and the latest in innovative research. Session Agenda 2063: Whole-of-society – Private sector, community and
- [Sustainable solutions for vulnerable populations: The role of science in Latin America](https://dndi.org/events/2021/sustainable-solutions-for-vulnerable-populations-the-role-of-science-in-latin-america/) - The COVID-19 pandemic has highlighted the need to harness the resources and capacities of all countries in the pursuit of science to address urgent global health needs. Our longstanding commitment to advancing inclusive and sustainable solutions to medical innovation is central to DNDi’s new 2021-2028 Strategic Plan, which charts our course to develop and deliver
- [COVID Moonshot end of year webinar](https://dndi.org/events/2021/covid-moonshot-end-of-year-webinar/) - As we approach the New Year, the COVID Moonshot team are running a special webinar to update on their 2021 progress and 2022 plans in moving open-science antiviral candidates closer to the clinic. Time: 16:00 GMT Panellists from: PostEraDNDiMedChemicaWeizmann Institute of ScienceEnamineDiamond Light Source More information Registration link
- [JITMM Virtual 2021](https://dndi.org/events/2021/jitmm-virtual-2021/) - Hosted by the Faculty of Tropical Medicine, Mahidol University, the Joint International Tropical Medicine Meeting (JITMM) aims to provide a platform for researchers and health practitioners from around the world to share and discuss the latest developments and trends in tropical medicine, global health, and infectious diseases. Presentation More information Event website
- [ISNTD Connect: What’s in the pipeline for mycetoma? Open science for new diagnostics & treatment](https://dndi.org/events/2021/isntd-connect-whats-in-the-pipeline-for-mycetoma/) - ISNTD Connect is a forum and series of short meetings online, where researchers and professionals in the fields of tropical diseases and public health are able to present and discuss ongoing research and topics. This online meeting focuses on mycetoma, one of the most neglected tropical diseases, affecting the poorest populations in the most remote
- [Tenth EDCTP Forum](https://dndi.org/events/2021/tenth-edctp-forum/) - The EDCTP Forum is a biennial event that provides an international platform for the presentation and discussion of cutting-edge research addressing the burden of poverty-related infectious diseases in sub-Saharan Africa and the capacity development and networking activities that support this goal. Symposium Addressing equity challenges in health for neglected populations Date: Wednesday, 20 October 2021Time:
- [ASTMH 2013](https://dndi.org/events/2013/astmh-2013/) - Overview Overview Panel Discussion American Society of Tropical Medicine and Hygiene, 62nd Annual Meeting DNDi @ ASTMH 2013 [PDF] DNDi @ ASTMH 2013 - At a glance [PDF] Thursday, November 14, 2013 POSTER (#LB-2117) SCYX-7158 (AN5568): CNS Exposure Predicted from First-in-Human Clinical Studies Indicates a Single Oral Dose Treatment is Possible for Sterile Cures of
- [ASTMH 2009](https://dndi.org/events/2009/astmh-2009/) - The Drugs for Neglected Diseases initiative (DNDi) participated in several sessions of the ASTMH 2009 , including a joint symposium with sanofi-aventis on pharmacovigilance of new anti-malarials in the field, a satelllite symposium on ASMQ, the anti-malarial Fixed-Dose Combination of Artesunate-Mefloquine, as well as several oral presentations and posters. Symposia Thursday, November 19, 2009 (7:00am—8:00am) Title: The
- [ASTMH 2010](https://dndi.org/events/2010/astmh-2010/) - The Drugs for Neglected Diseases initiative (DNDi) will participate in several activities at ASTMH 2010, including a joint symposium with Central Drug Research Institute (CDRI)on Visheral Leishmaniasis (VL) in the Indian Continent, a second symposium on VL in East Africa, a satellite symposium on Challenges and Successes of the FACT Project through Innovative Partnerships for the
- [ASTMH 2011](https://dndi.org/events/2011/astmh2011/) - DNDi participated with presentations on the Leishmaniasis East Africa Platform and on Chagas disease, and also had several posters and a DNDi booth. If you would like to download the Detailed Programme of DNDi attendance, please click here. Presentations "How regional platforms may facilitate innovation and access to new tools: The example of LEAP (Leishmaniasis
- [ASTMH 2012](https://dndi.org/events/2012/astmh2012/) - DNDi hosted a session entitled "Post-Kala-Azar Dermal Leishmaniasis (PKDL): A Neglected Entity in Visceral Leishmaniasis: Introduction of a PKDL Consortium", and also presented oral presentations and several posters. See a Summary of DNDi's activities ! DNDi hosted a session entitled "Post-Kala-Azar Dermal Leishmaniasis (PKDL): A Neglected Entity in Visceral Leishmaniasis: Introduction of a PKDL Consortium",
- [UNITE Global Summit 2021](https://dndi.org/events/2021/unite-global-summit-2021/) - The UNITE Global Summit is UNITE’s annual event to promote political impact & momentum towards ending infectious diseases as a global health threat. This year’s event aims to secure political leadership as a key determinant to a fairer and equitable global health ecosystem that promotes health & well-being for all. Virtual panel session Tackling a Silent Epidemic:
- [Improving access to NTD health products to achieve the 2030 Roadmap target](https://dndi.org/events/2021/improving-access-to-ntd-health-products-to-achieve-the-2030-roadmap-target/) - Organized by the World Health Organization, this webinar will highlight what is being done to ensure the safe delivery of quality assured NTD medicines and health products to more than a billion people annually. It will bring together experts from various fields to assess gaps, challenges and progress and the areas that require urgent and
- [2021 SAHCS](https://dndi.org/events/2021/2021-sahcs/) - The 2021 Southern African HIV Clinicians’ Society Conference (SAHCS) aims to provide practical advice and scientific updates to healthcare workers and the scientific and public health community. Workshop Cryptococcal Meningitis: The way forward for treatment and access Date: Wednesday, 20 October 2021Time: 10:00-12:00 Cryptococcal meningitis is a devastating fungal infection. People with advanced HIV are
- [Building Bridges Week 2021](https://dndi.org/events/2021/building-bridges-week-2021/) - Building Bridges is a joint initiative, launched in 2019 by Swiss public authorities, the finance community, the United Nations and other international partners to accelerate the transition to a global economic model aligned with the SDGs. As part of Building Bridges Week 2021 (29 November – 2 December) in Geneva, please join DNDi for an
- [HIV drug resistance prevention and response in the light of the WHO HIV drug resistance report 2021](https://dndi.org/events/2021/hiv-drug-resistance-prevention-and-response-in-the-light-of-the-who-hiv-drug-resistance-report-2021/) - This webinar organized by the World Health Organization aims to spread awareness of the burden of HIV drug resistance and to advocate to stop HIV drug resistance through implementation of a comprehensive prevention and response approach involving all stakeholders as outlined in the WHO global action plan to prevent, monitor and respond to HIV drug resistance. Moderator: Irene
- [Improving Access to Medicines in India: Medicare Benefits to Beneficiaries](https://dndi.org/events/2021/improving-access-to-medicines-in-india-highlighting-the-theme-medicare-benefits-to-beneficiaries/) - This event is the Associated Chambers of Commerce and Industry of India (ASSOCHAM)'s 2nd Knowledge Sharing Session on 'Improving Access to Medicines in India'. Time: 11:30 IST Speakers: Vivek V. Kamath, Managing Director & General Manager – Specialty Care, Established Pharmaceuticals, Abbott IndiaAnnaswamy Vaideesh, CEO, North Star Asia LLP, Former MD & VP, GSK Pharmaceuticals
- [Hepatitis C PACT Webinar Series: HCV models of care – Moving towards elimination](https://dndi.org/events/2021/hepatitis-c-pact-webinar-series-hcv-models-of-care-moving-towards-elimination/) - As the world continues to battle the COVID-19 pandemic in 2020-2021, countries with high HCV disease burden are working hard to ensure that HCV care disruption is minimised and those most in need have access to care and services. There are government and community actors responding to the needs of people living with HCV, and
- [Increasing access to testing and treatment for Chagas disease in the US: Understanding patient and community perspectives](https://dndi.org/events/2021/increasing-access-to-testing-and-treatment-for-chagas-disease-in-the-us-understanding-patient-and-community-perspectives/) - Join the Texas State University, San Diego State University, AHEC, UT Health, and Project ECHO for a free virtual learning event on Chagas disease in the United States. Time: 15:00 CST Moderators: Paula Stigler Granados, San Diego State University, and Zo H. Ramamonjiarivelo, Texas State University Speakers: Colin Forsyth, Research and Project Manager, DNDiRachel Marcus,
- [ICASA 2021](https://dndi.org/events/2021/icasa-2021/) - The 21st ICASA Conference is the largest HIV/AIDS conference in Africa. The theme of this year's conference is 'Africa’s AIDS response: The race to 2030 – Evidence. Scale Up. Accelerate'. Special session Examining how national laws/policies impact the global AIDS response Organized by GeorgeTown University: The HIV Policy Lab Date: Monday, 6 December 2021Time: 11:35
- [Neuro Open Science in Action Symposium 2021](https://dndi.org/events/2021/neuro-open-science-in-action-symposium-2021/) - Organized by the Tanenbaum Open Science Institute, the theme of this year's Neuro Open Science in Action Symposium is 'Adopting open models of collaboration in neuroscience, rare diseases, tropical diseases, and antivirals'. Session Open science and tropical and infectious diseases Date: Wednesday, 24 November 2021Time: 12:00 Keynote speaker and moderator: Matthew Todd, Professor at the
- [CaixaResearch Conference 'Pandemics: Overcoming Covid-19 and preparing for the future'](https://dndi.org/events/2021/caixaresearch-conference-pandemics-overcoming-covid-19-and-preparing-for-the-future/) - The CaixaResearch Conference 'Pandemics: Overcoming Covid-19 and preparing for the future', on behalf of ”la Caixa” Foundation, aims to foster discussion on available tools, current vaccines technologies and logistics to fight the current pandemic and other emerging infections, in order to improve preparedness and evidence-based decision-making. The event is co-organized by "la Caixa" Foundation and
- [Science Superpower: The vital role of British backed science in accelerating the fight against malaria and NTDs](https://dndi.org/events/2021/science-superpower-the-vital-role-of-british-backed-science-in-accelerating-the-fight-against-malaria-and-ntds/) - The All-Party Parliamentary Group on Malaria and Neglected Tropical diseases is hosting a webinar to explore the vital role of British backed science in the fight against malaria and NTDs, and the importance of continued long-term investment by the UK government to ensure that new tools are taken from development to delivery. Speakers: David Reddy,
- [ASTMH 2021](https://dndi.org/events/2021/astmh-2021/) - The ASTMH Annual Meeting draws tropical medicine and global health professionals representing academia, foundations, government, not for profit organizations, non-governmental organizations, the private sector, military and private practice. Symposia Clinical development of new treatments to support the global elimination of onchocerciasis Date: Saturday, 20 November 2021Time: 8:00Location: National Harbor 10/11 (National Harbor Level) Symposium organizer:
- [World Extreme Medicine Conference 2021](https://dndi.org/events/2021/world-extreme-medicine-conference-2021/) - The World Extreme Medicine Conference is organised as a ‘not for profit’ activity by World Extreme Medicine (WEM). The event brings together the most influential individuals and organizations in extreme medicine. Presentation Date: Sunday, 14 November 2021Time: 15:00 More information Event website
- [Health Economics and Pharmacoeconomics Opportunities for German - African Cooperation](https://dndi.org/events/2021/health-economics-pharmacoeconomics-opportunities-german-african-cooperation/) - This workshop aims to bring together experts from Europe and Africa to explore potential use and applications of pharmacoeconomic tools for medicines, medical devices, and diagnostics. Session Trends and methods in health economics Date: Sunday, 31 October 2021Time: 9:00 More information Event website
- [XX Simposio Internacional sobre Enfermedades Desatendidas](https://dndi.org/events/2021/xx-simposio-internacional-sobre-enfermedades-desatendidas/) - The XX International Symposium on Neglected Diseases is organized by Mundo Sano. Presentation Date: Thursday, 4 November 2021Time: 11:50-12:10 More information Event website
- [INHSU 2021](https://dndi.org/events/2021/inhsu-2021/) - The International Network on Health and Hepatitis in Substance Users (INHSU) is a global network dedicated to improving the health of people who use drugs, with a specific focus on hepatitis C, infectious diseases, and harms that can occur from drug use. Poster presentation More information Event website
- [A Decade of R&D for Neglected Diseases in Africa](https://dndi.org/events/2013/a-decade-of-r-d-for-neglected-diseases-in-africa/) - Overview Overview Programme Keynote Address Speech Presentations Press releases Press Clippings Videos Gallery DNDi in Africa Endemic Country Research and Development for Patient Access On the occasion of DNDi’s 10th anniversary, DNDi and founding partner KEMRI brought together key African decision-makers and public health actors for this special event to explore the challenges and opportunities
- [Epicentre Scientific Day 2014](https://dndi.org/events/2014/epicentre-2014/) - The Epicentre Scientific Day is an event to share knowledge and critical views on the practices and stakes of medicine in humanitarian situations. This event brought together MSF field players and world-renown experts. DNDi's Medical Director chaired a session on neglected infectious diseases: What should not be neglected in neglected infectious diseases - Chairman: Nathalie Strub,
- [Another triumph of science, but defeat for access? Ensuring innovation and equitable access for COVID-19 treatments and other pandemics](https://dndi.org/events/2021/another-triumph-of-science-but-defeat-for-access/) - In the face of global vaccine inequity, the need for treatments at all stages of COVID-19 is more pronounced than ever. Yet research and development of therapeutics has been relatively neglected in the global response to COVID-19 – and the few treatment innovations that do exist have been principally available in high-income countries. There is
- [Neglected tropical diseases in South Asia: Drug discovery, development, and access - Challenges and opportunities](https://dndi.org/events/2021/neglected-tropical-diseases-south-asia-drug-discovery-development-and-access-challenges-and-opportunities/) - The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit research and development organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected patients since 2003. The India office ensures South Asia partnerships and collaboration with Bangladesh, Nepal, and Sri Lanka. Nearly two decades later, DNDi has grown into a network
- [IDWeek 2021](https://dndi.org/events/2021/idweek-2021/) - IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). Poster presentation More information Event website
- [Innovation for NTDs in the next decade: The critical role of African leadership](https://dndi.org/events/2021/innovation-for-ntds-in-the-next-decade-the-critical-role-of-african-leadership/) - The Drugs for Neglected Diseases initiative (DNDi) was created in response to the frustration of clinicians and the desperation of patients faced with medicines that were ineffective, unavailable, and unaffordable. Nearly two decades later, we have grown into a network of more than 200 partner institutions that spans the globe and together, we have delivered nine
- [Strengthening the collection, analysis and use of data to accelerate global progress in the elimination of Chagas Disease](https://dndi.org/events/2021/strengthening-the-collection-analysis-and-use-of-data-to-accelerate-global-progress-in-the-elimination-of-chagas-disease/) - In the lead up to the culminating meeting for 2021, the COR-NTD Secretariat is co-hosting a series of webinars, working meetings, research updates, and other virtual events. Research Links Series aim to give the opportunity to discuss, in depth, specific research challenges facing the NTD programmes. Presentation More information Event website
- [Access barriers to COVID-19 therapeutics & diagnostics: A case for TRIPS waiver](https://dndi.org/events/2021/access-barriers-to-covid-19-therapeutics-diagnostics-a-case-for-trips-waiver/) - This webinar is organized by the People's Health Movement and Third World Network. Time: 14:00 CEST Chair: Jyotsna Singh, People's Health Movement Speakers: Michelle Childs, Director of Policy Advocacy, DNDiChrista Cepuch, Pharmacist Coordinator, MSF Access CampaignReshma Ramachandran, Physician Fellow, Yale National Clinician Scholars Program More information Registration link
- [The door is open: Can open source R&D improve access to medicines?](https://dndi.org/events/2021/the-door-is-open-can-open-source-rd-improve-access-to-medicines/) - Join Universities Allied for Essential Medicines (UAEM) and the Drugs for Neglected Diseases initiative (DNDi) for this online panel discussion exploring how open source R&D can be utilised to improve accessibility to medical products and drive innovation based on global health needs. Speakers: Alpha Lee, Co-founder, COVID Moonshot and Group Leader, University of CambridgeEls Torreele,
- [Elimination of hepatitis C: Building on Thailand’s hepatitis program successes](https://dndi.org/events/2021/elimination-hepc-building-on-thailands-hepatitis-program-successes/) - This virtual round-table was co-hosted by DNDi, THASL, TREAT Asia, and SICRES. It discussed the progress, challenges, and opportunities to eliminate hepatitis C in Thailand. Time: 14:30-16:30 (Bangkok) Moderator: Giten Khwairakpam, TREAT Asia/amfAR Watch the recording More information AgendaEvent website
- [TB Day 2021](https://dndi.org/events/2021/tb-day-2021/) - Doctors Without Borders (India), in collaboration with the National Institute of Tuberculosis & Respiratory Diseases (NITRD) organizes its first annual TB Day event. Session Lessons learnt of DR-TB care in resource-limited settings Moderator: Kavita Singh, Director DNDi South Asia Regional office More information Event website
- [12th ECTMIH](https://dndi.org/events/2021/12th-ectmih/) - The 12th European Congress on Tropical Medicine and International Health (ECTMIH) is hosted by the Centre for International Health (CIH) at the University of Bergen (UiB). The aim of the event is to provide a platform for experts, scientists, and researchers to present state of the arts updates, scientific developments, and breakthroughs in tropical medicine and global
- [MedTrop 2021](https://dndi.org/events/2021/medtrop-2021/) - MedTrop is the annual congress of the Brazilian Society of Tropical Medicine (SBMT). Round table Doença de Chagas - Metodologia de ensaios clínicos e pesquisa operacional diponibilizando acesso a populações negligenciadas Date: Tuesday, 26 October 2021Time: 13:30-15:00 More information Event website
- [WIRED Health:Tech Conference](https://dndi.org/events/2021/wired-healthtech-conference/) - WIRED Health:Tech explores the technological advances driving the future of patient care. This virtual conference gathers disruptors in health, medicine and science to investigate the long-term impact of COVID-19, explores AI, telehealth, and next-gen systems. Presentation Time: 14:40 BST The mission to solve science’s trickiest problemPushmeet Kohli, Head of AI for Science, DeepMindBen Perry, Discovery Open
- [21st RSC / SCI Medicinal chemistry symposium](https://dndi.org/events/2021/21st-rsc-sci-medicinal-chemistry-symposium/) - The RSC / SCI Medicinal chemistry symposium is organized by the Royal Society of Chemistry to discuss new strategies in medicinal chemistry. Presentation More information Event website
- [Deliver 18 new treatments by 2028 – the future of partnerships and role of Japan](https://dndi.org/events/2021/deliver-18-new-treatments-by-2028-the-future-of-partnerships-and-role-of-japan/) - The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients. Since 2003, we have grown into a network of more than 200 partner institutions that spans the globe, united in our pursuit of science for the people, driven by collaboration, not competition,
- [DND<em>i</em> Symposium "Overcoming the crisis in R&D for neglected diseases in Africa"](https://dndi.org/events/2004/dndi-symposium-qovercoming-the-crisis-in-rad-for-neglected-diseases-in-africaq/) - The 25th African Health Sciences Congress.
- [Where Do We Go From Here? Securing the Foundations of Health Systems](https://dndi.org/events/2021/where-do-we-go-from-here-securing-foundations-health-systems/) - Health systems strengthening is more important than ever, but what exactly does it look like in practice? Why is it so critical today—during and beyond the pandemic? Takeda Pharmaceutical Company Limited’s Global CSR Program is convening a virtual event on the sidelines of the 76th session of the UN General Assembly to respond to these
- [H20 Annual Summit](https://dndi.org/events/2021/h20-annual-summit/) - The annual Health20 Summit is hosted by The G20 Health and Development Partnership and brings together G20 Policymakers, International Organisations, the Global Health Community, Economists, Civil Society, and Academia to discuss and make concrete recommendations to G20 Health Ministers ahead of their summit about the future of global health crisis management and financing. Panel The role
- [World Health Summit Regional Meeting 2021 – Africa](https://dndi.org/events/2021/world-health-summit-regional-meeting-africa/) - Each year, the World Health Summit in Berlin is complimented by a Regional Meeting in a different part of the world, where local and regional topics come to the forefront. Each meeting is hosted by the M8 Alliance member holding the World Health Summit International Presidency, which rotates every year. Online workshop Collaborative biomedical innovation
- [World Health Summit 2021](https://dndi.org/events/2021/world-health-summit-2021/) - The World Health Summit is one of the world’s leading strategic forums for global health. The event brings together stakeholders and decision-makers from 100 countries and every field in healthcare to find solutions to global health challenges and set the agenda for a healthier future. Session Germany's role in interdisicplinary and cross-sector global health research
- [MSF Scientific Days – Asia 2021](https://dndi.org/events/2021/msf-scientific-days-asia-2021/) - MSF Scientific Days – Asia is a conference to showcase research, innovation, and experiences from treatment and humanitarian programmes across the region. MSF Scientific Days bring together researchers, practitioners, academics and patient representatives to catalyse improvements in the quality of care provided to patients and populations at risk. Panel discussion Hepatitis C: Decentralized approach in HCV
- [11<sup>th</sup> IAS Conference on HIV Science](https://dndi.org/events/2021/ias-conference-2021/) - This biennial conference presents the critical advances in basic, clinical, and operational research that moves science into policy and practice. Satellite sessions Ending cryptococcal meningitis deaths by 2030: Critical but invisible Co-organized by DNDi, St George's University of London & CDC Foundation Date: Sunday, 18 July 2021Time: 11:00-12:30 AM CEST Download programme Watch the recording:
- [Asian Pacific Digestive Week 2021](https://dndi.org/events/2021/asian-pacific-digestive-week-2021/) - The Asian Pacific Digestive Week aims to advance science and education in gastroenterology and hepatology for the benefit of public health. The theme of the 2021 edition is ‘Vision of Excellence in Digestive Disorders & Sciences’. Poster More information Event website
- [Medicines for people - or for profit?](https://dndi.org/events/2021/medicines-for-people-or-for-profit/) - On the sidelines of their General Assembly, BMVD (Bundesvertretung der Medizinstudierenden in Deutschland e.V.) is organizing an event on access to medecine. Discussion Date: Saturday, 3 July 2021Time: 10:00-12:00 Speakers: James Love, Director of Knowledge Ecology InternationalJoelle Tanguy, Director of External Affairs, DNDi More information Registration link
- [Sesión Científica en la Real Academia Nacional de Medecine de España](https://dndi.org/events/2021/sesion-cientifica-en-la-real-academia-nacional-de-medecine-de-espana/) - The Royal Academy of Medicine is holding a scientific session on Chagas disease. Enfermedad de Chagas. Estrategias para acelerar la eliminación de la transmisión congénita Date: Wednesday, 30 June 2021Time: 18:00 CET Speakers: Dr Pilar Aparicio, General Director of Public Health, Ministry of Health of SpainDr Bernard Pécoul, Executive Director, DNDiDr Silvia Gold, President, Mundo
- [IASC 2021 Knowledge Commons Virtual Conference](https://dndi.org/events/2021/iasc-2021-knowledge-commons-virtual-conference/) - The virtual conference aims to address problems defined by knowledge systems, including innovation spaces, digital resources like Wikipedia and Stack exchange, open-source software development, the future of science and education, the archival of existing knowledge, cultural commons, and citizen science. Presentation More information Event website
- [Global Health in the 21<sup>st</sup> Century](https://dndi.org/events/2021/global-health-in-the-21st-century/) - This virtual symposium is organized by Swiss TPH. Round table The role of the private sector in improving health Date: Wednesday, 30 June 2021Time: 14:00 Moderator: Kate Molesworth, Swiss TPH Speakers: Emmanuel Akpakwu, Chief Commercial Officer, Region SSA, NovartisPetra Laux, Chief Sustainability Officer, SyngentaNathalie Strub-Wourgaft, Director of Neglected Tropical Diseases, DNDiJutta Reinhard-Rupp, Head of Merck Global
- [DND<em>i</em> and founders’ symposium](https://dndi.org/events/2019/berlin-2019-symposium/) - Best science for the most neglected: How can needs-driven R&D advance universal health coverage? DNDi celebrated 15 years of delivering the best science for the most neglected by hosting an event in Berlin following the World Health Summit. The DNDi & Founders’ Symposium aimed to discuss the role of public interest R&D in delivering the
- [2030 Agenda Partnership Accelerator webinar series: Stakeholder engagement and partnerships during and beyond COVID-19](https://dndi.org/events/2021/2030-agenda-partnership-accelerator-webinar-series-stakeholder-engagement-and-partnerships/) - The 2030 Agenda Partnership Accelerator webinar series is short online workshops seeking to demonstrate how partnerships are critical to achieving the Sustainable Development Goals. The theme of the third webinar is "Stakeholder engagement and partnerships during and beyond COVID-19". Date: Monday, 3 May 2021Time: 07:30-08:45 EST Speakers: Lotta Tähtinen, Chief, Outreach and Partnerships, Division for
- [​P​​SE in Health webinar series: Strengthening collaboration towards needs-based R&D for lower-income settings​](https://dndi.org/events/2021/pse-in-health-webinar-series-strengthening-collaboration-towards-needs-based-rd-for-lower-income-settings/) - In alignment with Switzerland’s International Cooperation Strategy 2021-24 and the Agenda 2030’s orientation towards fostering public-private partnerships (SDG 17), the Swiss Agency for Development and Cooperation (SDC) recently published a Handbook on Private Sector Engagement. In this context, the SDC Health Network organises a series of webinars between March and September 2021 to explore the different forms of
- [ACS Spring 2021](https://dndi.org/events/2021/acs-spring-2021/) - Organized by the American Chemical Society, ACS Spring brings together chemistry professionals to share ideas and advance scientific and technical knowledge. Poster More information Event website
- [PQMD 2021 Global Health Policy Forum](https://dndi.org/events/2021/pqmd-2021-global-health-policy-forum/) - This year’s Partnership for Quality Medical Donations (PQMD) Global Health Policy Forum theme: Environment, Social, and Governance is about the expanding integration of corporate responsibility, sustainability practices and responsibilities of global healthcare stakeholders. Closing keynote Road to resilience: Global health & pandemics Date: Thursday, 29 April 2021Time: 12:50-13:20 More information Event website
- [What lessons from COVID-19 for advancing antibiotic R&D?](https://dndi.org/events/2021/what-lessons-from-covid-19-for-advancing-antibiotic-rd/) - The timely development of, and equitable global access to diagnostics, drugs and vaccines is a challenge not only for COVID-19, but also for other threats such as the silent pandemic of drug-resistant infections. There is an opportunity to take actions to better prepare and respond to current and future pandemics. The Graduate Institute Geneva is organizing
- [Ending Cryptococcal Meningitis Deaths by 2030: A new global initiative](https://dndi.org/events/2021/ending-cryptococcal-meningitis-deaths-by-2030-a-new-global-initiative/) - This webinar is part of a series of webinar organized by the CDC Foundation, the Clinton Health Access Initiative, and Unitaid on advanced HIV disease in the context of COVID-19. Date: Wednesday, 12 May 2021Time: 14:30 GMT Speakers include: Tom Chiller, CDCRadha Rajasingham, University of MinnesotaEmma Orefuwa, GAFFISolange Baptiste, ITCPNathan Ford, WHOCarmen Perez, UnitaidKaty Godfrey,
- [COVID-19 Global Research and Innovation Forum](https://dndi.org/events/2021/covid-19-global-research-and-innovation-forum/) - Organized by the World Health Organization, the objectives of the COVID-19 Global Research and Innovation Forum are to accelerate innovative research to help contain the spread of the pandemic and facilitate care for those affected, and to support research priorities that contribute to the development of global researchplatforms and, to build on the knowledge from
- [Chemical Networks: How to source small molecules in open discovery projects?](https://dndi.org/events/2021/chemical-networks-how-to-source-small-molecules-in-open-discovery-projects/) - This webinar is hosted by Mat Todd (UCL) and Ben Perry (Drugs for Neglected Diseases initiative). Date: Wednesday, 18 May 2021Time: 15:00 BST Speakers: Mat Todd, University College LondonBen Perry, Discovery Open Innovation Leader, DNDiLauren Webster, Wellcome Centre for Anti-Infectives Research (WCAIR)Ed Griffen, MedChemicaBill Scott, Indiana University–Purdue University Indianapolis (IUPUI)Paul Workman, The Institute of Cancer Research, London More
- [KSBMB International Conference 2021](https://dndi.org/events/2021/ksbmb-international-conference-2021/) - Organized by the Korean Society for Biochemistry and Molecular Biology, the theme of the KSBMB International Conference 2021 is 'Life is a fateful encounter beyond the pandemic'. Satellite session Emerging opportunities for drug discovery on infectious diseases Organized by Institut Pasteur Korea Date: Tuesday, 25 May 2021Time: 13:00-15:00 Chairs: Youngmee Jee, Chief Executive Officer, Institut
- [The 2nd Global Health Forum of the Boao Forum for Asia](https://dndi.org/events/2021/2nd-global-health-forum-of-the-boao-forum-for-asia/) - The Boao Forum for Asia aims to promote regional cooperation in Asia and common development across the world. Apart from traditional economic issues, the conference focuses on health issues closely related to economic development and the people's well-being. Session Sub-forum on hepatitis C - Towards elimination of hepatitis C in Asia: Moving from unaffordable treatments
- [COVID-19: Africa's Vaccine Challenge](https://dndi.org/events/2021/covid-19-africas-vaccine-challenge/) - The Department of Health Policy at the London School of Economics (LSE) is organising this panel discussion together with LSE’s Firoz Lalji Institute for Africa, Global Health Initiative, and the African Health Observatory - Platform on Health Systems and Policies. This event will ask what vaccine (and heath technology) equity means for global management of
- [BSP Conference 2021](https://dndi.org/events/2021/bsp-conference-2021/) - The BSP Conference is an online meeting organized by the British Society for Parasitology. Session The value of a data platform for drug development and for regulatory agencies: the case of Chagas disease Date: Monday, 21 June 2021Time: 12:45 Chair: Prof. John Kelly, London School of Hygiene and Tropical Medicine Speaker: Dr Nathalie Strub-Wourgaft, Director
- [The International Liver Congress 2021](https://dndi.org/events/2021/the-international-liver-congress-2021/) - In 2021, the International Liver Congress will be bringing the members of its community together to explore how to tackle liver disease using a multidisciplinary approach. Poster presentation More information Event website
- [COVID-19: The response from African nations](https://dndi.org/events/2021/covid-19-the-response-from-african-nations/) - Organized by Cité des sciences et de l'industrie, this conference brings together actors from the whole continent to discuss lessons learned from African institutions in the industries of research and technology in the fight against COVID-19 and what support these institutions bring to the people. Round table Africa and the Covid-19 crises: Assets and challenges
- [WuXi Healthcare Forum 2021](https://dndi.org/events/2021/wuxi-healthcare-forum-2021/) - The second annual WuXi Healthcare Forum titled “Partnership for Patients" aims to bring together colleagues from around the world who are working to address global healthcare challenges with global solutions. Session A conversation on global solutions for global challenges Date: Wednesday, 17 March 2021Time: 7:00 Host: Dave Madge, VP of Research Service Division, WuXi AppTec
- [Medicines for the people: What will the next decade look like?](https://dndi.org/events/2021/medicines-for-the-people-what-will-the-next-decade-look-like/) - DNDi was created in response to the frustration of clinicians and the desperation of patients faced with medicines that were ineffective, unsafe, unavailable, unaffordable, or that had never been developed at all. Nearly two decades later, we have grown into a network of more than 200 partner institutions that spans the globe, united in our pursuit of science for the people, driven
- [The 141st Annual Meeting of the Pharmaceutical Society of Japan](https://dndi.org/events/2021/annual-meeting-of-pharmaceutical-society-japan/) - The theme of the 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima) is "Harmonization of innovative drug development and sustainable health care from Hiroshima to the world". Symposium Recent progress in partnerships for NTD drug discovery in 2021 This symposium aims to report on the achievements and future development of the “NTD Drug Discovery Booster” that
- [Webinar: EDCTP COVID-19 Emergency Funding Mechanism](https://dndi.org/events/2021/webinar-edctp-covid-19-emergency-funding-mechanism/) - EDCTP is organizing a webinar to share experiences and study findings among the EDCTP-supported COVID-19 research consortia, discuss new emerging questions and current public health priorities in sub-Saharan Africa, and inform the global research community and stakeholders about EDCTP-funded COVID-19 research in sub-Saharan Africa. Panel discussion What are the key new emerging questions and knowledge
- [29th Annual Meeting of the German Society for Parasitology](https://dndi.org/events/2021/29th-annual-meeting-of-the-german-society-for-parasitology/) - This year’s focus of the German Society for Parasitology's Annual Meeting is on combating neglected tropical parasitic diseases under the 2030 Agenda for Sustainable Development Goals (SDGs), helminth immunology, drug development, and One Health approaches. Sessions Anti-Helminthic drug development Date: Monday, 15 March 2021Time: 10:00-11:30 Chair: Achim Hörauf, Bonn, Germany NTD elimination against the background
- [TRIPS waiver for COVID-19 tools – What are the implications for Africa?](https://dndi.org/events/2021/trips-waiver-for-covid19-tools-what-are-the-implications-for-africa/) - On 2 October 2020, India and South Africa asked the World Trade Organization (WTO) to allow all countries to choose to neither grant nor enforce patents and other intellectual property (IP) rights related to COVID-19 drugs, vaccines, diagnostics, and other technologies for the duration of the pandemic, until global herd immunity is achieved. All governments are facing challenges ensuring
- [Africa Health Agenda International Conference 2021](https://dndi.org/events/2021/africa-health-agenda-international-conference-2021/) - AHAIC 2021 is an African-led biennial global health convening hosted by Amref Health Africa, a leading health development organisation in Africa founded in 1957. This year, the virtual conference is co-convened by Africa CDC, Roche, Takeda Pharmaceuticals and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). The theme of this year's conference is "Decade
- [JAGntd Webinar Series on NTDs: Mycetoma](https://dndi.org/events/2021/jagntd-webinar-series-on-ntds-mycetoma/) - The Japan's Neglected Tropical Diseases Alliance (JAGntd) is organizing a series on "Neglected tropical diseases: World trends and Japan's experience". The theme of the 6th webinar is on mycetoma. Date: Thursday, 11 March 2021Time: 13: 30 - 14: 45 Speakers include: Aya Yajima, Neglected Tropical Diseases Specialist, World Health Organization Western Pacific Regional OfficeAkemi Kita,
- [International Clinical Research (Trials) during COVID-19 era: Should we suspend or continue?](https://dndi.org/events/2021/international-clinical-research-trials-during-covid-19-era-should-we-suspend-or-continue/) - The Department of International Trials of NCGM is organizing an online symposium on the theme "International Clinical Research (Trials) during COVID-19 era: Should we suspend or continue?". Session The new normal for clinical trials Date: Thursday, 11 March 2021Time: 15:45-18:35 Chairs: Hamana Mieko, NCGM-DIT and Muchanga Sifa, NCGM-DIT More information Event websiteEvent flyer
- [PREP Webinar: Examining synergies between regulators and ethics committees during public health emergencies](https://dndi.org/events/2021/prep-webinar-examining-synergies-between-regulators-and-ethics-committees-during-public-health-emergencies/) - The Good Clinical Practice Alliance (GCPA) & the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard are organizing a Preparedness Planning for Clinical Research During Public Health Emergencies (PREP) webinar on the theme "Examining synergies between regulators and ethics committees during public health emergencies". Date: Thursday, 4 March 2021Time: 13:00-14:00 UTC More information Registration
- [DIA Europe 2021](https://dndi.org/events/2021/dia-europe-2021/) - DIA Europe 2021 brings together different regulatory bodies from around the world to present updates related to the regional success stories and lessons learnt from the interactions with the healthcare stakeholders. Panel Sustaining regulatory systems in Africa during pandemics - AMA establishment journey Date: Thursday, 18 March 2021Time: 10:45 - 12:15 Chairs: Margareth Ndomondo-Sigonda, African
- [Partnership in the fight against NTDs in the next decade: what kind of innovation?](https://dndi.org/events/2021/partnership-in-the-fight-against-ntds-in-the-next-decade-what-kind-of-innovation/) - This webinar is organized by the Swiss Alliance against Neglected Tropical Diseases (SANTD) and the Swiss Agency for Development and Cooperation (SDC) to discuss the World Health Organization's Neglected Tropical Diseases Roadmap "Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030". Date: Monday, 1 March 2021Time: 14:00
- [Global Bio-India 2021](https://dndi.org/events/2021/global-bio-india-2021/) - Organized by the Department of Biotechnology, the Ministry of Science & Technology, the Government of India and it's Public Sector Undertaking, Biotechnology Industry Research Assistance Council, Global Bio-India 2021 aims to showcase opportunities in Indian Biotechnology sector to the world. Session Strategic partnership for medical innovation in India: Addressing critical treatment gaps for neglected tropical
- [International Viral Hepatitis Elimination Meeting (IVHEM) 2020](https://dndi.org/events/2020/international-viral-hepatitis-elimination-meeting-ivhem-2020/) - The International Viral Hepatitis Elimination Meeting (IVHEM) is a global forum for the exchange of practical experiences for translating diagnostic and therapy advances of viral hepatitis into broad applications that accelerate progress toward the elimination of viral hepatitis as a public health threat by 2030. Poster More information Event website
- [ASTMH 2019](https://dndi.org/events/2019/astmh2019/) - The American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting is designed for researchers, professors, government and public health officials, military personnel, travel clinic physicians, practicing physicians in tropical medicine, students and all health care providers working in the fields of tropical medicine, hygiene and global health. You can find DNDi at Booth #410! Download DNDi
- [Webinar: Chagas Disease in Central America – Project Alliances and healthcare in times of COVID-19](https://dndi.org/events/2020/webinar-chagas-disease-in-central-america-project-alliances-and-healthcare-in-times-of-covid19/) - Since 2018, the International Development Research Centre, the University of San Carlos de Guatemala, the Drugs for Neglected Diseases initiative, and the Fundación Mundo Sano, under the leadership of the Ministry of Public Health and Social Assistance, and the Pan American Health Organization in Guatemala, have joined forces to carry out the Partnerships Project for
- [Prince Mahidol Award Conference 2021](https://dndi.org/events/2021/prince-mahidol-award-conference-2021/) - The Prince Mahidol Award Conference (PMAC) is an annual gathering of global health experts to deliberate and forge a path for better health for the world population. Keynote Speach by Prince Mahidol Award Laureate Date: Thursday, 28 January 2021Time: 21.00 - 21.40 (GMT+7) Speakers: Prof. Dr Valentin Fuster, Director, Mount Sinai Heart and Physician-in-Chief of
- [WorldLeish 6](https://dndi.org/events/2017/worldleish6/) - Overview Overview Introduction 16 May 17 May 18 May 19 May 20 May 6th World Congress on Leishmaniasis The WHO ColIaborating Centre for Leishmaniasis at the Instituto de Salud Carlos III, Madrid and the Drugs for Neglected Diseases initiative, Geneva joined efforts to co-organize the WorldLeish-6 Congress. WorldLeish is the premier congress for leishmaniasis and
- [Geneva Health Forum 2020](https://dndi.org/events/2020/geneva-health-forum-2020/) - The Global Health Forum (GHF) is the forum for innovative practices in global health. The theme of the eight edition is "Improving access to health: Learning from the field". Side event A history of successful partnerships: towards the elimination of sleeping sickness Organized by DNDi and Sanofi Date: Tuesday, 17 November 2020Time: 12:30-13:30 Watch the
- [COR-NTD 2020](https://dndi.org/events/2020/cor-ntd-2020/) - The Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD) is a group of researchers, program implementers and their in-country partners with the shared goal of optimizing NTD control and elimination. COR-NTD meets formally each year in conjunction with the American Society of Tropical Medicine and Hygiene conference, with participation from researchers, the World Health
- [Asia-Pacific AIDS & Co-Infections Conference](https://dndi.org/events/2020/asia-pacific-aids-co-infections-conference/) - The Asia-Pacific AIDS & Co-Infections Conference (APACC) provides a scientific platform that focuses on HIV developments, issues, and needs in the Asia Pacific region. Poster presentation *Presenting author More information Event website
- [Keystone Conference: Drug Discovery for Parasitic Diseases](https://dndi.org/events/2016/keystone-conference-2016/) - The conference showcased cutting-edge anti-parasitic drug discovery programs that illustrate the path from parasite biology to lead identification and from optimization to candidate selection. Stéphanie Braillard, Béatrice Bonnet, Eric Chatelain, Charles Mowbray, and Ivan Scandale participated in this conference on drug discovery for parasitic diseases. Short Talk Poster Teaser Talk Posters * Presenting author More
- [137th Annual Meeting of the Pharmaceutical Society of Japan](https://dndi.org/events/2017/137th-am-pharmsci-japan/) - This annual meeting focused on the future of pharmaceutical sciences. Charles Mowbray, Head of Drug Discovery at DNDi, presented at the event. Presentation Symposium summary More information: Conference website [English]Conference website [Japanese]
- [RIGHT Fund Investment Forum 2020](https://dndi.org/events/2020/right-fund-investment-forum-2020/) - The RIGHT Fund Investment Forum is a global networking forum chaired annually by RIGHT Fund. This year's theme is "Global Cooperation to Overcome the Pandemic”. Session Global Health R&D Cooperation to Overcome Infectious Diseases Time: 13:30-15:10 More information Event website
- [EPHA Access to Medicines Dialogues: Pharma and COVID19 - Winners, Losers, Prospects](https://dndi.org/events/2020/epha-access-to-medicines-dialogues-pharma-and-covid19-winners-losers-prospects/) - Since the onset of the COVID19 pandemic, governments turned to the pharma sector for answers and solutions. The third EPHA Access to Medicines Dialogue will discuss how the present pandemic has reshaped the dynamics within the sector but also the power balance between this diverse business sector and governments in Europe. Discussion Date: Thursday, 19 November 2020Time:
- [ECTMIH 2015](https://dndi.org/events/2015/ectmih-2015/) - 9th European Congress on Tropical Medicine and International Health Introduction Introduction Programme and Presentations Press Releases The 9th European Congress on Tropical Medicine and International Health brought together some 2’000 of the most distinguished scientists and experts in the field of tropical medicine and international health. It is the premier European congress in this field.
- [Best Science for the most neglected: Where do we stand 10 years on?](https://dndi.org/events/2013/bestscienceformostneglected/) - Overview Overview Programme and Presentations Photos Awards Ceremony Press Release Press Clippings Symposium Symposium Photos Model Report Collection DNDi Ten Year Anniversary Event in collaboration with In 2013 DNDi celebrated its 10th anniversary and organized a series of events, of which the last one took place on 5 December 2013 in Paris, France, at the
- [Uniting to Combat Neglected Tropical Diseases](https://dndi.org/events/2014/uniting-combat-ntds-paris-2014/) - Uniting to Combat Neglected Tropical Diseases: A Conversation on Progress webcast and live Q&A took place at Institut Pasteur in Paris. Panelists addressed progress and challenges in the effort to control and eliminate 10 NTDs by 2020, with an overarching theme of how pharmaceutical companies, development agencies, endemic countries, research organizations and private foundations should
- [Lives in the Balance - NY](https://dndi.org/events/2012/lives-balance/) - Overview Overview Agenda Videos Overview Efforts to address medical catastrophes such as HIV/AIDS, malaria, and malnutrition have made progress, albeit incomplete, while further efforts are sorely needed to improve innovation and access for patients with drug-resistant TB; neglected tropical diseases with high mortality rates, such as Chagas disease; and vaccines for preventable diseases like measles,
- [Stakeholder Meeting](https://dndi.org/events/2008/stakeholders-meeting-june-2008-new-york/) - Overview Overview Presentations Videos & Photos DNDi’s First Stakeholders’ meeting took place on 26th June in New York and brought together 150 scientists, researchers, academics, and global health leaders from 25 countries to discuss how international research partnerships can best develop and deliver new lifesaving drugs for neglected diseases. If you would like to see
- [Chagas Disease in the Americas: Improving Access and Tools for Patient Diagnosis and Treatment](https://dndi.org/events/2009/chagas-event-los-angeles-oct-2/) - Overview Overview Symposium Speaker Bios Presentations Symposium Articles Materials Background Papers Campaign Documents Press releases Articles On October 2, 2009, in Los Angeles, Médecins Sans Frontières/Doctors Without Borders (MSF), the Drugs for Neglected Diseases initiative (DNDi), and the UCLA Program in Global Health convened a one-day symposium on Chagas disease, bringing together clinical researchers, drug
- [AIDS 2012 - XIX International AIDS Conference](https://dndi.org/events/2012/aids2012/) - DNDi-MSF-HGAP Symposium Overview DNDi-MSF-HGAP Symposium DNDi-IAS Symposium More information DNDi-MSF-HGAP Symposium DNDi, Médecins Sans Frontières and Health Global Access Project symposiumSunday July 22, 13:30-15:30 Proposals for a Global Innovation System that Responds to Patients Needs and Ensures both Innovation and AccessThe current innovation system that relies on high prices to recoup R&D costs is failing
- [DND<em>i</em> Innovation & Access - Partners’ Meeting 2016](https://dndi.org/events/2016/dndi-innovation-access-partners-meeting-2016/) - Information and programme Information and programme Photos DNDi Latin America organized a series of events with conferences, discussions and meetings. The final event, the Partners' Meeting, took place on June 8th 2016 in Rio de Janeiro, Brazil. Participants from the field of research & development on neglected diseases, including international scientists, product developers, policy-makers, and
- [Rockefeller Foundation's Next Century Innovators Awards Ceremony](https://dndi.org/events/2013/rockefeller-award/) - Innovation Forum Location 05509 W. 34th Street, 2nd Floor (between 10th & 11th Ave)New York, NY Program agenda [PDF] In 2013, The Rockefeller Foundation asked the global community to nominate organizations and individuals who are making a difference for poor and vulnerable populations through innovation. From those nominations—and the votes of individuals around the world—the
- [Repurposing for pediatric patients: Best practices and lessons learned](https://dndi.org/events/2020/cure-within-reach-repurposing-for-pediatric-patients-best-practices-and-lessons-learned/) - Cures Within Reach is organizing the patient education virtual event “Repurposing for pediatrics: Best practices and lessons learned”, where CWR will be honoring DNDi with the Patient Impact Philanthropy award. Discussion Date: Monday, 2 November 2020Time: 13:00 ET Moderator: Mary Leonard, MD, MSCE, Physician in Chief, Lucile Packard Children’s Hospital Stanford Speakers include: Ben McGraw, PharmD, Executive Chairman, Auration
- [Joint Congress on Global Health 2020](https://dndi.org/events/2020/joint-congress-on-global-health-2020/) - The 8th Japanese Joint Congress on Global Health brings together Japanese academic societies of the field of global health. Symposium The 7th symposium of diversity and gender equality: "Women and pregnancy in clinical trials in LMICs - new treatments for NTDs and COVID-19" Date: Monday, 2 November 2020Time: 15:25-16:55 Speakers: Nathalie Strub-Wourgaft, Director of NTDs,
- [ESPID 2020](https://dndi.org/events/2020/espid-2020/) - The European Society for Paediatric Infectious Diseases (ESPID)'s annual meeting brings together international infectious diseases experts, clinicians, researchers, residents, and students. Presentations Date: Thursday, 29 October 2020Time: 11:30 - 13:00 Time: 15:00-16:30 * Presenting authors More information Event website
- [Responding to COVID-19 in Africa: The myths, the lessons, and the future ](https://dndi.org/events/2020/webinar-responding-covid-19-africa-myths-lessons-future/) - At the start of the COVID-19 pandemic, the African continent was referred to as a ‘ticking time bomb’, with preliminary evidence indicating that existing health systems were too weak to withstand the strength of the outbreak. But months later, sub-Saharan Africa has so far averted the worst predictions, including the large-scale mortality seen in other
- [18th International Congress on Infectious Diseases](https://dndi.org/events/2018/18-international-congress-infectious-diseases/) - In collaboration with the XVIII Congreso de la Sociedad Argentina de Infectología (SADI, the Infectious Diseases Society of Argentina), the event's objective is to cover all of the fields of infectious diseases with particular attention to the major challenges of the region, with both regional and international expertise. DNDi is a co-operating organization of the event.
- [Workshop: Improving the current diagnostics for field use in VL and PKDL](https://dndi.org/events/2020/workshop-improving-current-diagnostics-for-field-use-in-visceral-leishmaniasis-and-pkdl/) - The Indian Council of Medical Research, in collaboration with DNDi and FIND, organizes a virtual workshop.
- [WHO webinar on NTDs and innovation](https://dndi.org/events/2020/who-webinar-on-ntds-and-innovation/) - The World Health Organization (WHO) organizes a webinar on the topic "Is it business as usual? What innovation is needed in NTDs to reach the 2030 targets across 20 diseases". Date: Friday, 18 September 2020Time: 14:00 UCT+2 Panel Speakers: Monique Wasunna, Director DNDi Africa, KenyaJutta Reinhard-Rupp, Head Translational Innovation Platform for Global Health, MerckAlicia White,
- [ISNTD d<sup>3</sup> 2017](https://dndi.org/events/2017/isntd-d3-2017/) - Diagnostics, drug discovery and development The International Society for Neglected Tropical Diseases organized ISNTD d3 to address the past shortfalls in R&D productivity and drive the development of future paths towards successful gains in the control, treatment or evaluation of NTDs. Ivan Scandale, Project Manager, DNDi, presented on drug development approaches for filarial diseases. Presentation
- [Fair Pricing Forum 2017](https://dndi.org/events/2017/fair-pricing-forum-2017/) - May 10-11, 2017 Amsterdam, The Netherlands Organized by the World Health Organization in collaboration with the Dutch Ministry of Health, the Fair Pricing Forum was held to discuss options for a fairer pricing system, that is sustainable for both health systems and innovation challenges to access and how to move forward. DNDi participated in the event.
- [9<sup>th</sup> International Workshop on HIV paediatrics](https://dndi.org/events/2017/9th-international-workshop-on-hiv-paediatrics/) - July 21-22, 2017 Paris, France DNDi participated in the workshop on paediatric, adolescent and maternal HIV infection.
- [IUPAC World Chemistry Congress 2017](https://dndi.org/events/2017/iupac-2017/) - The 46th IUPAC World Chemistry Congress promoted sustainability and diversity through chemistry. Charles Mowbray, Head of Discovery, DNDi presented on drug discovery for neglected diseases. More information: Event website
- [IAS 2017](https://dndi.org/events/2017/ias-2017/) - 9th IAS Conference on HIV Science Isabelle Andrieux-Meyer, Paediatric HIV/HCV Team Leader at DNDi, presented on DNDi's work on HIV. More information: IAS 2017 website
- [2nd Symposium on Medicinal Chemistry for Global Health](https://dndi.org/events/2017/2nd-symposium-on-medicinal-chemistry-for-global-health/) - June 18-20, 2017 GlaxoSmithKline, Tres Cantos, Madrid, Spain Ben Perry, NTD Drug Discovery Booster Project Manager, and Charles Mowbray, Head of Discovery, presented on the NTD Discovery Booster, aminopyrazoles and NTDs..
- [11<sup>th</sup> Congress of HIV/AIDS and the 4<sup>th</sup> Congress of Viral Hepatitis](https://dndi.org/events/2017/11th-congress-of-hivaids-4th-congress-of-viral-hepatitis/) - The two congresses aimed to bring together the scientific community, the civil society, people living with HIV and viral hepatitis, health professionals and public managers, to discuss the advances and challenges of the Brazilian response, with an increasingly integrated approach focused on individual needs and characteristics of each person. DNDi Latin America's Regional Policy Advocacy
- [4<sup>th</sup> International Conference on Tropical Medicine, Infectious Diseases & Public Health](https://dndi.org/events/2017/4th-international-conference-on-tropical-medicine-infectious-diseases-public-health/) - September 7-9, 2017 Edinburgh, Scotland DNDi presented an poster on the epidemiology of VL in Kenya.
- [IMTechCon 2017](https://dndi.org/events/2017/imtechcon-2017/) - The meeting aimed to create better engagement with key industry & academic leaders and establish a platform where the challenges of Industry and how academic/research institutions can forge new R&D partnerships and alliances can be discussed. One of the event's goal was to boost the discovery of new drugs and push towards healthcare innovation and
- [8<sup>th</sup> Trends in Medical Mycology](https://dndi.org/events/2017/timm-2017/) - Trends in Medical Mycology is a bi-annual meeting in the field of fungal infections. It is a forum in which researchers and clinicians from all over the world present the most important advances and research findings in mycology. Jean-Robert Ioset, Discovery Manager, and Benjamin Perry, Senior Discovery Manager – Open Innovation, presented posters at the
- [ISMOCD 2017](https://dndi.org/events/2017/ismocd-2017/) - XII Joint National Conference of Indian Society for Malaria and Other Communicable Diseases & Indian Association of Epidemiologists DNDi sponsored a plenary session on visceral leishmaniasis elimination at the XII Joint National Conference of Indian Society for Malaria and Other Communicable Diseases & Indian Association of Epidemiologists that was held on Friday, 1 September in
- [34<sup>th</sup> General Conference of the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC)](https://dndi.org/events/2017/34th-general-conference-of-the-international-scientific-council-for-trypanosomiasis-research-and-control-isctrc/) - This event aimed to promote information sharing on tsetse, human and animal trypanosomiasis, review control strategies and recommend appropriate approaches in research and control. Florent Mbo, HAT Platform Coordinator, DNDi presented a poster at the Conference. Presentation Platforme de renforcement des capacités en recherche clinique Florent Mbo, HAT Platform Coordinator, DNDi More information: Event webpage
- [Basel Life 2017](https://dndi.org/events/2017/basel-life-2017-2/) - Basel Life combines science, technology, and exhibition in a unique way to bridge not only between basic science and translational science but also between science and business.Bernard Pécoul, Executive Director, DNDi, spoke at the event. More information: Event website
- [Venoms 2017](https://dndi.org/events/2017/venoms-2017/) - .
- [Chagas disease in the United States: Improving patient diagnosis and treatment](https://dndi.org/events/2017/chagas-disease-in-the-united-states-improving-patient-diagnosis-and-treatment/) - The goal of this symposium was to increase healthcare provider awareness and knowledge of Chagas disease, including how to diagnose and manage patients with Chagas disease in the United States. Sergio Sosa Estani, Head of Chagas, DNDi Latin America, spoke at the event. More information: Symposium brochureEvent webpage
- [MedTrop 2017](https://dndi.org/events/2017/medtrop-2017-chagasleish-2017/) - Congress of the Brazilian Society of Tropical Medicine DNDi participated in the 53rd Congress of the Brazilian Society of Tropical Medicine and in ChagasLeish 2017, a meeting that was held within the congress. Presentation
- [19<sup>th</sup> Cambridge Medicinal Chemistry Symposium](https://dndi.org/events/2017/19th-cambridge-medicinal-chemistry-symposium/) - This conference aims to attract academic and industrial scientists engaged in all aspects of the drug discovery and development process. It aims to showcase first disclosures of significant new therapeutic agents across all disease areas, and provide a forum for discussion of current topics and thinking at the forefront of medicinal chemistry. Charles Mowbray, Discovery
- [Gordon Research Conference](https://dndi.org/events/2017/grc-natural-products-bioactive-compounds/) - 66th Gordon Research Conference on Natural Products and Bioactive Compounds The 66th Gordon Research Conference on Natural Products and Bioactive Compounds featured lectures describing state-of-the-art research by leaders in the fields of organic synthesis, chemical biology, rare and neglected disease research, glycochemistry, natural product isolation and biosynthesis. Benjamin Perry, Open Innovations Senior Manager, Discovery, DNDi
- [XXV Brazilian Parasitology Congress](https://dndi.org/events/2017/xxv-brazilian-parasitology-congress/) - This biennial event brings together professors, researchers, technicians, students, health managers in the field of parasitology. DNDi presented an abstract on LOLA hit-to-lead results. Abstract More information: Congress websiteAgenda
- [International Workshop on Onchocerciasis-associated Epilepsy (OAE)](https://dndi.org/events/2017/international-workshop-on-onchocerciasis-associated-epilepsy/) - The meeting gathered together onchocerciasis-associated epilepsy (OAE) experts from around the world to in an effort to form an OAE alliance between stakeholders with different backgrounds but with a common interest and commitment to address important research questions about OAE and to improve the quality of life of patients and families affected by OAE. Belén
- [Drug discovery workshops and symposium at the Medical Sciences Institute of the University of São Paulo](https://dndi.org/events/2018/drug-discovery-medical-sciences-institute-university-sao-paulo/) - Workshop on "Tools and platforms for phenotypic drug discovery" and symposium on "Innovation and translational research in academia" organized by the Institute of Biomedical Sciences of the University of São Paulo and DNDi. The symposium will introduce the new Phenotypic Screening Platform of the Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo. Workshop
- [7th European Congress of Tropical Medicine and Hygiene (ECTMIH)](https://dndi.org/events/2011/barcelona/) - At this major European conference, DNDi organized symposia on kinetoplatid diseases and VL-HIV co-infection. Bernard Pécoul spoke in a plenary session (video accessible here) on ‘The Science of Elimination’. See a Summary of DNDi's activities PRESENTATIONS Monday October 3, 15:00-16:30DNDi's session: Drug development for kinetoplastids Latest drug development and innovation for kinetoplastid diseasesNathalie Strub
- [Joint meeting of all DND<em>i</em> founding partners](https://dndi.org/events/2003/founding-partners-meetingjoint-meeting-of-all-founding-partners/)
- [Africa: DND<em>i</em> Conference](https://dndi.org/events/2003/africa-dndi-conferencedndi-regional-office-conference/) - DNDi regional office conference.
- [Neglected Diseases Group (NDG) Meeting](https://dndi.org/events/2004/neglected-diseases-group-ndg-meeting/) - [6-7 February 2004 ] Penang, Malaysia
- [Asia DND<em>i</em> Workshop](https://dndi.org/events/2004/asia-dndi-workshopfor-workshop-reports-and-presentations-please-contact/) - For workshop reports and presentations please contact: "dndi@dndi.org".
- [EDCTP WORKSHOP](https://dndi.org/events/2004/edctp-workshop-to-discuss-collaboration-of-international-initiatives-involved-in-interventions-for-poverty-related-diseases/) - Workshop organized to discuss the collaboration of international initiatives involved in interventions for Poverty Related Diseases.
- [ASTMH 2004 - DND<em>i</em> Symposium "A needs driven R&D agenda for neglected diseases"](https://dndi.org/events/2004/dndi-symposium-qa-needs-driven-rad-agenda-for-neglected-diseasesq/) - The 53rd annual meeting of the American Society of Tropical Medicine and Hygiene Consult ASTMH annual meeting archives to find DNDi symposium programme and presentations.
- [How can Britain and Europe do more to close the Neglected Diseases Research and Development Gap?](https://dndi.org/events/2005/how-can-britain-and-europe-do-more-to-close-the-neglected-diseases-research-and-development-gap/)
- [DND<em>i</em> Latin America Screens Chagas Film & Holds Panel Discussion with Buss, Pécoul, Preve & Rocha](https://dndi.org/events/2005/dndi-latin-america-screens-chagas-film-a-holds-panel-discussion-with-buss-pecoul-preve-a-rocha/)
- [DND<em>i</em> Symposium “Exploring combination therapies to increase efficacy of drugs for neglected diseases” at “Medicine and health in Tropics Marseille” health in Tropics Marseille”](https://dndi.org/events/2005/dndi-symposium/) - [11 September 2005 to 15 September 2005] Marseille, France
- [DND<em>i</em> symposium "New fixed-dose artemisinin combination therapies to treat falciparum malaria" at 54th annual American Society of Tropical Medicine and Hygiene (ASTMH) Conference](https://dndi.org/events/2005/dndi-symposium-qnew-fixed-dose-artemisinin-combination-therapies-to-treat-falciparum-malariaqat-54th-annual-american-society-of-tropical-medicine-and-hygiene-astmh-conference/) - The 54th annual American Society of Tropical Medicine and Hygiene (ASTMH) Conference. Session: The Final Leg: New Fixed-Dose Artesunate-Based Combination Therapies to Treat Falciparum Malaria.Session: Challenges Ahead: R&D of New Drugs for Sleeping Sickness.Consult ASTMH annual meeting archivePress Release: Two New Malaria Treatments Available in 2006
- [DND<em>i</em> speaks at EU Public Hearing on Neglected Diseases](https://dndi.org/events/2006/dndi-speaks-at-eu-public-hearing-on-neglected-diseases/) - Press release: "Greater EU Leadership Needed to Further Critical Research on Neglected Diseases"
- [FACT Symposium](https://dndi.org/events/2006/fact-symposium/)
- [ICOPA XI](https://dndi.org/events/2006/icopa-xi/) - 11th International Congress of Parasitology.
- [Second DND<em>i</em> Africa Meeting](https://dndi.org/events/2006/2nd-dndi-africa-meeting/) - Over 200 African scientists from 34 countries met in Nairobi, Kenya, 19-23 September at an international conference organised by the Drugs for Neglected Diseases initiative (DNDi), to explore developing greater regional research partnerships to combat the most neglected diseases, such as sleeping sickness, kala azar and malaria.Click here to read more
- [American Society of Tropical Medicine and Hygiene (ASTMH 2006)](https://dndi.org/events/2006/astmh-2006/) - DNDi participated in two symposiums at the ASTMH in Atlanta.In the sessions, DNDi discussed the challenges of R&D for new drugs against sleeping sickness, and the FACT and Public and Private Partnerships for R&D for malaria.
- [ASAQ Launch](https://dndi.org/events/2007/asaq-launch/) - Sanofi-aventis and DNDi launched ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), which is now available in 21 countries throughout sub-Saharan Africa (June 08). ASAQ, the first drug developed by DNDi, is an innovative product to treat malaria that is adapted to the needs of patients of all ages, simple to use,
- [5th European Congress on Tropical Medicine & International Health (ECTMIH)](https://dndi.org/events/2007/5th-european-congress-on-tropical-medicine-a-international-health-ectmih-amsterdam/) - DNDi, in two presentations, discussed how Product Development Partnerships could deliver innovative treatments to patients, and the sanofi-aventis / DNDi Partnership against malaria, at the 5th ECTMIH from 24 to 28 May in Amsterdam. See DNDi's participation flyer
- [The Pan-Asian Network for Neglected Diseases (PAN4ND) Annual Meeting](https://dndi.org/events/2007/the-pan-asian-network-for-neglected-diseases-pan4nd-annual-meeting-shanghai/) - The PAN4ND Annual Meeting was held at Shanghai Institute Materia Medica and included three sessions: The Annual Meeting of the Pan-Asian Screening Network; the Natural Product Working Group, and the Natural Product Symposium. Click to read press statement
- [Scientific Symposium on Visceral Leishmaniasis (VL)](https://dndi.org/events/2007/scientific-symposium-on-visceral-leishmaniasis-vl-london/) - DNDi and the Leishmaniasis East Africa Platform (LEAP) organised a scientific symposium on visceral leishmaniasis (VL): “A step together in the right direction” at the centenary meeting of the Royal Society of Tropical Medicine and Hygiene (RSTMH), in London. More than 120 scientists attended the meeting.DNDi sessions' programme
- [DND<em>i</em> Symposium on ACT: 56th American Society of Tropical Medicine and Hygiene (ASTMH 2007)](https://dndi.org/events/2007/symposium-56th-american-society-of-tropical-medicine-and-hygiene-astmh-philadelphia/) - Sanofi-aventis and DNDi held a symposium on the implementation of a new artemisinin combination therapy (ACT) in African endemic countries. Over 120 attendees from NGOs, academia, and the pharmaceutical sector heard presentations by FACT project partners on ASAQ and ASMQ. In addition, DNDi also presented the ethical considerations of malaria field studies, and screening of natural
- [10th Leishmaniasis East Africa Platform (LEAP) – Sudan](https://dndi.org/events/2008/10th-leishmaniasis-east-africa-platform-leap-sudan/) - The 10th Leishmaniasis East Africa Platform (LEAP) meeting took place in Khartoum, Sudan. A solid clinical trial network is being built, thanks to the serious commitment of all members. Capacity building is still ongoing, with one site in Kenya to be built and another in Uganda to be strengthened. In May 2008, DNDi and its
- [ASMQ Launch](https://dndi.org/events/2008/april-2008-asmq-launch-rio-de-janeiro/) - Farmanguinhos/Fiocruz and DNDi launched ASMQ, the new fixed-dose combination of artesunate (AS) and mefloquine (MQ), now registered in Brazil. Developed and delivered by a worldwide collaboration of public partners, ASMQ will soon be available throughout Latin American and Southeast Asia.PRESENTATIONS First Session – Status of Implementation and R&D of Artemisinin-based Combination Therapies (ACTs) (Bernard Pécoul/Drugs
- [3rd Annual Meeting of PASN – Tokyo](https://dndi.org/events/2008/3rd-annual-meeting-of-pasn-tokyo/) - Leading researchers from research institutes in Asia, DNDi, and MMV met from 9th-11th June to share their vision to make Asia a major player in drug development for the neglected diseases, utilizing local natural resources. This meeting of PAN4ND was co-hosted by DNDi and the Kitasato Institute.
- [DND<em>i</em> India Public Symposium “India: Catalyst in Drug Development for Neglected Diseases?”](https://dndi.org/events/2008/dndi-india-public-symposium-india-catalyst-in-drug-development-for-neglected-diseases/) - More than 100 scientists and researchers convened in New Delhi to discuss the present and future role of India in research and development (R&D), access, and capacity strengthening to develop and deliver new treatments needed by neglected patients. Agenda If you would like to download the full Agenda, please click here. Programme If you would
- [Symposium: 57th American Society of Tropical Medicine and Hygiene (ASTMH)](https://dndi.org/events/2008/symposium-57th-american-society-of-tropical-medicine-and-hygiene-astmh/) - DNDi sponsored a HAT Symposium: "Addressing R&D challenges in making new drugs available for HAT: potential in the pipeline and recent clinical results”, including presentations on HAT platform, NECT, fexinidazole, and DB289. DNDi also co-chaired a Malaria Symposium with sanofi-aventis. Agenda If you would like to download the full HAT Symposium with the HAT Platform's
- [World Leish 4](https://dndi.org/events/2009/world-leish-4-february-2009-lucknow-india/) - Every 4 years, leishmaniasis experts gather together from around the world. During World Leish 4, DNDi held 2 symposia on “partnering along the path to deliver better treatments”. Clinical Symposium“Improved Treatments for Visceral Leishmaniasis – Status of Ongoing Studies, and Challenges & Opportunities Ahead” Early-Stage R&D Symposium "Challenges for and Potential in the Early-Stage R&D
- [United Nations Economic and Social Council Special Event on Philanthropy and the Global Public Health Agenda](https://dndi.org/events/2009/united-nations-economic-and-social-council-special-event/) - Bernard Pécoul, Executive Director of DNDi, at the UN: “the time to wake up is now”. Speaking next, Mr. Pécoul asked whether Governments had contracted sleeping sickness, as public sector investments in neglected diseases had been abandoned. “We are far from finding solutions to these challenges, even if some Governments or some philanthropists have started
- [BIO 2009](https://dndi.org/events/2009/bio-2009/) - DNDi and iOWH held panel sessions at BIO 2009. Wednesday, May 20, 8:00am-9:30am: DNDi session “PDPs and Alternative IPManagement/Tech Transfer Strategies for Improved Global Health” Thursday, May 21, 2:00pm-3:30pm: iOWH session “Different Type of Partnerships Which Compose PDPs for Improved Global Health” Programme If you would like to download the full Programme, please
- [DND<em>i</em>’s 2nd Stakeholders’ Meeting & 3rd African Meeting](https://dndi.org/events/2009/stakeholders-2/) - [ June 23, 2009 ] Nairobi, Kenya Like last year in New York, Drugs for Neglected Diseases initiative (DNDi) will bring together more than 150 scientists, researchers, academics and global health leaders from Africa, Asia, Europe, Latin America and North America on June 23, 2009, to discuss how international research partnerships can best develop and deliver new lifesaving drugs for neglected diseases.
- [DND<em>i</em>'s Regulatory Workshop](https://dndi.org/events/2009/dndis-regulatory-workshop/) - How to Strengthen Capacity in Africa for the Registration of New Drugs for Neglected Diseases? That was the topic discussed by more than 50 attendees at the workshop which was held during DNDi's 2nd Stakeholders' and 3rd African Meetings, in Nairobi, Kenya. The workshop looked into present regulatory approaches and mechanisms, how they interact with each other
- [ECOSOC - United Nations Economic and Social Council Innovation Fair](https://dndi.org/events/2009/ecosoc-geneva/) - DNDi participated at ECOSOC's Innovation Fair at the High-Level Segment meeting, which took place in Geneva. This meeting and all the "satellite" activities presented good opportunities to discuss research & development issues, especially in the neglected diseases sector. DNDi had a booth at ECOSOC's Innovation Fair and made a presentation about the Leishmaniasis East Africa Platform (LEAP),
- [The Centenary of Chagas Disease Discovery International Symposium](https://dndi.org/events/2009/centenary-of-chagas-disease-rio/) - A three-day international symposium organised by Fiocruz to celebrate the 100 years of Chagas disease discovery by Brazilian researcher, Carlos Chagas, gathered more than 750 international experts. Speakers from five South American countries – together with speakers from France, Canada and the US, including Institut Pasteur, MSF, and DNDi - covered many aspects of Chagas disease: its history,
- [Film and Debate in Amsterdam: global campaign “Wake Up. Time to Treat Chagas Disease!”](https://dndi.org/events/2009/chagas-event-amsterdam/) - The Drugs for Neglected Diseases initiative (DNDi) and the Royal Tropical Institute (KIT) hosted an event to raise awareness for the need for research and development for better health tools and improved access for all Chagas’ patients. The event is part of the global campaign “Wake Up. Time to Treat Chagas Disease!” and brought a panel
- [XII International Symposium on Epidemiological Control of Diseases Transmitted by Vectors](https://dndi.org/events/2009/xii-symposium-argentina/) - The two-day international symposium organized by Mundo Sano Foundation is the biggest scientific meeting on Dengue Fever, Chagas Disease and other neglected diseases in Argentina. Many members of the Argentinean government were present, together with researches and students from several Latin American countries, to discuss and present tools and strategies to fight the challenges related
- [6th European Congress on Tropical Medicine and International Health (ECTMIH)](https://dndi.org/events/2009/ectmih-verona/) - Drugs for Neglected Diseases initiative (DNDi) and Médecins Sans Frontières (MSF) held a joint workshop at the most important European congress on tropical medicine to discuss the following topic: “Unfinished business on the road to elimination: experiences, needs, and priorities in accessing patients and adequate health tools to treat Chagas disease and sleeping sickness”MSF-DNDi Workshop
- [International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) Meeting](https://dndi.org/events/2009/isctrc-uganda/) - Drugs for Neglected Diseases initiative (DNDi) and the World Health Organisation (WHO) held a joint symposium on “Progress Made and Challenges Ahead in Clinical Research and Development of New Treatments for Human African Trypanosomiasis” followed by a Public Event organized by DNDi, the HAT Platform, along with NECT partners to celebrate the availability of the
- [Chagas Disease: Break the Silence – Time to Treat](https://dndi.org/events/2009/chagas-event-santa-monica-oct-1/) - The Drugs for Neglected Diseases initiative (DNDi) and Doctors Without Borders/Médecins Sans Frontières (MSF) hosted a panel discussion moderated by Univision’s Julio Cesar Ortiz on Chagas disease, a largely ignored infectious disease that kills thousands every year in Latin America. Since its discovery 100 years ago, very little has been done for the millions of
- [Cohred & Nepad Meeting: Strengthening Pharmaceutical Innovation in Africa](https://dndi.org/events/2010/cohred-nepad-meeting/) - The meeting addressed the problems and challenges faced by African countries in their quest to increase access to medicines and research for innovative products, and to stimulate production of medicines in Africa. DNDi presented the background need for strengthened regulatory capacity in Africa in the Plenary session, and also held a Regulatory workshop. DNDi and the
- [Capitol Hill Briefing - Congressional Malaria & NTD Caucus Briefing](https://dndi.org/events/2010/capitol-hill-briefing/) - In the US, the Obama Administration releases its 2011 budget asking Congress to approve $155M for the treatment of Neglected Tropical Diseases (NTDs), a $90M increase over 2010. DNDi and MSF are calling for the inclusion of deadly NTDs, such as HAT, VL, and Chagas disease and to include R&D for urgently needed new tools including
- ["$1 for 1 life" documentary on ARTE](https://dndi.org/events/2010/1for1life/) - April 23, 2010Malaria Day channel broadcasted this documentary on malaria, neglected diseases, and DNDi (French and German versions). A documentary by the filmmaker Frédéric Laffont. Watch on YouTube To read more about the film, the neglected diseases, patients and researchers: French summaryFrench Press kitGerman summaryGerman Press kit The press kit will
- [ICOPA 2010](https://dndi.org/events/2010/icopa-2010/) - The Drugs for Neglected Diseases initiative (DNDi) participated in several activities at the XIIth International Congress of Parasitology (ICOPA) 2010: the organisation of two symposia, (Malaria and Drug Discovery), as well as a preview of the documentary "1$ for 1 life". DNDi Symposia • Tuesday, August 17, 2010 (10:30am—12:00) Artesunate-based combination treatments for malaria Chairs:
- [DND<em>i</em> Intellectual Property Workshop](https://dndi.org/events/2010/dndi-intellectual-property-workshop/) - In collaboration with partners from the Program on Global health and Technology Access of Duke University, DNDi organized a workshop on intellectual property and open innovation on 4th December 2010 in New Delhi, India. The workshop gathered around 50 participants including DNDi partners, representatives of Indian civil society and DNDi staff. Representatives of ICMR, Indian civil
- [DND<em>i</em>’s 3rd Partners’ Meeting in collaboration with Indian Council of Medical Research (ICMR)](https://dndi.org/events/2010/partners-v15-735/) - Like in 2009 in Nairobi, Drugs for Neglected Diseases initiative (DNDi) brought together more than 150 Indian and international health researchers, policy makers, experts from 22 countries on December 3rd, at the Constitutional Club in New Delhi for the 3rd International Partners meeting organized by DNDi in collaboration with Indian Council for Medical Research
- [DND<em>i</em> Symposium - Artemisinin Combination Therapy (ACTs) in Myanmar: Status update and outlook](https://dndi.org/events/2011/acts-in-myanmar/) - Drugs for Neglected Diseases initiative (DNDi) and Cipla, jointly with Vimal, organised a symposium to discuss the use of Artemisin Combination Therapy in Myanmar. If you would like to download the Agenda, please click here. ASMQ Fixed-dose combination ASMQ brochure, click here. ASMQ Scientific overview, click here. Scientific publications Effectiveness of five artemisinin combination regimens with
- [ISID-NTD Meeting](https://dndi.org/events/2011/isid-metd/) - DNDi attended the firsts NTD meeting of ISID in the following sessions: "Developing the Tools Needed to Fight NTDs" and "Essential Elements: Drug Donations and Nongovernmental Development Programs" See meeting website
- [IAS 2011](https://dndi.org/events/2011/6th-ias/) - With the expansion of its portfolio to paediatric HIV, DNDi attended the IAS conference to advocate on R&D needs for better adapted drugs for infantsSee conference website
- [31st Conference of the ISCTRC](https://dndi.org/events/2011/isctrc/) - DNDi attended the 31st Conference of the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) in the session on HAT chemotherapy. Presentations: TARRAL Antoine, Head of HAT clinical Program, DNDi"Fexinidazole a new oral treatment for sleeping sickness– update of development" TARRAL Antoine, on behalf of DON Robert, Head of HAT Discovery and Preclinical Program,
- [16th LEAP & Stakeholders Meeting](https://dndi.org/events/2011/leap-meeting/) - All key LEAP platform members gathered to share recent progress in the field of Visceral Leishmaniasis. In the frame of the LEAP meeting, DNDi and the LEAP gave a press conference on their new treatment option for VL:"New treatment for kala azar, the most deadly parasitic disease after malaria. Urgent support needed for governments to
- [6th EDCTP Forum](https://dndi.org/events/2011/edctp-forum/) - DNDi attended the Forum whose theme for 2011 was “Strengthening Research Partnerships for Better Health and Sustainable Development” See the Forum's website
- [ASMQ Meeting](https://dndi.org/events/2011/asmq-meeting/) - The meeting "Artesunate-Mefloquine (ASMQ) Fixed-Dose Combination (FDC), an additional tool in the armamentarium to control malaria in Latin-America" was held in parallel with DNDi's annual partners' meeting in Rio de Janeiro. To address main challenges for improving access of ACT in general, and specifically of ASMQ FDC, DNDi organized a brainstorming session on December 1st,
- [DND<em>i</em> Partners' meeting 2011, Rio de Janeiro](https://dndi.org/events/2011/partners-meeting2011/) - ‘Moving Innovation to Access for Neglected Patients’ This year marks nearly a decade of progress since the foundations for DNDi were set forth at a remarkable meeting in Rio in 2002. Just nine years later, we come together again to review DNDi’s progress in bringing new treatments to neglected patients as well as to evaluate
- [Geneva Health Forum 2012](https://dndi.org/events/2012/ghf12/) - Giving voice to the frontliners of health, this year's edition of the GHF focuses on chronic conditions. DNDi and MSF co-hosted a session on adult chronic Chagas disease. DNDi/MSF's session Chagas Disease : Neglected, Global, Chronic Friday April 20, 12:30 Chair: François Chappuis, Division of International and Humanitarian Medicine, Geneva University Hospital, Geneva, Switzerland Summary:
- [Forum 2012: COHRED / Global Forum for Health Research](https://dndi.org/events/2012/forum2012/) - The Council on Health Research and Development Group (The COHRED Group) in collaboration with partners and Governments, launched a new series of Global Forum for Health Research meetings on the theme: ‘Beyond aid...research and innovation as key drivers of health, equity and development’ The Forum examined the prospects for a new vision of development that
- [Sanitary Regulation - challenges in a world without borders: improving cooperation among Drug Regulatory Agencies](https://dndi.org/events/2012/sanitaryregulation/) - DNDi attended this informal meeting organized by the Brazilian Health Surveillance Agency (ANVISA) and the WHO, previous to the World Health Assembly. This meeting brought together representatives of approximately 30 regulatory agencies from countries in the five continents such as Australia, Argentina, Portugal, United States, France, United Kingdom, South Africa, India, and Cape Verde, among
- [65th World Health Assenbly](https://dndi.org/events/2012/wha/) - DNDi-MSF press briefingMONDAY, MAY 21, 2012, 11:00 AM WHERE: Press Library, located in Salle de Presse 2, ground floor, Building C."Global R&D Convention Needed to Address the Unmet Health Needs of Developing Countries" The international medical humanitarian organization Médecins Sans Frontières (MSF) and non-profit drug research and development (R&D) organization Drugs for Neglected Diseases initiative
- [15th ICID](https://dndi.org/events/2012/15-icid/) - DNDi presented a poster on ASMQ partnerships. More on the meeting
- [Fexinidazole Investigators Training](https://dndi.org/events/2012/fexinidazole-investigators-training/) - DNDi, in collaboration with Swiss TPH and the DRC national HAT control programme, organized a 3-day-training for the investigators of the project: "Safety and efficacy of Fexinidazole in comparison with NECT in second stage HAT patients". The participants were trained on practical aspects as well as on questions of protocol, quality monitoring, ethics or community
- [ICTMM](https://dndi.org/events/2012/ictmm-2012/) - DNDi hosted 3 sessions at the XVIII International Congress for Tropical Medicine and Malaria. Cocktail Reception: Product Development Partnerships (PDPs) for Neglected DiseasesClosed session: 24 September, 19h-19h30 Co-hosted by the Medicines for Malaria Venture (MMV) and DNDi See invitation See programme Progressing NCEs through clinical development for the treatment of neglected tropical diseasesSession I: 25 September, 09h00-11h00
- [PKDL](https://dndi.org/events/2012/pkdl/) - OneWorld Health and Drugs for Neglected Diseases initiative Convene PKDL Forum International experts gathered in New Delhi, India, for three days of sessions and workshops to discuss post kala-azar dermal leishmaniasis (PKDL). This meeting, jointly hosted by OneWorld Health and DNDi, focused on the current state of PKDL in East Africa and South Asia, identify
- [Unicamp - Neglected Diseases Forum](https://dndi.org/events/2012/unicampforum/) - The State University of Campinas (UNICAMP) held the Forum "From basic to applied research: the challenges of drugs for neglected diseases." This forum not only aimed for the university to disseminate and promote ideas, but also, and especially, encouraged future partnerships between different sectors (academia, organizations such as DNDi, government bodies, and pharmaceutical industries) in:
- [ICTMM](https://dndi.org/events/2012/ictmm/) - DNDi hosted two session in the XVIII International Congress for Tropical Medicine and Malaria. See a Summary of DNDi's activities! Closed session: 24 September, 19h-19h30Cocktail Reception: Product Development Partnerships (PDPs) for Neglected DiseasesCo-hosted by the Medicines for Malaria Venture (MMV) and DNDi See invitationSee programmeSession I: 25 September, 09h00-11h00Progressing NCEs through clinical development for the treatment
- [A decade of R&D for Neglected Patients](https://dndi.org/events/2012/decade-malaysia/) - Hotel Istana, Kuala Lumpur, MalaysiaPublic event organized by DNDi and the Ministry of Health, MalaysiaProgramme [PDF 6MB] 09:30Welcome address by Organising Chairman, Tan Sri Dato’ Seri Dr Haji Mohd Ismail Merican 09:45Dr Bernard Pécoul, Executive Director, DNDi – Reflections on 10 Years of Challenges and Successes of the DNDi Partnership Model [PDF] 10:00Keynote address by the Right Honourable
- [1st LEAP Conference & 21st LEAP Meeting](https://dndi.org/events/2014/leap-2014/) - 1st LEAP Conference Programme & abstracts: Download conference agenda [PDF | 0.6MB] Download complete conference programme & abstracts (large file) [PDF | 28.4MB] Download by section: Conference programme [PDF | 10.3MB] Conference speakers [PDF | 3.7MB] Conference abstracts [PDF | 7.6MB] Conference posters & additional information [PDF | 6.6MB] 21st LEAP Meeting Download meeting agenda [PDF |
- [Chagas Week Cochabamba](https://dndi.org/events/2013/chagas-week-cochabamba/) - COHEMI Symposium on NTDs and Migration/International Symposium on Chagas Disease/Chagas Disease Clinical Research Platform Meeting.Symposia, April 15-19, 2013, Cochabamba, Bolivia PhotosEvent photos: http://on.fb.me/12nrlh0 VideosVideo message by international soccer star Lionel Messi, recorded for Chagas Week:http://youtu.be/Al7zfgXgvSk "Chagas: A Silent Killer", a new documentary short film by Argentinean director Ricardo Preve:Trailer: http://www.aljazeera.com/programmes/witness/2013/04/20134168253191412.htmlhttp://youtu.be/D14o84a-sws Full film on Al Jazeera's Witness TV
- [Swiss Malaria Group](https://dndi.org/events/2013/swiss-malaria-group/) - Malaria: The BIG Picture Have you got a photo that can tell a story about malaria?Click here to read more about Swiss Malaria Group Photo Competition
- [World Leish 5](https://dndi.org/events/2013/world-leish5/) - The Fifth World Leishmaniasis Congress was organized by the Oswaldo Cruz Foundation, the Brazilian Society of Tropical Medicine, the Brazilian Society of Protozoology, and the Brazilian Society of Parasitology. Click here to read more about World Leish 5. Posters Translation from WHO Recommendation to Implementation in National PolicyEllis S, Musa AM, Burza S, Alirol
- [GHIT 2013](https://dndi.org/events/2013/ghit-2013/) - Global Health Experts Comment on Japan’s First Public-Private Partnership to Advance Global Health R&D -A side event of the World Health Assembly, Palais des Nations, Geneva Click here for more details
- [International AIDS Society Conference 2013](https://dndi.org/events/2013/international-aids-society-conference-2013/) - 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention The world’s largest open scientific conference on HIV/AIDS – the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) was held at the Kuala Lumpur Convention Centre (KLCC ) in Kuala Lumpur, Malaysia from 30 June-3 July 2013. Press Release(Kuala Lumpur,
- [8th European Congress on Tropical Medicine and International Health](https://dndi.org/events/2013/8th-european-congress-on-tropical-medicine-and-international-health/) - The congress endeavored to look with critical eyes on current achievements in international health with focus on the link between scientific knowledge and practice, as well as creating a forum for interaction with colleagues around the globe and develop ideas for future research. Antoine Tarral, Head of HAT Clinical Program, DNDi, presented: Oral presentation -
- [6th MIM Pan-African Malaria Conference](https://dndi.org/events/2013/mim2013/) - Moving towards malaria elimination: Investing in research and control The MIM conference is the largest gathering of the malaria community and therefore provides the ideal opportunity to showcase novel findings, innovations and ground breaking research. DNDi participated in two symposia: Seasonal Malaria Chemoprevention: the broader picture co-organised with Médecins Sans FrontièresTuesday, 8 October from 5:00-6:30pmChair:
- [Paediatric HIV Roundtable with Industry](https://dndi.org/events/2013/paediatric-hiv-roundtable/) - A Paediatric HIV Roundtable with Industry was organized by DNDi in Dakar, Senegal on 24 October 2013 following the Conference on Paediatric Antiretroviral Drug Optimisation (PADO) organized by the World Health Organization (WHO) from 22 to 23 October 2013. This one-day ‘Paediatric HIV Roundtable with Industry’ brought together researchers, paediatricians, pharmacologists, regulatory representatives, NGOs, policy
- [First Biennial Scientific Conference on Medicines Regulation in Africa](https://dndi.org/events/2013/first-biennial-scientific-conference-on-medicines-regulation-in-africa/) - Building Partnerships for Sustainable Capacity Development in Medicines Regulation in AfricaBirchwood Hotel, Johannesburg, South AfricaThe NEPAD Agency in collaboration with the World Health Organization (WHO) and the organisational support of US-Food and Drugs Administration (USFDA) and the Drugs for Neglected Diseases initiative (DNDi) hosted the First Biennial Scientific Conference on Medicines Regulation in Africa, on
- [Swiss Malaria Champions: a Photographic Exploration](https://dndi.org/events/2013/swiss-malaria-photos/) - Special event to highlight the work of the Swiss Malaria Group in fighting malaria. Presented by the Swiss Agency for Development and Cooperation SDC. Swiss Malaria Group
- [4th KEMRI Annual Scientific and Health Conference](https://dndi.org/events/2014/kemri-kash/) - The 4th Annual KEMRI Annual Scientific and Health Conference organized by Kenya Medical Research Institute (KEMRI) focused on new scientific knowledge and offered many opportunities for structured dialogue on the major issues facing health research and innovation in Kenya and the African region. Dr Monique Wasunna, Head of DNDi Africa, delivered the key note address.Key
- [CROI 2014](https://dndi.org/events/2014/croi-14/) - POSTER PRESENTATION Poster Presentation [PDF | 271 KB] Simulation and Exposure-Based Assessment of Pediatric Lopinavir Fixed-Dose Combination Product Saïk Urien [1-3], Naïm Bouazza [1-3], Frantz Foissac [1-3], Floris Fauchet [1-3], David Burger [4], Jean-René Kiechel [5], Edmund Capparelli [6], Jean Marc Treluyer [1-3], Marc Lallemant [5] 1. Université Paris Descartes, Sorbonne, Paris, France 2. Unité
- [X Workshop on Chagas Disease](https://dndi.org/events/2014/x-workshop-chagas/) - Between 8-10 million people live with Chagas disease in Latin America and about 500,000 in Europe and North America. Despite recent advances in vectorial control, many public health challenges remain unadressed: the care and appropriate treatment to those affected, as it is estimated that less than 1% of them receive it. Blood bank control and
- [FINDECHAGAS](https://dndi.org/events/2014/findechagas-2014/) - 4th Meeting of the International Association of People Affected by Chagas Disease The Third General Assembly of the International Federation of People Affected by Chagas (FINDECHAGAS) and 4th Meeting of the International Association of People Affected by Chagas Disease was held in Santa Cruz de la Sierra, Bolivia, from 13 to 15 April, 2014. This
- [Integrating Malaria into Sustainable Development Goals](https://dndi.org/events/2014/malaria-fishbowl-ghf/) - The Swiss Malaria Group hosted a Malaria Fishbowl to encourage dialogue on how the global malaria community can integrate with non-health sectors to help eliminate malaria. Speakers: Moderator: Susanna Hausmann, Senior Health Advisor, Swiss Agency for Development and CooperationSilvia Ferazzi, Technical Officer, Roll Back Malaria PartnershipAmbassador Laurence Ishengoma, Special High Level Advisor to the Minister
- [5th FIP Pharmaceutical Sciences World Congress](https://dndi.org/events/2014/fip-2014/) - The leading pharmaceutical scientists from across the globe met to discuss the future: Where will the pharmaceutical sciences stand beyond 2020? What should be your focus? What will be the breakthroughs and the pitfalls? How can we meet the biggest challenges? Co-sponsored by many of the world’s leading pharmaceutical science and educational organisations, the International
- [AFRIVIH 2014](https://dndi.org/events/2014/7-francophone-afrivih/) - Conférence Internationale Francophone VIH/Hépatites The 7th international francophone conference against HIV and hepatitis was a large forum uniting francophone stakeholders fighting HIV. Marc Lallemant, DNDi's Head of HIV programme, spoke at a symposium organised by UNITAID: Les défis de l’accès aux traitements et diagnostics : nouveaux enjeux et réponses ciblées Symposium Flyer Symposium Agenda More
- [Swiss Malaria Group Photo Exhibition](https://dndi.org/events/2014/smg-exhibition-2014/) - The Swiss Malaria Group presented a photo exhibition. The photographs profile the impact of malaria around the world. The opening and apéro took place on World Malaria Day, April 25. Speakers: Maya Tissafi, Acting Director SDCChristian Lengeler, Director Swiss TPH Malaria CenterJoel Meir, Director SolidarMed Download flyer More information: SDC website
- [ESPID 2014 Congress](https://dndi.org/events/2014/espid-2014/) - Over 3000 clinicians, researchers, residents, and students gathered for the 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2014) to talk about the newest developments, innovative techniques, and advanced practices in Paediatric Infectious Diseases. ESPID 2014 included interactive case sessions, platform presentations, educational workshops, networking sessions, meet the professor sessions and
- [Towards New Therapeutics for Diseases of the Developing World](https://dndi.org/events/2014/sci-developingworlddiseases/) - Designing drugs to fight diseases that cause high mortality and morbidity amongst the people of the developing world is a global challenge. This meeting focused on medicinal chemistry approaches to making new medicines, with keynote talks from international experts, accompanied by a series of perspectives detailing case histories in drug discovery. The event took place
- [ISNTD d<sup>3</sup> 2014](https://dndi.org/events/2014/isntd-d3/) - ISNTD d3 brought together experts from within drug discovery and clinical trials to drive the debate and foster new partnerships & alliances leading to tangible outcomes in terms of new therapies to combat these diseases. ISNTD d3 aimed to accelerate the networking required for the development & distribution of new or improved drugs, vaccines, microbicides
- [World Health Assembly 2014](https://dndi.org/events/2014/world-health-assembly/) - The Role of Research & Innovation to achieve Health for All and Sustainable Development May 22, 2014 - 17.45 – 19.30World Health Assembly – UN Palais des Nations – Salle IX Organized by the Council on Health Research for Development (COHRED), the Drugs for Neglected Diseases initiative (DNDi), the Global Health Technologies Coalition (GHTC), the
- [GHIT Fund 1st Anniversary Event](https://dndi.org/events/2014/ghit-1st-anniversary/) - The GHIT Fund celebrated the first anniversary of its inauguration with the event “Global Health R&D Showcase,” in Tokyo, Japan, on June 6, 2014. Over 350 attendees, from diverse sectors including the government, private sectors, public sectors, academia, NGOs/NPOs, and media journalists, participated in the event. The panel discussion, presented by leaders from Japanese pharmaceutical
- [7th EDCTP Forum](https://dndi.org/events/2014/7th-edctp/) - The EDCTP Forum is a biennial event that provides an international platform for the presentation and discussion of frontier research for everyone involved in combating the three main poverty-related diseases (HIV/AIDS, tuberculosis and malaria) and their interaction with other neglected infectious diseases, the appropriate capacity development and networking activities. DNDi co-organised a satellite meeting on
- [AIDS 2014](https://dndi.org/events/2014/aids-2014/) - The International AIDS Conference is the premier gathering for those working in the field of HIV, as well as policy makers, persons living with HIV and other individuals committed to ending the pandemic. It is a chance to assess where we are, evaluate recent scientific developments and lessons learnt, and collectively chart a course forward.
- [WCP 2014](https://dndi.org/events/2014/wcp-2014/) - DNDi participated in a poster presentation on the population pharmacokinetics of benznidazole for Chagas disease. Poster Presentation Altcheh J, Ribeiro I, Caruso AM, Moscatelli G, Moroni S, Moran L, Ledesma O, Monla C, Bisio M, Mastrantonio G, García-Bournissen F Population pharmacokinetics of benznidazole in a cohort of children under 12 years old with Chagas disease [PDF
- [ICOPA XIII](https://dndi.org/events/2014/icopa-13/) - The ICOPA congress slogan “ancient parasites, old hosts, new knowledge” points to long lasting parasites, longevity of hosts and the new data shared during ICOPA. The ICOPA program includes symposia with invited speakers who were recommended by outstanding scientists around the world, by Presidents of National Societies of Parasitology, the International Scientific Advisory Board and
- [35th Annual Conference of the International Society for Clinical Biostatistics](https://dndi.org/events/2014/iscb35/) - The International Society for Clinical Biostatistics (ISCB) was founded in 1978 to stimulate research into the principles and methodology used in the design and analysis of clinical research and to increase the relevance of statistical theory to the real world of clinical medicine. Like previous annual conferences of ISCB the 2014 conference provided a scientific
- [Eurotox 2014 - 50th Congress of the European Societies of Toxicology](https://dndi.org/events/2014/eurotox-2014/) - SCYX-7158: Hard times for Trypanosoma brucei parasites [PDF | 0.6MB] by Giannotti E, Longo M, Messina M, Ghiglieri A, Launay D
- [MipTec 2014 - Translating Science into Drugs](https://dndi.org/events/2014/miptec-2014/) - Discovering and developing new and better drugs for patients requires the collaboration of an extraordinary number of specialists across many disciplines and organizations. MipTec 2014 introduced new topical forums to cover an even broader range of these disciplines: Infectious diseases, drug discovery information management, and clinical development. Eric Chatelain, Head of Drug Discovery at DNDi,
- [PharmSci 2014 - The Science of Medicines](https://dndi.org/events/2014/pharmsci-2014/) - The APS PharmSci 2014 Conference showcased the best of pharmaceutical science from the UK and around the world bringing together academic and industrial institutions, providing state of the art technologies and a platform for the development of new pharmaceutical talent. DNDi Head of Pharmaceutical Development, Steve Robinson, chaired a symposium. Symposium New Medicines: Future benefits
- [RSTMH 2014](https://dndi.org/events/2014/rstmh-2014/) - Measuring Progress The theme for the meeting was "Measuring Progress" and over the three days the focus was: how do we measure progress in our activities to ensure we are having maximum impact? DNDi presented a poster on progress in neglected diseases research and development by Belen Pedrique and Nathalie Strub-Wourgaft. Poster Presentation Date: September
- [Berlin World Health Summit](https://dndi.org/events/2014/berlin-worldhealth-2014/) - Since its first appearance in 2009, the World Health Summit (WHS) brings together opinion leaders from academia, politics, civil society, and the private sector to take responsibility in all health related challenges Nathalie Strub-Wourgaft, DNDi Medical Director, spoke at a workshop on ethics in research and business. Workshop Ethics in Research and Business Date: October
- [ASTMH 2014](https://dndi.org/events/2014/astmh-2014/) - DNDi presented a symposium on human African trypanosomiasis (sleeping sickness), presented new results from an ASMQ clinical study in children, participated in a symposium on Kinetoplastid diseases, and made oral and poster presentations. DNDi also co-sponsored a side event on Chagas disease. DNDi @ ASTMH Symposium DNDi Symposium: #164Towards the elimination of human African trypanosomiasis (HAT)
- [Ban Trop Tox 2014](https://dndi.org/events/2014/ban-trop-tox-2014/) - This conference brought together a range of key health researchers of this region to exchange and disseminate the latest knowledge in Tropical medicine and Toxicology. DNDi presented on challenges for treatment of kala-azar in the Indian sub-continent. Presentation Challenges for treatment of Kala-Azar in the Indian Sub-continent Suman Rijal, Director of DNDi Regional Office IndiaDownload
- [CROI 2015](https://dndi.org/events/2015/croi-2015/) - The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. DNDi presented a poster on the acceptability of Lopinavir/r in HIV-infected children. Poster
- [Advances & Challenges in the Fight Against Malaria: A 2000-2015 Retrospective](https://dndi.org/events/2015/malaria-retrospective/) - DNDi and MMV co-organized this event. A formal handover of DNDi's malaria projects to MMV took place. Opening RemarksProfessor Marcel Tanner, Director, Swiss Tropical and Public Health Institute Keynote AddressDr Pedro Alonso, Director, Global Malaria Programme, World Health Organization15 Years of Malaria Control and Elimination – How far have we come? What lies ahead Ministerial
- [6th Annual Conference on Research and Postgraduate Education](https://dndi.org/events/2015/khartoum-research-conference-2015/) - DNDi co-chaired and presented sessions on leishmaniasis, neglected tropical diseases and north-south collaboration. Sessions Leishmaniasis Fight Date: 21 February, 2015 Time: 14:30 - 16:00 Chairs: Ahmed Modawi Musa Monique Wasunna, Director DNDi Africa, Kenya A M EL Hassan, University of Khartoum, Sudan Assisting a marginalized community to lead a better life: 25 years of work in
- [XI Workshop on Chagas Disease](https://dndi.org/events/2015/xi-workshop-chagas/) - The XI edition of the Chagas Workshop gathered international experts to discuss the advances in clinical, pathophysiologic and immunologic knowledge on Chagas disease. DNDi was a sponsor of this workshop. Isabela Ribeiro, DNDi Head of Chagas Disease, was a member of the scientific committee. More information: IS Global website
- [Antimicrobial Resistance, Novel Drug Discovery and Development: Challenges and Opportunities](https://dndi.org/events/2015/antimicrobial-conference-2015/) - The conference focused on antimicrobial resistance, including multi & extensive drug resistant pathogens, hospital acquired infections, host-pathogen interactions, infection and immunity, microbial pathogenesis, bioinformatics, challenges and opportunities in drug discovery & development against infectious diseases with special focus on TB, malaria, kala azar, dengue, chikungunya, chickenpox, etc. It had invited talks and poster sessions of
- [GLOBVAC Conference 2015](https://dndi.org/events/2015/globvac-2015/) - How can research inform the post-2015 agenda for women's and children's health and rights? DNDi participated in a symposium on sleeping sickness. This conference presented Norwegian and international research on Women and Children's Health and Rights. Recent developments in other Norwegian global health research, as well as new potential partners for international collaboration, were part
- [2015 Gordon Research Conference](https://dndi.org/events/2015/grc-tropical-infectious-diseases/) - The 2015 Gordon Research Conference on "Tropical Infectious Diseases: Challenges, Opportunities and Successes", presented cutting edge research on the most prevalent and medically important tropical infectious diseases (TIDs). The conference gathered a multidisciplinary community of scientists for the purpose of discussing basic and field-based research with translational implications in TIDs, particularly emphasizing participation by junior
- [British Society of Parasitology Spring Meeting 2015](https://dndi.org/events/2015/bps-spring-2015/) - The theme of BSP2015 was “Malaria, Neglected Tropical Diseases (NTDs) and their Vectors”. The scientific programme with invited speakers covered research on: Drugs and diagnostic development, Parasite immunology, Parasite genomics and molecular biology, Geospatial epidemiology and mapping, General parasitology and much more. DNDi Discovery & Preclinical Director, Robert Don, presented in a plenary session on
- [Swiss Malaria Group Event - World Malaria Day](https://dndi.org/events/2015/smg-event-2015/) - The Swiss Malaria Group marked the occasion of World Malaria Day at the Natural History Museum in Basel. In the context of the Swiss Parliamentarian study tour to Tanzania from 6 - 12 April 2015, the group informed the public about the commitment of the Swiss Malaria Group Association in the fight against malaria and
- [MSF Scientific Day in India](https://dndi.org/events/2015/msf-scientific-day-india-2015/) - DNDi chaired and presented in a session on visceral leishmaniasis. Session Visceral leishmaniasis: an overview of detection & response Date: 8 May, 2015 Chair: Suman Rijal, Director of DNDi Regional Office India Manimoy Chakma, MSF Active and passive case detection strategies for control of leishmaniasis in Bangladesh Vishal Goyal, Clinical Manager, DNDi India Safety and effectiveness
- [ISNTD d<sup>3</sup> 2015](https://dndi.org/events/2015/isntd-d3-2015/) - The International Society for Neglected Tropical Diseases presented ISNTD d3 to address the past shortfalls in R&D productivity and drive the development of future paths towards successful gains in the control, treatment or evaluation of NTDs. ISNTD d3 brought together experts from within drug discovery and clinical trials to drive the debate and foster new
- [OpenClinica Global Conference 2015](https://dndi.org/events/2015/openclinica-2015/) - DNDi presented on achieving efficiency in clinical data management. Session Achieving Efficiency in Clinical Data Management through OpenClinica Integration with Patient Monitoring System Date: 1 June, 2015 Michael Ochieng, Information Systems Manager, DNDi Download presentation [PDF | 1.6MB] More information: OpenClinica website
- [Medtrop 2015](https://dndi.org/events/2015/medtrop-2015/) - Doenças tropicais: do ensino e pesquisa aos serviços de saúde DNDi presented at sessions on Chagas disease and leishmaniasis. Programa científico Mesa redonda (Leishmaniose) Desafios e oportunidades para o tratamento das leishmaniosis e co-infecções Segunda-feira, 15 de junho 9:35 – 10:50 Sala A Moderadora: Marina Boni, programa leishmaniose DNDi América Latina Jorge Alvar, Programa de
- [7th International Workshop on HIV Pediatrics](https://dndi.org/events/2015/7th-international-workshop-on-hiv-pediatrics/) - IAS 2015 The workshop brought together experts from different disciplines who are involved in daily clinical care for infants and children with HIV. This meeting offered an interactive setting where the latest developments in the field were presented, discussed, reviewed and evaluated. Helena Rabie presented interim study results from the study on RTV Superboosting for
- [11th Liver Update 2015](https://dndi.org/events/2015/11th-liver-update-2015/) - The Liver Update gathering is a biennial regional meeting jointly organised by the Malaysian Liver Foundation to keep doctors, specialists and allied health professionals updated on the latest advances in the diagnosis, management and research of hepatobiliary diseases. DNDi presented in a plenary and a symposium on hepatitis C. Plenary The Changing Landscape of Hepatitis
- [2nd International HIV/Viral Hepatitis Co-­Infection Meeting](https://dndi.org/events/2015/hiv-hepatitis-coinfection-meeting-2015/) - This meeting focused on antiviral therapy development access for HIV/Viral Hepatitis co-infection. It is an IAS affiliated event held just before IAS 2015.DNDi's Head of Paediatric HIV Programme participated in a panel on public health advocacy and access to HCV therapy. Panel Public Health Advocacy and Access to HCV therapy Date: July 18, 2015 Time:
- [UNITAID Stakeholders Briefing](https://dndi.org/events/2015/unitaid-stakeholders-briefing-ias-2015/) - Accelerating Innovation for Pediatric ARV Formulations: Review of Progress of Mutual Accountability Framework This stakeholder briefing took place at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. The briefing included updates from the Paediatric Treatment Initiative and the Global Pediatric ARV Commitment-­to‐Action. DNDi's Head of Paediatric HIV Programme, Marc Lallemant, took part in
- [ICC Leish 2015](https://dndi.org/events/2015/icc-leish-2015/) - International Conference on Cutaneous Leishmaniasis This conference brought together renowned national and international scientists to discuss the perspectives and challenges to be employed in the Surveillance and Control Programs. The conference covered epidemiology, parasitology, immunology, molecular diagnosis, treatment, technological innovation, prevention, and control of cutaneous leishmaniasis, as well as discussing new treatment strategies that are
- [Global Health Risk Framework: A Workshop on Research and Development of Medical Products](https://dndi.org/events/2015/workshop-research-and-development-of-medical-products/) - This U.S. Institute of Medicine (IOM) workshop focused on strategies to facilitate the development of medical products – including therapeutics, vaccines, diagnostics, and personal protective equipment. Key areas for consideration included: product development, clinical development, optimization for development, regulatory review standards and systems, manufacturing, legal issues, and indicators relevant to medical product research and development.
- [Strategic Orientations: DND<em>i</em> Business Plan 2015-2023](https://dndi.org/events/2015/stakeholder-event-business-plan-launch-2015-2024/) - On the occasion of the 9th European Congress on Tropical Medicine and International Health (ECTMIH) in Basel, Switzerland, DNDi hosted a Stakeholders’ Event to launch DNDi 's new Business Plan, 2015-2023. Business Plan Launch Date: September 07, 2015 Time: 18:30 Venue: Restaurant Safran Zunft, Basel, Switzerland Programme: - Opening, Prof. Marcel Tanner, Chair
- [33rd International Scientific Council for Trypanosomiasis Research and Control (ISCTRC)](https://dndi.org/events/2015/33-isctrc/) - This conference disseminated scientific information on tsetse, human and animal trypanosomiasis problem, reviewed control strategies and recommended appropriate approaches in research and control. DNDi made several presentations on sleeping sickness. Presentations HAT Platform activities Florent Mbo Download presentation [PDF | 0.6MB] DNDi Research & Development progress to tackle Sleeping Sickness Antoine Tarral, Olaf Valverde Mordt,
- [REINVENT: Conference on Neglected Diseases](https://dndi.org/events/2015/reinvent-ntd-2015/) - Reinvent was an interdisciplinary conference that brought together stakeholders from all sectors to cultivate a Toronto-based forum to reinvent how we think about neglected diseases. Panel Free Trade at What Cost? R&D for Neglected Diseases Date: Friday, October 2, 2015 Time: 1:30pm - 3:30pm Location: George Ignatieff Theatre In the area of neglected diseases, a
- [IMMUNOCON 2015](https://dndi.org/events/2015/immunocon-2015/) - Dr Suman Rijal, Director of DNDi Regional Office India, presented on the challenges for diagnosis in visceral leishmaniasis. The conference brought together young researchers and leaders from different facets of Immunology, a magnificent conglomeration of innovators to exchanging ideas. Presentation Date: Saturday, October 10, 2015 Challenges for the diagnosis of visceral leishmaniasis in the Kala-azar
- [DND<em>i</em> India Stakeholders' Event: New R&D Pathways to Address Neglected Patients’ Needs in the Indian Sub-Continent](https://dndi.org/events/2015/dndi-india-stakeholder-event-business-plan-launch-2015-2023/) - The Drugs for Neglected Diseases initiative in India organized its Stakeholders’ Event on October 15, 2015 in New Delhi and unveiled its Business Plan for India and the region to better respond to the needs of the patients suffering from neglected diseases. Over 100 global public health experts including government officials, scientists, researchers, civil society
- [COST 2015](https://dndi.org/events/2015/cost-cm-1307-2015/) - Jean-Robert Ioset, Discovery Manager, DNDi presented on drug discovery against kinetoplastid diseases. Closing Conference Date: Tuesday, October 29, 2015 Drug discovery against kinetoplastid diseases: The DNDi perspective The Drugs for Neglected Diseases initiative (DNDi) is a patients’ needs-driven organization committed to the development of new treatments for neglected diseases. At the discovery level, the main
- [ASTMH 2015](https://dndi.org/events/2015/astmh-2015/) - American Society of Tropical Medicine and Hygiene (ASTMH), 64th Annual Meeting ASTMH, founded in 1903, is a worldwide organization of scientists, clinicians and program professionals whose mission is to promote global health through the prevention and control of infectious and other diseases that disproportionately afflict the global poor. Research, health care and education are the
- [IV Symposium on Drug Design and Development for Neglected Diseases](https://dndi.org/events/2015/symposium-drug-development-neglected-diseases/) - Representatives of the pharmaceutical industry, national and international universities and government laboratories, met at the Faculty of Pharmaceutical Sciences (FCF), USP for the fourth Symposium Planning and Drug Development for Neglected Diseases. Jean-Pierre Paccaud, Business Development Director of DNDi spoke at the event. Lecture I - Top Scientists Developing drugs for neglected patients: challenges and
- [It is not healthy: Mending the broken medicines innovation model](https://dndi.org/events/2015/mending-the-broken-model-event/) - Organized by the Transatlantic Consumer Dialogue (TACD), the European Public Health Alliance (EPHA), Médecins du Monde (MdM) International network, Universities Allied for Essential Medicines (UAEM Europe), Salud Por Derecho, in collaboration with the European Parliament Working Group on innovation, access to medicines & poverty-related diseases. Dr Bernard Pécoul, Executive Director of DNDi, will be speaking
- [Glasgow Encounter with Tropical Disease](https://dndi.org/events/2015/glasgow-encounter-with-tropical-disease/) - Many diseases endemic to developing countries in the tropics are caused by parasites. An extraordinary number of these parasites were first discovered by Scottish scientists and doctors, many of whom were graduates of the University of Glasgow. This symposium, organized by the Wellcome Trust Centre for Molecular Parasitology will consider the contributions of Robert Leiper;
- [Health for Sale: Debate on Access to Medicines and Innovation](https://dndi.org/events/2016/health-for-sale-debate/) - During its Presidency of the Council of the European Union, the Government of the Netherlands has committed to improving affordable access to safe and effective medicines. But how can it create real and lasting change? Public health experts and government representatives debated these issues. The event was coordinated by DNDi and other partners; AIDS Fonds,
- [ASTMH in Kenya](https://dndi.org/events/2016/dndi-at-astmh-in-kenya/) - The symposium brought together experts from the government, non-governmental organizations, affected counties in Kenya, regional experts in neglected tropical diseases and research institutions to discuss innovative ways of increasing access to treatments for neglected diseases once trials are successfully completed. Flyer DNDi Access Symposium Report held during ASTMH in Kenya Symposium Innovation for Access to
- [Innovation for Health](https://dndi.org/events/2016/innovation-for-health/) - Innovation for Health is the premier event on healthcare innovations in the Netherlands. Christina Sander, Fundraising Coordinator, DNDi, presented at the Ministry of Foreign Affairs session, where six product development partnerships were invited to present their work. Session Developing better health products for the poor in public-private partnerships More information: Innovation for Health Website
- [Clinical Experts Meeting on Lymphatic Filariasis](https://dndi.org/events/2016/lymphatic-filariasis-clinical-expert-meeting/) - The DNDi Indian office and the Indian Council of Medical Research (ICMR) organized a clinical experts meeting on lymphatic filariasis (LF). The meeting objectives were; to identify the unmet needs for the treatment of LF patients in Asia and; to define the target product profile (TPP) for LF case management in Asia. Concept Note
- [CTDDR 2016](https://dndi.org/events/2016/ctddr-2016-india/) - The 6th CTDDR highlighted cutting-edge advances in drug discovery and development for infectious diseases (malaria, filaria, leishmania, HIV, tuberculosis), life style disorders, cancer and reproductive/bone disorders. Robert Don, Graeme Bilbe, and Suman Rijal presented in a session on infectious diseases. Session Infectious Diseases
- [Better together? Exploring the proposal for a pooled fund for global health R&D](https://dndi.org/events/2016/ghtc-oni-webinar/) - The GHTC and the O’Neill Institute organized a webinar/panel discussion about proposals for a pooled fund for global health R&D. The panelists explained current proposals and discussed the ways in which such a fund could be a vital resource in achieving the SDGs. Rachel Cohen, Regional Executive Director, DNDi North America was on the panel.
- [XII Workshop on Chagas Disease](https://dndi.org/events/2016/xii-workshop-on-chagas-disease/) - In collaboration with DNDi, the XII edition of the Chagas Workshop gathered together international experts to discuss the latest advances in the diagnosis and treatment of the disease. Isabela Ribeiro, DNDi Head of the Chagas Clinical Programme, was a member of the scientific committee. Carolina Batista, Regional Medical Manager, DNDi Latin America, presented a poster
- [Spanish Royal Academy of Medicine](https://dndi.org/events/2016/royal-academy-of-medicine/) - Jorge Alvar, Head of Visceral Leishmaniasis, DNDi presented on research in times of crisis. Presentation
- [Swiss Malaria Group Event: World Malaria Day](https://dndi.org/events/2016/swiss-malaria-group-event-world-malaria-day/) - The Swiss Malaria Group marked the occasion of World Malaria Day 2016 in Bern. The group informed the public about the commitment of the Swiss Malaria Group Association in the fight against malaria and about the devastation still caused by malaria in the world. Save the Date Full Programme Ceremony Symposium Session 1 Symposium Session
- [17th International Congress on Infectious Diseases](https://dndi.org/events/2016/17th-icid/) - The meeting focused on HIV, malaria, tuberculosis, pneumonia and enteric infections including typhoid fever and diarrhea. Major areas around neglected tropical diseases were also discussed. Suman Rijal, Director of DNDi Regional Office India, co-chaired a symposium on visceral leishmaniasis in South Asia. Vishal Goyal, Clinical Manager at DNDi India, presented on outcomes for kala-azar patients
- [ISGlobal Roundtable](https://dndi.org/events/2016/is-global-roundtable/) - El precio de los medicamentos No Es Sano: alternativas a un modelo de I+D roto Olaf Valverde, Medical Manager, DNDi took part in this roundtable event, co-organized by ISGlobal, Oxfam Intermón and the No es Sano (It`s Not Healthy) Campaign. Presenters Moderator: Gonzalo Fanjul, Policy Director, ISGlobal More information: ISGlobal Website
- [MSF Scientific Day Argentina](https://dndi.org/events/2019/msf-scientific-day-argentina/) - The aim of MSF Scientific Days is to help improve the quality of care provided to the patients and populations, by sharing and discussing the research conducted in MSF field programmes. Session ¿Un modelo alternativo de I+D es posible? Date: Friday 5 April 2019Time: 16:30 Moderator: Jorge Martin Presentation
- [Superbugs & Superdrugs - Pushing financial incentives and collaborative incentives to accelerate clinical success](https://dndi.org/events/2016/superbugs-superdrugs-dndi-2016/) - The Superbugs and Superdrugs conference addressed the core challenges in the industry from: Investment, R&D to hospital hygiene, consumer engagement and reviewed current strategies. Jean-Pierre Paccaud, Business Development Director from DNDi, discussed global product development partnerships as a means of fostering new antibiotic treatments and their responsible use. Session Date: Wednesday, March 16, 2016 More
- [The International Liver Congress](https://dndi.org/events/2016/ilc-dndi-press-briefing/) - DNDi launched its new Research & Development Strategy for Hepatitis C at the International Liver Congress (ILC) on April 13th. Press Briefing More information: ILC Website
- [International Congress of Dermatology Cosmetic & Laser](https://dndi.org/events/2016/icdclcongress/) - This meeting covered topics in clinical dermatology, dermatopathology, cutaneous surgery, lasers, and cosmetic dermatology. Byron Arana, Head of Cutaneous Leishmaniasis, DNDi presented on DNDi's cutaneous leishmaniasis strategy. Presentation
- [Geneva Health Forum 2016](https://dndi.org/events/2016/geneva-health-forum-2016/) - Held biannually, the Geneva Health Forum is an international conference that keeps the pulse on the global health agenda with a specific aim of contributing to bridge the gap between policy and practice. Carolina Batista, Regional Medical Manager, DNDi, presented on access to treatment for Chagas disease. Presentation More information: Geneva Health Forum website
- [Dundee Drug Discovery Unit: Celebrating 10 years](https://dndi.org/events/2016/10-years-dundee-ddu/) - The Dundee Drug Discover Unit hosted a scientific conference over 3 days to celebrate its tenth anniversary. Speakers discussed the future of drug discovery, academic and diseases of the developing world drug discovery, and new collaborative models. Graeme Bilbe, R&D Director, spoke at the event. Scientific Conference More information: DDU websiteFull Programme
- [Global health R&D: What’s at stake during the 69th WHA?](https://dndi.org/events/2016/ghtc-wha-2016-panel/) - GHTC Panel Discussion A lunchtime panel discussion and webinar hosted by the Global Health Technologies Coalition and the Geneva Centre for Security Policy. This panel discussion will explore the key issues in global health R&D and offer insight on what is at stake during the 69th World Health Assembly, including ensuring sustainable R&D to support
- [ISNTD d<sup>3</sup> 2016](https://dndi.org/events/2016/isntd-d3-2016/) - The International Society for Neglected Tropical Diseases presents ISNTD d3 to address the past shortfalls in R&D productivity and drive the development of future paths towards successful gains in the control, treatment or evaluation of NTDs. ISNTD d3 will bring together experts from within drug discovery and clinical trials to drive the debate and foster
- [Population Approach Group Europe (PAGE)](https://dndi.org/events/2016/page-2016-lisbon/) - PAGE represents a community with a shared interest in data analysis using the population approach. Each year a meeting is held in June at a different European location. Stephanie Braillard, Project Manager, DNDi and Charles Mowbray, Head of Drug Discovery, DNDi presented a poster at the event. Poster Presentation *Lead author More information: Page Website
- [Italian Society of Parasitology Conference](https://dndi.org/events/2016/italian-society-parasitology-conference/) - The 29th edition of soIPa National Congress focused on the most important parasitoses of medical and veterinary interest and their impact, particularly in developing countries where poor conditions and lack of economic resources may limit public health policies. Ivan Scandale, Project Manager, presented on new molecules for parasites. Session Research Highlights 1: Human and veterinary
- [Revolutionizing paediatric HIV treatment](https://dndi.org/events/2019/dndi-unitaid-grant-closure-event/) - This invitation-only event marks World AIDS Day and the end of DNDi’s multi-year Unitaid grant for the development and delivery of new paediatric HIV treatment formulations. The event will be followed by an extended virtual reality film screening for interested staff at the Global Health Campus from 11:30-14:00, aided by students from the International School
- [Partnering to address the needs of neglected patients in India and globally](https://dndi.org/events/2018/partnering-address-needs-of-neglected-patients-india-globally/) - Taking an end-to-end approach, from new chemical entities to patient access DNDi in India is organizing a 15 year anniversary celebration event in New Delhi, India on . The event will share DNDi’s journey in last 15 years, its achievements in the field of neglected diseases, and discuss opportunities for R&D and innovation for neglected patients. On
- [MedTrop 2016](https://dndi.org/events/2016/2016-medtrop/) - Doenças urbanas e mundiais DNDi actively participated in the 52nd Congress of the Brazilian Society of Tropical Medicine. DNDi was part of the scientific committee and also coordinated two round table discussions: New epidemiology of Chagas disease and Access barriers for neglected patients. DNDi also presented three posters at the event. Posters More information: ProgrammeMedTrop
- [EFMC-ISMC 2016](https://dndi.org/events/2016/efmc-ismc-2016/) - XXIV EFMC International Symposium on Medicinal Chemistry EFMC-ISMC 2016 presented the most recent advances in lead identification and optimization strategies, drug design and profiling technologies. Benjamin Perry, Project Manager NTD Drug Discovery Booster, and Charles Mowbray, Head of Drug Discovery, co-authored a poster about the NTD Drug Discovery Booster presented at the symposium. Poster *
- [TICAD 6 Post-Event ICREP-NTDs](https://dndi.org/events/2016/ticad-6-post-event-icrep-ntds/) - International Collaborative Research Program for Tackling the NTDs Challenges in African Countries This international Joint Symposium was organized in order to promote infectious disease research cooperation between Africa and Japan. Monique Wasunna, Director, DNDi Africa and Tatsuro Kuzuki, Scientific Liaison, DNDi Japan presented at the event. Post-Event ICREP-NTDs More information: Event flyer
- [The 7th APS International PharmSci 2016](https://dndi.org/events/2016/the-7th-aps-international-pharmsci-2016/) - Pharmaceutical Sciences: Improving World Health APS International PharmSci is the leading UK Pharmaceutical Science conference and has firmly established itself as the premier pharmaceutical science event in the UK. Steve Robinson, Head of Pharmaceutical Development at DNDi, presented on neglected diseases. Presentation More information: ProgrammePharmSci 2016 website
- [4th Joint Scientific Meeting HAT Platform - EANETT](https://dndi.org/events/2016/4th-sci-meeting-hat-eanett/) - The 4th Joint Scientific Meeting HAT Platform - EANETT is taking place on September 20-22. Topics are based on the elimination of human African trypanosomiasis. Antoine Tarral, Head of HAT Clinical Program, DNDi, Christelle Perdieu, Clinical Project Manager, DNDi and Olaf Valverde, Medical Manager, DNDi, presented at the event. Presentations
- [XIX International Congress of Tropical Medicine and Malaria](https://dndi.org/events/2016/itcmm2016/) - ICTMM Brisbane, AustraliaThe 19th International Congress of Tropical Medicine and Malaria. The International Congress on Tropical Medicine (ICTM) was founded in London in 1913 and has developed a rich history over the past 100 years. Robert Don, Discovery & Preclinical Director, DNDi and Eduard Ziljstra, Senior Consultant, DNDi presented at this event. Symposium DNDi-MMV Special
- [10º ENIFarMed](https://dndi.org/events/2016/10-enifarmed/) - Encontro Nacional da Inovação em Fármacos e Medicamentos The 10th ENIFarMed event focused on access to medicines by exploring public access policies. Joël Keravec, Regional Executive Director, DNDi Latin America, Carolina Batista, Head of Access and Medical Affairs, DNDi Latin America and Jadel Kratz, Lead Optimization Latin America Coordinator, DNDi Latin America took part in the event.
- [EDCTP Forum](https://dndi.org/events/2016/edctp-forum-8th-zambia/) - European & Developing Countries Clinical Trials Partnership The Eighth EDCTP Forum will be held from 6-9 November 2016 in Lusaka, Zambia. The theme of the Forum is Defeating poverty-related and neglected diseases in Africa: harnessing research for evidence-informed policies. The EDCTP Forum is a biennial event that provides an international platform for the presentation and
- [CIPIP](https://dndi.org/events/2016/cipip/) - 8th International Congress on Infectious and Parasitic Diseases The 8th International Congress on Infectious and Parasitic Diseases (CIPIP) was co-organized by INRB, the DRC’s National Institute of Biomedical Research and The Institute of Tropical Medicine in Antwerp, Belgium (ITM). The main theme of the congress was based around the issues of infectious diseases, co-morbidities,
- [The 7th KASH Conference](https://dndi.org/events/2016/7-kash-conference-kemri/) - KEMRI Annual Scientific and Health Conference The theme of the 7 th annual KASH conference was about investing in health, through the strengthening of country health systems towards the prevention and control of diseases. Gina Ouattara, Project Coordinator for HIV/HCV, and Kevin Onyango, Project Coordinator for Mycetoma, both from the DNDi Africa office, presented at
- [Prince Mahidol Award Conference 2017](https://dndi.org/events/2016/pmac-2017/) - Assessing the health of vulnerable population for an inclusive society Marc Lallemant, Head of Paediatric HIV Program at DNDi spoke at the event and Jean-Michel Piedagnel, Head of DNDi South East-Asia Regional Office hosted a Q&A session. The conference brought together leading public health leaders and stakeholders from around the world to discuss high priority global
- [Academic Drug Discovery 2017](https://dndi.org/events/2017/academic-drug-discovery-2017/) - This event explored the current challenges and opportunities faced in academic drug discovery. Robert Don, Discovery & Preclinical Director, DNDi, spoke at the event. More information: Conference website
- [13th Conference on Vectors and Vector Borne Diseases](https://dndi.org/events/2017/cvvbd2017/) - The conference showcased advances and good practices on vector borne diseases. Suman Rijal, Director of the DNDi Regional Office in India, presented at the event. Presentation Chair: R.K. Das Gupta
- [CROI 2017](https://dndi.org/events/2017/croi-2017/) - The conference brought together top researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. DNDi took part in an oral presentation on the superboosting approach for children co-infected with HIV and tuberculosis. Oral Presentation * Presenting author More
- [ISNTD Festival](https://dndi.org/events/2017/isntd-festival/) - International Society for Neglected Tropical Diseases Festival DNDi was a patron of this unique event aimed at bringing creative industries together for global health and change. James Arkinstall, DNDi's Head of Communications & Advocacy, presented on the fundraising campaign for sleeping sickness with the Huffington Post. The DNDi film Mycetoma: Hope for a devastating neglected
- [ECCMID 27<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases](https://dndi.org/events/2017/eccmid-27th-european-congress-of-clinical-microbiology-and-infectious-diseases/) - The world’s leading experts came together to discuss the latest developments in infectious diseases, infection control and clinical microbiology. DNDi participated in the event. More information: Congress website
- [British Society for Parasitology: Spring Meeting 2017](https://dndi.org/events/2017/bsp-spring-meeting-2017/) - This event hosted an integrated programme united veterinarians, epidemiologists, therapeutics, and molecular sciences focusing on parasitology and research.Charles Mowbray, Head of Drug Discovery at DNDi presented on catalyzing R&D for neglected diseases. More information: Programme
- [EASL - The 4th International Liver Congress](https://dndi.org/events/2017/easl-2017/) - The International Liver Congress™ (ILC) is the annual meeting of the European Association for the Study of the Liver. Isabelle Andrieux-Meyer, HIV/HCV Team Leader, DNDi, took part in the event. More information: Conference websiteScientific programme
- [253rd American Chemical Society National Meeting and Exposition](https://dndi.org/events/2017/acs-national-meeting/) - The event focuses on advanced materials, technologies, systems and processes. Benjamin Perry, Open Innovation Senior Manager, Discovery at DNDi presented on the NTD Drug Discovery Booster.
- [Tackling TB: Bridging the Divide Between Innovation and Access](https://dndi.org/events/2017/tackling-tb-bridging-the-divide-between-innovation-and-access/) - Leaders in global health tackled the issues surrounding TB, in a conference organized by the McGill chapter of Universities Allied for Essential Medicines (UAEM-McGill), in honour of World TB Day. Rachel Cohen, Head of the DNDi office in North America, took part in a panel discussion on access to treatment. More information: Meeting websiteNewsletter
- [Scientific Day of Humanitarian and Solidarity Health](https://dndi.org/events/2017/medecins-du-monde-scientific-day/) - Médecins du Monde organized the third scientific day. This annual exchange on the issues of health, precariousness and humanitarian action in France and internationally, aimed to highlight the results of research and innovation in the medical field. Pascale Boulet, IP & Policy Advisor at DNDi, spoke at the event. More information: Conference website
- [ISNTD Chagas Disease Roundtable](https://dndi.org/events/2017/isntd-chagas/) - ISNTD Chagas brought together the R&D community, patient advocates, experts in the field, civic groups and policy makers in a dynamic engagement to heighten awareness around Chagas disease with influential stakeholders in the U.S. Colin Forsyth, Chagas Epidemiologist at DNDi North America, presented in an R&D session and took part in a Chagas disease Q&A
- [NTD Summit 2017](https://dndi.org/events/2017/ntd-summit-2017/) - This year marked the fifth anniversary of the World Health Organization's roadmap on NTDs and the London Declaration. To celebrate this milestone, Uniting to Combat NTDs, the World Health Organization and the NTD community hosted the NTD Summit. Bernard Pécoul, Executive Director, and Wilfried Mutombo HAT Project Coordinator at DNDi, spoke at the event. Meeting
- [XIII Workshop on Chagas disease](https://dndi.org/events/2017/xiii-workshop-on-chagas-disease/) - Advances in the treatment and care of patients with Chagas disease In collaboration with DNDi, the XII edition of the Chagas Workshop gathered together international experts to discuss the latest advances in the diagnosis and treatment of the disease. Sergio Sosa Estani, Fabiana Barreira, Carolina Batista and Isabela Ribeiro from DNDi, participated at the event.
- [Fair Pricing Forum 2017](https://dndi.org/events/2017/fair-pricing-forum-2017-2/) - Organized by the World Health Organization in collaboration with the Dutch Ministry of Health, the Fair Pricing Forum was held to discuss options for a fairer pricing system, that is sustainable for both health systems and innovation challenges to access and how to move forward. DNDi participated in the event. More information: Forum websiteMeeting report
- [Accès aux médicaments pour tous : des solutions existent !](https://dndi.org/events/2018/acces-aux-medicaments-pour-tous-des-solutions-existent/) - Organized by the AFD (Agence Française de Développement), the objective of the event is to discuss how to make medical innovation accessible for all. Discussion Time: 17:30-19:30Venue: Amphithéâtre du Mistral Moderator: Gaël Giraud, Chef économiste à l’Agence Française de Développement More information: AFD Research Paper about DNDiEvent website
- [Sixth International Conference on Mycetoma](https://dndi.org/events/2018/sixth-international-conference-on-mycetoma/) - The Sixth International Conference on Mycetoma is organized by the Mycetoma Research Centre, University of Khartoum in partnership with the World Health Organisation and the Global Mycetoma Working Group. DNDi is co-sponsoring the event. Sessions Mycetoma international collaboration Date: Saturday, 16 February 2019Time: 11:00-12:30 Chairs: Naeema Al Gasseer, WR-Sudan, SudanMonique Wasuna, Director DNDi AfricaAfia Zafar, Department of
- [4th National Hepatitis Conference 2019](https://dndi.org/events/2019/4th-national-hepatitis-conference-2019/) - Organized by the Gastroenterology & Hepatology Unit, Ampang Hospital, the theme of the 4th National Hepatitis Conference 2019 is "Towards eliminating viral hepatitis". Panel discussion Collaborative R&D Model – Malaysia, world leaders in Hepatitis C Date: Thursday, 7 March 2019Time: 9:00 Moderator: Meera Sivasothy, General Manager, BFM Presentation Date: Thursday, 7 March 2019Time: 15:20
- [MedTrop 2019](https://dndi.org/events/2019/medtrop-2019/) - Congress of the Brazilian Society of Tropical Medicine The Brazilian Society of Tropical Medicine (SBMT) organizes its annual meeting on the theme “Convergence and inclusion: In search of sustainable solutions for the diagnosis, treatment and control of tropical diseases”. The XXXIV Annual Meeting of Applied Research in Chagas Disease and the XXII Annual Meeting of Applied Research in
- [Global Challenges Seminar: Innovation in Global Health Crises](https://dndi.org/events/2019/global-challenges-seminar-innovation-global-health-crises/) - This Global Challenges Seminar organized by WIPO Re:Search entitled Urgent Innovation – Policies and Practices for Effective Response to Global Health Crises aimed to bring together experts in R&D, policy, and delivery to discuss around this issue. Discussion More information: Event website
- [TICAD7](https://dndi.org/events/2019/ticad7/) - The 7th Tokyo International Conference on African Development (TICAD7) is organized by the Government of Japan and co-hosted by the United Nations, the United Nations Development Programme (UNDP), the World Bank, and the African Union Commission (AUC). The theme of the conference is "Advancing Africa's Development through People, Technology and Innovation". Symposium Africa will be
- [Scaling up synergies between the Global Fund and innovators to break down barriers to health innovation for the most vulnerable](https://dndi.org/events/2019/scaling-up-synergies-global-fund-and-innovators/) - Ahead of the Global Fund's Sixth Replenishment Conference, this event will bring together influential speakers and participants to discuss how synergistic investments in the Global Fund and in research and development can translate into accelerated delivery of innovative health tools which are affordable and accessible to the most vulnerable populations, thus saving many more lives and
- [World Health Summit 2019](https://dndi.org/events/2019/world-health-summit-2019/) - The World Health Summit is the annual conference of the M8 Alliance of Academic Health Centers, Universities and National Academies (25 members, 18 countries). This annual gathering aims to improve global health through collaboration and open dialogue to advance research, education, healthcare, and policy outcomes. The World Health Summit brings together researchers, physicians, key government
- [Chimie et Nouvelles Thérapies](https://dndi.org/events/2019/chimie-et-nouvelles-therapies/) - Organized by the "Fondation de la Maison de la Chimie", this event aims to discuss medical innovation and the role of chemistry in the development of innovative treatments. Discussion Time: 09:00-18:00Venue: Amphithéâtre Lavoisier, Maison de la Chimie More information: Website
- [3rd World Conference on Access to Medical Products](https://dndi.org/events/2019/3rd-world-conference-access-medical-products/) - The theme of the 3rd World Conference on Access to Medical Products is "Achieving the SDGs 2030". Sessions Incentives for development of antibiotics, global AMR R&D Hub Date: Tuesday, 19 November 2019Time: 14:30-15:45 Medical products for end game for HIV/AIDS, tuberculosis, malaria Date: Wednesday, 20 November 2019Time: 14:30-16:00 More information: Website
- [Guest Speaker Series at the International School of Geneva](https://dndi.org/events/2019/guest-speakers-series-international-school-geneva/) - Geneva, Switzerland​ The International School of Geneva invites guest speakers to discuss various topics such as environmental issues, race relations, human and civil rights, conflict and reconciliation, or science. Speaker More information: Event websiteRegistration
- [Democratic Republic of the Congo's National Sleeping Sickness Day](https://dndi.org/events/2020/drc-national-sleeping-sickness-day/) - The Swiss Tropical and Public Health Institute organizes a stakeholder roundtable on the occasion of the Democratic Republic of the Congo's National Sleeping Sickness Day, a local initiative that brings together international partners to concert efforts in the elimination of this NTD in DRC. Participation More information: Event website
- [World Health Summit 2017](https://dndi.org/events/2017/world-health-summit-2017/) - The World Health Summit is the annual conference of the M8 Alliance of Academic Health Centers, Universities and National Academies. Through the Inter Academy Medical Panel (IAMP), it is organized in collaboration with national academies of science in more than 97 countries. Monique Wasunna, Director of DNDi Africa, presented on strengthening capacity for visceral leishmaniasis clinical research
- [ECTMIH 2017](https://dndi.org/events/2017/ectmih-2017/) - 10th European Congress on Tropical Medicine and International Health The main objective of ECTMIH 2017 was to provide a platform for state-of-the-art updates and recent breakthroughs in the field of tropical medicine and global health. DNDi presented on sleeping sickness, visceral leishmaniasis, mycetoma, and onchocerciasis. Download DNDi@ECTMIH flyer Symposium Phase II/III results for fexinidazole, the
- [COR-NTD - 2017](https://dndi.org/events/2017/cor-ntd-2017/) - The aim of the Coalition for Operational Research on NTDs COR-NTD event is to create new synergies within the operational research arena for NTDs and align that research with the programme needs. Colin Forysyth, Epidemiologist, DNDi North America, presented on Chagas disease. Presentation More information: Event webpage
- [Realist 2017](https://dndi.org/events/2017/realist-2017/) - International Conference for Realist Research, Evaluation and Synthesis: From Promise to Practice The aim of the conference was to continue the tradition of building a community of practice, sharing and discussing methods for use in realist approaches. Janice Lee, and Olawale Salami, DNDi presented on the paediatric HIV RELIVING Study. Presentation New therapeutic research for
- [World Hepatitis Summit](https://dndi.org/events/2017/world-hepatitis-summit/) - The World Hepatitis Summit is a large-scale, global biennial event with the goal of advancing the viral hepatitis agenda. It is a joint initiative between World Health Organization (WHO) and the World Hepatitis Alliance. Francisco Viegas Neves da Silva, Regional Policy Advocacy Consultant, DNDi Latin America, presented on the DNDi strategy on access to hepatitis
- [SEMTSI 2017](https://dndi.org/events/2017/semtsi-2017/) - X National Congress of Tropical Medicine and International Health The event aims to guide both tropical medicine and international health. The motto of the 10th edition of the congress was 'The road to the elimination of NTDs in the 2020 horizon'. Representatives from DNDi and GARDP took part in the event. Parallel Sessions Elimination of
- [AASLD The Liver Meeting®](https://dndi.org/events/2017/aasld-liver-meeting/) - American Association for the Study of Liver Diseases The Liver Meeting® provided a forum for the exchange of groundbreaking basic, translational and clinical research in diseases of the liver and biliary tract and in liver transplantation. This meeting aimed to create an arena for the presentation and interchange of opinions on state-of-the-art care and management
- [ASTMH 2017](https://dndi.org/events/2017/astmh-2017/) - 66th Annual Meeting This annual meeting is designed for researchers, professors, government and public health officials, military personnel, travel clinic physicians, practicing physicians in tropical medicine, students and all health care providers working in the fields of tropical medicine, hygiene and global health. DNDi took part in symposia, poster and oral presentation sessions at the
- [Argentine Society of Protozoology & Society of Experimental Pharmacology and Others](https://dndi.org/events/2017/argentine-society-of-protozoology-society-of-experimental-pharmacology-and-others/) - This Joint Meeting was the result of the convergence and effort of ten Scientific Societies of Argentina, all of each with its history, its difficulties and its merits. These Societies decided to create an interdisciplinary space with the objective of broadening their scientific horizons in the field of Life Sciences that integrates the participation of
- [II International Symposium on Biological Sciences](https://dndi.org/events/2017/ii-international-symposium-on-biological-sciences/) - Sergio Sosa-Estani, Head of Chagas at DNDi, presented on Chagas disease. Presentation The current landscape for new treatments on Chagas diseaseSergio Sosa-Estani, DNDi Latin America More information: Event website
- [Lutte contre les maladies tropicales négligées : Conférence–débat](https://dndi.org/events/2017/lutte-contre-les-maladies-tropicales-negligees/) - The International Solidarity Office from the Republic and Canton of Geneva in collaboration with Geneva University Hospitals (HUG) hosted a conference on neglected tropical diseases. Bernard Pécoul, DNDi‘s Executive Director, presented on the prospects of sleeping sickness elimination. Presentation More information: Event flyer
- [GHIT R&D Forum](https://dndi.org/events/2017/ghit-rd-forum/) - GHIT has facilitated international product development partnerships between Japanese and non-Japanese entities with the goal of leveraging Japan’s unique capabilities and innovations to accelerate global health innovation. The forum's aim is to create opportunities for GHIT’s development partners to share project overviews, R&D progress to date, and lessons learned. DNDi presented at the event on the NTD Drug Discovery Booster,
- [FLAP XXIV Latin American Parasitology Congress](https://dndi.org/events/2017/flap-xxiv-latin-american-parasitology-congress/) - Organized by the Chilean Society of Parasitology (SOCHIPA), this event brought together scientists in the field of parasitology. Sergio Sosa-Estani, Head of Chagas, DNDi Latin America presented on Chagas disease at the event. Workshop Diagnóstico y Tratamiento de la Enfermedad de Chagas Accesible a Escala Gobal Date: Tuesday, December 12, 2017Chair: Roberto Salvatella, OPS-OMS, Uruguay Pre-Congress Course
- [UHC Forum 2017](https://dndi.org/events/2017/uhc-forum-2017/) - The Universal Health Coverage (UHC) forum aimed to galvanize the health sector, countries, development partners, civil society, and the private sector towards the common goal of UHC. It was jointly organised with the Government of Japan, the World Bank, the World Health Organization, the United Nations Children's Fund (UNICEF), and UHC2030. DNDi co-hosted a side event on NTDs. Side
- [Chagas Symposium IC-18](https://dndi.org/events/2018/chagas-symposium-ic-18/) - The Department of Infectious Disease Epidemiology at Imperial College London in collaboration with Princeton University and the Pan American Health Organization (PAHO) is convening a symposium funded by the Neglected Tropical Disease Modelling Consortium. The aim of the symposium is to define challenges and research priorities, explore opportunities, develop collaborations, and build strategies towards control
- [The 8th KASH Conference](https://dndi.org/events/2018/8th-kash-conference/) - KASH is the KEMRI Annual Scientific and Health annual conference. The theme of this year's edition is health research for sustainable development. The conference is open to research scientists, health professionals and diploma, graduate and postgraduate students undertaking scientific and health related causes. Session HIV Date: Wednesday 14 February 2018Time: 14:00 - 16:30Venue: Cub Room Chair: Raphel Lihana, Center
- [3rd National Conference of Society of Internal Medicine of Nepal](https://dndi.org/events/2018/3rd-national-conference-of-society-internal-medicine-nepal/) - The theme of the 3rd National Conference of Society of Internal Medicine of Nepal is 'Journey against tropical infection: where and how Nepal stands?' Presentation Date: Friday 16 February 2018Time: 11:25 - 12:05Venue: Hotel Asiatique More information: Website
- [25th LEAP Platform Meeting](https://dndi.org/events/2018/25th-leap-platform-meeting/) - The theme of the 25th LEAP Platform Meeting is “Improving Access to Treatments for Leishmaniasis Patients through Partnerships". Opening session Date: Wednesday, 3 October 2018Time: 8:30-9:00 Sessions LEAP@15 – The past, the present & the future Time: 9:00-10:40 Chairs: Eltahir Khalil Gasim, Institute of Endemic Diseases (IEND), University of Khartoum, Sudan & Nathalie Strub-Wourgaft, NTD Director,
- [ISGlobal XIV Taller sobre la enfermedad de Chagas](https://dndi.org/events/2018/isglobal-xiv-taller-sobre-chagas/) - Organized by the Institute for Global Health Barcelona (ISGlobal), this workshop's objective is to discuss the advances in the prevention of Chagas disease. Presentation Date: 7 March 2018Time: 9:30-10:30Venue: Sala Paranimf, Barcelona University Annual Meeting Chagas Coalition Date: 7 March 2018Time: 14:30-15:00Venue: Facultad de Medicina, Barcelona University More information: ISGlobal workshop websiteProgrammeChagas Coalition website
- [Batsheva de Rothschild Seminar on Frontiers in Parasitology](https://dndi.org/events/2018/batsheva-rothschild-seminar-frontiers-in-parasitology/) - The Frontiers in Parasitology conference gathers leading scientists from around the world working in the parasitology field to share their latest findings in molecular and translational advances and to synthesize knowledge to drive future research agendas. Novel collaborative R&D networks for neglected tropical diseases in endemic areas - the case of DNDi Lead Optimization Latin
- [CROI 2018](https://dndi.org/events/2018/croi-2018/) - The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. Effectiveness and safety of LPV/R pellets'-based art in children: 48-week analysisAndrieux-Meyer I, Salami
- [3rd Colombian Meeting on Leishmaniasis and Chagas](https://dndi.org/events/2018/3rd-colombian-meeting-leishmaniasis-chagas/) - The Colombian meeting on leishmaniasis and Chagas is an annual event organized by the Universities of Antioquia and los Ande. The 3rd edition will happen at the same time as the XVI PECET Symposium on advances in the research of tropical diseases. Oral Presentation Date: Thursday 22 March 2018Time: 8:15 - 9:00Venue: Edificio de Extensión, University of Antioquia
- [AFRAVIH 2018](https://dndi.org/events/2018/afravih-2018/) - AFRAVIH organizes its 9th International Francophone Conference on HIV and Hepatitis. Panel Discussion Assurer le traitement et le suivi du VIH/sida : vers une approche intégrée et axée sur les besoins du patient Date: Wednesday, 4 April 2018Time: 16:15Venue: Amphitéâtre B Side Session Date: Saturday, 7 April 2018Time: 9:30Venue: Salle E *Presenting author More information:
- [ISNTD Festival 2018](https://dndi.org/events/2018/isntd-festival-2018/) - The International Society for Neglected Tropical Diseases organizes ISNTD Festival to help complex public health messages reach patients, the public, and global health professionals worldwide. Film More information: ISNTD Festival websiteList of films submittedProgramme
- [Geneva Health Forum](https://dndi.org/events/2018/geneva-health-forum-2018/) - 7th Edition: Precision Global Health in the Digital Age The Global Health Forum (GHF) is the forum for innovative practices in global health. Plenary Talk Emerging infectious diseases crisis Date: Thursday, 12 April 2018Time: 9:00 - 10:30 Parallel Session Are neglected tropical diseases affected by ehealth? Date: Tuesday, 10 April 2018Time: 16:00 - 17:30 Chair:
- [28th European Congress of Clinical Microbiology and Infectious Diseases](https://dndi.org/events/2018/eccmid-2018/) - The ECCMID congress gathers leading experts in infectious diseases, infection control, and clinical microbiology to present and discuss the latest results. Session Africa & Middle East Date: Saturday, 21 April 2018 Time: 11:00-13:00Venue: Hall B Chairs: Eskild Petersen, Editor-in-Chief, International Journal of Infectious Diseases, Aarhus University Hospital, DenmarkAmel Letaief, Department of Internal Medicine and Infectious Diseases
- [DIA Europe 2018](https://dndi.org/events/2018/dia-europe-2018/) - DIA Europe 2018 is unique in presenting the entire health care value chain ranging from policy and regulations to R&D, marketing, and access. Keynote Panel Towards access 2030: How can strengthening of regulatory systems contribute? Date: Tuesday, 17 April 2018 Time: 9:00-10:30 Session Chair: Petra Dörr, Deputy Executive Director, Swissmedic, Switzerland More information: Event website
- [The International Liver Congress 2018](https://dndi.org/events/2018/the-international-liver-congress-2018/) - The International Liver Congress™ (ILC) is the annual meeting of the European Association for the Study of the Liver. Presentation Date: Thursday, 12 April 2018 * Presenting author More information: Event websiteOnline programme
- [11èmes journées scientifiques du Réseau Francophone de Métabolomique et Fluxomique](https://dndi.org/events/2018/journees-scientifiques-rfmf/) - The Réseau Francophone de Métabolomique et Fluxomique (RFMR) organizes its yearly meeting on the application of metabolomics and fluxomics in different fields including health. Poster More information: Event website
- [IV Simpósio Brasileiro de Doenças Negligenciadas](https://dndi.org/events/2018/iv-simposio-brasileiro-de-doencas-negligenciadas/) - The Brazilian Symposium on Neglected Diseases (SBDN) was launched in 2014, from the need to discuss leishmaniasis. The objective of the fourth edition is to reestablish the bridge between universities and public and private health administration. Presentation Date: Friday, 25 May 2018Time: 14:20 More information: Event website
- [MSF Scientific Days 2018](https://dndi.org/events/2018/msfscientificdays2018/) - The MSF Scientific Days share the knowledge of what works in humanitarian medical programming. The aim is to help improve the quality of care provided to patients and populations by sharing research conducted in field programmes. Poster Presentation Virological outcomes, safety, and acceptability of LPV/r pellets-based ART in young children: 48-Week interim analysis of the
- [PAGE 2018 Meeting](https://dndi.org/events/2018/page-meeting/) - The Population Approach Group in Europe (PAGE) represents a community with a shared interest in data analysis using the population approach. Poster Presentation *Presenting author More information: Event website
- [XXXVI Congreso Nacional de Cardiología 2018](https://dndi.org/events/2018/xxxvi-congreso-nacional-cardiologia-2018/) - The Argentinian Cardiology Federation organizes their annual National Congress of Cardiology. Session Etiological treatment on chronic phase of Chagas disease Date: Saturday, 2 June 2018 More information: Event website
- [ISNTD Festival 2019](https://dndi.org/events/2019/isntd-festival-2019/) - The ISNTD Festival brings together the best in communication, arts, entertainment and science to help complex public health messages reach patients, the public and global health professionals worldwide. Film More information: Event website
- [Biotech Outsourcing Strategies 2018](https://dndi.org/events/2018/biotech-outsourcing-strategies-2018/) - Biotech Outsourcing Strategies is a new partnering event for both stakeholders of CMC outsourcing and pharmaceutical discovery outsourcing. Session Technical operations outsourcing – Target ID & validation to hit identification Date: Tuesday, 19 June 2018Time: 14h00 Chair: Sergio Lociuro, CSO, BioVersys AG, Switzerland More information: Event website
- [ISNTD <em>d³</em> 2018](https://dndi.org/events/2018/isntd-d³/) - The 2018's ISNTD d³ event focuses on recent developments, gaps, and future needs of paediatric drug discovery, treatments, and diagnostics in context of global health as well as broader challenges. Sessions Pipeline, platforms & current gaps in treatment for diseases of poverty Date: Monday 25 June 2018Time: 9:15Venue: Institute of Child Health Redefining Access to Medicines Time: 16:00Chair:
- [9ème Congrès International sur la Pathologie Infectieuse et Parasitaire (CIPIP)](https://dndi.org/events/2018/cipip-2018/) - The theme of the 9th International Congress on Infectious Pathology and Parasites (CIPIP) is "Co-morbidity, global health, and environment". Presentation Poster *Presenting author
- [2nd International Conference on Global Challenges in NTDs](https://dndi.org/events/2018/gcntd-2018/) - The theme of the second International Conference on Global Challenges in Neglected Tropical Diseases (GCNTD 2018) is "United to eradicate the global threat of Neglected Tropical Diseases". Presentation Date: Tuesday, 26 June 2018Time: 10:55-11:15 More information: Event websiteProgramme
- [Swiss Pharma Science Day 2018](https://dndi.org/events/2018/swiss-pharma-science-day/) - Organized by the Swiss Academy of Pharmaceutical Sciences (SAPhS), the meeting's objective is to foster scientific exchange. Poster Presentation *Presenting author More information: Event websiteProgramme
- [Forum Entwicklung](https://dndi.org/events/2018/forum-entwicklung/) - Co-organized by Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ), Frankfurter Rundschau, and hr-iNFO, the theme of the forum is "Pills for the poor - medical care in developing countries". Discussion Time: 18:30Location: Saalbau Südbahnhof Moderator: Tobias Schwab, Editor, Frankfurter Rundschau, Germany More information: Event website
- [22nd International AIDS Conference](https://dndi.org/events/2018/aids2018/) - The International AIDS Conference brings together science, leadership, and community to advance treatment and prevention of HIV. You can find DNDi in the Exhibition Hall at Booth #215! DNDi @ AIDS 2018 Side Event Diagnose, Treat, Innovate: A paradigm shift for ending paediatric AIDS Co-organized by the African Society for Laboratory Medicine (ASLM), the Clinton
- [18th World Congress of Basic and Clinical Pharmacology](https://dndi.org/events/2018/wcp-2018/) - The 18th World Congress of Basic and Clinical Pharmacology (WCP 2018) is organized by the Japanese Pharmacological Society (JPS) and the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT). The congress main theme is "Pharmacology for the Future: Science, Drug Development and Therapeutics". Session All for Global Health, Global Health for All Date: Wednesday, 4 July
- [Affordable Medicines Now](https://dndi.org/events/2018/affordable-medicines-now/) - Affordbale Medicines Now is a training conference designed to build skills, knowledge, and community among the activists who power the movement for affordable medicines at the state, federal, and international levels. Session How to Survive Pharma Profiteering - Lessons from Global Struggles for Affordable Medicines Date: Friday, 29 June 2018Time: 9:00
- [20th Congress of the International Society for Human and Animal Mycology](https://dndi.org/events/2018/20th-isham/) - Congresses of the International Society for Human and Animal Mycology (ISHAM) are held every three years and provide clinicians, scientists, and students an opportunity to meet at an international forum dedicated to the study of medical mycology. The 20th ISHAM is co-hosted by the Netherland Society of Medical Mycology (NVMy). Parallel Session Closing the mycetoma knowledge
- [22nd International Mass Spectrometry Conference](https://dndi.org/events/2018/imsc-2018/) - The International Mass Spectrometry Conference (IMSC) is organized by the Division of Mass Spectrometry (DSM) of the Italian Chemical Society. Poster More information: Event websiteProgramme
- [14th ICOPA: International Congress of Parasitology](https://dndi.org/events/2018/icopa2018/) - The 14th International Congress of Parasitology (ICOPA 2018) is an opportunity for participants to share information in the areas of parasitology, under the theme “Parasites: harms and benefits”, including discussions on the possible scientific use of parasites. Session The need for new treatments for filariasis to ensure that no-one is left behind Date: Friday, 24
- [MedTrop 2018](https://dndi.org/events/2018/medtrop/) - Congress of the Brazilian Society of Tropical Medicine The Brazilian Society of Tropical Medicine (SBMT) organizes its annual meeting on "Communicable Diseases: Prediction and challenges for coping with new and old epidemics". The XXXIII Annual Meeting of Applied Research in Chagas Disease and the XXI Annual Meeting of Applied Research in Leishmanioses, commonly called ChagasLeish is held at
- [Swiss Chemical Society Fall Meeting](https://dndi.org/events/2018/swiss-chemical-society-fall-meeting/) - Organized by the Swiss Chemical Society (SCS), the meeting gathers together chemists to discuss their research initiatives. Poster Presentation *Presenting author More information: Event website
- [Ninth EDCTP Forum](https://dndi.org/events/2018/ninth-edctp-forum/) - The theme of the ninth EDCTP Forum, held in partnership with the Portuguese Foundation for Science and Technology and the Calouste Gulbenkian Foundation, is "Clinical research and sustainable development in sub-Saharan Africa: the impact of North-South partnerships". Symposia Synergies between diagnostics and treatment studies in human African trypanosomiasis: Examples of collaboration from the DiTECT-HAT and HAT-r-ACC
- [5th Joint Scientific Meeting HAT Platform - EANETT](https://dndi.org/events/2018/5th-joint-scientific-meeting-hatplatform-eanett/) - The theme of the 5th Joint Scientific Meeting HAT Platform-EANETT is “Research and control activities challenges in keeping HAT below the elimination threshold beyond 2020”. Sessions NTD Elimination: The progress of HAT and new treatment perspectives Date: Wednesday, 3 October 2018Time: 9:45-11:20 Chairperson: Abdoulaye Diarra, Regional Office for Africa, World Health OrganizationDeputy Chairman: Imna Malele, Vector & Vector-Borne
- [Onchocerciasis Network Meeting](https://dndi.org/events/2018/onchocerciasis-network-meeting/) - The Onchocerciasis Research Network Meeting took place during the 11th DNDi Partners' Meeting. Opening Date: Wednesday, 3 October 2018Time: 08:00-8:15Venue: Room Royal, Speke Resort and Conference Centre Sessions Onchocerciasis in Africa Time: 08:15-10:45 Platforms and Research Centres: Sharing experiences Time: 11:00-14:30 Current research landscape in onchocerciasis - Part 1 Time: 14:30-15:30 Current research landscape in onchocerciasis - Part 2 Date: Thursday,
- [National Regulatory Conference (NRC) 2018](https://dndi.org/events/2018/nationalregulatoryconference/) - The theme for the 2018 edition of the National Regulatory Conference conference is “’Regulatory excellence: the new normal’”. Presentation Date: Tuesday, 2 October 2018Time: 14:30-15:00 Forum discussion How to improve collaborative efforts between regulators & stakeholders Date: Tuesday, 2 October 2018Time: 16:00-17:00 Moderator: Ramli Zainal, Director, National Pharmaceutical Regulatory Agency (NPRA), Malaysia More information:
- [11th DND<em>i</em> Partners' Meeting: From innovation to access in Africa - the way forward](https://dndi.org/events/2018/11th-dndi-partners-meeting/) - DNDi organized several days of meetings with partners from 3-5 October 2018 in Kampala, Uganda. These began with annual disease-specific research platform and network meetings and culminate in the XIth DNDi Partners' Meeting on the afternoon of . 5th Joint Scientific Meeting HAT Platform – EANETT 25th LEAP Platform Meeting Onchocerciasis Network Meeting Paediatric HIV
- [Paediatric HIV Stakeholders' Meeting](https://dndi.org/events/2018/paediatric-hiv-stakeholders-meeting/) - The 2018 Paediatric HIV Stakeholder's Meeting brings together key partners of DNDi to discuss vital issues concerning access to ART adapted to the needs of infants and young children living with HIV, their families, and their caregivers. Opening Date: Wednesday, 3 October 2018 Time: 09:00-09:20 Venue: Speke Resort, Munyonyo, Kampala, Uganda Opening speech and meeting objectives
- [International Conference on Innovations for the Elimination and Control of Visceral Leishmaniasis (IEC-VL)](https://dndi.org/events/2018/iec-vl-conference/) - The major objective of the International Conference on Innovations for the Elimination and Control of Visceral Leishmaniasis (IEC-VL) is to bring together leading scientists from academia and industry around the world to deliberate upon new tools, new approaches, and routes to implementation. Session VL & PKDL– Current status from control to elimination Date: Wednesday, 28
- [ASTMH 2018](https://dndi.org/events/2018/astmh2018/) - 67th Annual Meeting The 67th American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting is designed for researchers, professors, government and public health officials, military personnel, travel clinic physicians, practicing physicians in tropical medicine, students and all health care providers working in the fields of tropical medicine, hygiene and global health. You can find DNDi at Booth
- [COR-NTD Annual Meeting](https://dndi.org/events/2018/cor-ntd-annual-meeting/) - Organized by the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD), the theme of the 2018 Annual Meeting is "Engage to Eliminate". Session Innovative strategies for the comprehensive transmission control and care of Chagas disease in health networks Date: Friday, 26 October 2018Time: 13:00-16:00 Chairs: Javier Sancho, Chagas Disease Global Coalition, and Sergio Sosa-Estani,
- [26th Young Research Fellows Meeting](https://dndi.org/events/2019/26th-young-research-fellows-meeting/) - This meeting, an initiative of the French Medicinal Chemistry Society (SCT), brings together young European scientists (PhD students, post-doctoral fellows and young academic/industrial confirmed researchers) and gives them the opportunity to present and discuss the latest innovations and future trends in Medicinal Chemistry. Poster presentation More information: Event website
- [10th NTD NGO Network Conference](https://dndi.org/events/2019/10th-ntd-ngo-network-conference/) - Organized by the Neglected Tropical Diseases NGO Network, the theme of the 10th edition of the conference is "Our Vision Beyond 2020: Many Partners, One Voice". Workshop National NTD advocacy networks: Uniting forces in support of the 2021-2030 NTD road map Date: Tuesday, 17 September 2019Time: 16.00 - 17.30 More information: Website
- [9th Brazilian Symposium on Medicinal Chemistry](https://dndi.org/events/2019/9th-brazilian-symposium-on-medicinal-chemistry/) - The Brazilian Symposium on Medicinal Chemistry (BrazMedChem) is a large scientific event dedicated to Medicinal Chemistry in Latin America. The theme of the 9th edition is "Bridging the gap between Academia and Pharmaceutical Industries for Advancing Drug Discovery". Session Open innovation Date: Monday, 2 September 2019Time: 11:00-12:40 More information: Event website
- [American Chemical Society National Meeting](https://dndi.org/events/2019/american-chemical-society-national-meeting/) - The theme of the 2019 American Chemical Society's national meeting is "Chemistry and Water". Poster presentation *Presenting authors More information: Event website
- [Gordon Research Conference: Medicinal Chemistry](https://dndi.org/events/2019/gordon-research-conference-medicinal-chemistry/) - The theme of the Gordon Research conference is "Therapeutically Targeted Small Molecules & Enabling Technologies in Drug Discovery". Poster presentation More information: Event website
- [MSF Scientific Days - Asia 2019](https://dndi.org/events/2019/msf-scientific-days-asia/) - MSF Scientific Days – Asia is a conference to showcase research, innovation, and experiences from treatment and humanitarian programmes across the region. Session Gearing up for the biggest fight - Drug resistance and expensive drugs Time: 13:15-14:25 Chair: Suman Rijal, Director DNDi in India More information: Event website
- [PAGE 2019 Meeting](https://dndi.org/events/2019/page-2019-meeting/) - The Population Approach Group in Europe (PAGE) represents a community with a shared interest in data analysis using the population approach. Posters More information: Event website
- [Epicentre Scientific Day 2019](https://dndi.org/events/2019/epicentre-scientific-day-2019/) - Each year, Epicentre organizes a Scientific Day during which their team of epidemiologist reports on the works of the previous year. The event brings together experts from other organizations as well to share knowledge and critical views on the practice of medicine and the stakes in humanitarian situations. Epicentre conducts field epidemiology activities, research projects
- [European Conferences on Biomedical Optics](https://dndi.org/events/2019/european-conferences-on-biomedical-optics/) - The European Conferences on Biomedical Optics brings together scientists, engineers, and clinicians who work with optics and photonics to solve problems in biomedicine. Poster presentation More information: Event website
- [Reaching the Last Mile Forum](https://dndi.org/events/2019/reaching-the-last-mile-forum/) - Reaching the Last Mile Forum is hosted by His Highness Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi, in partnership with the Bill & Melinda Gates Foundation. Under the overarching theme ‘Accelerating the Pace’, the Forum convenes more than 250 preeminent global leaders to tackle issues central to infectious disease elimination and
- [Workshop in Techniques and Technologies in Drug Discovery](https://dndi.org/events/2019/workshop-in-techniques-and-technologies-in-drug-discovery/) - The Workshop in Techniques and Technologies in Drug Discovery is a 3-day course on the drug discovery process. Presentation More information: Event website
- [35th ISCTRC Conference](https://dndi.org/events/2019/35th-isctrc-conference/) - The International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) 35th edition aims to discuss the impact of African trypanosomiasis on human and animal health, sustainable agriculture, and rural development in the face of challenges to sustainable investment in AAT control and HAT elimination. Sessions Diagnostic and treatment I Date: Tuesday, 24 September 2019Time: 14:30
- [Scientific Session at the Royal Academy of Medicine](https://dndi.org/events/2020/scientific-session-royal-academy-of-medicine/) - The Royal Academy of Medicine organizes a scientific session on 'Neglected tropical diseases and sustainable goals of the millennium: Therapeutic needs for their elimination by 2030'. Presentations Time: 18:30 Time: 18:55 More information: Royal Academy of Medicine website
- [Wellcome Centre for Anti-Infective Research at the University of Dundee](https://dndi.org/events/2019/wellcome-centre-for-anti-infective-research-at-the-university-of-dundee/) - The aim of the conference is to harness cross-disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate attrition rates for infectious diseases affecting low and middle income countries. Sessions The current situation Date: Sunday, 12 May 2019Time: 17:00-17:40 Clinical development and connectivity to the preclinical situation Date: Monday, 13 May 2019Time: 10:20-11:00
- [Keystone Conference 2018](https://dndi.org/events/2018/keystonesymposiaglobalhealth-drug-discovery-and-development/) - 21st Century Drug Discovery and Development for Global Health The conference is part of the Keystone Symposia Global Health Series and is supported by the Bill & Melinda Gates Foundation. Session New therapeutics for global health Date: Thursday, 18 October 2018Time: 8:30-10:00Location: Bordeaux I-II Importance of chemical diversity in seeking new leads Date: Friday, 19
- [Southern African HIV Clinicians Society Conference](https://dndi.org/events/2018/southern-african-hiv-clinicians-society-conference/) - The Southern African HIV Clinicians Society's mission is to promote evidence-based, quality HIV healthcare in Southern Africa.The conference focuses on HIV/AIDS clinical content. Session Date: Thursday, 25 October 2018 Time: 10:30 Infant testing: optimizing formulations Carol Ruffel, Head of South Africa Office, DNDi More information: Event website Programme
- [5th Symposium on Drug Design and Development for Neglected Diseases](https://dndi.org/events/2018/5th-symposium-on-drug-design-and-development-for-neglected-diseases/) - The 5th Symposium on Drug Design and Development for Neglected Diseases is organized by Prof. Elizabeth Igne Ferreira from the Pharmaceutical Sciences Department and the theme of the symposium is "Drug Repositioning and Medicinal Chemistry". Presentation Date: Monday, 29 October 2018Time: 12:30 More information: Event website
- [4th Scientific Meeting of ResNet NPND + Drug Discovery for Neglected Diseases International Congress 2018](https://dndi.org/events/2018/4th-scientific-meeting-resnet-npnd-drug-discovery-neglected-diseases-international-congress/) - The main objective of the Drug Discovery for Neglected Diseases International Congress is to present the latest advances in the field of discovery and development of drugs for the treatment of neglected diseases and other diseases that are relevant for public health in Argentina and worldwide. Presentation Date: Wednesday, 5 December 2018Time: 17:30-18:00 More information:
- [Launch of the 2018 G-FINDER Report](https://dndi.org/events/2018/launch-of-the-2018-g-finder-report/) - The Policy Cures Research organizes an event to launch the 2018 G-FINDER Report, marking 11 years of tracking investment into neglected disease R&D. The G-FINDER Report provides a detailed analysis of neglected disease R&D funding, including funding allocation across diseases and products, and funding trends over time. It is designed to help donors and funders better
- [14th International Conference on Vectors and Vector Borne Diseases](https://dndi.org/events/2018/international-conference-vectors-vectorbornediseases/) - Organized by the ICMR-Regional Medical Research Centre and the National Academy of Vector Borne Diseases (NAVBD), the theme of the 14th International Conference on Vectors and Vector Borne Diseases is "Vector borne diseases: evolution to elimination". DNDi India is sponsoring the event. Satellite Conference Research and development for vector borne diseases of elimination - Need
- [Unite Global Summit 2020](https://dndi.org/events/2020/unite-global-summit-2020/) - Unite Global Summit aims to commit, inspire, and empower policymakers towards the achievement of the UN SDGs over the next decade, while building a roadmap on clear policy actions to eliminate the threat posed by communicable diseases. Panel session How can innovation aid the global health response? - Covid-19 and beyond Date: Tuesday, 8 September
- [CTDDR 2019](https://dndi.org/events/2019/ctddr-2019/) - Organized by the CSIR-Central Drug Research Institute, the 7th International Symposium on Current Trends in Drug Discovery Research (CTDDR 2019) addresses cutting-edge advances in drug discovery and development for infectious diseases (malaria, leishmania & microbial infections), life style disorders (CNS & CVS-metabolic disorders), cancer, and bone health. Presentation
- [Chagas disease - Breaking the Silence](https://dndi.org/events/2019/chagas-disease-breaking-the-silence/) - The World Heart Federation in collaboration with the Chagas Coalition is working to 'Break the Silence' around Chagas disease. The event aims to give exposure to testimonials from patients living with the disease, to discuss the major hurdles preventing access to quality care and treatment, and to understand how the global health community can best
- [XV Chagas disease workshop - ISGlobal](https://dndi.org/events/2019/xv-chagas-disease-workshop/) - Organized by the Institute for Global Health Barcelona (ISGlobal), this workshop’s objective is to discuss the advances in antiparasitic treatment and care in people with Chagas disease. Presentations Time: 11:30-12:10 Time: 12.50- 13.30 More information: Event websiteRegistration link
- [Innovation en santé mondiale](https://dndi.org/events/2019/innovation-en-sante-mondiale/) - Organized by UNITAID, the Global Fund, and Friends of the Global Fund Europe, the theme of this event is "From conception to ownership of new health tools and services". Discussion Freins et incitations à l’innovation en santé mondiale Time: 11:05-11:45Venue: Hub Institute Moderator: Gaël Giraud, Chef économiste à l’Agence Française de Développement More information: Programme and
- [6th Annual World Open Innovation Conference](https://dndi.org/events/2019/6th-annual-world-open-innovation-conference/) - The World Open Innovation Conference is designed to engage senior executives of global firms and top academic experts from around the world to address corporate challenges and provide focus for further research. The theme of this year’s conference is “Opening up for managing business and societal challenges”. Session Meet the Editor “Shark Tank” Date: Friday,
- [HealthTalks@swissnex: Tuberculosis?](https://dndi.org/events/2019/healthtalks-swissnex-tuberculosis/) - Swissnex Brazil organizes a panel on tuberculosis with researchers from Switzerland and Brazil to present different perspectives on this disease that still persists and challenges us. Discussion Time: 18:30Venue: Swissnex Brazil Moderator: Jadel Kratz, Discovery Manager, DNDi Latin America More information: Event website
- [SADI 2019](https://dndi.org/events/2019/sadi-2019/) - The Argentine Society of Infectious Diseases (Sociedad Argentina de Infectología) organizes its annual meeting that brings together professionals working on infectious diseases and their impact on the Argentinian population. Presentation More information: Event website
- [XXXVII Congreso Nacional de Cardiología 2019](https://dndi.org/events/2019/congreso-nacional-cardiologia-2019/) - The Argentinian Cardiology Federation organizes their annual National Congress of Cardiology. Round table Chronic Chagas: Have we changed the prognosis in these patients? Date: Friday, 31 May 2019Time: 10:45Location: Libertador C Room More information: Event website
- [Free public event on the sidelines of ECTMIH 2019](https://dndi.org/events/2019/ectmih-2019-public-event-mycetoma-cutaneous-leishmaniasis/) - Better than boiling oil or amputation? Stories behind the treatment needs of two of the world’s most neglected tropical diseases, cutaneous leishmaniasis and mycetoma Monday, 16 September 2019, 14:00-15:30Foresight Centre, Liverpool, UK What links someone bitten by a sandfly while paddling down the Essequibo River in Guyana to a shepherd in Sudan who steps on
- [Launch of the PITE FAPESP Consortium](https://dndi.org/events/2019/pite-fapesp-consortium-event/) - The event is organized by the the São Paulo Research Foundation (FAPESP), DNDi, Medicines for Malaria Venture (MMV), University of São Paulo, and University of Campinas (UNICAMP) for the launch of the project Research Partnership for Technological Innovation (PITE-FAPESP) to discover novel drug candidates for the treatment of parasitic tropical diseases. The goal of the
- [Creative approaches to improving access to medicines globally: Ideas from the hepatitis C experience](https://dndi.org/events/2019/creative-approaches-improving-access-to-medicines-globally/) - Access to medical products is a complex global challenge at the interface between health, economics, politics and development. This one-day symposium organised in collaboration with the Swiss Federal Institute of Intellectual Property and the Federal Office of Public Health focuses on a sub-set of access to medicines challenges, using Hepatitis C virus (HCV) as an extended
- [13th Annual NTD Conference](https://dndi.org/events/2019/13th-annual-ntd-conference/) - The theme of the 13th Annual NTD Conference is "Cross border partnerships towards achieving control and elimination of NTDs". Scientific session DNDi AfriKADIA Consortium: Innovative visceral leishmaniasis trials in the East Africa region Date: Thursday, 5 December 2019Time: 10:00 – 10:30 More information about the AfriKADIA Consortium More information: Event website
- [Keystone Symposia Global Health 2019](https://dndi.org/events/2019/keystonesymposiaglobalhealth-helminths/) - This symposium is part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation. The theme is "Helminths: New insights from immunity to global health". Session Helminth control: Drug development Date: Wednesday, 11 December 2019Time: 17:00-19:00 Chairs: Makedonka Mitreva, Washington University School of Medicine, USA, and Peter Nejsum, Aarhus University,
- [5th National Hepatitis Conference Malaysia](https://dndi.org/events/2020/5th-national-hepatitis-conference-malaysia/) - Organized by the Gastroenterology & Hepatology Unit, Ampang Hospital, the theme of the 5th National Hepatitis Conference is “Towards eliminating viral hepatitis“. Update April 2020: This event has been cancelled. More information Publication Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”by Radzi Abu
- [CROI 2020](https://dndi.org/events/2020/croi-2020/) - The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. Symposium Hepatitis C: Parallels, pitfalls, and promise Date: Wednesday, 11 March 2020Time: 16:00-18:00 More
- [10th KASH Conference](https://dndi.org/events/2020/10th-kash-conference/) - 11-14 February 2020 Nairobi, Kenya Presentation on neonatal sepsis
- [ASTMH 2016](https://dndi.org/events/2016/astmh-2016/) - American Society of Tropical Medicine and Hygiene (ASTMH), 65th Annual Meeting DNDi presented in symposia on sleeping sickness and Chagas disease, they also co-authored poster presentations on filarial diseases. Download DNDi @ ASTMH 2016 DNDi Symposia Date: November 15 Approaches, advances and needs for the elimination of human African trypanosomiasis (HAT) Chair: Gerardo Priotto, Department
- [1st Sudanese Swiss Science Forum](https://dndi.org/events/2020/1st-sudanese-swiss-science-forum/) - Under the patronage of the Ministry of Higher Education, Sudan and the Swiss Embassy to Khartoum, and organized by the Sudanese National Academy of Sciences and the Swiss Academy of Sciences, the purpose of this forum is to promote cooperation and collaboration between Swiss and Sudanese scientists and to promote policy, technology, and skills development
- [IASC 2020 Web Conference on African Commons](https://dndi.org/events/2020/iasc-2020-web-conference-on-african-commons/) - The objective of the IASC 2020 Web Conference on African Commons is to share the research done in Africa by African scholars and scholars abroad in order to improve governance and management of shared resources and create sustainable solutions for commons, common-pool resources, or any other form of shared resources. Panel Knowledge Commons Comprendre les
- [ISNTD Festival 2020](https://dndi.org/events/2020/isntd-festival-2020/) - The ISNTD Festival brings together the best in communication, arts, entertainment and science to help complex public health messages reach patients, the public and global health professionals worldwide. Film DNDi: 15 years of putting patients before profits More information: Event website
- [Online MSF webinar: Global access to medicines and vaccines for COVID-19](https://dndi.org/events/2020/online-msf-webinar-global-access-to-medicines-and-vaccines-for-covid-19/) - Organized by Doctors Without Borders/Médecins Sans Frontières (MSF), this online webinar aims to discuss the race to develop COVID-19 vaccines and treatments, and why they must be accessible and affordable to everyone. Webinar Ensuring global access to medicines and vaccines for COVID-19 Time: 13:00-14:00 EDT Speakers: Joe Belliveau, Executive Director, MSF CanadaJason Nickerson, Humanitarian Affairs
- [Online webinar: The WHO Covid-19 Technology Pool](https://dndi.org/events/2020/online-webinar-the-who-covid-19-technology-pool/) - Health Action International, Knowledge Ecology International, Medicines Law & Policy, Pharmaceutical Accountability Foundation, and Wemos are organizing a briefing in advance of the virtual 73rd session of the World Health Assembly. Webinar The WHO Covid-19 Technology Pool: The solution to ensure global access to Covid-19 health technologies Time: 15:00 CEST Moderator: Ellen ‘t Hoen, LLM,
- [COVID-19: What can Malaysia and Kerala, India teach the rest of the world?](https://dndi.org/events/2020/webinar-covid19-what-can-malaysia-kerala-india-teach-rest-world/) - With much of the world reeling from the impact of COVID-19, Malaysia and the state of Kerala in India have mounted innovative responses, keeping numbers of infections and hospitalization rates remarkably low. DNDi and the COVID-19 Clinical Research Coalition are thrilled to be jointly hosting their first webinar with two ‘heroes’ of the COVID-19 response who
- [Next Einstein Forum Global Gathering 2020](https://dndi.org/events/2020/next-einstein-forum-global-gathering-2020/) - Under the sub-theme “Research and Innovation Pathways to Africa’s Transformation”, the 2020 edition of the Next Einstein Forum (NEF) Global Gathering aims to provide an operational roadmap for a Pan-African Digital Economy. Update 5 March 2020: The NEF Global Gathering 2020 has been postponed. More information Parallel session Building clinical trials capacity in Africa Date: Friday,
- [IS Global XVI Workshop on Chagas disease](https://dndi.org/events/2020/isglobal-xvi-workshop-on-chagas-disease/) - Organized by IS Global, the theme of the XVI Workshop on Chagas disease is “Health care focused on people who live with T. cruzi infection-Chagas disease“. Update 6 March 2020: The IS Global XVI Workshop on Chagas disease has been cancelled. More information Presentations Results of the Fexi-12 StudyFabiana Barreira, Chagas Senior Clinical Project and Medical Manager,
- [The Digital International Liver Congress 2020](https://dndi.org/events/2020/the-digital-international-liver-congress-2020/) - The International Liver Congress™ (ILC) is the annual meeting of the European Association for the Study of the Liver. Poster The HEAD-Start project: Introduction of rapid diagnostic tests for hepatitis C screening in primary healthcare sites as a first step towards decentralizing hepatitis C care in MalaysiaHassan MRA, Zain RBM, Nasir NHB, Yuswan FB, Siva S, Menétrey
- [Projection et discussion: Délocalisation des tests de médicament](https://dndi.org/events/2020/projection-et-discussion-delocalisation-des-tests-de-medicament/) - The Geneva regional group of Public Eye, the Amnesty Unige group, Cetim, and Swissaid-Geneva are holding an event on ethics risks related to the relocation of drug tests at the University of Geneva, Switzerland. Discussion Délocalisation des tests de médicaments dans les pays pauvres: Quels risques de violation des droits humains par les multinationales? Time:
- [ReAct](https://dndi.org/events/2017/react/) - Action on Antibiotic Resistance (ReAct) Africa Annual Conference 2017 September 18-19, 2017 Machakos, Kenya DNDi Africa's Director, Monique Wasunna, gave a presentation on DNDi's various programme models.

## News

- [2025 DNDi Financial Report](https://dndi.org/publications/2026/2025-dndi-financial-report/) - download the report
- [DRC approves the use of acoziborole, a breakthrough one-day oral treatment against sleeping sickness](https://dndi.org/press-releases/2026/drc-approves-use-acoziborole-breakthrough-one-day-oral-treatment-against-sleeping-sickness/) - The registration follows successful clinical trials conducted in the DRC and Guinea and paves the way for use across all African countries where the most common form of the disease, caused by gambiense human African trypanosomiasis, is endemic. The medicine will be available free of charge to patients.
- [Cryptococcal meningitis: Africa’s neglected HIV killer](https://dndi.org/stories/2026/cryptococcal-meningitis-africas-neglected-hiv-killer/) - Congolese physician Dr Jack Zawadi Tsulokpa is a 2024 fellow of the WHO-TDR Clinical Research Leadership program, contributing to DNDi research on river blindness.
- [Open Science in a Closed World](https://dndi.org/publications/2025/open-science-in-a-closed-world/) - DNDi's Policy Report shares lessons and opportunities for securing openness and equitable access in R&D collaborations.
- [Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report](https://dndi.org/scientific-articles/2026/advancing-diagnostics-for-chagas-disease-key-product-characteristics-and-harmonized-evaluation-strategies-an-expert-meeting-report/) - Bohorquez LC, Schijman AG, Perez F, Coto H, Marchiol A, Pinazo M-J. BMC Infectious Diseases 2026,26(Suppl 1):1160 doi.org/10.1186/s12879-026-13565-3 Summary: Streamlining diagnostic methods and evaluating and developing point-of-care diagnostics are priority actions for the elimination of Chagas disease by 2030. The authors of this manuscript convened 44 researchers, test developers, and health authorities to provide scientific
- [What Is in a Structure? Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs](https://dndi.org/scientific-articles/2026/what-is-in-a-structure-cell-permeability-and-solubility-of-series-of-macrocycles-and-linear-matched-pairs/) - Tyagi M, Poongavanam V, Zich S, Lindhagen M, Asproudis I, Putra OD, Yang J, Ashworth ZJR, Guadagni A, Hagemeyer LJ, Oliva A, Sjö P, Schiesser S, Kihlberg J. Journal of Medicinal Chemistry 2026 doi:10.1021/acs.jmedchem.6c00830 Summary: Macrocycles can be useful for modulating difficult-to-drug targets, but often reside in chemical space where it is challenging to obtain
- [Eric Easom, Dr Marcus Lacerda, and Mathieu Lamiaux join the DNDi Board of Directors ](https://dndi.org/news/2026/eric-easom-dr-marcus-lacerda-and-mathieu-lamiaux-join-the-dndi-board-of-directors/) - DNDi is very pleased to announce the appointment of Dr Javid Abdelmoneim, Dr Mahathar Abd Wahab, Dr Taruna Madan, Violet Naanyu, and Dr Mario Santos Moreira as members of the organization’s Board of Directors.
- [Advancing global health innovation through Europe-Africa collaboration](https://dndi.org/publications/2026/advancing-global-health-innovation-through-europe-africa-collaboration/) - Eight Product Development Partnerships (PDPs) are joining forces to call for sustained investment in the European and Developing Countries Clinical Trials Partnership (EDCTP) under the next EU Framework Programme for Research and Innovation and other EU funding frameworks under discussion. For more than 20 years, EDCTP has demonstrated the impact of Europe–Africa collaboration, supporting clinical
- [La RDC approuve l’utilisation de l’acoziborole, un traitement oral à dose unique contre la maladie du sommeil](https://dndi.org/press-releases-translations/2026/rdc-approuve-utilisation-acoziborole-un-traitement-oral-dose-unique-contre-maladie-sommeil/) - L’enregistrement du médicament fait suite à des essais cliniques menés avec succès en RDC et en Guinée, et ouvre la voie à l’utilisation de l’acoziborole dans tous les pays africains où la forme la plus courante de la maladie, causée par le parasite Trypanosoma brucei gambiense, est endémique. Le médicament sera disponible gratuitement pour les patients.
- [Severe visceral leishmaniasis in Ethiopia: Outcomes, co-infections and mortality in a prospective real-world cohort](https://dndi.org/scientific-articles/2026/severe-visceral-leishmaniasis-in-ethiopia-outcomes-co-infections-and-mortality-in-a-prospective-real-world-cohort/) - Ayele E, Henten Sv, Getahun Ayalew D, Atnafu S, Engidaw Mereed A, Yohannes H, Mekonnen T, Bogale T, Mossa A, Lema Legese G, Yasin J, Berens-Riha N, Pham T-T, Boodman C, Mondelaers A, Adriaensen WJ, Abdellati S, Diro E, Mohammed R, Alves F, Silamsaw Asres M, Pareyn M, Kassa M, van Griensven J. PLOS Neglected
- [The DNDi-MMV Joint Regulatory Platform: ‘a pioneering programme project for non-profit medical research organizations to speak with one voice’](https://dndi.org/stories/2026/dndi-mmv-pool-regulatory-expertise-accelerate-access-lifesaving-medicines/) - Congolese physician Dr Jack Zawadi Tsulokpa is a 2024 fellow of the WHO-TDR Clinical Research Leadership program, contributing to DNDi research on river blindness.
- [DNDi and Medicines for Malaria Venture (MMV) pool regulatory expertise to accelerate access to lifesaving medicines](https://dndi.org/news/2026/dndi-and-medicines-for-malaria-venture-mmv-pool-regulatory-expertise-to-accelerate-access-to-lifesaving-medicines/) - Congolese physician Dr Jack Zawadi Tsulokpa is a 2024 fellow of the WHO-TDR Clinical Research Leadership program, contributing to DNDi research on river blindness.
- [Lab lessons that matter: Pharmacy students help bridge the gap in research for neglected diseases](https://dndi.org/stories/2026/lab-lessons-that-matter-pharmacy-students-help-bridge-the-gap-in-research-for-neglected-diseases/) - Congolese physician Dr Jack Zawadi Tsulokpa is a 2024 fellow of the WHO-TDR Clinical Research Leadership program, contributing to DNDi research on river blindness.
- [From invisibility to political power: Policy lessons from a decade of Brazil’s Social Forum for Infectious and Neglected Diseases](https://dndi.org/scientific-articles/2026/from-invisibility-political-power-policy-lessons-from-decade-brazils-social-forum-infectious-neglected/) - Pinheiro EdS, Araújo CEL, Cunha ESM, Rocha AMd, Galvão DLN, de Souza EA, da Silva MPCAM, Ramos Jr AN. PLOS Neglected Tropical Diseases 2026, 20(5): e0014336. doi:10.1371/journal.pntd.0014336 Summary: In Brazil, people living with neglected tropical diseases (NTDs), together with community organizations, researchers, and health professionals, created the Brazilian Social Forum for Combating Infectious and Neglected
- [DNDi Statement at the UN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)](https://dndi.org/statements/2026/dndi-statement-at-the-un-multi-stakeholder-hearing-on-pandemic-prevention-preparedness-and-response-pppr/) - Delivered by Rachel Cohen, DNDi Senior Advisor Thank you, Chair, for the opportunity to share the perspective of the Drugs for Neglected Diseases initiative (DNDi), an international not-for-profit research and development (R&D) organization. I will focus my comments on three critical points: First, the need for Member States to consider R&D as a key part of outbreak and pandemic preparedness and reflect this in the Political Declaration; second, the essential task
- [In vitro profiling of Trypanosoma cruzi inhibitors identified from high throughput screening and application to parasite painting](https://dndi.org/scientific-articles/2026/in-vitro-profiling-of-trypanosoma-cruzi-inhibitors-identified-from-high-throughput-screening-and-application-to-parasite-painting/) - Baek K-H, Lee H, Byun S, Genilloud O, Ioset J-R, Shum D, No JH. International Journal for Parasitology: Drugs and Drug Resistance 2026,31:100651. doi: 10.1016/j.ijpddr.2026.100651 Summary: Thus far, most drug discovery efforts for Chagas disease, caused by Trypanosoma cruzi, have relied upon cell-based assays. The failure of posaconazole in clinical trials has highlighted the need
- [Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression](https://dndi.org/scientific-articles/2026/chemical-genetics-reveals-leishmania-kkt2-and-crk9-kinase-activity-is-required-for-cell-cycle-progression/) - Carnielli JBT, Brannigan JA, Ramos PZ, Jones NG, Couñago RM, Sjö P, Lima APCA, Wilkinson AJ, Mottram JC. PLOS Pathogens 2026,22(5): e1014194. doi.org/10.1371/journal.ppat.1014194 Summary: Protein kinases are key regulators of the eukaryotic cell cycle and have emerged as attractive targets for drug development. The Leishmania kinome, shaped by diverse evolutionary processes, harbours a unique repertoire
- [DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need](https://dndi.org/press-releases/2026/dndi-gardp-and-mmv-join-forces-to-accelerate-drug-development-for-patients-in-greatest-need/) - The three non-profit research and development (R&D) organizations have signed a strategic cooperation agreement to explore opportunities to pool resources and maximize their impact amid global aid cuts and calls to reform the global health architecture.
- [New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations ](https://dndi.org/news/2025/new-dndi-report-open-science-in-closed-world/) - DNDi's new policy report explores how open, collaborative science and pro-access IP approaches can accelerate medical innovation and equitable access to health tools for all.
- [The Long, Strange Journey of Mycetoma Research](https://dndi.org/in-the-media/2026/thailand-approves-ravidasvir-a-new-drug-for-hepatitis-c-increasing-chances-of-complete-cure-2/) - access the article
- [Mycetoma as a major cause of limb amputation in Northeastern Ethiopia: A facility-based retrospective study](https://dndi.org/scientific-articles/2026/mycetoma-as-a-major-cause-of-limb-amputation-in-northeastern-ethiopia-a-facility-based-retrospective-study/) - Enbiale W, Nyaoke B, Bekele A, Mohammed KA, Bedane D. PLOS Neglected Tropical Diseases 2026,20(5): e0013886. doi:10.1371/journal.pntd.0013886 Summary: The authors of this manuscript reviewed medical records of patients diagnosed with mycetoma at Dubti Referral Hospital, Ethiopia, to document the contribution made by mycetoma to limb loss. Most of the 143 patients included were young men
- [DNDi interventions at the 79<sup>th</sup> World Health Assembly](https://dndi.org/statements/2026/dndi-interventions-at-the-79th-world-health-assembly/) - DNDi's interventions (posted here following delivery): Agenda item 12.3: Road map for neglected tropical diseases 2021–2030 The development of new health tools remains a fundamental pillar for achieving NTD control and elimination. Sustained commitment and partnership have enabled the development of simpler, safer, effective new treatments – such as acoziborole, a one-day, single-dose oral treatment
- [Kenya seeks global partnerships to tackle NTDs](https://dndi.org/in-the-media/2026/kenya-seeks-global-partnerships-to-tackle-ntds/) - access the article
- [DNDi's briefing note for 79<sup>th</sup> World Health Assembly](https://dndi.org/statements/2026/dndis-briefing-note-for-79th-world-health-assembly/) - This briefing sets out DNDi's comments for consideration by WHO Member States on agenda items included in the 79th meeting of the World Health Assembly.
- [DNDi statement on hantavirus outbreak: 'Investment in pandemic preparedness efforts remains insufficient.'](https://dndi.org/statements/2026/dndi-statement-on-hantavirus-outbreak-investment-in-pandemic-preparedness-efforts-remains-insufficient/) - The hantavirus outbreak highlights a broader, recurring challenge: the need to invest early in medical R&D as a core part of pandemic preparedness.
- [DNDi welcomes GHIT support for global evaluation and registration of fosravuconazole for eumycetoma, in collaboration with Eisai](https://dndi.org/press-releases/2026/dndi-welcomes-ghit-support-registration-fosravuconazole-for-eumycetoma-collaboration-with-eisai/) - The Drugs for Neglected Diseases initiative welcomes new financial support from the Global Health Innovative Technology (GHIT) Fund to enable the global evaluation and registration of fosravuconazole for eumycetoma
- [Thailand approves ravidasvir, a new drug for hepatitis C, increasing chances of complete cure](https://dndi.org/in-the-media/2026/thailand-approves-ravidasvir-a-new-drug-for-hepatitis-c-increasing-chances-of-complete-cure/) - access the article
- [‘Estamos na fase de eliminação’: RD Congo avança no combate à doença que matou milhões na África](https://dndi.org/in-the-media/2026/estamos-na-fase-de-eliminacao-rd-congo-avanca-no-combate-a-doenca-que-matou-milhoes-na-africa/) - access the article
- [ไทยรับรอง "ราวิดาสเวียร์" ยาใหม่รักษาไวรัสตับอักเสบซี เพิ่มโอกาสรักษาหายขาด](https://dndi.org/in-the-media/2026/ไทยรบรอง-ราวดาสเวยร/) - access the article
- [Fourteen days to recovery from kala-azar](https://dndi.org/in-the-media/2026/fourteen-days-to-recovery-from-kala-azar/) - access the article
- [Overcoming Trypanosoma cruzi persistence with a mechanistically distinct drug combination](https://dndi.org/scientific-articles/2026/overcoming-trypanosoma-cruzi-persistence-with-a-mechanistically-distinct-drug-combination/) - Francisco AF, Olmo F, Escudié F, Chatelain E, Kelly JM. NPJ Antimicrob Resist 2026,4(1):30. doi:10.1038/s44259-026-00205-8 Summary: Infections with Trypanosoma cruzi are widespread in the Americas and can lead to severe cardiac and/or gastrointestinal pathology. Current treatments are limited to monotherapies characterised by prolonged dosing regimens, disputed efficacy and toxic side-effects. Sterile cure is often confounded by
- [Beni: Surviving Sleeping Sickness](https://dndi.org/videos/2025/beni-surviving-sleeping-sickness/) - Beni, a young boy from the Democratic Republic of Congo, survived sleeping sickness thanks to timely diagnosis and innovative oral treatments. This films tells the story of Beni and all the heroes who helped save his life. Not all heroes were capes.
- [Thailand registers ravidasvir, a simple-to-use and effective antiviral for hepatitis C, expanding treatment options for Thai patients](https://dndi.org/press-releases/2026/thailand-registers-ravidasvir-simple-use-effective-antiviral-for-hepatitis-c-expanding-treatment-options-thai-patients/) - Thailand’s Food and Drug Administration has approved ravidasvir as a safe and effective treatment against hepatitis C following clinical trials conducted in Thailand and Malaysia. Ravidasvir is approved for use in combination with another antiviral called sofosbuvir. The combination oral treatment is taken once daily for 12 weeks.
- [DNDi is looking for a Board Treasurer to join its Board of Directors](https://dndi.org/news/2026/dndi-is-looking-for-a-board-treasurer-to-join-its-board-of-directors/) - DNDi is looking for an expert in the private sector to join its Board of Directors.
- [Dengue treatments in 2-3 years, but cases set to rise with climate change](https://dndi.org/in-the-media/2026/dengue-treatments-in-2-3-years-but-cases-set-to-rise-with-climate-change/) - access the article
- [India eyes dengue treatment rollout within five years as vaccine pipeline advances](https://dndi.org/in-the-media/2026/india-eyes-dengue-treatment-rollout-within-five-years-as-vaccine-pipeline-advances/) - access the article
- [Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis](https://dndi.org/scientific-articles/2026/translational-pharmacokinetic-pharmacodynamic-modeling-efficacious-human-dose-prediction-dndi-6148-treatment-cutaneous-leishmaniasis/) - Henninger RH, Schouten WM, Arana B, Gillon J-Y, Mowbray CE, Müller Kratz J, Van Bocxlaer K, Dorlo TPC Clinical and Translational Science 2026,19(4):e70535 doi: 10.1111/cts.70535 Summary: There is only one oral treatment for cutaneous leishmaniasis. DNDI-6148 is an orally bioavailable compound with potent antiparasitic activity in preclinical studies. To enable clinical development, the authors of
- [Un golpe de efecto para acabar con la enfermedad del sueño: "Aspiramos a eliminar el trastorno en 2030"](https://dndi.org/in-the-media/2026/un-golpe-de-efecto-para-acabar-con-la-enfermedad-del-sueno-aspiramos-a-eliminar-el-trastorno-en-2030/) - access the article
- [La milagrosa cura de la enfermedad del sueño](https://dndi.org/in-the-media/2026/la-milagrosa-cura-de-la-enfermedad-del-sueno/) - access the article
- [Face à la dengue, la recherche s’active alors que le réchauffement laisse craindre une saison 2026 record](https://dndi.org/in-the-media/2026/face-a-la-dengue-la-recherche-sactive-alors-que-le-rechauffement-laisse-craindre-une-saison-2026-record/) - access the article
- [One dose, one cure](https://dndi.org/stories/2026/one-dose-one-cure/) - Today, we celebrate what once seemed impossible: a new oral treatment that can safely cure sleeping sickness in just one dose of three pills. Without hospitalization, without painful injections, and without fear.
- [Manufacturing medicines for NTDs, with Dr Stephen Robinson](https://dndi.org/videos/2026/manufacturing-medicines-for-ntds-with-dr-stephen-robinson/) - This short documentary film from Devex tells the remarkable story of the Democratic Republic of the Congo’s progress towards sleeping sickness elimination.
- [A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery Data](https://dndi.org/scientific-articles/2026/a-computational-community-blind-challenge-on-pan-coronavirus-drug-discovery-data/) - by Data MacDermott-Opeskin H, Scheen J, Wognum C, Horton JT, West D, Payne AM, Castellanos MA, Colby S, Griffen E, Cousins D, Stacey J, Reid L, Aschenbrenner JC, Fearon D, Balcomb B, Marples P, Tomlinson CWE, Lithgo R, Godoy AS, Winokan M, Barr H, Lahav N, Lavi M, Duberstein S, Cohen G, Fate G, Lefker
- [Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review](https://dndi.org/scientific-articles/2026/https-dndi-org-news-unintended-consequences-social-sciences-stocktake-decade-global-action-plan-inspired-antimicrobial-governance-2/) - Wilson JP, Chowdhury F, Hassan S, Harriss E, Alves F, Musa A, Dahal P, Stepniewska K, Guérin PJ BMJ Public Health 2026, 4:e001196. doi:10.1136/bmjph-2024-001196 Summary: Prognostic models can steer clinical decision-making for visceral leishmaniasis by identifying patients at high risk of adverse outcomes. The authors of systematic review aimed to identify, summarise, and critically appraise
- [Marking DNDi’s 20th year of driving medical innovation for the most neglected](https://dndi.org/news/2023/marking-dndi-20-year-driving-medical-innovation-for-most-neglected/) - From founding to delivering 14 new treatments for neglected patients!
- [The lifecycle of <em>Phlebotomus argentipes</em> (Diptera: Psychodidae) sand fly in a newly developed colony in Bangladesh](https://dndi.org/scientific-articles/2025/lifecycle-phlebotomus-argentipes-sand-fly-colony-bangladesh/) - by D Ghosh, Sagar SK, Molina R, Alim A, Chowdhury R, Alam MS, Alvar J, Mondal D. The American Journal of Tropical Medicine and Hygiene 2025, 112(6):1201-1206. doi: 10.110.4269/ajtmh.23-0683 Summary: The authors of this study established a colony of Phlebotomus argentipes sand flies from 430 wild-caught females in a controlled laboratory environment in Bangladesh. Over multiple generations,
- [Modular and divergent synthesis of 2,N3-disubstituted 4-quinazolinones facilitated by regioselective N-alkylation](https://dndi.org/scientific-articles/2024/modular-and-divergent-synthesis-of-2n3-disubstituted-4-quinazolinones-facilitated-by-regioselective-n-alkylation/) - by Kim KE, Comber JR, Pursel AJ, Hobby GC, McCormick CJ, Fisher MF, Marasa K, Perry B. Organic and Biomolecular Chemistry 2024, 22(24):4940-4949. doi: 10.1039/D4OB00564C. Summary: Libraries of structurally diverse compounds allow the influence of molecular structure on bioactivity to be assessed. In partnership with DNDi, researchers at the University of Washington designed a project
- [The burden of eumycetoma in Africa: a neglected fungal disease](https://dndi.org/scientific-articles/2026/burden-eumycetoma-africa-neglected-fungal-disease/) - Smith DJ, Sow D, Enbiale W, Colom MF, Ekai JL, Nyaoke BA, Fahal AH The Lancet Regional Health – Africa 2026, 100032. doi: 10.1016/j.lanafr.2026.100032 Summary:The authors of this comment note that an article by Bongomin et al. describing health disparities and the burden of fungal infections in Africa does not mention eumycetoma, despite high rates
- [Tres pastillas para eliminar la enfermedad del sueño en un contexto de recortes globales en ayuda al desarrollo](https://dndi.org/in-the-media/2026/tres-pastillas-para-eliminar-la-enfermedad-del-sueno-en-un-contexto-de-recortes-globales-en-ayuda-al-desarrollo/) - access the article
- [Boron plays a key role in new sleeping sickness drug](https://dndi.org/in-the-media/2026/boron-plays-a-key-role-in-new-sleeping-sickness-drug/) - access the article
- [A new drug could be the beginning of the end for sleeping sickness](https://dndi.org/in-the-media/2026/a-new-drug-could-be-the-beginning-of-the-end-for-sleeping-sickness/) - access the article
- [The Best Weapon Yet Against Sleeping Sickness](https://dndi.org/in-the-media/2026/the-best-weapon-yet-against-sleeping-sickness/) - access the article
- [RD Congo : Un nouveau traitement contre la maladie du sommeil](https://dndi.org/in-the-media/2026/rd-congo-un-nouveau-traitement-contre-la-maladie-du-sommeil/) - Watch video here
- [Why sleeping sickness pill is raising hopes in Africa](https://dndi.org/in-the-media/2026/why-sleeping-sickness-pill-is-raising-hopes-in-africa/) - access the article
- [Tres pastillas en una dosis única, la bala de plata contra la enfermedad del sueño](https://dndi.org/in-the-media/2026/tres-pastillas-en-una-dosis-unica-la-bala-de-plata-contra-la-enfermedad-del-sueno/) - access the article
- [Africa’s one-dose cure brings sleeping sickness elimination within reach](https://dndi.org/in-the-media/2026/africas-one-dose-cure-brings-sleeping-sickness-elimination-within-reach/) - access the article
- [(Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance](https://dndi.org/scientific-articles/2026/https-dndi-org-news-unintended-consequences-social-sciences-stocktake-decade-global-action-plan-inspired-antimicrobial-governance/) - Kirchhelle C, Alas Portillo M, Davis M, Doron A, Dreser A, Fortané N, Haddad C, Hinchliffe S, Kariuki S, Lewycka S, Molyneux S, Lozano CM, Mutua E, Okeke IN, Zhang Betancourt M, Clare I R Chandler CIR. The Lancet Microbe 2026, 7(3). doi: 10.1016/j.lanmic.2025.101315 Summary: Despite increasing international attention, antimicrobial resistance (AMR) governance has often
- [Antitrypanosomal quinazolines targeting lysyl-tRNA synthetase show partial efficacy in a mouse model of acute Chagas disease](https://dndi.org/scientific-articles/2025/antitrypanosomal-quinazolines-targeting-lysyl-trna-synthetase-show-partial-efficacy-in-a-mouse-model-of-acute-chagas-disease/) - by Tulloch LB, Tawell H, Taylor AE, Lopes Lima L, Dawson A, Carvalho S, Wall RJ, Corpas-Lopez V, Dey G, Duggan J, Godoy Magalhaes L, Torrie LS, Frame L, Robinson D, Patterson S, Tinti M, Weaver GW, Robinson WJ, Cal M, Kaiser M, Mäser P, Sjö P, Perry B, Kelly JM, Fortes Francisco A, Bhambra
- [DNDi statement at the sixth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement](https://dndi.org/statements/2026/dndi-statement-at-the-sixth-meeting-of-the-intergovernmental-working-group-igwg-on-the-who-pandemic-agreement/) - DNDi's interventions at the 156th WHO Executive Board on universal health coverage; communicable diseases; women's, children's, and adolescents' health; and climate change and health.
- [L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif de l’Agence Européenne des Médicaments (EMA) en tant que traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil](https://dndi.org/press-releases-translations/2026/acoziborole-winthrop-developpe-par-dndi-et-sanofi-recoit-avis-positif-agence-europeenne-medicaments-maladie-sommeil/) - La recommandation s’appuie sur une étude de Phase II/III, qui démontre jusqu’à 96% de taux de réussite à 18 mois à des stades précoces et avancés de T.b. gambiense, la forme la plus courante de maladie du sommeil.
- [Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness](https://dndi.org/press-releases/2026/acoziborole-winthrop-developed-dndi-sanofi-receives-european-medicines-agency-positive-opinion-sleeping-sickness/) - The recommendation is based on Phase II/III study demonstrating up to 96% success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness.
- [Combate à dengue: estratégias inovadoras para uma doença negligenciada](https://dndi.org/in-the-media/2025/combate-a-dengue-estrategias-inovadoras-para-uma-doenca-negligenciada/) - ACCESS THE ARTICLE
- [A simulation-based method to inform serosurvey designs for estimating the force of infection using existing blood samples](https://dndi.org/scientific-articles/2023/a-simulation-based-method-to-inform-serosurvey-designs-for-estimating-the-force-of-infection-using-existing-blood-samples/) - by Vicco A, McCormack CP, Pedrique B, Amuasi JH, Awuah AAA, Obirikorang C, Struck NS, Lorenz E, May J, Ribeiro I, Malavige GN, Donnelly CA, Dorigatti I. PLOS Computational Biology 2023, 19(11): e1011666. doi: 10.1371/journal.pcbi.1011666 Summary: The extent to which dengue virus has been circulating globally, and especially in Africa, is largely unknown. Blood samples from previous cross-sectional serological surveys can
- [A scoping literature review of global dengue age-stratified seroprevalence data: estimating dengue force of infection in endemic countries](https://dndi.org/scientific-articles/2024/a-scoping-literature-review-of-global-dengue-age-stratified-seroprevalence-data-estimating-dengue-force-of-infection-in-endemic-countries/) - by Vicco V, McCormack C, Pedrique B, Ribeiro I, Malavige GN, Dorigatti I. eBioMedicine 2024, 104:105134. doi: 10.1016/j.ebiom.2024.105134 Summary: The authors of this scoping literature review updated a previous study of dengue transmission intensity by collating global age-stratified dengue seroprevalence data published in Medline, Embase and Web of Science from 2014 to 2023. These data
- [Single-dose sleeping sickness drug set for approval](https://dndi.org/in-the-media/2026/single-dose-sleeping-sickness-drug-set-for-approval/) - access the article
- [Falta de medicamentos, centros médicos destruidos y recortes: cómo la guerra en Sudán ha golpeado a las enfermedades más olvidadas](https://dndi.org/in-the-media/2026/falta-de-medicamentos-centros-medicos-destruidos-y-recortes-como-la-guerra-en-sudan-ha-golpeado-a-las-enfermedades-mas-olvidadas/) - access the article
- [Faire des morsures de serpent une priorité de santé publique](https://dndi.org/in-the-media/2026/faire-des-morsures-de-serpent-une-priorite-de-sante-publique/) - access the article
- [Entretien avec Dr Hélène Mahenzi à propos d'un nouveau médicament développé contre la maladie du sommeil](https://dndi.org/in-the-media/2026/entretien-avec-dr-helene-mahenzi-a-propos-dun-nouveau-medicament-developpe-contre-la-maladie-du-sommeil/) - LISTEN TO THE INTERVIEW
- [2025 R&D programmes in review: Sleeping sickness](https://dndi.org/news/2026/2025-rd-programmes-in-review-sleeping-sickness/) - DNDi and our partners are working to deliver breakthrough treatments and expedite access to eliminate sleeping sickness – for good.
- [2025 R&D programmes in review: Pandemic preparedness](https://dndi.org/news/2026/2025-rd-programmes-in-review-pandemic-preparedness/) - DNDi and our partners are working to accelerate research to prepare for future viral pandemics.
- [2025 R&D programmes in review: Chagas disease](https://dndi.org/news/2026/2025-rd-programmes-in-review-chagas-disease/) - DNDi and our partners are searching for shorter, safer, more effective treatments to stop a silent killer. In the short term, we are working to develop improved treatment regimens with the existing drug benznidazole, reduce mother-to-child transmission, and help roll out ‘test-and-treat’ strategies to reach people living with Chagas disease in remote areas of Latin America. Our longer-term goal is to discover and develop entirely new drug candidates, with the aim of launching at least one Phase III trial by 2028.
- [2025 R&D programmes in review: Leishmaniasis](https://dndi.org/news/2026/2025-rd-programmes-in-review-leishmaniasis/) - DNDi and our partners are working to deliver safer, simpler treatments to save lives, reduce social stigma, and eliminate leishmaniasis as a public health problem​.
- [2025 R&D programmes in review: HIV](https://dndi.org/news/2026/2025-rd-programmes-in-review-hiv/) - DNDi and our partners are working to improve access to optimal treatments for people with advanced HIV disease.
- [2025 R&D programmes in review: Dengue](https://dndi.org/news/2026/2025-rd-programmes-in-review-dengue/) - DNDi and our partners are working to tackle the urgent need for treatments that can prevent progression to severe disease.
- [2025 R&D programmes in review: Mycetoma](https://dndi.org/news/2026/2025-rd-programmes-in-review-mycetoma/) - DNDi and our partners are working to develop safe, affordable treatments to prevent devastating amputation and disability – and to improve access for all people in need.
- [2025 R&D programmes in review: Parasitic worms](https://dndi.org/news/2026/2025-rd-programmes-in-review-parasitic-worms/) - DNDi and our partners are working to develop a first-ever cure for millions at risk.
- [2025 R&D programmes in review: Hepatitis C](https://dndi.org/news/2026/2025-rd-programmes-in-review-hepatitis-c/) - DNDi and our partners are supporting global elimination efforts by accelerating access to affordable treatments.
- [Pharmacokinetics, safety, and tolerability of an oxfendazole tablet formulation: A phase 1, randomized, placebo-controlled trial in healthy African volunteers](https://dndi.org/scientific-articles/2026/pharmacokinetics-safety-tolerability-oxfendazole-tablet-formulation-phase-1-randomized-placebo-controlled-trial-healthy-african-volunteers/) - Jongo S, Ackermann E, Nyaulingo G, Mbaraka H, Reus E, Cicconi S, Saxena M, Kassim K, Tumbo A, Rashid MA, Robinson S, Louis M, Satam V, Barreira F, Scandale I, Assmus F, Keiser J, Specht S. Antimicrobial Agents Chemotherapy 2026, other0:e01315-25. doi: 10.1128/aac.01315-25 Summary: The authors of this manuscript conducted a phase I bioavailability study
- [Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections and associated risk factors among pregnant women and key populations in Kenya: A multi-centre cross-sectional study](https://dndi.org/scientific-articles/2026/prevalence-chlamydia-trachomatis-neisseria-gonorrhoeae-infections-associated-risk-factors-among-pregnant-women-key-populations-kenya-multi-centre-cross-sectional-study/) - by Ngugi C, Nyaoke BA, Kingwara L, Akinyi P, Mmbone M, Egondi TW, Nyangweso GM, Broadhurst H, Kornmann G, Mathur R, Bettiol E. PLOS Global Public Health 2026, 6(2): e0005479. doi:10.1371/journal.pgph.0005479 Summary: Accurate prevalence estimates are essential for the public health control of Chlamydia trachomatis and Neisseria gonorrhoeae. The authors of this manuscript describe a
- [Design and analysis of randomized clinical trials for onchocerciasis, loiasis and mansonellosis: A systematic review](https://dndi.org/scientific-articles/2026/design-analysis-randomized-clinical-trials-onchocerciasis-loiasis-and-mansonellosis-systematic-review/) - by Lotola Mougeni F, Bofill Roig M, Hübner MP, Klarmann-Schulz U, Lenz B, Specht S, Posch M, Zehetmayer S. PLOS Neglected Tropical Diseases 2026, 20(2): e0013992. doi:10.1371/journal.pntd.0013992 Summary: Filarial diseases such as onchocerciasis, loiasis, and mansonellosis affect millions of people. However, conducting and analyzing trials of potential treatments can be difficult because patient numbers are
- [Elimination of visceral leishmaniasis as a public health problem in Bangladesh: Lessons learned and questions remaining](https://dndi.org/scientific-articles/2026/elimination-of-visceral-leishmaniasis-as-a-public-health-problem-in-bangladesh-lessons-learned-and-questions-remaining/) - by Chowdhury R, Hazarika A, Sultana S, Hossain MS, Saha S, Nabi SG, Sohel ANM, Rana MJ, Rahman M, Khan MH, Maheswary NP, Kroeger A, Yajima A, Mondal D, Adnan SD, Jhora ST, Islam MN, Basher A, Shamsuzzaman AKM, Ahmed BN, Faiz MA, Alvar J, Bern C, Aktaruzzaman MM. PLOS Neglected Tropical Diseases 2026;20(2):e0013949. doi:
- [An MRC-5 cell based high-throughput, high-content imaging assay to identify hits against Trypanosoma cruzi intracellular parasites](https://dndi.org/scientific-articles/2026/an-mrc-5-cell-based-high-throughput-high-content-imaging-assay-identify-hits-against-trypanosoma-cruzi-intracellular-parasites/) - by Zulfiqar B, Sykes ML, Escudié FB, Chatelain E, Avery VM. SLAS Discovery 2026,100298. doi: 10.1016/j.slasd.2026.100298 Summary: The discovery of effective therapies for Trypanosoma cruzi, the causative agent of Chagas disease, remains one of the most pressing challenges in parasitology and global health. Development of new therapies requires innovative and physiologically relevant assay platforms for
- [“Female Genital Schistosomiasis: Translational Challenges and Opportunities”: Outputs and actions from a consultative, collaborative and translational workshop](https://dndi.org/scientific-articles/2025/female-genital-schistosomiasis-translational-challenges-and-opportunities-outputs-and-actions-from-a-consultative-collaborative-and-translational-workshop/) - by Wasson PS, Kavanagh Williamson M, Hallas-Potts A, Lopez-Jimen B,Koscielniak M, Tait S, Gyapong M, Lamberti O, Ndubani R, Preston A, Musaya J, Kayuni SA, Kumwenda D, van Lieshout L, Webster BL, Downs JA, Sturt A, Specht S, Lemin ME, Long EF, Kjetland EF, Randrianasolo BS, Stothard JR, Gouvras A, Rollinson D, Secor WE, Shanaube
- [Evaluation of drug–drug interaction potential between the oral antibiotic zoliflodacin and the CYP3A4 inhibitor itraconazole: A phase 1 study in healthy participants](https://dndi.org/scientific-articles/2026/evaluation-drugdrug-interaction-potential-between-oral-antibiotic-zoliflodacin-cyp3a4-inhibitor-itraconazole/) - by Luckey A, Larson KB, Rayad N, Heep M, Delhomme S, Kornmann G, Mueller JP, O'Donnell JP, O'Brien S, Fuhr R, Gillon J-Y. Clinical and Translational Science 2026,19(3): e70515. doi: 10.1111/cts.70515 Summary: Zoliflodacin, a first-in-class oral spiropyrimidinetrione antibiotic under development for patients with uncomplicated gonorrhea, is metabolized by cytochrome P450 3A4 (CYP3A4), meaning concomitant administration
- [被忽视疾病的希望](https://dndi.org/in-the-media/2026/被忽视疾病的希望/) - access the article
- [Leishmaniasis: a story of two continents](https://dndi.org/in-the-media/2026/leishmaniasis-a-story-of-two-continents/) - access the article
- [Traitement à dose unique approuvé pour la maladie du sommeil](https://dndi.org/in-the-media/2026/single-dose-treatment-approved-for-sleeping-sickness-2/) - access the article
- [Single-dose treatment approved for sleeping sickness](https://dndi.org/in-the-media/2026/single-dose-treatment-approved-for-sleeping-sickness/) - access the article
- [Europa da el visto bueno a una terapia más sencilla contra la enfermedad del sueño](https://dndi.org/in-the-media/2026/europa-da-el-visto-bueno-a-una-terapia-mas-sencilla-contra-la-enfermedad-del-sueno/) - access the article
- [After CHMP nod, Moderna CEO applauds EU's 'rigorous scientific review'](https://dndi.org/in-the-media/2026/after-chmp-nod-moderna-ceo-applauds-eus-rigorous-scientific-review/) - access the article
- [EMA gives positive opinion for single-dose sleeping sickness medication](https://dndi.org/in-the-media/2026/ema-gives-positive-opinion-for-single-dose-sleeping-sickness-medication/) - access the article
- [Single-dose sleeping sickness pill clears major EU regulatory milestone](https://dndi.org/in-the-media/2026/single-dose-sleeping-sickness-pill-clears-major-eu-regulatory-milestone/) - access the article
- [Ascletis completed bridging study of ASC18, a one-pill, once-a-day complete HCV oral regimen](https://dndi.org/in-the-media/2020/ap-ascletis-completed-bridging-study-asc18-one-pill-once-a-day-hcv-regimen/) - read the article
- [WHO member countries agree on a draft ‘pandemic treaty’ to try to avoid COVID-19 mistakes](https://dndi.org/in-the-media/2025/who-member-countries-agree-on-a-draft-pandemic-treaty-to-try-to-avoid-covid-19-mistakes/) - ACCESS THE ARTICLE
- [New sleeping sickness pill gets nod, paving the way for use in Africa](https://dndi.org/in-the-media/2026/new-sleeping-sickness-pill-gets-nod-paving-the-way-for-use-in-africa/) - access the article
- [Breakthrough single-dose treatment for sleeping sickness gets EU nod](https://dndi.org/in-the-media/2026/breakthrough-single-dose-treatment-for-sleeping-sickness-gets-eu-nod/) - access the article
- [Pandemic preparedness: Novo Nordisk Foundation renews its support to DNDi and THSTI to continue the development of broad-spectrum antivirals](https://dndi.org/press-releases/2026/pandemic-preparedness-novo-nordisk-foundation-renews-support-dndi-thsti-development-broad-spectrum-antivirals/) - This grant will enable the continuation of a lead-optimization partnership initiated by DNDi and THSTI in March 2024, building on previous work that demonstrated the promise of this antiviral approach.
- [New pill has potential to eliminate deadly sleeping sickness](https://dndi.org/in-the-media/2026/new-pill-has-potential-to-eliminate-deadly-sleeping-sickness/) - access the article
- [Maladie du sommeil : l’autorisation européenne d’un nouveau traitement laisse entrevoir une élimination de la maladie d’ici à 2030](https://dndi.org/in-the-media/2026/maladie-du-sommeil-lautorisation-europeenne-dun-nouveau-traitement-laisse-entrevoir-une-elimination-de-la-maladie-dici-a-2030/) - access the article
- [La maladie du sommeil bientôt éliminée ? Feu vert européen à un nouveau traitement](https://dndi.org/in-the-media/2026/la-maladie-du-sommeil-bientot-eliminee-feu-vert-europeen-a-un-nouveau-traitement/) - watch the recording
- [‘Truly spectacular’ drug for sleeping sickness simplifies treatment, raising hopes for eradication](https://dndi.org/in-the-media/2026/truly-spectacular-drug-for-sleeping-sickness-simplifies-treatment-raising-hopes-for-eradication/) - ACCESS THE ARTICLE
- [Still no specific treatment for dengue despite global risk](https://dndi.org/in-the-media/2026/still-no-specific-treatment-for-dengue-despite-global-risk/) - read the article
- [DNDi welcomes GHIT support for lead identification of a novel chemical series in the Eisai-led Chagas disease project](https://dndi.org/news/2026/dndi-welcomes-ghit-support-lead-identification-novel-chemical-series-eisai-led-chagas-project/) - The objective of this project is to identify phosphodiesterase inhibitor lead compounds with favourable profiles and demonstrated efficacy in an acute Chagas disease model.
- [Neglected killer: Kala-azar disease surges in Kenya](https://dndi.org/in-the-media/2026/neglected-killer-kala-azar-disease-surges-in-kenya/) - Read the article
- [FGS mislabeled as an STI: The neglected waterborne parasite costing African women their dignity](https://dndi.org/in-the-media/2026/fgs-mislabeled-as-an-sti-the-neglected-waterborne-parasite-costing-african-women-their-dignity/) - read the article
- [Kala-azar in India: Treading the last mile towards elimination](https://dndi.org/in-the-media/2026/kala-azar-in-india-treading-the-last-mile-towards-elimination/) - read the article
- [Neglected tropical diseases: Hope to eliminate](https://dndi.org/in-the-media/2026/neglected-tropical-diseases-hope-to-eliminate/) - watch the episode
- [Kala-azar cases rise in Kajiado West, children most affected](https://dndi.org/in-the-media/2026/kala-azar-cases-rise-in-kajiado-west-children-most-affected/) - ACCESS THE ARTICLE
- [World NTD Spotlight: Dr Monique Wasunna](https://dndi.org/in-the-media/2026/world-ntd-spotlight-dr-monique-wasunna/) - read the article
- [Why India still carries the heaviest burden of neglected tropical diseases](https://dndi.org/in-the-media/2026/why-india-still-carries-the-heaviest-burden-of-neglected-tropical-diseases/) - read the article
- [Repurposing oxfendazole for onchocerciasis: Population pharmacokinetics of a tablet formulation in healthy African adults](https://dndi.org/scientific-articles/2026/repurposing-oxfendazole-for-onchocerciasis-population-pharmacokinetics-of-a-tablet-formulation-in-healthy-african-adults/) - by Assmus F, Adehin A, Hoglund RM, Nyaulingo G, Mbarak H, Jongo S, Ackermann E, Reus E, Keiser J, Barreira Da Silva Rocha F, Specht S, Scandale I, Tarning J. CPT: Pharmacometrics & Systems Pharmacology 2026;15(2):e70189. doi: 10.1002/psp4.70189 Summary: A Phase I bioavailability trial of oxfendazole, a veterinary anthelminthic with macrofilaricidal activity, evaluated a tablet
- [DNDi interventions at the 158<sup>th</sup> Session of the WHO Executive Board](https://dndi.org/statements/2026/dndi-interventions-at-the-158th-session-of-the-who-executive-board/) - DNDi's interventions at the 156th WHO Executive Board on universal health coverage; communicable diseases; women's, children's, and adolescents' health; and climate change and health.
- [Statement on Brazil’s draft National Action Plan for Antimicrobial Resistance](https://dndi.org/statements/2026/statement-brazil-draft-national-action-plan-antimicrobial-resistance/) - GARDP and DNDi welcome Brazil’s leadership in developing the new draft National action plan for the prevention and control of antimicrobial resistance (PAN BR 2026–2030).
- [DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases](https://dndi.org/press-releases/2026/dndi-and-dubai-health-launch-first-middle-east-partnership-to-advance-research-and-training-in-neglected-diseases/) - The partnership brings together DNDi’s global expertise in needs driven drug development and Dubai Health’s integrated academic health system to support research and capacity building across priority global health areas.
- [Maladies négligées : un modèle qui tient ses promesses](https://dndi.org/in-the-media/2026/maladies-negligees-un-modele-qui-tient-ses-promesses/) - The February 2026 edition (No. 334) of Pharmaceutiques features an in‑depth article on DNDi’s model for developing new treatments for neglected diseases through public–private partnerships. The piece highlights the recent submission by DNDi and Sanofi’s Foundation S to the EMA for scientific review of a novel molecule targeting sleeping sickness, as well as several other ongoing
- [DND<i>i</i> calls for nominations for a new Audit Committee Member](https://dndi.org/news/2022/call-nominations-audit-committee-member/) - The DNDi Foundation Board is seeking a new Audit Committee Member to provide the Audit Committee Chair with advice and guidance to ensure finance and compliance oversight of the Foundation, in its organization and projects.
- [Science can end the neglect: but only if we act together - World NTD Day 2026](https://dndi.org/news/2026/world-ntd-day-2026/) - We spoke out to raise awareness and urge commitments to develop the missing health tools still needed to save lives and make the control and elimination of NTDs possible.
- [Analysis of the consultations on the InfoChagas digital platform](https://dndi.org/scientific-articles/2026/analysis-consultations-infochagas-digital-platform/) - by Posada Diago E, Iglesias Rodríguez IM, Losada-Galván I, Aldasoro Irastorza E, Rubio Figuerola P, Alonso-Vega C, Gascon J, Rojas-Cortez M, Herazo R, Marchiol A, Abril M, Hernández E, Alonso-Padilla J, Sancho Mas F. PLOS Neglected Tropical Diseases 2026, 20(1):e0013469. doi: 10.1371/journal.pntd.0013469 Summary: Many individuals at risk Trypanosoma cruzi infection face barriers accessing information and
- [顧みられない患者に治療を　アフリカ睡眠病の新薬開発し野口英世賞](https://dndi.org/in-the-media/2026/顧みられない患者に治療をアフリカ睡眠病の新/) - ACCESS THE ARTICLE
- [Kronopolitides A–F, a family of 36-membered polyol macrolides with antiparasitic activity against Chagas disease](https://dndi.org/scientific-articles/2025/kronopolitides-a-f-a-family-of-36-membered-polyol-macrolides-with-antiparasitic-activity-against-chagas-disease/) - by Pérez-Bonilla M, Sánchez-Hidalgo M, González I, Martín J, Tormo JR, Cho A, Byun SY, Shum D, Ioset J-R, Reyes F, Genilloud O. Journal of Natural Products 2026;89(1):170–188. doi: 10.1021/acs.jnatprod.5c01249 Summary: The authors of this manuscript describe a joint effort between Fundación Medina, Institut Pasteur Korea, and DNDi to explore the chemical diversity of microbial
- [Bidirectional interaction between liposomal amphotericin B pharmacokinetics and parasite dynamics in patients with post-kala-azar dermal leishmaniasis: Potential implications for optimal dosing](https://dndi.org/scientific-articles/2025/bidirectional-interaction-between-liposomal-amphotericin-b-pharmacokinetics-and-parasite-dynamics-in-patients-with-post-kala-azar-dermal-leishmaniasis-potential-implications-for-optimal-dosing/) - by Chu W-Y, Prakash Singh O, Sundar S, Mondal D, Pandey K, Das P, Roseboom IC, Raja S, Torres A, Carrillo E, Huitema ADR, Alves F, Dorlo TPC. Clinical Pharmacology & Therapeutics 2026;119(2):437-446. doi: 10.1002/cpt.70124 Summary: The authors of this study characterized the interaction between liposomal amphotericin B (LAmB) pharmacokinetics, the mononuclear phagocyte system, and
- [Evaluation of quality of care in Chagas disease cardiomyopathy](https://dndi.org/scientific-articles/2026/evaluation-of-quality-of-care-in-chagas-disease-cardiomyopathy/) - by Gulayin PE, Pinazo M-J, Marcus R, Bern C, Clark EH, Nunes MCP, Nascimento BR, Shrikhande S, Taylor S, Perel P, Ribeiro AL. Global Heart 2026;21(1):6. doi: 10.5334/gh.1518 Summary: Despite existing guidelines, fragmented health systems, low provider awareness, and limited access to care hinder effective management of chronic Chagas cardiomyopathy. The authors of this manuscript
- [Message on the passing of Professor Sir Nicholas White from DNDi Board Chair Dr Marie-Paule Kieny and DNDi Executive Director Dr Luis Pizarro](https://dndi.org/news/2026/message-on-the-passing-of-sir-nicholas-white-from-dndi/) - Nick served as Chair of DNDi's Scientific Advisory Committee from 2016 to 2025. We extend our heartfelt condolences to Nick’s family, friends, and colleagues around the world.
- [From risk to remedy: Fast-tracking the end of sleeping sickness](https://dndi.org/videos/2026/from-risk-to-remedy-fast-tracking-the-end-of-sleeping-sickness/) - This short documentary film from Devex tells the remarkable story of the Democratic Republic of the Congo’s progress towards sleeping sickness elimination.
- [Innovations fast-tracking the end of sleeping sickness in the DRC](https://dndi.org/in-the-media/2026/innovations-fast-tracking-the-end-of-sleeping-sickness-in-the-drc/) - ACCESS THE ARTICLE
- [DNDi welcomes GHIT Fund’s renewed support to optimize novel compounds to treat Chagas disease](https://dndi.org/press-releases/2024/dndi-welcomes-ghit-funds-renewed-support-optimize-novel-compounds-chagas/) - Japan’s Global Health Innovative Technology (GHIT) Fund awarded a two-year, JPY 294 million (approx. EUR 1.8 million) grant to the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) and its partner Mitsubishi Tanabe Pharma Corporation (MTPC), to continue their lead optimization work on a novel compound to treat Chagas disease, with the ultimate goal to deliver a new safe and effective medicine.
- [Imperial and DNDi strengthen partnership to accelerate treatments for neglected diseases ](https://dndi.org/news/2026/imperial-and-dndi-strengthen-partnership-to-accelerate-treatments-for-neglected-diseases/) - Researchers from Imperial College London and DNDi met on 19 January to strengthen a growing partnership focused on developing new treatments, diagnostics and digital tools for diseases that disproportionately affect people in low- and middle-income countries
- [Will we have a treatment for dengue one day?](https://dndi.org/in-the-media/2025/will-we-have-a-treatment-for-dengue-one-day/) - ACCESS THE ARTICLE
- [Dengue on the rise](https://dndi.org/in-the-media/2025/dengue-on-the-rise/) - ACCESS THE ARTICLE
- [Brasil pode aumentar protagonismo na saúde global após turbulências nos EUA em 2025](https://dndi.org/in-the-media/2025/brasil-pode-aumentar-protagonismo-na-saude-global-apos-turbulencias-nos-eua-em-2025/) - ACCESS THE ARTICLE
- [When kala-azar delays motherhood: The regional burden women carry in West Pokot County](https://dndi.org/in-the-media/2026/when-kala-azar-delays-motherhood-the-regional-burden-women-carry-in-west-pokot-county/) - ACCESS THE ARTICLE
- [Beyond 'smaller men': The dangerous medical gap putting women’s lives at risk](https://dndi.org/in-the-media/2026/beyond-smaller-men-the-dangerous-medical-gap-putting-womens-lives-at-risk/) - ACCESS THE ARTICLE
- [DNDi and APHRC sign MoU to forge strategic alliance to bridge research and capacity enhancement gaps](https://dndi.org/news/2026/dndi-and-aphrc-sign-mou-forge-strategic-alliance-to-bridge-research-and-capacity-enhancement-gaps/) - Centring on engagement with academic institutions, policymakers, practitioners, and communities, this partnership is a commitment to transforming African-led research into impactful health policy and life-saving medical tools.
- [Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa](https://dndi.org/scientific-articles/2026/determinants-of-long-term-sars-cov-2-immune-responses-in-asymptomatic-to-moderate-covid-19-patients-in-sub-saharan-africa/) - by de Rioja VL, Goovaerts O, Vidal M, Amuasi J, Afum-Adjei Awuah A, Kahusu Mwan-za-k’a C, Mbala-Kingebeni P, Nyembu Kibambe R, Tshitamba M, Kazadi C, Embiale Yeshaneh W, Bedane Hunde D, Asres M, Tajebe F, Mutisse Massinga M, Maphossa V, Strauss R, Maiga Ascofare O, Monnot F, Ibnou Zekri Lassout N, Musa A, Adriaensen W,
- [DNDi's briefing note for 158<sup>th</sup> Session of the WHO Executive Board](https://dndi.org/statements/2026/dndi-briefing-note-for-158th-session-of-the-who-executive-board/) - This briefing sets out DNDi's comments for considerations by WHO Member States on agenda items covering strategy for women’s, children’s and adolescents’ health, universal health coverage, preparedness and response for health emergencies, and WHO global strategy on health, environment and climate change.
- [Making Medical History](https://dndi.org/stories/2018/making-medical-history/) - More than 180 friends, supporters, partners, celebrities, and global health influencers celebrated our 15-year anniversary with us at our Making Medical History Gala in New York City.
- [Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges](https://dndi.org/scientific-articles/2026/liposomal-antimicrobials-in-the-fight-against-bacterial-and-fungal-pathogens-clinical-successes-and-development-challenges/) - by Kenaan HT, Duncan RM, Al-Jamal WT, Jones DS, Andrews GP, Gilmore B, Yardley V, Farrington N, Stott KE, Lawrence D, Jarvis JN, Harrison TS, Robinson S, Ribeiro I, Hope W, Tian Y. International Journal of Pharmaceutics X 2026;11:100478. doi: 10.1016/j.ijpx.2025.100478 Summary: Bacterial, fungal, and protozoan infections pose a rapidly escalating threat to global health,
- [Dengue therapeutics consortium 2025: a global collaboration in action](https://dndi.org/scientific-articles/2026/dengue-therapeutics-consortium-2025-a-global-collaboration-in-action/) - by McBride A, Quang Chanh H, Trung Trieu H, Bang Tran H, Anderson KB, Aogo RA, Avirutnan P, Hoai Bao Tran L, Hui Chan X, Chandra R,7 Chang A, Ying Chia P, Daniel V, Demidova A, Rodriguez MPC, Figueiredo-Mello C, Garcia-Gallo E, Garrood W, Thi Hoai Tam D, Jaenisch T, Kain M, Katzelnick L, Khanh
- [Global health is in crisis: to reach neglected patients, we need to reimagine medical research](https://dndi.org/scientific-articles/2026/global-health-is-in-crisis-to-reach-neglected-patients-we-need-to-reimagine-medical-research/) - by Pizarro L. BMJ Global Health 2026;11:e022292. doi: 10.1136/bmjgh-2025-022292 Summary: The alternative, non-profit model for developing health tools faces a double challenge of foreign aid cuts and structural changes in the pharmaceutical industry. These radical shifts raise concerns about the future of non-profit medical innovation. The author of this Commentary suggests some possible ways to
- [Target product profile for the development of pediatric formulations of new drugs for the treatment of children with <i>T. cruzi</i> infection](https://dndi.org/scientific-articles/2026/target-product-profile-for-the-development-of-pediatric-formulations-of-new-drugs-for-the-treatment-of-children-with-t-cruzi-infection/) - by Forsyth C, Garcia-Bournissen F, Moscatelli G, Moroni S, Pereiro A, Ortiz-Daza L, Hernández Cuevas E-I, Tinajeros F, Marques T, Marchiol A, Herazo R, Seu S, Sancho J, Altcheh J, Pinazo M-J. PLOS Neglected Tropical Diseases 2026;20(1): e0013597. doi: 10.1371/journal.pntd.0013597 Summary: The authors of this target product profile (TPP) aimed to guide the development of
- [Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis](https://dndi.org/scientific-articles/2026/skin-pharmacokinetics-and-pharmacodynamics-in-patients-with-post-kala-azar-dermal-leishmaniasis/) - by Chu W-Y, Singh OP, Sundar S, Pandey K, Das P, Mondal D, Younis BM, Musa AM, Kumar Singh AK, Verma DK, Chaubey R, Kumari P, Chakravarty J, Madhukar M, Topno RK, Kumar A, Kumar V, Rashid U, Maruf S, Ghosh P, Saeed MA, Khalil EAG, Ahmed AE, Ali MA, Noureldin A, Roseboom IC, Moreno
- [DNDi 2025 in Review](https://dndi.org/news/2025/dndi-2025-in-review/) - As we near the end of 2024, Dr Luis Pizarro shares highlights from our work advancing science that answers the needs of communities impacted by neglected diseases.
- [DNDi 2024 in Review](https://dndi.org/news/2024/dndi-2024-in-review/) - As we near the end of 2024, Dr Luis Pizarro shares highlights from our work advancing science that answers the needs of communities impacted by neglected diseases.
- [The motorcyclist fighting a deadly disease in the African bush](https://dndi.org/in-the-media/2025/the-motorcyclist-fighting-a-deadly-disease-in-the-african-bush/) - ACCESS THE ARTICLE
- [Barbituric acid derivatives as covalent inhibitors of <em>Leishmania braziliensis</em> dihydroorotate dehydrogenase](https://dndi.org/scientific-articles/2025/barbituric-acid-derivatives-as-covalent-inhibitors-of-leishmania-braziliensis-dihydroorotate-dehydrogenase/) - by Quadros Froes T, Omowumi Alegbejo Price T, Fleck Godoi B, Menezes Vaidergorn M, dos Santos T, Ivo Palacio Leite P, Gedder Silva D, Dias da Purificação A, Loch L, Schenkman S, Kratz JM, da Silva Emery F, Cristina Nonato M. Journal of Medicinal Chemistry 2025, 68(18):18869–18884. doi: 10.1021/acs.jmedchem.5c00462 Summary: The authors of this manuscript
- [Target product profile and discovery and development path for novel cryptococcal disease treatments](https://dndi.org/scientific-articles/2025/target-product-profile-and-discovery-and-development-path-for-novel-cryptococcal-disease-treatments/) - by Meya DB, De Rycker M, Gilbert IH, Hope W, Jelagat Odionyi J, Keegane M, Loysef A, Moral-Lopezg P, Williamson PR, Tane LK, Ribeiro I, Miles TJ. Journal of Infection 2025, 91(5):106643. doi: 10.1016/j.jinf.2025.106643 Summary: The World Health Organization has designated Cryptococcus neoformans and Cryptococcus gattii as critical and medium priority pathogens, respectively. These mainly impact people with
- [The biggest mosquito-borne disease in the world has a cure. There’s just one problem](https://dndi.org/in-the-media/2025/the-biggest-mosquito-borne-disease-in-the-world-has-a-cure-theres-just-one-problem/) - ACCESS THE ARTICLE
- [Explainer: Chagas disease spreads to richer countries](https://dndi.org/in-the-media/2025/explainer-chagas-disease-spreads-to-richer-countries/) - by Michelle Childs, Policy Advocacy Director at DNDi. Read the article
- [Host-derived molecules as novel chagas disease biomarkers: hypercoagulability markers and extracellular vesicles](https://dndi.org/scientific-articles/2025/host-derived-molecules-as-novel-chagas-disease-biomarkers-hypercoagulability-markers-and-extracellular-vesicles/) - by Barnadas-Carceller B, Tàssies D, Losada Galván I, Alonso-Padilla J, Carles Reverter J, Fernandez-Becerra C, Pinazo M-J. In: Gómez, K.A., Buscaglia, C.A. (eds). Methods in Molecular Biology 2026, 2982. Humana, New York, NY. doi: 10.1007/978-1-0716-4848-3_19 Summary: Due to the lack of reliable biomarkers for disease prognosis and treatment monitoring of Chagas disease, there has been
- [Noma as a neglected tropical disease: an opportunity to reconsider neglect in global health](https://dndi.org/scientific-articles/2025/noma-as-a-neglected-tropical-disease-an-opportunity-to-reconsider-neglect-in-global-health/) - by Elysium Noma Survivors Association E, Izzett D, Izzett B, Trotter A, Nunes J, Cismas I, Jeantet C, Kabengele E, Benzian H, Gebretsadik H, Merrill L, Ribes M, Comparet M, Sherlock M, Bhakuni H. BMJ Global Health 2025, 10:e019152. doi: 10.1136/bmjgh-2025-019152 Summary: The rise of neglected tropical diseases (NTDs) as a global health category has
- [Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations](https://dndi.org/statements/2025/dndi-statement-on-conclusion-of-who-pandemic-agreement-negotiations/) - DNDi welcomes the historic consensus on the WHO Pandemic Agreement—a first-of-its-kind treaty that, if implemented, could help reshape global health equity by ensuring public funding delivers public benefit.
- [Structure–activity relationships of fenarimol analogues with potent in vitro and in vivo activity against Madurella mycetomatis, the main causative agent of eumycetoma](https://dndi.org/scientific-articles/2025/structure-activity-relationships-fenarimol-analogues-against-madurella-mycetomatis-eumycetoma/) - by Duong HP, Melechov D, Lim W, Jingyi M, Scroggie KR, Rajendra L, Perry B, Cruz LR, Saleem RSZ, Rutledge P, Motion A, van de Sande WWJ, Todd MH. RSC Medicinal Chemistry 2025, 16:6094-6108. doi: 10.1039/D5MD00427F Summary: The fenarimol analogue EPL-BS1246 is potent against Madurella mycetomatis, the causative agent of eumycetoma. Further evaluation of a
- [Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants](https://dndi.org/scientific-articles/2025/safety-tolerability-and-pharmacokinetics-of-dndi-6148-a-novel-agent-for-leishmaniasis-a-randomized-controlled-single-ascending-dose-study-in-healthy-participants/) - by Gillon J-Y, Delhomme S, Launay D, Blesson S, Braillard S, Maghdooni P, Assmus F, Hoglund R, Tarning J, Loyau S, Arana B, Latreille-Barier M, Donazzolo Y. British Journal of Clinical Pharmacology 2025;1-11. doi: 10.1002/bcp.70328 Summary: The benzoxaborole derivative DNDI-6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. The authors of this
- [The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities](https://dndi.org/scientific-articles/2025/the-development-of-a-global-research-agenda-and-individual-participant-data-platform-for-visceral-leishmaniasis-challenges-and-future-opportunities/) - by Singh-Phulgenda S, Dahal P, Maguire BJ, Alvar J, Alves F, Chatterjee M, Costa C, Croft SL, Guerin PJ, Mondal D, Musa A, Pandey K, Ritmeijer K, Romero G, Sundar S. Parasites & Vectors 2025;18, 496. doi: 10.1186/s13071-025-07121-2 Summary: The authors of this manuscript describe the development of a global visceral leishmaniasis (VL) research agenda
- [DNDi statement on COP30: Advancing health in the climate agenda](https://dndi.org/news/2025/dndi-statement-on-cop30-advancing-health-in-the-climate-agenda/) - The COP30 climate summit came to an end with mixed feelings. But within the complex and often demanding negotiations, one development stood out as both meaningful and long overdue: health finally gained the visibility it deserves.
- ["Como si me comiera desde dentro": la enfermedad que ataca los huesos en el norte de Kenia](https://dndi.org/in-the-media/2025/como-si-me-comiera-desde-dentro-la-enfermedad-que-ataca-los-huesos-en-el-norte-de-kenia/) - ACCESS THE ARTICLE
- [Innovating together to eliminate NTDs - World NTD Day 2024](https://dndi.org/news/2024/innovating-together-world-ntd-day-2024/) - On World NTD Day on 30 January, join our call for innovation and medical research for all!
- [Onchocerciasis drug discovery: In vitro evaluation of FDA-approved drugs against <i>onchocerca gutturosa</i> in Gambia](https://dndi.org/scientific-articles/2024/onchocerciasis-drug-discovery-in-vitro-evaluation-fda-approved-drugs-against-onchocerca-gutturosa-gambia/) - by Gokool S, Townson S, Freeman A, Siemienski-Kleyn J, Zubrzycki J, Tagboto S, Hübner MP, Scandale I. Pharmaceutics 2024, 16(2): 210. doi: 10.3390/pharmaceutics16020210 Summary: Onchocerciasis is mainly treated and controlled with ivermectin, which has high activity against the microfilarial stage of Onchocerca volvulus but limited activity against the long-lived, tissue-dwelling adult nematodes. We urgently need new drugs
- [Empowering Tanzanian journalists and researchers in science communication](https://dndi.org/news/2024/empowering-tanzanian-journalists-and-researchers-in-science-communication/) - DNDi collaborates with Ifakara Health Institute to translate scientific content into engaging media stories
- [2023 R&D portfolio in review: Filaria - river blindness](https://dndi.org/news/2024/2023-rd-portfolio-in-review-filaria-river-blindness/) - DNDi and our partners are working to develop a first-ever cure for millions at risk. Our goal is to advance the development of new drug candidates, complete Phase II clinical trials, and launch a Phase III confirmatory trial that we hope will result in new treatment options – not only for onchocerciasis but also for a range of filarial diseases.
- [DNDi receives grant to develop treatments for NTDs](https://dndi.org/in-the-media/2024/dndi-receives-grant-to-develop-treatments-for-ntds/) - ACCESS THE ARTICLE
- [DNDi 2023 Annual Report](https://dndi.org/publications/2024/dndi-2023-annual-report/) - 20 years of innovating together
- [The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis](https://dndi.org/scientific-articles/2024/new-treatments-filaria/) - by Risch F, Kazakov A, Specht S, Pfarr K, Fischer PU, Hoerauf A, Hübner MP. Trends in Parasitology 2024. doi: 10.1016/j.pt.2024.07.005 1 Summary: Although lymphatic filariasis and onchocerciasis have been targeted for global elimination, these helminth infections are still a major public health problem across the tropics and subtropics. Despite decades of research, treatment options
- [De l’Ituri à Genève, à la recherche de nouveaux médicaments contre la cécité des rivières](https://dndi.org/news-translations/2024/de-lituri-a-geneve-a-la-recherche-de-nouveaux-medicaments-contre-la-cecite-des-rivieres-dr-jack-zawadi/) - Le chercheur et médecin congolais Dr Jack Zawadi est l’un des boursiers (ou fellows) 2024 du programme de Leadership en Recherche Clinique de l'OMS-TDR.
- [From Ituri to Geneva, in the search for new medicines for river blindness](https://dndi.org/stories/2024/from-ituri-to-geneva-dr-jack-zawadi-river-blindness/) - Congolese physician Dr Jack Zawadi Tsulokpa is a 2024 fellow of the WHO-TDR Clinical Research Leadership program, contributing to DNDi research on river blindness.
- [Parasitic worms factsheet](https://dndi.org/publications/2024/parasitic-worms-factsheet-2024/) - Breaking the cycle of infection, disability, and stigma
- [Science and collaboration can end the neglect - World NTD Day 2025](https://dndi.org/news/2025/science-and-collaboration-can-end-the-neglect-world-ntd-day-2025/) - We spoke out to raise awareness and urge commitments to develop the missing health tools still needed to save lives and make the control and elimination of NTDs possible.
- [DNDi와 소외질환 치료제 개발 공동 연구 나선다](https://dndi.org/press-releases-translations/2025/kmedi-dndi-initiate-collaborative-rd-to-develop-treatment-neglected-diseases-ko/) - 전세계 보급이 용이한 회선사상충증 치료제 개발 공동 연구기관 선정 DNDi 주관, 총 32억 원 규모의 공익적 프로젝트 수행
- [DNDi Brochure](https://dndi.org/publications/2025/dndi-brochure/) - Find out about DNDi's mission to discover, develop, and deliver safe, effective, and affordable treatments for the most neglected patients.
- [Switzerland renews commitment to DNDi to advance medical innovation for neglected patients ](https://dndi.org/press-releases/2025/switzerland-renews-commitment-to-dndi-to-advance-medical-innovation-for-neglected-patients/) - The Swiss Agency for Development and Cooperation (SDC) has renewed its commitment to health for all with a contribution of CHF 7.2 million (EUR 7.6 million) to DNDi for the period 2025–2028.
- [Neglecting infectious diseases is a market failure](https://dndi.org/viewpoints/2025/neglecting-infectious-diseases-is-a-market-failure/) - by Michelle Childs, Policy Advocacy Director at DNDi. By Michelle Childs, Policy Advocacy Director, DNDi For the past two decades, large multinational pharmaceutical companies have increasingly withdrawn from researching medicines for infectious diseases — particularly those affecting poor and vulnerable populations — while focusing instead on cancer, obesity and autoimmune diseases. This is a textbook market failure. Infectious diseases affect hundreds of millions
- [K-MEDI and DNDi have initiated collaborative R&D to develop a treatment for neglected diseases](https://dndi.org/press-releases/2025/kmedi-dndi-initiate-collaborative-rd-to-develop-treatment-neglected-diseases/) - K-MEDI has been chosen as a collaborating institute for developing an affordable and globally accessible medicine for river blindness. The project is led by DNDi and supported by a 3.2 billion KRW grant from the RIGHT Foundation.
- [DNDi 2024 Annual Report](https://dndi.org/publications/2025/dndi-2024-annual-report/) - Read our Annual Report to learn how solidarity in science is benefiting the most neglected.
- [DNDi <i>2025 Projects of the Year</i> recognize contributions of DNDi teams and partners working to deliver urgently needed innovations for people affected by Chagas disease and river blindness](https://dndi.org/news/2025/2025-projects-of-the-year-recognize-contributions-teams-partners-working-innovations-chagas-disease-river-blindness/) - DNDi's 2025 Projects of the Year are Biomarkers for Chagas disease and emodepside for river blindness.
- [2024 R&D programmes in review: Filaria - river blindness](https://dndi.org/news/2025/2024-rd-programmes-in-review-filaria-river-blindness/) - DNDi and our partners are working to develop a first-ever cure for millions at risk.
- [Dr Javid Abdelmoneim, Datuk Dr Mahathar bin Abd Wahab, Dr Taruna Madan, Violet Naanyu, and Dr Mario Santos Moreira join the Board of Directors at DNDi](https://dndi.org/news/2025/javid-abdelmoneim-mahathar-abd-wahab-taruna-madan-violet-naanyu-and-mario-moreira-join-dndi-board-of-directors/) - DNDi is very pleased to announce the appointment of Dr Javid Abdelmoneim, Dr Mahathar Abd Wahab, Dr Taruna Madan, Violet Naanyu, and Dr Mario Santos Moreira as members of the organization’s Board of Directors.
- [Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)](https://dndi.org/scientific-articles/2025/core-outcome-measurement-set-for-clinical-trials-in-dengue-an-international-delphi-consensus-study-den-core/) - by Yacoub S, Demidova A, Chan XHS, Ajam A, Baimukhambetova D, Horn A, Kakotkina E, Kosenko M, Mursalova A, Nuil JIV, Phuong CL, Xiao L, Adhikari S, Alvarez JDA, Anderson KB, Avirutnan P, Buchholz S, Chandra R, Chang AY, Chanh HQ, Rodríguez MPC, Daniel V, Diaz JV, Figueiredo-Mello C, Gelvez-Ramírez RM, Huyen TB, Kestelyn E,
- [International seminar explores the development of treatments for dengue for populations not covered by vaccines](https://dndi.org/press-releases/2025/seminar-explores-trials-for-dengue-treatments/) - English English Español Português Researchers and health authorities from Brazil, India, Malaysia, and Thailand gathered on 26 November in Brasília for the seminar ‘Global South Cooperation in the Search for Dengue Treatments.’ The event was organized by the Dengue Alliance – a coalition formed by the Drugs for Neglected Diseases initiative (DNDi), Fiocruz, the Federal
- [Policies to promote affordability and access across the life cycle of costly new drugs](https://dndi.org/in-the-media/2025/policies-to-promote-affordability-and-access-across-the-life-cycle-of-costly-new-drugs/) - ACCESS THE ARTICLE
- [India bears 42% of global burden of neglected tropical diseases: WHO](https://dndi.org/in-the-media/2025/india-bears-42-of-global-burden-of-neglected-tropical-diseases-who/) - read the article
- [Varios activistas climáticos invaden el área restringida de la COP30 durante una protesta](https://dndi.org/in-the-media/2025/varios-activistas-climaticos-invaden-el-area-restringida-de-la-cop30-durante-una-protesta/) - ACCESS THE ARTICLE
- [Hope for millions as over sh180b invested to develop new drugs for dengue fever](https://dndi.org/in-the-media/2025/hope-for-millions-as-over-sh180b-invested-to-develop-new-drugs-for-dengue-fever/) - ACCESS THE ARTICLE
- [Fra flue til flue har denne fjende hærget Afrika. Men nu er sejren mod sovesyge lige om hjørnet](https://dndi.org/in-the-media/2025/fra-flue-til-flue-har-denne-fjende-haerget-afrika-men-nu-er-sejren-mod-sovesyge-lige-om-hjornet/) - read the article
- [Warming temperature and humidity expand dengue’s reach](https://dndi.org/in-the-media/2025/warming-temperature-and-humidity-expand-dengues-reach/) - ACCESS THE ARTICLE
- [Leishmaniasis](https://dndi.org/scientific-articles/2025/leishmaniasis/) - by Pareyn M, Alves F, Burza S, Chakravarty J, Alvar J, Diro E, Kaye PM, van Griensven J. Nature Reviews Disease Primers 2025;11, 81. doi: 10.1038/s41572-025-00663-w Summary: In this disease primer, the authors provide an overview of Leishmania biology and leishmaniasis epidemiology and immunopathogenesis, highlighting clinical features, diagnostic and treatment strategies, and prevention and control measures.
- [DNDi statement on the approval of the Instituto Butantan’s dengue vaccine and the need for a dengue treatment](https://dndi.org/news/2025/statement-approval-instituto-butantans-dengue-vaccine-and-need-for-dengue-treatment/) - DNDi congratulates the Instituto Butantan in Brazil for the approval of its single-dose dengue vaccine by the Brazilian regulatory authority Anvisa and reinforces the need for a medicine against dengue.
- [Interview with Dr Pauline Williams, new DNDi Scientific Advisory Committee (SAC) Chair](https://dndi.org/videos/2025/interview-dr-pauline-williams-new-dndi-scientific-advisory-committee-chair/) - Dr Pauline Williams shares her perspective on why the SAC’s scientific opinions are so crucial to DNDi's work – along with her views on non-profit medical R&D, current shifts in the global health innovation ecosystem, and how organizations like DNDi can tackle future challenges.
- [Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans](https://dndi.org/scientific-articles/2025/mass-balance-pharmacokinetics-metabolism-excretion-of-radiolabeled-acoziborole-following-single-microtracer-oral-dose/) - by Gillon J, Simon F, Sidhu S, Louis M, Launay D, Wauthier V, Pelay-Gimeno M, Andel LV, Loyau S, Rembry S, Weinling E, Tarral A. Antimicrobial Agents and Chemotherapy 2025, 69(11): e00580-25. doi: 110.1128/aac.00580-25 Summary: Acoziborole is an oxaborole 6-carboxamide active against Trypanosoma brucei gambiense and rhodesiense, the parasites responsible for human African trypanosomiasis. The authors of this
- [A doctor's dream: The story behind the development of fexinidazole](https://dndi.org/stories/2018/a-doctors-dream/) - The faces behind the development of a new drug for sleeping sickness.
- [Short film - A doctor’s dream: A pill for sleeping sickness](https://dndi.org/videos/2018/a-doctors-dream-a-pill-for-sleeping-sickness/) - From the rediscovery of an abandoned molecule to a breakthrough medicine: follow the stories of sleeping sickness patients, doctors, and researchers. Find out more about the development of fexinidazole Deutsch EspañolFrançaisJapaneseKoreanMandarin ChinesePortuguês The discovery of fexinidazole - Interview with Els Torreele Clinical trials for fexinidazole - A conversation with Dr Antoine Tarral and Dr Olaf
- [Joint statement by CEPI, DNDi, MMV, and Unitaid on the Belém Health Action Plan (BHAP)](https://dndi.org/statements/2025/joint-statement-cepi-dndi-mmv-and-unitaid-on-belem-health-action-plan-bhap/) - CEPI, DNDi, MMV, and Unitaid jointly welcome the Belém Health Action Plan for inclusion of proposed actions on responding to infectious diseases.
- [COP 30: The climate crisis is also a crisis for neglected diseases, warns DNDi](https://dndi.org/press-releases/2025/cop30-the-climate-crisis-is-also-crisis-for-neglected-diseases-warns-dndi/) - DNDi will attend a meeting on 13 November led by Brazil’s Minister of Health, Alexandre Padilha, focused on the Belém Health Action Plan, an international framework for climate and health adaptation policies introduced by Brazil.
- [COVID-19 Policy Report](https://dndi.org/publications/2021/covid19-policy-report/) - This DNDi Policy Report urges the international community to learn the positive lessons and avoid repeating mistakes that would hinder innovation of and access to COVID-19 therapeutics, offering a series of recommendations for immediate course-correction based on our experience as an R&D organization.
- [Dengue : l’Europe investit 20 millions d’euros pour développer de nouveaux traitements](https://dndi.org/in-the-media/2025/dengue-leurope-investit-20-millions-deuros-pour-developper-de-nouveaux-traitements/) - ACCESS THE ARTICLE
- [Pharma’s shift away from infectious disease research could spell disaster for the world’s poorest people](https://dndi.org/viewpoints/2025/pharmas-shift-away-from-infectious-disease-research-could-spell-disaster-worlds-poorest-people/) - By Laurent Fraisse, Research & Development Director, DNDi By Laurent Fraisse, Research & Development Director, DNDi In 2023, Johnson & Johnson announced it had stopped research and development on therapeutics for many infectious diseases, including hepatitis and tuberculosis. Less visibly, AbbVie shuttered last year its pro bono technical R&D support on infectious diseases such as malaria and Chagas’ disease. These are not isolated cases. An
- [Twenty years of the Regional Kala-azar Elimination Initiative in South Asia](https://dndi.org/news/2025/twenty-years-of-the-regional-kala-azar-elimination-initiative-in-south-asia/) - At the 78th session of the WHO Regional Committee for South-East Asia held in Colombo, Sri Lanka, on 14 October 2025, global health leaders, policymakers, researchers, and partners came together to celebrate two decades of progress against kala-azar (visceral leishmaniasis) – one of South Asia’s most devastating neglected tropical diseases.
- [Vita dhidi ya ugonjwa wa Kala-azar vyazaa matunda Pokot baada ya mgonjwa kutibiwa na kupona](https://dndi.org/in-the-media/2025/vita-dhidi-ya-ugonjwa-wa-kala-azar-vyazaa-matunda-pokot-baada-ya-mgonjwa-kutibiwa-na-kupona/) - ACCESS THE ARTICLE
- [European Commission invests EUR 20 million to develop urgently-needed medicines against dengue in partnership with AFD and DNDi](https://dndi.org/press-releases/2025/european-union-invests-eur-20-million-develop-medicines-dengue-partnership-with-afd-dndi/) - Dengue is spreading fast because of climate change and globalization, with a growing number of cases in previously unaffected European countries. Yet, there is still no specific treatment for the disease.
- [La Commission européenne investit 20 millions d’euros pour développer des médicaments contre la dengue en partenariat avec l’Agence française de développement et DNDi](https://dndi.org/press-releases-translations/2025/union-europeenne-investit-20-millions-euros-developper-medicaments-contre-dengue-avec-agence-francaise-de-developpement-et-dndi/) - La dengue se propage rapidement sous l’effet du changement climatique et de la mondialisation, avec une augmentation du nombre de cas dans plusieurs pays européens auparavant non-touchés. Pourtant, il n’existe toujours aucun traitement spécifique contre la maladie.
- [Chagas Platform Newsletter N°15](https://dndi.org/publications/2025/chagas-platform-newsletter-n15/) - The Chagas Platform newsletter reports on the platform's recent activities and latest research on Chagas disease in Latin America.
- [Open science yields broad-spectrum coronavirus antiviral](https://dndi.org/in-the-media/2025/open-science-yields-broad-spectrum-coronavirus-antiviral/) - ACCESS THE ARTICLE
- [Mobilisers on motorbikes: The complex process of involving communities in clinical trials](https://dndi.org/in-the-media/2025/mobilisers-on-motorbikes-the-complex-process-of-involving-communities-in-clinical-trials/) - ACCESS THE ARTICLE
- [DNDi receives global award for developing new treatments for NTDs](https://dndi.org/in-the-media/2025/dndi-receives-global-award-for-developing-new-treatments-for-ntds/) - ACCESS THE ARTICLE
- [Ce que le Prix Hideyo Noguchi change pour les patients africains, DNDi répond](https://dndi.org/in-the-media/2025/ce-que-le-prix-hideyo-noguchi-change-pour-les-patients-africains-dndi-repond/) - ACCESS THE ARTICLE
- [Jessica Robbins: A long and difficult journey with cutaneous leishmaniasis](https://dndi.org/stories/2025/jessica-robbins-a-long-and-difficult-journey-with-cutaneous-leishmaniasis/) - Congolese physician Dr Jack Zawadi Tsulokpa is a 2024 fellow of the WHO-TDR Clinical Research Leadership program, contributing to DNDi research on river blindness.
- [Road to Elimination of Kala-azar in South Asia](https://dndi.org/videos/2025/road-to-elimination-of-kala-azar-in-south-asia/) - Kala-azar (visceral leishmaniasis) once devastated the poorest and most vulnerable communities, standing as one of South Asia’s toughest public health challenges. Today, that story is being rewritten.
- [Medicines for Africa: with cutting-edge research, Ghana is at the forefront](https://dndi.org/in-the-media/2025/medicines-for-africa-with-cutting-edge-research-ghana-is-at-the-forefront/) - read the article
- [Hepatitis C treatment can be safely shortened](https://dndi.org/in-the-media/2025/hepatitis-c-treatment-can-be-safely-shortened/) - ACCESS THE ARTICLE
- [Breakthrough in sleeping sickness treatment](https://dndi.org/in-the-media/2025/breakthrough-in-sleeping-sickness-treatment/) - ACCESS THE ARTICLE
- [What to know about the potentially deadly 'kissing bugs'](https://dndi.org/in-the-media/2025/what-to-know-about-the-potentially-deadly-kissing-bugs/) - ACCESS THE ARTICLE
- [Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials](https://dndi.org/scientific-articles/2025/quantifying-anti-trypanosomal-treatment-effects-chagas-disease-secondary-analysis-data-two-proof-of-concept-trials/) - by Watson JA, Cruz C, Barreira F, Forsyth C, Schijman AG, Peploe R, Assmus F, Naylor C, Lee J, Mehra S, Tarning J, Torrico F, Gascon J, Ortiz L, Ribeiro I, Sosa-Estani S, Tipple C, Hugonnet S, Guérin PJ, Fraisse L, Pinazo M-J, White NJ, on behalf of the E1224 and BENDITA Study Groups. The
- [野口英世アフリカ賞」授賞式 マリ出身の研究者らが受賞](https://dndi.org/in-the-media/2025/野口英世アフリカ賞授賞式-マリ出身の研究者ら/) - ACCESS THE ARTICLE
- [「元の足がほしい」治療届かず切断も　貧困の連鎖招くマイセトーマ](https://dndi.org/in-the-media/2025/元の足がほしい治療届かず切断も貧困の連/) - ACCESS THE ARTICLE
- [El acuerdo sobre pandemias es nuestra oportunidad de priorizar a las personas](https://dndi.org/viewpoints/2025/el-acuerdo-sobre-pandemias-es-nuestra-oportunidad-de-priorizar-a-las-personas/) - By Dr Luis Pizarro, Executive Director, DNDi Más de cinco años después del inicio de la pandemia del coronavirus, los gobiernos han alcanzado un Acuerdo Mundial sobre Pandemias. Han sido necesarios tres años de negociaciones en la Organización Mundial de la Salud (OMS), e incluso una votación bien avanzada la noche en la Asamblea Mundial de la Salud celebrada
- [The Boy Who Beat the Sandfly](https://dndi.org/videos/2025/the-boy-who-beat-the-sandfly/) - The Boy Who Beat the Sandfly tells Henry’s story of courage and recovery, showing the impact visceral leishmaniasis can have on children and the communities that cherish them. It’s also a call to action for better, simpler treatments for both children and adults affected by one of the world’s deadliest parasitic diseases.
- [Open-science approach delivers a promising pre-clinical candidate for broad-spectrum coronavirus antiviral ](https://dndi.org/press-releases/2025/open-science-approach-delivers-preclinical-candidate-broad-spectrum-coronavirus-antiviral/) - ASAP-0017445 is designed to be a direct-to-generic, globally accessible treatment ready for future coronavirus pandemics.
- [Le développement de médicaments pour les maladies négligées doit tenir compte des enfants](https://dndi.org/viewpoints/2025/le-developpement-de-medicaments-pour-les-maladies-negligees-doit-tenir-compte-des-enfants/) - By Dr Justine Odionyi, Head of Disease, HIV, DNDi L’inclusion des enfants dans les essais cliniques et l’élaboration de réglementations locales pourraient permettre de mettre au point des traitements plus sûrs et plus efficaces en Afrique. Lorsque Faith, âgée de trois ans, a entendu l’infirmière l’appeler dans le service de leishmaniose viscérale de l’hôpital de référence du sous-comté
- [Drug development for neglected diseases must account for kids](https://dndi.org/viewpoints/2025/drug-development-for-neglected-diseases-must-account-for-kids/) - By Dr Justine Odionyi, Head of Disease, HIV, DNDi Including children in trials, shaping regulation locally, could deliver safer, more effective therapies in Africa. When three-year-old Faith heard her name called by the nurse in the visceral leishmaniosis ward in Kacheliba Sub-County Referral Hospital in West Pokot, Kenya, she burst into tears. Her cry echoed through the
- [Malaysia’s progress in treating hepatitis C](https://dndi.org/in-the-media/2025/malaysias-progress-in-treating-hepatitis-c/) - ACCESS THE ARTICLE
- [Performance evaluation of rapid diagnostic tests for Chagas disease in Jutiapa, Guatemala](https://dndi.org/scientific-articles/2025/performance-evaluation-of-rapid-diagnostic-tests-for-chagas/) - by Lange K, Marchiol A, Herazo R, Menes M, Monroy C, Rodas A, Alcántara B, Carrillo K, Pinazo MJ. Journal of the Brazilian Society of Tropical Medicine 2025, 58:e00652025. doi: 10.1590/0037-8682-0065-2025 Summary: Chagas disease remains a public health problem in Guatemala, with ongoing transmission, both regionally and globally. Diagnosis is complex and often inaccessible. The
- [New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial](https://dndi.org/scientific-articles/2025/new-benznidazole-regimens-chagas-disease-clinical-trial-protocol/) - by Marques T, Forsyth C, Barreira F, Lombas C, Blum de Oliveira B, Laserna M, Molina I, Bangher M C, Fernández R J, Lloveras S, Fernández M L, Scapellato P, Patterson P, Garcia W, Ortiz L, Schijman A, Moreira O C, García L, Viele K, Longhi S, Vaillant M, Tipple C, Fraisse L, Silvestre-Sousa A,
- [米国不在のパンデミック条約　トランプ氏だけでなく製薬業界の意向も](https://dndi.org/in-the-media/2025/米国不在のパンデミック条約トランプ氏だけでなく製薬業界の意向も/) - Access the article
- [Uncovering Turkana's silent plague: The gruesome disease crippling a region](https://dndi.org/in-the-media/2025/uncovering-turkanas-silent-plague-the-gruesome-disease-crippling-a-region/) - watch the video
- [VIH avancé : DNDi innove et décentralise les soins pour sauver des vies en RDC](https://dndi.org/in-the-media/2025/vih-avance-dndi-innove-et-decentralise-les-soins-pour-sauver-des-vies-en-rdc/) - access the article
- [Opinion: Patentes: uma proposta para a Ciência Aberta](https://dndi.org/viewpoints/2025/opinion-patentes-uma-proposta-para-a-ciencia-aberta/) - by Ed Griffen and Pascale Boulet By Ed Griffen and Pascale Boulet The relationship between intellectual property (IP) and access to the fruits of science has always been tumultuous. The unequal distribution of messenger RNA vaccines during the COVID-19 pandemic pitted patent holders against advocates of access to medicines in the latest confirmation of this truism. In global health, rationing costs
- [Collaborative synthesis for neglected diseases through the Open Synthesis Network: structure–activity relationships of arylaminopyrazoles as Chagas disease treatments](https://dndi.org/scientific-articles/2025/collaborative-synthesis-for-neglected-diseases-open-synthesis-network-structure-activity-relationships-arylaminopyrazoles-chagas-disease/) - by Abdulai Z, Agbo N, Anderson JI, Astley F, Chan B, Atkinson-Evans O, Avelar JL, Aparecida-Silva C, Bhardwaj KD, Bowley WJ, Breitkreuz N, Canby R, Cartwright E, Clifford C, Cordell SA, Donker WJ, Driscoll J, Grady M, Higginbotham L, Hsu D, Hutchinson J, Imberg L, Jackson HF, Johns F, Jones E, Kalinin DV, Kardeşler C,
- [DNDi calls for nominations for private sector Board member ](https://dndi.org/news/2025/dndi-calls-for-nominations-for-private-sector-board-member/) - DNDi is looking for an expert in the private sector to join its Board of Directors.
- [Luke Kanyang’areng becomes first Kenyan to receive Human Rights and Nursing Award](https://dndi.org/news/2025/luke-kanyangareng-becomes-first-kenyan-to-receive-human-rights-and-nursing-award/) - Luke Kanyang’areng, a nurse from West Pokot County, Kenya, became the first Kenyan to receive the Human Rights and Nursing Award.
- [DNDi receives Japan’s Hideyo Noguchi Africa Prize 2025 for its work to develop new treatments for neglected diseases in Africa ](https://dndi.org/press-releases/2025/dndi-receives-japans-hideyo-noguchi-africa-prize-2025-for-work-develop-new-treatments-for-neglected-diseases-africa/) - DNDi has been awarded the fifth Hideyo Noguchi Africa Prize in the medical services category in a ceremony held today in Tokyo in the presence of Their Majesties the Emperor and Empress of Japan and hosted by Shigeru Ishiba, Prime Minister of Japan.
- [Dengue, and the future of DND<i>i</i>](https://dndi.org/in-the-media/2022/dengue-and-the-future-of-dndi/) - access the episode
- [A leap of faith](https://dndi.org/in-the-media/2022/a-leap-of-faith/) - access the episode
- [The cutting edge](https://dndi.org/in-the-media/2022/the-cutting-edge/) - Access the episode
- [Open source, open science](https://dndi.org/in-the-media/2022/open-source-open-science/) - access the episode
- [Medicine Maker Without Borders: Who are the DND<i>i</i>?](https://dndi.org/in-the-media/2022/medicine-maker-without-borders-who-are-the-dndi/) - Access the episode
- [Neglected diseases, and how to beat them](https://dndi.org/in-the-media/2022/neglected-diseases-and-how-to-beat-them/) - access the episode
- [DND<i>i</i> Brochure](https://dndi.org/publications/2015/dndi-brochure-2015/) - 2015EnglishDeutschEspañolFrançaisPortuguês العربية (Arabic)日本語 (Japanese)Browse Online »
- [HIV factsheet](https://dndi.org/publications/2024/hiv-factsheet-2024/) - Confronting urgent threats to people with advanced HIV disease
- [Hepatitis C factsheet](https://dndi.org/publications/2024/hepatitis-c-factsheet-2024/) - Supporting global elimination efforts by accelerating ‘test-and-treat’ strategies
- [Chagas disease factsheet](https://dndi.org/publications/2024/chagas-disease-factsheet-2024/) - Searching for shorter, safer, more effective treatments to stop a silent killer
- [Dengue factsheet](https://dndi.org/publications/2024/dengue-factsheet-2024/) - Developing urgently needed treatments for a rapidly spreading climate-sensitive disease
- [Mycetoma factsheet](https://dndi.org/publications/2024/mycetoma-factsheet-2024/) - Developing safe, affordable treatments to prevent devastating disability
- [Leishmaniasis factsheet](https://dndi.org/publications/2024/leishmaniasis-factsheet-2024/) - Delivering safer, simpler treatments to save lives and reduce social stigma
- [Sleeping sickness factsheet](https://dndi.org/publications/2024/sleeping-sickness-factsheet-2024/) - Delivering all-new treatments to eliminate a deadly disease
- [Acceptance address, Dr Luis Pizarro – Fifth Hideyo Noguchi Africa Prize Ceremony](https://dndi.org/news/2025/acceptance-address-dr-luis-pizarro-fifth-hideyo-noguchi-africa-prize-ceremony/) - DNDi has been awareded Japan's Hideyo Noguchi Africa Prize 2025 for its work to develop new treatments for neglected diseases in Africa.
- [2023 Princess of Asturias Award for International Cooperation](https://dndi.org/news/2023/2023-princess-of-asturias-award-for-international-cooperation/) - DNDi is very honoured to be the recipient of the Princess of Asturias Award, the most prestigious award in Spain.
- [TICAD spotlight: Japan’s pharma commitment to global health](https://dndi.org/in-the-media/2025/ticad-spotlight-japans-pharma-commitment-to-global-health/) - ACCESS THE ARTICLE
- [DNDi wins prestigious Japan prize for medical services](https://dndi.org/in-the-media/2025/dndi-wins-prestigious-japan-prize-for-medical-services/) - ACCESS THE ARTICLE
- [Acceptance address, Dr Luis Pizarro – 2023 Princess of Asturias Awards Ceremony](https://dndi.org/news/2023/acceptance-address-dr-luis-pizarro-2023-princess-asturias-awards-ceremony/) - DNDi's Executive Director Dr Luis Pizarro's acceptance address at the 2023 Princess of Asturias Award Ceremony.
- [DNDi's briefing note for the 75<sup>th</sup> Session of the World Health Organization Regional Committee for Africa](https://dndi.org/statements/2025/dndi-briefing-note-75th-session-who-regional-committee-africa/) - This briefing note sets out DNDi’s comments for consideration by World Health Organization (WHO) African Region Member States on the following agenda items of the 75th Session of the WHO Regional Committee for Africa.
- [新薬開発の非営利組織に野口賞　アフリカの保健や福祉向上に貢献](https://dndi.org/in-the-media/2025/kyodo-news-noguchi-prize-awarded-to-nonprofit-organization-developing-new-drugs/) - read the article
- [Traitement oral de la trypanosomiase humaine africaine : faisabilité dans les communautés du littoral Guinéen](https://dndi.org/scientific-articles/2025/traitement-oral-trypanosomiase-humaine-africaine-faisabilite-communautes-littoral-guineen/) - by Layba Camara M, Kagbadouno M, Kourouma A, Diallo M-B, Soumah A-M-M, Camara O, Mutumbo W, Ngolo D, Lubukulu G, Musawu Y, Ilboudo H, Bart J-M, Camara M, Kokolomami J. Santé Publique 2025, 37(2):173-184. doi: 10.3917/spub.252.0173 Summary: The authors of this study conducted an analytical cross-sectional study to assess the feasibility of launching fexinidazole for human
- [Non-profits wade in where for-profit life science investment fears to tread](https://dndi.org/in-the-media/2025/non-profits-wade-in-where-for-profit-life-science-investment-fears-to-tread/) - ACCESS THE ARTICLE
- [Researchers link iron to mycetoma's deadly progress, offers hope to patients](https://dndi.org/in-the-media/2025/researchers-link-iron-to-mycetomas-deadly-progress-offers-hope-to-patients/) - Read the article
- [China deploys ‘cannibal’ mosquitoes and killer fish to fight chikungunya](https://dndi.org/in-the-media/2025/china-deploys-cannibal-mosquitoes-and-killer-fish-to-fight-chikungunya/) - ACCESS THE ARTICLE
- [América Latina combate el auge de la transmisión del chagas de madre a hijo](https://dndi.org/in-the-media/2025/america-latina-combate-el-auge-de-la-transmision-del-chagas-de-madre-a-hijo/) - ACCESS THE ARTICLE
- [Statement from DNDi on Kenya’s elimination of rhodesiense sleeping sickness as a public health problem ](https://dndi.org/news/2025/statement-kenyas-elimination-rhodesiense-sleeping-sickness-as-public-health-problem/) - This milestone reflects years of dedicated efforts by health workers, communities, researchers, and policymakers, and marks a significant step forward in the global fight against neglected tropical diseases.
- [Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi](https://dndi.org/news/2025/statements-dr-luis-pizarro-and-daisuke-imoto-about-hideyo-noguchi-africa-prize-awarded-to-dndi/) - DNDi has been named the recipient of the 5th prestigious Hideyo Noguchi Africa Prize in the medical services category, as announced today by the Government of Japan.
- [ADB and DNDi sign MoU to advance healthcare cooperation on neglected diseases in Asia and the Pacific](https://dndi.org/news/2025/adb-dndi-mou-advance-healthcare-cooperation-neglected-diseases-asia-and-pacific/) - The Asian Development Bank (ADB) and DNDi have signed a Memorandum of Understanding to formalize a non-exclusive framework of cooperation to promote programmes and projects in the field of healthcare across Asia and the Pacific.
- [AN2 Therapeutics and DNDi collaborate on clinical development of promising new oral compound to treat chronic Chagas disease](https://dndi.org/press-releases/2025/an2-therapeutics-and-dndi-collaborate-on-clinical-development-of-promising-new-oral-compound-to-treat-chronic-chagas-disease/) - DNDi will share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease. Startup activities are underway for a Phase I first-in-human study for oral AN2-502998, with a Phase II study initiation planned for 2026.
- [A Kinshasa, DNDi en collaboration avec le gouvernement lance le projet visant à améliorer l’accès aux soins des personnes atteintes de VIH à un stade avancé](https://dndi.org/in-the-media/2025/a-kinshasa-dndi-en-collaboration-avec-le-gouvernement-lance-le-projet-visant-a-ameliorer-lacces-aux-soins-des-personnes-atteintes-de-vih-a-un-stade-avance/) - ACCESS THE ARTICLE
- [Guinea marca el camino contra la enfermedad del sueño](https://dndi.org/in-the-media/2025/guinea-marca-el-camino-contra-la-enfermedad-del-sueno/) - ACCESS THE ARTICLE
- [Why drug donation programs are a lifeline for NTD elimination efforts](https://dndi.org/in-the-media/2025/why-drug-donation-programs-are-a-lifeline-for-ntd-elimination-efforts/) - ACCESS THE ARTICLE
- [New drug to be registered with FDA](https://dndi.org/in-the-media/2025/new-drug-to-be-registered-with-fda/) - ACCESS THE ARTICLE
- [First all-oral treatment for deadly strain of sleeping sickness now available in Africa](https://dndi.org/in-the-media/2025/first-all-oral-treatment-for-deadly-strain-of-sleeping-sickness-now-available-in-africa/) - ACCESS THE ARTICLE
- [¿Qué es la enfermedad de chagas? Habla hombre que resucitó tras padecerla](https://dndi.org/in-the-media/2025/que-es-la-enfermedad-de-chagas-habla-hombre-que-resucito-tras-padecerla/) - watch here
- [Bringing life-saving care closer to people living with HIV in Kinshasa ](https://dndi.org/news/2025/bringing-life-saving-care-closer-to-people-living-with-hiv-in-kinshasa/) - Over 70 healthcare workers and members of civil society organizations in Kinshasa, DRC, took part in capacity-strengthening sessions to strengthen the management of Advanced HIV Disease, especially in primary healthcare facilities, and improve access to care for people living with HIV.
- [New HIV project in the DRC brings life-saving care closer to people with advanced HIV disease](https://dndi.org/press-releases/2025/new-hiv-project-drc-brings-life-saving-care-closer-to-people-advanced-hiv-disease/) - The programme aims to reduce AIDS-related deaths by strengthening early screening and improving patient referral and treatment at primary-level health facilities. It is part of the Improved Access to AHD Care and Treatment for HIV (IMPAACT4HIV) project, a global consortium led by the Aurum Institute and funded by Unitaid.
- [Un nouveau projet en RDC vise à améliorer l’accès aux soins des personnes atteintes de la maladie à VIH à un stade avancé](https://dndi.org/press-releases-translations/2025/nouveau-projet-rdc-ameliorer-lacces-aux-soins-personnes-atteintes-vih-stade-avance/) - Le projet vise à améliorer le diagnostic, le traitement et l’accès aux soins pour les personnes vivant avec le VIH à un stade avancé dans six pays qui représentent le quart de la mortalité mondiale liée au VIH.
- [LEO Foundation partners with DNDi to develop breakthrough drug discovery model for mycetoma ](https://dndi.org/news/2025/leo-foundation-partners-with-dndi-develop-breakthrough-drug-discovery-model-mycetoma/) - The LEO Foundation’s commitment of DKK 4,000,000 over three years will enable the development of a clinically relevant, skin-specific, dynamic model of fungal mycetoma to facilitate pre-clinical drug evaluation.
- [Validated LC-MS/MS method for quantifying the antiparasitic nitroimidazole DNDI-0690 in preclinical target site PK/PD studies](https://dndi.org/scientific-articles/2025/validated-lcmsms-method-quantifying-antiparasitic-nitroimidazole-dndi-0690-preclinical-target-site-pk-pd-studies/) - by Schouten WK, van Bocxlaer H, Rosing H, Huitema ADR, Beijnen JH, Kratz JM, Mowbray CE, Dorlo TPC. Biomedical Chromatography 2025, 39(8): e70158. doi: 10.1002/bmc.70158 Summary: It is important to understand the target site pharmacokinetics of potential treatments for leishmaniasis, because of the diversity of infected tissue sites and potential variability in drug penetration. The authors of this
- [Severe dengue–related deaths in the elderly population soared in Southern Brazil in 2024](https://dndi.org/scientific-articles/2025/severe-dengue-related-deaths-elderly-population-southern-brazil/) - by Sarmento Queiroga A, Mendes Barbosa DA, Campos TdL, Vargas Schwarzbold A, Siqueira AM, Steiner Salvato R, Luz Wallau G. IJID Regions 2025, 14:100577. doi: 10.1016/j.ijregi.2025.100577 Summary: About 6.5 million of the 14 million cases of dengue fever reported in 2024 were reported in Brazil. Lethality in severe cases was particularly high in Rio Grande do
- [Thailand’s Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment  ](https://dndi.org/press-releases/2025/thailand-government-pharmaceutical-organization-partners-dndi-pharco-register-hepatitisc-treatment/) - K-MEDI has been chosen as a collaborating institute for developing an affordable and globally accessible medicine for river blindness. The project is led by DNDi and supported by a 3.2 billion KRW grant from the RIGHT Foundation.
- [2024 DNDi Financial Report](https://dndi.org/publications/2025/2024-dndi-financial-report/) - This issue brief examines findings from the Advanced HIV Disease (AHD) Dashboard. The dashboard tracks, visualizes, and compares national guidelines across 35 African countries to understand the pace and scale of adoption of WHO-recommended treatment guidelines shown to reduce deaths from AHD and cryptococcal meningitis.
- [Meet the DNDi Eastern Africa 2024-2025 Media Fellows](https://dndi.org/stories/2025/meet-the-dndi-eastern-africa-2024-2025-media-fellows/) - DNDi launched a Media Fellowship programme aimed at empowering health journalists from Eastern Africa to tell impactful stories about neglected tropical diseases and the often-overlooked communities they affect.
- [DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 ](https://dndi.org/news/2025/dndi-partnering-msf-south-asia-without-borders-media-fellowship-2025/) - About the fellowship Médecins Sans Frontières (MSF) South Asia is calling for proposals by journalists, photographers, filmmakers, and newsrooms editors to apply for the 2025-2026 Without Borders Media Fellowship. The fellowship aims to encourage humanitarian and health-related journalism and reporting through scientific storytelling that draws attention to emerging local and cross-border issues in the South
- [Efficient constitution of a library of rotenoid analogs active against <em>Trypanosoma cruzi</em> from a digitalized plant extract collection](https://dndi.org/scientific-articles/2025/efficient-constitution-of-a-library-of-rotenoid-analogs-active-against-trypanosoma-cruzi-from-a-digitalized-plant-extract-collection/) - by Gaudry A, Marcourt L, Kaiser M, Flückiger J, David B, Grondin A, Ioset J-R, Mäser P, Queiroz EF, Allard P-M, Wolfender J-L. RSC Advances 2025; 15:15240–15251. doi: 10.1039/D4RA08652J. Summary: The potent anti-Trypanosoma cruzi activity of two rotenoids, deguelin and rotenone, identified in six active extracts from four plant species, has recently been described. The authors of
- [Can the use of AI in the pharmaceutical sector deliver new medicines, not new risks?](https://dndi.org/in-the-media/2025/can-the-use-of-ai-in-the-pharmaceutical-sector-deliver-new-medicines-not-new-risks/) - ACCESS THE ARTICLE
- [Serum, DNDi join hands to fast-track development of new treatment for dengue](https://dndi.org/in-the-media/2025/serum-dndi-join-hands-to-fast-track-development-of-new-treatment-for-dengue/) - ACCESS THE ARTICLE
- [Serum Institute signs MoU with DNDi to develop dengue treatment candidate](https://dndi.org/in-the-media/2025/serum-institute-signs-mou-with-dndi-to-develop-dengue-treatment-candidate/) - read the article
- [Serum Institute to conduct Brazilian trials of late-stage dengue candidate with DNDi](https://dndi.org/in-the-media/2025/serum-institute-to-conduct-brazilian-trials-of-late-stage-dengue-candidate-with-dndi/) - ACCESS THE ARTICLE
- [Serum, DNDi to develop affordable dengue treatment](https://dndi.org/in-the-media/2025/serum-dndi-to-develop-affordable-dengue-treatment/) - read the article
- [SII, DNDi partner for expanding human trials for dengue treatment](https://dndi.org/in-the-media/2025/sii-dndi-partner-for-expanding-human-trials-for-dengue-treatment/) - read the article
- [‘Timely’ alliance to develop effective dengue treatment](https://dndi.org/in-the-media/2025/timely-alliance-to-develop-effective-dengue-treatment/) - read the article
- [Kenya: le mycétome, une maladie endémique pourtant encore négligée](https://dndi.org/in-the-media/2025/kenya-le-mycetome-une-maladie-endemique-pourtant-encore-negligee/) - Regardez la vidéo ici
- [数奇な運命でスーダンに　エーザイ発の新薬候補、熱帯病に挑む](https://dndi.org/in-the-media/2025/数奇な運命でスーダンにエーザイ発の新薬候補/) - read the article
- [Sudanese doctors on mission to rebuild Mycetoma Research Centre](https://dndi.org/in-the-media/2025/sudanese-doctors-on-mission-to-rebuild-mycetoma-research-centre/) - Read the article
- [24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation](https://dndi.org/scientific-articles/2025/24-week-all-oral-regimens-for-pulmonary-rifampicin-resistant-tuberculosis-in-tb-practecal-trial-sites-an-economic-evaluation/) - by Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, Fielding K, Kazounis E, Moodliar R, Solodovnikova V, Tigay Z, Liverko I, Parpieva N, Butabekov I, Usmanova R, Rassool M, Motta I, Nyangweso GM, Jolivet P, Abdrasuliev T, Moe S, Aw PS, Samieva N, Nyang'wa BT. Lancet Global Health 2025;13(2):e355-e363. doi: 10.1016/s2214-109x(24)00467-4. Summary: The authors
- [Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries](https://dndi.org/press-releases/2025/serum-institute-india-signs-mou-dndi-advance-development-new-treatment-dengue-in-lmics/) - The collaboration aims to accelerate the development of an effective and affordable monoclonal antibody treatment for dengue caused by any of the four serotypes of dengue virus, in close cooperation with endemic countries, including Thailand, Malaysia, and Brazil. Despite the growing burden of dengue, there is still no specific treatment available.
- [First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa](https://dndi.org/press-releases/2025/first-all-oral-treatment-for-strain-sleeping-sickness-now-available-and-used-in-endemic-countries-africa/) - A handful of patients in Ethiopia, Malawi, and Zimbabwe, as well as foreign travellers, have now been treated with a medicine that is revolutionizing care for patients with rhodesiense sleeping sickness.
- [The Children of the Sierra](https://dndi.org/videos/2025/the-children-of-the-sierra/) - This short film takes us to Brazil, one of the flashpoints of Latin America’s 2024 epidemic, as well as to Sri Lanka and Thailand, to show the devastating impact dengue outbreaks are having across the world.
- [Colombia becomes first country to recommend rapid tests to diagnose Chagas disease](https://dndi.org/press-releases/2025/colombia-becomes-first-country-to-recommend-rapid-tests-to-diagnose-chagas-disease/) - New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.
- [Spirocyclic compounds as innovative tools in drug discovery for medicinal chemists](https://dndi.org/scientific-articles/2025/spirocyclic-compounds-as-innovative-tools-in-drug-discovery-for-medicinal-chemists/) - by Varela MT, Dias GG, de Oliveira LFN, de Oliveira RG, Aguiar FD, Nogueira JP, Cruz LR, Dias LC. European Journal of Medicinal Chemistry 2025; 287:117368. doi: 10.1016/j.ejmech.2025.117368. Summary: Spirocyclic motifs allow the improvement of drug-like properties and are increasingly being included in clinical candidates and approved drugs. Spirocycles are becoming widely accessible to medicinal chemists
- [Global health initiatives and mycetoma management: the unmet promise](https://dndi.org/scientific-articles/2025/global-health-initiatives-and-mycetoma-management-the-unmet-promise/) - by Fahal AH, Smith DJ, Saeed AA, Nyaoke B, Alves F, Asiedu K, Hay R. Transactions of The Royal Society of Tropical Medicine and Hygiene 2025. doi: 10.1093/trstmh/traf001. Summary: The authors of this Letter to the editor explain that while global health initiatives have fuelled substantial progress in combating many NTDs, mycetoma remains underserved. Despite the
- [The STROGHAT study protocol: An intervention study to evaluate safety, effectiveness and feasibility of treating gambiense HAT seropositive subjects with acoziborole](https://dndi.org/scientific-articles/2025/the-stroghat-study-protocol-an-intervention-study-to-evaluate-safety-effectiveness-and-feasibility-of-treating-gambiense-hat-seropositive-subjects-with-acoziborole/) - by Nicco E, Lejon V, Mwamba Miaka E, Mumba D, Mpanya A, Kambo C, Ngolo D, Mutombo W, Hugonnet S, Rembry S, Tipple C, Da Luz RI, Snijders R, Vander Kelen C, Rogé S, Van Reet N, Tarral A, Verlé P, Hasker E. Open Research Europe 2025; 5:23. doi: 110.12688/openreseurope.19077.1. Summary: The authors of this manuscript
- [Defining the noma research agenda](https://dndi.org/scientific-articles/2025/defining-the-noma-research-agenda/) - by Galli A, Comparet M, Dagne DA, Baratti-Mayer D, Cao TH, Guérin PJ, Guevara M, Hetzel MW, Jeantet C, Mpinga EK, Muendane V, Okanlawon M, Placella E, Ribes M, Sherlock M, Utzinger J, Steinmann P. PLOS Neglected Tropical Diseases 2025;19(4): e0012940. doi: 10.1371/journal.pntd.0012940 Summary: The authors of this article report on a symposium that brought individuals with lived experience of noma
- [A ‘groundbreaking’ pandemic agreement for tackling disease outbreaks has been agreed. What does it mean?](https://dndi.org/in-the-media/2025/a-groundbreaking-pandemic-agreement-for-tackling-disease-outbreaks-has-been-agreed-what-does-it-mean/) - read the article
- [アフリカ特有の感染症に対応する新たな治療法を開発！DNDiが第5回野口英世アフリカ賞を受賞へ！](https://dndi.org/in-the-media/2025/アフリカ特有の感染症に対応する新たな治療法を/) - read the article
- [野口英世賞にマラリア研究者ら](https://dndi.org/in-the-media/2025/野口英世賞にマラリア研究者ら/) - read the article
- [「野口英世アフリカ賞」マラリア研究者らに　政府が発表](https://dndi.org/in-the-media/2025/野口英世アフリカ賞マラリア研究者らに政/) - read the article
- [WHA approves landmark resolutions on health finance, rare diseases and skin diseases](https://dndi.org/in-the-media/2025/wha-approves-landmark-resolutions-on-health-finance-rare-diseases-and-skin-diseases/) - ACCESS THE ARTICLE
- [La OMS adopta un plan para afrontar las enfermedades sensibles al cambio climático](https://dndi.org/in-the-media/2025/la-oms-adopta-un-plan-para-afrontar-las-enfermedades-sensibles-al-cambio-climatico/) - ACCESS THE ARTICLE
- [Model-informed drug development of a sustained release formulation of flucytosine in the treatment of cryptococcal meningitis: A case study using physiologically based pharmacokinetic modeling](https://dndi.org/scientific-articles/2025/model-informed-drug-development-sustained-release-formulation-flucytosine-in-cryptococcal-meningitis/) - by Eriksson J, Sjögren E, Gillon JY, Caplain H, Goyal V, Satam V, Robinson S, Ribeiro I, Chenel M. CPT Pharmacometrics & Systems Pharmacology 2025, 14(4):651-657. doi: 10.1002/psp4.13309 Summary: This case study explores the application of model-informed drug development (MIDD) in the development of a sustained release formulation of flucytosine for cryptococcal meningoencephalitis patients with HIV.
- [Pharmacokinetics and pharmacodynamics of fosravuconazole, itraconazole, and hydroxyitraconazole in Sudanese patients with eumycetoma](https://dndi.org/scientific-articles/2025/pharmacokinetics-pharmacodynamics-fosravuconazole-itraconazole-hydroxyitraconazole-eumycetoma/) - by Chu WY, Fahal AH, Ahmed ES, Bakhiet SM, Bakhiet OE, Fahal LA, Mohamed AA, Wadaa ES, Mohamedelamin MEN, Bahar HYA, Attalla EES, Mhmoud NA, Musa AM, Oyieko P, Egondi T, Brüggemann RJ, Hata K, Strub-Wourgaft N, Alves F, Nyaoke BA, Zijlstra EE, Dorlo TPC. The Journal of Infectious Diseases 2025, jiaf279. doi: 10.1093/infdis/jiaf279/8151980 Summary: The
- [Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial](https://dndi.org/scientific-articles/2024/efficacy-and-safety-of-fexinidazole-for-treatment-of-chronic-indeterminate-chagas-disease-fexi-12-a-multicentre-randomised-double-blind-phase-2-trial/) - by Pinazo M-J, Forsyth C, Losada I, Esteban ET, García-Rodríguez M, Villegas ML, Molina I, Crespillo-Andújar C, Gállego M, Ballart C, Ramirez JC, Aden T, Hoerauf A, Pfarr K, Vaillant M, Marques T, Fernandes J, Blum B, Ribeiro I, Sosa-Estani S, Barreira F, Gascón J, on behalf of the FEXI-12 Study Team. The Lancet Infectious
- [Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens](https://dndi.org/scientific-articles/2024/bioluminescence-imaging-reveals-enhanced-sars-cov-2-clearance-in-mice-with-combinatorial-regimens/) - by Ullah I, Escudie F, Scandale I, Gilani Z, Gendron-Lepage G, Gaudette F, Mowbray C, Fraisse L, Bazin R, Finzi A, Mothes W, Kumar P, Chatelain E, Uchil PD. iScience 2024. doi: 10.1016/j.isci.2024.109049. Direct acting antivirals (DAAs) are critical tools for combating SARS-CoV-2 variants of concern. The authors of this manuscript used bioluminescence imaging to
- [Population pharmacokinetics of pediatric lopinavir/ritonavir oral pellets in children living with HIV in Africa](https://dndi.org/scientific-articles/2024/population-pharmacokinetics-of-pediatric-lopinavir-ritonavir-oral-pellets-in-children-living-with-hiv-in-africa/) - by Chupradit S, Wamalwa DC, Maleche-Obimbo E, Kekitiinwa AR, Mwanga-Amumpaire J, Bukusi EA, Nyandiko WM, Mbuthia JK, Swanson A, the DNDi Clinical Team, Cressey TR, Punyawudho B, Musiime V, for the LIVING Study Team. Clinical Pharmacology and Therapeutics 2024, 115(5):1105-1113. doi: 10.1002/cpt.3174 Summary: Antiretroviral therapy for children living with HIV under 3 years of age commonly
- [DNDi interventions at the 78<sup>th</sup> World Health Assembly](https://dndi.org/statements/2025/dndi-interventions-78th-world-health-assembly/) - DNDi's interventions (posted here following delivery): Agenda item 16.2: Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response We congratulate Member States on the adoption of the Pandemic Agreement, and for their leadership and commitment to reaching this important milestone. While the text
- [Late-stage diversification of pyrazoles as antileishmanial agents](https://dndi.org/scientific-articles/2024/late-stage-diversification-pyrazoles-antileishmanial-agents/) - by Winge T, Perry B, Matheeussen A, Caljon G, Wünsch B. ChemMedChem 2024, 19: e202400028. doi: 10.1002/cmdc.202400028 Summary: N-Pyrazolylcarboxamides and N-pyrazolylureas are promising lead compounds for the development of novel drugs against leishmaniasis. The authors of this manuscript report on the modification of 3-bromopyrazoles using Pd-catalyzed Sonogashira and Suzuki-Miyaura cross coupling reactions. A large set of pyrazoles with diverse
- [Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains](https://dndi.org/scientific-articles/2024/generation-and-evaluation-of-protease-inhibitor-resistant-sars-cov-2-strains/) - by Bouzidi HS, Driouich J-S, Klitting R, Bernadin O, Piorkowski G, Amaral R, Fraisse L, Mowbray CE, Scandale I, Escudié F, Chatelain E, de Lamballerie X, Nougairède A, Touret F. Antiviral Research 2024, 222: 105814. doi: 10.1016/j.antiviral.2024.105814 Summary: To date, the protease inhibitor nirmatrelvir has shown the best results in clinical trials of treatments for
- [Towards enhanced control of mycetoma: a roadmap to achieve the UN's sustainable development goals by 2030](https://dndi.org/scientific-articles/2024/towards-enhanced-control-of-mycetoma-a-roadmap-to-achieve-the-uns-sustainable-development-goals-by-2030/) - by Fahal A, Smith DJ, Nyaoke B, Asiedu K, Alves F, Warusavithanas S, Argaw D, Hay R, on behalf of the Global Mycetoma Working Group. Transactions of The Royal Society of Tropical Medicine and Hygiene 2024, trae016. doi: 10.1093/trstmh/trae016 Summary: The WHO’s 2020 neglected tropical disease roadmap set targets for addressing mycetoma, however, little progress
- [Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteers](https://dndi.org/scientific-articles/2024/bioavailability-of-three-novel-oral-sustained-release-pellets-relative-to-an-immediate-release-tablet-containing-500-mg-flucytosine-a-randomized-open-label-crossover-study-in-healthy-volu/) - by Goyal V, Krantz E, Simon F, Neven A, Eriksson J, Saayman A, Zekri Lassout NI, Louis M, Robinson S, Deshmukh A, Antarkar A, Ruffell C, Victor S, Chenel M, Celebic A, Caplain H, Gillon JY, Ribeiro I. Clinical and Translational Science 2024. doi: 10.1111/cts.13756 Summary: The authors of this manuscript report pharmacokinetic and safety
- [Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development](https://dndi.org/scientific-articles/2024/involving-patients-in-drug-development-for-neglected-tropical-diseases-ntds-a-qualitative-study-exploring-and-incorporating-preferences-of-patients-with-cutaneous-leishmaniasis-into-target-product/) - by Castro MdM, Erber AC, Arana B, Cota G, Denkinger CM, Harrison N, Kutyi J, López-Carvajal L, Plugge E, Walochnik J, Olliaro P. PLOS Neglected Tropical Diseases 2024, 18(2): e0011975. doi: 10.1371/journal.pntd.0011975 Summary: Target product profiles (TPP) identify the characteristics required for medical products to meet their intended need. They should be aligned with users’ preferences and needs, however, patients
- [A sample-centric and knowledge-driven computational framework for natural products drug discovery](https://dndi.org/scientific-articles/2024/a-sample-centric-and-knowledge-driven-computational-framework-for-natural-products-drug-discovery/) - by Gaudry A, Pagni M, Mehl F, Moretti S, Quiros-Guerrero L-M, Cappelletti L, Rutz A, Kaiser M, Marcourt L, Ferreira Queiroz E, Ioset J-R, Grondin A, David B, Wolfender J-L, Allard P-M. ACS Central Science 2024, 10(3):494-510. doi: 10.1021/acscentsci.3c00800 Summary: In this manuscript, the authors describe a novel approach based on semantic web technology to
- [High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant <i>A. baumannii</i> and <i>K. pneumoniae</i>](https://dndi.org/scientific-articles/2024/high-throughput-screening-of-small-molecules-libraries-identified-antibacterials-against-clinically-relevant-multidrug-resistant-a-baumannii-and-k-pneumoniae/) - by Blasco B; Jang S; Terauchi H; Kobayashi N; Suzuki S; Akao Y; Ochida A; Morishita N; Takagi T; Nagamiya H; Suzuki Y; Watanabe T; Lee H; Lee S; David Shum D; Cho A; Koh D; Park S; Lee H; Kim K; Ropponen HK; Augusto da Costa RM; Dunn S; Ghosh S; Sjö P; Piddock
- [Practical Synthesis of 6-Amino-1-hydroxy-2,1-benzoxaborolane: A Key Intermediate of DNDI-6148](https://dndi.org/scientific-articles/2024/practical-synthesis-of-6-amino-1-hydroxy-21-benzoxaborolane-a-key-intermediate-of-dndi-6148/) - by Khairnar PV, Saathoff JM, Cook DW, Hochstetler SR, Pandya U, Robinson SJ, Satam V, Donsbach KO, Gupton BF, Jin L-M, Shanahan CS. Organic Process Research & Development 2024, 28(4):1213-1223. doi: 10.1021/acs.oprd.4c00031 Summary: DNDI-6148 is a promising drug candidate under evaluation for the treatment of visceral leishmaniasis, however, the current process for producing the key
- [Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform](https://dndi.org/scientific-articles/2024/post-kala-azar-dermal-leishmaniasis-pkdl-drug-efficacy-study-landscape-a-systematic-scoping-review-of-clinical-trials-and-observational-studies-to-assess-the-feasibility-of-establishing-an-individu/) - by Singh-Phulgenda S, Kumar R, Dahal P, Munir A, Rashan S, Chhajed S, Naylor C, Maguire BJ, Ali Siddiqui N, Harriss E, Rahi M, Alves F, Sundar S, Stepniewska K, Musa A, Guerin PJ, Pandey K. PLOS Neglected Tropical Diseases 2024, 18(4):e0011635. doi: 10.1371/journal.pntd.0011635 Summary: There are numerous gaps in our knowledge about post-kala-azar dermal leishmaniasis (PKDL), a public health problem
- [AI is a viable alternative to high throughput screening: a 318-target study](https://dndi.org/scientific-articles/2024/ai-is-a-viable-alternative-to-high-throughput-screening-a-318-target-study/) - by The Atomwise AIMS Program, including Perry B, Kratz JM. Nature Scientific Reports 2024, 14:7526. doi: 10.1038/s41598-024-54655-z Summary: High throughput screening is the most widely-used tool to identify bioactive small molecules. All physical screening methods are limited because they require molecules that have been synthesized. Computational methods enable a fundamental shift to a test-then-make paradigm. The
- [<i>Leishmania</i> blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model](https://dndi.org/scientific-articles/2024/leishmania-blood-parasite-dynamics-during-and-after-treatment-eastern-africa/) - by Verrest L, Monnerat S, Musa AM, Mbui J, Khalil EAG, Olobo J, Wasunna M, Chu W-Yu, Huitema ADR, Schallig HDFH, Alves F, Dorlo TPC. PLOS Neglected Tropical Diseases 2024, 18(4): e0012078. doi: 10.1371/journal.pntd.0012078 Summary: Some patients treated for visceral leishmaniasis experience disease relapse. To understand why this happens, the authors of this study used Leishmania DNA loads in blood from East
- [Representations of Chagas disease among Bolivian immigrants in the city of São Paulo](https://dndi.org/scientific-articles/2024/representations-of-chagas-disease-among-bolivian-immigrants-in-the-city-of-sao-paulo/) - by Silveira C, Forsyth C, Junior NC, Goldberg A, da Silva LMB, da Silva RA, Shikanai-Yasuda MA. Frontiers in Tropical Diseases 2024, 18:1331026. doi: 10.3389/fitd.2024.1331026 Summary: Transnational immigrants are particularly impacted by neglected diseases, which take a heavy biological, social, and emotional toll in these marginalized communities. The authors of this manuscript explored problems of
- [Blood transfusion in the care of patients with visceral leishmaniasis: a review of practices in therapeutic efficacy studies](https://dndi.org/scientific-articles/2024/blood-transfusion-in-the-care-of-patients-with-visceral-leishmaniasis-a-review-of-practices-in-therapeutic-efficacy-studies/) - by Dahal P, Singh-Phulgenda S, Wilson J, Cota G, Ritmeijer K, Musa A, Alves F, Kasia Stepniewska K, Philippe J, Guerin PJ. Transactions of The Royal Society of Tropical Medicine and Hygiene 2024, trae018. doi: 10.1093/trstmh/trae018 Summary: Blood transfusion is an important aspect of patient management in visceral leishmaniasis, but practice in clinical trials is
- [N-Pyrazolyl- and N-Triazolylamines and -Ureas as antileishmanial and antitrypanosomal drugs](https://dndi.org/scientific-articles/2024/n-pyrazolyl-n-triazolylamines-ureas-as-antileishmanial-and-antitrypanosomal-drugs/) - by Winge T, Imberg I, Perry B, Matheeussen A, Caljon G, Kalinin D, Wünsch B. ChemMedChem 2024, 19: e202400220. doi: 10.1002/cmdc.202400220 Summary: The authors of this manuscript report on the synthesis and antileishmanial and antitrypanosomal activity of a series of pyrazoles and triazoles. In order to broaden the structure activity relationships for pyrazoles with antileishmanial and antitrypanosomal activity, a set
- [Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns](https://dndi.org/scientific-articles/2024/further-preclinical-characterization-of-molnupiravir-against-sars-cov-2-antiviral-activity-determinants-and-viral-genome-alteration-patterns/) - by Petit PR, Touret F, Driouich JS, Cochin M, Luciani L, Bernadin O, Laprie C, Piorkowski G, Fraisse L, Sjö P, Mowbray CE, Escudié F, Scandale I, Chatelain E, de Lamballerie X, Solas C, Nougairède A. Helyon 2024, 10(10): e30862. doi: 10.1016/j.heliyon.2024.e30862 Summary: The authors of this manuscript investigated molnupiravir as a potential broad-spectrum drug
- [Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia](https://dndi.org/scientific-articles/2024/skin-pharmacokinetics-miltefosine-treatment-post-kala-azar-dermal-leishmaniasis-south-asia/) - by Palić S, Chu W-Y, Sundar S, Mondal D, Das P, Pandey K, Raja S, Rijal S, Roseboom IC, Hamadeh A, Malik PRV, Beijnen JH, Huitema ADR, Sjögren E, Alves F, Dorlo TPC. Journal of Antimicrobial Chemotherapy 2024, 79(7):1547–1554. doi: 10.1093/jac/dkae129 Summary: Current treatments for post-kala-azar dermal leishmaniasis (PKDL) are unsatisfactory, and the distribution of
- [Climate change, malaria and neglected tropical diseases: a scoping review](https://dndi.org/scientific-articles/2024/climate-change-malaria-and-neglected-tropical-diseases-a-scoping-review/) - by Klepac P, Hsieh JL, Ducker CL, Assoum M, Booth M, Byrne B, Dodson S, Martin DL, Turner CMR, van Daalen KR, Abela B, Akamboe J, Alves F, Brooker SJ, Ciceri-Reynolds K, Cole J, Desjardins A, Drakeley C, Ediriweera DS, Ferguson NM, Francesco Gabrielli A, Gahir J, Jain S, John MR, Juma E, Kanayson P,
- [Synthesis and anti-<i>Trypanosoma cruzi</i> activity of 3-cyanopyridine derivatives](https://dndi.org/scientific-articles/2024/synthesis-and-anti-trypanosoma-cruzi-activity-of-3-cyanopyridine-derivatives/) - by Slafer BW, Dessoy MA, de Oliveira RG, Mollo MC, Lee E, Matheeussen A, Maes L, Caljon G, Ferreira LLG, Krogh R, Andricopulo AD, Cruz LR, Mowbray CE, Kratz JM, Dias LC. ACS Omega 2024. doi: 10.1021/acsomega.4c01919 Summary: The authors of this manuscript present a hit-to-lead campaign for novel cyanopyridine analogues active against Trypanosoma cruzi,
- [<i>In vivo</i> bioluminescence imaging reveals differences in <i>Leishmania infantum</i> parasite killing kinetics by antileishmanial reference drugs](https://dndi.org/scientific-articles/2024/in-vivo-bioluminescence-imaging-differences-leishmania-infantum-parasite-killing-kinetics/) - by Hendrickx S, Feijens P-B, Escudié F, Chatelain E, Maes L, Caljon G. ACS Infectious Diseases 2024, 10(6): 2101-2107. doi: 10.1021/acsinfecdis.4c00109 Summary: The authors of this manuscript used a bioluminescent Leishmania infantum BALB/c mouse model to evaluate the parasiticidal kinetics of the reference drugs miltefosine, paromomycin, sodium stibogluconate, and liposomal amphotericin B. They monitored parasite burdens over time
- [Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment](https://dndi.org/scientific-articles/2024/population-pharmacokinetics-ravidasvir-in-adults-with-chronic-hcv-and-impact-antiretroviral-treatment/) - by Panjasawatwong N, Avihingsanon A, Menétrey C, Ribeiro I, Salvadori N, Swanson A, Gillon J-Y, Tan S, Thanprasertsuk S, Thongsawat S, Cressey TR. Antimicrobial Agents and Chemotherapy 2024, 68: e00008-24. doi: 10.1128/aac.00008-24 Summary: Sofosbuvir plus ravidasvir is a novel direct acting antiviral treatment for hepatitis C (HCV) that was shown to be safe and efficacious
- [Chagas disease in the United States: a call for increased investment and collaborative research](https://dndi.org/scientific-articles/2024/chagas-disease-in-united-states-call-for-increased-investment-and-collaborative-research/) - by Agudelo Higuita NI, Beatty NL, Forsyth C, Henao-Martínez AF, Manne-Goehlerg J, on behalf of the US Chagas Research Consortium. The Lancet Regional Health – Americas 2024, 34:100768. doi: 10.1016/j.lana.2024.100768 Summary: Chagas disease, caused by the protozoan Trypanosoma cruzi, affects an estimated 300,000 individuals in the United States. While many contract the disease in Latin
- [Demystifying <i>in vivo</i> bioluminescence imaging of a Chagas disease mouse model for drug efficacy studies](https://dndi.org/scientific-articles/2024/demystifying-in-vivo-bioluminescence-imaging-of-a-chagas-disease-mouse-model-for-drug-efficacy-studies/) - by da Silva AC, Kratz JM, Morgado PGM, Freitas-Junior LH, Moraes CB. Journal of Visualized Experiments 2024, 207:e66740. doi: 10.3791/66740 Summary: Drug discovery for neglected tropical diseases is challenging due to comparatively limited funding and highly complex parasite biology and disease pathogenesis. Models that sufficiently reproduce infection and key disease features, while providing rational use
- [A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh](https://dndi.org/scientific-articles/2024/phase-ii-trial-two-treatments-pkdl-india-bangladesh/) - by Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R, Kumar A, Kumar V, Kumar Verma D, Chakravarty J, Chaubey R, Kumari P, Rashid U, Maruf S, Ghosh P, Raja S, Rode J, den Boer M, Das P, Alvar J, Rijal S, Alves F. PLOS Neglected Tropical Diseases 2024, 18(6): e0012242. doi: 10.1371/journal.pntd.0012242
- [Design, conduct, analysis, and reporting of therapeutic efficacy studies in visceral leishmaniasis: A systematic review of published reports, 2000–2021](https://dndi.org/scientific-articles/2024/design-conduct-analysis-reporting-visceral-leishmaniasis-systematic-review/) - by Dahal P, Singh-Phulgenda S, Naylor C, Brack M, Chatterjee M, Alves F, Guerin PJ, Stepniewska K. American Journal of Tropical Medicine and Hygiene 2024. doi: 10.4269/ajtmh.23-0458 Summary: Syntheses of evidence from clinical studies on the efficacy of treatments for visceral leishmaniasis have usually focused on describing the patient population enrolled, heterogeneity in treatment regimens,
- [Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements](https://dndi.org/scientific-articles/2024/enabling-equitable-and-affordable-access-novel-therapeutics-pandemic-preparedness-and-response-via-creative-intellectual-property-agreements/) - by Griffen EJ, Boulet P, ASAP Discovery Center and COVID Moonshot. Wellcome Open Research 2024, 9:374. Summary: Drug discovery and development organizations usually recoup their investment using patents, giving them a time-limited monopoly on the manufacture, sale or licensing of their drug, which can create distortions in access. Using an ‘Open Science’ approach, R&D organizations
- [Differences in the cellular immune response during and after treatment of Sudanese patients with post-kala-azar dermal leishmaniasis, and possible implications for outcome](https://dndi.org/scientific-articles/2024/treatment-sudanese-patients-pkdl-possible-implications-outcome/) - by Torres A, Younis BM, Alamin M, Tesema S, Bernardo L, Solana JC, Moreno J, Mustafa A-a, Alves F, Mudawi Musa A, Carrillo E. Journal of Epidemiology and Global Health 2024. doi: 10.1007/s44197-024-00270-0 Summary: Little is known about the cellular immune response for post-kala-azar dermal leishmaniasis (PKDL). The authors of this manuscript report changes in
- [How do we classify organ involvement in Chagas disease? A systematic review of organ involvement since 1909, highlighting the urgent need for a universal classification system in chronic Chagas disease](https://dndi.org/scientific-articles/2024/systematic-review-organ-involvement-since-1909-highlighting-urgent-need-for-universal-classification-system-chagas/) - by Galván IL, García M, Hasslocher-Moreno AM, Ortiga A, Sanz S, Molina I, Gascón J, Pinazo M-J. PLOS Neglected Tropical Diseases 2024. doi: 10.1371/journal.pntd.0012367 Summary: Chagas disease is a serious global health issue, with an estimated six million people currently infected with the disease. Some 30-40% of people living with Chagas disease may develop cardiac
- [Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial](https://dndi.org/scientific-articles/2024/once-weekly-fosravuconazole-vs-daily-itraconazole-in-patients-with-eumycetoma/) - by Fahal AH, Ahmed ES, Bakhiet SM, Bakhiet OE, Fahal LA, Mohamed AA, Mohamedelamin ESW, Bahar MEN, Attalla HY, Siddig EE, Mhmoud NA, Musa AM, van de Sande WWJ, Scherrer B, Oyieko P, Egondi TW, Onyango KO, Hata K, Chu WY, Dorlo TPC, Brüggemann RJ, Nyaoke BA, Strub-Wourgaft N, Zijlstra EE. Lancet Infectious Diseases 2024,
- [Paving the way for affordable and equitable liposomal amphotericin B access worldwide](https://dndi.org/scientific-articles/2024/paving-way-for-lamb-access/) - by Lee J, Cohen RM, Khan RA, Burry J, Casas EC, Chung HY, Costa LH, Ford N, Galvao D, Giron N, Jarvis JN, Mondal M, Odionyi JJ, Casas CP, Rangaraj A, Rode J, Ruffell C, Sued O, Ribeiro I. The Lancet Global Health 2024;12(9):e1552-e1559. doi: 10.1016/S2214-109X(24)00225-0. Summary: The conventional formulation of amphotericin B, used to
- [A guide for the generation of repositories of clinical samples for research on Chagas disease](https://dndi.org/scientific-articles/2024/generation-of-repositories-of-clinical-samples-for-chagas-research/) - by Martínez-Peinado N, Gabaldón-Figueira JC, Rodrigues Ferreira R, Carmen Thomas M, López MC, Araújo-Jorge TC, Alarcón de Noya B, Berón S, Ramsey J, Losada-Galván I, Schijman AG, González Martínez A, Ruiz AM, Rojas G, Saraiva RM, Noya-González O, Gómez A, Maldonado RA, Pinto J, Torrico F, Scandale I, Agüero F, Pinazo M-J, Gascón J, Hasslocher-Moreno AM, Alonso-Padilla. PLOS Neglected Tropical
- [Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in Eastern Africa](https://dndi.org/scientific-articles/2024/disease-specific-differences-pharmacokinetics-paromomycin-miltefosine-pkdl-visceral-leishmaniasis-eastern-africa/) - by Chu W-Y, Verrest L, Younis BM, Musa AN, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Monnerat S, Wasunna M, Roseboom IC, Solomos A, Huitema ADR, Alves F, Dorlo TPC. The Journal of Infectious Diseases 2024, 230(6): e1375–e1384. doi:10.1093/infdis/jiae413 Summary: Since the pharmacokinetics of paromomycin and miltefosine have not been studied in patients with
- [A standardized clinical database for research in Chagas disease: The NHEPACHA network](https://dndi.org/scientific-articles/2024/a-standardized-clinical-database-for-chagas-research-nhepacha-network/) - by González Martínez A, Losada-Galván I, Gabaldón-Figueira JC, Martínez-Peinado N, Saraiva RM, Fernández ML, Ramsey JM, Noya-González O, Alarcón de Noya B, Schijman AG, Berón S, Abril M, Gascón J, Sosa-Estani S, Pinazo M-J, Alonso-Padilla J, Hasslocher-Moreno AM. PLOS Neglected Tropical Diseases 2024, 18(8): e0012364. doi: 10.1371/journal.pntd.0012364. Summary: The NHEPACHA Iberoamerican Network, founded on the initiative of a group of
- [Hope amidst neglect: Mycetoma Research Center, University of Khartoum. A holistic management approach to achieve the United Nations’ Sustainable Development Goals](https://dndi.org/scientific-articles/2024/hope-amidst-neglect-mycetoma-research-center-university-khartoum/) - by Fahal AH, Ahmed IS, Saaed AA, Smith DJ, Alves F, Nyaoke B, Asiedu K, Hay R. PLOS Neglected Tropical Diseases 2024, 18(9): e0012420. doi: 10.1371/journal.pntd.0012420 Summary: The authors of this viewpoint describe the work of the Mycetoma Research Center (MRC), based in Khartoum, Sudan, which is the only World Health Organization collaborating center for mycetoma. Mycetoma is a debilitating chronic
- [The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases](https://dndi.org/scientific-articles/2024/case-for-global-therapeutics-development-coalition-building-therapeutics-pipeline-for-pandemic-and-endemic-diseases/) - by Machingaidze S, Casas CP, Mburu S, Draghia-Akli R, Mowbray CE, Rosen J, Burrone E, Nemer M, Dzau V. PLOS Global Public Health 2024, 4(8): e0003654. doi: 10.1371/journal.pgph.0003654 Summary: The COVID-19 pandemic exposed the inadequate pipeline of therapeutics for diseases with pandemic potential. We need a sustainable and responsive end-to-end research and development ecosystem that
- [Bioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitis](https://dndi.org/scientific-articles/2024/bioavailability-sustained-release-pellet-formulation-5-flucytosine-healthy-fed-participants-cryptococcal-meningitis/) - by Zekri Lassout NI, Goyal V, Krantz E, Simon F, Neven A, Eriksson J, Saayman A, Satam V, Ruffell C, Victor S, Chenel M, Celebic A, Caplain H, Gillon J-Y, Deshmukh A, Antarkar A, Sjögren E, Ribeiro I. Clinical and Translational Science 2024, 17(9): e13908. doi: 10.1111/cts.13908 Summary: 5-flucytosine, a treatment for cryptococcal meningoencephalitis, has a limited plasma half-life and must be administered every 6 hours. This poses major practical challenges that may
- [Epidemiological, clinical and etiological treatment aspects in the Chagas clinic of the municipality of Comapa - Jutiapa, Guatemala](https://dndi.org/scientific-articles/2025/epidemiological-clinical-and-etiological-treatment-aspects-in-the-chagas-clinic-of-the-municipality-of-comapa-jutiapa-guatemala/) - by Berganza E, Herazo R, García E, Marchiol A, Menes M, Alvarado E, Trampe R, Pinazo MJ. Acta Tropica 2025; 9:107648. doi: 10.1016/j.actatropica.2025.107648. Summary: The municipality of Comapa, in department of Jutiapa, Guatemala, is in a "hot spot" for Chagas disease (CD) control in Central America. The Departmental Directorate of Integrated Health Services Networks of Jutiapa
- [Climate change and <i>Trypanosoma cruzi</i> transmission in North and central America](https://dndi.org/scientific-articles/2024/climate-change-trypanosoma-cruzi-transmission-north-and-central-america/) - by Forsyth C, Agudelo Higuita NI, Hamer SA, Ibarra-Cerdeña CN, Valdez-Tah A, Stigler Granados P, Hamer GL, Vingiello M, Beatty NL. The Lancet Microbe 2024, 100946. doi: 10.1016/j.lanmic.2024.07.009 Summary: As it disrupts patterns of human habitation and land use, climate change may affect the epidemiology of Chagas disease by influencing the distribution of vector and host species. The authors of
- [Challenges and advancements in the development of vaccines and therapies against Chagas disease](https://dndi.org/scientific-articles/2024/challenges-advancements-development-vaccines-and-therapies-chagas-disease/) - by Pinazo M-J, Malchiodi E, Ioset J-R, Bivona A, Gollob KJ, Dutra WO. The Lancet Microbe 2024, 5(10): 100972. doi: 10.1016/j.lanmic.2024.100972 Summary: In order to develop effective vaccines and therapies against Chagas disease, it is essential to understand the intricate dynamics of parasite-host interactions and the resulting immune responses, which contribute to both protection and
- [خسارة علمية كبرى.. حرب السودان تدمّر مركز أبحاث المايستوما الوحيد في العالم.. شاهد التفاصيل ⁣](https://dndi.org/https/wwwinstagramcom/reel/di9mcavvpx7/igshotb4mmpwz2tjogl3/) - ACCESS THE REEL
- [Les membres de l'Organisation mondiale de la Santé adoptent un accord historique sur la lutte contre les pandémies (à partir de 4'45)](https://dndi.org/in-the-media/2025/les-membres-de-lorganisation-mondiale-de-la-sante-adoptent-un-accord-historique-sur-la-lutte-contre-les-pandemies-a-partir-de-445/) - ACCESS THE recording
- [Cross-border collaboration gains political traction as Africa targets visceral leishmaniasis elimination](https://dndi.org/in-the-media/2025/cross-border-collaboration-gains-political-traction-as-africa-targets-visceral-leishmaniasis-elimination/) - ACCESS THE ARTICLE
- [The promise of health for all: a collaborative model to close treatment gaps for neglected diseases](https://dndi.org/scientific-articles/2024/promise-health-for-all-collaborative-model-close-treatment-gaps-neglected-diseases/) - by Attipoe D. Clinical Pharmacology and Therapeutics 2024. doi: 10.1002/cpt.3427 Summary: This perspective traces the history of DNDi from its origins in the Drugs for Neglected Diseases Working Group and the Fatal Imbalance report, to the thirteen treatments for six neglected tropical diseases achieved so far thanks to local expertise, regional and disease-specific research platforms, and
- [Immunotherapeutic strategies as potential treatment options for cutaneous leishmaniasis](https://dndi.org/scientific-articles/2024/immunotherapeutic-strategies-as-potential-treatment-options-for-cutaneous-leishmaniasis/) - by Lafleur A, Daffis S, Mowbray C, Arana B. Vaccines 2024, 12(10):1179. doi: 10.3390/vaccines12101179 Summary: Current systemic treatments for cutaneous leishmaniasis (CL), including pentavalent antimonials and miltefosine, are associated with significant toxicity and reduced efficacy, and are frequently ineffective in severe or chronic CL. Immunotherapies offer a promising adjunct or alternative approach, but the heterogeneous clinical
- [Discovery of a series of macrocycles as potent inhibitors of <i>Leishmania Infantum</i>](https://dndi.org/scientific-articles/2024/discovery-series-macrocycles-potent-inhibitors-leishmania-infantum/) - by Riu F, Ruppitsch LA, Vo DD, Hong RS, Tyagi M, Matheeussen A, Hendrickx S, Poongavanam V, Caljon G, Sheikh AY, Sjö P, Kihlberg H . Journal of Medicinal Chemistry 2024. doi: 10.1021/acs.jmedchem.4c01370 Summary: Macrocycles are prominent among drugs for treatment of infectious disease, with many originating from natural products. The authors of this article report
- [Changes in lipid abundance are associated with disease progression and treatment response in chronic <i>Trypanosoma cruzi</i> infection](https://dndi.org/scientific-articles/2024/changes-lipid-abundance-associated-disease-progression-treatment-response-chagas-disease/) - by Gabaldón-Figueira JC, Ros-Lucas A, Martínez-Peinado N, Blackburn G, Losada-Galvan I, Posada E, Ballart C, Escabia E, Capellades J, Yanes O, Pinazo M-J, Gascón J, Alonso-Padilla J. Parasites Vectors 2024, 17:459. doi: 10.1186/s13071-024-06548-3 Summary: Current diagnostics for Chagas disease, caused by Trypanosoma cruzi, are limited, hindering evaluation of patient prognosis and treatment efficacy. T. cruzi disrupts several host
- [Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices](https://dndi.org/scientific-articles/2024/mass-spectrometry-methods-for-quantitative-analysis-of-dndi-6148-in-human-plasma-and-mouse-biomatrices/) - by Schouten WM, Van Bocxlaer K, Rosing H, Huitema ADR, Beijnen JH, Kratz JM, Mowbray CE, Dorlo TPC. Journal of Chromatography B 2024, 1250: 124377. doi: 10.1016/j.jchromb.2024.124377 Summary: Preclinical pharmacokinetics studies are necessary to evaluate the exposure of Leishmania parasites in the skin to DNDI-6148, a promising new oral drug for the treatment of cutaneous leishmaniasis.
- [Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay](https://dndi.org/scientific-articles/2024/early-assessment-antibodies-decline-chagas-patients-following-treatment-serological-multiplex-immunoassay/) - by Saade U, de Boer J, Scandale I, Altcheh J, Pottel H, Chatelain E, Zrein M. Nature Communications 2024,15:10530. doi: 10.1038/s41467-024-54910-x Summary: Currently available drugs for Chagas disease, nifurtimox and benznidazole, have not been sufficiently evaluated for efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the
- [Congenital Chagas disease: A cohort study to assess molecular diagnostic methods at the Chagas disease national reference center of Argentina](https://dndi.org/scientific-articles/2025/congenital-chagas-disease-cohort-study-to-assess-molecular-diagnostic-methods-argentina/) - by Lopez-Albizu C, Cura CI, Ramirez JC, Peyran P, Benchetrit A, Danesi E, Sosa-Estani S. PLOS Neglected Tropical Diseases 2025,19(1): e0012785. doi: 10.1371/journal.pntd.0012785 Summary: Mother-to-child transmission of Trypanosoma cruzi, the causative agent of Chagas disease, is the main route of transmission in vector-free areas. The National Institute of parasitology in Argentina and the PAHO/WHO Collaborating Center for Chagas Disease conducted a
- [Challenges of sharing individual participant data for secondary research on neglected tropical diseases: the experience of Drugs for Neglected Diseases initiative and a call for action](https://dndi.org/scientific-articles/2024/challenges-sharing-individual-participant-data-for-secondary-research-on-neglected-tropical-diseases/) - by Tarwid J, Childs M, Junod-Moser D, Negrouk A, Egondi T, Tipple C. BMJ Open 2024, 14:e078862. doi: 10.1136/bmjopen-2023-078862 Summary: DNDi is committed to maximising the scientific value of the individual participant data (IPD) it collects, while ensuring participant privacy and transparency in data processing. The authors of this article share what DNDi has learnt while working on its commitment to data sharing
- [Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India](https://dndi.org/scientific-articles/2025/patient-experience-and-current-management-vl-india/) - by Sundar S, Alves F, Ritmeijer K, den Boer M, Forsyth C, Hughes B, Zamble C, Carter K, Angyalosi. PLOS Neglected Tropical Diseases 2025,19(2):e0012326. doi: 10.1371/journal.pntd.0012326. Summary: Few studies have explored the perspectives of patients affected by visceral leishmaniasis (VL), particularly their experiences outside of clinical research settings. The authors of this qualitative study of
- [Unsupervised machine learning identifies biomarkers of disease progression in post-kala-azar dermal leishmaniasis in Sudan](https://dndi.org/scientific-articles/2025/unsupervised-machine-learning-identifies-biomarkers-of-disease-progression-in-pkdl-in-sudan/) - by Torres A, Younis BM, Tesema S, Solana JC, Moreno J, Martín-Galiano AJ, Musa AM, Alves F, Carrillo E. PLOS Neglected Tropical Diseases 2025,19(3): e0012924. doi: 10.1371/journal.pntd.0012924 Summary: Post-kala-azar dermal leishmaniasis (PKDL) is a rash that may appear after recovery from visceral leishmaniasis caused by Leishmania donovani. The factors influencing progression to a severe form of the disease are not well understood.
- [Contre la leishmaniose viscérale, une maladie tropicale négligée, plusieurs pays africains s’unissent](https://dndi.org/in-the-media/2025/contre-la-leishmaniose-viscerale-une-maladie-tropicale-negligee-plusieurs-pays-africains-sunissent/) - ACCESS THE ARTICLE
- [Accelerating access to paediatric medicines: lessons learned from the Global Accelerator for Paediatric Formulations, a WHO-hosted network](https://dndi.org/scientific-articles/2025/accelerating-access-to-paediatric-medicines-lessons-learned-from-gap-f/) - by Penazzato M, Hafiz A, Morin S, Malik F, Cappello B, Cohn J, Cressey TR, Fassinou P, Garcia-Prats AJ, Hatane L, Lee J, Masini T, Ojoo A, Ruel T, Villafranca DR, Valentin M, Reeder JC. The Lancet Child & Adolescent Health 2025, 9859: 337-348. doi: 10.1016/S2352-4642(25)00040-9 Summary: The Global Accelerator for Paediatric Formulations (GAP-f), a WHO-hosted
- [Discovery and early optimization of 1H-indole-2-carboxamides with anti-Trypanosoma cruzi activity](https://dndi.org/scientific-articles/2025/discovery-and-early-optimization-of-1h-indole-2-carboxamides-with-anti-trypanosoma-cruzi-activity/) - by de Oliveira RG, Cruz LR, Dessoy MA, Koovits PJ, dos Santos DA, de Oliveira LFN, Ferreira RA, Mollo MC, Lee E, Duarte SM, Krogh R, Ferreira LLG, Chelucci RC, Dichiara M, Simpson QJ, Feltrin C, da Silva AC, dos Santos BM, Broering MF, Pollastri MP, Ferrins L, Moraes CB, Andricopulo AD, Kratz JM, Sjö
- [A balancing act: Navigating the advantages and challenges of pioneering mycetoma treatment in Sudan – A landmark trial by the Mycetoma Research Center](https://dndi.org/scientific-articles/2025/navigating-advantages-and-challenges-of-pioneering-mycetoma-treatment-in-sudan/) - by Fahal AH, Ahmed ES, Saeed AA, Fahal LA, Hussein SME, Nakano K, Hata K, Alves F, Nyaoke BA. PLOS Neglected Tropical Diseases 2025, 19(4): e0013000. doi: 10.1371/journal.pntd.0013000 Summary: The authors of this viewpoint discuss the trial of fosravuconazole for the treatment of mycetoma, conducted by the Mycetoma Research Center (MRC) at the University of Khartoum,
- [Fexinidazole as a new oral treatment for human African trypanosomiasis due to <i>Trypanosoma brucei rhodesiense</i>: A prospective, open-label, single-arm, Phase II–III, non-randomised study](https://dndi.org/scientific-articles/2025/fexinidazole-new-oral-treatment-for-rhodesiense-human-african-trypanosomiasis-phase-23-non-randomised-study/) - by Matovu E, Nyirenda W, Eriatu A, Alves D, Perdrieu C, Lemerani M, Wamboga C, Lejon V, Seixas J, Signorell A, Reymondier A, Baudin E, Scherrer B, Valverde Mordt O. The Lancet Global Health 2025, 13(5):e910-e919. doi: 10.1016/S2214-109X(25)00016-6 Summary: Fexinidazole is a safe and effective treatment for gambiense human African trypanosomiasis (HAT). The authors of this
- [Effectiveness and safety of fexinidazole for <i>gambiense</i> human African trypanosomiasis and exploration of adherence in outpatients: A phase IIIb, prospective, open-label, non-randomised, cohort study](https://dndi.org/scientific-articles/2025/effectiveness-and-safety-fexinidazole-gambiense-human-african-trypanosomiasis-and-exploration-adherence-outpatients/) - by Kande Betu Kumeso V, Perdrieu C, Menétrey C, Ilunga Wa Kyhi M, Ngolo Tete T, Camara M, Tampwo J, Kavunga P, Layba Camara M, Kourouma A, Kuziena Mindele W, Akwaso Masa F, Mahenzi H, Makaya J, Mayala Malu T, Mandula G, Mpoyi Muamba Nzambi D, Luwawu Ntoya S, Reymondier A, Mutombo Kalonji W, Scherrer
- [Mieux connaître et parfois mieux combattre les champignons microscopiques dangereux qui sont partout](https://dndi.org/in-the-media/2025/mieux-connaitre-et-parfois-mieux-combattre-les-champignons-microscopiques-dangereux-qui-sont-partout/) - Écoutez ici
- [Mycetoma’s only research centre destroyed](https://dndi.org/in-the-media/2025/mycetoma-research-centre-destroyed/) - Listen now
- [Rare bone-eroding disease ruining lives in Kenya's poorest county](https://dndi.org/in-the-media/2025/mycetoma-ruining-lives-in-kenya-s-poorest-county/) - Read the article
- [Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis](https://dndi.org/press-releases/2025/six-african-nations-commit-eliminate-visceral-leishmaniasis/) - During a ceremony organized under the auspices of the African Union and the World Health Organization and on the sidelines of the 78th World Health Assembly in Geneva, representatives from six African countries signed a Memorandum of Understanding aimed at eliminating visceral leishmaniasis, one of the deadliest neglected diseases.
- [Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease](https://dndi.org/scientific-articles/2025/pk-pd-modeling-of-benznidazole-and-its-antitrypanosomal-activity-in-chagas-disease-model/) - by Assmus F, Adehin A, Hoglund RM, Fortes Francisco A, Lewis MD, Kelly JM, Charman SA, White KL, Shackleford DM, Escudié F, Chatelain E, Scandale I, Tarning J. PLOS Neglected Tropical Diseases 2025, 19(5): e0012968. doi: 10.1371/journal.pntd.0012968. Summary: Benznidazole, the standard treatment for Chagas disease, is poorly tolerated and has variable efficacy in chronic infections.
- [The Science Explained: Evaluating new treatment regimens for visceral leishmaniasis in people living with HIV in India and Ethiopia](https://dndi.org/publications/2022/the-science-explained-evaluating-new-treatment-regimens-for-visceral-leishmaniasis-in-people-living-with-hiv-in-india-and-ethiopia/) - DOWNLOAD
- [DND<i>i</i> briefing document: Best science for all](https://dndi.org/publications/2022/best-science-for-all/) - DNDi briefing document for the Kigali Summit on Malaria and Neglected Tropical Diseases
- [Countermeasure R&D: Global norms for financing risk reduction, resilience & equity](https://dndi.org/publications/2022/countermeasure-rd-global-norms-financing-risk-reduction-resilience-equity/) - This publication was developed as the outcome of the workshop 'Countermeasure R&D: Global Norms for Financing Risk Reduction, Resilience and Equity' that took place on 18 and 19 January 2022. Co-convenors of the workshop were the Government of Norway, Government of Mexico, Global Health Centre at the Graduate Institute of Geneva, and the Drugs for
- [DND<i>i</i>'s Commitment to the Kigali Declaration](https://dndi.org/publications/2022/dndi-commitment-kigali-declaration/) - DOWNLOAD
- [DND<i>i</i> 2021 Annual Report](https://dndi.org/publications/2022/dndi-2021-annual-report/) - Unlocking the promise of medical innovation for all
- [2021 DND<i>i</i> Financial Report](https://dndi.org/publications/2022/financial-report-2021/) - download
- [The Opportunity to Eliminate Hepatitis C through Alternative Financing Mechanisms](https://dndi.org/publications/2022/the-opportunity-to-eliminate-hepatitis-c-through-alternative-financing-mechanisms/) - DOWNLOAD
- [The Science Explained: Evaluating an alternative treatment regimen for visceral leishmaniasis in Eastern Africa](https://dndi.org/publications/2022/the-science-explained-evaluating-alternative-treatment-regimen-for-visceral-leishmaniasis-in-eastern-africa/) - DOWNLOAD
- [Leishmaniasis factsheet](https://dndi.org/publications/2022/leishmaniasis-factsheet-2022/) - Delivering safer, simpler treatments to save lives and reduce social stigma
- [Sleeping sickness factsheet](https://dndi.org/publications/2022/sleeping-sickness-factsheet-2022/) - Delivering breakthrough treatments and expediting access to eliminate the disease – for good
- [Chagas disease factsheet](https://dndi.org/publications/2022/chagas-disease-factsheet-2022/) - Searching for shorter, safer, more effective treatments to stop a silent killer
- [COVID-19 and pandemic preparedness factsheet](https://dndi.org/publications/2022/covid-19-and-pandemic-preparedness-factsheet-2022/) - Accelerating research, advocating for equity, and preparing for future pandemics
- [DNDi 2022 Annual Report](https://dndi.org/publications/2023/dndi-2022-annual-report/) - 20 years of innovating together
- [Cryptococcal meningitis factsheet](https://dndi.org/publications/2022/cryptococcal-meningitis-factsheet/) - Bridging treatment gaps for a deadly HIV co-infection
- [2022 DNDi Financial Report](https://dndi.org/publications/2023/financial-report-2022/) - download
- [LEAP Newsletter](https://dndi.org/publications/2023/leap-newsletter-issue-8/) - The LEAP Newsletter highlights recent major developments addressing the diagnostics and treatment needs of neglected leishmaniasis patients.
- [Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study](https://dndi.org/scientific-articles/2025/quantitative-analysis-of-dndi-6174-using-uplc-ms-ms-a-preclinical-target-site-pharmacokinetic-study/) - by Schouten WM, Van Bocxlaer K, Rosing H, Huitema ADR, Beijnen JH, Kratz JM, Mowbray CE, Dorlo TPC. Journal of Chromatography B 2025. doi: 10.1016/j.jchromb.2025.124652. Summary: The authors of this study developed and validated a novel ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) method to quantify DNDI-6174, a novel orally active investigational drug
- [Hepatitis C factsheet](https://dndi.org/publications/2023/hepatitis-c-factsheet-2023/) - Supporting global elimination efforts by accelerating access to affordable treatments
- [Filaria: River blindness factsheet](https://dndi.org/publications/2023/filaria-river-blindness-factsheet-2023/) - Searching for a cure for millions at risk
- [Chagas disease factsheet](https://dndi.org/publications/2023/chagas-disease-factsheet-2023/) - Searching for shorter, safer, more effective treatments to stop a silent killer
- [Dengue factsheet](https://dndi.org/publications/2023/dengue-factsheet-2023/) - Leveraging global partnerships to tackle a rapidly spreading climate-sensitive disease
- [Mycetoma factsheet](https://dndi.org/publications/2023/mycetoma-factsheet-2023/) - Developing safe, affordable treatments to prevent devastating disability
- [Sleeping sickness factsheet](https://dndi.org/publications/2023/sleeping-sickness-factsheet-2023/) - Delivering all-new treatments to eliminate a deadly disease
- [Leishmaniasis factsheet](https://dndi.org/publications/2023/leishmaniasis-factsheet-2023/) - Delivering safer, simpler treatments to save lives and reduce social stigma
- [HIV factsheet](https://dndi.org/publications/2023/hiv-factsheet-2023/) - Ensuring access to optimal treatment for children and people with advanced HIV disease
- [Advanced HIV Disease: Issue Brief](https://dndi.org/publications/2023/ahd-dashboard-brief/) - This issue brief examines findings from the Advanced HIV Disease (AHD) Dashboard. The dashboard tracks, visualizes, and compares national guidelines across 35 African countries to understand the pace and scale of adoption of WHO-recommended treatment guidelines shown to reduce deaths from AHD and cryptococcal meningitis.
- [2023 DNDi Financial Report](https://dndi.org/publications/2024/financial-report-2023/) - This issue brief examines findings from the Advanced HIV Disease (AHD) Dashboard. The dashboard tracks, visualizes, and compares national guidelines across 35 African countries to understand the pace and scale of adoption of WHO-recommended treatment guidelines shown to reduce deaths from AHD and cryptococcal meningitis.
- [The Science Explained: Good news for people living with PKDL in Eastern Africa](https://dndi.org/publications/2024/science-explained-pkdl-eastern-africa/) - 20 years of innovating together
- [The Science Explained: Evaluating an alternative treatment regimen for fungal mycetoma](https://dndi.org/publications/2024/the-science-explained-evaluating-alternative-treatment-fungal-mycetoma/) - A Phase II superiority trial to assess the safety and efficacy of two regimens of fosravuconazole compared to itraconazole
- [Slovakia to challenge adoption of 'critical' global pandemic agreement](https://dndi.org/in-the-media/2025/slovakia-to-challenge-adoption-of-critical-global-pandemic-agreement/) - ACCESS THE ARTICLE
- [Los países de la OMS aprueban por unanimidad un histórico tratado de pandemias: estas son las claves del acuerdo que “protegerá mejor al mundo”](https://dndi.org/in-the-media/2025/los-paises-de-la-oms-aprueban-por-unanimidad-un-historico-tratado-de-pandemias-estas-son-las-claves-del-acuerdo-que-protegera-mejor-al-mundo/) - ACCESS THE ARTICLE
- [LEAP Newsletter](https://dndi.org/publications/2024/leap-newsletter-2024/) - The LEAP Newsletter highlights recent major developments addressing the diagnostics and treatment needs of neglected leishmaniasis patients.
- [MycetOS factsheet](https://dndi.org/publications/2025/mycetos-factsheet/) - Leveraging open science to find new treatments for fungal mycetoma
- [Open Synthesis Network factsheet](https://dndi.org/publications/2025/open-synthesis-network-factsheet-2025/) - Engaging master’s and undergraduate students in research for neglected diseases.
- [DNDi supporting a pioneering project that integrates Indigenous knowledge in the treatment of Chagas](https://dndi.org/stories/2025/dndi-supporting-pioneering-project-integrates-indigenous-knowledge-treatment-chagas/) - The innovation lies in the coordination and participation of Indigenous leaders and local health authorities to implement the treatment strategies.
- [Bölët Mouna! Ending sleeping sickness in Guinea](https://dndi.org/videos/2025/guineafilm/) - Bölët Mouna means ‘sleeping sickness no more’ in Guinea’s national language Susu and tells the story of how research, innovation, and science are ending the the nightmare of sleeping sickness in Guinea.
- [DNDi's briefing note for 78<sup>th</sup> World Health Assembly](https://dndi.org/statements/2025/dndis-briefing-note-for-78th-world-health-assembly/) - This briefing sets out DNDi's comments for consideration by WHO Member States on agenda items included in the 77th meeting of the World Health Assembly.
- [DNDi looking for a new Patient Representative to join its Board of Directors](https://dndi.org/news/2025/dndi-looking-for-a-new-patient-representative-to-join-its-board-of-directors/) - DNDi's mission to develop life-saving treatments for neglected patients around the world can only be done by putting patients and communities at the heart of everything we do — treating patients not as beneficiaries, but as partners. We have always had patient representatives on our Board of Directors, ensuring their voices are heard at the
- [L’élimination de la maladie du sommeil en Guinée, vue de l'intérieur](https://dndi.org/stories/2025/elimination-maladie-sommeil-en-guinee/) - Bölët Mouna signifie « finissons-en avec la maladie du sommeil » en susu, la langue nationale guinéenne. Cette histoire raconte comment la recherche et la science sont en train de mettre fin au fléau de la maladie du sommeil en Guinée.
- [Gleaming labs turned to rubble: scientists mourn the loss of decades of medical progress in Sudan](https://dndi.org/in-the-media/2025/gleaming-lab-turned-to-rubble-mrc/) - ACCESS THE ARTICLE
- [UK city leads fight against one of Africa, Asia and Brazil's deadliest parasites](https://dndi.org/in-the-media/2025/liverpool-uni-trials-new-potential-treatment-vl/) - ACCESS THE ARTICLE
- [Uni study trials new treatment for deadly disease](https://dndi.org/in-the-media/2025/uni-study-trials-new-treatment-leishmaniasis/) - ACCESS THE ARTICLE
- [World’s only research centre for flesh-eating infection ransacked in Sudan](https://dndi.org/in-the-media/2025/guinea-has-wiped-out-sleeping-sickness-will-the-rest-of-africa-follow-2/) - ACCESS THE ARTICLE
- [Sudan war destroys world's only research centre on skin disease mycetoma: director](https://dndi.org/in-the-media/2025/sudan-war-destroys-worlds-only-research-centre-on-skin-disease-mycetoma-director/) - Read the article
- [Strategic Plan 2021-2028: Mid-Term Review](https://dndi.org/publications/2025/strategic-plan-2021-2028-mid-term-review/) - In 2024, we conducted a mid-term review of our Strategic Plan to assess progress and to identify and propose changes to guide our work over the next four years.
- [Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz](https://dndi.org/news/2025/message-on-the-passing-of-marco-krieger/) - Drugs for Neglected Diseases initiative (DNDi) extends its deepest condolences to the family, friends, and colleagues of Dr Marco Aurélio Krieger, a pivotal advocate for public health and innovation in Latin America. Dr Krieger played a crucial role in strengthening and expanding DNDi’s partnership with the Oswaldo Cruz Foundation (Fiocruz), a pioneering public health research
- [Race against time: New treatment for deadly HIV complication enters trials](https://dndi.org/in-the-media/2025/race-against-time-new-treatment-for-deadly-hiv-complication-enters-trials/) - ACCESS THE ARTICLE
- [New treatment for deadly HIV-linked meningitis enters phase II trial](https://dndi.org/in-the-media/2025/new-treatment-for-deadly-hiv-linked-meningitis-enters-phase-ii-trial/) - ACCESS THE ARTICLE
- [Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease](https://dndi.org/press-releases/2025/liverpool-clinical-trial-to-advance-treatment-visceral-leishmaniasis/) - A clinical trial is underway in Liverpool, bringing together NHS University Hospitals of Liverpool Group, the University of Liverpool, and DNDi in the effort to address visceral leishmaniasis – one of the world’s deadliest parasitic diseases.
- [Un nouveau traitement contre la méningite à cryptocoque, en phase d'essai](https://dndi.org/in-the-media/2025/un-nouveau-traitement-contre-la-meningite-a-cryptocoque-en-phase-dessai/) - Ecoutez ici
- [DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease](https://dndi.org/press-releases/2025/dndi-welcomes-ghit-support-new-project-japanese-universities-chagas-disease/) - Over the 18-month project that was started in March 2025, Kitasato University, Nagasaki University, the University of Tokyo, and DNDi will utilize their expertise to identify at least five novel compounds derived from natural products with the potential to become medicines against Chagas.
- [Como acabar de vez com as doenças negligenciadas?](https://dndi.org/viewpoints/2025/como-acabar-de-vez-com-as-doencas-negligenciadas/) - By Sergio Sosa-Estani, Continental Lead Americas and Latin America Director, DNDi By Sergio Sosa-Estani, Continental Lead Americas and Latin America Director, DNDi Dengue, Chagas, leishmaniose… As doenças tropicais negligenciadas (DTNs) afetam, anualmente, mais de 1 milhão de pessoas e fazem mais de 200 mil vítimas fatais, de acordo com a Organização Mundial da Saúde (OMS). Elas formam um grupo de 21 enfermidades determinadas pela OMS que
- [Accord historique à l'OMS sur la préparation et la lutte contre les futures pandémies](https://dndi.org/in-the-media/2025/accord-historique-a-loms-sur-la-preparation-et-la-lutte-contre-les-futures-pandemies/) - ACCESS THE ARTICLE
- [WHO-Mitglieder einigen sich auf historisches Pandemieabkommen](https://dndi.org/in-the-media/2025/who-mitglieder-einigen-sich-auf-historisches-pandemieabkommen/) - ACCESS THE ARTICLE
- [WHO strikes deal on future pandemic response](https://dndi.org/in-the-media/2025/who-strikes-deal-on-future-pandemic-response/) - ACCESS THE ARTICLE
- [Luz verde para un “histórico” tratado mundial contra pandemias impulsado por la OMS](https://dndi.org/in-the-media/2025/luz-verde-para-un-historico-tratado-mundial-contra-pandemias-impulsado-por-la-oms/) - ACCESS THE ARTICLE
- [Countries Say YES to Pandemic Agreement](https://dndi.org/in-the-media/2025/countries-say-yes-to-pandemic-agreement/) - ACCESS THE ARTICLE
- [Countries reach historic pandemic treaty deal after prolonged stalemate](https://dndi.org/in-the-media/2025/countries-reach-historic-pandemic-treaty-deal-after-prolonged-stalemate/) - ACCESS THE ARTICLE
- [Moment of reckoning for pandemic agreement talks at WHO](https://dndi.org/in-the-media/2025/moment-of-reckoning-for-pandemic-agreement-talks-at-who/) - ACCESS THE ARTICLE
- [First global pandemic treaty agreed — without the US](https://dndi.org/in-the-media/2025/first-global-pandemic-treaty-agreed-without-the-us/) - ACCESS THE ARTICLE
- [Countries agree on treaty aimed at preventing global health crises](https://dndi.org/in-the-media/2025/countries-agree-on-treaty-aimed-at-preventing-global-health-crises/) - ACCESS THE ARTICLE
- [Drug discovery explained: Chagas - How to prove treatments work?](https://dndi.org/stories/2025/drug-discovery-explained-chagas-biomarkers/) - Chagas disease: A breakthrough method to address the longstanding biomarkers challenge. DNDi researcher and series host Fanny Escudié explains how scientists are using the most advanced technologies to improve the lives of millions of neglected patients around the world.
- [New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease](https://dndi.org/press-releases/2025/new-treatment-cryptococcal-meningitis-enters-phase-ii-trial/) - Cryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases.
- [Drug discovery explained: What is lead optimization?](https://dndi.org/stories/2025/drug-discovery-explained-lead-optimization/) - The magic of lead optimization: how researchers design molecules to treat neglected diseases. DNDi researcher and series host Fanny Escudié explains how scientists are using the most advanced technologies to improve the lives of millions of neglected patients around the world.
- [Drug discovery explained: What is high-throughput screening?](https://dndi.org/stories/2024/drug-discovery-explained-high-throughput-screening/) - High-throughput screening: testing millions of molecules to find drugs for neglected diseases.
- [Opinion: How patents can serve the common good](https://dndi.org/viewpoints/2025/opinion-how-patents-can-serve-the-common-good/) - by Ed Griffen and Pascale Boulet By Ed Griffen and Pascale Boulet The relationship between intellectual property (IP) and access to the fruits of science has always been tumultuous. The unequal distribution of messenger RNA vaccines during the COVID-19 pandemic pitted patent holders against advocates of access to medicines in the latest confirmation of this truism. In global health, rationing costs
- [Ending sleeping sickness in Guinea](https://dndi.org/in-the-media/2025/ending-sleeping-sickness-in-guinea/) - ACCESS THE ARTICLE
- [Comme la Guinée avec la maladie du sommeil, 44 pays ont réussi à éradiquer des pathologies depuis cinq ans](https://dndi.org/in-the-media/2025/comme-la-guinee-avec-la-maladie-du-sommeil-44-pays-ont-reussi-a-eradiquer-des-pathologies-depuis-cinq-ans/) - ACCESS THE ARTICLE
- [Africa’s greatest health challenges won’t be solved without female scientists](https://dndi.org/viewpoints/2025/africas-greatest-health-challenges-wont-be-solved-without-female-scientists/) - By Damaris Matoke-Muhia and Monique Wasunna Damaris Matoke-Muhia and Monique Wasunna are two African women scientists who have spent decades working in infectious disease and tropical medicine research. Despite proving that African women can lead inclusive, groundbreaking research and shape global health solutions, the authors find that women - particularly African women - are still far too underrepresented in By Damaris Matoke-Muhia and Monique Wasunna Damaris Matoke-Muhia and Monique Wasunna are two African women scientists who have spent decades working in infectious disease and tropical medicine research. Despite proving that African women can lead inclusive, groundbreaking research and shape global health solutions, the authors find that women - particularly African women - are still far too underrepresented in
- [La Guinée a vaincu la maladie du sommeil](https://dndi.org/in-the-media/2025/la-guinee-a-vaincu-la-maladie-du-sommeil/) - Ce reportage publié le 28 mars 2025 par T, le magazine du Temps, explique comment la Guinée a réussi à éliminer la maladie du sommeil en tant que problème de santé publique. Un succès historique en grande partie dû à la science : les nouveaux médicaments développés par DNDi et les pièges à mouches tsé-tsé mis
- [A new pan-coronavirus protease inhibitor possibility](https://dndi.org/in-the-media/2025/a-new-pan-coronavirus-protease-inhibitor-possibility/) - ACCESS THE ARTICLE
- [Antiviral unveiled that goes after multiple coronaviruses](https://dndi.org/in-the-media/2025/antiviral-unveiled-that-goes-after-multiple-coronaviruses/) - ACCESS THE ARTICLE
- [Comment la Guinée s'est débarassée de la maladie du sommeil?](https://dndi.org/in-the-media/2025/comment-la-guinee-sest-debarassee-de-la-maladie-du-sommeil/) - Écoutez ici
- [Luke Kanyang'areng: The nurse who turned his pain into purpose](https://dndi.org/in-the-media/2025/luke-kanyangareng-the-nurse-who-turned-his-pain-into-purpose/) - ACCESS THE ARTICLE
- [アフリカで感染症対策が逆境　米政権が援助削減　日本の関与に期待](https://dndi.org/in-the-media/2025/infectious-disease-control-africa-japan-involvement/) - "Infectious disease control in Africa is adversely affected, U.S. administration cuts aid, hopes for Japan's involvement" Click here to read the article
- [Tricky to spot and cumbersome to treat, visceral leishmaniasis turns deadly in arid east Africa](https://dndi.org/in-the-media/2025/tricky-to-spot-and-cumbersome-to-treat-visceral-leishmaniasis-turns-deadly-in-arid-east-africa/) - Click here to access the article
- [DNDi welcomes GHIT support for new collaboration with Shionogi to identify novel drug candidates for neglected Chagas disease](https://dndi.org/press-releases/2025/dndi-welcomes-ghit-support-collaboration-shionogi-identify-novel-drug-candidates-chagas-disease/) - Shionogi and DNDi aim to identify novel hit series with potential to be developed into safer, more effective drugs for Chagas disease, a life-threatening illness with limited and suboptimal therapeutic options.
- [8 mars : Dr Hélène Mahenzi : une vie dédiée à la lutte contre les maladies négligées en RDC](https://dndi.org/in-the-media/2025/8-mars-dr-helene-mahenzi-une-vie-dediee-a-la-lutte-contre-les-maladies-negligees-en-rdc/) - access the article
- [Biomedical innovation: Answer for climate-sensitive diseases](https://dndi.org/viewpoints/2023/biomedical-innovation-answer-for-climate-sensitive-diseases/) - By Kavita Singh, South Asia Director, DNDi By Kavita Singh, South Asia Director, DNDi There is consensus among scientists that climate change is having a disastrous impact on health, particularly on the incidence of infectious diseases – that health, in short, is the human face of climate change. That global leaders are listening was demonstrated during the recent COP28, where a dedicated
- [Las enfermedades desatendidas necesitan investigación, pero la financiación no está a la altura](https://dndi.org/viewpoints/2024/las-enfermedades-desatendidas-necesitan-investigacion-pero-la-financiacion-no-esta-a-la-altura/) - By Terín Beca, Consultant, DNDi and Belén Pedrique, Senior Medical Manager, Viral Diseases Cluster HCV, HIV, Dengue and Crypto, DNDi By Terín Beca, Consultant, DNDi and Belén Pedrique, Senior Medical Manager, Viral Diseases Cluster HCV, HIV, Dengue and Crypto, DNDi First published in The Conversation on 5 February 2023 Español Português Las enfermedades tropicales desatendidas (ETD) son un grupo de 21 enfermedades que prevalecen principalmente entre las comunidades desfavorecidas de las zonas tropicales y subtropicales, aunque algunas tienen una
- [The EU must continue to support development of drugs for neglected infectious diseases in Framework Programme 10](https://dndi.org/viewpoints/2024/the-eu-must-continue-to-support-development-of-drugs-for-neglected-infectious-diseases-in-framework-programme-10/) - By Michael Makanga, Executive Director, Global Health EDCTP3 Joint Undertaking and Luis Pizarro, Executive Director, DNDi By Michael Makanga, Executive Director, Global Health EDCTP3 Joint Undertaking and Luis Pizarro, Executive Director, DNDi We received our medical training on opposite sides of the world, but were both horrified to learn about the nightmare illness human African trypanosomiasis, also known as sleeping sickness. For one of us, studying to be a doctor in
- [Doença do sono derrotada: lições de uma bem-sucedida missão na África](https://dndi.org/viewpoints/2025/veja-doenca-do-sono-derrotada-licoes-de-uma-bem-sucedida-missao-na-africa/) - By Dr Luis Pizarro, Executive Director, DNDi By Dr Luis Pizarro, Executive Director, DNDi A Guiné alcançou, recentemente, um marco memorável, que serviu para mostrar ao mundo o impacto que a ciência e a cooperação internacional podem ter na vida de milhões de pessoas em condições de vulnerabilidade extrema. O país da África Ocidental anunciou que conseguiu eliminar a doença do sono
- [World AIDS Day - This is how we can fight the second biggest killer of people with HIV](https://dndi.org/viewpoints/2024/world-aids-day-this-is-how-we-can-fight-the-second-biggest-killer-of-people-with-hiv/) - By Justine Odionyi, Head of Disease, HIV, DNDi By Justine Odionyi, Head of Disease, HIV, DNDi When I recently visited a hospital ward in Kinshasa, Democratic Republic of Congo, I left feeling deeply distraught. Over a dozen patients with HIV were admitted with cryptococcal meningitis - a fungal disease which is the second-leading cause of HIV- related death. Many were diagnosed late, which
- [On World Meningitis Day, too many people are dying of cryptococcal meningitis in Africa](https://dndi.org/viewpoints/2024/on-world-meningitis-day-too-many-people-are-dying-of-cryptococcal-meningitis-in-africa/) - By Justine Odionyi, Head of Disease, HIV, DNDi By Justine Odionyi, Head of Disease, HIV, DNDi When Zikhona, a young woman from New Crossroads in Cape Town, arrived at Khayelitsha Hospital, she thought she was going to die. She was in severe pain, had an excruciating, crippling headache, a stiff neck, and was almost blind. She was diagnosed with cryptococcal meningitis – a
- [Más cerca de la eliminación de la enfermedad del sueño](https://dndi.org/viewpoints/2023/mas-cerca-de-la-eliminacion-de-la-enfermedad-del-sueno/) - By Olaf Valverde, Clinical Project Leader (HAT), DNDi By Olaf Valverde, Clinical Project Leader (HAT), DNDi La primera vez que tuve pacientes con la enfermedad del sueño fue en Uganda en 1989. Trabajaba para Médicos sin Fronteras (MSF) como médico en campos de refugiados que cruzaron la frontera desde el sur de Sudán, huyendo de la guerra. Tuvimos que trasladar a algunos pacientes afectados por
- [Una sugerencia concreta que podría salvar millones de vidas en una futura pandemia](https://dndi.org/viewpoints-translations/2024/una-sugerencia-concreta-que-podria-salvar-millones-de-vidas-en-una-futura-pandemia/) - By Dr Luis Pizarro, Executive Director, DNDi By Dr Luis Pizarro, Executive Director, DNDi Español English La cuestión no es si habrá otra pandemia, sino cuándo. Por eso, desde hace más de dos años se llevan a cabo intensas negociaciones en la Organización Mundial de la Salud (OMS) para crear un Acuerdo sobre Pandemias que defina en líneas generales cómo puede el mundo prevenir
- [Las guerreras del Chagas](https://dndi.org/viewpoints/2024/las-guerreras-del-chagas/) - By María Jesús Pinazo, Head of Chagas disease, DNDi By María Jesús Pinazo, Head of Chagas disease, DNDi Yolanda es su nombre, y la conocí hace unos 18 años mientras le prestaba atención en un servicio médico en Barcelona. Tres años después traté a su madre en Cochabamba, Bolivia, enviada por su hija con un mensaje claro desde el otro lado del océano, el
- [A concrete suggestion that could save millions of lives in a future pandemic](https://dndi.org/viewpoints/2024/a-concrete-suggestion-that-could-save-millions-of-lives-in-a-future-pandemic/) - By Dr Luis Pizarro, Executive Director, DNDi By Dr Luis Pizarro, Executive Director, DNDi English Español The question is not whether there will be another pandemic, but when. And so, for more than two years, the World Health Organization has been involved in intense negotiations to create a pandemic agreement that will define in general terms how the world can better prevent and
- [What Kenya can do to achieve its elimination targets for neglected diseases](https://dndi.org/viewpoints/2024/what-kenya-can-do-achieve-elimination-targets-neglected-diseases/) - By Samuel Kariuki, Eastern Africa Director, DNDi By Samuel Kariuki, Eastern Africa Director, DNDi As a scientist dedicated to neglected tropical diseases, I have noticed with concern the shifting patterns in the spread of visceral leishmaniasis (also known as kala-azar) in Kenya. Once confined to specific regions, this deadly parasitic disease has been spreading to previously unaffected counties. It's not just kala-azar
- [Women are poorly represented in clinical trials. That’s problematic](https://dndi.org/viewpoints/2025/nature-india-women-poorly-represented-clinical-trials-problematic/) - By Dr Kavita Singh, Continental Lead Asia and South Asia Director, DNDi By Dr Kavita Singh, Continental Lead Asia and South Asia Director, DNDi Clinical research is the foundation of modern medicine, shaping the safety and efficacy of drugs. But for decades women — particularly those of childbearing potential — are routinely excluded from clinical trials. Fewer than 30% of participants in industry-sponsored early-phase trials are women,
- [Pandemic preparedness: DNDi and THSTI receive financial support from Novo Nordisk Foundation to develop broad-spectrum, host-directed antivirals](https://dndi.org/news/2024/dndi-thsti-receive-financial-support-novo-nordisk-foundation-develop-broad-spectrum-host-directed-antivirals/) - DNDi and the Translational Health Science and Technology Institute (THSTI) of India are collaborating in the field of drug discovery to improve and optimize promising molecules that could become affordable, broad-spectrum antiviral treatments for influenza and other viruses of pandemic potential.
- [2024 R&D programmes in review: Pandemic preparedness](https://dndi.org/news/2025/2024-rd-programmes-in-review-pandemic-preparedness/) - DNDi and our partners are working to accelerate research to prepare for future viral pandemics.
- [2024 R&D programmes in review: Hepatitis C](https://dndi.org/news/2025/2024-rd-programmes-in-review-hepatitis-c/) - DNDi and our partners are supporting global elimination efforts by accelerating access to affordable treatments.
- [2024 R&D programmes in review: HIV](https://dndi.org/news/2025/2024-rd-programmes-in-review-hiv/) - DNDi and our partners are working to improve access to optimal treatments for people with advanced HIV disease.
- [2024 R&D programmes in review: Dengue](https://dndi.org/news/2025/2024-rd-programmes-in-review-dengue/) - DNDi and our partners are working to tackle the urgent need for treatments that can prevent progression to severe disease.
- [2024 R&D programmes in review: Mycetoma](https://dndi.org/news/2025/2024-rd-programmes-in-review-mycetoma/) - DNDi and our partners are working to develop safe, affordable treatments to prevent devastating amputation and disability – and to improve access for all people in need.
- [2024 R&D programmes in review: Chagas disease](https://dndi.org/news/2025/2024-rd-programmes-in-review-chagas-disease/) - DNDi and our partners are searching for shorter, safer, more effective treatments to stop a silent killer. In the short term, we are working to develop improved treatment regimens with the existing drug benznidazole, reduce mother-to-child transmission, and help roll out ‘test-and-treat’ strategies to reach people living with Chagas disease in remote areas of Latin America. Our longer-term goal is to discover and develop entirely new drug candidates, with the aim of launching at least one Phase III trial by 2028.
- [2024 R&D programmes in review: Leishmaniasis](https://dndi.org/news/2025/2024-rd-programmes-in-review-leishmaniasis/) - DNDi and our partners are working to deliver safer, simpler treatments to save lives, reduce social stigma, and eliminate leishmaniasis as a public health problem​.
- [2024 R&D programmes in review: Sleeping sickness](https://dndi.org/news/2025/2024-rd-programmes-in-review-sleeping-sickness/) - DNDi and our partners are working to deliver breakthrough treatments and expedite access to eliminate sleeping sickness – for good.
- [Congreso Futuro: El impacto mundial de la salida de EEUU de la Organización Mundial de la Salud (OMS) con Luis Pizarro](https://dndi.org/in-the-media/2025/congreso-futuro-el-impacto-mundial-de-la-salida-de-eeuu-de-la-organizacion-mundial-de-la-salud-oms-con-luis-pizarro/) - ACCESS THE episode
- [Ending neglect of tropical diseases](https://dndi.org/in-the-media/2025/ending-neglect-of-tropical-diseases/) - ACCESS THE episode
- [Comment le travail sur le terrain m'a fait passer du statut de médecin à celui de chercheur](https://dndi.org/in-the-media/2025/comment-le-travail-sur-le-terrain-ma-fait-passer-du-statut-de-medecin-a-celui-de-chercheur/) - ACCESS THE ARTICLE
- [How fieldwork transformed me from a doctor to a researcher](https://dndi.org/in-the-media/2025/how-fieldwork-transformed-me-from-a-doctor-to-a-researcher/) - ACCESS THE ARTICLE
- [2023 R&D portfolio in review: HIV](https://dndi.org/news/2024/2023-rd-portfolio-in-review-hiv/) - DNDi and our partners are working to improve access to optimal treatments for children and people with advanced HIV disease. Following the development of our 4-in-1 treatment for infants and young children living with HIV, DNDi is advancing the development of a sustained-release formulation of flucytosine for cryptococcal meningitis, a life-threatening fungal infection and leading cause of death in people with advanced HIV. We are also working with partners to address access barriers and encourage full adoption of current WHO-recommended tools and interventions for cryptococcal meningitis and advanced HIV.
- [2023 R&D portfolio in review: Mycetoma](https://dndi.org/news/2024/2023-rd-portfolio-in-review-mycetoma/) - DNDi and our partners are working to develop safe, affordable treatments to prevent devastating amputation and disability – and to improve access for all people in need. With evidence from our Phase II trial showing the efficacy of treatment with itraconazole and fosravuconazole, the latter having practical advantages, we are now working to help facilitate access to the two treatments and close epidemiological knowledge gaps in key endemic countries.
- [2023 R&D portfolio in review: Chagas](https://dndi.org/news/2024/2023-rd-portfolio-in-review-chagas/) - DNDi and our partners are searching for shorter, safer, more effective treatments to stop a silent killer. In the short term, we are working to develop improved treatment regimens with the existing drug benznidazole, reduce mother-to-child transmission, and help roll out ‘test-and-treat’ strategies to reach people living with Chagas disease in remote areas of Latin America. Our longer-term goal is to discover and develop entirely new drug candidates, with the aim of launching at least one Phase III trial by 2028.
- [2023 R&D portfolio in review: Leishmaniasis](https://dndi.org/news/2024/2023-rd-portfolio-in-review-leishmaniasis/) - DNDi and our partners are working to deliver safer, simpler treatments to save lives, reduce social stigma, and eliminate leishmaniasis as a public health problem. In the short term, we aim to build on our successes in delivering safer, shorter treatments with existing drugs. To bring prompt diagnosis and treatment closer to patients and help facilitate sustainable disease elimination, our longer-term goal is to develop all-new treatments with new chemical entities that are safe, effective, and easier to manage at the primary healthcare level.
- [2023 R&D portfolio in review: Hepatitis C](https://dndi.org/news/2024/2023-rd-portfolio-in-review-hepatitis-c/) - DNDi and our partners are supporting global elimination efforts by accelerating access to affordable treatments. Following development of ravidasvir, the first all-oral treatment for hepatitis C developed through South-South collaboration, we are now exploring ravidasvir’s advantages for specific sub-populations of patients living with HCV. We are also working with national governments, civil society organizations, and other partners to help enable access to affordable direct-acting antiviral treatments and foster the political will needed for wide-scale roll-out of test-and-treat strategies.
- [2023 R&D portfolio in review: Sleeping sickness](https://dndi.org/news/2024/2023-rd-portfolio-in-review-sleeping-sickness/) - DNDi and our partners are working to deliver breakthrough treatments and expedite access to eliminate sleeping sickness – for good. Our current goal is to finalize the development of acoziborole, an all-new, single-dose oral drug that can be given at the point of care, opening the possibility of simplified ‘test-and-treat’ approaches in primary healthcare settings. At the same time, we are continuing work to ensure broad access to fexinidazole for sleeping sickness caused by the parasites T.b. gambiense and T.b. rhodesiense, the more acute, less common form of the disease.
- [2023 R&D portfolio in review: Pandemic preparedness](https://dndi.org/news/2024/2023-rd-portfolio-in-review-pandemic-preparedness/) - DNDi and our partners are working to accelerate research to prepare for future viral pandemics. Utilizing our experience in non-profit drug development and partnerships with medical research institutions worldwide, our drug discovery teams are focused on identifying new broad-spectrum antivirals targeting several families of viruses recognized by WHO as presenting the greatest epidemic and pandemic potential in humans. Employing open science, AI, and cutting-edge research tools, our goal is to advance new drug candidates through Phase I safety trials to have them ready for testing against emerging viruses with pandemic potential.
- [2023 R&D portfolio in review: Dengue](https://dndi.org/news/2024/2023-rd-portfolio-in-review-dengue/) - DNDi and our partners are working to tackle the urgent need for treatments that can prevent progression to severe disease. Collaborating with leading public health institutes in the Dengue Alliance, our goal is to accelerate innovation to deliver an affordable and accessible dengue treatment solution, complete our assessment of the burden of dengue in Africa, and identify biomarkers that can accurately predict progression to severe disease.
- [Pièges bleus et médicament « miracle » : comment la Guinée a réussi à éliminer la maladie du sommeil](https://dndi.org/in-the-media/2025/pieges-bleus-et-medicament-miracle-comment-la-guinee-a-reussi-a-eliminer-la-maladie-du-sommeil/) - ACCESS THE ARTICLE
- [How a country wiped out sleeping sickness – the ‘frightening’ disease that requires a deadly drug to treat](https://dndi.org/in-the-media/2025/how-a-country-wiped-out-sleeping-sickness-the-frightening-disease-that-requires-a-deadly-drug-to-treat/) - ACCESS THE ARTICLE
- [Doctor in the house: Access to hepatitis C treatment](https://dndi.org/in-the-media/2018/bfm-doctor-in-the-house-access-to-hepatitis-c-treatment/) - Jean-Michel Piedagnel, Head of South-East Asia Liaison Office, DNDi, and Chee Yoke Ling, Third World Network Director, join Dr George to discuss the development around access to hepatitis C treatment in Malaysia.
- [Avancées porteuses d'espoir en Indonésie pour éradiquer la dengue et l'hépatite C](https://dndi.org/in-the-media/2021/rts-avancees-porteuses-despoir-indonesie-pour-eradiquer-dengue-hepatite-c/) - Radio interview with Jean-Michel Piedagnel, Director of DNDi South-East Asia More information
- [What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review](https://dndi.org/scientific-articles/2021/what-china-can-learn-from-malaysia-to-achieve-goal-eliminate-hepatitisc-as-public-health-threat-by-2030/) - by Sun J, Cheng H, Hassan MRA, Chan H-K, Piedagnel J-M. The Lancet Regional Health – Western Pacific 2021;15:100261. doi: 10.1016/j.lanwpc.2021.100261 Summary: Although approximately 8 million people are living with hepatitis C virus in China, less than 1.3% of patients with chronic infection have received treatment, while Malaysia has made direct acting antiviral (DAA) treatment highly accessible. This paper, jointly authored by academics and healthcare professionals from the
- [Ravidasvir: equitable access through an alternative drug development pathway](https://dndi.org/scientific-articles/2021/ravidasvir-equitable-access-through-an-alternative-drug-development-pathway/) - by Cheong MWL, Piedagnel J-M, Khor SK. The Lancet Global Health 2021; 9(11)e1496-1497. doi: 10.1016/S2214-109X(21)00357-0 Summary: Direct-acting antiviral (DAA) treatments for hepatitis C are not available to many patients around the world because of high prices, intellectual property protections, and inaccessible testing and treatment services. DNDi has developed a safe and effective DAA, ravidasvir, through
- [Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study](https://dndi.org/scientific-articles/2021/assessing-impact-simplified-hcv-care-on-linkage-to-care-amongst-high-risk-patients-primary-healthcare-clinics-malaysia/) - by Markby J, Shilton S, Sem X, Chan HK, Md Said R, Siva S, Zainuddin Z, Bakar NA, Omar H, Ruiz RJ, Gaeddert M, Tyshkovskiy A, Adee M, Chhatwal J, Kumar S, Piedagnel J-M, Zain RM, Menétrey C, Yuswan F, Nasir NH, Andrieux-Meyer I, Ismail F, Zakaria R, Hasim R, Murad S, Easterbrook P, Hassan
- [Facing the escalating burden of dengue: Challenges and perspectives](https://dndi.org/scientific-articles/2023/facing-the-escalating-burden-of-dengue-challenges-and-perspectives/) - by Malavige GN, Sjö P, Singh K, Piedagnel JM, Mowbray C, Estani S, Chee Loon Lim S, Siquierra AM, Ogg GS, Fraisse L, Ribeiro I. PLOS Global Public Health 2023, 3(12): e0002598. doi: 10.1371/journal.pgph.0002598 Summary: Dengue is the most rapidly emerging mosquito-borne infection, overwhelming heath care facilities in endemic countries. Previously a predominantly childhood illness, dengue now affects mostly adults
- [En Guinée, la lutte victorieuse contre la maladie du sommeil](https://dndi.org/in-the-media/2025/en-guinee-la-lutte-victorieuse-contre-la-maladie-du-sommeil/) - ACCESS THE ARTICLE
- [AU signs pact with DNDi to combat neglected diseases in Africa](https://dndi.org/in-the-media/2025/au-signs-pact-with-dndi-to-combat-neglected-diseases-in-africa/) - ACCESS THE ARTICLE
- [RDC : 340 cas de la trypanosomiase humaine africaine enregistrés en 2024](https://dndi.org/in-the-media/2025/rdc-340-cas-de-la-trypanosomiase-humaine-africaine-enregistres-en-2024/) - ACCESS THE ARTICLE
- [«Das ist historisch»: Medikament könnte erstmals Infektionskrankheit ausrotten](https://dndi.org/in-the-media/2025/das-ist-historisch-medikament-konnte-erstmals-infektionskrankheit-ausrotten/) - ACCESS THE ARTICLE
- [Strategic Plan 2021-2028](https://dndi.org/publications/2021/strategic-plan-2021-2028/) - 25 treatments in 25 years
- [DNDi announces organizational strategy update and strengthened executive team](https://dndi.org/press-releases/2025/dndi-announces-organizational-strategy-update-and-strengthened-executive-team/) - In order to preserve and enhance its proximity to the evolving needs of neglected patients and the communities it serves, DNDi has refreshed its organizational strategy and the composition of its executive team.
- [DNDi statement on recent US government executive actions and the escalating retreat from global health and medical research](https://dndi.org/statements/2025/dndi-statement-on-recent-us-government-executive-actions-and-the-escalating-retreat-from-global-health-and-medical-research/) - As an international non-profit organization that discovers, develops, and delivers treatments for neglected communities, the Drugs for Neglected Diseases initiative (DNDi) expresses its alarm at drastic and devastating cuts to global health programmes and assaults on international health cooperation. The fundamental values that underpin all of DNDi’s actions – of solidarity, collaboration and partnership, scientific
- [‘The tsetse fly is attracted to the color blue’: How Guinea has managed to eliminate sleeping sickness as a public health problem](https://dndi.org/in-the-media/2025/the-tsetse-fly-is-attracted-to-the-color-blue-how-guinea-has-managed-to-eliminate-sleeping-sickness-as-a-public-health-problem/) - ACCESS THE ARTICLE
- [Pourquoi les derniers cas de maladie du sommeil seront les plus difficiles à éliminer ?](https://dndi.org/in-the-media/2025/pourquoi-les-derniers-cas-de-maladie-du-sommeil-seront-les-plus-difficiles-a-eliminer/) - ACCESS THE ARTICLE
- [The African Union Commission Strengthens Collaboration with the Drugs for Neglected Diseases initiative](https://dndi.org/press-releases/2025/african-union-commission-strengthens-collaboration-with-dndi/) - In a landmark partnership to bolster Africa's fight against neglected tropical diseases, the African Union Commission's Department of Health, Humanitarian Affairs, and Social Development signed a Memorandum of Understanding with DNDi to advance policy advocacy, research and development, and access to treatments for NTDs across the continent.
- [DNDi interventions at the 156<sup>th</sup> Session of the WHO Executive Board](https://dndi.org/statements/2025/dndi-interventions-156-who-executive-board/) - DNDi's interventions at the 156th WHO Executive Board on universal health coverage; communicable diseases; women's, children's, and adolescents' health; and climate change and health.
- [Guinea eliminates sleeping sickness](https://dndi.org/in-the-media/2025/guinea-eliminates-sleeping-sickness/) - ACCESS THE ARTICLE
- [Treating a feverish planet: The Dengue Alliance](https://dndi.org/videos/2024/treating-a-feverish-planet-the-dengue-alliance/) - This short film takes us to Brazil, one of the flashpoints of Latin America’s 2024 epidemic, as well as to Sri Lanka and Thailand, to show the devastating impact dengue outbreaks are having across the world.
- [Hyundai Bio (HDB) and DNDi sign MOU for joint development of Xafty-based dengue treatment](https://dndi.org/press-releases/2025/hyundai-bio-and-dndi-sign-mou-for-potential-dengue-treatment/) - Hyundai Bioscience and DNDi jointly announced the signing of a Memorandum of Understanding (MOU) to develop Xafty into a potential treatment for dengue.
- ["C'est une très bonne nouvelle" : la Guinée élimine à son tour "la maladie du sommeil" et nourrit l'espoir d'une éradication mondiale](https://dndi.org/in-the-media/2025/cest-une-tres-bonne-nouvelle-la-guinee-elimine-a-son-tour-la-maladie-du-sommeil-et-nourrit-lespoir-dune-eradication-mondiale/) - ACCESS THE ARTICLE
- [スナノミ症新薬普及へ課題　ケニア、貧困層に流行　「顧みられない病気」](https://dndi.org/in-the-media/2025/sanyonews-challenges-in-spreading-new-drug-for-sand-flea-disease/) - ACCESS THE ARTICLE
- [Belle victoire médicale pour la Guinée et pour les autorités sanitaires mondiales (à partir de 15'30)](https://dndi.org/in-the-media/2025/belle-victoire-medicale-pour-la-guinee-et-pour-les-autorites-sanitaires-mondiales-a-partir-de-1530/) - ACCESS THE recording
- [Maladies tropicales négligées: «Les gouvernements et les donateurs doivent collaborer avec les scientifiques»](https://dndi.org/in-the-media/2025/maladies-tropicales-negligees-les-gouvernements-et-les-donateurs-doivent-collaborer-avec-les-scientifiques/) - ACCESS THE recording
- [IRD, DNDi and Institut Pasteur welcome the WHO validation for the elimination of sleeping sickness in Guinea](https://dndi.org/press-releases/2025/ird-dndi-institut-pasteur-welcome-who-validation-elimination-sleeping-sickness-guinea/) - Guinea celebrates today the elimination of sleeping sickness (also known as human African trypanosomiasis or HAT) as a public health problem.
- [L’OMS valide l’élimination de la maladie du sommeil en Guinée : une nouvelle saluée par l'IRD, DNDi, et l’Institut Pasteur](https://dndi.org/press-releases-translations/2025/oms-valide-elimination-maladie-sommeil-en-guinee-nouvelle-saluee-par-ird-dndi-institut-pasteur/) - La Guinée célèbre aujourd’hui l’élimination de la maladie du sommeil (aussi appelée trypanosomiase humaine africaine – THA) comme problème de santé publique.
- [Enfermedad de Chagas: más del 70% de los afectados desconocen su condición](https://dndi.org/in-the-media/2025/enfermedad-de-chagas-mas-del-70-de-los-afectados-desconocen-su-condicion/) - ACCESS THE ARTICLE
- [Kala-azar burden in Baringo county](https://dndi.org/in-the-media/2025/kala-azar-burden-in-baringo-county/) - ACCESS THE ARTICLE
- [Climate change is fuelling leishmaniasis in northern Kenya](https://dndi.org/in-the-media/2025/climate-change-is-fuelling-leishmaniasis-in-northern-kenya/) - ACCESS THE ARTICLE
- [Cooperación para erradicar enfermedades olvidadas](https://dndi.org/in-the-media/2025/cooperacion-para-erradicar-enfermedades-olvidadas/) - ACCESS THE recording
- [Guinea has wiped out sleeping sickness – will the rest of Africa follow?](https://dndi.org/in-the-media/2025/guinea-has-wiped-out-sleeping-sickness-will-the-rest-of-africa-follow/) - ACCESS THE ARTICLE
- [Les maladies tropicales négligées](https://dndi.org/in-the-media/2025/les-maladies-tropicales-negligees-2/) - ACCESS THE recording
- [Ne vous endormez pas sur la maladie du sommeil !](https://dndi.org/in-the-media/2025/ne-vous-endormez-pas-sur-la-maladie-du-sommeil/) - ACCESS THE ARTICLE
- [“La mosca tsetsé se siente atraída por el azul”: así ha conseguido Guinea eliminar la enfermedad del sueño como problema de salud pública](https://dndi.org/in-the-media/2025/la-mosca-tsetse-se-siente-atraida-por-el-azul-asi-ha-conseguido-guinea-eliminar-la-enfermedad-del-sueno-como-problema-de-salud-publica/) - ACCESS THE ARTICLE
- [The new reality of R&D funding for neglected tropical diseases](https://dndi.org/in-the-media/2025/the-new-reality-of-rd-funding-for-neglected-tropical-diseases/) - ACCESS THE ARTICLE
- [Inside Guinea's quest to eliminate sleeping sickness](https://dndi.org/stories/2025/guineastory/) - Bölët Mouna - Eliminating sleeping sickness in Guinea Bölët Mouna means ‘sleeping sickness no more’ in Guinea’s national language Susu and tells the story of how research, innovation, and science are ending the the nightmare of sleeping sickness in Guinea. Enter keywords
- [DNDi welcomes GHIT support for new collaboration with Eisai for dengue and Zika virus disease](https://dndi.org/press-releases/2025/ghit-support-new-collaboration-with-eisai-for-dengue-and-zika/) - During the one-year project, Eisai and DNDi will search for compounds that exhibit antiviral activity against dengue virus and Zika virus.
- [DNDi's briefing note for 156<sup>th</sup> Session of the WHO Executive Board](https://dndi.org/statements/2025/dndi-briefing-note-156-who-executive-board/) - This briefing sets out DNDi's comments for considerations by WHO Member States on agenda items covering strategy for women’s, children’s and adolescents’ health, universal health coverage, preparedness and response for health emergencies, and WHO global strategy on health, environment and climate change.
- [Drugmakers tap AI to develop new treatments](https://dndi.org/in-the-media/2025/drugmakers-tap-ai-to-develop-new-treatments/) - ACCESS THE ARTICLE
- [DND<em>i</em> welcomes GHIT support for a new collaboration with Mitsubishi Tanabe Pharma Corporation](https://dndi.org/news/2019/dndi-welcomes-ghit-support-new-collaboration-mitsubishi-tanabe-pharma-corporation/) - Mitsubishi Tanabe Pharma Corporation and DNDi are pleased to announce the financial support of the Global Health Innovative Technology (GHIT) Fund for their new discovery collaboration, with a grant of EUR 130’000/JPY 15 million.
- [DNDi <i>2023 Projects of the Year</i> recognize contributions of DNDi teams and partners working to deliver medical innovations for people affected by Chagas disease and mycetoma](https://dndi.org/news/2023/2023-projects-the-year-recognize-contributions-teams-partners-working-medical-innovations-chagas-disease-mycetoma/) - DNDi is pleased to announce its 2023 Projects of the Year: early discovery for Chagas disease and fosravuconazole for mycetoma.
- [Why the last cases of sleeping sickness will be the hardest to eliminate](https://dndi.org/in-the-media/2025/why-the-last-cases-of-sleeping-sickness-will-be-the-hardest-to-eliminate/) - ACCESS THE ARTICLE
- [Transmission dynamics of visceral leishmaniasis in the Indian subcontinent – A systematic literature review](https://dndi.org/scientific-articles/2016/vl-transmission-dynamics/) - by Hirve S, Boelaert M, Matlashewski G, Mondal D, Arana B, Kroeger A, Olliaro P. PLOS Neglected Tropical Diseases, August 2016
- [Investments in research and surveillance are needed to go beyond elimination and stop transmission of <em>Leishmania</em> in the Indian subcontinent](https://dndi.org/scientific-articles/2017/leish-india-stop-transmission/) - by Olliaro P, Shamsuzzaman TAKM, Marasini B, Dhariwal AC, Be-Nazir A, Mondal D, Banjara MR, Das P, Sundar S, Rijal S, Arana B, Alvar J, Argaw D, Peeling RW, Kroeger A, Matlashewski G. PLOS Neglected Tropical Diseases, January 2017
- [Drug discovery for leishmaniasis](https://dndi.org/scientific-articles/2017/drug-discovery-for-leishmaniasis/) - This book aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania. Royal Society of Chemistry, November 2017
- [Towards elimination of visceral leishmaniasis in the Indian subcontinent - Translating research to practice to public health](https://dndi.org/scientific-articles/2017/towards-elimination-of-vl-in-indian-subcontinent/) - by Hirve S, Kroeger A, Matlashewski G, Mondal D, Banjara MR, Das, P, Be-Nazir A, Arana B, Olliaro P. PLOS Neglected Tropical Diseases, October 2017
- [Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation](https://dndi.org/scientific-articles/2018/plosntds-clinical-trial-methodologies-cutaneous-leishmaniasis/) - by Olliaro P, Boni M, Carvalho EM, Chebli H, Cisse M, Diro E, Fernandes Cota G, Erber AC, Gadisa E, Handjani F, Khamesipour A, Llanos-Cuentas A, López Carvajal L, Grout L, Lmimouni BE, Mokni M, Nahzat MS, Ben Salah A, Ozbel Y, Pascale JM, Rizzo Molina N, Rode J, Romero G, Ruiz-Postigo JA, Gore Saravia N, Soto J, Uzun S, Mashayekhi V, Vélez ID, Vogt F, Zerpa O, Arana B. PLoS Neglected Tropical Diseases, January 2018
- [Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia region kala-azar elimination programme](https://dndi.org/scientific-articles/2017/post-kala-azar-dermal-leishmaniasis-indian-subcontinent/) - by Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J PLOS Neglected Tropical Diseases, November 2017
- [A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia](https://dndi.org/scientific-articles/2018/plosntds-anfoleish-phaseii-colombia/) - by López L, Vélez I, Asela C, Cruz C, Alves F, Robledo S, Arana B. PLOS Neglected Tropical Diseases, July 2018
- [An international qualitative study exploring patients’ experiences of cutaneous leishmaniasis: Study set-up and protocol](https://dndi.org/scientific-articles/2018/bmj-international-qualitative-study-patients-experiences-cutaneous-leishmaniasis/) - by Erber AC, Arana B, Bennis I, Salah AB, Boukthir A, del Mar Castro Noriega M, Cissé M, Cota GF, Handjani F, Kebede MG, Lang T, López Carvajal L, Marsh K, Martinez Medina D, Plugge E, Olliaro P. BMJ Open, June 2018
- [Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives](https://dndi.org/scientific-articles/2018/clinicalmicrobiologyreviews-development-visceralleishmaniasis-treatments/) - by Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, Muthoni Ouattara G, Pécoul B, Rijal S, Rode J, Solomos A, Strub-Wourgaft N, Wasunna M, Wells S, Zijlstra EE, Arana B, and Alvar J. Clinical Microbiology Reviews, August 2018
- [Target Product Profile for a point-of-care diagnostic test for dermal leishmaniases](https://dndi.org/scientific-articles/2019/target-product-profile-dermal-leishmaniases/) - by Cruza I, Albertini A, Barbeitas M, Arana B, Picado A, Ruiz-Postigo JA, Ndung'u JM. Parasite Epidemiology and Control, January 2019
- [Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis](https://dndi.org/scientific-articles/2019/route-map-discovery-pre-clinical-development-new-drugs-treatments-cutaneous-leishmaniasis/) - by Caridha D, Vesely B, van Bocxlaer K, Arana B, Mowbray CE, Rafati S, Reguera R, Kreishman-Deitrick M, Buffet P, Croft SL. International Journal for Parasitology: Drugs and Drug Resistance, June 2019
- [Patients’ preferences of cutaneous leishmaniasis treatment outcomes: Findings from an international qualitative study](https://dndi.org/scientific-articles/2020/patients-preferences-of-cutaneous-leishmaniasis-treatment-outcomes-findings-from-an-international-qualitative-study/) - by Erber AC, Arana B, Salah AB, Bennis I, Boukthir A, del Mar Castro Noriega M, Cissé M, Fernandes Cota G, Handjani F, López-Carvajal L, Marsh K, Martínez Medina D, Plugge E, Lang T, Olliaro P. PLOS Neglected Tropical Diseases 2020, 14(2): e0007996. doi: 10.1371/journal.pntd.0007996 Summary: Cutaneous leishmaniasis often affects exposed skin areas and may leave lifelong
- [CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis](https://dndi.org/scientific-articles/2020/plosntds-cpgodnd35-improves-response-abbreviated-low-dose-pentavalent-antimonial-treatment-cutaneous-leishmaniasis/) - by Thacker SG, McWilliams IL, Bonnet B, Halie L, Beaucage S, Rachuri S, Dey R, Duncan R, Modabber F, Robinson S, Bilbe G, Arana B, Verthelyi D. PLOS Neglected Tropical Diseases, February 2020
- [A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World](https://dndi.org/scientific-articles/2022/phase-ii-multicenter-randomized-study-evaluate-safety-efficacy-combining-thermotherapy-short-course-miltefosine-cutaneous-leishmaniasis/) - by López L, Alvarez F, Ramos AP, Llanos-Cuentas A, Echevarria J, Vélez I, Boni M, Rode J, Quintero J, Jiménez A, Tabares Y, Méndez C, Arana B. PLOS Neglected Tropical Diseases 2022; 16(3):e0010238. doi: 10.1371/journal.pntd.0010238 Summary: For more than 70 years, pentavalent antimonials have been the first line treatment for cutaneous leishmaniasis, despite their toxicity, varying efficacy and need for
- [Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study](https://dndi.org/scientific-articles/2023/cutaneous-leishmaniasis-treatment-therapeutic-outcomes-special-populations/) - by Castro M, Rode J, Machado PRL, Llanos-Cuentas A, Hueb M, Cota G, Rojas IV, Orobio Y, Sarmiento OO, Rojas E, Quintero J, Pimentel MIF, Soto J, Suprien C, Alvarez F, Ramos AP, Arantes RBdS, da Silva RE, Arenas CM, Vélez ID, Lyra MR, Saravia NG, Arana B, Alexander N. PLOS Neglected Tropical Diseases 2023,
- [A promising fight against a silent killer](https://dndi.org/in-the-media/2025/a-promising-fight-against-a-silent-killer/) - read the article
- [We asked global thinkers how to improve life on earth in 2025. Here are their wishes](https://dndi.org/in-the-media/2025/we-asked-global-thinkers-how-to-improve-life-on-earth-in-2025-here-are-their-wishes/) - ACCESS THE ARTICLE
- [Message on the passing of Dr Yves Champey from DNDi Executive Director Dr Luis Pizarro](https://dndi.org/news/2024/message-on-the-passing-of-dr-yves-champey-from-dndi-executive-director-dr-luis-pizarro/) - We are deeply saddened by news of the passing of Dr Yves Champey. Our condolences to his family, colleagues, and friends.
- [Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue](https://dndi.org/scientific-articles/2021/development-validation-hplc-ms-ms-method-for-quantification-anti-leishmanial-drug-miltefosine-human-skin-tissue/) - by Roseboom IC, Thijssen B, Rosing H, Alves F, Mondal D, Teunissen MBM, Beijnen JH, Dorlo TPC. Journal of Pharmaceutical and Biomedical Analysis 2021, 207: 114402. doi: 10.1016/j.jpba.2021.114402 Summary: Miltefosine is under investigation for the treatment of cutaneous and post-kala-azar dermal leishmaniasis, where the dermis of the skin is infected with Leishmania parasites. Accurate target-site quantification of miltefosine
- [“顧みられない熱帯病” 治療薬開発でAIに期待 研究開発機関](https://dndi.org/in-the-media/2024/nhk-ai-expected-to-help-develop-treatments-for-neglected-tropical-diseases/) - ACCESS THE ARTICLE
- [Drug discovery explained: What are host-directed therapies?](https://dndi.org/stories/2024/drug-discovery-explained-what-are-host-directed-therapies/) - How are life-saving drugs discovered? Join DNDi researcher and series host Fanny Escudié to learn how scientists are using the most advanced technologies to improve the lives of millions of neglected patients around the world.
- [エーザイ、認知症治療薬の次は「まん延する顧みられない熱帯病」](https://dndi.org/in-the-media/2024/エーザイ認知症治療薬の次はまん延する顧み/) - ACCESS THE ARTICLE
- [«Pour convaincre le capital privé d’investir en faveur de la nature, il faut lui offrir des options de sortie»](https://dndi.org/in-the-media/2024/pour-convaincre-le-capital-prive-dinvestir-en-faveur-de-la-nature-il-faut-lui-offrir-des-options-de-sortie/) - read the article
- [Interview de Laurent Fraisse sur les besoins pédiatriques liés aux maladies tropicales négligées](https://dndi.org/in-the-media/2024/interview-de-laurent-fraisse-sur-la-carence-de-recherche-et-developpement-dans-le-soin-des-maladies-tropicales-negligees/) - access the radio recording
- [Comment développer des médicaments contre ces maladies négligées et intéresser l’industrie pharmaceutique à ces questions ?](https://dndi.org/in-the-media/2013/comment-developper-des-medicaments-contre-ces-maladies-negligees-et-interesser-lindustrie-pharmaceutique-a-ces-questions/)
- [Interview radio de Pr Marcel Tanner](https://dndi.org/in-the-media/2013/interview-radio-de-pr-marcel-tanner/) - Pr Marcel Tanner, directeur de l’Institut tropical et de santé publique suisse et président du Conseil d’administration de DNDi, parle des maladies négligées. De 19’40’’
- [L'Alliance contre les maladies tropicales négligées](https://dndi.org/in-the-media/2014/prioritesante-alliance-contre-ntds/) - "The alliance against neglected tropical diseases" Interview de Bill Gates Click here to read the article
- [Résultats d’une étude antipaludique pour les enfants en Afrique](https://dndi.org/in-the-media/2014/rfi-gracieladiap-asmq/) - Interview de Graciela Diap, coordinatrice médicale de DNDi pour le paludisme, au sujet des résultats d’une étude antipaludique pour les enfants en Afrique. © Priorité Santé, RFI
- [Le Prix Nobel de Médecine](https://dndi.org/in-the-media/2015/rfi-nobelprize/) - Interview de Bernard Pécoul, directeur de DNDi © Priorité Santé, RFI
- [Maladies tropicales négligées](https://dndi.org/in-the-media/2016/rfi-nathalie-s-w-dndi/) - Dr Nathalie Strub Wourgaft, directrice médicale de DNDi, présente les enjeux actuels pour le traitement et le diagnostic de maladies tropicales négligées, telles que la maladie du sommeil, la leishmaniose viscérale et la maladie de Chagas. Listen to the full radio programme
- [Les maladies tropicales négligées](https://dndi.org/in-the-media/2019/rfi-les-maladies-tropicales-negligees/) - Programme on neglected tropical diseases including an interview with Dr Bernard Pécoul, Executive Director at DNDi (from 14:48).
- [The Kissing Bug Doctors of Florida](https://dndi.org/videos/2024/the-kissing-bug-doctors-of-florida/) - Over 300,000 people live with Chagas disease in the US, but very few people have been tested and treated. In Gainesville, Florida, a group of scientists and doctors led by Dr Norm Beatty at the The Emerging Pathogens Institute (EPI), University of Florida are trying to end the neglect of this parasitic killer.
- [Afrique de l'Est: la bataille contre la maladie de leishmaniose [2/2]](https://dndi.org/in-the-media/2024/afrique-de-lest-la-bataille-contre-la-maladie-de-leishmaniose-2-2/) - access the article and radio recording
- [Elimination by 2027? India’s final push against lymphatic filariasis](https://dndi.org/in-the-media/2024/elimination-by-2027-indias-final-push-against-lymphatic-filariasis/) - read the article
- [Out of the Shadows: The Story of DNDi](https://dndi.org/videos/2023/out-of-the-shadows-the-story-of-dndi/) - In a world affected by climate change, conflict, and economic instability, it is always the most vulnerable people that suffer – often from neglected diseases for which there is no cure. Out of the Shadows tells the story of DNDi researchers working to develop treatments for patients who have lived in the shadows for too long.
- [How women in UP confront a neglected disease–and stigma](https://dndi.org/in-the-media/2024/how-women-in-up-confront-a-neglected-disease-and-stigma/) - read the article
- [La leishmaniose, une maladie oubliée [1/2]](https://dndi.org/in-the-media/2024/la-leishmaniose-une-maladie-oubliee-1-2/) - access the article and radio recording
- [Naivasha Hospital leads the way in tackling advanced HIV complications on World AIDS Day](https://dndi.org/in-the-media/2024/naivasha-hospital-leads-the-way-in-tackling-advanced-hiv-complications-on-world-aids-day/) - watch the recording
- [Kenya: Fighting leishmaniasis a neglected tropical disease](https://dndi.org/in-the-media/2024/kenya-fighting-leishmaniasis-a-neglected-tropical-disease/) - watch the tv programme
- [New cures for Africa’s most gruesome diseases](https://dndi.org/in-the-media/2024/new-cures-for-africas-most-gruesome-diseases/) - read the article
- [Prof. Sam Kariuki on antimicrobial resistance](https://dndi.org/in-the-media/2024/prof-sam-kariuki-on-antimicrobial-resistance/) - ACCESS THE episode
- [Les enfants, grands oubliés de la recherche contre les maladies tropicales négligées](https://dndi.org/in-the-media/2024/les-enfants-grands-oublies-de-la-recherche-contre-les-maladies-tropicales-negligees/) - ACCESS THE ARTICLE
- [Brazil-led G20 to target hunger, poverty, and inequities](https://dndi.org/in-the-media/2024/brazil-led-g20-to-target-hunger-poverty-and-inequities/) - ACCESS THE ARTICLE
- [What the G20 Coalition for Local and Regional Production, Innovation, and Equitable Access should do next](https://dndi.org/viewpoints/2024/what-the-g20-coalition-for-local-and-regional-production-innovation-and-equitable-access-should-do-next/) - The G20 Coalition for Local and Regional Production, Innovation, and Equitable Access marks a promising step towards addressing some of the world’s most pressing health challenges for neglected diseases. By Michelle Childs, DNDi Policy Advocacy Director At last week’s G20 meeting in Rio de Janeiro, G20 Health Ministers took a major step towards addressing the problem that is at the heart of DNDi’s mission: the lack of diagnostics, treatments, and vaccines to diagnose, treat, and prevent diseases that affect the world’s most neglected communities.
- [How climate change made 2024 the deadliest year of dengue](https://dndi.org/in-the-media/2024/how-climate-change-made-2024-the-deadliest-year-of-dengue/) - ACCESS THE ARTICLE
- [The great medicines scandal](https://dndi.org/in-the-media/2006/the-great-medicines-scandal/) - Click here to read the full article
- [DNDi welcomes new G20 coalition focused on innovation, local and regional production, and equitable access to health tools](https://dndi.org/press-releases/2024/dndi-welcomes-g20-coalition-innovation-local-regional-production-equitable-access-health-tools/) - The Coalition could lead to greater innovation of life-saving treatments, diagnostics, and vaccines for current and future health threats.
- [6ème Conférence Scientifique de Conakry](https://dndi.org/in-the-media/2024/6eme-conference-scientifique-de-conakry/) - Watch the recording
- [A new model for R&D](https://dndi.org/in-the-media/2024/a-new-model-for-rd/) - ACCESS THE ARTICLE
- [Integrated pest management strategies targeting the Florida kissing bug, <i>Triatoma sanguisuga</i>: Preventing this vector of Chagas disease from invading your home](https://dndi.org/scientific-articles/2023/integrated-pest-management-strategies-targeting-florida-kissing-bug-chagas-preventing-invading-your-home/) - by Beatty NL, Bhosale CR, Torhorst CW, Burkett-Cadena ND, Oi FM, Forsyth CJ, Wisely SM. Current Research in Parasitology & Vector-Borne Diseases 2023, 4:100144. doi: 10.1016/j.crpvbd.2023.100144 Summary: Triatomines, commonly called “kissing bugs”, are vectors of the protozoan parasite Trypanosoma cruzi, the causative agent of Chagas disease. Eleven species of kissing bugs occur throughout the southern half of
- [Structure–property optimization of a series of imidazopyridines for visceral leishmaniasis](https://dndi.org/scientific-articles/2023/structureproperty-optimization-series-imidazopyridines-visceral-leishmaniasis/) - by Dichiara M, Simpson QJ, Quotadamo A, Jalani HB, Huang AX, Millard CC, Klug DM, Tse EG, Todd MH, Silva GD, da Silva Emery F, Carlson JE, Zheng S-L, VleminckxM, Matheeussen A, Caljon G, Pollastri MP, Sjö P, Perry B, Ferrins L. ACS Infectious Diseases 2023, 9(8):1470–1487. doi: 10.1021/acsinfecdis.3c00040 Summary: Existing treatments for visceral leishmaniasis have
- [Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis](https://dndi.org/scientific-articles/2023/evaluating-pediatric-tuberculosis-dosing-guidelines-model-based-individual-data-pooled-analysis/) - by Galileya LT, Wasmann RE, Chabala C, Rabie H, Lee J, Njahira Mukui I, Hesseling A, Zar H, Aarnoutse R, Turkova A, Gibb D, Cotton MF, McIlleron H, Denti P. PLOS Medicine 2023; 20(11): e1004303. doi: 10.1371/journal.pmed.1004303 Summary: Current World Health Organization pediatric tuberculosis dosing guidelines lead to suboptimal drug exposures. The authors of this manuscript pooled data from large pharmacokinetic
- [Therapeutic efficacy and safety of artesunate + amodiaquine and artemether + lumefantrine in treating uncomplicated <i>Plasmodium falciparum</i> malaria in children on the rainy south-east coast of Madagascar](https://dndi.org/scientific-articles/2023/therapeutic-efficacy-safety-artesunate-amodiaquine-artemether-lumefantrine-uncomplicated-plasmodium-falciparum-malaria-children-madagascar/) - by Irinantenaina J, Carn G, Liantsoa Randriamiarinjatovo DNA , Harimanana AN , Razanatsiorimalala S, Ralemary N, Randriarison M, Razafinjato C, Hotahiene R, Randrianarivelojosia M. Parasite 2023, 30, 32. doi: 10.1051/parasite/2023034 Summary: The authors of this manuscript conducted a randomized controlled trial to assess the efficacy and safety of artesunate + amodiaquine (ASAQ) and artemether + lumefantrine
- [Climate change, migration, and health: perspectives from Latin America and the Caribbean](https://dndi.org/scientific-articles/2024/climate-change-migration-and-health-perspectives-from-latin-america-caribbean/) - by Batista C, Knipper M, Sedas AC, Farante SV, Wainstock D, Borjas-Cavero DB, Rojas Araya K, Arteaga España JC, Yglesias-González M. The Lancet Regional Health – Americas 2024, 100926. doi: 10.1016/j.lana.2024.100926 Summary: The authors of this ‘personal view’ delve into the complex relationship between climate change, migration patterns, and health outcomes in Latin America and the
- [¿Dónde están los fondos para las enfermedades que atacan a mil millones de pobres?](https://dndi.org/in-the-media/2024/donde-estan-los-fondos-para-las-enfermedades-que-atacan-a-mil-millones-de-pobres/) - ACCESS THE ARTICLE
- [DNDi media fellowship for Eastern African health journalists](https://dndi.org/news/2024/dndi-media-fellowship-for-eastern-african-health-journalists/) - This fellowship is designed to empower Eastern African health journalists to tell compelling and impactful stories about neglected tropical diseases and the often-overlooked patients that they affect.
- [Black fever, brought to you by climate change](https://dndi.org/in-the-media/2024/black-fever-brought-to-you-by-climate-change/) - ACCESS THE ARTICLE
- [Registering new drugs: The African context](https://dndi.org/publications/2010/registering-new-drugs-the-african-context/) - Download the report More information about the report
- [Registering New Drugs: The African Context](https://dndi.org/news/2010/registering-new-drugs-african-context/) - A new report sponsored by DNDi and commissioned to the Health Policy Division of the George Institute for International Health analyzes the challenges of registering new drugs for neglected diseases in the African context.
- [Nobel prize for chemistry awarded to Demis Hassabis and John Jumper for AlphaFold, an AI model used by DNDi for neglected diseases](https://dndi.org/news/2024/nobel-prize-chemistry-awarded-for-alphafold-an-ai-model-used-dndi-for-neglected-diseases/) - DNDi congratulates Demis Hassabis, John Jumper and David Baker for being awarded the 2024 Nobel Prize in Chemistry for their work on protein structure prediction and computational protein design.
- [New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine](https://dndi.org/in-the-media/2024/new-who-guidelines-for-treating-rhodesiense-human-african-trypanosomiasis-expanded-indications-for-fexinidazole-and-pentamidine/) - ACCESS THE ARTICLE
- [DNDi <i>2024 Projects of the Year</i> recognize contributions of DNDi teams and partners working to deliver medical innovations for people affected by leishmaniasis and sleeping sickness](https://dndi.org/news/2024/dndi-2024-projects-of-the-year-recognizes-medical-innovations-leishmaniasis-sleeping-sickness/) - DNDi is pleased to announce its 2024 Projects of the Year: DNDI-6899 in pre-clinical research and Fexinidazole for T.b. rhodesiense in clinical research.
- [Loiasis: bringing an end to neglect](https://dndi.org/in-the-media/2024/loiasis-bringing-an-end-to-neglect/) - ACCESS THE ARTICLE
- [HAT Platform Newsletter No. 23](https://dndi.org/publications/2024/hat-platform-newsletter-23/) - English Français
- [تقود وزارة الصحة بماليزيا بالتعاون مع Drugs for Neglected Diseases initative المعركة ضد حمى الضنك](https://dndi.org/press-releases-translations/2022/ministry-health-malaysia-and-dndi-combine-forces-lead-battle-against-dengue-ar/) - ماليزيا تنضم لتصبح شريكًا في تحالف دولي جديد بقيادة الدول الموبوءة بحمى الضنك للبحث عن علاج
- [กระทรวงสาธารณสุข มาเลเซีย และ Drugs for Neglected Diseases initiative ผนึกกำลังเพื่อสู้กับโรคไข้เลือดออก](https://dndi.org/press-releases-translations/2022/ministry-health-malaysia-and-dndi-combine-forces-lead-battle-against-dengue-th/) - มาเลเซีย เป็นอีกหนึ่งประเทศที่เข้าร่วมกับพันธมิตรระดับโลก เพื่อค้นคว้าหายารักษาโรคไข้เลือดออก โดยประเทศที่เข้าร่วมล้วนแล้วแต่เป็นกลุ่มประเทศที่โรคดังกล่าวเป็นโรคประจำถิ่น
- [Kerjasama antara Kementerian Kesihatan Malaysia dengan Drugs for Neglected Diseases <i>initiative</i> bagi memimpin usaha memerangi wabak denggi](https://dndi.org/press-releases-translations/2022/kerjasama-antara-kementerian-kesihatan-malaysia-dengan-drugs-for-neglected-diseases-initiative-bagi-memimpin-usaha-memerangi-wabak-denggi/) - Malaysia menjadi rakan kongsi dalam pakatan antarabangsa baharu yang diterajui oleh negara-negara endemik denggi untuk penyelidikan rawatan denggi
- [Nouveau partenariat mondial de recherche pour un traitement contre la dengue – DND<i>i</i>](https://dndi.org/press-releases-translations/2022/nouveau-partenariat-mondial-de-recherche-pour-un-traitement-contre-la-dengue/) - Plusieurs pays affectés par la dengue lancent un partenariat de recherche pour lutter contre cette maladie qui se propage rapidement, notamment en raison du réchauffement climatique.
- [Ministry of Health, Malaysia and Drugs for Neglected Diseases <i>initiative</i> combine forces to lead the battle against dengue](https://dndi.org/press-releases/2022/ministry-health-malaysia-and-dndi-combine-forces-lead-battle-against-dengue/) - Malaysia joins to become a partner in a new international alliance led by dengue-endemic countries to search for dengue treatment.
- [New global research partnership to find treatment for dengue – DND<i>i</i>](https://dndi.org/press-releases/2022/new-global-research-partnership-find-treatment-for-dengue/) - Dengue endemic-countries to take the lead in effort to tackle the rapidly spreading climate-sensitive disease with 390 million infections a year.
- [Siete jóvenes asturianos visibilizan las enfermedades tropicales desatendidas ante la OMS](https://dndi.org/in-the-media/2024/siete-jovenes-asturianos-visibilizan-las-enfermedades-tropicales-desatendidas-ante-la-oms/) - ACCESS THE ARTICLE
- [Claves de “la propagación silenciosa del dengue”: cifras históricas de infecciones y casos en lugares nunca vistos](https://dndi.org/in-the-media/2024/claves-de-la-propagacion-silenciosa-del-dengue-cifras-historicas-de-infecciones-y-casos-en-lugares-nunca-vistos/) - ACCESS THE ARTICLE
- [With AI tools, scientists can crack the code of life](https://dndi.org/in-the-media/2024/with-ai-tools-scientists-can-crack-the-code-of-life/) - read the article
- [O remédio inovador contra malária que começou a ser distribuído para crianças na Amazônia](https://dndi.org/in-the-media/2024/o-remedio-inovador-contra-malaria-que-comecou-a-ser-distribuido-para-criancas-na-amazonia/) - ACCESS THE ARTICLE
- [East African countries launch framework to guide kala-azar disease elimination](https://dndi.org/in-the-media/2024/east-african-countries-launch-framework-to-guide-kala-azar-disease-elimination/) - ACCESS THE ARTICLE
- [Scientists discover new effective treatment for neglected skin disease](https://dndi.org/in-the-media/2024/scientists-discover-new-effective-treatment-for-neglected-skin-disease/) - ACCESS THE ARTICLE
- [WHO comes up with new framework to combat kala-azar in eastern Africa](https://dndi.org/in-the-media/2024/who-comes-up-with-new-framework-to-combat-kala-azar-in-eastern-africa/) - read the article
- [Scientists find alternative cure for Kala-azar skin infection](https://dndi.org/in-the-media/2024/scientists-find-alternative-cure-for-kala-azar-skin-infection/) - ACCESS THE ARTICLE
- [Lo que dejó la Cumbre Mundial de Preparación para Pandemias](https://dndi.org/in-the-media/2024/lo-que-dejo-la-cumbre-mundial-de-preparacion-para-pandemias/) - ACCESS THE ARTICLE
- [What is kala-azar, and why are health experts alarmed by its rising spread?](https://dndi.org/in-the-media/2024/what-is-kala-azar-and-why-are-health-experts-alarmed-by-its-rising-spread/) - ACCESS THE ARTICLE
- [Le point sur la dengue dans le Journal de 12h30](https://dndi.org/in-the-media/2024/le-point-sur-la-dengue-dans-le-journal-de-12h30/) - '10:50 Interview avec la Dr. Belen Pedrique, Senior Medical Manager à DNDi. ACCESS THE interview
- [Dengue fever is — unfortunately — having a banner year. Can it be quelled?](https://dndi.org/in-the-media/2024/dengue-fever-is-unfortunately-having-a-banner-year-can-it-be-quelled/) - ACCESS THE ARTICLE
- [Bolivia: a twenty-year battle against a silent disease, Chagas](https://dndi.org/in-the-media/2024/bolivia-a-twenty-year-battle-against-a-silent-disease-chagas/) - ACCESS THE ARTICLE
- [Partners in drug discovery: how to collaborate with non-governmental organizations](https://dndi.org/in-the-media/2024/partners-in-drug-discovery-how-to-collaborate-with-non-governmental-organizations/) - ACCESS THE ARTICLE
- [Brazil to distribute paediatric antimalarial in Amazon](https://dndi.org/in-the-media/2024/brazil-to-distribute-paediatric-antimalarial-in-amazon/) - ACCESS THE ARTICLE
- [Summer profiles: unlocking treatment for neglected diseases](https://dndi.org/in-the-media/2024/summer-profiles-unlocking-treatment-for-neglected-diseases/) - ACCESS THE ARTICLE
- [InfoLEISH 8<sup>th</sup> edition](https://dndi.org/publications/2024/infoleish-8th-edition/) - InfoLEISH, the redeLEISH newsletter, reports on the latest research on leishmaniasis in Latin America.
- [Chagas Platform Newsletter N°14](https://dndi.org/publications/2024/chagas-platform-newsletter-n14/) - The Chagas Platform newsletter reports on the platform's recent activities and latest research on Chagas disease in Latin America.
- [Chagas: una cumbre de expertos reveló los últimos avances sobre los tratamientos para la enfermedad](https://dndi.org/in-the-media/2024/chagas-una-cumbre-de-expertos-revelo-los-ultimos-avances-sobre-los-tratamientos-para-la-enfermedad/) - ACCESS THE ARTICLE
- [15 years of needs-driven innovation for access](https://dndi.org/publications/2019/15-years-of-needs-driven-innovation-for-access/) - EnglishDeutsch Executive summaryEnglishEspañolFrançaisDeutschKorean中文ไทยاللغة العربية
- [Latest advances in control of sleeping sickness: Towards elimination](https://dndi.org/scientific-articles/2020/latest-advances-in-control-of-sleeping-sickness-towards-elimination/) - by Valverde Mordt O. Bulletin of the Netherlands Society for Tropical Medicine and International Health 2020:6-8. Summary: Sleeping sickness is on the verge of elimination due to collective case detection and treatment efforts by many stakeholders, coordinated by the WHO and led by national control programmes in the field. Because of rigorous research carried out
- [WHO recommends first all-oral treatment for acute sleeping sickness found in Eastern and Southern Africa](https://dndi.org/press-releases/2024/who-recommends-first-all-oral-treatment-for-acute-sleeping-sickness-found-in-eastern-and-southern-africa/) - The use of Fexinidazole Winthrop – a treatment developed by Sanofi and DNDi – against the rhodesiense form of the disease has been recommended following a clinical trial conducted in Malawi and Uganda.
- [Message on the passing of Dr Alwyn Mwinga from DNDi Executive Director Dr Luis Pizarro](https://dndi.org/news/2024/message-on-the-passing-of-dr-alwyn-mwinga/) - Dr Mwinga first joined DNDi’s Board in 2015, and over the last nine years served as the patient representative. We send our condolences to her friends, family, and everyone who knew and worked with her.
- [DND<i>i</i> media workshops – bringing together reporters and researchers to cover neglected disease research](https://dndi.org/news/2022/media-workshops-bringing-together-reporters-and-researchers-to-cover-neglected-disease-research/) - DNDi has created a media workshop programme for health and science reporters from Africa, Asia, and Latin America with the aim to help reporters better understand neglected diseases and the complex science that is in play to discover, develop, and deliver treatments.
- [DNDi response to Request for Information on draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning](https://dndi.org/statements/2024/dndi-response-rfi-draft-nih-policy-equity-through-access-planning/) - DNDi is pleased to have the opportunity to respond to the US National Institutes of Health (NIH) Request for Information on the draft NIH Intramural Research Program Policy on Promoting Equity Through Access Planning.
- [DND<i>i</i> Key Performance Indicators 2011](https://dndi.org/publications/2012/dndi-key-performance-indicators-2011/) - English
- [DND<i>i</i> Annual Report 2018](https://dndi.org/publications/2019/dndi-annual-report-2018/) - Download the PDF Browse online R&D Programmes in Focus DNDi Financial and Performance Report 2018
- [DND<i>i</i> Financial and Performance Report 2018](https://dndi.org/publications/2019/dndi-financial-and-performance-report-2018/) - English
- [DND<i>i</i> Financial and Performance Report 2017](https://dndi.org/publications/2018/dndi-financial-and-performance-report-2017/) - English
- [Early diagnosis and treatment can save millions of lives](https://dndi.org/stories/2022/world-chagas-day-early-diagnosis-and-treatment-can-save-millions-of-lives/) - Many people with Chagas disease spend their whole lives unaware they have it. This World Chagas Day, DNDi is joining partners in a global effort to raise awareness about the disease.
- [Paediatric malaria treatment developed in Brazil by not-for-profit organizations distributed to Indigenous children in the Amazon region](https://dndi.org/press-releases/2024/paediatric-malaria-treatment-developed-in-brazil-distributed-children-amazon/) - A paediatric malaria treatment, developed in partnership with Brazil’s Instituto de Tecnologia em Fármacos (Farmanguinhos/Fiocruz) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi), will be distributed free of charge through the Brazilian Universal Health System (SUS) to Indigenous children in the Amazon.
- [Clinical trial in Eastern Africa finds a shorter, safer, and more effective treatment for PKDL, a stigmatizing skin disease](https://dndi.org/press-releases/2024/clinical-trial-eastern-africa-finds-shorter-safer-more-effective-treatment-for-pkdl/) - A paediatric malaria treatment, developed in partnership with Brazil’s Instituto de Tecnologia em Fármacos (Farmanguinhos/Fiocruz) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi), will be distributed free of charge through the Brazilian Universal Health System (SUS) to Indigenous children in the Amazon.
- [Abacavir drug exposures in African children under 14 kg using paediatric solid fixed dose combinations according to World Health Organization weight bands](https://dndi.org/scientific-articles/2023/abacavir-drug-exposures-in-african-children-under-14-kg-using-paediatric-solid-fixed-dose-combinations-according-to-world-health-organization-weight-bands/) - by Chupradit S, Wamalwa DC, Maleche-Obimbo E, Kekitiinwa AR, Mwanga-Amumpaire J, Bukusi EA, Nyandiko WM, Mbuthia JK, Swanson A, DNDi Clinical Team, Cressey TR, Punyawudho B, Musiime V, LIVING Study Team. Journal of the Pediatric Infectious Diseases Society 2023, 12(11). doi: 10.1093/jpids/piad082 Summary: There is limited information about the pharmacokinetics of abacavir, taken as part
- [Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis](https://dndi.org/scientific-articles/2023/population-pharmacokinetics-of-a-combination-of-miltefosine-and-paromomycin-in-eastern-african-children-and-adults-with-visceral-leishmaniasis/) - by Verrest L, Roseboom IC, Wasunna M, Mbui J, Njenga S, Musa AM, Olobo J, Mohammed R, Ritmeijer K, Chu W-Y, Huitema ADR, Solomos A, Alves F, Dorlo TPC. Journal of Antimicrobial Chemotherapy 2023. doi: doi.org/10.1093/jac/dkad286 Summary: Most patients affected by visceral leishmaniasis (VL) are children, thus adequate paediatric exposure to miltefosine and paromomycin is
- [Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen](https://dndi.org/scientific-articles/2023/preclinical-data-do-not-support-the-use-of-amiodarone-or-dronedarone-as-antiparasitic-drugs-for-chagas-disease-at-the-approved-human-dosing-regimen/) - by Francisco AF, Chen Gong WW, Sykes ML, Escudié F, Scandale I, Olmo F, Shackleford DM, Zulfiqar B, Kratz JM, Pham T, Saunders J, Hu M, Avery VM, Charman SA, Kelly JM, Chatelain E. Frontiers in Tropical Diseases 2023, 4. doi: doi.org/10.3389/fitd.2023.1254061 Summary: Two approved antiarrhythmic agents, amiodarone and dronedarone, are reported to have potential
- [Treatments for dengue: a Global Dengue Alliance to address unmet needs](https://dndi.org/scientific-articles/2023/treatments-for-dengue-a-global-dengue-alliance-to-address-unmet-needs/) - by The Dengue Alliance. The Lancet Global Health 2023. doi: doi.org/10.1016/S2214-109X(23)00362-5 Summary: Half of the world's population is currently at risk of becoming infected with dengue. An integrated approach, comprising vector control, vaccines, and treatment, is needed to face this growing challenge. However, finding a treatment for dengue has not been prioritised. DNDi recently formed
- [Laboratory evaluation of eleven rapid diagnostic tests for serological diagnosis of Chagas disease in Colombia](https://dndi.org/scientific-articles/2023/laboratory-evaluation-of-eleven-rapid-diagnostic-tests-for-serological-diagnosis-of-chagas-disease-in-colombia/) - by Marchiol A, Florez Sanchez AC, Caicedo A, Segura M, Bautista J, Ayala Sotelo MS, Herazo R, Forsyth C, Bohorquez LC. PLOS Neglected Tropical Diseases 2023, 17(8): e0011547. doi: doi.org/10.1371/journal.pntd.0011547 Summary: Only an estimated 1.2% of people at risk of Chagas disease in Colombia have accessed diagnosis. Rapid diagnostic tests (RDTs) could simplify diagnosis, but
- [The VolREthics initiative to protect the well-being of healthy volunteers in biomedical research](https://dndi.org/scientific-articles/2023/the-volrethics-initiative-to-protect-the-well-being-of-healthy-volunteers-in-biomedical-research/) - by Bompart F, Fisher JA, Allen E, Sevene E, Kumar N, Chew CK, Fink V, Lanzerath D, Hirsch F. Nature Medicine 2023. doi: doi.org/10.1038/s41591-023-02490-6 Summary: Current regulations and ethical guidance do not distinguish between healthy volunteers and patients who participate in clinical trials. Healthy volunteers, who put themselves at potential risk, may be vulnerable to financial pressure if
- [Evaluación del cambio del algoritmo de diagnóstico serológico para la enfermedad de Chagas en Colombia](https://dndi.org/scientific-articles/2023/evaluacion-del-cambio-del-algoritmo-de-diagnostico-serologico-para-la-enfermedad-de-chagas-en-colombia/) - by Marchiol AR, Herazo R, Flórez Sánchez C, Ayala Sotelo MS, Segura ML, Cortés Cortés LJ, Caicedo Díaz RA. Pan American Journal of Public Health 2023,47. doi: doi.org/10.26633/RPSP.2023.141 Summary: The authors of this study evaluated the effect of changing the algorithm for serological diagnosis of T. cruzi infection in departmental-level public health laboratories and the
- [Prognostic prediction models for clinical outcomes in patients diagnosed with visceral leishmaniasis: protocol for a systematic review](https://dndi.org/scientific-articles/2023/prognostic-prediction-models-for-clinical-outcomes-in-patients-diagnosed-with-visceral-leishmaniasis-protocol-for-a-systematic-review/) - by Wilson J, Chowdhury F, Hassan S, Harriss EK, Alves F, Dahal P, Stepniewska K, Guérin PJ. BMJ Open 2023,13(10): e075597. doi: 10.1136/bmjopen-2023-075597 Summary: Patients with visceral leishmaniasis often struggle to access effective treatment. Risk prediction tools support clinical teams and policymakers in identifying high-risk patients who could benefit from more intensive management pathways. The authors of this paper aim to
- [Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors](https://dndi.org/scientific-articles/2023/open-science-discovery-of-potent-noncovalent-sars-cov-2-main-protease-inhibitors/) - by Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC, The COVID moonshot consortium*, Chodera JD, Lee AA, London N, von Delft A, von Delft F. Science 2023, 382(6671): e075597. doi: 10.1126/science.abo7201*including Perry B, Fraisse L, Sjö P, Boulet P, Hahn S, Mowbray C Summary: The authors report the results of the ‘COVID
- [Safety and efficacy of paromomycin/ miltefosine/ liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study](https://dndi.org/scientific-articles/2023/safety-efficacy-paromomycin-miltefosine-liposomal-amphotericin-b-combinations-fo-post-kala-azar-dermal-leishmaniasis-sudan/) - by Younis BM, Mudawi Musa A, Monnerat S, Abdelrahim Saeed M, Awad Gasim Khalil E, Elbashir Ahmed A, Ahmed Ali M, Noureldin A, Muthoni Ouattara G, Nyakaya GM, Teshome S, Omollo T, Ochieng M, Egondi T, Mmbone M, Chu W-Y, Dorlo TPC, Zijlstra EE, Wasunna M, Alvar J, Alves F. PLOS Neglected Tropical Diseases 2023, 17(11):
- [Clinical use of molecular methods for <i>Trypanosoma cruzi</i> infection in endemic and non-endemic countries: Benefits, limitations and challenges](https://dndi.org/scientific-articles/2023/clinical-use-of-molecular-methods-for-trypanosoma-cruzi-infection-in-endemic-and-non-endemic-countries-benefits-limitations-and-challenges/) - by Pinazo MJ, Forsyth CJ, Lopez-Albizu C, Bisio MMC, González-Martínez A, Bohorquez L, Pinto J, Molina I, Marchiol A, Herazo R, Galván IL, Marques T, Barreira F, Villar JC, Sguassero Y, Santini MS, Altcheh J, Alarcón de Noya B, Sosa-Estani S. Frontiers in Parasitology 2023, 2. doi: 10.3389/fpara.2023.1241154 Summary: Infection with the causative agent of Chagas
- [Using (1,3)-β-D-glucan concentrations in serum to monitor the response of azole therapy in patients with eumycetoma caused by <i>Madurella mycetomatis</i>](https://dndi.org/scientific-articles/2023/using-13-β-d-glucan-concentrations-in-serum-to-monitor-the-response-of-azole-therapy-in-patients-with-eumycetoma-caused-by-madurella-mycetomatis/) - by Nyuykonge B, Siddig EE, Nyaoke BA, Zijlstra EE, Verbon A, Bakhiet SM, Fahal AH, van de Sande WWJ. Mycoses 2023, 00:1-8. doi: doi.org/10.1111/myc.13664 Summary: (1,3)-β-D-glucan is a panfungal biomarker present in serum of patients with eumycetoma. In this study, the authors used the WAKO (1,3)-β-D-glucan assay to measure (1,3)-β-D-glucan concentrations in the serum of 104 patients with eumycetoma who were
- [Estimating the proportion of relapse following treatment of visceral leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review](https://dndi.org/scientific-articles/2023/estimating-the-proportion-of-relapse-following-treatment-of-visceral-leishmaniasis-meta-analysis-using-infectious-diseases-data-observatory-iddo-systematic-review/) - by Chhajed R, Dahal P, Singh-Phulgenda S, Brack M, Naylor C, Sundar S, Alves F, Stepniewska K, Guerin PJ. Lancet Regional Health Southeast Asia 2023. 10.1016/j.lansea.2023.100317 Summary: The follow-up period in trials of treatments for visceral leishmaniasis is typically six months, within which a proportion of initially cured patients relapse. Recent studies have reported a
- [DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc<sub>1</sub>](https://dndi.org/scientific-articles/2023/dndi-6174-preclinical-candidate-for-visceral-leishmaniasis-targets-cytochrome-bc1/) - by Braillard S, Keenan M, Breese KJ, Heppell J, Abbott M, Islam R, Shackleford DM, Katneni K, Crighton E, Chen G, Patil R, Lee G, White KL, Carvalho S, Wall RJ, Chemi G, Zuccotto F, González S, Marco M, Deakyne J, Standing D, Brunori G, Lyon JJ, Castañeda-Casado P, Camino I, Martinez MS, Zulfiqar B,
- [Short-course combination treatment for experimental chronic Chagas disease](https://dndi.org/scientific-articles/2023/short-course-combination-treatment-for-experimental-chronic-chagas-disease/) - by González S, Wall R J, Thomas J, Braillard S, Brunori G, Camino Díaz I, Cantizani J, Carvalho S, Castañeda Casado P, Chatelain E, Cotillo I, Fiandor JM, Francisco AF, Grimsditch D, Keenan M, Kelly JM, Kessler A, Luise C, Lyon JJ, MacLean L, Marco M, Martin JJ, Martinez Martinez MS, Paterson C, Read KD,
- [Madurastatins with imidazolidinone rings: Natural products or side-reaction products from extraction solvents?](https://dndi.org/scientific-articles/2023/madurastatins-with-imidazolidinone-rings-natural-products-or-side-reaction-products-from-extraction-solvents/) - by Pérez-Bonilla M, Sánchez-Hidalgo M, González I, Oves-Costales D, Martín J, Murillo-Alba J, Tormo JR, Cho A, Byun S-Y, No J-H, David S, Ioset J-R, Genilloud O, Reyes F. International Journal of Molecular Sciences 2023, 25(1): 301. doi: 10.3390/ijms25010301 Summary: Madurastatins are a group of pentapeptides containing an oxazoline moiety, and, in a few cases,
- [Consider This: Dengue vaccine (part 3) — Pandemic lessons: Prevent vaccine inequity](https://dndi.org/in-the-media/2024/consider-this-dengue-vaccine-part-3-pandemic-lessons-prevent-vaccine-inequity/) - ACCESS THE ARTICLE
- [Framework to help curb visceral leishmaniasis in East Africa](https://dndi.org/in-the-media/2024/framework-to-help-curb-visceral-leishmaniasis-in-east-africa/) - ACCESS THE ARTICLE
- [Identificaron un compuesto que puede actuar contra el dengue y Zika](https://dndi.org/in-the-media/2024/identificaron-un-compuesto-que-puede-actuar-contra-el-dengue-y-zika/) - ACCESS THE ARTICLE
- [What role does capacity development play in transforming health research?](https://dndi.org/in-the-media/2024/what-role-does-capacity-development-play-in-transforming-health-research/) - ACCESS THE ARTICLE
- [Striking fair deals for equitable access to medicines](https://dndi.org/scientific-articles/2023/striking-fair-deals-for-equitable-access-to-medicines/) - by Junod Moser D, Boulet P, Childs M, Shieh M, Pécoul B. Journal of Intellectual Property Law & Practice 2023, jpad025. doi: doi.org/10.1093/jiplp/jpad025 Summary: There is growing policy interest in public returns on public investments and ensuring that investments in pharmaceutical research and development result in innovation and equitable access. One approach is to include
- [Kalaazar disease affects hundreds of learners in West Pokot](https://dndi.org/in-the-media/2024/kalaazar-disease-affects-hundreds-of-learners-in-west-pokot/) - ACCESS THE ARTICLE
- [Dengue surge grips Latin America](https://dndi.org/in-the-media/2024/dengue-surge-grips-latin-america/) - ACCESS THE ARTICLE
- [Kalaazar disease torments young learners in West Pokot](https://dndi.org/in-the-media/2024/kalaazar-disease-torments-young-learners-in-west-pokot/) - ACCESS THE ARTICLE
- [New framework for visceral leishmaniasis elimination launched for Eastern Africa](https://dndi.org/press-releases/2024/new-framework-visceral-leishmaniasis-elimination-eastern-africa/) - A new, comprehensive framework has been released to guide health authorities, policy makers, and other stakeholders in Eastern Africa in eliminating visceral leishmaniasis (VL) as a public health problem.
- [50 years of developing global health leaders](https://dndi.org/in-the-media/2024/50-years-of-developing-global-health-leaders/) - ACCESS THE ARTICLE
- [Hope for global pandemic treaty rises — despite missed deadline](https://dndi.org/in-the-media/2024/hope-for-global-pandemic-treaty-rises-despite-missed-deadline/) - ACCESS THE ARTICLE
- [Celebrating 20 Years of LEAP: Innovation and Impact](https://dndi.org/videos/2024/celebrating-20-years-of-leap-innovation-and-impact/) - Over the past two decades, the Leishmaniasis East Africa Platform (LEAP) has made significant progress in fighting leishmaniasis in Eastern Africa, which currently has the highest number of visceral leishmaniasis (VL) cases world-wide. LEAP and DNDi have been collaborating to develop and introduce better treatments for leishmaniasis. LEAP's success is a testament to the power of collaboration. The platform brings together researchers, clinicians, healthcare workers, and community members to fight leishmaniasis.
- [DNDi interventions at the 77<sup>th</sup> World Health Assembly](https://dndi.org/statements/2024/dndi-interventions-77th-world-health-assembly/) - DNDi's interventions: Agenda item 11.6: Road map for neglected tropical diseases 2021–2030 We welcome the reported progress against some NTDs. For others, reaching elimination and eradication goals and achieving UHC require safer, more effective, patient-friendly treatments that can be used in primary healthcare settings. Advancements in R&D – including new treatments for sleeping sickness, mycetoma,
- [Journal de 8h45](https://dndi.org/in-the-media/2024/journal-de-8h45/)
- [Defying the odds: One doctor’s remarkable journey to helping patients with kala-azar](https://dndi.org/stories/2024/defying-the-odds-one-doctors-remarkable-journey-to-helping-patients-with-kala-azar/) - Dr Loyce Faith Nangiro, a medical officer at Amudat Hospital, in Karamoja, Northern Uganda, has been treating patients with visceral leishmaniasis (also known as Kala-azar) for four years now – but few would guess she was never meant to go to school.
- [Benznidazole and Posaconazole in experimental Chagas disease: Positive interaction in concomitant and sequential treatments](https://dndi.org/scientific-articles/2013/benznidazole-and-posaconazole-in-experimental-chagas-disease-positive-interaction-in-concomitant-and-sequential-treatments/) - by de Figueiredo Diniz L, Urbina JA, Mayer de Andrade I, Mazzeti AL, Martins TAF, Santana Caldas I,Talvani A, Ribeiro I, Terezinha MB. PLoS Negl Trop Dis., August 2013
- [Fexinidazole: A potential new drug candidate for Chagas disease](https://dndi.org/scientific-articles/2012/fexinidazole-a-potential-new-drug-candidate-for-chagas-disease/) - by Bahia MT, Mayer de Andrade I, Fontes Martins TA, da Silva do Nascimento AF, de Figueiredo Diniz L, Santana Caldas I, Talvani A, Bourdin Trunz B, Torreele E, Ribeiro I. PLoS Negl Trop Dis, November 2012
- [Complexes of Trypanosoma cruzi sterol 14alpha-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: Structural basis for pathogen-selectivity](https://dndi.org/scientific-articles/2013/structural-basis-for-pathogen-selectivity-chagas/) - by Hargrove TY, Wawrzak Z, Alexander PW, Chaplin JH, Keenan M, Charman SA, Perez CJ, Waterman MR, Chatelain E and Lepesheva GI. J. Biol. Chem., September 2013.
- [An unfolding tragedy of Chagas disease in North America](https://dndi.org/scientific-articles/2013/chagas-disease-in-north-america/) - by Hotez PJ, Dumonteil E, Betancourt Cravioto M, Bottazzi ME, Tapia-Conyer R, Meymandi S, Karunakara U, Ribeiro I, Cohen RM, Pécoul B. PLoS Negl Trop Dis., October 2013
- [New metabolic signature for Chagas disease reveals sex steroid perturbation in humans and mice](https://dndi.org/scientific-articles/2022/new-metabolic-signature-for-chagas-disease-reveals-sex-steroid-perturbation-in-humans-and-mice/) - by Golizeh M, Nam J, Chatelain E, Jackson Y, Ohlund LB, Rasoolizadeh A, Camargo FV, Mahrouche L, Furtos A, Sleno L, Ndao M. Heliyon 2022;8(12)E12380. doi: 10.1016/j.heliyon.2022.e12380 Summary: Current diagnostic tools for Chagas disease are inadequate for chronically infected patients. The authors of this study have previously shown that fragments of apolipoprotein A1 and fibronectin
- [DNDi's briefing note for 77<sup>th</sup> World Health Assembly](https://dndi.org/statements/2024/dndis-briefing-note-for-77th-world-health-assembly/) - This briefing sets out DNDi's comments for consideration by WHO Member States on agenda items included in the 77th meeting of the World Health Assembly.
- [Conflict's impact on a neglected disease](https://dndi.org/in-the-media/2024/conflicts-impact-on-a-neglected-disease/) - ACCESS THE ARTICLE
- [Negociación para un tratado sobre pandemias en su recta final y con resultado imprevisible](https://dndi.org/in-the-media/2024/negociacion-para-un-tratado-sobre-pandemias-en-su-recta-final-y-con-resultado-imprevisible/) - ACCESS THE ARTICLE
- [Global effort aims to protect health and safety of human ‘guinea pigs’ in drug trials](https://dndi.org/in-the-media/2024/global-effort-aims-to-protect-health-and-safety-of-human-guinea-pigs-in-drug-trials/) - ACCESS THE ARTICLE
- [Pandemic treaty talks will go on after missed deadline, some progress, WHO says](https://dndi.org/in-the-media/2024/pandemic-treaty-talks-will-go-on-after-missed-deadline-some-progress-who-says/) - ACCESS THE ARTICLE
- [Les Etats membres de l’Organisation mondiale de la santé peinent à s’accorder sur la réponse aux pandémies](https://dndi.org/in-the-media/2024/les-etats-membres-de-lorganisation-mondiale-de-la-sante-peinent-a-saccorder-sur-la-reponse-aux-pandemies/) - ACCESS THE ARTICLE
- [Japan's GHIT invests $10.8 M to develop new drugs for malaria & NTDs](https://dndi.org/in-the-media/2024/japans-ghit-invests-10-8-m-to-develop-new-drugs-for-malaria-ntds/) - ACCESS THE ARTICLE
- [በኢትዮጵያ በምርምር ላይ የሚገኘው የካላዛር ህክምና መድሃኒት ወደ ምዕራፍ ሁለት ክሊኒካል ሙከራ ደረጃ ተሸጋገረ](https://dndi.org/in-the-media/2024/kala-azar-a-drug-under-research-in-ethiopia-has-moved-to-phase-two-clinical-trials/) - ACCESS THE ARTICLE
- [دخول علاج فموي جديد وواعد وصديق لمرضى الكالازار المرحلة الثانية من التطوير السريري في إثيوبيا](https://dndi.org/in-the-media/2024/new-promising-and-friendly-oral-treatment-for-kala-azar-patients-enters-the-second-phase-of-clinical-development-in-ethiopia/) - ACCESS THE ARTICLE
- [Clinical trial for oral treatment against Kala-azar enters phase II](https://dndi.org/in-the-media/2024/clinical-trial-for-oral-treatment-against-kala-azar-enters-phase-ii/) - ACCESS THE ARTICLE
- [Phase 2 of a clinical trial for drug targeting](https://dndi.org/in-the-media/2024/phase-2-of-a-clinical-trial-for-drug-targeting/) - ACCESS THE ARTICLE
- [Pill to cure kala-azar moves closer to reality](https://dndi.org/in-the-media/2024/pill-to-cure-kala-azar-moves-closer-to-reality/) - ACCESS THE ARTICLE
- [Control of mucocutaneous leishmaniasis, a neglected disease: results of a control programme in Satipo Province, Peru](https://dndi.org/scientific-articles/2005/control-of-mucocutaneous-leishmaniasis-a-neglected-disease-results-of-a-control-programme-in-satipo-province-peru/) - by Guthmann JP, Arlt D, Garcia LM, Rosales M, de Jesus Sanchez J, Alvarez E, Lonlas S, Conte M, Bertoletti G, Fournier C, Huari R, Torreele E, Llanos-Cuentas A. Trop Med Int Health, September 2006
- [Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis](https://dndi.org/scientific-articles/2007/topical-buparvaquone-formulations-for-the-treatment-of-cutaneous-leishmaniasis/) - by Garnier T, Mantyla A, Jarvinen T, Lawrence MJ, Brown MB, Croft SL. J Pharm Pharmacol, January 2007
- [Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis](https://dndi.org/scientific-articles/2007/consultative-meeting-to-develop-a-strategy-for-treatment-of-cutaneous-leishmaniasis/) - by Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Kinetoplastid Biol Dis, April 2007
- [Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia](https://dndi.org/scientific-articles/2011/who-is-a-typical-patient-with-visceral-leishmaniasis-characterizing-the-demographic-and-nutritional-profile-of-patients-in-brazil-east-africa-and-south-asia/) - by Harhay MO, Olliaro PL, Vaillant M, Chappuis F, Lima MA, Ritmeijer K, Costa CH, Costa DL, Rijal S, Sundar S, Balasegaram M. Am J Trop Med Hyg, 2011
- [Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial](https://dndi.org/scientific-articles/2012/sodium-stibogluconate-ssg-paromomycin-combination/) - by Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, et al. PLoS Negl Trop Dis, June 2012
- [Safety and efficacy of single dose versus multiple doses of AmBisome® for treatment of visceral leishmaniasis in Eastern Africa: A randomized trial](https://dndi.org/scientific-articles/2014/ambisome-vl-east-africa/) - by Khalil EAG, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid A, Dorlo TPC, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AH, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A. PLoS Neglected Tropical Diseases, 2014
- [How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data](https://dndi.org/scientific-articles/2014/plosntds-elimination-bangladesh/) - by Chowdhury R, Mondal D, Chowdhury V, Faria S, Alvar J, Nabi SG, Boelaert M, Dash AP. PLOS NTDs, August 2014
- [Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations](https://dndi.org/scientific-articles/2014/antiviral-dose-ratios-paediatric/) - by Bouazza N, Foissac F, Fauchet F, Burger D, Kiechel JR, Treluyer JM, Capparelli EV, Lallemant M, Urien S. Antiviral Therapy, October 2014
- [Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis](https://dndi.org/scientific-articles/2013/methodology-of-clinical-trials-aimed-at-assessing-interventions-for-cutaneous-leishmaniasis/) - by Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A. PLoS Negl Trop Dis., March 2013
- [Antidepressant use and its association with 28-day mortality in inpatients with SARS-CoV-2: Support for the FIASMA model against COVID-19](https://dndi.org/scientific-articles/2022/antidepressant-use-and-association-with-28-day-mortality-inpatients-sarscov2/) - by Hoertel N, Sánchez-Rico M, Kornhuber J, Gulbins E, Reiersen AM, Lenze EJ, Fritz BA, Jalali F, Mills EJ, Cougoule C, Carpinteiro A, Mühle C, Becker KA, Boulware DR, Blanco C, Alvarado JM, Strub-Wourgaft N, Lemogne C, Limosin F, on behalf of AP-HP/Université Paris Cité/INSERM COVID-19 Research Collaboration, AP-HP COVID CDR Initiative and “Entrepôt de
- [Comienza con incertidumbre última ronda negociadora para un tratado global antipandemias](https://dndi.org/in-the-media/2024/comienza-con-incertidumbre-ultima-ronda-negociadora-para-un-tratado-global-antipandemias/) - ACCESS THE ARTICLE
- [Entrevista con Dr Pizarro sobre el Premio Asturias y la lucha de DNDi en pro de los desatendidos](https://dndi.org/videos/2023/entrevista-con-dr-pizarro-sobre-el-premio-asturias-y-la-lucha-de-dndi-en-pro-de-los-desatendidos/) - Entrevista con el Director Ejecutivo de DNDi, el Dr. Luis Pizarro, en ocasión del recibimiento, por la organización, del Premio Princesa de Asturias de Cooperación Internacional 2023. El medico explica como la DNDi fue creada, el trabajo con las enfermedades desatendidas y el orgullo de ganar uno de los galardones más prestigiosos de España. 'Estamos profundamente agradecidos por este premio, que es una oportunidad fantástica para dar visibilidad a las millones de personas que son desatendidas por los responsables de políticas públicas y la investigación farmacéutica con fines comerciales', declaró el Dr. Luis Pizarro, Director Ejecutivo de DNDi.
- [DNDi Medical Camp & Charity Run: Kacheliba, West Pokot-Kenya](https://dndi.org/videos/2024/dndi-medical-camp-charity-run-kacheliba-west-pokot-kenya/) - To celebrate our 20th anniversary, DNDi organized a charity run called 'Run for the Neglected Patients' in Kacheliba, West Pokot, Kenya in November 2023. This is where we've been conducting clinical trials and providing treatment for patients with visceral leishmaniasis since 2005. Our aim was to raise awareness about neglected diseases and provide an opportunity for our partners, friends, and supporters to share current advances and gaps in tools for neglected diseases.
- [Last chance for pandemic agreement talks](https://dndi.org/in-the-media/2024/last-chance-for-pandemic-agreement-talks/) - ACCESS THE ARTICLE Lire l'article
- [Out of the Shadows: The Story of DNDi (short version)](https://dndi.org/videos/2023/out-of-the-shadows-the-story-of-dndi-short-version/) - In a world affected by climate change, conflict, and economic instability, it is always the most vulnerable people that suffer – often from neglected diseases for which there is no cure. Out of the Shadows tells the story of DNDi researchers working to develop treatments for patients who have lived in the shadows for too long.
- [En mission avec les Safari Doctors au Kenya](https://dndi.org/in-the-media/2024/en-mission-avec-les-safari-doctors-au-kenya/) - ACCESS THE ARTICLE
- [Geplantes Pandemieabkommen: Was es regelt und wo es hakt](https://dndi.org/in-the-media/2024/geplantes-pandemieabkommen-was-es-regelt-und-wo-es-hakt/) - ACCESS THE ARTICLE
- [DNDi comments on WHO Pandemic Agreement – Recommendations for Article 9: Research and Development](https://dndi.org/statements/2024/dndi-comments-on-who-pandemic-agreement-recommendations-for-article-9-research-and-development/) - DNDi has closely followed the negotiations of the WHO Pandemic Agreement, with special attention to the area of research and development (Article 9) and how these provisions may help or hinder addressing the key issue of lack of equitable access to treatments, vaccines, diagnostics, and other health tools. The revised draft text was circulated on 18 April and will be considered by Member States in what should be the final round of negotiations to begin on 29 April.
- [When dengue affects rich countries, will we take it more seriously?](https://dndi.org/in-the-media/2024/when-dengue-affects-rich-countries-will-we-take-it-more-seriously/) - ACCESS THE ARTICLE
- [Cuáles son las terapias específicas contra el virus del dengue que investiga la ciencia](https://dndi.org/in-the-media/2024/cuales-son-las-terapias-especificas-contra-el-virus-del-dengue-que-investiga-la-ciencia/) - ACCESS THE ARTICLE
- [አዲሱ የካላዛር ህክምና ወደ ምእራፍ ሁለት የክሊኒካል ሙከራ መሸጋገሩ ተገለጸ](https://dndi.org/press-releases-translations/2024/oral-drug-against-visceral-leishmaniasis-enters-clinical-trial-ethiopia-am/) - The new molecule has the potential to revolutionize treatment for the deeply neglected and hard-to-treat disease, as the Eastern Africa region charts the way to its elimination.
- [Promising patient-friendly oral drug against visceral leishmaniasis enters Phase II clinical trial in Ethiopia](https://dndi.org/press-releases/2024/oral-drug-against-visceral-leishmaniasis-enters-clinical-trial-ethiopia/) - The new molecule has the potential to revolutionize treatment for the deeply neglected and hard-to-treat disease, as the Eastern Africa region charts the way to its elimination.
- [Battle against black fever in India nears victory](https://dndi.org/in-the-media/2024/battle-against-black-fever-in-india-nears-victory/) - ACCESS THE ARTICLE
- [DNDi signs memorandum of understanding with Kenya Medical Research Institute](https://dndi.org/press-releases/2024/dndi-signs-memorandum-of-understanding-with-kenya-medical-research-institute/) - The Kenya Medical Research Institute (KEMRI) and the Drugs for Neglected Diseases initiative (DNDi) have signed a memorandum of understanding to collaborate in the execution of research and development (R&D) projects and bridge the existing research gaps on neglected diseases. The MOU, which seeks to increase access to diagnosis and treatment, also aims to support policy change in Kenya.
- [Why we need a Global Dengue Alliance](https://dndi.org/in-the-media/2024/why-we-need-a-global-dengue-alliance/) - ACCESS THE ARTICLE
- [La pionera en la lucha contra las enfermedades desatendidas que anima a las niñas a seguir su ejemplo: 'Vuestros sueños son válidos'](https://dndi.org/in-the-media/2024/la-pionera-en-la-lucha-contra-las-enfermedades-desatendidas-que-anima-a-las-ninas-a-seguir-su-ejemplo-vuestros-suenos-son-validos-2/) - ACCESS THE ARTICLE
- [La pionera en la lucha contra las enfermedades desatendidas que anima a las niñas a seguir su ejemplo: 'Vuestros sueños son válidos'](https://dndi.org/in-the-media/2024/la-pionera-en-la-lucha-contra-las-enfermedades-desatendidas-que-anima-a-las-ninas-a-seguir-su-ejemplo-vuestros-suenos-son-validos/) - ACCESS THE ARTICLE
- [L’accès très inégal aux traitements contre les hépatites B et C, qui ont causé 1,3 million de morts en 2022](https://dndi.org/in-the-media/2024/lacces-tres-inegal-aux-traitements-contre-les-hepatites-b-et-c-qui-ont-cause-13-million-de-morts-en-2022/) - ACCESS THE ARTICLE
- [Inside the push to make intellectual property work for African pharma](https://dndi.org/in-the-media/2024/inside-the-push-to-make-intellectual-property-work-for-african-pharma/) - ACCESS THE ARTICLE
- [Oral drug promises better treatment for mycetoma](https://dndi.org/in-the-media/2024/oral-drug-promises-better-treatment-for-mycetoma/) - ACCESS THE ARTICLE
- [DNDi submission to Global Goal on Adaptation](https://dndi.org/statements/2024/dndi-submission-to-global-goal-on-adaptation/) - DNDi's submission to Global Goal on Adaptation
- [A drug development model for the diseases the world forgot](https://dndi.org/viewpoints/2023/a-drug-development-model-for-the-diseases-the-world-forgot/) - Viewpoint by Dr Monique Wasunna, DNDi's Africa Ambassador, published in Africa Arguments.
- [Africa should bolster research into climate-sensitive diseases](https://dndi.org/viewpoints/2023/africa-should-bolster-research-into-climate-sensitive-diseases/) - By Samuel Kariuki, Eastern Africa Director, DNDi As a scientist working in a country affected by over 15 neglected diseases, I have witnessed with deep concern the changing disease patterns caused by climate change. There is mounting evidence that climate change is worsening the geographical spread and incidence of infectious diseases. Scientists have found that vectors such as mosquitoes and
- [Aligning to combat dengue](https://dndi.org/in-the-media/2024/aligning-to-combat-dengue/) - ACCESS THE ARTICLE
- [Ravidasvir journey](https://dndi.org/news/2024/ravidasvir-journey/) - Thailand’s Mahidol University and Egyptian pharmaceutical company Pharco joined forces with DNDi in a tripartite collaborative and license agreement with the objective of introducing ravidasvir in Thailand, and thereby offering a much-needed additional affordable treatment option for people living with hepatitis C.
- [Political will needed to end the unnecessary suffering of hepatitis C patients](https://dndi.org/in-the-media/2022/political-will-needed-to-end-the-unnecessary-suffering-of-hepatitis-c-patients/) - read the article
- [Waiting for the Cure](https://dndi.org/videos/2021/waiting-for-the-cure/) - The quest to deliver an affordable treatment for hepatitis C in Malaysia
- [Pandemic accord talks at loggerheads as time ticks away](https://dndi.org/in-the-media/2024/pandemic-accord-talks-at-loggerheads-as-time-ticks-away/) - ACCESS THE ARTICLE
- [Dr. Borna Nyaoke-Anoke: The clinical researcher fighting ‘the neglect’ in mycetoma disease](https://dndi.org/in-the-media/2024/dr-borna-nyaoke-anoke-the-clinical-researcher-fighting-the-neglect-in-mycetoma-disease/) - ACCESS THE ARTICLE
- [Mycetoma: Neglected but not Forgotten](https://dndi.org/videos/2023/mycetoma-neglected-but-not-forgotten/) - Results from a clinical trial conducted by DNDi in partnership with the Mycetoma Research Center, Erasmus MC, and Eisai Co., Ltd. show that a new oral treatment is safe, patient-friendly, and effective in treating the disease.
- [Ninth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response](https://dndi.org/statements/2024/ninth-meeting-of-the-intergovernmental-negotiating-body-inb-for-a-who-instrument-on-pandemic-prevention-preparedness-and-response/) - DNDi's intervention at the 9th meeting of the Intergovernmental Negotiating Body.
- [With a million cases of dengue so far this year, Brazil is in a state of emergency](https://dndi.org/in-the-media/2024/with-a-million-cases-of-dengue-so-far-this-year-brazil-is-in-a-state-of-emergency/) - ACCESS THE ARTICLE
- [The story of Dr. Justine Odionyi who works for the DNDI, a not-for-profit organization](https://dndi.org/in-the-media/2024/the-story-of-dr-justine-odionyi-who-works-for-the-dndi-a-not-for-profit-organization/) - ACCESS THE ARTICLE
- [Dkt Borna Nyaoke ,sogora katika utafiti wa ugonjwa wa Mycetoma nchini Kenya](https://dndi.org/in-the-media/2024/dkt-borna-nyaoke-sogora-katika-utafiti-wa-ugonjwa-wa-mycetoma-nchini-kenya/) - ACCESS THE ARTICLE
- [A corrida 'urgente' para encontrar remédios efetivos contra a dengue](https://dndi.org/in-the-media/2024/a-corrida-urgente-para-encontrar-remedios-efetivos-contra-a-dengue/) - ACCESS THE ARTICLE
- [The ‘exotic’ dengue disease is biting Europe hard, warn experts](https://dndi.org/in-the-media/2024/the-exotic-dengue-disease-is-biting-europe-hard-warn-experts/) - ACCESS THE ARTICLE
- [Can non-profits beat antibiotic resistance and soaring drug costs?](https://dndi.org/in-the-media/2024/this-super-gonorrhoea-drug-holds-a-lesson-for-avoiding-microbial-armageddon/) - ACCESS THE ARTICLE
- [Lutte contre la trypanosomiase : les parties prenantes invitées à multiplier les stratégies d’élimination](https://dndi.org/in-the-media/2024/lutte-contre-la-trypanosomiase-les-parties-prenantes-invitees-a-multiplier-les-strategies-delimination/) - ACCESS THE ARTICLE
- [Wagonjwa wanaougua Kaalazar Pokot Magharibi waongezeka](https://dndi.org/in-the-media/2024/wagonjwa-wanaougua-kaalazar-pokot-magharibi-waongezeka/) - ACCESS THE ARTICLE
- [Eighth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response](https://dndi.org/statements/2024/eighth-meeting-of-the-intergovernmental-negotiating-body-inb-for-a-who-instrument-on-pandemic-prevention-preparedness-and-response/) - DNDi's interventions at the 8th meeting of the Intergovernmental Negotiating Body.
- [Treating the tsetse's curse](https://dndi.org/in-the-media/2024/treating-the-tsetses-curse/) - ACCESS THE ARTICLE
- [Mulheres na ciência: 5 pesquisadoras brasileiras que fazem a diferença](https://dndi.org/in-the-media/2024/mulheres-na-ciencia-5-pesquisadoras-brasileiras-que-fazem-a-diferenca/) - ACCESS THE ARTICLE
- [As doenças negligenciadas precisam de pesquisas, mas o financiamento é insuficiente](https://dndi.org/viewpoints-translations/2024/as-doencas-negligenciadas-precisam-de-pesquisas-mas-o-financiamento-e-insuficiente/) - By Terín Beca, Consultant, DNDi and Belén Pedrique, Senior Medical Manager, Viral Diseases Cluster HCV, HIV, Dengue and Crypto, DNDi First published in The Conversation on 8 February 2023 Português Español As doenças tropicais negligenciadas (DTNs) são um grupo de 21 doenças que prevalecem principalmente em comunidades carentes de áreas tropicais e subtropicais, embora algumas tenham uma distribuição geográfica By Terín Beca, Consultant, DNDi and Belén Pedrique, Senior Medical Manager, Viral Diseases Cluster HCV, HIV, Dengue and Crypto, DNDi First published in The Conversation on 8 February 2023 Português Español As doenças tropicais negligenciadas (DTNs) são um grupo de 21 doenças que prevalecem principalmente em comunidades carentes de áreas tropicais e subtropicais, embora algumas tenham uma distribuição geográfica
- [Bangladesh eradicates kala-azar, India on track too but challenges remain](https://dndi.org/in-the-media/2023/bangladesh-eradicates-kala-azar-india-on-track-too-but-challenges-remain/) - ACCESS THE ARTICLE
- [NTD DAY: Expanding research into dengue treatment](https://dndi.org/in-the-media/2024/ntd-day-expanding-research-into-dengue-treatment/) - ACCESS THE ARTICLE
- [Quelles sont les avancées et les défis à relever dans la lutte contre les MTN ?](https://dndi.org/in-the-media/2024/quelles-sont-les-avancees-et-les-defis-a-relever-dans-la-lutte-contre-les-mtn/) - ACCESS THE ARTICLE
- [Journée Mondiale des Maladies Tropicales Négligées](https://dndi.org/in-the-media/2024/journee-mondiale-des-maladies-tropicales-negligees/) - ACCESS THE ARTICLE
- [Kenya seeks to eradicate 20 Neglected Tropical diseases](https://dndi.org/in-the-media/2024/kenya-seeks-to-eradicate-20-neglected-tropical-diseases/) - ACCESS THE ARTICLE
- [Bangladesh eliminates visceral leishmaniasis](https://dndi.org/in-the-media/2024/bangladesh-eliminates-visceral-leishmaniasis/) - ACCESS THE ARTICLE
- [Advanced HIV as a neglected disease](https://dndi.org/in-the-media/2024/advanced-hiv-as-a-neglected-disease/) - ACCESS THE ARTICLE
- [India on the verge of eliminating 'black fever' kala-azar](https://dndi.org/in-the-media/2024/india-on-the-verge-of-eliminating-black-fever-kala-azar/) - ACCESS THE ARTICLE
- [Waiting for universal dengue vaccine and drugs, South Asia battles 'silent pandemic'](https://dndi.org/in-the-media/2024/waiting-for-universal-dengue-vaccine-and-drugs-south-asia-battles-silent-pandemic/) - ACCESS THE ARTICLE
- [Wakaazi wa maeneo kame waraiwa kipimwa](https://dndi.org/in-the-media/2023/wakaazi-wa-maeneo-kame-waraiwa-kipimwa/) - ACCESS THE ARTICLE
- [세계 10억 명을 위한 소외질병 연구 지원, 한국이 필요하다](https://dndi.org/viewpoints/2024/기고-세계-10억-명을-위한-소외질병-연구-지원-한국이/) - By Luis Pizarro, Executive Director, DNDi 1월 30일은 세계소외열대질환(Neglected tropical diseases∙NTD)의 날이다. 소외열대질환은 매년 전 세계적으로 10억 명 이상의 사람들에게 영향을 미치고 있지만, 아직도 관심과 투자는 부족하다. 세계소외열대질환의 날은 이 질병들의 심각성을 일깨우는 동시에 지금까지 일궈낸 성과를 널리 알려 더 나은 미래를 위한 실천을 독려하고자 만들어졌다. Read the viewpoint published in Segye Ilbo By Luis Pizarro, Executive Director, DNDi 1월 30일은 세계소외열대질환(Neglected tropical diseases∙NTD)의 날이다. 소외열대질환은 매년 전 세계적으로 10억 명 이상의 사람들에게 영향을 미치고 있지만, 아직도 관심과 투자는 부족하다. 세계소외열대질환의 날은 이 질병들의 심각성을 일깨우는 동시에 지금까지 일궈낸 성과를 널리 알려 더 나은 미래를 위한 실천을 독려하고자 만들어졌다. Read the viewpoint published in Segye Ilbo
- [Día Mundial de las Enfermedades Tropicales Desatendidas: qué son y por qué es importante prevenir y controlar los brotes](https://dndi.org/in-the-media/2024/dia-mundial-de-las-enfermedades-tropicales-desatendidas-que-son-y-por-que-es-importante-prevenir-y-controlar-los-brotes/) - ACCESS THE ARTICLE
- [DNDi receives USD 20 million to develop innovative treatments to further elimination goals for sleeping sickness and river blindness](https://dndi.org/press-releases/2024/dndi-receives-usd-20-million-develop-innovative-treatments-elimination-sleeping-sickness-river-blindness/) - The Drugs for Neglected Diseases initiative (DNDi) has received new grant support totaling USD 20 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – USD 12 million) and river blindness (onchocerciasis – USD 8.2 million) from the Bill & Melinda Gates Foundation.
- [Forschung auf der Suche nach Breitband-Virostatika](https://dndi.org/in-the-media/2024/forschung-auf-der-suche-nach-breitband-virostatika/) - ACCESS THE ARTICLE
- [DNDi interventions at the 154<sup>th</sup> Session of the WHO Executive Board](https://dndi.org/statements/2024/dndi-interventions-154-who-executive-board/) - DNDi's interventions at the 154th WHO Executive Board on the Roadmap for NTDs, maternal health and child mortality, AMR, climate change, and economic and health for all.
- [Clinical trial confirms the tolerability of the drug fexinidazole in the treatment of Chagas disease](https://dndi.org/press-releases/2024/clinical-trial-confirms-tolerability-fexinidazole-treatment-chagas/) - A clinical trial for the treatment of Chagas disease carried out in Spain with a mostly Latin American population showed that the drug fexinidazole was well tolerated by patients in low doses, although it was not effective in the sustained elimination of the parasite Trypanosoma cruzi, which causes the disease.
- [DNDi's briefing note for 154<sup>th</sup> Session of the WHO Executive Board](https://dndi.org/statements/2024/dndi-briefing-note-154-who-executive-board/) - This briefing sets out DNDi's comments for considerations by WHO Member States on agenda items covering strategy for women’s, children’s and adolescents’ health, universal health coverage, preparedness and response for health emergencies, and WHO global strategy on health, environment and climate change.
- [DNDi welcomes WHO communiqué on climate change, neglected tropical diseases, and malaria](https://dndi.org/statements/2024/dndi-welcomes-who-communique-on-climate-change-neglected-tropical-diseases-and-malaria/) - DNDi's comment on Article 9 Negotiating Text and oral statement given at INB7.
- [Luis Emilio Pizarro, el médico chileno que emigró a África y logró el título de Caballero y el Premio Princesa de Asturias](https://dndi.org/in-the-media/2024/luis-emilio-pizarro-el-medico-chileno-que-emigro-a-africa-y-logro-el-titulo-de-caballero-y-el-premio-princesa-de-asturias/) - ACCESS THE ARTICLE
- [Luis Emilio Pizarro: “Si todo privado, público o investigadores ponemos un poquito de lo que sabemos hacer, podemos desarrollar un bien común para todo el mundo y eso es lo que tratamos de hacer en el DNDI”](https://dndi.org/in-the-media/2024/luis-emilio-pizarro-si-todo-privado-publico-o-investigadores-ponemos-un-poquito-de-lo-que-sabemos-hacer-podemos-desarrollar-un-bien-comun-para-todo-el-mundo-y-eso-es-lo-que-tratamos-de-hac/) - ACCESS THE ARTICLE
- [Treatment for acute sleeping sickness has been brutal — until now](https://dndi.org/in-the-media/2024/treatment-for-acute-sleeping-sickness-has-been-brutal-until-now/) - ACCESS THE ARTICLE
- [Nthambi  yowunika mankhwala ku ulaya yavomereza kuti Fexinidazole Winthrop ndi mankhwala omwe apezeka koyamba okumwa oti amachilitsa matenda ogonagona (sleeping sickness)  mmaiko a madera a kum’mawa ndi ku madzulo kwa Africa](https://dndi.org/press-releases-translations/2023/nthambi-yowunika-mankhwala-ku-ulaya-yavomereza-kuti-fexinidazole-winthrop-ndi-mankhwala-omwe-apezeka-koyamba-okumwa-oti-amachilitsa-matenda-ogonagona-sleeping-sickness-mmaiko-a-madera-a-kum/) - Mgwirizano wa mabungwe aSanofi, DNDi ndi HAT-r-ACC ukulengeza zoti nthambi yowunika mankhwala ya European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) lavomereza zotsatira za kafukufuku yemwe wapeza kuti Fexinidazole Winthrop ndi mankhwala oyamba kupezeka okumwa oti ndiochilitsa matenda ogona (sleeping sickness).
- [EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa](https://dndi.org/press-releases/2023/ema-gives-positive-opinion-fexinidazole-winthrop-first-oral-treatment-sleeping-sickness-rhodesiense/) - Sanofi, DNDi, and the HAT-r-ACC consortium announced the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).
- [L’EMA a rendu un avis favorable au sujet du Fexinidazole comme premier traitement oral de la forme aiguë (rhodesiense) de la maladie du sommeil, présente en Afrique de l’Est et australe](https://dndi.org/press-releases-translations/2023/ema-a-rendu-avis-favorable-fexinidazole-comme-premier-traitement-oral-forme-aigue-rhodesiense-de-maladie-du-sommeil/) - Sanofi, DNDi et le consortium HAT-r-ACC ont annoncé que le Comité des médicaments à usage humain de l’Agence européenne des médicaments a rendu un avis favorable concernant le Fexinidazole Winthrop comme premier traitement par voie orale de la forme aigüe (rhodesiense) de la maladie du sommeil.
- [Entrevistas CF 2024 - Luis Pizarro](https://dndi.org/in-the-media/2023/entrevistas-cf-2024-luis-pizarro/) - ACCESS THE ARTICLE
- [MSF uses 1999 Nobel Peace Prize to help found pioneering not-for-profit drug development organization](https://dndi.org/news/2023/msf-uses-1999-nobel-peace-prize-to-help-found-pioneering-not-for-profit-drug-development-organization/) - In 1999, medical humanitarian organization Médecins Sans Frontières was awarded the Nobel Peace Prize. MSF applied its Nobel Peace Prize proceeds toward confronting a growing injustice: the failure of the market-driven model of pharmaceutical research and development to deliver safe, affordable, and effective medicines for millions of neglected patients.
- [New hope — and an old hurdle — for a terrible disease with terrible treatments](https://dndi.org/in-the-media/2023/new-hope-and-an-old-hurdle-for-a-terrible-disease-with-terrible-treatments/) - ACCESS THE ARTICLE
- [A decade and 4 deadlines later, India set to eliminate kala azar this year](https://dndi.org/in-the-media/2023/a-decade-and-4-deadlines-later-india-set-to-eliminate-kala-azar-this-year/) - ACCESS THE ARTICLE
- [Nagasaki University, DNDi, and GHIT Fund sign agreement to collaborate on drug screening for Chagas disease](https://dndi.org/press-releases/2023/nagasaki-university-dndi-ghit-fund-sign-agreement-collaborate-drug-screening-chagas-disease/) - With the support of GHIT Fund, DNDi and Nagasaki University will partner to apply this new method to screen compound libraries made available by BINDS Project of Grad. Sch. Pharm. Sci., Osaka University.
- [How bacteria and AI are helping in fight against dengue fever](https://dndi.org/in-the-media/2023/how-bacteria-and-ai-are-helping-in-fight-against-dengue-fever/) - ACCESS THE ARTICLE
- [Cómo es el nuevo estudio clínico contra el Chagas que se realiza en la Argentina](https://dndi.org/in-the-media/2023/como-es-el-nuevo-estudio-clinico-contra-el-chagas-que-se-realiza-en-la-argentina/) - ACCESS THE ARTICLE
- [Doenças negligenciadas ameaçam saúde pública global](https://dndi.org/viewpoints/2023/doencas-negligenciadas-ameacam-saude-publica-global/) - By Dr Sergio Sosa-Estani, Latin America Director, DNDi Cerca de 68 milhões de pessoas nas Américas são afetadas por doenças tropicais negligenciadas, segundo a Organização Mundial da Saúde. Enquanto algumas doenças estão no foco do clássico sistema de pesquisa e desenvolvimento (P&D) de medicamentos, outras recebem pouco investimento para inovação e descoberta de novos tratamentos seguros, eficazes e acessíveis.
- [Africa Statistics Day: Statistics save lives, especially those of neglected patients](https://dndi.org/viewpoints/2023/africa-statistics-day-statistics-save-lives-especially-those-of-neglected-patients/) - By Collins Mutua, Head of Biostatistics, DNDi Have you ever wondered how the pills in your medicine cabinet actually make it to you? It takes a village to develop new medicines. The village comprises researchers, clinicians, clinical trial participants, regulatory authorities, and distributors. Drug companies undergo a rigorous process of experimentation to discover new drugs
- [The Agenda Podcast](https://dndi.org/in-the-media/2023/the-agenda-podcast/) - ACCESS THE ARTICLE
- [Acceptability of a new 4-in-1 Abacavir/ Lamivudine/ Lopinavir/ Ritonavir paediatric fixed-dose combination: The caregiver–child dyads’ perspective](https://dndi.org/scientific-articles/2023/acceptability-new-4in1-abacavir-lamivudine-lopinavir-ritonavir-paediatric-fixed-dose-combination/) - by Rotsaert A, Ogara C, Mwanga-Amumpaire J, Kekitiinwa AR, Musiime V, Najjingo E, Kisitu GP, Nazzinda R, Nambi E, Lee J, Diallo M, Kyomuhendo F, Waweru M, Andrieux-Meyer I, Nöstlinger C. Therapeutic Advances in Infectious Disease 2023, 10. doi: https://doi.org/10.1177/20499361231159993 Summary: Lack of age-appropriate antiretroviral formulations is the main obstacle to paediatric access to HIV
- [Cryptococcal meningitis: new report highlights slow uptake of guidelines shown to reduce deaths in Africa](https://dndi.org/press-releases/2023/cryptococcal-meningitis-new-report-highlights-slow-uptake-guidelines-shown-reduce-deaths-africa/) - With more than 600,000 AIDS-related deaths each year over the past four years, proven interventions must be implemented quickly to save lives.
- [La première étude clinique jamais réalisée sur le mycétome, une maladie fongique dévastatrice, met en évidence l’efficacité d'un nouveau traitement prometteur](https://dndi.org/press-releases-translations/2023/premiere-etude-clinique-jamais-realisee-mycetome-une-met-en-evidence-lefficacite-dun-nouveau-traitement-prometteur/) - Ces nouveaux résultats obtenus au Soudan, le pays qui compte le plus grand nombre de cas documentés de mycétome, offrent un espoir à des patients négligés depuis des décennies.
- [World’s first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment](https://dndi.org/press-releases/2023/worlds-first-clinical-trial-for-mycetoma-shows-efficacy-new-promising-treatment/) - These new results from Sudan, the country with the most documented mycetoma cases in the world, offer hope to patients who have suffered decades of neglect.
- [Das Bundesministerium für wirtschaftliche Zusammenarbeit und Entwicklung (BMZ) bewilligt über die KfW Fördermittel für den beschleunigten Zugang zu Medikamenten gegen armutsassoziierte und vernachlässigte Krankheiten](https://dndi.org/press-releases-translations/2023/bmz-bewilligt-fordermittel-zugang-medikamenten-gegen-armutsassoziierte-vernachlassigte-krankheiten/) - Das Bundesministerium für wirtschaftliche Zusammenarbeit und Entwicklung (BMZ) hat DNDi über die KfW Entwicklungsbank eine Förderung in Höhe von 20 Mio. EUR über fünf Jahre zugesagt. So trägt das BMZ dazu bei, dass Menschen, die an armutsassoziierten und vernachlässigten Krankheiten (PRNDs) leiden, einen schnelleren Zugang zu Behandlungen in Schwerpunktländern in Afrika, Asien und Lateinamerika erhalten.
- [Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) through KfW grants funding to fast-track access to medicines for poverty-related and neglected diseases](https://dndi.org/press-releases/2023/germanys-federal-ministry-for-economic-cooperation-and-development-bmz-through-kfw-grants-funding-to-fast-track-access-to-medicines-for-poverty-related-and-neglected-diseases/) - The German Federal Ministry for Economic Cooperation and Development through the KfW Development Bank has awarded DNDi a five-year EUR 20 million grant to support faster access to treatments for people affected by poverty-related and neglected diseases in priority countries in Africa, Asia, and Latin America.
- [DNDi Climate and Environmental Roadmap](https://dndi.org/publications/2023/dndi-climate-environmental-roadmap/) - This DNDi Climate and Environmental Roadmap outlines the steps we need to take to reduce the emissions we control, from our offices and travel, and the emissions we do not directly control, including from outsourced R&D and treatment access programmes.
- [DNDi commits to cutting carbon emissions in half by 2030](https://dndi.org/news/2023/dndi-commits-to-cutting-carbon-emissions-half-2030/) - The DNDi Board of Directors has approved a Climate and Environmental Roadmap that will cut DNDi’s global carbon emissions by 50% by 2030, from a baseline of 2019 emissions. The roadmap includes ambitious targets to reduce emissions from our R&D and treatment access activities, as well as from our offices and travel.
- [Wakaazi wa Kacheliba, West Pokot wanufaika na matibabu ya bure](https://dndi.org/in-the-media/2023/wakaazi-wa-kacheliba-west-pokot-wanufaika-na-matibabu-ya-bure/) - ACCESS THE ARTICLE
- [State to roll out internet connectivity in ASAL counties](https://dndi.org/in-the-media/2023/state-to-roll-out-internet-connectivity-in-asal-counties/) - ACCESS THE ARTICLE
- [PS Omollo urges NGAOs to partner with health sector to combat Neglected Diseases](https://dndi.org/in-the-media/2023/ps-omollo-urges-ngaos-to-partner-with-health-sector-to-combat-neglected-diseases-2/) - ACCESS THE ARTICLE
- [Enos Kales and Brenda Tuwei win Charity race in Kacheliba](https://dndi.org/in-the-media/2023/enos-kales-and-brenda-tuwei-win-charity-race-in-kacheliba/) - ACCESS THE ARTICLE
- [PS Omollo urges NGAOs to partner with health sector to combat Neglected Diseases](https://dndi.org/in-the-media/2023/ps-omollo-urges-ngaos-to-partner-with-health-sector-to-combat-neglected-diseases/) - ACCESS THE ARTICLE
- [West Pokot records the highest cases of disease spread by sandflies](https://dndi.org/in-the-media/2023/west-pokot-records-the-highest-cases-of-disease-spread-by-sandflies/) - ACCESS THE ARTICLE
- [West Pokot residents benefit from free medical camp](https://dndi.org/in-the-media/2023/west-pokot-residents-benefit-from-free-medical-camp/) - ACCESS THE ARTICLE
- [Hundreds benefit from free medical camp for neglected diseases in West Pokot](https://dndi.org/in-the-media/2023/hundreds-benefit-from-free-medical-camp-for-neglected-diseases-in-west-pokot/) - ACCESS THE ARTICLE
- [Mamia Ya Wakazi Katika Maeneo Makavu Ya Kaunti Ya West Pokot Wamepokea Matibabu Ya Bila Malipo](https://dndi.org/in-the-media/2023/mamia-ya-wakazi-katika-maeneo-makavu-ya-kaunti-ya-west-pokot-wamepokea-matibabu-ya-bila-malipo/) - ACCESS THE ARTICLE
- ['The power of open innovation for drug discovery': COVID-19 Moonshot pioneers share their story](https://dndi.org/in-the-media/2023/the-power-of-open-innovation-for-drug-discovery-covid-19-moonshot-pioneers-share-their-story/) - ACCESS THE ARTICLE
- [Medicine for the most neglected](https://dndi.org/in-the-media/2023/medicine-for-the-most-neglected/) - ACCESS THE ARTICLE
- [O aquecimento global contribuiu para o aumento de doenças](https://dndi.org/in-the-media/2023/o-aquecimento-global-contribuiu-para-o-aumento-de-doencas/) - ACCESS THE ARTICLE
- [Ellos se ocultan, el mundo les olvida](https://dndi.org/in-the-media/2023/ellos-se-ocultan-el-mundo-les-olvida/) - ACCESS THE ARTICLE
- [Medikament für ärmste Kranke der Welt gefunden](https://dndi.org/in-the-media/2023/medikament-fur-armste-kranke-der-welt-gefunden/) - ACCESS THE ARTICLE
- [“Sin ingenio y humanidad el dinero no sirve para nada”](https://dndi.org/in-the-media/2023/sin-ingenio-y-humanidad-el-dinero-no-sirve-para-nada/) - ACCESS THE ARTICLE
- [Cheap over-the-counter nail drug found to work on crippling flesh-eating disease](https://dndi.org/in-the-media/2023/cheap-over-the-counter-nail-drug-found-to-work-on-crippling-flesh-eating-disease/) - ACCESS THE ARTICLE
- [Flesh-eating disease leading to amputation gets treatment hope](https://dndi.org/in-the-media/2023/flesh-eating-disease-leading-to-amputation-gets-treatment-hope/) - ACCESS THE ARTICLE
- [Sudan could be winning war against mycetoma cases](https://dndi.org/in-the-media/2023/sudan-could-be-winning-war-against-mycetoma-cases/) - ACCESS THE ARTICLE
- [Utafiti wa tiba ya ugonjwa wa Madura Foot](https://dndi.org/in-the-media/2023/utafiti-wa-tiba-ya-ugonjwa-wa-madura-foot/) - ACCESS THE ARTICLE
- [DNDi's briefing note for 76<sup>th</sup> World Health Assembly](https://dndi.org/statements/2023/briefing-note-76th-world-health-assembly/) - This briefing sets out DNDi's comments for considerations by WHO Member States on agenda items covering strategy for women’s, children’s and adolescents’ health, universal health coverage, preparedness and response for health emergencies, and WHO global strategy on health, environment and climate change.
- [DNDi@20 charity run shines the spotlight on neglected diseases in Kenya](https://dndi.org/news/2023/dndi-20-years-racing-against-neglect/) - On Saturday, 18 November, over 1,000 people joined DNDi and our partners in a charity run to mobilize support for neglected patients and raise awareness about neglected diseases.
- [코오롱생명과학, 국제 소외질환신약개발재단과 ‘회선사상충’ 개발 협약](https://dndi.org/in-the-media/2023/코오롱생명과학-국제-소외질환신약개발재단과/) - ACCESS THE ARTICLE
- [DNDi, 소외계층 신약 개발 파트너로 코오롱생명과학 택한 이유는](https://dndi.org/in-the-media/2023/dndi-소외계층-신약-개발-파트너로-코오롱생명과학-택한/) - ACCESS THE ARTICLE
- [Covid Moonshot yields novel coronavirus antivirals](https://dndi.org/in-the-media/2023/covid-moonshot-yields-novel-coronavirus-antivirals/) - ACCESS THE ARTICLE
- [Il est difficile de garder les maladies tropicales négligées à l’agenda politique](https://dndi.org/in-the-media/2023/il-est-difficile-de-garder-les-maladies-tropicales-negligees-a-lagenda-politique/) - ACCESS THE ARTICLE
- [Maladie du sommeil : l’élimination d’un fléau à portée de main](https://dndi.org/in-the-media/2023/maladie-du-sommeil-lelimination-dun-fleau-a-portee-de-main/) - ACCESS THE ARTICLE
- [DNDi: 20 years of delivering treatments for neglected patients](https://dndi.org/viewpoints/2023/dndi-20-years-of-delivering-treatments-for-neglected-patients/) - By MSF Access Campaign It is often said that Innovation and Access are two sides to the same coin when it comes to ensuring that people in developing countries are able to get the healthcare products they need to stay alive and well. And it is through the lens of these two complementary activities that
- [India committed to eliminate Lymphatic Filariasis by 2027: All you need to know](https://dndi.org/in-the-media/2023/india-committed-to-eliminate-lymphatic-filariasis-by-2027-all-you-need-to-know/) - ACCESS THE ARTICLE
- [How open-source drug discovery could help us in the next pandemic](https://dndi.org/in-the-media/2023/how-open-source-drug-discovery-could-help-us-in-the-next-pandemic/) - ACCESS THE ARTICLE
- [Seventh meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response](https://dndi.org/statements/2023/7th-meeting-inb-for-who-instrument-on-pandemic-prevention-preparedness-and-response/) - DNDi's comment on Article 9 Negotiating Text and oral statement given at INB7.
- [Dr Luis Pizarro, director ejecutivo de la DNDi y premio Princesa de Asturias por cooperación internacional: 'Son las personas las que son desatendidas'](https://dndi.org/in-the-media/2023/dr-luis-pizarro-director-ejecutivo-de-la-dndi-y-premio-princesa-de-asturias-por-cooperacion-internacional-son-las-personas-las-que-son-desatendidas/) - ACCESS THE ARTICLE
- [Quién es Luis Pizarro, el médico chileno que recibió el Premio Princesa de Asturias junto a Meryl Streep y Murakami](https://dndi.org/in-the-media/2023/quien-es-luis-pizarro-el-medico-chileno-que-recibio-el-premio-princesa-de-asturias-junto-a-meryl-streep-y-murakami/) - ACCESS THE ARTICLE
- [InfoLEISH 7<sup>th</sup> edition](https://dndi.org/publications/2023/infoleish-7th-edition/) - InfoLEISH, the redeLEISH newsletter, reports on the latest research on leishmaniasis in Latin America.
- [Médico chileno recibió Premios Princesa de Asturias 2023](https://dndi.org/in-the-media/2023/medico-chileno-recibio-premios-princesa-de-asturias-2023/) - ACCESS THE ARTICLE
- [Premio Princesa de Cooperación: el avance de las infecciones impulsará la investigación](https://dndi.org/in-the-media/2023/premio-princesa-de-cooperacion-el-avance-de-las-infecciones-impulsara-la-investigacion-2/) - ACCESS THE ARTICLE
- [Hora de olhar para as doenças negligenciadas](https://dndi.org/in-the-media/2023/hora-de-olhar-para-as-doencas-negligenciadas/) - ACCESS THE ARTICLE
- [Orgullo nacional: Médico chileno recibió 'Premio Princesa de Asturias' por ayudar a los más pobres](https://dndi.org/in-the-media/2023/orgullo-nacional-medico-chileno-recibio-premio-princesa-de-asturias-por-ayudar-a-los-mas-pobres/) - ACCESS THE ARTICLE
- [Avanços na descoberta de medicamentos para doenças negligenciadas em áreas endêmicas](https://dndi.org/in-the-media/2023/avancos-na-descoberta-de-medicamentos-para-doencas-negligenciadas-em-areas-endemicas/) - ACCESS THE ARTICLE
- [O que são as doenças negligenciadas?](https://dndi.org/in-the-media/2023/o-que-sao-as-doencas-negligenciadas/) - ACCESS THE ARTICLE
- [Evento em Campinas marca apoio à ciência latino-americana contra doenças negligenciadas](https://dndi.org/in-the-media/2023/evento-em-campinas-marca-apoio-a-ciencia-latino-americana-contra-doencas-negligenciadas/) - ACCESS THE ARTICLE
- [ONG dirigida por chileno recibe Premio Princesa de Asturias](https://dndi.org/in-the-media/2023/ong-dirigida-por-chileno-recibe-premio-princesa-de-asturias/) - ACCESS THE ARTICLE
- [Enfermedades que no le interesan a la industria farmacéutica - Dr. Sergio Sosa en #ciudadu](https://dndi.org/in-the-media/2023/enfermedades-que-no-le-interesan-a-la-industria-farmaceutica-dr-sergio-sosa-en-ciudadu/) - ACCESS THE ARTICLE
- [Médico chileno recibió Premio Princesa de Asturias: desarrolla tratamientos a enfermedades desatendidas](https://dndi.org/in-the-media/2023/medico-chileno-recibio-premio-princesa-de-asturias-desarrolla-tratamientos-a-enfermedades-desatendidas/) - ACCESS THE ARTICLE
- [Luis Pizarro, el médico chileno de las enfermedades olvidadas: 'Con cambio climático y migración, estos males van a estar más presentes'](https://dndi.org/in-the-media/2023/luis-pizarro-el-medico-chileno-de-las-enfermedades-olvidadas-con-cambio-climatico-y-migracion-estos-males-van-a-estar-mas-presentes/) - ACCESS THE ARTICLE
- [Discours d'acceptation, Dr. Luis Pizarro – Cérémonie de remise de prix Princesse des Asturies 2023](https://dndi.org/news-translations/2023/discours-dacceptation-dr-luis-pizarro-ceremonie-de-remise-de-prix-princesse-des-asturies-2023/) - Français English Español Français regarder le discours « Vos Majestés, Vos Altesses Royales, distingués membres du jury, excellentissimes lauréats, très illustres autorités, Mesdames et Messieurs, Pour vous dire la vérité, dans un monde idéal, je ne devrais pas être ici aujourd’hui avec vous. En effet, dans un monde idéal, aucun patient ne serait négligé, et
- [Discurso de recepción, Dr. Luis Pizarro – Ceremonia de entrega de los Premios Princesa de Asturias 2023](https://dndi.org/news-translations/2023/discurso-recepcion-dr-luis-pizarro-ceremonia-de-entrega-de-los-premios-princesa-de-asturias-2023/) - Español English Español Français Vea el discurso del Dr. Luis Pizarro "Majestades, altezas reales, distinguidos miembros del jurado, excelentísimos premiados, ilustrísimas autoridades, damas y caballeros, Para ser sincero, en un mundo ideal, no debería estar hoy aquí con ustedes. Y claro, en un mundo ideal, ningún paciente sería ignorado y DNDi no tendría razón de
- [Inovação nas universidades: a saída contra doenças negligenciadas](https://dndi.org/viewpoints/2023/inovacao-nas-universidades-a-saida-contra-doencas-negligenciadas/) - By Jadel Kratz, Head of Discovery and R&D Partnership, Latin America, DNDi and Luiz Carlos Dias, Professor Titular - Instituto de Química, Universidade Estadual de Campinas (Unicamp) First published in The Conversation on 17 October 2023 Algumas enfermidades tropicais, como a doença de Chagas e as leishmanioses, afetam milhões de pessoas ao redor do mundo. Os tratamentos disponíveis são muito
- [Chileno, al recibir Premio Princesa de Asturias, pone el foco en los olvidados](https://dndi.org/in-the-media/2023/chileno-al-recibir-premio-princesa-de-asturias-pone-el-foco-en-los-olvidados-2/)
- [Organización liberada por médico chileno gana Premio Princesa de Asturias](https://dndi.org/in-the-media/2023/organizacion-liberada-por-medico-chileno-gana-premio-princesa-de-asturias/) - ACCESS THE ARTICLE
- [¿Quién es el chileno que recibió el prestigioso Premio Princessa de Asturias este año?](https://dndi.org/in-the-media/2023/quien-es-el-chileno-que-recibio-el-prestigioso-premio-princessa-de-asturias-este-ano/) - ACCESS THE ARTICLE
- [Chileno, al recibir Premio Princesa de Asturias, pone el foco en los olvidados](https://dndi.org/in-the-media/2023/chileno-al-recibir-premio-princesa-de-asturias-pone-el-foco-en-los-olvidados/) - ACCESS THE ARTICLE
- ['Son ignorados por la investigación farmacéutica por ser demasiado pobres': el emotivo discurso de médico chileno en España](https://dndi.org/in-the-media/2023/son-ignorados-por-la-investigacion-farmaceutica-por-ser-demasiado-pobres-el-emotivo-discurso-de-medico-chileno-en-espana/) - ACCESS THE ARTICLE
- [Neglected tropical diseases go global](https://dndi.org/in-the-media/2023/neglected-tropical-diseases-go-global/) - ACCESS THE ARTICLE
- [El cambio climático traerá a España enfermedades como el Chagas, advierte la DNDi](https://dndi.org/in-the-media/2023/el-cambio-climatico-traera-a-espana-enfermedades-como-el-chagas-advierte-la-dndi-2/) - ACCESS THE ARTICLE
- [Los Premios Princesa de Asturias 2023, los más vistos desde 2010 en RTVE con casi 1,3 millones de espectadores](https://dndi.org/in-the-media/2023/los-premios-princesa-de-asturias-2023-los-mas-vistos-desde-2010-en-rtve-con-casi-13-millones-de-espectadores/) - ACCESS THE ARTICLE
- [Oviedo empieza a recibir mañana a los galardonados con los Premios Princesa](https://dndi.org/in-the-media/2023/oviedo-empieza-a-recibir-manana-a-los-galardonados-con-los-premios-princesa/) - ACCESS THE ARTICLE
- [Premio Princesa de Asturias: una ONG dedicada a las enfermedades 'desatendidas' recibe importante galardón](https://dndi.org/in-the-media/2023/premio-princesa-de-asturias-una-ong-dedicada-a-las-enfermedades-desatendidas-recibe-importante-galardon/) - ACCESS THE ARTICLE
- [Premio Princesa de Asturias para la DNDi (enfermedades desatendidas)](https://dndi.org/in-the-media/2023/premio-princesa-de-asturias-para-la-dndi-enfermedades-desatendidas/) - ACCESS THE ARTICLE
- [El Chagas será en unos años la primera causa de transplante cardiaco en España, advierten desde DNDi](https://dndi.org/in-the-media/2023/el-chagas-sera-en-unos-anos-la-primera-causa-de-transplante-cardiaco-en-espana-advierten-desde-dndi-4/) - ACCESS THE ARTICLE
- [Pizarro (DNDi) resalta la importancia de ayudar a los 'olvidados por la investigación tradicional'](https://dndi.org/in-the-media/2023/pizarro-dndi-resalta-la-importancia-de-ayudar-a-los-olvidados-por-la-investigacion-tradicional-3/) - ACCESS THE ARTICLE
- [Pizarro (DNDi) resalta la importancia de ayudar a los 'olvidados por la investigación tradicional'](https://dndi.org/in-the-media/2023/pizarro-dndi-resalta-la-importancia-de-ayudar-a-los-olvidados-por-la-investigacion-tradicional-2/) - ACCESS THE ARTICLE
- [Pizarro, en los Princesa de Asturias: 'Son ignorados por la investigación porque son demasiado pobres'](https://dndi.org/in-the-media/2023/pizarro-en-los-princesa-de-asturias-son-ignorados-por-la-investigacion-porque-son-demasiado-pobres/) - ACCESS THE ARTICLE
- [Luis Pizarro: «Si nuestros pacientes se ven privados de los avances de la investigación médica es porque nacieron en el lugar equivocado»](https://dndi.org/in-the-media/2023/luis-pizarro-si-nuestros-pacientes-se-ven-privados-de-los-avances-de-la-investigacion-medica-es-porque-nacieron-en-el-lugar-equivocado/) - ACCESS THE ARTICLE
- [Pizarro reclama a la comunidad científica que anteponga los pacientes al lucro](https://dndi.org/in-the-media/2023/pizarro-reclama-a-la-comunidad-cientifica-que-anteponga-los-pacientes-al-lucro/) - ACCESS THE ARTICLE
- [Pizarro (DNDi) resalta la importancia de ayudar a los 'olvidados por la investigación tradicional'](https://dndi.org/in-the-media/2023/pizarro-dndi-resalta-la-importancia-de-ayudar-a-los-olvidados-por-la-investigacion-tradicional/) - ACCESS THE ARTICLE
- [Spaniens „Nobelpreise“: Meryl Streep und Kinderhilfswerk Mary’s Meal ausgezeichnet](https://dndi.org/in-the-media/2023/spaniens-nobelpreise-meryl-streep-und-kinderhilfswerk-marys-meal-ausgezeichnet/) - ACCESS THE ARTICLE
- [Dr Kavita Singh: ‘Climate change is altering patterns for dengue fever and other diseases. Before, we didn’t have as many cases, or as many deaths’](https://dndi.org/in-the-media/2023/dr-kavita-singh-climate-change-is-altering-patterns-for-dengue-fever-and-other-diseases-before-we-didnt-have-as-many-cases-or-as-many-deaths/) - ACCESS THE ARTICLE
- [Quijotes](https://dndi.org/in-the-media/2023/quijotes/) - ACCESS THE ARTICLE
- [Discurso Princesa de Asturias de Cooperación Internacional](https://dndi.org/in-the-media/2023/discurso-princesa-de-asturias-de-cooperacion-internacional/) - ACCESS THE ARTICLE
- [AECID se compromete a colaborar en la lucha contra las enfermedades olvidadas](https://dndi.org/in-the-media/2023/aecid-se-compromete-a-colaborar-en-la-lucha-contra-las-enfermedades-olvidadas/) - ACCESS THE ARTICLE
- [Luis Pizarro: «Esperamos eliminar la enfermedad del sueño en 2030»](https://dndi.org/in-the-media/2023/luis-pizarro-esperamos-eliminar-la-enfermedad-del-sueno-en-2030/) - ACCESS THE ARTICLE
- [Las mañanas de RNE con Iñigo Alfonso](https://dndi.org/in-the-media/2023/las-mananas-de-rne-con-inigo-alfonso/) - ACCESS THE ARTICLE
- [Interview of Dr Luis Pizarro about the Princess of Asturias Award](https://dndi.org/in-the-media/2023/interview-of-dr-luis-pizarro-about-the-princess-of-asturias-award/) - ACCESS THE ARTICLE
- [Princesa de Asturias reconoce a gente extraordinaria](https://dndi.org/in-the-media/2023/princesa-de-asturias-reconoce-a-gente-extraordinaria/) - ACCESS THE ARTICLE
- [Drugs for Neglected Diseases Initiative earns prestigious Princess of Asturias award](https://dndi.org/in-the-media/2023/drugs-for-neglected-diseases-initiative-earns-prestigious-princess-of-asturias-award/) - ACCESS THE ARTICLE
- [Meryl Streep mit Asturien-Preis geehrt](https://dndi.org/in-the-media/2023/meryl-streep-mit-asturien-preis-geehrt/) - ACCESS The article
- [Luis Pizarro, Princesa de Asturias de Cooperación: 'Son pacientes ignorados porque no hay mercado lucrativo'](https://dndi.org/in-the-media/2023/luis-pizarro-princesa-de-asturias-de-cooperacion-son-pacientes-ignorados-porque-no-hay-mercado-lucrativo/) - ACCESS THE ARTICLE
- [Dr Luis Pizarro: 'Son enfermos olvidados y enfermos pobres'](https://dndi.org/in-the-media/2023/dr-luis-pizarro-son-enfermos-olvidados-y-enfermos-pobres/) - ACCESS THE ARTICLE
- ['Las enfermedades desatendidas afectan a personas pobres'](https://dndi.org/in-the-media/2023/las-enfermedades-desatendidas-afectan-a-personas-pobres/) - ACCESS THE ARTICLE
- [Kavita Singh, científica india: 'Los patrones del dengue y otras enfermedades se ven alterados por el cambio climático. Antes no teníamos ni tantos casos ni tantos muertos'](https://dndi.org/in-the-media/2023/kavita-singh-cientifica-india-los-patrones-del-dengue-y-otras-enfermedades-se-ven-alterados-por-el-cambio-climatico-antes-no-teniamos-ni-tantos-casos-ni-tantos-muertos/) - ACCESS THE ARTICLE
- [«Muchas enfermedades que tratamos cruzan fronteras»](https://dndi.org/in-the-media/2023/muchas-enfermedades-que-tratamos-cruzan-fronteras/) - ACCESS THE ARTICLE
- [El Chagas será en unos años la primera causa de transplante cardiaco en España, advierten desde DNDi](https://dndi.org/in-the-media/2023/el-chagas-sera-en-unos-anos-la-primera-causa-de-transplante-cardiaco-en-espana-advierten-desde-dndi-3/) - ACCESS THE ARTICLE
- [El Chagas será en unos años la primera causa de transplante cardiaco en España, advierten desde DNDi](https://dndi.org/in-the-media/2023/el-chagas-sera-en-unos-anos-la-primera-causa-de-transplante-cardiaco-en-espana-advierten-desde-dndi-2/) - ACCESS THE ARTICLE
- [El Chagas será en unos años la primera causa de transplante cardiaco en España, advierten desde DNDi](https://dndi.org/in-the-media/2023/el-chagas-sera-en-unos-anos-la-primera-causa-de-transplante-cardiaco-en-espana-advierten-desde-dndi/) - ACCESS THE ARTICLE
- ['En un futuro cercano, el Chagas se convertirá en la principal razón por la cual se necesitarán trasplantes de corazón en España, según DNDi.'](https://dndi.org/in-the-media/2023/en-un-futuro-cercano-el-chagas-se-convertira-en-la-principal-razon-por-la-cual-se-necesitaran-trasplantes-de-corazon-en-espana-segun-dndi/) - ACCESS THE ARTICLE
- [Pizarro, a los políticos asturianos: 'Tomen decisiones para investigar enfermedades desatendidas'](https://dndi.org/in-the-media/2023/pizarro-a-los-politicos-asturianos-tomen-decisiones-para-investigar-enfermedades-desatendidas/) - ACCESS THE ARTICLE
- [El cambio climático traerá a España enfermedades como el Chagas, advierte la DNDi](https://dndi.org/in-the-media/2023/el-cambio-climatico-traera-a-espana-enfermedades-como-el-chagas-advierte-la-dndi/) - ACCESS THE ARTICLE
- [Jorge Alvar, médico: «Nuestro modelo funciona. Hemos desarrollado 12 medicamentos y tendremos otros 15 en 2030»](https://dndi.org/in-the-media/2023/jorge-alvar-medico-nuestro-modelo-funciona-hemos-desarrollado-12-medicamentos-y-tendremos-otros-15-en-2030/) - ACCESS THE ARTICLE
- [Pizarro destaca en la Junta «la importancia de las decisiones políticas en la investigación»](https://dndi.org/in-the-media/2023/pizarro-destaca-en-la-junta-la-importancia-de-las-decisiones-politicas-en-la-investigacion/) - ACCESS THE ARTICLE
- [Luis Pizarro: "Este galardón es el mejor altavoz para hacer visibles a las personas con enfermedades que a nadie interesan"](https://dndi.org/in-the-media/2023/luis-pizarro-este-galardon-es-el-mejor-altavoz-para-hacer-visibles-a-las-personas-con-enfermedades-que-a-nadie-interesan/) - ACCESS THE ARTICLE
- [Luis Pizarro agradece este «gran altavoz»](https://dndi.org/in-the-media/2023/luis-pizarro-agradece-este-gran-altavoz/) - ACCESS THE ARTICLE
- ['Los políticos deben poner reglas para que la distribución de la ciencia sea equitativa'](https://dndi.org/in-the-media/2023/los-politicos-deben-poner-reglas-para-que-la-distribucion-de-la-ciencia-sea-equitativa/) - ACCESS THE ARTICLE
- [Pizarro: 'El Premio Princesa es un gran altavoz para las enfermedades desatendidas'](https://dndi.org/in-the-media/2023/pizarro-el-premio-princesa-es-un-gran-altavoz-para-las-enfermedades-desatendidas/) - ACCESS THE ARTICLE
- [Fears grow that new pandemic treaty won’t correct COVID mistakes](https://dndi.org/in-the-media/2023/fears-grow-that-new-pandemic-treaty-wont-correct-covid-mistakes/)
- [La Iniciativa para las Enfermedades Desatendidas, explicada en teatro](https://dndi.org/in-the-media/2023/la-iniciativa-para-las-enfermedades-desatendidas-explicada-en-teatro/) - ACCESS THE ARTICLE
- [Pizarro, premio 'Princesa' de Cooperación Internacional 2023: 'Estos premios para las enfermedades desatendidas son un gran altavoz'](https://dndi.org/in-the-media/2023/pizarro-premio-princesa-de-cooperacion-internacional-2023-estos-premios-para-las-enfermedades-desatendidas-son-un-gran-altavoz/) - ACCESS THE ARTICLE
- [Pizarro: 'El premio Princesa de Asturias es un gran altavoz para visibilizar las enfermedades olvidadas'](https://dndi.org/in-the-media/2023/pizarro-el-premio-princesa-de-asturias-es-un-gran-altavoz-para-visibilizar-las-enfermedades-olvidadas/) - ACCESS THE ARTICLE
- [Draft pandemic accord: IP waivers and benefits for sharing pathogen information are in – for now](https://dndi.org/in-the-media/2023/draft-pandemic-accord-ip-waivers-and-benefits-for-sharing-pathogen-information-are-in-for-now/) - ACCESS THE ARTICLE
- [Les drapeaux de DNDi flottent sur le pont du Mont-Blanc à Genève à l’occasion de notre 20ème anniversaire](https://dndi.org/news-translations/2023/les-drapeaux-de-dndi-flottent-sur-le-pont-du-mont-blanc-a-geneve-a-loccasion-de-notre-20eme-anniversaire/) - Du 16 au 22 octobre, le pont du Mont-Blanc à Genève sera orné de drapeaux DNDi à l’occasion de nos 20 ans d’existence pour fournir le meilleur de la science pour les plus négligés.
- [DNDi 20th anniversary flags fly on Geneva’s Mont-Blanc bridge](https://dndi.org/news/2023/dndi-20th-anniversary-flags-fly-on-genevas-mont-blanc-bridge/) - From 16-22 October, Geneva’s Mont-Blanc bridge will be adorned with flags commemorating DNDi’s 20th year of delivering the best science for the most neglected.
- [La DNDi firma un memorando de entendimiento con la Agencia Española de Cooperación Internacional para el Desarrollo](https://dndi.org/press-releases-translations/2023/la-dndi-firma-un-memorando-de-entendimiento-con-la-agencia-espanola-de-cooperacion-internacional-para-el-desarrollo/) - Con el compromiso mutuo de incentivar la investigación y el desarrollo, la DNDi y la AECID buscan innovar y acceder a nuevas herramientas de salud para las enfermedades tropicales desatendidas (o ETD) y otras enfermedades infecciosas que afectan a poblaciones vulnerables.
- [DNDi signs memorandum of understanding with Spanish Agency for International Development Cooperation](https://dndi.org/press-releases/2023/dndi-signs-memorandum-of-understanding-with-spanish-agency-for-international-development-cooperation/) - DNDi and AECID share a commitment to strengthen research and development for innovation and access to new health tools for neglected tropical diseases and other infectious diseases affecting vulnerable populations.
- [DNDi recibe el Premio Princesa de Asturias de Cooperación Internacional 2023](https://dndi.org/press-releases-translations/2023/dndi-recibe-el-premio-princesa-de-asturias-de-cooperacion-internacional-2023/) - El galardón, el más prestigioso de España, brinda la tan necesaria visibilidad a millones de personas desatendidas por los responsables de políticas públicas y la investigación farmacéutica con fines comerciales.
- [DNDi receives 2023 Princess of Asturias Award for International Cooperation](https://dndi.org/press-releases/2023/dndi-receives-2023-princess-asturias-award-for-international-cooperation/) - The award, the most prestigious in Spain, gives much-needed visibility to millions of people neglected by policymakers and commercially driven pharmaceutical research.
- [Fiocruz signs agreement to register hepatitis C medication with Brazilian health regulatory agency](https://dndi.org/press-releases/2023/fiocruz-signs-agreement-register-hepatitis-c-medication-brazilian-health-regulatory-agency/) - This announcement is a milestone in Brazil’s efforts to achieve the World Health Organization (WHO) goal to eliminate hepatitis C by 2030.
- [Chagas Platform Newsletter N°13](https://dndi.org/publications/2023/chagas-platform-newsletter-n13/) - The Chagas Platform newsletter reports on the platform's recent activities and latest research on Chagas disease in Latin America.
- [2022 Activity Report Latin America](https://dndi.org/publications/2023/2022-activity-report-latin-america/) - Português Español
- [Acoziborole : l’étude d’un nouveau traitement, oral et à dose unique, suscite l'espoir d'éliminer la maladie du sommeil en Afrique](https://dndi.org/press-releases-translations/2022/acoziborole-etude-nouveau-traitement-oral-dose-unique-suscite-espoir-eliminer-la-maladie-du-sommeil-en-afrique/) - DNDi et Sanofi annoncent un taux de réussite allant jusqu'à 95 % d’un traitement de recherche, l’acoziborole, enregistré dans le cadre d'une étude de phase II/III portant sur la sécurité et l'efficacité de ce traitement à dose unique qui pourrait bien transformer la prise en charge de la maladie du sommeil.
- [DNDi: First oral drug for treating kala-azar to be ready by 2024](https://dndi.org/in-the-media/2023/dndi-first-oral-drug-for-treating-kala-azar-to-be-ready-by-2024/) - ACCESS THE ARTICLE
- [Ganar dinero no puede ser la única razón para decidir qué enfermedades se investigan](https://dndi.org/in-the-media/2023/ganar-dinero-no-puede-ser-la-unica-razon-para-decidir-que-enfermedades-se-investigan/) - ACCESS THE ARTICLE
- [New hope for leishmaniasis](https://dndi.org/publications/2022/new-hope-for-leishmaniasis/) - DNDi R&D and access programmes in focus
- [Tegla Loroupe named ambassador for neglected diseases race](https://dndi.org/in-the-media/2023/tegla-loroupe-named-ambassador-for-neglected-diseases-race/) - ACCESS THE ARTICLE
- [Mark Sullivan joins the DNDi Scientific Advisory Committee](https://dndi.org/news/2023/mark-sullivan-joins-the-dndi-scientific-advisory-committee/) - DNDi is pleased to announce the appointment of Mark Sullivan to the organization’s Scientific Advisory Committee.
- [Killer mosquitoes spreading deadly disease ‘setting up shop in Europe’](https://dndi.org/in-the-media/2023/killer-mosquitoes-spreading-deadly-disease-setting-up-shop-in-europe/) - ACCESS THE ARTICLE
- [Why dengue in Europe could spell disaster for the rest of the world](https://dndi.org/in-the-media/2023/why-dengue-in-europe-could-spell-disaster-for-the-rest-of-the-world/) - ACCESS THE ARTICLE
- [#Semasa: Great potential for Malaysia-Brazil to combat health challenges](https://dndi.org/in-the-media/2023/semasa-great-potential-for-malaysia-brazil-to-combat-health-challenges/) - ACCESS THE ARTICLE
- [DNDi's Centres of Excellence: Towards the sustainable elimination of visceral leishmaniasis in India](https://dndi.org/news/2023/dndi-centres-of-excellence-towards-sustainable-elimination-visceral-leishmaniasis-india/) - Providing diagnosis, treatment, and acting as focal points for managing complicated visceral leishmaniasis cases, the Centres of Excellence bring cutting-edge medical advances closer to the homes of people most at risk.
- [DNDi and Rotary collaborate to prevent and treat diseases affecting neglected communities in Eastern Africa](https://dndi.org/news/2023/dndi-and-rotary-collaborate-prevent-treat-diseases-affecting-neglected-communities-eastern-africa/) - On 29 August 2023, Rotary Kenya and DNDi signed a five-year agreement to collaborate on research and access activities that support the health needs of neglected patients and communities.
- [How India can put the spotlight back on neglected tropical diseases](https://dndi.org/in-the-media/2022/how-india-can-put-the-spotlight-back-on-neglected-tropical-diseases/) - Listen to the podcast
- [Climate change creates the perfect conditions for dengue to spread: Is fogging enough to beat that?](https://dndi.org/in-the-media/2022/climate-change-creates-the-perfect-conditions-for-dengue-to-spread-is-fogging-enough-to-beat-that/) - ACCESS THE ARTICLE
- [DND<em>i</em> interventions at the 148<sup>th</sup> session of the WHO Executive Board](https://dndi.org/statements/2021/dndi-interventions-at-148-session-who-executive-board/) - DNDi interventions on antimicrobial resistance and the global health sector strategies on HIV, viral hepatitis, and sexually transmitted infections
- [EU-African Union summit – Why we need to invest in clinical research infrastructure in Africa](https://dndi.org/viewpoints/2022/eu-african-union-summit-why-need-to-invest-clinical-research-infrastructure-africa/) - As European and African heads of state gather in Brussels to discuss deepening ties, we, as African and European scientists, believe another issue should feature high on the agenda: the development of robust clinical research infrastructure across the continent.
- [DND<i>i</i> intervention at the Intergovernmental Negotiating Body first round of public hearings](https://dndi.org/statements/2022/dndi-intervention-intergovernmental-negotiating-body-first-round-of-public-hearings/) - As a not-for-profit research and development organization, DNDi focuses these comments on how an international instrument can best ensure investment in, discovery, and development of, and equitable access to essential health tools as global public goods.
- [DND<i>i</i> intervention at the Intergovernmental Negotiating Body second round of public hearings](https://dndi.org/statements/2022/dndi-intervention-at-intergovernmental-negotiating-body-second-round-public-hearings/) - As a not-for-profit R&D organization, DNDi focuses these comments on how international agreement can ensure a fundamental shift in approach to avoid having to struggle for access to new health tools disease by disease, product by product, country by country.
- [DNDi interventions at the 152<sup>nd</sup> session of the WHO Executive Board](https://dndi.org/statements/2023/dndi-interventions-152-session-who-executive-board/) - During the 152nd session of the WHO Executive Board, DNDi gave interventions on Universal Health Coverage and public health emergencies (preparedness and response).
- [Publication demonstrates how equitable deals for access to medicines can be signed with pharmaceutical industry](https://dndi.org/press-releases/2023/publication-demonstrates-how-equitable-deals-for-access-to-medicines-can-be-signed-with-pharmaceutical-industry/) - DNDi publishes model contracts as new examples of how principles that secure access to medicines can be operationalized in R&D collaboration agreements.
- [Consider This: Public health - tackling dengue through collaboration](https://dndi.org/in-the-media/2023/consider-this-public-health-tackling-dengue-through-collaboration/) - ACCESS THE ARTICLE
- [Climate change a threat to health](https://dndi.org/in-the-media/2023/climate-change-a-threat-to-health/) - ACCESS THE ARTICLE
- [Silent killer disease known as 'sleeping sickness' - 4 key signs to look for](https://dndi.org/in-the-media/2023/silent-killer-disease-known-as-sleeping-sickness-4-key-signs-to-look-for/) - ACCESS THE ARTICLE
- [Un teléfono, inteligencia artificial y una pastilla para avanzar en la cura de la leishmaniasis visceral](https://dndi.org/in-the-media/2023/un-telefono-inteligencia-artificial-y-una-pastilla-para-avanzar-en-la-cura-de-la-leishmaniasis-visceral/) - ACCESS THE ARTICLE
- [In memoriam: Kamran Rafiq](https://dndi.org/news/2023/in-memoriam-kamran-rafiq/) - We are deeply saddened by the unexpected passing of Kamran Rafiq, co-founder of the International Society for Neglected Tropical Diseases and a tireless advocate for a world free of neglected tropical diseases.
- [Africa should bolster research into climate-sensitive diseases](https://dndi.org/in-the-media/2023/africa-should-bolster-research-into-climate-sensitive-diseases/) - ACCESS THE ARTICLE
- [Biotech leader Delali Attiogbe Attipoe joins DNDi as North America Director](https://dndi.org/press-releases/2023/biotech-leader-delali-attiogbe-attipoe-joins-dndi-north-america-director/) - Delali Attiogbe Attipoe, an accomplished global executive leader and board member within the biopharma and health sector, has joined the non-profit medical research organization DNDi as its North America Director.
- [La Société de Pathologie Exotique décerne sa Médaille d’Or à DND<em>i</em> pour son engagement contre les maladies négligées](https://dndi.org/press-releases-translations/2009/la-societe-de-pathologie-exotique-decerne-sa-medaille-dor-a-dndi/) - [ Paris, Genève - 23 juin 2008 ] A l’occasion de son Centenaire, célébré les 20 et 21 Juin 2008 à l’Institut Pasteur à Paris, la Société de Pathologie Exotique (SPE) a décerné sa Médaille d’Or à la Fondation Initiative Médicaments contre les Maladies Négligées (Drugs for Neglected Diseases initiative - DNDi). Marcel Tanner, Président du Conseil d’Administration de DNDi, a reçu cette distinction du Pr. Pierre Ambroise-Thomas, Président de la SPE. [English]
- [DND<em>i</em> Partners With Pharma, Biotech, Academia, Public Health Institutes & NGOs to Deliver Lifesaving Drugs](https://dndi.org/press-releases/2008/dndi-partners-with-pharma-biotech-academia-public-health-institutes-a-ngos-to-deliver-lifesaving-drugs/) - [ New York - June 23, 2008 ] More Than 150 Scientists and Researchers from Around the World Convene in New York to Mobilize R&D Resources for Neglected Diseases. [Français]
- [Coalition launched to accelerate research on the prevention and treatment of COVID-19 in low- and middle-income countries](https://dndi.org/press-releases/2020/coalition-launched-accelerate-research-covid19-low-middle-income-countries/) - 2 April 2020 A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings. The COVID-19 Clinical Research Coalition aims to accelerate desperately needed COVID-19 research in those areas where the virus could wreak havoc on already-fragile health systems and cause the greatest health impact on vulnerable populations.
- [DND<i>i</i> participates in the 2nd International Conference on Public Health in Africa](https://dndi.org/news/2022/dndi-participates-2nd-international-conference-on-public-health-africa/) - DNDi hosted the only side event at the conference on neglected tropical diseases (NTDs) titled NTDs in Africa: Why we must innovate and act now.
- [African researchers trained on science communication](https://dndi.org/news/2022/african-researchers-trained-on-science-communication/) - Fifteen scientists, researchers, and programme managers from nine African countries attended a virtual science communication workshop organized by DNDi.
- [Avancée « majeure » dans la lutte contre les maladies tropicales négligées](https://dndi.org/in-the-media/2023/avancee-majeure-dans-la-lutte-contre-les-maladies-tropicales-negligees/) - ACCESS THE ARTICLE
- [How climate change is changing dengue fever](https://dndi.org/in-the-media/2023/how-climate-change-is-changing-dengue-fever/) - ACCESS THE ARTICLE
- [The forgotten burden of paediatric Kala-azar](https://dndi.org/in-the-media/2023/the-forgotten-burden-of-paediatric-kala-azar/) - ACCESS THE ARTICLE
- [Dengue fever, chikungunya moving inland, say experts](https://dndi.org/in-the-media/2023/dengue-fever-chikungunya-moving-inland-say-experts/) - ACCESS THE ARTICLE
- [A global dengue coalition to deliver treatment within 5 years: Lancet comment](https://dndi.org/in-the-media/2023/a-global-dengue-coalition-to-deliver-treatment-within-5-years-lancet-comment/) - ACCESS THE ARTICLE
- [Dengue Alliance sets goal to deliver treatment within 5 years](https://dndi.org/in-the-media/2023/dengue-alliance-sets-goal-to-deliver-treatment-within-5-years/) - ACCESS THE ARTICLE
- [Germany’s Federal Ministry of Education and Research (BMBF) grants funding to advance the fight against poverty-related and neglected tropical diseases](https://dndi.org/news/2023/germanys-federal-ministry-of-education-and-research-bmbf-grants-funding-advance-fight-against-poverty-related-neglected-tropical-diseases/) - This funding for 2023-2028 continues the German government's ongoing support of product development partnerships, which began in 2011.
- [Responding to COVID-19](https://dndi.org/news/2020/responding-to-covid-19/) - The majority of COVID-19 research studies are taking place in high-income countries. DNDi is mobilizing its networks to help protect vulnerable communities in resource-limited settings.
- [Global coalition to accelerate COVID-19 clinical research in resource-limited settings](https://dndi.org/scientific-articles/2020/lancet-global-coalition-accelerate-covid19-research-resource-limited-settings/) - by COVID-19 Clinical Research Coalition. The Lancet, April 2020
- [How best to prevent and treat COVID-19 in resource-limited settings?](https://dndi.org/viewpoints/2020/how-best-prevent-treat-covid19-resource-limited-settings-by-bernard-pecoul/) - Viewpoint by Dr Bernard Pécoul, Executive Director, DNDi
- [Priorities for COVID-19 research response and preparedness in low-resource settings](https://dndi.org/scientific-articles/2021/priorities-for-covid-19-research-response-and-preparedness-in-low-resource-settings/) - by The GloPID-R, UKCDR, and COVID-19 Clinical Research Coalition Cross-Working Group on COVID-19 Research in LMICs. The Lancet 2021. doi: 10.1016/S0140-6736(21)00980-6 Summary: This Comment highlights the findings of a two-day meeting entitled “COVID-19 Research in Low- and Middle-income Countries”, which was organized by the COVID CIRCLE funders group (comprising UKCDR and GloPID-R) and the COVID-19
- [Global COVID-19 research agenda still missing the priorities of low- and middle-income countries](https://dndi.org/press-releases/2021/global-covid-19-research-agenda-still-missing-priorities-low-middle-income-countries/) - An article published today in The Lancet calls for urgent collaboration and coordination for unmet, underfunded COVID-19 research priorities in low-resource settings.
- [Reboot biomedical R&D in the global public interest](https://dndi.org/scientific-articles/2022/reboot-biomedical-rd-in-the-global-public-interest/) - by Swaminathan S, Pécoul B, Abdullah H, Christou C, Gray G, IJsselmuiden C, Kieny M-P, Mazzucato M, von Messling V, Ogutu B, Reeder J, Røttingen J-A, Swarup R, Tanner M, Lima NT, Childs M, Harris A, Torreele E, Moon S. Nature 2022;602:207-210 doi: https://doi.org/10.1038/d41586-022-00324-y Summary: Challenges in ensuring global, equitable access to the fruits of
- [Launch of first platform for emergency research preparedness and response in Africa](https://dndi.org/press-releases/2022/launch-of-first-platform-for-emergency-research-preparedness-and-response-in-africa/) - PANTHER will pounce on pandemics in remote, at-risk areas before they break.
- [Mycetoma stories: Neg Eldin El Albagir](https://dndi.org/videos/2023/mycetoma-stories-neg-eldin-el-albagir/) - Nagim Mohammed, narrates the story of his brother Neg Eldin El Albagir. Albagir is a 35-year-old man from El Rawashad village in El Gaziera State, Sudan. The village has reported many cases of mycetoma. He developed mycetoma on his left foot 20 years ago and 5 years later he developed mycetoma on his right foot. He has a disability and cannot express his feelings. Mycetoma exacerbates his condition. He underwent below-knee amputation of the left foot and still has right foot mycetoma.
- [Mycetoma stories: Mohammed El Safi](https://dndi.org/videos/2023/mycetoma-stories-mohammed-el-safi/) - Mohammed El Safi is a musician who lives in Khartoum, Sudan. His experience with mycetoma started several years ago, during his traditional wedding ceremony preparation, when his sister noted a small painless mass between his toes. She asked him to consult a doctor. Because it was not painful, he ignored it. The mass gradually increased, until he visited the Mycetoma Research Centre. However, he was not regular with the follow-up and treatment. When he eventually went back for treatment, an amputation had to be carried out as the only treatment option.
- [Prof. Fahal On The 20 Years of Innovating Together In Helping Mycetoma Patients](https://dndi.org/videos/2023/prof-fahal-on-the-20-years-of-innovating-together-in-helping-mycetoma-patients/) - Professor Ahmed Hassan Fahal MBBS, FRCS, FRCSI, FRCS (Glas), FRCP (London), a Professor of Surgery at The Mycetoma Research Centre, University of Khartoum, Sudan, congratulates DNDi for 20 years of partnership in helping mycetoma patients in Sudan.
- [El Faro](https://dndi.org/in-the-media/2023/tropical/) - ACCESS THE ARTICLE
- [A drug development model for the diseases the world forgot](https://dndi.org/in-the-media/2023/a-drug-development-model-for-the-diseases-the-world-forgot/) - ACCESS THE ARTICLE
- [Essais cliniques : vers un code de bonne conduite pour le recours aux volontaires sains](https://dndi.org/in-the-media/2023/clinical-trials-towards-a-code-of-conduct-for-the-use-of-healthy-volunteers/) - ACCESS THE ARTICLE
- [Will 2023 be the year of dengue?](https://dndi.org/in-the-media/2023/will-2023-be-the-year-of-dengue/) - ACCESS THE ARTICLE
- [Gender bites: Rising dengue cases in India are putting pregnant women at risk](https://dndi.org/in-the-media/2023/gender-bites-rising-dengue-cases-in-india-are-putting-pregnant-women-at-risk/) - ACCESS THE ARTICLE
- [WHO publish fungal priority pathogens list](https://dndi.org/in-the-media/2023/who-publish-fungal-priority-pathogens-list/) - ACCESS THE ARTICLE
- [‘The silent disease’: Chagas is a killer. Now carriers want their voices heard](https://dndi.org/in-the-media/2023/the-silent-disease-chagas-is-a-killer-now-carriers-want-their-voices-heard/) - ACCESS THE ARTICLE
- [Experten plädieren für mehr Forschung zu vernachlässigten Tropenkrankheiten](https://dndi.org/in-the-media/2023/experten-pladieren-fur-mehr-forschung-zu-vernachlassigten-tropenkrankheiten/) - ACCESS THE ARTICLE
- [Eliminating neglected diseases in Africa: there are good reasons for hope](https://dndi.org/in-the-media/2023/eliminating-neglected-diseases-in-africa-there-are-good-reasons-for-hope/) - ACCESS THE ARTICLE
- [Trusting relationships with partners hold the key to NTDs therapeutic drug development ー Mr. Tatsuro Kuzuki, DNDi Japan](https://dndi.org/in-the-media/2023/trusting-relationships-with-partners-hold-the-key-to-ntds-therapeutic-drug-development-ー-mr-tatsuro-kuzuki-dndi-japan/) - ACCESS THE ARTICLE
- [La importancia de atender las enfermedades que están en el olvido](https://dndi.org/in-the-media/2023/la-importancia-de-atender-las-enfermedades-que-estan-en-el-olvido/) - ACCESS THE ARTICLE
- [Right time to take a stab at innovations to sustain kala-azar elimination](https://dndi.org/in-the-media/2023/neglect-at-your-own-peril/) - ACCESS THE ARTICLE
- [Doenças negligenciadas: Ação busca conscientizar a população](https://dndi.org/in-the-media/2023/doencas-negligenciadas-acao-busca-conscientizar-a-populacao/) - watch the recording
- [Maladie du sommeil en RDC : réduction de cas de 6.000 en à 510 en 10 ans](https://dndi.org/in-the-media/2023/maladie-du-sommeil-en-rdc-reduction-de-cas-de-6-000-en-a-510-en-10-ans/) - ACCESS THE ARTICLE
- [Your World - Neglected tropical diseases](https://dndi.org/in-the-media/2023/your-world-neglected-tropical-diseases/) - watch the recording
- [Lutte contre les maladies tropicales négligées : bilan et perspectives ?](https://dndi.org/in-the-media/2023/lutte-contre-les-maladies-tropicales-negligees-bilan-et-perspectives/) - ACCESS THE ARTICLE
- [The interview: Dr Luis Pizarro](https://dndi.org/in-the-media/2023/the-interview-dr-luis-pizarro/) - ACCESS THE ARTICLE
- [Maladie du sommeil : Le nombre de cas est passé de 6000 à 510 de 2012 à 2022](https://dndi.org/in-the-media/2023/maladie-du-sommeil-le-nombre-de-cas-est-passe-de-6000-a-510-de-2012-a-2022/) - ACCESS THE ARTICLE
- [RDC : Le ministre de la Santé appelle à la consolidation des efforts déployés pour l'élimination de la maladie du sommeil d'ici 2030](https://dndi.org/in-the-media/2023/rdc-le-ministre-de-la-sante-appelle-a-la-consolidation-des-efforts-deployes-pour-lelimination-de-la-maladie-du-sommeil-dici-2030/) - ACCESS THE ARTICLE
- [Sie erhalten Fördergelder für die Start-up-Gründung](https://dndi.org/in-the-media/2023/sie-erhalten-fordergelder-fur-die-start-up-grundung/) - ACCESS THE ARTICLE
- [Kampf gegen Erreger X](https://dndi.org/in-the-media/2023/kampf-gegen-erreger-x/) - ACCESS THE ARTICLE
- [Not just prevention needed to fight dengue in India](https://dndi.org/in-the-media/2023/not-just-prevention-needed-to-fight-dengue-in-india/) - ACCESS THE ARTICLE
- [Artificial intelligence facilitates low-cost drug repurposing, says GlobalData](https://dndi.org/in-the-media/2023/artificial-intelligence-facilitates-low-cost-drug-repurposing-says-globaldata/) - ACCESS THE ARTICLE
- [Africa is winning the war against neglected tropical diseases](https://dndi.org/in-the-media/2023/africa-arguments-africa-is-winning-the-war-against-neglected-tropical-diseases/) - ACCESS THE ARTICLE
- [South-South collaboration & compulsory license can benefit public health](https://dndi.org/in-the-media/2023/south-south-collaboration-compulsory-license-can-benefit-public-health/) - ACCESS THE ARTICLE
- [Viewpoint: it’s time to further boost Europe’s leading role in tackling neglected infectious diseases](https://dndi.org/in-the-media/2023/viewpoint-its-time-to-further-boost-europes-leading-role-in-tackling-neglected-infectious-diseases/) - ACCESS THE ARTICLE
- [Pan-African platform aims to hasten clinical trials](https://dndi.org/in-the-media/2023/pan-african-platform-aims-to-hasten-clinical-trials/) - ACCESS THE ARTICLE
- [Sleeping sickness is nearing elimination. An experimental drug could help](https://dndi.org/in-the-media/2023/sleeping-sickness-is-nearing-elimination-an-experimental-drug-could-help/) - ACCESS THE ARTICLE
- [مبادرة DNDi تكرّم بروفيسور أحمد حسن فحل](https://dndi.org/in-the-media/2023/مبادرة-dndi-تكرم-بروفيسور-أحمد-حسن-فحل/) - ACCESS THE ARTICLE
- [Postcodeloterij doneert € 1 miljoen voor therapieën kinderen](https://dndi.org/in-the-media/2023/postcodeloterij-doneert-e-1-miljoen-voor-therapieen-kinderen/) - ACCESS THE ARTICLE
- [Neglected tropical disease mycetoma research gains momentum](https://dndi.org/in-the-media/2023/neglected-tropical-disease-mycetoma-research-gains-momentum/) - ACCESS THE ARTICLE
- [University Hospital Bonn coordinates eWHORM project to combat worm infections in sub-Saharan Africa](https://dndi.org/in-the-media/2023/university-hospital-bonn-coordinates-ewhorm-project-to-combat-worm-infections-in-sub-saharan-africa/) - ACCESS THE ARTICLE
- [DNDi offers model for pandemic accord negotiators on how governments can leverage drug R&D investment](https://dndi.org/in-the-media/2023/dndi-offers-model-for-pandemic-accord-negotiators-on-how-governments-can-leverage-drug-rd-investment/) - ACCESS THE ARTICLE
- [Caminho para diagnóstico e tratamento de Chagas passa pela atenção primária](https://dndi.org/in-the-media/2023/caminho-para-diagnostico-e-tratamento-de-chagas-passa-pela-atencao-primaria/) - ACCESS THE ARTICLE
- [El fuerte avance del dengue en los últimos 50 años: cuáles son las estrategias científicas en América para frenarlo](https://dndi.org/in-the-media/2023/el-fuerte-avance-del-dengue-en-los-ultimos-50-anos-cuales-son-las-estrategias-cientificas-en-america-para-frenarlo/) - ACCESS THE ARTICLE
- [First-ever dengue ‘census’ in SL yields valuable data](https://dndi.org/in-the-media/2023/first-ever-dengue-census-in-sl-yields-valuable-data/) - ACCESS THE ARTICLE
- [African scientists urge enhanced preparedness to contain infectious diseases](https://dndi.org/in-the-media/2023/african-scientists-urge-enhanced-preparedness-to-contain-infectious-diseases/) - ACCESS THE ARTICLE
- [Le mycétome, terrible maladie fongique des plus pauvres, gagne enfin en visibilité](https://dndi.org/in-the-media/2023/le-mycetome-terrible-maladie-fongique-des-plus-pauvres-gagne-enfin-en-visibilite/) - ACCESS THE ARTICLE
- [“顧みられない熱帯病”対策強化を 長崎で国際シンポジウム](https://dndi.org/in-the-media/2023/顧みられない熱帯病対策強化を-長崎で国際シ/) - ACCESS THE ARTICLE
- [Indian Council of Medical Research to prioritise vector-borne diseases](https://dndi.org/in-the-media/2023/indian-council-of-medical-research-to-prioritise-vector-borne-diseases/) - ACCESS THE ARTICLE
- [‘All stakeholders need to come together to tackle burden of dengue in India’](https://dndi.org/in-the-media/2023/all-stakeholders-need-to-come-together-to-tackle-burden-of-dengue-in-india/) - ACCESS THE ARTICLE
- [Neglected tropical diseases continue to pose significant health burden in India: Expert](https://dndi.org/in-the-media/2023/neglected-tropical-diseases-continue-to-pose-significant-health-burden-in-india-expert/) - ACCESS THE ARTICLE
- [National Dengue Day: Experts call for increased efforts to combat deadly mosquito-borne disease](https://dndi.org/in-the-media/2023/national-dengue-day-experts-call-for-increased-efforts-to-combat-deadly-mosquito-borne-disease/) - ACCESS THE ARTICLE
- [Parliamentarians call on G7 leaders to invest in neglected tropical diseases](https://dndi.org/in-the-media/2023/parliamentarians-call-on-g7-leaders-to-invest-in-neglected-tropical-diseases/) - ACCESS THE ARTICLE
- [Bortglömda sjukdomar sprids till nya platser](https://dndi.org/in-the-media/2023/bortglomda-sjukdomar-sprids-till-nya-platser/) - ACCESS THE ARTICLE
- [顧みられぬ病の薬を求めて](https://dndi.org/in-the-media/2023/顧みられぬ病の薬を求めて/) - ACCESS THE ARTICLE
- [La Iniciativa Medicamentos para Enfermedades Desatendidas, Premio Princesa de Asturias de Cooperación Internacional 2023](https://dndi.org/in-the-media/2023/la-iniciativa-medicamentos-para-enfermedades-desatendidas-premio-princesa-de-asturias-de-cooperacion-internacional-2023-3/) - ACCESS THE ARTICLE
- [Eliminar la enfermedad del sueño no es une quimera](https://dndi.org/in-the-media/2023/eliminar-la-enfermedad-del-sueno-no-es-une-quimera/) - ACCESS THE ARTICLE
- [La Iniciativa Medicamentos para Enfermedades Desatendidas, Premio Princesa de Asturias de Cooperación Internacional 2023](https://dndi.org/in-the-media/2023/la-iniciativa-medicamentos-para-enfermedades-desatendidas-premio-princesa-de-asturias-de-cooperacion-internacional-2023-2/) - ACCESS THE ARTICLE
- [La oenegé que promueve medicamentos para enfermedades desatendidas, premio Princesa de Asturias de Cooperación Internacional](https://dndi.org/in-the-media/2023/la-oenege-que-promueve-medicamentos-para-enfermedades-desatendidas-premio-princesa-de-asturias-de-cooperacion-internacional/) - ACCESS THE ARTICLE
- [Una iniciativa para medicamentos de enfermedades desatendidas gana el Premio Princesa de Asturias de Cooperación](https://dndi.org/in-the-media/2023/una-iniciativa-para-medicamentos-de-enfermedades-desatendidas-gana-el-premio-princesa-de-asturias-de-cooperacion/) - ACCESS THE ARTICLE
- [La Iniciativa Medicamentos para Enfermedades Desatendidas, Premio Princesa de Asturias de Cooperación Internacional](https://dndi.org/in-the-media/2023/la-iniciativa-medicamentos-para-enfermedades-desatendidas-premio-princesa-de-asturias-de-cooperacion-internacional-2/) - ACCESS THE ARTICLE
- [La Iniciativa Medicamentos para Enfermedades Desatendidas, Premio Princesa de Cooperación Internacional 2023](https://dndi.org/in-the-media/2023/la-iniciativa-medicamentos-para-enfermedades-desatendidas-premio-princesa-de-cooperacion-internacional-2023/) - ACCESS THE ARTICLE
- [El Princesa de Asturias premia la lucha contra las enfermedades olvidadas](https://dndi.org/in-the-media/2023/el-princesa-de-asturias-premia-la-lucha-contra-las-enfermedades-olvidadas/) - ACCESS THE ARTICLE
- [La Iniciativa Medicamentos para Enfermedades Desatendidas, Princesa de Asturias de Cooperación Internacional 2023](https://dndi.org/in-the-media/2023/la-iniciativa-medicamentos-para-enfermedades-desatendidas-princesa-de-asturias-de-cooperacion-internacional-2023/) - ACCESS THE ARTICLE
- [Drugs for Neglected Diseases Initiative wins Spain’s Princess of Asturias award](https://dndi.org/in-the-media/2023/drugs-for-neglected-diseases-initiative-wins-spains-princess-of-asturias-award/) - ACCESS THE ARTICLE
- [Inside the nascent industry of AI-designed drugs](https://dndi.org/in-the-media/2023/inside-the-nascent-industry-of-ai-designed-drugs/) - ACCESS THE ARTICLE
- [Sri Lankan authorities rush to contain dengue fever outbreak](https://dndi.org/in-the-media/2023/sri-lankan-authorities-rush-to-contain-dengue-fever-outbreak/) - ACCESS THE ARTICLE
- ["Después de los primeros doce medicamentos entregados hay un plan para otros 15 antes de 2030"](https://dndi.org/in-the-media/2023/despues-de-los-primeros-doce-medicamentos-entregados-hay-un-plan-para-otros-15-antes-de-2030/) - ACCESS THE ARTICLE
- [«Tiene que haber reglas internacionales que obliguen a dar acceso a los medicamentos»](https://dndi.org/in-the-media/2023/tiene-que-haber-reglas-internacionales-que-obliguen-a-dar-acceso-a-los-medicamentos/) - ACCESS THE ARTICLE
- [Luis Pizarro: "No se trata sólo de enfermedades desatendidas, sino de personas desatendidas"](https://dndi.org/in-the-media/2023/luis-pizarro-no-se-trata-solo-de-enfermedades-desatendidas-sino-de-personas-desatendidas/) - ACCESS THE ARTICLE
- [Un espoir pour éliminer la maladie du sommeil](https://dndi.org/in-the-media/2023/un-espoir-pour-eliminer-la-maladie-du-sommeil/) - Un interview avec le Digas Ngolo Tete, médecin en République Démocratique du Congo et chef de project clinique à DNDi, Kinshasa. more information
- [Un climat plus propice aux maladies causées par des champignons](https://dndi.org/in-the-media/2023/un-climat-plus-propice-aux-maladies-causees-par-des-champignons/) - Un interview avec Nathalie Strub-Wourgaft, COVID-19 Response & Pandemic Preparedness Director, DNDi more information
- [Les femmes sont prétéritées dans la prise en charge des maladies tropicales négligées](https://dndi.org/in-the-media/2023/les-femmes-sont-preteritees-dans-la-prise-en-charge-des-maladies-tropicales-negligees/) - ACCESS THE ARTICLE
- [Dengue situation becoming as bad as record outbreak in 2017](https://dndi.org/in-the-media/2023/dengue-situation-becoming-as-bad-as-record-outbreak-in-2017/) - ACCESS THE ARTICLE
- [Professor Neelika Malavige](https://dndi.org/in-the-media/2023/professor-neelika-malavige/) - ACCESS THE ARTICLE
- [DNDi : de la révolte à l’innovation](https://dndi.org/in-the-media/2023/dndi-de-la-revolte-a-linnovation/) - ACCESS THE ARTICLE
- [Maladie de Chagas : quels sont les symptômes de cette pathologie transmise par les punaises](https://dndi.org/in-the-media/2023/maladie-de-chagas-quels-sont-les-symptomes-de-cette-pathologie-transmise-par-les-punaises/) - ACCESS THE ARTICLE
- [The dangers of dengue](https://dndi.org/in-the-media/2023/the-dangers-of-dengue/) - ACCESS THE ARTICLE
- [Un premio para azuzar conciencias](https://dndi.org/in-the-media/2023/un-premio-para-azuzar-conciencias/) - ACCESS THE ARTICLE
- [Cámara Real 24.06.2023](https://dndi.org/in-the-media/2023/camara-real-24-06-2023/) - ACCESS THE ARTICLE
- [Dengue spikes in Peru, threatening to spread to new areas](https://dndi.org/in-the-media/2023/dengue-spikes-in-peru-threatening-to-spread-to-new-areas/) - ACCESS THE ARTICLE
- [DNDi: Best science for the most neglected](https://dndi.org/in-the-media/2023/dndi-best-science-for-the-most-neglected/) - ACCESS THE ARTICLE
- [El Niño return spells trouble for health, WHO warns](https://dndi.org/in-the-media/2023/el-nino-return-spells-trouble-for-health-who-warns/) - ACCESS THE ARTICLE
- [La Iniciativa Medicamentos para Enfermedades Desatendidas, Premio Princesa de Cooperación 2023](https://dndi.org/in-the-media/2023/la-iniciativa-medicamentos-para-enfermedades-desatendidas-premio-princesa-de-cooperacion-2023/) - ACCESS THE ARTICLE
- [Luis Pizarro, investigador y premio Princesa de Asturias: 'Las personas pobres no son objetivo de la investigación farmacéutica'](https://dndi.org/in-the-media/2023/luis-pizarro-investigador-y-premio-princesa-de-asturias-las-personas-pobres-no-son-objetivo-de-la-investigacion-farmaceutica/) - ACCESS THE ARTICLE

## Partners

- [National Institutes of Health (NIH), National Center for Advancing Translational Science (NCATS)](https://dndi.org/partnerships/partners/universities-research/national-institutes-of-health-nih-national-center-for-advancing-translational-science-ncats/)
- [Rabat Collaborating Center (RCC)](https://dndi.org/partnerships/partners/ngos-networks/rabat-collaborating-center-rcc/)
- [Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES)](https://dndi.org/partnerships/partners/universities-research/instituto-conmemorativo-gorgas-de-estudios-de-la-salud-icges/)
- [Angola Medicines and Health Technologies Regulatory Agency (ARMED)](https://dndi.org/partnerships/partners/mohs-gov/angola-medicines-and-health-technologies-regulatory-agency-armed/)
- [Tanzania Medicines and Medical Devices Authority (TMDA)](https://dndi.org/partnerships/partners/mohs-gov/tanzania-medicines-and-medical-devices-authority-tmda/)
- [Direccion de Salud Quiché](https://dndi.org/partnerships/partners/mohs-gov/direccion-de-salud-quiche/)
- [Colombian Association of Parasitology and Tropical Medicine (ACPMT)](https://dndi.org/partnerships/partners/ngos-networks/colombian-association-of-parasitology-and-tropical-medicine-acpmt/)
- [Hospital Regional De La Orinoquia ESE](https://dndi.org/partnerships/partners/healthcare/hospital-regional-de-la-orinoquia-ese-2/)
- [International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS)](https://dndi.org/partnerships/partners/ngos-networks/international-federation-of-associations-of-people-affected-by-chagas-disease-findechagas/)
- [Northeastern University](https://dndi.org/partnerships/partners/universities-research/northeastern-university/)
- [São Carlos Institute of Physics (IFSC), Laboratory of Medicinal and Computational Chemistry (LQMC)](https://dndi.org/partnerships/partners/universities-research/sao-carlos-institute-of-physics-ifsc-laboratory-of-medicinal-and-computational-chemistry-lqmc/)
- [Universidade de São Paulo, Faculty of Pharmaceutical Sciences (FCF/USP)](https://dndi.org/partnerships/partners/universities-research/universidade-de-sao-paulo-faculty-of-pharmaceutical-sciences-fcf-usp/)
- [Universidad Nacional de La Plata (UNLP)](https://dndi.org/partnerships/partners/universidad-nacional-de-la-plata-unlp/)
- [Instituto de Investigaciones en Microbiología y Parasitología Médica (IMPaM)](https://dndi.org/partnerships/partners/universities-research/instituto-de-investigaciones-en-microbiologia-y-parasitologia-medica-impam/)
- [Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)](https://dndi.org/partnerships/partners/universities-research/helmholtz-institute-for-pharmaceutical-research-saarland-hips/)
- [Fungal Infections Study Forum (FISF)](https://dndi.org/partnerships/partners/universities-research/fungal-infections-study-forum-fisf/)
- [Cirugía en Turkana](https://dndi.org/partner/cirugia-en-turkana/)
- [Turkana County Referral Hospital](https://dndi.org/partnerships/partners/healthcare/turkana-county-referral-hospital/)
- [West Pokot County Health Department](https://dndi.org/partnerships/partners/healthcare/west-pokot-county-health-department/)
- [Federal University of Recôncavo da Bahia ](https://dndi.org/partnerships/partners/universities-research/federal-university-of-reconcavo-da-bahia/)
- [University of the North (Uninorte)](https://dndi.org/partnerships/partners/universities-research/university-of-the-north-uninorte/)
- [Amref Health Africa](https://dndi.org/partnerships/partners/ngos-networks/amref-health-africa/)
- [African Pharmaceutical Technology Foundation (APTF)](https://dndi.org/partnerships/partners/ngos-networks/african-pharmaceutical-technology-foundation-aptf/)
- [Kwame Nkrumah University of Science and Technology (KNUST) ](https://dndi.org/partnerships/partners/universities-research/kwame-nkrumah-university-of-science-and-technology-knust/)
- [Laboratorios Liconsa SA ](https://dndi.org/partnerships/partners/industry-partners/laboratorios-liconsa-sa/)
- [Kwame Nkrumah University of Science and Technologyy (KNUST), Faculty of Allied Health Sciences](https://dndi.org/partnerships/partners/universities-research/kwame-nkrumah-university-of-science-and-technologyy-knust-faculty-of-allied-health-sciences/)
- [University of California San Diego (UCSD), Skaggs School of Pharmacy and Pharmaceutical Sciences](https://dndi.org/partnerships/partners/universities-research/university-of-california-san-diego-ucsd-skaggs-school-of-pharmacy-and-pharmaceutical-sciences/)
- [Aberystwyth University, Department of Life Sciences](https://dndi.org/partnerships/partners/universities-research/aberystwyth-university-department-of-life-sciences/)
- [University of Giessen, Institute of Parasitology](https://dndi.org/partnerships/partners/universities-research/university-of-giessen-institute-of-parasitology/)
- [FioSchisto - Fiocruz](https://dndi.org/partnerships/partners/universities-research/fioschisto-fiocruz/)
- [Guarulhos University (UNG), Neglected Diseases Research Centre](https://dndi.org/partnerships/partners/universities-research/guarulhos-university-ung-neglected-diseases-research-centre/)
- [Wits Health Consortium Pty Ltd](https://dndi.org/partnerships/partners/industry-partners/wits-health-consortium-pty-ltd/)
- [University Cheikh Anta Diop-FMPO-UCAD](https://dndi.org/partnerships/partners/universities-research/university-cheikh-anta-diop-fmpo-ucad/)
- [Gaston Berger University](https://dndi.org/partnerships/partners/universities-research/gaston-berger-university/)
- [Bahir Dar University](https://dndi.org/partnerships/partners/universities-research/bahir-dar-university/)
- [Arba Minch University](https://dndi.org/partnerships/partners/universities-research/arba-minch-university/)
- [FIND, the global alliance for diagnostics](https://dndi.org/partnerships/partners/ngos-networks/foundation-for-innovative-new-diagnostics-find/)
- [Fundación SANIT](https://dndi.org/partnerships/partners/ngos-networks/fundacion-sanit/)
- [Chagas Disease Global Coalition](https://dndi.org/partnerships/partners/coalizao-chagas/)
- [WomenLift Health](https://dndi.org/partnerships/partners/ngos-networks/womenlift-health/)
- [Public Health Foundation of India](https://dndi.org/partnerships/partners/ngos-networks/public-health-foundation-of-india/)
- [Médecins sans Frontières (MSF) Japan](https://dndi.org/partnerships/partners/ngos-networks/medecins-sans-frontieres-msf-japan/)
- [Plataforma de Pesquisa Clínica da Fiocruz/VPPCB](https://dndi.org/partnerships/partners/universities-research/plataforma-de-pesquisa-clinica-da-fiocruz-vppcb/)
- [National Institute of Pharmaceutical Education and Research, Kolkata (NIPER-K)](https://dndi.org/partnerships/partners/universities-research/national-institute-of-pharmaceutical-education-and-research-kolkata-niper-k/)
- [Universidade de São Paulo - Faculdade de Ciências Farmacêuticas (FCF/USP)](https://dndi.org/partnerships/partners/universities-research/faculdade-de-ciencias-farmaceuticas-universidade-de-sao-paulo-fcf-usp/)
- [University of Edinburgh](https://dndi.org/partnerships/partners/universities-research/university-of-edinburgh/)
- [Universidade Federal do Maranhão](https://dndi.org/partnerships/partners/universities-research/universidade-federal-do-maranhao/)
- [Lambaréné Medical Research Center (CERMEL)](https://dndi.org/partnerships/partners/universities-research/lambarene-medical-research-center/)
- [University of Lucknow](https://dndi.org/partnerships/partners/universities-research/universities-research-university-of-lucknow/)
- [Punjabi University](https://dndi.org/partnerships/partners/universities-research/ngos-networks-punjabi-university/)
- [National Institute of Pharmaceutical Education and Research, Hajipur](https://dndi.org/partnerships/partners/ngos-networks/ngos-networks-national-institute-of-pharmaceutical-education-and-research-hajipur/)
- [Uniting to Combat NTDs](https://dndi.org/partnerships/partners/ngos-networks/ngos-networks-uniting-to-combat-ntds/)
- [Global Institute for Disease Elimination (GLIDE)](https://dndi.org/partnerships/partners/ngos-networks/ngos-networks-global-institute-for-disease-elimination-glide/)
- [Post Graduate Institute of Medical Education and Research (PGIMER)](https://dndi.org/partnerships/partners/universities-research/universities-research-post-graduate-institute-of-medical-education-and-research-pgimer/)
- [Africa CDC](https://dndi.org/partnerships/partners/mohs-gov/mohs-gov-africa-cdc/)
- [Dr. S N Medical College](https://dndi.org/partnerships/partners/universities-research/universities-research-dr-s-n-medical-college/)
- [National Kala-azar Elimination Program (NKEP)](https://dndi.org/partnerships/partners/mohs-gov/mohs-gov-national-kala-azar-elimination-program-nkep/)
- [Mymensingh Medical College](https://dndi.org/partnerships/partners/healthcare/healthcare-providers-mymensingh-medical-college/)
- [Infectious Diseases Hospital](https://dndi.org/partnerships/partners/healthcare/healthcare-providers-infectious-diseases-hospital/)
- [University of Dundee, Drug Discovery Unit](https://dndi.org/partnerships/partners/universities-research/drug-discovery-unit-university-of-dundee/)
- [Institute of Tropical Medicine Antwerp](https://dndi.org/partnerships/partners/institute-of-tropical-medicine-antwerp/)
- [University of British Columbia (UBC)](https://dndi.org/partnerships/partners/universities-research/universities-research-university-of-british-columbia-ubc/)
- [Zydus Cadila Healthcare Ltd.](https://dndi.org/partnerships/partners/industry-partners/industry-partners-zydus-cadila-healthcare-ltd/)
- [Macleods Pharmaceuticals Ltd](https://dndi.org/partnerships/partners/industry-partners/industry-partners-macleods-pharmaceuticals-ltd/)
- [Georgetown University, O’Neill Institute for National and Global Health Law](https://dndi.org/partnerships/partners/universities-research/universities-research-georgetown-university-oneill-institute-for-national-and-global-health-law/)
- [Aurum Institute NPC](https://dndi.org/partnerships/partners/ngos-networks/ngos-networks-aurum-institute-npc/)
- [The Queen's University of Belfast](https://dndi.org/partnerships/partners/universities-research/the-queens-university-of-belfast/)
- [University Hospital Bonn, Institute for Medical Microbiology, Immunology and Parasitology](https://dndi.org/partnerships/partners/hospitals/institute-of-medical-microbiology-immunology-and-parasitology-immip/)
- [SRM Medical College Hospital & Research Centre](https://dndi.org/partnerships/partners/universities-research/universities-research-srm-medical-college-hospital-research-centre/)
- [King George's Medical University, KGMU](https://dndi.org/partnerships/partners/healthcare/healthcare-providers-king-georges-medical-university-kgmu/)
- [JSS Hospital](https://dndi.org/partnerships/partners/healthcare/jss-hospital/)
- [Foundation for Neglected Disease Research](https://dndi.org/partnerships/partners/ngos-networks/ngo-networks-foundation-for-neglected-disease-research/)
- [CSIR-Central Drug Research Institute (CSIR-CDRI)](https://dndi.org/partnerships/partners/mohs-gov/csir-central-drug-research-institute-csir-cdri/)
- [Oswaldo Cruz Foundation - Fiocruz](https://dndi.org/partnerships/partners/universities-research/fiocruz-fundacao-oswaldo-cruz/)
- [Shionogi & Co., Ltd.](https://dndi.org/partnerships/partners/pharma-biotech/shionogi-co-ltd/)
- [Eisai Co., Ltd.](https://dndi.org/partnerships/partners/pharma-biotech/eisai-co-ltd/)
- [Phytobios](https://dndi.org/partnerships/partners/industry-partners/industry-partners-phytobios/)
- [Centro Nacional de Pesquisa em Energia e Materiais (CNPEM)](https://dndi.org/partnerships/partners/universities-research/centro-nacional-de-pesquisa-em-energia-e-materiais-cnpem/)
- [SAS Institute Inc. – Data for Good](https://dndi.org/partnerships/partners/industry-partners/sas-data-for-good/)
- [Instituto de Salud Carlos III](https://dndi.org/partnerships/partners/universities-research/instituto-de-salud-carlos-iii/)
- [PHPT-AMS Laboratory](https://dndi.org/partnerships/partners/associated-medical-sciences-phpt-international-research-unit/)
- [Necker Institute](https://dndi.org/partnerships/partners/necker-institute/)
- [Kenya Medical Research Institute (KEMRI)](https://dndi.org/partnerships/partners/kenya-medical-research-institute-kemri/)
- [Joint Clinical Research Centre](https://dndi.org/partnerships/partners/joint-clinical-research-centres/)
- [Ifakara Health Institute](https://dndi.org/partnerships/partners/ifakara-health-institute/)
- [Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso (UFMT)](https://dndi.org/partnerships/partners/universidade-federal-de-mato-grosso-hospital-universitario-julio-muller/)
- [Bruno Scherrer](https://dndi.org/partnerships/partners/bruno-scherrer/)
- [Muséum National d’Histoire Naturelle](https://dndi.org/partnerships/partners/ngos-networks/national-museum-of-natural-history-paris-mnhn/)
- [Unitaid](https://dndi.org/partnerships/partners/unitaid/)
- [NHEPACHA network](https://dndi.org/partnerships/partners/universities-research/nhepacha-network/)
- [Médecins Sans Frontières (MSF)](https://dndi.org/partnerships/partners/medecins-sans-frontieres/)
- [Infectious Diseases Data Observatory (IDDO), University of Oxford](https://dndi.org/partnerships/partners/universities-research/infectious-diseases-data-observatory-iddo-university-of-oxford/)
- [Family AIDS Care and Education Services (FACES) Project](https://dndi.org/partnerships/partners/family-aids-care-and-education-services-faces-project/)
- [Epicentre (MSF) - Uganda](https://dndi.org/partnerships/partners/epicentre-uganda/)
- [Clinton Health Access Initiative (CHAI)](https://dndi.org/partnerships/partners/clinton-health-access-initiative-chai/)
- [Walter Reed Army Institute](https://dndi.org/partnerships/partners/mohs-gov/walter-reed-army-institute/)
- [National Institutes of Health (NIH) USA](https://dndi.org/partnerships/partners/mohs-gov/national-institutes-of-health/)
- [Centre interdisciplinaire de Bioéthique pour l’Afrique Francophone (CIBAF)](https://dndi.org/partnerships/partners/mohs-gov/centre-interdisciplinaire-de-bioethique-pour-lafrique-francophone-cibaf/)
- [Programa Nacional de Leishmaniasis Colombia](https://dndi.org/partnerships/partners/universities-research/programa-nacional-de-leishmaniasis/)
- [National sleeping sickness control programmes, research institutions, and national laboratories of public health of the most affected endemic countries: Angola, Central African Republic, Chad, Democratic Republic of the Congo, Guinea, Republic of Congo, South Sudan, Sudan, Uganda](https://dndi.org/partnerships/partners/national-sleeping-sickness-control-programmes-research-institutions-and-national-laboratories-of-public-health-of-the-most-affected-endemic-countries-angola-central-african-republic-chad-democra/)
- [National Department of Health South Africa](https://dndi.org/partnerships/partners/department-of-health/)
- [Centre for Disease Control and Prevention (CDC)](https://dndi.org/partnerships/partners/centre-for-disease-control-and-prevention-cdc-presidents-emergency-plan-for-aids-relief/)
- [Salvensis](https://dndi.org/partnerships/partners/pharma-biotech/salvensis/)
- [Brazilian Biosciences National Laboratory (LNBio)](https://dndi.org/partnerships/partners/pharma-biotech/brazilian-biosciences-national-laboratory-lnbio/)
- [Núcleo de Desenvolvimento Farmacêutico e Cosmético (NUDFAC)](https://dndi.org/partnerships/partners/universities-research/nucleus-of-pharmaceutical-and-cosmetics-development-nudfac/)
- [Merck](https://dndi.org/partnerships/partners/universities-research/merck/)
- [LAT Research](https://dndi.org/partnerships/partners/universities-research/lat-research/)
- [Janssen Research & Development LLC](https://dndi.org/partnerships/partners/universities-research/janssen-research-development/)
- [Hammersmith Medicines Research](https://dndi.org/partnerships/partners/universities-research/hammersmith-medicines-research/)
- [Eurofins-Optimed](https://dndi.org/partnerships/partners/eurofins-optimed/)
- [Cambrex (formerly Avista Pharma and SCYNEXIS Inc)](https://dndi.org/partnerships/partners/avista-pharma/)
- [Mycetoma Research Centre (MRC)](https://dndi.org/partnerships/partners/universities-research/mycetoma-research-centre-mrc-soba-university-hospital-khartoum/)
- [Moi Teaching and Referral Hospital](https://dndi.org/partnerships/partners/moi-teaching-and-referral-hospital/)
- [Mbagathi District Hospital](https://dndi.org/partnerships/partners/mbagathi-district-hospital/)
- [Kenyatta National Hospital](https://dndi.org/partnerships/partners/kenyatta-national-hospital/)
- [i+solutions](https://dndi.org/partnerships/partners/pharma-biotech/isolutions/)
- [Cipla Ltd.](https://dndi.org/partnerships/partners/cipla-ltd-2/)
- [Cipla Ltd.](https://dndi.org/partnerships/partners/cipla-ltd/)
- [Gertrude’s Children’s Hospital](https://dndi.org/partnerships/partners/gertrudes-childrens-hospital/)
- [Komfo Anokye Teaching Hospital (KATH)](https://dndi.org/partnerships/partners/hospitals/komfo-anokye-teaching-hospital-kath/)
- [Erasmus MC](https://dndi.org/partnerships/partners/hospitals/erasmus-medical-center/)
- [Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de Clermont-Ferrand, Lille et Bichat-Claude Bernard](https://dndi.org/partnerships/partners/universities-research/centres-dinvestigation-clinique-des-centres-hospitaliers-universitaires-de-clermont-ferrand-lille-et-bichat-claude-bernard/)
- [Academic Medical Center in Amsterdam](https://dndi.org/partnerships/partners/universities-research/academic-medical-center-in-amsterdam/)
- [Alliance for International Medical Action (ALIMA)](https://dndi.org/partnerships/partners/ngos-networks/alliance-for-internationalmedicalaction-alima/)
- [Department of Medicine/ Gastroenterology, University Malaya Medical Centre](https://dndi.org/partnerships/partners/healthcare/department-of-medicine-gastroenterology-university-malaya-medical-centre/)
- [Department of Medicine/ Gastroenterology, Hospital Tengku Ampuan Afzan Hospital](https://dndi.org/partnerships/partners/healthcare/department-of-medicine-gastroenterology-hospital-tengku-ampuan-afzan-hospital/)
- [Department of Medicine/ Gastroenterology, Hospital Sultanah Bahiyah](https://dndi.org/partnerships/partners/healthcare/department-of-medicine-gastroenterology-hospital-sultanah-bahiyah/)
- [Department of Medicine/ Gastroenterology, Hospital Ampang](https://dndi.org/partnerships/partners/healthcare/department-of-medicine-gastroenterology-hospital-ampang/)
- [Centro de Investigação em Saúde de Manhiça (CISM)](https://dndi.org/partnerships/partners/universities-research/centro-deinvestigacaoemsaudedemanhica/)
- [Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC), Instituto Nacional de Saúde](https://dndi.org/partnerships/partners/universities-research/centro-deinvestigacaoetreinoemsaudeda-polanacanicocispoc-institutonacionaldesaude/)
- [Bernhard-Nocht-Institut für Tropenmedizin (BNITM)](https://dndi.org/partnerships/partners/universities-research/bernhard-nocht-institutfurtropenmedizinbnitm/)
- [WuXi AppTech](https://dndi.org/partnerships/partners/wuxi-apptech/)
- [Drugabilis](https://dndi.org/partnerships/partners/drugabilis/)
- [Advinus Therapeutics Ltd](https://dndi.org/partnerships/partners/advinus-therapeutics-ltd/)
- [Mylan Laboratories Limited (a Viatris company)](https://dndi.org/partnerships/partners/pharma-biotech/viatris/)
- [Fred Hutchinson Cancer Center](https://dndi.org/partnerships/partners/universities-research/fred-hutchinson-cancer-center/)
- [Stanford University School of Medicine](https://dndi.org/partnerships/partners/universities-research/stanford-university-school-of-medicine/)
- [Malaysian AIDS Council (MAC)](https://dndi.org/partnerships/partners/ngos-networks/malaysian-aids-council-mac/)
- [Celgene (now Bristol Myers Squibb Inc.)](https://dndi.org/partnerships/partners/pharma-biotech/celgene-corporation/)
- [Anacor Pharmaceuticals (now Pfizer Inc.)](https://dndi.org/partnerships/partners/pharma-biotech/anacor-pharmaceuticals/)
- [Pfizer Inc. (formerly Anacor Pharmaceuticals)](https://dndi.org/partnerships/partners/pharma-biotech/pfizer-inc-formerly-anacor-pharmaceuticals/)
- [ITR Japan, BoZo Research Center](https://dndi.org/partnerships/partners/industry-partners/itr-japan-bozo-research-center/)
- [Eurice – European Research and Project Office GmbH](https://dndi.org/partnerships/partners/industry-partners/eurice-european-research-and-project-office-gmbh/)
- [Medical University of Vienna](https://dndi.org/partnerships/partners/universities-research/medical-university-of-vienna/)
- [other student groups and individuals who contribute to community research inputs](https://dndi.org/partnerships/partners/other-student-groups-and-individuals-who-contribute-to-community-research-inputs/)
- [Pharmaniaga Berhad](https://dndi.org/partnerships/partners/pharma-biotech/pharmaniaga/)
- [University of Bayreuth](https://dndi.org/partnerships/partners/universities-research/university-of-bayreuth/)
- [University of Sydney](https://dndi.org/partnerships/partners/universities-research/the-university-of-sydney/)
- [University of Toulouse](https://dndi.org/partnerships/partners/universities-research/university-of-toulouse/)
- [Universidade de São Paulo (USP)](https://dndi.org/partnerships/partners/universities-research/universidade-de-sao-paolo-usp/)
- [Atomwise, Inc.](https://dndi.org/partnerships/partners/industry-partners/atomwise-inc/)
- [National Institute of Advanced Industrial Science and Technology (AIST)](https://dndi.org/partnerships/partners/universities-research/national-institute-of-advanced-industrial-science-and-technology-aist/)
- [AstraZeneca UK](https://dndi.org/partnerships/partners/industry-partners/astrazeneca-uk/)
- [World Health Organization (WHO)](https://dndi.org/partnerships/partners/ngos-networks/world-health-organization-who/)
- [Swiss Tropical and Public Health Institute (Swiss TPH)](https://dndi.org/partnerships/partners/universities-research/swiss-tropical-and-public-health-institute-swiss-tph/)
- [Sequella Inc.](https://dndi.org/partnerships/partners/pharma-biotech/sequella-inc/)
- [Nagasaki University](https://dndi.org/partnerships/partners/universities-research/nagasaki-university/)
- [Merck KGaA](https://dndi.org/partnerships/partners/pharma-biotech/merck-kgaa/)
- [Daiichi Sankyo RD Novare Co., Ltd.](https://dndi.org/partnerships/partners/pharma-biotech/daiichi-sankyo-rd-novare/)
- [Astellas Pharma Inc.](https://dndi.org/partnerships/partners/pharma-biotech/astellas-pharma/)
- [Banaras Hindu University](https://dndi.org/partnerships/partners/universities-research/institute-of-medical-sciences-banaras-hindu-university/)
- [Farmanguinhos - Fiocruz](https://dndi.org/partnerships/partners/pharma-biotech/farmanguinhos/)
- [Universidade Estadual de Campinas (UNICAMP), Institute of Chemistry](https://dndi.org/partnerships/partners/universities-research/instituto-de-quimica-university-estadual-of-campinas/)
- [Universidade de São Paulo (USP), Institute of Physics](https://dndi.org/partnerships/partners/universities-research/instituto-de-fisica-universidade-de-sao-paulo-usp/)
- [Universidade de São Paulo (USP), Institute of Biomedical Sciences](https://dndi.org/partnerships/partners/universities-research/universidade-de-sao-paolo-instituto-de-ciencias-biomedicas/)
- [National Pharmacovigilance Center, Ministry of Health of Morocco](https://dndi.org/partnerships/partners/mohs-gov/national-pharmacovigilance-center-ministry-of-health-of-morocco/)
- [National Institute to Combat and Control Trypanosomiasis (ICCT), Ministry of Health of Angola](https://dndi.org/partnerships/partners/mohs-gov/national-institute-to-combat-and-control-trypanosomiasis-icct-ministry-of-health-of-angola/)
- [National HAT Control Programmes of the Central African Republic](https://dndi.org/partnerships/partners/mohs-gov/national-control-programmes-of-the-central-african-republic/)
- [Ministry of Health Ivory Coast](https://dndi.org/partnerships/partners/mohs-gov/ministere-de-la-sante-et-de-lhygiene-publique-de-la-republique-de-cote-divoire/)
- [Ministry of Health Burkina Faso](https://dndi.org/partnerships/partners/mohs-gov/ministere-de-la-sante-et-de-lhygiene-publique-burkina-faso/)
- [Ministry of Public Health Cameroon](https://dndi.org/partnerships/partners/mohs-gov/ministere-de-la-sante-publique/)
- [Ministry of Public Health DRC](https://dndi.org/partnerships/partners/mohs-gov/ministere-provincial-de-la-sante-publique-des-affaires-sociales-et-humanitaires/)
- [Association Réseau EVA](https://dndi.org/partnerships/partners/universities-research/reseau-eva/)
- [Treatment Action Group (TAG)](https://dndi.org/partnerships/partners/universities-research/treatment-action-group-tag/)
- [National HAT Control Programme (PNLTHA) Guinea](https://dndi.org/partnerships/partners/mohs-gov/national-control-programme-of-guinea/)
- [Federal Ministry of Health South Sudan](https://dndi.org/partnerships/partners/mohs-gov/federal-ministry-of-health-south-sudan/)
- [Ministry of Health Malawi](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-and-population-malawi/)
- [University Hospital Bonn](https://dndi.org/partnerships/partners/universities-research/university-of-bonn-rheinische-friedrich-wilhelms-universitat-bonn/)
- [University of Bonn](https://dndi.org/partnerships/partners/universities-research/university-of-bonn/)
- [Washington University - School of Medicine (Saint Louis)](https://dndi.org/partnerships/partners/universities-research/washington-university-in-st-louis/)
- [University of Washington](https://dndi.org/partnerships/partners/universities-research/university-of-washington/)
- [Bayer Healthcare AG](https://dndi.org/partnerships/partners/pharma-biotech/bayer-ag/)
- [Programme national de lutte contre les maladies tropicales négligées à chimiothérapie préventive (PNLMTN-CTP)](https://dndi.org/partnerships/partners/mohs-gov/programme-national-de-lutte-contre-les-maladies-tropicales-negligees-a-chimiotherapie-preventive-pnlmtn-ctp/)
- [Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management (SVKM’s NMIMS)](https://dndi.org/partnerships/partners/universities-research/shobhaben-pratapbhai-patel-school-of-pharmacy-technology-management-at-narsee-monjee-institute-of-management-studies-nmims/)
- [Calibr at Scripps Research](https://dndi.org/partnerships/partners/industry-partners/calibr-at-scripps-research/)
- [Charité University Hospital Berlin](https://dndi.org/partnerships/partners/universities-research/charite-universitatsmedizin-berlin-charite-university-hospital-berlin/)
- [University of Hamburg](https://dndi.org/partnerships/partners/universities-research/universitat-hamburg-university-of-hamburg/)
- [University of Oxford](https://dndi.org/partnerships/partners/universities-research/oxford-university/)
- [Thames Pharma Partners LCC](https://dndi.org/partnerships/partners/thames-pharma-partners/)
- [Compass Business Partners Ltd.](https://dndi.org/partnerships/partners/industry-partners/compass-business-partners/)
- [Shiv Nadar University](https://dndi.org/partnerships/partners/universities-research/shiv-nadar-university/)
- [Franciscan University of Steubenville](https://dndi.org/partnerships/partners/universities-research/franciscan-university-of-steubenville/)
- [Nantes Université](https://dndi.org/partnerships/partners/universities-research/nantes-universite/)
- [Universidade Federal de Uberlândia](https://dndi.org/partnerships/partners/universities-research/universidade-federal-de-uberlandia/)
- [Instituto René Rachou (IRR) - Fiocruz Minas](https://dndi.org/partnerships/partners/universities-research/rene-rachou-research-center-fiocruz-mg/)
- [Universidade Federal de Mato Grosso (UFMT)](https://dndi.org/partnerships/partners/universities-research/universidade-federal-de-mato-grosso-ufmt/)
- [Universidade Federal da Bahia (UFBA)](https://dndi.org/partnerships/partners/universities-research/universidade-federal-da-bahia-ufba/) - new
- [Universidad Peruana Cayetano Heredia](https://dndi.org/partnerships/partners/universities-research/universidad-peruana-cayetano-heredia/)
- [FUNDERMA - Fundación Nacional de Dermatología](https://dndi.org/partnerships/partners/ngos-networks/fundacion-nacional-de-dermatologia-funderma/)
- [PECET - Programa de Estudios y Control de Enfermedades Tropicales](https://dndi.org/partnerships/partners/universities-research/programa-de-estudios-y-control-de-enfermedades-tropicales-pecet/)
- [Secretaría de Salud, Protección y Bienestar Social Colombia](https://dndi.org/partnerships/partners/mohs-gov/secretaria-de-salud-proteccion-y-bienestar-social-colombia/)
- [Responsable Programa de Chagas - Ministerio de Salud](https://dndi.org/partnerships/partners/mohs-gov/responsable-programa-de-chagas-ministerio-de-salud/)
- [Pan American Health Organization (PAHO) Colombia](https://dndi.org/partnerships/partners/ngos-networks/pan-american-health-organization-paho-colombia/)
- [Pan American Health Organization (PAHO) Bolivia](https://dndi.org/partnerships/partners/ngos-networks/pan-american-health-organization-paho-bolivia/)
- [Olive View-UCLA Medical Center, Center of Excellence for Chagas Disease (CECD)](https://dndi.org/partnerships/partners/universities-research/center-of-excellence-for-chagas-disease-cecd-at-olive-view-ucla-medical-center/)
- [National Institute of Health Colombia](https://dndi.org/partnerships/partners/universities-research/national-institute-of-health-colombia/)
- [Ministry of Health Guatemala](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-and-social-assistance-guatemala/)
- [Ministry of Health Colombia](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-and-social-protection-colombia/)
- [Ministry of Health (Bolivia)](https://dndi.org/partnerships/partners/mohs-gov/ministerio-de-salud-programa-de-chagas-bolivia/)
- [Médicos Sem Fronteiras (MSF) Brasil](https://dndi.org/partnerships/partners/ngos-networks/medecins-sans-frontieres-brazil/)
- [Ministério da Saúde Brasil](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-brazil/)
- [Médecins Sans Frontières (MSF) México](https://dndi.org/partnerships/partners/ngos-networks/medicos-sin-fronteras-mexico-y-centroamerica/)
- [Médecins Sans Frontières (MSF) Spain](https://dndi.org/partnerships/partners/ngos-networks/medecins-sans-frontieres-spain/)
- [Médecins Sans Frontières (MSF) Bolivia](https://dndi.org/partnerships/partners/ngos-networks/medicos-sin-fronteras-msf-bolivia/)
- [Lafepe Laboratório Farmacêutico do Estado de Pernambuco S/A](https://dndi.org/partnerships/partners/pharma-biotech/lafepe-pharmaceutical-laboratory-of-pernambuco/)
- [Health secretary of Soatá](https://dndi.org/partnerships/partners/mohs-gov/health-secretary-of-soata/)
- [Health Area Direction of Jutiapa](https://dndi.org/partnerships/partners/mohs-gov/dirrecion-area-de-salud-de-jutiapa/)
- [Health Area Direction of Jalapa](https://dndi.org/partnerships/partners/mohs-gov/direccion-del-area-de-salud-de-jalapa/)
- [Laboratorio Elea Phoenix S.A.](https://dndi.org/partnerships/partners/pharma-biotech/laboratorio-elea-phoenix/)
- [INP Dr. Mario Fatala Cháben](https://dndi.org/partnerships/partners/universities-research/instituto-nacional-de-epidemiologia-dr-fatala-chaben/)
- [Platforms of Integral Care for Patients with Chagas Disease](https://dndi.org/partnerships/partners/ngos-networks/platform-of-integral-care-for-patients-with-chagas-disease/)
- [PhinC Development](https://dndi.org/partnerships/partners/pharma-biotech/phinc/)
- [Sanofi Merial (now Boehringer Ingelheim Animal Health Business Unit)](https://dndi.org/partnerships/partners/pharma-biotech/sanofi-merial-boehringer-ingelheim-animal-health/)
- [ISGlobal, Barcelona Institute for Global Health](https://dndi.org/partnerships/partners/universities-research/is-global-institute-for-global-health/)
- [Université de Genève](https://dndi.org/partnerships/partners/universities-research/university-of-geneva/)
- [Northeastern University](https://dndi.org/partnerships/partners/universities-research/northeastern-university-boston/)
- [Mitsubishi Tanabe Pharma Corporation Group](https://dndi.org/partnerships/partners/pharma-biotech/mitsubishi-tanabe-pharma-corporation/)
- [Griffith University](https://dndi.org/partnerships/partners/universities-research/griffith-institute-for-drug-discovery-gridd-griffith-university/)
- [Indian Institute of Technology-Gandhinagar (IIT-G)](https://dndi.org/partnerships/partners/indian-institute-of-technology/)
- [ST Pharm, Co., Ltd.](https://dndi.org/partnerships/partners/industry-partners/st-pharm/)
- [Instituto de Medicina Tropical de São Paulo - USP](https://dndi.org/partnerships/partners/universities-research/universidade-de-sao-paulo-usp-instituto-medicina-tropical/)
- [InfYnity Biomarkers](https://dndi.org/partnerships/partners/pharma-biotech/infynity-biomarkers/)
- [Centro de Enfermedad de Chagas y Patologia Regional Hospital Independencia](https://dndi.org/partnerships/partners/hospitals/centro-de-chagas-y-patologia-regional-hospital-independencia-argentina/)
- [Medicines for All Institute, Virginia Commonwealth University](https://dndi.org/partnerships/partners/universities-research/medicines-for-all-institute-virginia-commonwealth-university/)
- [Vall d’Hebron University Hospital](https://dndi.org/partnerships/partners/hospitals/vall-dhebron-university-hospital/)
- [BioAster](https://dndi.org/partnerships/partners/universities-research/bioaster/)
- [World Health Organization (WHO) South-East Asia](https://dndi.org/partnerships/partners/ngos-networks/world-health-organization-who-south-east-asia/)
- [Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kwame Nkrumah University of Science and Technologyy (KNUST)](https://dndi.org/partnerships/partners/universities-research/kumasi-centre-for-collaborative-research-in-tropical-medicine-kccr/)
- [National HAT Control Programme of the Democratic Republic of Congo (PNLTHA)](https://dndi.org/partnerships/partners/mohs-gov/national-trypanosomiasis-control-programme-drc/)
- [Epichem](https://dndi.org/partnerships/partners/pharma-biotech/epichem/)
- [Amudat District Hospital](https://dndi.org/partnerships/partners/hospitals/amudat-hospital/)
- [International Centre for Diarrhoeal Disease Research (ICDDR)](https://dndi.org/partnerships/partners/universities-research/international-centre-for-diarrhoeal-disease-research/)
- [World Health Organization (WHO) India](https://dndi.org/partnerships/partners/ngos-networks/world-health-organization-who-india/)
- [National Reference Laboratory of Guatemala](https://dndi.org/partnerships/partners/universities-research/laboratorio-nacional-de-salud/)
- [Special Administrative Health Unit, Arauca Department](https://dndi.org/partnerships/partners/mohs-gov/special-administrative-health-unit-arauca-department/)
- [Instituto Nacional de Laboratorios de Salud (INLASA)](https://dndi.org/partnerships/partners/industry-partners/instituto-nacional-de-laboratorios-de-salud-inlasa/)
- [Lilongwe Medical Relief Fund Trust (UNC Project - Malawi)](https://dndi.org/partnerships/partners/ngos-networks/lilongwe-medical-relief-fund-trust-unc-project-malawi/)
- [Hôpitaux Universitaires de Genève (HUG)](https://dndi.org/partnerships/partners/hospitals/university-hospitals-of-geneva-hug/)
- [FARMOVS, University of the Free State](https://dndi.org/partnerships/partners/pharma-biotech/farmovs-pty-ltd/)
- [Diamond Light Source](https://dndi.org/partnerships/partners/ngos-networks/diamond-light-source/)
- [Universidade Federal do Ceará](https://dndi.org/partnerships/partners/universities-research/universidade-federal-do-ceara/)
- [Universidade Federal de Goiás (UFG)](https://dndi.org/partnerships/partners/universities-research/universidade-federal-de-goias/)
- [Vice-Presidência de Pesquisa e Coleções Biológicas - VPPCB](https://dndi.org/partnerships/partners/universities-research/vice-presidencia-de-pesquisa-e-colecoes-biologicas-vppcb/)
- [BenevolentAI](https://dndi.org/partnerships/partners/industry-partners/benevolentai/)
- [Institut Bouisson Bertrand (IBB)](https://dndi.org/partnerships/partners/universities-research/institut-bouisson-bertrand/)
- [Interactive Research School for Health Affairs (IRSHA)](https://dndi.org/partnerships/partners/universities-research/interactive-research-school-for-health-affairs-irsha/)
- [Institut Pasteur de Dakar](https://dndi.org/partnerships/partners/universities-research/institut-pasteur-de-dakar/)
- [University of Marburg - Philipps-Universität Marburg](https://dndi.org/partnerships/partners/universities-research/university-of-marburg-philipps-universitat-marburg/)
- [Justus Liebig University Giessen](https://dndi.org/partnerships/partners/universities-research/justus-liebig-university-giessen/)
- [Helmholtz Centre for Infection Research](https://dndi.org/partnerships/partners/universities-research/helmholtz-centre-for-infection-research/)
- [Heidelberg University Hospital](https://dndi.org/partnerships/partners/universities-research/heidelberg-university-hospital/)
- [Universidade Federal de Minas Gerais (UFMG)](https://dndi.org/partnerships/partners/universities-research/universidade-federal-de-minas-gerais-ufmg/)
- [Translational Health Science and Technology Institute (THSTI)](https://dndi.org/partnerships/partners/universities-research/translational-health-science-and-technology-institute-thsti/)
- [Mahidol University, Faculty of Medicine Siriraj Hospital](https://dndi.org/partnerships/partners/universities-research/mahidol-university-faculty-of-medicine-siriraj-hospital/)
- [UNITE, The Global Parliamentarians Network to End Infectious Diseases](https://dndi.org/partnerships/partners/ngos-networks/unite-the-global-parliamentarians-network-to-end-infectious-diseases/)
- [University of Gadarif](https://dndi.org/partnerships/partners/universities-research/university-of-gedaraf/)
- [University College London (UCL)](https://dndi.org/partnerships/partners/universities-research/university-college-london-ucl/)
- [Center for Medicinal Chemistry (CQMED)](https://dndi.org/partnerships/partners/universities-research/center-for-medicinal-chemistry-cqmed/)
- [Médecins Sans Frontières (MSF) - Artsen zonder Grenzen](https://dndi.org/partnerships/partners/ngos-networks/medecins-sans-frontieres-the-netherlands/)
- [Assistance Publique-Hôpitaux de Paris (AP-HP)](https://dndi.org/partnerships/partners/healthcare/assistance-publique-hopitaux-de-paris-ap-hp/)
- [O’Neill Institute for National and Global Health Law, George Town University](https://dndi.org/partnerships/partners/universities-research/oneill-institute-george-town-university/)
- [Ministry of Health Tanzania](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-tanzania/)
- [Ministry of Health Kenya](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-kenya/)
- [ICAP](https://dndi.org/partnerships/partners/universities-research/icap-columbia-university/)
- [Ministère des Affaires Sociales et de la Santé Sénégal](https://dndi.org/partnerships/partners/mohs-gov/ministere-des-affaires-sociales-et-de-la-sante-senegal/)
- [Ministry of Health Uganda](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-uganda-2/)
- [Epicentre (MSF) - France](https://dndi.org/partnerships/partners/universities-research/epicentre-france/)
- [NOVA University Lisbon, Institute of Hygiene and Tropical Medicine (IHMT/NOVA)](https://dndi.org/partnerships/partners/universities-research/nova-university-lisbon-institute-of-hygiene-and-tropical-medicine-ihmt-nova/)
- [World Health Organization (WHO) Regional Office for Africa](https://dndi.org/partnerships/partners/ngos-networks/world-health-organization-who-regional-office-for-africa/)
- [Sanofi](https://dndi.org/partnerships/partners/pharma-biotech/sanofi/)
- [NOVA University Lisbon](https://dndi.org/partnerships/partners/universities-research/nova-university-lisbon/)
- [Institut Pasteur of Guinea](https://dndi.org/partnerships/partners/universities-research/institut-pasteur-of-guinea/)
- [Liverpool School of Tropical Medicine (LSTM)](https://dndi.org/partnerships/partners/universities-research/liverpool-school-of-tropical-medicine-lstm/)
- [Centre National de Recherche Scientifique (CNRS)](https://dndi.org/partnerships/partners/universities-research/centre-national-de-recherche-scientifique-cnrs/)
- [GlaxoSmithKline (GSK) - Spain](https://dndi.org/partnerships/partners/pharma-biotech/glaxosmithkline/)
- [University of Sussex (UNISU)](https://dndi.org/partnerships/partners/universities-research/university-of-sussex-unisu/)
- [Fundación MEDINA](https://dndi.org/partnerships/partners/ngos-networks/fundacion-medina/)
- [Instituto de Cardiología de Corrientes](https://dndi.org/partnerships/partners/universities-research/instituto-de-cardiologia-de-corrientes/)
- [Hospital Francisco Javier Muñiz](https://dndi.org/partnerships/partners/healthcare/hospital-francisco-javier-muniz/)
- [Hospital Donación Francisco Santojanni](https://dndi.org/partnerships/partners/healthcare/hospital-donacion-francisco-santojanni/)
- [Fundación Huésped](https://dndi.org/partnerships/partners/ngos-networks/fundacion-huesped/)
- [Daiichi Sankyo](https://dndi.org/partnerships/partners/pharma-biotech/daiichi-sankyo/)
- [Nagasaki University, Institute of Tropical Medicine](https://dndi.org/partnerships/partners/universities-research/nagasaki-university-institute-of-tropical-medicine/)
- [Mahidol Oxford Tropical Medicine Research Unit (MORU)](https://dndi.org/partnerships/partners/universities-research/mahidol-oxford-tropical-medicine-research-unit/)
- [Centre National de Pharmacovigilance  (CNPV), Université de Kinshasa](https://dndi.org/partnerships/partners/universities-research/centre-national-de-pharmacovigilance-cnpv-universite-de-kinshasa/)
- [University of Antwerp, Laboratory of Microbiology, Parasitology, and Hygiene (LMPH)](https://dndi.org/partnerships/partners/universities-research/laboratory-of-microbiology-parasitology-and-hygiene-lmph-university-of-antwerp/)
- [London School of Hygiene & Tropical Medicine (LSHTM)](https://dndi.org/partnerships/partners/universities-research/london-school-of-hygiene-tropical-medicine-lshtm/)
- [Universidad Nacional de San Martin](https://dndi.org/partnerships/partners/universities-research/universidad-san-martin/)
- [Instituto Oswaldo Cruz (IOC/Fiocruz)](https://dndi.org/partnerships/partners/universities-research/instituto-oswaldo-cruz-ioc-fiocruz/)
- [Pontificia Universidad Católica del Ecuador](https://dndi.org/partnerships/partners/universities-research/pontificia-universidad-catolica-del-ecuador/)
- [Universidad Mayor de San Simon](https://dndi.org/partnerships/partners/universities-research/universidad-mayor-de-san-simon/)
- [Universidad Central de Venezuela (UCV)](https://dndi.org/partnerships/partners/universities-research/universidad-central-de-venezuela/)
- [Novartis Institutes for BioMedical Research](https://dndi.org/partnerships/partners/pharma-biotech/novartis-institutes-for-biomedical-research/)
- [Hospital Eva Perón](https://dndi.org/partnerships/partners/healthcare/hospital-eva-peron/)
- [Fundación Mundo Sano](https://dndi.org/partnerships/partners/ngos-networks/fundacion-mundo-sano/)
- [Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI-CONICET)](https://dndi.org/partnerships/partners/universities-research/instituto-de-investigaciones-en-ingenieria-genetica-y-biologia-molecular-dr-hector-n-torres-ingebi-conicet/)
- [National Scientific and Technical Research Council (CONICET)](https://dndi.org/partnerships/partners/universities-research/national-council-of-scientific-and-technological-research-ingebi-conicet/)
- [Centro Nacional de Diagnóstico e Investigación de Endemo-epidemias (CeNDIE)](https://dndi.org/partnerships/partners/universities-research/centro-nacional-de-diagnostico-e-investigacion-de-endemo-epidemias-cendie/)
- [Universidad de los Andes](https://dndi.org/partnerships/partners/universities-research/universidad-de-los-andes/)
- [Instituto de Parasitología y Biomedicina López-Neyra](https://dndi.org/partnerships/partners/universities-research/instituto-de-parasitologia-y-biomedicina-lopez-neyra/)
- [Hospital Público Materno Infantil, Salta](https://dndi.org/partnerships/partners/hospitals/hospital-publico-materno-infantil-salta-argentina/)
- [Ministério de Salud, Província de Jujuy](https://dndi.org/partnerships/partners/mohs-gov/ministerio-de-salud-provincia-de-jujuy-argentina/)
- [Hospital de Niños Dr Hector Quintana Jujuy](https://dndi.org/partnerships/partners/hospitals/hospital-de-ninos-de-jujuy-argentina/)
- [Secretaría de Salud departamental de Boyacá](https://dndi.org/partnerships/partners/mohs-gov/health-secretary-of-boyaca/)
- [E.S.E. Hospital San Antonio de Tame](https://dndi.org/partnerships/partners/hospitals/e-s-e-san-antonio-de-tame/)
- [Chagas Programme of Santa Cruz](https://dndi.org/partnerships/partners/mohs-gov/chagas-programme-of-santa-cruz/)
- [Secretaría de Salud, Protección y Bienestar Social de Mogotes](https://dndi.org/partnerships/partners/mohs-gov/health-secretary-of-mogotes/)
- [Guatemala Chagas Programme](https://dndi.org/partnerships/partners/mohs-gov/guatemala-chagas-programme/)
- [Pan American Health Organization (PAHO)](https://dndi.org/partnerships/partners/ngos-networks/pan-american-health-organization-paho/)
- [The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS Colombia)](https://dndi.org/partnerships/partners/ngos-networks/the-international-federation-of-associations-of-people-affected-by-chagas-disease-findechagas-colombia/)
- [The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS Brazil)](https://dndi.org/partnerships/partners/ngos-networks/the-international-federation-of-associations-of-people-affected-by-chagas-disease-findechagas-brazil/)
- [Instituto Nacional de Infectologia Evandro Chagas (INI) - Fiocruz](https://dndi.org/partnerships/partners/universities-research/instituto-evandro-chagas/)
- [Massachusetts College of Pharmacy and Health Sciences](https://dndi.org/partnerships/partners/universities-research/massachusetts-college-of-pharmacy-and-health-sciences/)
- [Miami University, Ohio](https://dndi.org/partnerships/partners/universities-research/miami-university/)
- [Instituto de Infectologia Emilio Ribas](https://dndi.org/partnerships/partners/universities-research/instituto-de-infectologia-emilio-ribas/)
- [Universidade Estadual do Rio de Janeiro](https://dndi.org/partnerships/partners/universities-research/universidade-estadual-do-rio-de-janeiro/)
- [University of York](https://dndi.org/partnerships/partners/universities-research/university-of-york/)
- [Universidade Federal do Rio de Janeiro (UFRJ)](https://dndi.org/partnerships/partners/universities-research/universidade-federal-do-rio-de-janeiro-ufrj/)
- [ImaBiotech](https://dndi.org/partnerships/partners/industry-partners/imabiotech/)
- [Netherlands Cancer Institute, Research Foundation](https://dndi.org/partnerships/partners/universities-research/research-foundation-of-the-netherlands-cancer-institute/)
- [Institut Pasteur Korea (IPK)](https://dndi.org/partnerships/partners/universities-research/institut-pasteur-korea-ipk/)
- [BioSquare](https://dndi.org/partnerships/partners/industry-partners/biosquare/)
- [Mologic Ltd.](https://dndi.org/partnerships/partners/industry-partners/mologic-ltd/)
- [Albert David Limited](https://dndi.org/partnerships/partners/industry-partners/albert-david-limited/)
- [Ajinomoto Bio-Pharma Services (GeneDesign, Inc.)](https://dndi.org/partnerships/partners/pharma-biotech/genedesign-inc/)
- [TOGETHER trial](https://dndi.org/partnerships/partners/universities-research/together-trial/)
- [Spotlab](https://dndi.org/partnerships/partners/industry-partners/spotlab/)
- [Armauer Hansen Research Institute (AHRI)](https://dndi.org/partnerships/partners/universities-research/armauer-hansen-research-institute-ahri/)
- [and other partners](https://dndi.org/partnerships/partners/and-other-partners/)
- [Uppsala University](https://dndi.org/partnerships/partners/universities-research/uppsala-university/)
- [Utrecht University](https://dndi.org/partnerships/partners/universities-research/utrecht-university/)
- [Gilead Sciences](https://dndi.org/partnerships/partners/pharma-biotech/gilead-sciences/)
- [BaseCon A/S](https://dndi.org/partnerships/partners/pharma-biotech/basecon/)
- [Medical Research Council](https://dndi.org/partnerships/partners/universities-research/medical-research-council/)
- [Elizabeth Glaser Pediatric AIDS Foundation](https://dndi.org/partnerships/partners/ngos-networks/elizabeth-glaser-pediatric-aids-foundation/)
- [Baylor College of Medicine Children’s Foundation](https://dndi.org/partnerships/partners/baylor-college-of-medicine-childrens-foundation/)
- [MedChemica Ltd.](https://dndi.org/partnerships/partners/medchemica-ltd/)
- [Icahn School of Medicine at Mount Sinai](https://dndi.org/partnerships/partners/universities-research/icahn-school-of-medicine-at-mount-sinai/)
- [Enamine Ltd.](https://dndi.org/partnerships/partners/industry-partners/enamine-ltd/)
- [University of Otago](https://dndi.org/partnerships/partners/universities-research/university-of-otago/)
- [Pharmetheus AB](https://dndi.org/partnerships/partners/pharma-biotech/pharmatheus/)
- [Cardinal Systems](https://dndi.org/partnerships/partners/pharma-biotech/cardinal-systems/)
- [Cryptococcal Meningitis Action Group (CryptoMAG)](https://dndi.org/partnerships/partners/ngos-networks/cryptococcal-meningitis-action-group-cryptomag/)
- [MSF Access Campaign](https://dndi.org/partnerships/partners/ngos-networks/msf-access-campaign/)
- [ANRS | Maladies infectieuses émergentes](https://dndi.org/partnerships/partners/universities-research/agence-nationale-de-recherche-sur-le-sida-et-les-hepatites-virales-anrs/)
- [Weizmann Institute of Science](https://dndi.org/partnerships/partners/weizmann-institute-of-science/)
- [PostEra](https://dndi.org/partnerships/partners/postera/)
- [Nuffield Department of Medicine at the University of Oxford](https://dndi.org/partnerships/partners/nuffield-department-of-medicine-at-the-university-of-oxford/)
- [Memorial Sloan Kettering Cancer Center](https://dndi.org/partnerships/partners/memorial-sloan-kettering-cancer-center/)
- [Institut de Recherche pour le Développement (IRD) - Sénégal](https://dndi.org/partnerships/partners/universities-research/institute-of-research-for-development-ird/)
- [Institut de Recherche pour le Développement (IRD) - France](https://dndi.org/partnerships/partners/universities-research/institut-de-recherche-pour-le-developpement/)
- [AbbVie](https://dndi.org/partnerships/partners/industry-partners/abbvie-2/)
- [DeepMind](https://dndi.org/partnerships/partners/industry-partners/deepmind/)
- [Aix-Marseille Université, Unité de Virus émergents](https://dndi.org/partnerships/partners/universities-research/universite-daix-marseille-unite-de-virus-emergents/)
- [Stellenbosch University](https://dndi.org/partnerships/partners/universities-research/stellenbosch-university/)
- [Institut National de Recherche Biomédicale (INRB)](https://dndi.org/partnerships/partners/universities-research/institut-national-de-recherche-biomedicale-drc/)
- [Programme National de Lutte contre les Maladies Non Transmissibles](https://dndi.org/partnerships/partners/mohs-gov/programme-national-de-lutte-contre-les-maladies-non-transmissibles/)
- [Medicines for Malaria Venture (MMV)](https://dndi.org/partnerships/partners/ngos-networks/medicines-for-malaria-venture-mmv/)
- [University of Gondar Hospital](https://dndi.org/partnerships/partners/universities-research/university-of-gondar/)
- [Kacheliba District Hospital](https://dndi.org/partnerships/partners/hospitals/kacheliba-district-hospital/)
- [GlaxoSmithKline (GSK)](https://dndi.org/partnerships/partners/pharma-biotech/glaxosmithkline-uk/)
- [Fiotec](https://dndi.org/partnerships/partners/ngos-networks/fiotec/)
- [Baylor College of Medicine](https://dndi.org/partnerships/partners/baylor-college-of-medicine-tropical-medicine/)
- [Zürcher Hochschule für Angewandte Wissenschaften](https://dndi.org/partnerships/partners/universities-research/zurcher-hochschule-fur-angewandte-wissenschaften/)
- [The University of Tokyo](https://dndi.org/partnerships/partners/universities-research/the-university-of-tokyo/)
- [Instituto Conmemorativo Gorgas de Estudios de la Salud](https://dndi.org/partnerships/partners/universities-research/instituto-conmemorativo-gorgas-de-estudios-de-la-salud/)
- [Medicines Development for Global Health](https://dndi.org/partnerships/partners/ngos-networks/medicines-development-for-global-health/)
- [Institute for Clinical Research (ICR)](https://dndi.org/partnerships/partners/universities-research/clinical-research-centre-crc/)
- [Hospital Kuala Lumpur](https://dndi.org/partnerships/partners/hospitals/hospital-kuala-lumpur/)
- [Ministry of Public Health Thailand](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-and-ministry-of-industry-science-and-technology-thailand/)
- [Hospital Sultanah Nur Zahirah, Kuala Terengganu](https://dndi.org/partnerships/partners/hospitals/hospital-sultanah-nur-zahirah-kuala-terengganu/)
- [Hospital Sultanah Aminah, Johor Bharu](https://dndi.org/partnerships/partners/hospitals/hospital-sultanah-aminah-johor-bharu/)
- [Hospital Raja Perempuan Zainab II, Kota Bharu](https://dndi.org/partnerships/partners/hospitals/hospital-raja-perempuan-zainab-ii-kota-bharu/)
- [Department of Medicine/Infectious Disease, Hospital Sungai Buloh](https://dndi.org/partnerships/partners/hospitals/department-of-medicine-infectious-disease-hospital-sungai-buloh/)
- [Department of Hepatology, Hospital Selayang](https://dndi.org/partnerships/partners/hospitals/department-of-hepatology-hospital-selayang/)
- [CAD Middle East Pharmaceutical Industries](https://dndi.org/partnerships/partners/pharma-biotech/cad-middle-east-pharmaceutical-industries/)
- [Bamrasnaradura Infectious Diseases Institute](https://dndi.org/partnerships/partners/universities-research/bamrasnaradura-infectious-diseases-institute/)
- [King Chulalongkorn Memorial Hospital/HIVNAT](https://dndi.org/partnerships/partners/universities-research/hiv-nat-aids-research-centre/)
- [Tokyo Institute of Technology, The University of Tokyo](https://dndi.org/partnerships/partners/universities-research/tokyo-institute-of-technology/)
- [Clinique Ngaliema](https://dndi.org/partnerships/partners/hospitals/la-clinique-ngaliema/)
- [Hôpital Saint Joseph](https://dndi.org/partnerships/partners/hospitals/lhopital-saint-joseph/)
- [Katholieke Universiteit Leuven](https://dndi.org/partnerships/partners/universities-research/katholieke-universiteit-leuven/)
- [Elanco Animal Health](https://dndi.org/partnerships/partners/pharma-biotech/elanco-animal-health/)
- [Programme National de Lutte contre les Maladies Tropicales Négligées (PNLMTN)](https://dndi.org/partnerships/partners/mohs-gov/programme-national-de-lutte-contre-les-maladies-tropicales-negligees-pnlmtn/)
- [Luxembourg Institute of Health](https://dndi.org/partnerships/partners/universities-research/luxembourg-institute-of-health/)
- [Université de Bordeaux - Institut National de la Santé et de la Recherche Médicale  (INSERM)](https://dndi.org/partnerships/partners/universities-research/universitede-bordeaux-institut-national-de-la-sante-et-de-larecherchemedicale-inserm/)
- [Centre Suisse de Recherches Scientifiques (CSRS)](https://dndi.org/partnerships/partners/universities-research/centre-suisse-de-recherches-scientifiques-csrs/)
- [Centre Pour Le Développement Des Vaccins, Ministry of Health](https://dndi.org/partnerships/partners/mohs-gov/centre-pour-le-developpement-des-vaccins-ministry-ofhealth/)
- [Centre Pasteur du Cameroun (CPC)](https://dndi.org/partnerships/partners/universities-research/centre-pasteur-du-cameroun-cpc/)
- [Centre for Research in Therapeutic Sciences](https://dndi.org/partnerships/partners/universities-research/centre-for-research-in-therapeutic-sciences/)
- [Centre Muraz, Institut National de Santé Publique](https://dndi.org/partnerships/partners/universities-research/centremuraz-institut-national-de-sante-publique/)
- [National Science and Technology Development Agency (NSTDA)](https://dndi.org/partnerships/partners/mohs-gov/national-science-and-technology-development-agency-nstda/)
- [Nakornping Hospital](https://dndi.org/partnerships/partners/hospitals/nakornping-hospital/)
- [Maharaj Nakorn Chiang Mai University](https://dndi.org/partnerships/partners/universities-research/maharaj-nakorn-chiang-mai-university/)
- [Institute of Medical Research (IMR)](https://dndi.org/partnerships/partners/universities-research/institute-of-medical-research-imr/)
- [Institut Pasteur](https://dndi.org/partnerships/partners/universities-research/institut-pasteur/)
- [Royal Society of Chemistry](https://dndi.org/partnerships/partners/ngos-networks/royal-society-of-chemistry/)
- [Novartis Institute for Tropical Diseases](https://dndi.org/partnerships/partners/universities-research/novartis-institute-for-tropical-diseases/)
- [Otsuka Pharmaceutical Co., Ltd.](https://dndi.org/partnerships/partners/pharma-biotech/otsuka-pharmaceutical-co-ltd/)
- [Mott McDonald Ltd.,](https://dndi.org/partnerships/partners/universities-research/mott-mcdonald-ltd/)
- [Charles River Laboratories (formerly WIL Research)](https://dndi.org/partnerships/partners/pharma-biotech/charles-river/)
- [Accelera](https://dndi.org/partnerships/partners/pharma-biotech/accelera/)
- [Médecins Sans Frontières (MSF) France](https://dndi.org/partnerships/partners/ngos-networks/medecins-sans-frontieres-msf-france/)
- [Ministry of Health Malaysia](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-malaysia/)
- [Eurofarma](https://dndi.org/partnerships/partners/pharma-biotech/eurofarma/)
- [Seattle Structural Genomics Center for Infectious Disease (SSGCID)](https://dndi.org/partnerships/partners/ngos-networks/seattle-structural-genomics-center-for-infectious-disease-ssgcid/)
- [Structural Genomics Consortium (SGC)](https://dndi.org/partnerships/partners/ngos-networks/structural-genomics-consortium-sgc/)
- [Roowin](https://dndi.org/partnerships/partners/pharma-biotech/roowin/)
- [Central Diagnostics](https://dndi.org/partnerships/partners/pharma-biotech/central-diagnostics/)
- [Catalent](https://dndi.org/partnerships/partners/pharma-biotech/catalent/)
- [Calvert Labs](https://dndi.org/partnerships/partners/pharma-biotech/calvert-labs/)
- [Ministry of Health and Child Care Zimbabwe](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-zimbabwe/)
- [Seattle Institute for Biomedical and Clinical Research (SIBCR)](https://dndi.org/partnerships/partners/universities-research/seattle-institute-for-biomedical-and-clinical-research-sibcr/)
- [B.P Koirala Institute of Health Sciences](https://dndi.org/partnerships/partners/universities-research/b-p-koirala-institute-of-health-sciences/)
- [Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (FIPEC)](https://dndi.org/partnerships/partners/universities-research/fundacion-para-el-estudio-de-las-infecciones-parasitarias-y-enfermedad-de-chagas-fipec/)
- [London School of Pharmacy (now UCL School of Pharmacy)](https://dndi.org/partnerships/partners/universities-research/london-school-of-pharmacy-now-ucl-school-of-pharmacy/)
- [Genzyme (now Sanofi-Genzyme)](https://dndi.org/partnerships/partners/pharma-biotech/genzyme/)
- [Analyticon Discovery Gmbh](https://dndi.org/partnerships/partners/pharma-biotech/analyticon-discovery-gmbh/)
- [The Task Force for Global Health](https://dndi.org/partnerships/partners/ngos-networks/the-task-force-for-global-health/)
- [Research Foundation for Tropical Diseases and the Environment (REFOTDE)](https://dndi.org/partnerships/partners/universities-research/research-foundation-for-tropical-diseases-and-the-environment-refotde/)
- [Programme national de lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive](https://dndi.org/partnerships/partners/mohs-gov/programme-national-de-lutte-contre-les-maladies-tropicales-negligees-a-chimiotherapie-preventive/)
- [MC Toxicology Consulting GmbH](https://dndi.org/partnerships/partners/pharma-biotech/mc-toxicology-consulting-gmbh/)
- [Margan Clinical Research Organization](https://dndi.org/partnerships/partners/pharma-biotech/margan-clinical-research-organization/)
- [Datametrix AG](https://dndi.org/partnerships/partners/pharma-biotech/datametrix-ag/)
- [Commissariat à l’énergie atomique et aux énergies alternatives](https://dndi.org/partnerships/partners/universities-research/commissariat-a-lenergie-atomique-et-aux-energies-alternatives/)
- [Syneos Health, Llc.](https://dndi.org/partnerships/partners/pharma-biotech/syneos-health-llc/)
- [Ministry of Health Brazil, Leishmaniasis Control Programme](https://dndi.org/partnerships/partners/mohs-gov/leishmaniasis-control-programme-ministry-of-health/)
- [International Development Research Centre (IDRC) Uruguay](https://dndi.org/partnerships/partners/universities-research/international-development-research-centre-idrc-uruguay/)
- [Instituto de Efectividad Clínica Y Sanitaria (IECS)](https://dndi.org/partnerships/partners/universities-research/instituto-de-efectividad-clinica-y-sanitaria-iecs/)
- [Institut d’Investigacio Biomedica de Bellvitge](https://dndi.org/partnerships/partners/universities-research/institut-dinvestigacio-biomedica-de-bellvitge/)
- [Hospital Universitario La Paz](https://dndi.org/partnerships/partners/hospitals/hospital-universitario-la-paz/)
- [Fundación Instituto de Investigaciones Biotecnológicas](https://dndi.org/partnerships/partners/universities-research/fundacion-instituto-de-investigaciones-biotecnologicas/)
- [Fundación Cardioinfantil, Instituto de Cardiología](https://dndi.org/partnerships/partners/universities-research/fundacion-cardioinfantil-instituto-de-cardiologia/)
- [Exeltis](https://dndi.org/partnerships/partners/pharma-biotech/exeltis/)
- [Chembrige Corporation](https://dndi.org/partnerships/partners/universities-research/chembrige-corporation/)
- [University of Glasgow](https://dndi.org/partnerships/partners/universities-research/university-of-glasgow/)
- [Thermosurgery Technologies Inc.](https://dndi.org/partnerships/partners/pharma-biotech/thermosurgery-technologies-inc/)
- [Takeda Pharmaceutical Company Limited](https://dndi.org/partnerships/partners/pharma-biotech/takeda-pharmaceutical-company-ltd/)
- [State Health Society, Bihar](https://dndi.org/partnerships/partners/mohs-gov/bihar-state-health-society/)
- [Rajendra Memorial Research Institute of Medical Sciences (RMRIMS)](https://dndi.org/partnerships/partners/universities-research/rajendra-memorial-research-institute-of-medical-sciences-rmrims/)
- [Universidad de Antioquia Medellin, Programa de Estudio y Control de Enfermedades Tropicales](https://dndi.org/partnerships/partners/universities-research/programa-de-estudio-y-control-de-enfermedades-tropicales-universidad-de-antioquia-medellin/)
- [Polytherics (now Abzena)](https://dndi.org/partnerships/partners/pharma-biotech/polytherics-now-abzena/)
- [Pierre Fabre Laboratories](https://dndi.org/partnerships/partners/pharma-biotech/pierre-fabre-laboratories/)
- [Phi Pharma SA](https://dndi.org/partnerships/partners/pharma-biotech/phi-pharma-sa/)
- [Pentlands Management Systems Ltd.](https://dndi.org/partnerships/partners/pharma-biotech/pentlands-management-systems-ltd/)
- [Pasteur Institute of Iran](https://dndi.org/partnerships/partners/universities-research/pasteur-institute-of-iran/)
- [Ministry of Health Uganda, Leishmaniasis Control Programme](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-uganda/)
- [Ministry of Health Sudan, Neglected Tropical Diseases Unit, Leishmaniasis Programme](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-sudan/)
- [Ministry of Health Kenya, Neglected Tropical Diseases Unit, Leishmaniasis Programme](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-kenya-neglected-tropical-diseases-unit-leishmaniasis-programme/)
- [Ministry of Health Ethiopia, Neglected Tropical Disease Directorate](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-ethiopia/)
- [Kimalel Hospital](https://dndi.org/partnerships/partners/hospitals/kimalel-hospital/)
- [Intertek](https://dndi.org/partnerships/partners/pharma-biotech/intertek/)
- [Universidade Estadual de Campinas (UNICAMP)](https://dndi.org/partnerships/partners/universities-research/universidade-estadual-de-campinas-unicamp/)
- [Iktos](https://dndi.org/partnerships/partners/pharma-biotech/iktos/)
- [Genomics Institute of The Novartis Research Foundation (GNF)](https://dndi.org/partnerships/partners/pharma-biotech/genomics-institute-of-the-novartis-research-foundation-gnf/)
- [Eurofins Panlabs Thailand](https://dndi.org/partnerships/partners/pharma-biotech/eurofins-panlabs-thailand/)
- [Eurofins Panlabs](https://dndi.org/partnerships/partners/pharma-biotech/eurofins-panlabs/)
- [E.I du Pont de Nemours](https://dndi.org/partnerships/partners/pharma-biotech/dupont-formerly-e-i-du-pont-nemours/)
- [Dermalaser](https://dndi.org/partnerships/partners/hospitals/dermalaser/)
- [Cornell University](https://dndi.org/partnerships/partners/universities-research/cornell-university/)
- [Centro de Inovação e Ensaios Pré-Clinicos (CIENP)](https://dndi.org/partnerships/partners/universities-research/centro-de-inovacao-e-ensaios-pre-clinicos-cienp/)
- [NEPHAK](https://dndi.org/partnerships/partners/ngos-networks/nephak/)
- [Moi University](https://dndi.org/partnerships/partners/universities-research/moi-university/)
- [International Community of Women Living with HIV](https://dndi.org/partnerships/partners/ngos-networks/international-community-of-women-living-with-hiv/)
- [i-Base](https://dndi.org/partnerships/partners/ngos-networks/hiv-i-base/)
- [University of Cape Town (UCT), Division of Clinical Pharmacology, Department of Medicine](https://dndi.org/partnerships/partners/universities-research/division-of-clinical-pharmacology-department-of-medicine-university-of-cape-town/)
- [AMPATH](https://dndi.org/partnerships/partners/ngos-networks/ampath/)
- [Zhejiang Ausun Pharmaceutical Co., Ltd.](https://dndi.org/partnerships/partners/pharma-biotech/zhejiang-ausun-pharmaceutical-co-ltd/)
- [Public Health Promotion Research and Training Thailand](https://dndi.org/partnerships/partners/mohs-gov/public-health-promotion-research-and-training-thailand/)
- [BioDelivery Sciences International Inc.](https://dndi.org/partnerships/partners/pharma-biotech/biodelivery-sciences-international-inc/)
- [Bio Zeq Kenya Ltd.](https://dndi.org/partnerships/partners/pharma-biotech/bio-zeq/)
- [Venn Life Sciences](https://dndi.org/partnerships/partners/pharma-biotech/venn-life-sciences/)
- [Trade Factors Overseas Ltd.](https://dndi.org/partnerships/partners/pharma-biotech/trade-factors-overseas-ltd/)
- [Top Institute Pharma (TI Pharma)](https://dndi.org/partnerships/partners/ngos-networks/top-institute-pharma-ti-pharma/)
- [Tehran University](https://dndi.org/partnerships/partners/universities-research/tehran-university/)
- [Roche](https://dndi.org/partnerships/partners/pharma-biotech/roche/)
- [Pharmadyn Inc.](https://dndi.org/partnerships/partners/pharma-biotech/pharmadyn-inc/)
- [Novartis](https://dndi.org/partnerships/partners/pharma-biotech/novartis/)
- [HES-SO Valais Wallis](https://dndi.org/partnerships/partners/universities-research/hes-so-valais-wallis/)
- [Foundation for the National Institutes of Health (FNIH)](https://dndi.org/partnerships/partners/ngos-networks/foundation-for-the-national-institutes-of-health-fnih/)
- [Evolva SA](https://dndi.org/partnerships/partners/pharma-biotech/evolva-sa/)
- [Evanston Northwestern Healthcare (now NorthShore University HealthSystem)](https://dndi.org/partnerships/partners/hospitals/evanston-northwestern-healthcare-now-northshore-university-healthsystem/)
- [Dow AgroSciences LLC](https://dndi.org/partnerships/partners/pharma-biotech/dow-agrosciences-llc/)
- [Debiopharm SA](https://dndi.org/partnerships/partners/pharma-biotech/debiopharm-sa/)
- [Chiron Corporation (now Novartis)](https://dndi.org/partnerships/partners/pharma-biotech/chiron-corporation-now-novartis/)
- [BIOTEC](https://dndi.org/partnerships/partners/universities-research/biotec/)
- [Basilea Pharmaceutica AG](https://dndi.org/partnerships/partners/pharma-biotech/basilea-pharmaceutica-ag/)
- [Asinex Corporation](https://dndi.org/partnerships/partners/pharma-biotech/asinex-corporation/)
- [Médecins Sans Frontières (MSF) Ukraine](https://dndi.org/partnerships/partners/ngos-networks/medecins-sans-frontieres-ukraine/)
- [WHO-TDR, Special Programme for Research and Training in Tropical Diseases](https://dndi.org/partnerships/partners/ngos-networks/special-programme-for-research-and-training-in-tropical-diseases-who-tdr/)
- [OneWorld Health (OWH)](https://dndi.org/partnerships/partners/ngos-networks/oneworld-health/)
- [Médecins Sans Frontières (MSF) Switzerland](https://dndi.org/partnerships/partners/ngos-networks/medecins-sans-frontieres-switzerland/)
- [Ministry of Health and Family Welfare Bangladesh](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-and-family-welfare-bangladesh/)
- [Management and Development for Health (MDH)](https://dndi.org/partnerships/partners/ngos-networks/management-and-development-for-health-mdh/)
- [University of Melbourne](https://dndi.org/partnerships/partners/universities-research/university-of-melbourne/)
- [Walter and Eliza Hall Institute of Medical Research (WEHI)](https://dndi.org/partnerships/partners/universities-research/walter-and-eliza-hall-institute-of-medical-research-wehi/)
- [Ministry of Health Argentina](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-argentina/)
- [Certara (formerly Quantitative Solutions)](https://dndi.org/partnerships/partners/pharma-biotech/quantitative-solutions/)
- [Ministry of Health Ghana](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-ghana/)
- [University of Georgia, Center for Tropical & Emerging Global Diseases](https://dndi.org/partnerships/partners/universities-research/center-for-tropical-emerging-global-diseases-university-of-georgia/)
- [Monash University, Centre for Drug Candidate Optimisation (CDCO)](https://dndi.org/partnerships/partners/universities-research/centre-for-drug-candidate-optimisation-cdco-monash-university/)
- [Murdoch University, Department of Parasitology and Veterinary Sciences](https://dndi.org/partnerships/partners/universities-research/department-of-parasitology-and-veterinary-sciences-murdoch-university/)
- [Texas Biomedical Research Institute](https://dndi.org/partnerships/partners/universities-research/texas-biomedical-research-institute/)
- [Institute of Endemic Diseases (IEND), Khartoum University](https://dndi.org/partnerships/partners/universities-research/institute-of-endemic-diseases-iend-khartoum-university/)
- [National Malaria Control Programme, Ministry of Health Burundi](https://dndi.org/partnerships/partners/mohs-gov/national-malaria-control-programme-ministry-of-health-burundi/)
- [National Institute of Pathology India](https://dndi.org/partnerships/partners/universities-research/national-institute-of-pathology-india/)
- [KIT (Kononklijk Instituut voor de Tropen) Royal Tropical Institute](https://dndi.org/partnerships/partners/universities-research/royal-tropical-institute-kit/)
- [Instituto Nacional de Salud Pública – INSP](https://dndi.org/partnerships/partners/universities-research/instituto-nacional-de-salud-publica-insp/)
- [Instituto Medico la Floresta](https://dndi.org/partnerships/partners/universities-research/instituto-medico-la-floresta/)
- [Department of Parasitology, Public Health Training Program – U.S. Naval Medical Research Unit No. 6](https://dndi.org/partnerships/partners/universities-research/department-of-parasitology-public-health-training-program-u-s-naval-medical-research-unit-no-6/)
- [Universidad del Valle](https://dndi.org/partnerships/partners/universities-research/universidad-del-valle/)
- [Instituto Colombiano de Medicina Tropical](https://dndi.org/partnerships/partners/universities-research/instituto-colombiano-de-medicina-tropical/)
- [Centro Internacional de Entrenamiento e Investigaciones Medicas (CIDEIM)](https://dndi.org/partnerships/partners/universities-research/centro-internacional-de-entrenamiento-e-investigaciones-medicas-cideim/)
- [Centro Dermatológico Federico Lleras Acosta](https://dndi.org/partnerships/partners/universities-research/centro-dermatologico-federico-lleras-acosta/)
- [Universidade Federal do Piauí (UFPI)](https://dndi.org/partnerships/partners/universities-research/universidade-federal-do-piaui-ufpi/)
- [Universidade Federal do Pará (UFPA)](https://dndi.org/partnerships/partners/universities-research/universidade-federal-do-para-ufpa/)
- [Universidade Federal de Santa Catarina (UFSC)](https://dndi.org/partnerships/partners/universities-research/universidade-federal-de-santa-catarina-ufsc/)
- [Universidade do Estado do Pará (UEPA)](https://dndi.org/partnerships/partners/universities-research/universidade-do-estado-do-para-uepa/)
- [Universidade de Pernambuco (UFPE)](https://dndi.org/partnerships/partners/universities-research/universidade-de-pernambuco-ufpe/)
- [Universidade de Brasília – Núcleo de Medicina Tropical (UnB)](https://dndi.org/partnerships/partners/universities-research/universidade-de-brasilia-nucleo-de-medicina-tropical-unb/)
- [Secretaria Municipal de Saúde Unidade Referência em Atenção Primária Drª Claudia Vitorino](https://dndi.org/partnerships/partners/mohs-gov/secretaria-municipal-de-saude-unidade-referencia-em-atencao-primaria-dra-claudia-vitorino/)
- [Plataforma de Pesquisa Clínica – Fiocruz RJ](https://dndi.org/partnerships/partners/universities-research/plataforma-de-pesquisa-clinica-fiocruz-rj/)
- [Instituto Nacional de Pesquisa da Amazônia (INPA)](https://dndi.org/partnerships/partners/universities-research/instituto-nacional-de-pesquisa-da-amazonia-inpa/)
- [Instituto Nacional de Infectologia – Fiocruz RJ](https://dndi.org/partnerships/partners/universities-research/instituto-nacional-de-infectologia-fiocruz-rj/)
- [Fundação de Medicina Tropical Heitor Vieira Dourado](https://dndi.org/partnerships/partners/ngos-networks/fundacao-de-medicina-tropical-heitor-vieira-dourado/)
- [Centro de Pesquisa Gonçalo Moniz-Fiocruz BA](https://dndi.org/partnerships/partners/universities-research/centro-de-pesquisa-goncalo-moniz-fiocruz-ba/)
- [University of California](https://dndi.org/partnerships/partners/universities-research/university-of-california/)
- [Universidad Nacional de Córdoba](https://dndi.org/partnerships/partners/universities-research/universidad-nacional-de-cordoba/)
- [Universidad Nacional Autónoma de México (UNAM)](https://dndi.org/partnerships/partners/universities-research/universidad-nacional-autonoma-de-mexico-unam/)
- [Grupo de Didáctica de las Ciencias (IFLYSIB, CONICET-UNLP)](https://dndi.org/partnerships/partners/universities-research/grupo-de-didactica-de-las-ciencias-iflysib-conicet-unlp/)
- [National Control Programme of the Republic of the Congo](https://dndi.org/partnerships/partners/mohs-gov/national-control-programme-of-the-republic-of-the-congo/)
- [Tropical Medicine Research Institute (TMRI)](https://dndi.org/partnerships/partners/universities-research/tropical-medicine-research-institute-tmri/)
- [Kenya Agricultural Research Institute – Trypanosomiasis Research Centre (KARI-TRC)](https://dndi.org/partnerships/partners/universities-research/kenya-agricultural-research-institute-trypanosomiasis-research-centre-kari-trc/)
- [Juba University](https://dndi.org/partnerships/partners/universities-research/juba-university/)
- [INZI Project, University of Edinburgh](https://dndi.org/partnerships/partners/universities-research/inzi-project-university-of-edinburgh/)
- [Institut Pasteur Bangui](https://dndi.org/partnerships/partners/universities-research/institut-pasteur-bangui/)
- [Eastern Africa Network for Trypanosomosis (EANETT)](https://dndi.org/partnerships/partners/ngos-networks/eastern-africa-network-for-trypanosomosis-eanett/)
- [Federal Bureau of Health, Ethiopia](https://dndi.org/partnerships/partners/mohs-gov/federal-bureau-of-health-ethiopia/)
- [Drug Regulatory Authorities, Sudan](https://dndi.org/partnerships/partners/mohs-gov/drug-regulatory-authorities-sudan/)
- [Drug Regulatory Authorities, Uganda](https://dndi.org/partnerships/partners/mohs-gov/drug-regulatory-authorities-uganda/)
- [Drug Regulatory Authorities, Kenya](https://dndi.org/partnerships/partners/mohs-gov/drug-regulatory-authorities-kenya/)
- [Drug Regulatory Authorities, Ethiopia](https://dndi.org/partnerships/partners/mohs-gov/drug-regulatory-authorities-ethiopia/)
- [University of North Carolina Project-Malawi](https://dndi.org/partnerships/partners/universities-research/university-of-north-carolina-project-malawi/)
- [St George’s, University of London](https://dndi.org/partnerships/partners/universities-research/st-georges-university-of-london/)
- [Ministry of Health, Sierra Leone](https://dndi.org/partnerships/partners/mohs-gov/ministry-of-health-sierra-leone/)
- [Bertin Pharma](https://dndi.org/partnerships/partners/pharma-biotech/bertin-pharma/)
- [Université de Bordeaux Faculté de Pharmacie](https://dndi.org/partnerships/partners/universities-research/universite-de-bordeaux-faculte-de-pharmacie/)
- [Zenufa](https://dndi.org/partnerships/partners/pharma-biotech/zenufa/)
- [European Agency for Development and Health (AEDES)](https://dndi.org/partnerships/partners/ngos-networks/european-agency-for-development-and-health-aedes/)
- [Worldwide Antimalarial Resistance Network (WWARN)](https://dndi.org/partnerships/partners/ngos-networks/worldwide-antimalarial-resistance-network-wwarn/)
- [Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Burkina Faso](https://dndi.org/partnerships/partners/universities-research/centre-national-de-recherche-et-de-formation-sur-le-paludisme-cnrfp-burkina-faso/)
- [Centre Hospitalier Universitaire Vaudois (CHUV)](https://dndi.org/partnerships/partners/hospitals/centre-hospitalier-universitaire-vaudois-chuv/)
- [National Institute of Medical Research (NIMR), Tanzania](https://dndi.org/partnerships/partners/universities-research/national-institute-of-medical-research-nimr-tanzania/)
- [Universiti Sains](https://dndi.org/partnerships/partners/universities-research/universiti-sains/)
- [Shoklo Malaria Research Unit](https://dndi.org/partnerships/partners/universities-research/shoklo-malaria-research-unit/)
- [Presidio Pharmaceuticals, Inc](https://dndi.org/partnerships/partners/pharma-biotech/presidio-pharmaceuticals-inc/)
- [Pharco Pharmaceuticals, Inc](https://dndi.org/partnerships/partners/pharma-biotech/pharco-pharmaceuticals-inc/)
- [Insud Pharma](https://dndi.org/partnerships/partners/pharma-biotech/insud-pharma/)
- [AMG Consultants](https://dndi.org/partnerships/partners/pharma-biotech/amg-consultants/)
- [Universidad de San Carlos](https://dndi.org/partnerships/partners/universities-research/universidad-de-san-carlos/)
- [Soatá Town Hall, Boyacá](https://dndi.org/partnerships/partners/mohs-gov/soata-town-hall-boyaca/)
- [International Development Research Centre (IDRC), Canada](https://dndi.org/partnerships/partners/universities-research/international-development-research-centre-idrc-canada/)
- [Hospital Regional de la Orinoquía ESE](https://dndi.org/partnerships/partners/hospitals/hospital-regional-de-la-orinoquia-ese/)
- [Health Secretary of Santader](https://dndi.org/partnerships/partners/mohs-gov/health-secretary-of-santader/)
- [Goiás State Department of Health](https://dndi.org/partnerships/partners/mohs-gov/goias-state-department-of-health/)
- [E.S.E. San Antonio de Soatá Hospital](https://dndi.org/partnerships/partners/hospitals/e-s-e-san-antonio-de-soata-hospital/)
- [E.S.E Hospital San Pedro Claver Mogotes](https://dndi.org/partnerships/partners/hospitals/e-s-e-hospital-san-pedro-claver-mogotes/)
- [Casa de Chagas, Pernambuco](https://dndi.org/partnerships/partners/ngos-networks/casa-de-chagas-pernambuco/)
- [Centro Nacional de Diagnóstico e Investigación de Endemo-epidemias,  Administración Nacional de Laboratorios e Institutos de Salud (ANLIS), Argentina](https://dndi.org/partnerships/partners/universities-research/centro-nacional-de-diagnostico-e-investigacion-de-endemo-epidemias-argentina/)
- [FP Clinical Pharma – Ethel Feleder](https://dndi.org/partnerships/partners/pharma-biotech/fp-clinical-pharma-ethel-feleder/)
- [Shaheed Suhrawardy Medical College and Hospital](https://dndi.org/partnerships/partners/hospitals/shaheed-suhrawardy-medical-college-and-hospital/)
- [PATH](https://dndi.org/partnerships/partners/ngos-networks/path/)
- [National Vector Borne Disease Control Programme, India](https://dndi.org/partnerships/partners/mohs-gov/national-vector-borne-disease-control-programme-india/)
- [Indian Council of Medical Research](https://dndi.org/partnerships/partners/universities-research/indian-council-of-medical-research/)
- [Arba Minch Hospital](https://dndi.org/partnerships/partners/hospitals/arba-minch-hospital/)
- [IDA Foundation](https://dndi.org/partnerships/partners/ngos-networks/ida-foundation/)
- [SGS, France](https://dndi.org/partnerships/partners/pharma-biotech/sgs/)
- [Communauté Baptiste du Congo (CBCO)](https://dndi.org/partnerships/partners/ngos-networks/communaute-baptiste-du-congo-cbco/)
- [University of Buea](https://dndi.org/partnerships/partners/universities-research/university-of-buea/)
- [Michigan State University](https://dndi.org/partnerships/partners/universities-research/michigan-state-university/)
- [University of California San Francisco (UCSF)](https://dndi.org/partnerships/partners/universities-research/university-of-california-san-francisco-ucsf/)
- [Federal University of Ouro Preto (UFOP)](https://dndi.org/partnerships/partners/universities-research/federal-university-of-ouro-preto-ufop/)
- [Murdoch University](https://dndi.org/partnerships/partners/universities-research/murdoch-university/)
- [Bioclinica](https://dndi.org/partnerships/partners/pharma-biotech/bioclinica/)
- [Endolytics](https://dndi.org/partnerships/partners/pharma-biotech/endolytics/)
- [Humax Pharmaceutical](https://dndi.org/partnerships/partners/pharma-biotech/humax-pharmaceutical/)
- [Sanofi-Chinoin](https://dndi.org/partnerships/partners/pharma-biotech/sanofi-chinoin/)
- [Addis Ababa University](https://dndi.org/partnerships/partners/universities-research/addis-ababa-university/)
- [Sergipe Federal University](https://dndi.org/partnerships/partners/universities-research/sergipe-federal-university/)
- [Piaui Federal University](https://dndi.org/partnerships/partners/universities-research/piaui-federal-university/)
- [Paediatric Hospital Joao Paulo II – FHEMIG](https://dndi.org/partnerships/partners/hospitals/paediatric-hospital-joao-paulo-ii-fhemig/)
- [Montes Claros State University](https://dndi.org/partnerships/partners/universities-research/montes-claros-state-university/)
- [Hospital Sao José de Doencas Infecciosas](https://dndi.org/partnerships/partners/hospitals/hospital-sao-jose-de-doencas-infecciosas/)
- [Brasilia University](https://dndi.org/partnerships/partners/universities-research/brasilia-university/)
- [Williams College, Massachusetts](https://dndi.org/partnerships/partners/universities-research/williams-college-massachusetts/)
- [University of Washington Tacoma](https://dndi.org/partnerships/partners/universities-research/university-of-washington-tacoma/)
- [University of Nottingham](https://dndi.org/partnerships/partners/universities-research/university-of-nottingham/)
- [University of Münster](https://dndi.org/partnerships/partners/universities-research/university-of-munster/)
- [University of Ghana](https://dndi.org/partnerships/partners/universities-research/university-of-ghana/)
- [University of Dundee](https://dndi.org/partnerships/partners/universities-research/university-of-dundee/)
- [University of Birmingham](https://dndi.org/partnerships/partners/universities-research/university-of-birmingham/)
- [Montclair State University](https://dndi.org/partnerships/partners/universities-research/montclair-state-university/)
- [Illinois Mathematics and Science Academy (IMSA)](https://dndi.org/partnerships/partners/universities-research/illinois-mathematics-and-science-academy-imsa/)
- [Haverford College](https://dndi.org/partnerships/partners/universities-research/haverford-college/)
- [De Montfort University, Leicester](https://dndi.org/partnerships/partners/universities-research/de-montfort-university-leicester/)
- [Augusta University](https://dndi.org/partnerships/partners/universities-research/augusta-university/)
- [SK Hospital, Mymensingh](https://dndi.org/partnerships/partners/hospitals/sk-hospital-mymensingh/)
- [Netherlands Cancer Institute](https://dndi.org/partnerships/partners/universities-research/netherlands-cancer-institute/)
- [Leishmaniasis East Africa Platform (LEAP)](https://dndi.org/partnerships/partners/ngos-networks/leishmaniasis-east-africa-platform-leap/)
- [Kala Azar Medical Research Centre](https://dndi.org/partnerships/partners/universities-research/kala-azar-medical-research-centre/)
- [University of Liverpool](https://dndi.org/partnerships/partners/universities-research/university-of-liverpool/)
- [AWOL](https://dndi.org/partnerships/partners/ngos-networks/awol/)
- [University of Health and Allied Sciences](https://dndi.org/partnerships/partners/universities-research/university-of-health-and-allied-sciences/)
- [Mahidol University](https://dndi.org/partnerships/partners/universities-research/mahidol-university/)
- [Imperial College London](https://dndi.org/partnerships/partners/universities-research/imperial-college-london/)
- [University of North Carolina, Office of Technology Development](https://dndi.org/partnerships/partners/universities-research/university-of-north-carolina-office-of-technology-development/)
- [Novartis Centre de la Recherche Santé Animale](https://dndi.org/partnerships/partners/pharma-biotech/novartis-centre-de-la-recherche-sante-animale/)
- [University of Texas at El Paso](https://dndi.org/partnerships/partners/universities-research/university-of-texas-at-el-paso/)
- [University of Georgia Research Foundation](https://dndi.org/partnerships/partners/universities-research/university-of-georgia-research-foundation/)
- [McGill University](https://dndi.org/partnerships/partners/universities-research/mcgill-university/)
- [Hospital de Niños Ricardo Gutiérrez, Buenos Aires](https://dndi.org/partnerships/partners/hospitals/hospital-de-ninos-ricardo-gutierrez-buenos-aires/)
- [US Food and Drug Administration (FDA)](https://dndi.org/partnerships/partners/mohs-gov/us-food-and-drug-administration-fda/)
- [Osaka University](https://dndi.org/partnerships/partners/universities-research/osaka-university/)
- [Ohio State University](https://dndi.org/partnerships/partners/universities-research/ohio-state-university/)
- [Uganda National Health Research Organisation (UNHRO)](https://dndi.org/partnerships/partners/universities-research/uganda-national-health-research-organisation-unhro/)
- [Makerere University](https://dndi.org/partnerships/partners/universities-research/makerere-university/)
- [Auckland University](https://dndi.org/partnerships/partners/universities-research/auckland-university/)
- [Aptuit](https://dndi.org/partnerships/partners/pharma-biotech/aptuit/)
- [Eurofins CEREP](https://dndi.org/partnerships/partners/pharma-biotech/eurofins-cerep/)
- [HAT Platform](https://dndi.org/partnerships/partners/ngos-networks/hat-platform/)
- [Sandexis](https://dndi.org/partnerships/partners/pharma-biotech/sandexis/)
- [Zoetis (formerly Pfizer Animal Health)](https://dndi.org/partnerships/partners/pharma-biotech/zoetis-formerly-pfizer-animal-health/)
- [University of Cape Town (UCT)](https://dndi.org/partnerships/partners/universities-research/university-of-cape-town-uct/)
- [TB Alliance](https://dndi.org/partnerships/partners/ngos-networks/tb-alliance/)
- [Boehringer Ingelheim](https://dndi.org/partnerships/partners/pharma-biotech/boehringer-ingelheim/)
- [Northwick Park Institute for Medical Research](https://dndi.org/partnerships/partners/universities-research/northwick-park-institute-for-medical-research/)
- [Kitasato Institute for Life Sciences](https://dndi.org/partnerships/partners/universities-research/kitasato-institute-for-life-sciences/)
- [Johnson & Johnson](https://dndi.org/partnerships/partners/pharma-biotech/johnson-johnson/)
- [Institute of Microbial Chemistry](https://dndi.org/partnerships/partners/universities-research/institute-of-microbial-chemistry/)
- [Broad Institute, M.I.T and Harvard](https://dndi.org/partnerships/partners/universities-research/broad-institute-m-i-t-and-harvard/)
- [Bristol-Myers Squibb](https://dndi.org/partnerships/partners/pharma-biotech/bristol-myers-squibb/)
- [AstraZeneca](https://dndi.org/partnerships/partners/pharma-biotech/astrazeneca/)
- [Universidad Autónoma Juan Misael Saracho](https://dndi.org/partnerships/partners/universities-research/universidad-autonoma-juan-misael-saracho/)
- [Unidad de Enfermedades Infecciosas, Seccion de Salud Internacional y Consejo al Viajero, Spain](https://dndi.org/partnerships/partners/mohs-gov/unidad-de-enfermedades-infecciosas-seccion-de-salud-internacional-y-consejo-al-viajero-spain/)
- [Platform of Integral Care for Patients with Chagas Disease, Tarija and Cochabamba](https://dndi.org/partnerships/partners/ngos-networks/platform-of-integral-care-for-patients-with-chagas-disease-tarija-and-cochabamba/)
- [Hospital General de l’Hospitalet and Hospital de Sant Joan Despí Moisès Broggi, Consorci Sanitari Integral](https://dndi.org/partnerships/partners/hospitals/hospital-general-de-lhospitalet-and-hospital-de-sant-joan-despi-moises-broggi-consorci-sanitari-integral/)
- [Hospital Clínic de Barcelona](https://dndi.org/partnerships/partners/hospitals/hospital-clinic-de-barcelona/)
- [Fundacio Investigacio Hospital General Valencia](https://dndi.org/partnerships/partners/hospitals/fundacio-investigacio-hospital-general-valencia/)
- [SCYNEXIS Inc](https://dndi.org/partnerships/partners/pharma-biotech/scynexis-inc/)
- [Pace University](https://dndi.org/partnerships/partners/universities-research/pace-university/)
- [Collective of Applied Studies and Social Development (CEADES)](https://dndi.org/partnerships/partners/ngos-networks/collective-of-applied-studies-and-social-development-ceades/)
- [Enhancing Care Foundation](https://dndi.org/partnerships/partners/ngos-networks/enhancing-care-foundation/)
- [Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital](https://dndi.org/partnerships/partners/hospitals/empilweni-services-and-research-unit-rahima-moosa-mother-and-child-hospital/)
- [Shandukani Research Centre, Wits Reproductive Health and HIV Institute](https://dndi.org/partnerships/partners/universities-research/shandukani-research-centre-wits-reproductive-health-and-hiv-institute/)
- [Perinatal HIV Research Unit, University of Witswatersrand](https://dndi.org/partnerships/partners/universities-research/perinatal-hiv-research-unit-university-of-witswatersrand/)
- [Tygerberg Children’s Hospital](https://dndi.org/partnerships/partners/hospitals/tygerberg-childrens-hospital/)
- [Department of Science and Technology, South Africa](https://dndi.org/partnerships/partners/mohs-gov/department-of-science-and-technology-south-africa/)
- [University of Nairobi](https://dndi.org/partnerships/partners/universities-research/university-of-nairobi/)
- [St Lumumba Health Centre](https://dndi.org/partnerships/partners/hospitals/st-lumumba-health-centre/)
- [Nyumbani Lea Toto Project, Children of God Relief Institute (COGRI)](https://dndi.org/partnerships/partners/universities-research/nyumbani-lea-toto-project-children-of-god-relief-institute-cogri/)

## People Profiles

- [Marcus Lacerda](https://dndi.org/our-people/marcus-lacerda/)
- [Eric Easom](https://dndi.org/our-people/eric-easom/)
- [Mathieu Lamiaux](https://dndi.org/our-people/mathieu-lamiaux/)
- [Violet Naanyu](https://dndi.org/people-profile/violet-naanyu/)
- [Alexandra Bettencourt](https://dndi.org/our-people/alexandra-bettencourt/)
- [Javid Abdelmoneim](https://dndi.org/our-people/javid-abdelmoneim/)
- [Olga Lacroix](https://dndi.org/our-people/olga-lacroix/)
- [Stéphanie Braillard](https://dndi.org/our-people/stephanie-braillard/)
- [Rudi Paye](https://dndi.org/our-people/rudi-paye/)
- [Thi Hanh Cao](https://dndi.org/our-people/thi-hanh-cao/)
- [Patricia Caldwell](https://dndi.org/our-people/patricia-caldwell/)
- [Delali Attiogbe Attipoe](https://dndi.org/our-people/delali-attiogbe-attipoe/)
- [Anup Anvikar](https://dndi.org/our-people/anup-anvikar/)
- [Olivier Thomas](https://dndi.org/our-people/olivier-thomas/)
- [Vijay Satam](https://dndi.org/our-people/vijay-satam/)
- [Nick White](https://dndi.org/our-people/nick-white/)
- [Thibaut Charles](https://dndi.org/our-people/thibaut-charles/)
- [Christina Sander](https://dndi.org/our-people/christina-sander/)
- [Christophine Moreau](https://dndi.org/our-people/christophine-moreau/)
- [Ivan Scandale](https://dndi.org/our-people/ivan-scandale/)
- [Guillaume Drapeau](https://dndi.org/our-people/guillaume-drapeau/)
- [Anna Crago](https://dndi.org/our-people/anna-crago/)
- [Dearie Okwu](https://dndi.org/our-people/dearie-okwu/)
- [Jean-Robert Ioset](https://dndi.org/our-people/jeanrobert-ioset/)
- [Dominique Junod-Moser](https://dndi.org/our-people/dominique-junod-moser/)
- [Mario Santos Moreira](https://dndi.org/our-people/mario-santos-moreira/)
- [Taruna Madan](https://dndi.org/our-people/taruna-madan/)
- [Noor Hisham Abdullah](https://dndi.org/our-people/noor-hisham-abdullah/)
- [Mahathar Abd Wahab](https://dndi.org/our-people/mahathar-abd-wahab/)
- [Wilfried Mutombo Kalonji](https://dndi.org/our-people/wilfried-mutombo-kalonji/)
- [Fabrice Mulangu](https://dndi.org/our-people/fabrice-mulangu/)
- [Chirac Bulanga Milemba](https://dndi.org/our-people/chirac-bulanga/)
- [Caroline Menétrey](https://dndi.org/our-people/caroline-menetrey/)
- [Anderson Leal](https://dndi.org/our-people/anderson-leal/)
- [Charles Mowbray](https://dndi.org/our-people/mowbray/)
- [Laurence Vielfaure](https://dndi.org/our-people/laurence-vielfaure/)
- [Amelia Folkes](https://dndi.org/our-people/amelia-folkes/)
- [Craig Tipple](https://dndi.org/our-people/craig-tipple/)
- [Sanjay Sarin](https://dndi.org/our-people/sanjay-sarin/)
- [Pauline Williams](https://dndi.org/our-people/pauline-williams/)
- [Kavita Singh](https://dndi.org/our-people/kavita-singh/)
- [Justine Odionyi](https://dndi.org/our-people/justine-odionyi/)
- [Saye Khoo](https://dndi.org/our-people/saye-khoo/)
- [Silvia Gold](https://dndi.org/our-people/silvia-gold/)
- [Pascal Carpentier](https://dndi.org/our-people/pascal-carpentier/)
- [Marie-Paule Kieny](https://dndi.org/our-people/marie-paule-kieny/)
- [Ayushi Agnihotri](https://dndi.org/our-people/ayushi-agnihotri/)
- [Kristine Husøy Onarheim](https://dndi.org/our-people/kristine-husoy-onarheim/)
- [Fabienne Benoist](https://dndi.org/our-people/fabienne-benoist/)
- [Phoutthasone Bouppha](https://dndi.org/our-people/phoutthasone-bouppha/)
- [André Siqueira](https://dndi.org/our-people/andre-siqueira/)
- [Simon Bolo](https://dndi.org/our-people/simon-bolo/)
- [François Bompart](https://dndi.org/our-people/bompart/)
- [Dorothy Mbori-Ngacha](https://dndi.org/our-people/dorothy-mbori-ngacha/)
- [Daisuke Imoto](https://dndi.org/our-people/daisuke-imoto/)
- [Sergio Sosa-Estani](https://dndi.org/our-people/sergio-sosa-estani/)
- [Samuel Kariuki](https://dndi.org/our-people/samuel-kariuki/)
- [Stéphane Hugonnet](https://dndi.org/our-people/stephane-hugonnet/)
- [María Jesús Pinazo](https://dndi.org/our-people/maria-jesus-pinazo/)
- [Eric Stobbaerts](https://dndi.org/our-people/eric-stobbaerts/)
- [Kaori Nakatani](https://dndi.org/our-people/kaori-nakatani/)
- [Vanessa Daniel](https://dndi.org/our-people/vanessa-daniel/)
- [Sabine Specht](https://dndi.org/our-people/sabine-specht/)
- [Olaf Valverde](https://dndi.org/our-people/olaf-valverde/)
- [Justyna Tarwid](https://dndi.org/our-people/justyna-tarwid/)
- [Jean-Michel Piedagnel](https://dndi.org/our-people/jean-michel-piedagnel/)
- [Junior Matangila](https://dndi.org/our-people/junior-matangila/)
- [Beate Aurich](https://dndi.org/our-people/beate-aurich/)
- [Rachel M. Cohen](https://dndi.org/our-people/rachel-cohen/)
- [Byron Arana](https://dndi.org/our-people/arana/)
- [Neelika Malavige](https://dndi.org/our-people/neelika-malavige/)
- [Maja Carrion](https://dndi.org/our-people/maja-carrion/)
- [Borna Nyaoke-Anoke](https://dndi.org/our-people/borna-nyaoke/)
- [Glaucia Cota](https://dndi.org/our-people/glaucia-cota/)
- [Frédéric Monnot](https://dndi.org/our-people/frederic-monnot/)
- [Michelle Childs](https://dndi.org/our-people/michelle-childs/)
- [Joelle Tanguy](https://dndi.org/our-people/joelle-tanguy/)
- [Alistair Swanson](https://dndi.org/our-people/swanson/)
- [Ilan Moss](https://dndi.org/our-people/ilan-moss/)
- [Luis Pizarro](https://dndi.org/our-people/luis-pizarro/)
- [Nor Fariza Ngah](https://dndi.org/our-people/nor-fariza-ngah/)
- [Valérie Faillat](https://dndi.org/our-people/valerie-faillat/)
- [Bernard Pécoul](https://dndi.org/our-people/bernard-pecoul/)
- [Yasmine Belkaid](https://dndi.org/our-people/yasmin-belkaid/)
- [Mae Shieh](https://dndi.org/our-people/mae-shieh/)
- [Monique Wasunna](https://dndi.org/our-people/monique-wasunna/)
- [James Arkinstall](https://dndi.org/our-people/james-arkinstall/)
- [Isabela Ribeiro](https://dndi.org/our-people/isabela-ribeiro/)
- [Stephen Robinson](https://dndi.org/our-people/robinson/)
- [Fabiana Alves](https://dndi.org/our-people/fabiana-alves/)
- [Laurent Fraisse](https://dndi.org/our-people/laurent-fraisse/)
- [Maricianah Onono](https://dndi.org/our-people/maricianah-onono/)
- [Chris Bird](https://dndi.org/our-people/chris-bird/)
- [Suchi Verma](https://dndi.org/our-people/suchi-verma/)
- [Dale Kempf](https://dndi.org/our-people/dalekempf/)
- [Mark Sullivan](https://dndi.org/our-people/mark-sullivan/)
- [Stephane Daffis](https://dndi.org/our-people/stephane-daffis/)
- [Linet Otieno](https://dndi.org/our-people/linet-otieno/)
- [Janice Lee](https://dndi.org/our-people/janice-lee/)
- [Nathalie Strub-Wourgaft](https://dndi.org/our-people/nathalie-strub-wourgaft/)
- [Mousumi Mondal](https://dndi.org/our-people/mousum-mondal/)
- [Tomoyoshi Nozaki](https://dndi.org/our-people/tomo-nozaki/)
- [Collins Mutua](https://dndi.org/our-people/collins-mutua/)
- [Vincent Billoët](https://dndi.org/our-people/vincent-billoet/)
- [Lois Larsen](https://dndi.org/our-people/lois-larsen/)
- [Joseph Camardo](https://dndi.org/our-people/joseph-camardo/)
- [Florent Mbo Kuikumbi](https://dndi.org/our-people/florent-mbo-kuikumbi/)
- [Pascale Boulet](https://dndi.org/our-people/pascale-boulet/)
- [Jadel Kratz](https://dndi.org/our-people/jadel-kratz/)
- [Fabiana Barreira](https://dndi.org/our-people/fabiana-barreira/)
- [Amit Malik](https://dndi.org/our-people/amit-malik/)
- [Delphine Launay](https://dndi.org/our-people/delphine-launay/)
- [Mike Barrett](https://dndi.org/our-people/mike-barrett/)
- [Antoine Tarral](https://dndi.org/our-people/antoine-tarral/)
- [Suman Rijal](https://dndi.org/our-people/suman-rijal/)
- [Ben Perry](https://dndi.org/our-people/ben-perry/)
- [Irene Mukui](https://dndi.org/our-people/irene-mukui/)
- [Michel Lotrowska](https://dndi.org/our-people/michel-lotrowska/)
- [Marion Laumonier](https://dndi.org/our-people/marion-laumonier/)
- [Greg S. Garrett](https://dndi.org/our-people/greg-garrett/)
- [Mariama Diallo](https://dndi.org/our-people/mariama-diallo/)
- [Isabelle Andrieux-Meyer](https://dndi.org/our-people/isabelle-andrieux-meyer/)
- [Jorge Alvar](https://dndi.org/our-people/alvar/)
- [Jean-François Alesandrini](https://dndi.org/our-people/jean-francois-alesandrini/)
- [Olawale Ajose](https://dndi.org/our-people/ajose/)
- [Isabel Gutierrez](https://dndi.org/our-people/isabel-gutierrez/)
- [Denise Guimaraes](https://dndi.org/our-people/denise-guimaraes/)
- [Peter Sjö](https://dndi.org/our-people/peter-sjo/)
- [Sandra Rembry](https://dndi.org/our-people/sandra-rembry/)
- [Wendy Keller](https://dndi.org/our-people/wendy-keller/)
- [Jean-Yves Gillon](https://dndi.org/our-people/jean-yves-gillon/)
- [Eric Chatelain](https://dndi.org/our-people/eric-chatelain/)
- [Walderez Dutra](https://dndi.org/our-people/walderez-dutra/)
- [Frédéric Vallat](https://dndi.org/our-people/frederic-vallat/)
- [Paul Herrling](https://dndi.org/people-profile/paul-herrling/)
- [Rashmi Barbhaiya](https://dndi.org/our-people/rashmi-barbhaiya/)
- [Lucy Lum Chai See](https://dndi.org/our-people/lucy-lum-chai-see/)
- [Lisa Frigati](https://dndi.org/our-people/lisa-frigati/)
- [Andre Daher](https://dndi.org/our-people/andre-daher/)
- [Suerie Moon](https://dndi.org/our-people/suerie-moon/)
- [Koert Ritmeijer](https://dndi.org/our-people/koert-ritmeijer/)
- [Steve King](https://dndi.org/our-people/steve-king/)

## Projects

- [Acoziborole](https://dndi.org/research-development/portfolio/acoziborole/) - A single-dose oral treatment for sleeping sickness that could be given at community level and become a major tool to facilitate elimination of the disease.
- [Acceptability of contraceptive use in NTD-endemic regions](https://dndi.org/research-development/evidence-for-impact/acceptability-contraceptive-use-ntd-endemic-regions/) - The objective of this project is to assess the acceptability of contraceptive use when medically indicated during treatment for leishmaniasis and Chagas or participation in clinical trials.
- [DNDI-6899 (GSK899/DDD853651)](https://dndi.org/research-development/portfolio/dndi-6899/) - The project objective is to progress development of the DNDI-6899 (GSK899/DDD853651) compound for leishmaniasis.
- [GSK245 (DDD1305143)](https://dndi.org/research-development/portfolio/gsk245/) - The project objective is to progress development of the GSK245 (DDD1305143) compound for leishmaniasis.
- [Dengue seroprevalence in Africa and the impact of new control interventions on the global burden](https://dndi.org/research-development/evidence-for-impact/dengue-seroprevalence-and-burden-studies/) - The project objective is both to characterise dengue transmission in Africa, and assess the burden of dengue and the impact of new control interventions globally.
- [Integrated strategies for mycetoma prevention and management: A social-behavioural change approach](https://dndi.org/research-development/evidence-for-impact/integrated-strategies-mycetoma-prevention-management/) - The objective of this project is to assess the social, behavioural, and economic factors influencing the prevention, diagnosis, treatment, and management of mycetoma in Turkana County, Kenya.
- [Visceral leishmaniasis burden among Pokot pastoralists](https://dndi.org/research-development/evidence-for-impact/visceral-leishmaniasis-burden-pastoralists/) - The objective of this project is to determine the burden, risk factors, and knowledge, attitudes, and practices associated with visceral leishmaniasis among the pastoralist community of West Pokot, Kenya.
- [Estimating the burden of mycetoma: A cross-sectional community-based study](https://dndi.org/research-development/evidence-for-impact/estimating-burden-mycetoma-community/) - The objective of this project is to describe the prevalence of mycetoma and characteristics of those cases in selected regions of Ethiopia.
- [Estimating the burden of mycetoma: A retrospective analysis of hospital records](https://dndi.org/research-development/evidence-for-impact/estimating-burden-mycetoma-hospital-records/) - The objective of this project is to describe mycetoma cases detected in health care facilities in India and Senegal in a 10-year period.
- [Oxfendazole for river blindness](https://dndi.org/research-development/portfolio/oxfendazole-river-blindness/) - Based on encouraging pre-clinical data, DNDi and our partners in the HELP Consortium are moving forward with the pharmaceutical development of oxfendazole, identified in 2016 as a potential treatment for river blindness capable of eliminating adult worms.
- [Flavivirus screening](https://dndi.org/research-development/portfolio/flavivirus-screening/) - This project with Eisai and the Institut Pasteur Korea aims to discover compounds that can inhibit viral replication in flaviviruses - a group of viruses that cause a range of diseases of pandemic potential.
- [Schistosomiasis Translation Platform](https://dndi.org/research-development/portfolio/schistosomiasis-translation-platform/) - The objective of this project is to identify new larvicidal pre-clinical candidates for the treatment of schistosomiasis.
- [Fexinidazole for <i>T.b. gambiense</i>](https://dndi.org/research-development/portfolio/fexinidazole/) - DNDi’s first ‘new chemical entity’ cures the most common form of sleeping sickness in just 10 days of simple, 1-pill-per-day treatment.
- [Pre-clinical profiling](https://dndi.org/research-development/portfolio/pre-clinical-profiling-dengue/) - The project objective is to accelerate innovation in therapeutics to prevent the progression of dengue to severe disease.
- [New treatments for PKDL (South Asia)](https://dndi.org/research-development/portfolio/new-treatments-pkdl-south-asia/) - This project aims to determine the safety and efficacy of two treatment regimens for patients with PKDL in South Asia, and understand the role of PKDL in visceral leishmaniasis transmission.
- [Series-5824 (MT)](https://dndi.org/research-development/portfolio/series-5824-mt/) - The project objective is to deliver an optimized lead candidate for Chagas disease.
- [LXE408 Novartis for CL](https://dndi.org/research-development/portfolio/lxe408-novartis-for-cutaneous-leishmaniasis/) - This project objective is to assess the suitability of LXE408 for the treatment of patients with localized cutaneous leishmaniasis.
- [Improving access to diagnosis and treatment for people with advanced HIV disease](https://dndi.org/research-development/portfolio/access-diagnosis-treatment-advanced-hiv-disease/) - The project objective is to address the supply and demand barriers limiting access to immediate-release flucytosine and liposomal amphotericin B in low- and middle-income countries.
- [Chagas Implementation and Access Project](https://dndi.org/research-development/portfolio/chagas-access-project/) - Fewer than 10% of people with Chagas know they have the disease. We are working with Ministries of Health and a broad range of partners in Colombia, Brazil, Guatemala, and elsewhere to expand people’s access to diagnosis and treatment.
- [Chagas Hit-to-lead](https://dndi.org/research-development/portfolio/chagas-h2l/) - Through collaborative hit-to-lead projects, this aims to identify new leads with activity in animal models of disease and the potential for further optimization.
- [DNDI-6148](https://dndi.org/research-development/portfolio/dndi-6148/) - The project objective is to progress DNDI-6148, an oxaborole compound, through clinical development for the treatment of leishmaniasis.
- [DNDI-6148 Chagas disease](https://dndi.org/research-development/portfolio/dndi-6148-chagas/) - The project objective is to develop an oxaborole for Chagas disease.
- [New VL treatments (South Asia)](https://dndi.org/research-development/portfolio/new-vl-treatments-south-asia/) - A DNDi-led consortium identified new combinations with cure rates above 95% to replace treatments with severe side effects or poor efficacy due to drug resistance. Trials generated the key evidence needed for policy change in South Asia.
- [New treatments for VL/HIV](https://dndi.org/research-development/portfolio/new-treatments-vl-hiv/) - New hope for a deadly co-infection. Studies conducted by DNDi, Médecins Sans Frontières, and partners in Ethiopia and India showed that a combination of miltefosine and liposomal amphotericin B had high efficacy rates for treating visceral leishmaniasis in people living with HIV.
- [New treatments for PKDL (Eastern Africa)](https://dndi.org/research-development/portfolio/new-treatments-pkdl-eastern-africa/) - This project aims to determine the safety and efficacy of two treatment regimens for patients with PKDL in Eastern Africa.
- [Miltefosine + Paromomycin combination (Africa)](https://dndi.org/research-development/portfolio/miltefosine-paromomycin-combo/) - The project objective is to compare the efficacy and safety of two combination regimens of miltefosine and paromomycin with the current standard treatment.
- [LXE408 Novartis for VL](https://dndi.org/research-development/portfolio/lxe408-novartis-visceral-leishmaniasis/) - The project objective is to develop LXE408 as a potential new oral treatment for visceral leishmaniasis.
- [DNDI-6174](https://dndi.org/research-development/portfolio/dndi-6174/) - The project objective is to develop DNDI-6174 as a new chemical entity for the treatment of visceral leishmaniasis with the aim of bringing an additional entity with a novel mechanism of action to the visceral leishmaniasis portfolio; and potentially for the treatment of cutaneous leishmaniasis​.
- [DNDI-0690](https://dndi.org/research-development/portfolio/dndi-0690/) - The project objective is to advance the non-clinical and early clinical development of DNDI-0690, a selected nitroimidazole for the treatment of visceral leishmaniasis and possibly cutaneous leishmaniasis.
- [Screening Chagas disease](https://dndi.org/research-development/portfolio/screening-chagas/) - The project objective is to deliver a robust portfolio of early hits and lead series to enable drug discovery for Chagas disease.
- [Emodepside](https://dndi.org/research-development/portfolio/emodepside/) - We are working with Bayer Pharma to develop emodepside as a new treatment for river blindness with the potential to kill both adult filarial worms and their embryonic larvae, which can cause debilitating and disfiguring clinical symptoms.
- [DNDI-6166 (CC6166)](https://dndi.org/research-development/portfolio/dndi-6166/) - This project aims to develop a advance pre-clinical development of DNDI-6166 as a macrofilaricide candidate for filarial diseases.
- [TMEM16 series](https://dndi.org/research-development/portfolio/tmem16-series/) - This project between DNDi and the Translational Health Science and Technology Institute (THSTI) in India is improving and optimizing molecules that could become affordable antiviral treatments for influenza and other viruses of pandemic potential.
- [COVID Moonshot](https://dndi.org/research-development/portfolio/covid-moonshot/) - A non-profit, open-science consortium of scientists dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19.
- [Nucleoside Booster](https://dndi.org/research-development/portfolio/nucleoside-booster/) - Screening of a selection of nucleoside drugs for the broadest possible antiviral activity against families of viruses presenting epidemic and pandemic threats.
- [AViDD ASAP](https://dndi.org/research-development/portfolio/avidd-asap/) - The ASAP project uses cutting-edge technology to accelerate open science drug discovery to deliver novel oral antivirals against viruses of pandemic potential.
- [ASAP-0017445 (Moonshot ASAP)](https://dndi.org/research-development/portfolio/asap-0017445/) - With partners in the AI-driven Structure-enabled Antiviral Platform (ASAP), AViDD Center, funded by the NIH, we are developing ASAP-0017445, abroad-spectrum oral antiviral with potent activity against SARS-CoV-2 and viruses from the same family.
- [2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC](https://dndi.org/research-development/portfolio/lpvr-pellets/) - Our implementation study with over 1,000 children in Kenya, Uganda, and Tanzania was designed to help improve uptake of newer treatments for kids.
- [Open Chagas](https://dndi.org/research-development/portfolio/open-chagas/) - Open Chagas aims to boost research into new treatments for Chagas disease by forging collaborations and empowering the drug discovery community in Latin America.
- [New mycetoma treatments](https://dndi.org/research-development/portfolio/new-mycetoma-treatments/) - The project objective is to advance the clinical development of oxfendazole as an anti-parasitic macrofilaricidal treatment.
- [MycetOS](https://dndi.org/research-development/portfolio/mycetos/) - DNDi is partnering with this virtual drug discovery community to find all-new treatments to end the neglect of fungal mycetoma – using a community-driven, fully transparent process that publishes data and results immediately in real time.
- [Fosravuconazole](https://dndi.org/research-development/portfolio/fosravuconazole/) - Ran at the world’s only specialized centre for mycetoma, in Khartoum, Sudan, this study tested fosravuconazole against the current standard treatment which is expensive, must be dosed twice a day for a year, and taken with food.
- [Open Synthesis Network](https://dndi.org/research-development/portfolio/open-synthesis-network/) - This global collaboration of students from over 20 participating institutions is working to explore data and design new compounds for DNDi to test for anti-parasitic activity.
- [Ravidasvir + sofosbuvir](https://dndi.org/research-development/portfolio/ravidasvir-sofosbuvir/) - We aim to develop a new simple-to-use, affordable treatment for hepatitis C to increase access and minimize financial burden on patients and health systems.
- [Fexinidazole for <i>T.b. rhodesiense</i>](https://dndi.org/research-development/portfolio/fexinidazole-tb-rhodesiense/) - We evaluated fexinidazole to treat the less common T.b. rhodesiense strain of sleeping sickness found in Eastern and Southern Africa. It was approved by the European Medicines Agency in 2023.
- [ACOZI-KIDS](https://dndi.org/global-networks/acozi-kids/) - ACOZI-KIDS aims to make treatment of children with sleeping sickness much simpler. New treatments need to reach all people who need them – including the smallest patients. We are working to finalize the development of acoziborole as a simpler, safer treatment for children with sleeping sickness.
- [AI-guided discovery](https://dndi.org/research-development/portfolio/ai-guided-discovery/) - The project objective is to identify mechanistic pathways, potential biological targets, and therapies that could be repurposed for dengue to prevent disease progression.
- [5FC HIV-Crypto](https://dndi.org/research-development/portfolio/5fc-cryptococcal-meningitis/) - The project objective is to advance the development of sustained-release flucytosine to simplify inpatient and outpatient treatment of cryptococcal infections.
- [CpG-D35 (DNDI-2319)](https://dndi.org/research-development/portfolio/dndi-2319/) - We are working to produce an ‘immunomodulator’ that can stimulate the innate immune system to fight the parasitic infection that causes cutaneous leishmaniasis.
- [Miltefosine + thermotherapy for cutaneous leishmaniasis](https://dndi.org/research-development/portfolio/miltefosine-thermotherapy-cutaneous-leishmaniasis/) - Preliminary results from our Phase II trial in Peru and Colombia showed better outcomes combining thermotherapy and miltefosine compared to treatment with thermotherapy alone. A Phase III study is ongoing in four countries in Latin America.
- [UW series](https://dndi.org/research-development/portfolio/uw-series/) - The project objective is to optimize the lead compound of the UW series for Chagas disease.
- [New benznidazole regimens](https://dndi.org/research-development/portfolio/new-benz-regimens/) - A DNDi-led study showed that a shorter two-week course of benznidazole was as effective and caused fewer side effects than the standard eight-week treatment. Phase III studies are now planned to confirm results.
- [Biomarkers](https://dndi.org/research-development/portfolio/biomarkers/) - The lack of a reliable test to monitor treatment efficacy is a major hurdle for developing new drugs for Chagas disease. We are supporting research and raising awareness of the need for ‘biomarkers’ that can be measured with quick and accurate tests.
- [Oxfendazole for lymphatic filariasis](https://dndi.org/research-development/portfolio/oxfendazole-for-lymphatic-filariasis/) - We are working with the Indian Council of Medical Research to test oxfendazole as a potential treatment for lymphatic filariasis. Already under investigation as potential treatment for other filarial and helminthic infections, oxfendazole could transform treatment for the disease – and help eliminate it altogether – if proven effective.
- [Fusidic Acid Macrofilaricide Evaluation (FAME)](https://dndi.org/global-networks/fusidic-acid-macrofilaricide-evaluation-fame/) - The Fusidic Acid Macrofilaricide Evaluation (FAME) project aims to evaluate fusidic acid as a potential short-course treatment for river blindness, particularly in regions co-endemic with Loa loa.
- [Paediatric ivermectin](https://dndi.org/research-development/portfolio/paediatric-ivermectin/) - Ivermectin is a critical drug in use against parasitic worm diseases such as lymphatic filariasis – but children have long been excluded from receiving the treatment due to lack of data and lack of a suitable paediatric formulation. We are working with partners across Europe and sub-Saharan Africa to develop and test a safe, child-friendly, field-adapted formulation of ivermectin.
- [Praziquantel/anti-inflammatory for female genital schistosomiasis](https://dndi.org/research-development/portfolio/praziquantel-anti-inflammatory-for-female-genital-schistosomiasis/) - Together with our partners, we are investigating combination treatments (anti-inflammatory medications with standard anti-parasitic praziquantel) for the management of morbidity associated with female genital schistosomiasis (FGS). We are also working to increase awareness of FGS, evaluate the feasibility of a community-based diagnostic procedure, and assess barriers and facilitators for the integration of diagnosis and treatment into existing health services.
- [VL-INNO](https://dndi.org/global-networks/vl-inno/) - VL-INNO is a three-year project that embraces the use of innovation in diagnosis and discovery of new safe oral drugs to tackle current treatment challenges for visceral leishmaniasis in Eastern Africa.
- [Dengue Alliance](https://dndi.org/global-networks/dengue-alliance/) - The Dengue Alliance aims to develop affordable and accessible treatments for dengue through partnerships with institutions in the most affected countries.
- [AfriKADIA](https://dndi.org/global-networks/afrikadia/) - AfriKADIA is a consortium of ten organizations working to find improved treatments and diagnostic tools for visceral leishmaniasis in eastern Africa.
- [Capacity development to facilitate access to fexinidazole](https://dndi.org/global-networks/capacity-development-access-fexinidazole/) - Funding This project (grant CSA2018HS-2526) is part of the European and Developing Countries Clinical Trials Partnership Association (EDCTP2) programme supported by the European Union. Other funding: Democratic Republic of the Congo - Ministère de la Santé de la République Démocratique du Congo (Projet de Développement du Système de Santé financé par la Banque Mondiale) France
- [Helminth Elimination Platform (HELP)](https://dndi.org/global-networks/helminth-elimination-platform/) - The Helminth Elimination Platform (HELP) is a consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies, formed in 2019 to develop new drugs for infections caused by parasitic worms (helminths).
- [Screening leishmaniasis](https://dndi.org/research-development/portfolio/screening-leishmaniasis/) - The project objective is to deliver a robust portfolio of drug discovery, hit and lead series for leishmaniasis.
- [Chagas Platform](https://dndi.org/global-networks/chagas-platform/) - The Chagas Clinical Research Platform is advancing pharmaceutical R&D for Chagas disease through stakeholder partnerships in endemic countries.
- [4-in-1 (ABC/3TC/LPV/r)](https://dndi.org/research-development/portfolio/4-in-1-lpv-r-abc-3tc/) - A strawberry-flavoured, ‘4-in-1’ - quadrimune meets the treatment needs of the youngest children living with HIV. The combination of four antiretrovirals in easy-to-administer granules is now under US FDA review.
- [redeLEISH Network](https://dndi.org/global-networks/redeleish-network/) - The redeLEISH Network aims to promote research for improved cutaneous leishmaniasis treatments by increasing collaboration and maximizing resources in Latin America.
- [LEAP Platform](https://dndi.org/global-networks/leap-platform/) - LEAP aims to strengthen clinical research capacity and advance the leishmaniasis elimination agenda across affected countries in Eastern Africa.
- [HAT Platform](https://dndi.org/global-networks/hat-platform/) - The HAT Platform aims to advance the development and implementation of improved treatments for sleeping sickness through partnerships.
- [CERCLE](https://dndi.org/global-networks/cercle/) - In 2020, DNDi co-launched CERCLE (formerly COVID-19 Clinical Research Coalition), a coalition of 900 researchers & research institutions aiming to accelerate research on infectious diseases of pandemic potential by ensuring the participation – and meeting the specific needs of low-resource settings.
- [Super-booster therapy](https://dndi.org/research-development/portfolio/superbooster-therapy-paediatric-hiv/) - Drugs used to treat TB can interfere with HIV treatment, reducing its effectiveness. A successful study with our South African partners paved the way for better treatment for children living with both diseases.
- [PANTHER](https://dndi.org/global-networks/panther/) - Launched in late 2022, PANTHER aims to prepare and respond rapidly to pandemics on the African continent by providing the human, technical, scientific, and administrative infrastructure on emerging infectious diseases through a network of experienced African research centres.
- [Paediatric Benznidazole](https://dndi.org/research-development/portfolio/paediatric-benznidazole/) - With our partners, we developed and registered the first-ever formulations of benznidazole for treating infants and children with Chagas disease.
- [Nifurtimox-eflornithine combination therapy (NECT)](https://dndi.org/research-development/portfolio/nect/) - Before DNDi delivered a combination therapy in 2009, doctors had no choice but to treat sleeping sickness with melarsoprol, a highly toxic, arsenic-based drug.
- [ASMQ](https://dndi.org/research-development/portfolio/asmq/) - The project objective is to develop and register a new fixed-dose combination of artesunate (AS) and mefloquine (MQ) in response to patient need.
- [ASAQ](https://dndi.org/research-development/portfolio/asaq/) - The project objective is to develop and register a fixed-dose combination of artesunate (AS) and amodiaquine (AQ) to treat paediatric and adult uncomplicated falciparum malaria.
- [ANTICOV](https://dndi.org/research-development/portfolio/anticov/) - Conducted across 29 clinical trial sites in 13 African countries and Brazil by 27 medical research organizations, the ANTICOV study tested treatments that could reduce the risk of hospitalization.
- [Hepatitis C PACT](https://dndi.org/global-networks/hepatitis-c-pact/) - Launched in 2021, the Hepatitis C PACT aimed to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus in low- and middle-income countries.
- [DNDI-8526 (S07 series)](https://dndi.org/research-development/portfolio/dndi-8526/) - The project objective is to progress a lead compound from the S07 series into clinical development as a potential new treatment for leishmaniasis.
- [Azoles E1224](https://dndi.org/research-development/portfolio/azoles-e1224/) - The project objective is to conclude Proof-of-Concept (PoC), Phase II evaluation for E1224 in adults with chronic indeterminate Chagas disease.
- [Fexinidazole for Chagas](https://dndi.org/research-development/portfolio/fexinidazole-chagas/) - The aim of this project was to evaluate efficacy and safety of short-course and low-dose regimens of fexinidazole in adults with chronic Chagas disease.
- [SSG&PM (East Africa)](https://dndi.org/research-development/portfolio/ssg-pm/) - DNDi-led clinical trials showed a combination of sodium stibogluconate (SSG) and paromomycin was safe and as effective as treatment with SSG alone. More affordable, easier for patients and cuts treatment time.
- [Flubentylosin](https://dndi.org/research-development/portfolio/flubentylosin/) - The aim of this project was to advance the clinical development of flubentylosin as a macrofilaricidal treatment that targets Wolbachia bacteria.
- [LeishAccess](https://dndi.org/global-networks/leishaccess/) - LeishAccess is a three-year project implemented by a consortium of experts and key health institutions leading access that aims to improve access to care for leishmaniasis patients for the various forms of the disease.
- [New VL treatments (Latin America)](https://dndi.org/research-development/portfolio/new-vl-treatments-latam/) - DNDi collaborated with partners in Brazil to implement a large clinical trial to assess a new combination therapy. Liposomal amphotericin B was shown to be more efficacious and safer.
- [Hit-to-lead broad-spectrum antivirals](https://dndi.org/research-development/portfolio/hit-to-lead-broad-spectrum-antivirals/) - We are working to contribute to pandemic preparedness through longer-term initiatives to discover novel antiviral drug candidates for the treatment of SARS-CoV-2, future generations of coronavirus, and potentially also other pandemic-prone viruses.
- [Pre-clinical support](https://dndi.org/research-development/portfolio/pre-clinical-support-covid19/) - DNDi supported the ANTICOV clinical trial by identifying and validating repurposed drug candidates, beginning with the in vitro and in vivo experimental work needed to provide supporting pre-clinical evidence.
- [Leishmaniasis hit-to-lead](https://dndi.org/research-development/portfolio/leish-h2l/) - Through collaborative hit-to-lead projects, identifying new leads with activity in animal models of disease and the potential for further optimization.
- [Pandemic Response Box](https://dndi.org/research-development/portfolio/pandemic-response-box/) - Launched by MMV and DNDi in 2019, this project aims to accelerate drug discovery by providing researchers with free drug-like molecules selected by disease experts for screening against infectious and neglected diseases.
- [NTD Drug Discovery Booster Hit-to-lead](https://dndi.org/research-development/portfolio/drug-discovery-booster/) - We brought together eight pharmaceutical companies to search millions of compounds, accelerating progress and cutting costs to find new leads for potential drug candidates for leishmaniasis and Chagas disease.
- [Hepatitis C Screening in Malaysia - #MYmissingmillions](https://dndi.org/research-development/portfolio/hcv-screening-malaysia-mymissingmillions/) - A pioneer in efforts to tackle hepatitis C, the Malaysian government is joining with DNDi partner FIND to pilot the use of simple rapid diagnostic tests to link more people to lifesaving treatment and care.
- [Anfoleish (CL)](https://dndi.org/research-development/portfolio/anfoleish-cl/) - This project aimed to develop a topical anti-parasitic treatment containing amphotericin B for the treatment of cutaneous leishmaniasis.
- [Source data from neglected disease R&D pipeline review](https://dndi.org/research-development/portfolio/fatalimbalance_data/) - This project reviewed product approvals granted by different national Regulatory Authorities between 2000 and 2011 to establish how many were for neglected diseases
- [WEHI Library – Screening identifies new compounds for HAT](https://dndi.org/research-development/portfolio/wehi/) - This project aimed to screen a large library of compounds against the related trypanosome subspecies
- [Two series of fenarimols for the treatment of Chagas disease](https://dndi.org/research-development/portfolio/2nd-release-fenarimol-data/) - Fenarimol, a plant fungicide, was found to be a potent inhibitor of Trypanosoma cruzi, the parasite which causes Chagas disease, and was chosen as a starting point for lead optimisation to improve its activity.
- [Successful screening collaboration leads to a new lead optimization project](https://dndi.org/research-development/portfolio/vl-series-lead-optimisation/) - This project aimed to identify hit compounds active against Leishmania donovani from an innovative screening collaboration with Pfizer.
- [Screening and lead optimization of new compounds for Chagas disease (>300,000 compounds)](https://dndi.org/research-development/portfolio/screening-lead-optimization-new-compounds-chagas/) - The project objective is to evaluate multiple hits generated from a high-throughput screen of over 300,000 compounds to identify inhibitors of T. cruzi.
- [Flubendazole Macrofilaricide](https://dndi.org/research-development/portfolio/flubendazole-macrofilaricide/) - The project objective is to complete the pre-clinical development of flubendazole in collaboration with Johnson & Johnson.
- [Development and validation of a novel <i>Leishmania</i> screening cascade](https://dndi.org/research-development/portfolio/development-and-validation-of-novel-leishmania-screening-cascade/) - This project aimed to use a new screening cascade based on a modified axenic Leishmania assay.
- [Daiichi Sankyo series](https://dndi.org/research-development/portfolio/daiichi-sankyo-ch2l/) - The project objective is to develop an optimized drug candidate for Chagas disease.
- [Daiichi Sankyo Hit-to-lead for leishmaniasis](https://dndi.org/research-development/portfolio/daiichi-sankyo-lh2l/) - The project objective is to identify at least one – possibly two – progressable lead series, meeting DNDi lead stage criteria for visceral leishmaniasis.
- [Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning](https://dndi.org/research-development/portfolio/antiprotozoal-activity-profiling/) - This project screened a set of 100 registered drugs with drug repositioning potential for neglected tropical diseases.
- [Aminopyrazoles](https://dndi.org/research-development/portfolio/aminopyrazoles/) - The project objective is to select a pre-clinical candidate from the aminopyrazole series for the treatment of leishmaniasis.
- [VL-0208](https://dndi.org/research-development/portfolio/vl-0208/) - This project aimed to assess the efficacy and safety of miltefosine in East Africa.
- [iNTRODB – an Integrated system for searching drug-target proteins from parasitic protozoa genomes](https://dndi.org/research-development/portfolio/introdb/) - This project was an integrated system for searching drug-target proteins from parasitic protozoa genomes that cause neglected tropical disease including leishmaniasis, Chagas’ disease and human African trypanosomiasis.
- [Generic AmBisome](https://dndi.org/research-development/portfolio/generic-ambisome/) - This project aimed to have pre-qualified generic AmBisome® by 2017.
- [Fexinidazole/Miltefosine Combination (VL)](https://dndi.org/research-development/portfolio/fexinidazole-vl/) - The project objective is to develop an oral-only therapy for the treatment of VL with a combination of fexinidazole and miltefosine.
- [Celgene Global Health visceral leishmaniasis series 1](https://dndi.org/research-development/portfolio/chgvl-series-1/) - This project aimed to select a pre‑clinical candidate from the CGH VL series for the treatment of visceral leishmaniasis.
- [CF series](https://dndi.org/research-development/portfolio/cf-series/) - The project objective is to select a pre-clinical candidate from the CF series for the treatment of leishmaniasis.
- [DND<i>i</i> Screening of the MMV Open Access Malaria Box for HAT, VL, and Chagas disease](https://dndi.org/research-development/portfolio/mmv-malaria-box-4/) - The Medicines for Malaria Venture (MMV) made a freely available box of 400 compounds with anti-malarial activity, in a bid to catalyse research in malaria and neglected diseases.
- [Pathogen Box](https://dndi.org/research-development/portfolio/pathogen-box/) - The Pathogen Box project helped catalyse neglected disease drug discovery
- [VL-2098](https://dndi.org/research-development/portfolio/vl-2098/) - The project objective is to fully investigate the profile of VL-2098 as an NCE for VL.
- [SCYX-1330682 & SCYX-1608210 oxaboroles](https://dndi.org/research-development/portfolio/scyx-1330682/) - The project objective is to maintain the back-up drug candidate oxaboroles to replace the drug candidate acoziborole.
- [Screening Filarial disease](https://dndi.org/research-development/portfolio/screening-filarial-diseases/) - Identifying new drug candidates, by accessing and evaluating registered drugs, pre-clinical and clinical candidates, focused sets and libraries with known anthelminthic activity from animal and human health companies
- [Leishmaniasis L205 series](https://dndi.org/research-development/portfolio/leish-l205-series/) - The project objective is to progress a compound from the 205 series towards candidate selection and nomination for further pre-clinical development for visceral leishmaniasis.
- [Guides to free computational chemistry tools for drug discovery](https://dndi.org/research-development/portfolio/guides-computational-chemistry-tools/) - The project objective is to develop computational chemistry tools to improve the computational design and analysis environment for drug discovery.
- [DNDI-5561](https://dndi.org/research-development/portfolio/dndi-5561/) - The project objective is to progress DNDi-5561, a selected aminopyrazole compound, to Phase I clinical trials and realize some activities including formulation development, drug product manufacture and start single ascending dose stage of first-in-human.
- [DNDI-5421 & DNDI-5610](https://dndi.org/research-development/portfolio/oxaleish/) - The project objective is to maintain back-up oxaboroles which could replace the pre-clinical candidate DNDI-6148 in case it does not succeed in development.
- [Chagas C205 series](https://dndi.org/research-development/portfolio/chagas-c205-series/) - The project objective is to optimize leads issued from the hit-to-lead 205 series, and identify pre-clinical candidates with the potential to fulfill the target product profile for Chagas disease.
- [SCYX-2035811](https://dndi.org/research-development/portfolio/nitroimidazole-backup/) - The project objective is to progress a backup nitroimidazole into pre-clinical development for HAT.
- [Oxachagas](https://dndi.org/research-development/portfolio/oxachagas/) - This project aimed to generate new drug candidates for the treatment of Chagas disease to be assessed in clinical trial.
- [Nitroimidazole (Chagas)](https://dndi.org/research-development/portfolio/nitroimidazole-chagas/) - This project generated new drug candidates for the treatment of Chagas to be assessed in clinical trials.
- [Fenarimol](https://dndi.org/research-development/portfolio/fenarimol-series-v15-1050/) - This project completed the non-regulatory pre-clinical review on the selected candidate compound.
- [K777 (Chagas)](https://dndi.org/research-development/portfolio/k777/) - This 28-day toxicity study in non-human primates, completed the IND package for clinical evaluation of K777 for the treatment of Chagas disease.
- [SCYNEXIS Inc. as part of the DND<i>i</i> HAT Lead Optimization Consortium](https://dndi.org/research-development/portfolio/scynexis-lo/) - This project aimed to conduct Hit-to-Lead and Lead Optimization programmes on compounds found to be active against Trypanosoma brucei in two structural classes.

## Regions

- [DNDi South Asia](https://dndi.org/region/dndi-south-asia/) - DNDi began its activities in South Asia in 2004, aiming to build and strengthen regional partnerships for research and development on neglected diseases.
- [DNDi West and Central Africa](https://dndi.org/region/dndi-west-central-africa/) - Since 2005, the DNDi West and Central Africa office has provided essential logistical and financial support for the nifurtimox-eflornithine clinical trial (NECT), the fexinidazole trials, and the HAT Platform.
- [DNDi Japan](https://dndi.org/region/dndi-japan/) - DNDi began working in Japan in 2004, by establishing projects and providing support to developing discovery projects, in better positioning DNDi within the country, as well as with fundraising activities.
- [DNDi South-East Asia](https://dndi.org/region/dndi-south-east-asia/) - The office is involved in DNDi’s hepatitis C clinical studies that take place in the country.
- [DNDi Latin America](https://dndi.org/region/dndi-latin-america/) - With the primary aim to support regional R&D activities for Chagas disease, malaria, and leishmaniasis, the Latin American office also undertakes advocacy and communications activities to increase neglected diseases awareness in the region.
- [DNDi Eastern Africa](https://dndi.org/region/dndi-east-africa/) - DNDi Eastern Africa DNDi Eastern Africa Established in 2003, the DNDi Eastern Africa office provides support to R&D projects in the region, including the LEAP Platform. Additionally, the office works to build awareness about neglected diseases and realities in the field through regional advocacy and communications activities. Projects 2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC4-in-1
- [DNDi Switzerland](https://dndi.org/region/dndi-switzerland/) - Established in 2003 in Genva, DNDi Switzerland is active in research & development activities, as well as in administrative and support departments, including finance, human resources, IT, policy advocacy, communications, and fundraising.

## Requests for Proposals

- [Request for proposals (RFP) from interior architecture and design firms to develop and implement the workplace layout for DNDi's new office space in Geneva.](https://dndi.org/work-with-us/2026/rfp/request-for-proposals-interior-architecture-and-design-firms-develop-implement-workplace-layout-new-office-geneva/) - DNDi is seeking a qualified and experienced implementers to collaborate with us in the implementation of leishmaniasis CoE to serve as a reference and training centre in Nepal.

## Testimonials

- [Dr Justine Odionyi](https://dndi.org/testimonial/dr-irene-mukui/) - For too long, people with cryptococcal meningitis have faced treatments that are complex and difficult to complete. A friendly sustained release flucytosine formulation has the potential to transform care by easing the burden on patients and health care workers alike. Our goal is to ease adherence to treatment to ensure more people survive, recover and
- [Katey Owen](https://dndi.org/testimonial/katey-owen/) - Fexinidazole is a true game-changer for sleeping sickness. If acoziborole, a single-dose treatment, is shown to be safe and effective, we’re hopeful it would provide national programmes an even better tool to help achieve global elimination goals.
- [Dr Zaliha Mustafa](https://dndi.org/testimonial/dr-zaliha-mustafa/) - The Ministry of Health, Malaysia is proud to be a founding partner of DNDi. Our partnership puts patients first. We have shown that together, we can improve the lives of millions.
- [Marcia Hueb](https://dndi.org/testimonial/marcia-hue/) - We hope our research partnership with DNDi can confirm earlier positive results of a new treatment combination that could help improve the lives of people with cutaneous leishmaniasis in Latin America.
- [Dr Farhat Mantoo](https://dndi.org/testimonial/dr-farhat-mantoo/) - DNDi’s innovative and collaborative approach to pharmaceutical research and development has made a difference in the lives of so many. We are proud to have been a founding partner of DNDi and to stand by you in the fight for equitable access to life-saving medicines.
- [Nirmal Ganguly](https://dndi.org/testimonial/nirmal-ganguly/) - Over the past 20 years, DNDi has made a significant contribution to manufacturing drugs that are affordable in low- and middle-income countries, empowering governments in their disease elimination programmes.
- [Prof. Shyam Sundar](https://dndi.org/testimonial/shyam-sundar/) - Our invaluable partnership with DNDi has been a source of immense pride for us. Your dedication and commitment over the past two decades have made a remarkable difference to people living with neglected diseases.
- [Dr Dinesh Mondal](https://dndi.org/testimonial/dr-dinesh-mondal/) - Because PKDL is not fatal it has largely been ignored by public health efforts, but our research with DNDi shows that early treatment of PKDL patients will be a critical element of any leishmaniasis public health and elimination strategy.
- [Tawaba Say Watson](https://dndi.org/testimonial/tawaba-say-watson/) - The training in good clinical practice and the site initiation of the clinical study, help me on a daily basis to improve the way we take care of all patients.
- [David Shum](https://dndi.org/testimonial/david-shum/) - IPK joined DNDi’s new initiative, the NTD Drug Discovery Booster programme, that cuts the cost of early-stage drug discovery, accelerates and expands discovery of new drugs for NTDs. In 2016, we identified four hit series that are currently advancing to further development. It is our hope that we can soon identify a breakthrough compound for
- [Dr Muhammad Radzi Abu Hassan](https://dndi.org/testimonial/dr-muhammad-radzi-abu-hassan/) - We are deeply grateful and proud to have been a part of the team that brought a new, affordable treatment for hepatitis C to the world. We remain committed to collaborating with DNDi and partners to ensure that innovative, affordable treatments reach all those in need.
- [Dr Shahnaz Murad](https://dndi.org/testimonial/dr-shahnaz-murad/) - DNDi's dynamic approach to finding solutions, with their unique ability to coordinate partners like an orchestra conductor, has resulted in bringing together different stakeholders in hepatitis C and dengue. Their innovative approach and collaborative spirit have not only brought hope to millions worldwide but have also set a new standard for neglected disease treatment.
- [Prof. Jean-Jacques Muyembe](https://dndi.org/testimonial/prof-jean-jacques-muyembe/) - Partnerships are essential to the success of clinical research advances in the treatment of NTDs. The fexinidazole treatment for sleeping sickness is a perfect example of how collaboration can fuel the discovery of drugs that are effective, easy to use and with few side effects.
- [Dr Noor Hisham Abdullah](https://dndi.org/testimonial/dr-noor-hisham-abdullah/) - With the necessary will and commitment, we know hepatitis C can be eliminated. Our local and global partnerships, notably with DNDi, are ensuring we have the medical tools and strategies in place to succeed.
- [Dr Yusuf Hamied](https://dndi.org/testimonial/dr-yusuf-hamied/) - Treatment for children living with HIV is a humanitarian effort. At Cipla, we are proud to have partnered with DNDi in this important mission.
- [Christian Frutiger](https://dndi.org/testimonial/christian-frutiger/) - People affected by neglected diseases must have access to treatments. DNDi helps to ensure that new medical products are available and affordable for all.
- [Prof. Ahmed Hassan Fahal](https://dndi.org/testimonial/prof-ahmed-hassan-fahal/) - DNDi's innovative approach and collaborative spirit have revolutionized the treatment of neglected diseases, bringing hope and health to millions of patients. Thanks to our collaboration, the Mycetoma Research Centre is conducting the first-ever double-blind, randomized clinical trial for an effective mycetoma treatment.
- [Dr Naomie Awaca Uvon](https://dndi.org/testimonial/dr-naomie-awaca-uvon/) - In the DRC, the treatment of NTDs over the past 17 years has been supported by DNDi in a broad partnership with the government and other donors. We urge governments, public and private funders around the world to continue to support research and development efforts to meet the need for access to treatment for patients.
- [Prof. Elijah Songok](https://dndi.org/testimonial/prof-elijah-songok/) - The value of pharmaceutical research and development cannot be overstated, especially in sub-Saharan Africa. DNDi is fostering collaboration and investment in R&D that is addressing the pressing need for access to safe, effective, and affordable treatments. Together we are working towards creating a brighter future for our communities.
- [Concepción Zúñiga Valeriano](https://dndi.org/testimonial/concepcion-zuniga-valeriano/) - Enabling discussions among researchers is an important tool for the improvement of efficiency, diagnosis, and treatment.
- [Dr Kapil Juvale](https://dndi.org/testimonial/dr-kapil-juvale/) - This partnership will contribute to real-life medicinal chemistry projects featuring neglected disease research. By participating in the OSN project, our students will get an opportunity to enhance their skills in medicinal chemistry research and will develop an interest to work on real drug discovery projects.
- [Graeme Bilbe](https://dndi.org/testimonial/graeme-bilbe/) - The goal is to help shorten the time between the emergence of a new pandemic and the availability of new drugs to treat it. History has repeatedly shown that saving time, saves lives.
- [Dr Bernard Pécoul](https://dndi.org/testimonial/dr-bernard-pecoul/) - This experiment could significantly reduce the time and money it takes to find new, promising treatment leads, and echoes the great potential of innovative research and development collaborations.

## Tags

- [Advocacy](https://dndi.org/tag/advocacy/)
- [Funding](https://dndi.org/tag/funding/)
- [Sleeping sickness (HAT)](https://dndi.org/tag/hat-sleeping-sickness/)
- [Partnership](https://dndi.org/tag/partnership/)
- [Treatment](https://dndi.org/tag/treatment/)
- [Malaria](https://dndi.org/tag/malaria/)
- [Chagas disease](https://dndi.org/tag/chagas-disease/)
- [Leishmaniasis](https://dndi.org/tag/leishmaniasis/)
- [Strengthening capacities](https://dndi.org/tag/strengthening-capacities/)
- [Paediatric HIV](https://dndi.org/tag/paediatric-hiv/)
- [Regulatory](https://dndi.org/tag/regulatory/)
- [Access](https://dndi.org/tag/access/)
- [Filarial diseases](https://dndi.org/tag/filarial-diseases/)
- [Hepatitis C](https://dndi.org/tag/hepatitis-c/)
- [Mycetoma](https://dndi.org/tag/mycetoma/)
- [Drug discovery](https://dndi.org/tag/drug-discovery/)
- [Antimicrobial Resistance](https://dndi.org/tag/amr/)
- [ASMQ](https://dndi.org/tag/asmq/)
- [ASAQ](https://dndi.org/tag/asaq/)
- [Gonorrhoea](https://dndi.org/tag/gonorrhoea/)
- [Cutaneous leishmaniasis](https://dndi.org/tag/cutaneous-leishmaniasis/)
- [Radio](https://dndi.org/tag/radio/)
- [WorldLeish7](https://dndi.org/tag/worldleish7/)
- [clinical trials](https://dndi.org/tag/clinical-trials/)

## Categories

- [Treatments delivered](https://dndi.org/ctl-stories/treatments/)
- [Treatments developed for neglected tropical diseases](https://dndi.org/ctl-stories/neglected-tropical-disease/)

## Diseases

- [Sleeping sickness](https://dndi.org/ct-disease/sleeping-sickness/)
- [Filaria: river blindness](https://dndi.org/ct-disease/filaria-river-blindness/)
- [Cutaneous leishmaniasis](https://dndi.org/ct-disease/cutaneous-leishmaniasis/)
- [Visceral leishmaniasis](https://dndi.org/ct-disease/visceral-leishmaniasis/)
- [Mycetoma](https://dndi.org/ct-disease/mycetoma/)
- [Hepatitis C](https://dndi.org/ct-disease/hepatitis-c/)
- [Pandemic Preparedness](https://dndi.org/ct-disease/pandemic-preparedness/)
- [Chagas disease](https://dndi.org/ct-disease/chagas-disease/)
- [Cryptococcal meningitis](https://dndi.org/ct-disease/cryptococcal-meningitis/)

## Donor Types

- [Private donors](https://dndi.org/donor-type/private-donors/)
- [Private Foundations and Private Individual Donors](https://dndi.org/donor-type/private-foundations-and-private-individual-donors/)
- [Public donors](https://dndi.org/donor-type/public-donors/)
- [Prizes](https://dndi.org/donor-type/prizes/)

## Locations

- [Africa](https://dndi.org/location-place/africa/)
- [Asia](https://dndi.org/location-place/asia/)
- [Europe](https://dndi.org/location-place/europe/)
- [Latin America](https://dndi.org/location-place/latin-america/)
- [North America](https://dndi.org/location-place/north-america/)
- [Oceania](https://dndi.org/location-place/oceania/)
- [Australia](https://dndi.org/location-place/oceania/australia/)
- [United States](https://dndi.org/location-place/north-america/united-states/)
- [Germany](https://dndi.org/location-place/europe/germany/)
- [Netherlands](https://dndi.org/location-place/europe/netherlands/)
- [Norway](https://dndi.org/location-place/europe/norway/)
- [Spain](https://dndi.org/location-place/europe/spain/)
- [Switzerland](https://dndi.org/location-place/europe/switzerland/)
- [United Kingdom](https://dndi.org/location-place/europe/united-kingdom/)
- [Bangladesh](https://dndi.org/location-place/asia/bangladesh/)
- [India](https://dndi.org/location-place/asia/india/)
- [Japan](https://dndi.org/location-place/asia/japan/)
- [Malaysia](https://dndi.org/location-place/asia/malaysia/)
- [Pakistan](https://dndi.org/location-place/asia/pakistan/)
- [Thailand](https://dndi.org/location-place/asia/thailand/)
- [Central African Republic](https://dndi.org/location-place/africa/central-african-republic/)
- [Democratic Republic of Congo](https://dndi.org/location-place/africa/democratic-republic-of-congo/)
- [Egypt](https://dndi.org/location-place/africa/egypt/)
- [Ethiopia](https://dndi.org/location-place/africa/ethiopia/)
- [Kenya](https://dndi.org/location-place/africa/kenya/)
- [Malawi](https://dndi.org/location-place/africa/malawi/)
- [Senegal](https://dndi.org/location-place/africa/senegal/)
- [South Africa](https://dndi.org/location-place/africa/south-africa/)
- [South Sudan](https://dndi.org/location-place/africa/south-sudan/)
- [Sudan](https://dndi.org/location-place/africa/sudan/)
- [Tanzania](https://dndi.org/location-place/africa/tanzania/)
- [Uganda](https://dndi.org/location-place/africa/uganda/)
- [Bolivia](https://dndi.org/location-place/latin-america/bolivia/)
- [Colombia](https://dndi.org/location-place/latin-america/colombia/)
- [Mexico](https://dndi.org/location-place/latin-america/mexico/)
- [Brazil](https://dndi.org/location-place/latin-america/brazil/)
- [Argentina](https://dndi.org/location-place/latin-america/argentina/)
- [Guinea](https://dndi.org/location-place/africa/guinea/)
- [Peru](https://dndi.org/location-place/latin-america/peru/)
- [Nepal](https://dndi.org/location-place/asia/nepal/)
- [Republic of Congo](https://dndi.org/location-place/africa/republic-of-congo/)
- [Vietnam](https://dndi.org/location-place/asia/vietnam/)
- [Guatemala](https://dndi.org/location-place/latin-america/guatemala/)
- [China](https://dndi.org/location-place/asia/china/)
- [Paraguay](https://dndi.org/location-place/latin-america/paraguay/)
- [Mali](https://dndi.org/location-place/africa/mali/)
- [Ghana](https://dndi.org/location-place/africa/ghana/)
- [Chile](https://dndi.org/location-place/latin-america/chile/)
- [Sweden](https://dndi.org/location-place/europe/sweden/)
- [Sri Lanka](https://dndi.org/location-place/asia/sri-lanka/)
- [Mozambique](https://dndi.org/location-place/africa/mozambique/)
- [South Korea](https://dndi.org/location-place/asia/south-korea/)

## Member Groups

- [Leadership](https://dndi.org/member-group/our-leadership/)
- [Scientific Committee](https://dndi.org/member-group/scientific-committee/)
- [Board of Directors](https://dndi.org/member-group/board-of-directors/)
- [Executive Team](https://dndi.org/member-group/leadership/executive/)
- [R&D](https://dndi.org/member-group/leadership/r-and-d/)
- [External Relations](https://dndi.org/member-group/leadership/external-relations/)
- [Operations](https://dndi.org/member-group/leadership/operations/)
- [Regional leaders](https://dndi.org/member-group/leadership/regional-offices-leaders/)
- [Founder](https://dndi.org/our-people/leadership/founder/)
- [Policy Advocacy](https://dndi.org/our-people/leadership/policy-advocacy/)

## News Groups

- [Annual reports](https://dndi.org/news-group/annual-reports/)
- [Financial reports](https://dndi.org/news-group/financial-reports/)
- [TV](https://dndi.org/news-group/tv/)
- [Radio](https://dndi.org/news-group/radio/)
- [Factsheets](https://dndi.org/news-group/factsheets/)
- [Disease briefs](https://dndi.org/news-group/disease-briefs/)
- [Newsletters](https://dndi.org/news-group/newsletters/)
- [Policy documents](https://dndi.org/news-group/policy/)
- [Podcasts](https://dndi.org/news-group/podcasts/)
- [Regional brochures](https://dndi.org/news-group/regional-brochures/)
- [Strategic plans](https://dndi.org/news-group/strategic-plans/)
- [Other publications](https://dndi.org/news-group/other-publications/)

## News Types

- [News](https://dndi.org/news-and-stories/news/)
- [Press releases](https://dndi.org/press/press-releases/)
- [In the media](https://dndi.org/press/in-the-media/)
- [Scientific articles](https://dndi.org/resources/scientific-articles/)
- [Videos](https://dndi.org/resources/videos/)
- [Viewpoints](https://dndi.org/news-and-stories/viewpoints/)
- [Stories](https://dndi.org/news-and-stories/stories/)
- [Press Releases Translations](https://dndi.org/news-post-type/press-releases-translations/)
- [Statements](https://dndi.org/news-and-stories/statements/)
- [News Translations](https://dndi.org/news-post-type/news-translations/)
- [Publications](https://dndi.org/resources/publications/)
- [Viewpoints Translations](https://dndi.org/news-post-type/viewpoints-translations/)

## Partner Categories

- [Industry partners and service providers](https://dndi.org/partner-category/industry-partners/)
- [Universities and research centres](https://dndi.org/partner-category/universities-research/)
- [Non-profit organizations and networks](https://dndi.org/partner-category/ngos-networks/)
- [Healthcare providers](https://dndi.org/partner-category/healthcare/)
- [Ministries of health and governments](https://dndi.org/partner-category/mohs-gov/)

## Project Phases

- [Drug discovery](https://dndi.org/project-phase/drug-discovery/)
- [Clinical trials](https://dndi.org/project-phase/clinical-trials/)
- [Translational research](https://dndi.org/project-phase/translational-research/)
- [Registration & access](https://dndi.org/project-phase/registration-access/)

## Testimonial Categories

- [Featured](https://dndi.org/testimonial-category/featured/)

## Topics

- [Policy advocacy](https://dndi.org/topic-type/advocacy/)
- [Funding](https://dndi.org/topic-type/funding/)
- [Partnership](https://dndi.org/topic-type/partnership/)
- [Strengthening Capacities](https://dndi.org/topic-type/strengthening-capacities/)
- [Climate change](https://dndi.org/topic-type/climate-change/)
- [Gender](https://dndi.org/topic-type/gender/)
- [Children](https://dndi.org/topic-type/children/)
- [Conflict](https://dndi.org/topic-type/conflict/)
- [Universal Health Coverage](https://dndi.org/topic-type/universal-health-coverage/)
- [Sustainable Development](https://dndi.org/topic-type/sustainable-development/)
- [Stigma](https://dndi.org/topic-type/stigma/)
- [Drug discovery](https://dndi.org/topic-type/drug-discovery/)
- [Translational research](https://dndi.org/topic-type/translational-research/)
- [Clinical trials](https://dndi.org/topic-type/clinical-trials/)
- [Registration & access](https://dndi.org/topic-type/registration-and-access/)
- [AI & New Tech](https://dndi.org/topic-type/ai-new-tech/)
- [Evidence for impact](https://dndi.org/topic-type/evidence-for-impact/)